Unnamed: 0,reference,protein,mutation_pos,mutation_from,mutation_to,ligand_name,ligand_idtype,ligand_id,ligand_class,exp_type,exp_func,exp_wt_value,exp_wt_unit,exp_mu_effect_sign,exp_mu_effect_type,exp_mu_effect_value,exp_fold_change,exp_mu_effect_qual,exp_mu_effect_ligand_prop,exp_mu_ligand_ref,opt_receptor_expression,opt_basal_activity,opt_gain_of_activity,opt_ligand_emax,opt_agonist,Uniprot,FoldX,mutation data,SYMBOL
0,8903934,hrh1_human,194,T,A,(S)-cetirizine,ChEMBL Compound ID,CHEMBL1334217,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.0,,=,,8.0,-10.0,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
8,8198587,hrh1_human,194,T,A,2-methylhistamine,ChEMBL Compound ID,CHEMBL12620,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,42.0,µM,=,,25.0,-1.681,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
12,11809864,hrh1_human,194,T,A,(S)-cetirizine,ChEMBL Compound ID,CHEMBL1334217,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,8.2,-12.658,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
19,8093027,hrh1_human,194,T,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.04,nM,=,,0.33,-3.155,,,[3H]-mepyramine (radioligand),122.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
20,8198587,hrh1_human,194,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.2,µM,=,,28.0,2.295,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
23,11809864,hrh1_human,194,T,A,(R)-ucb 29992,SMILES,O=C(COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3)OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.9,-3.984,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
26,8903934,hrh1_human,194,T,A,Levocetirizine,ChEMBL Compound ID,CHEMBL1201191,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.5,,=,,8.5,1.0,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
30,14978232,hrh1_human,194,T,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,8.7,,=,,9.0,-1.996,,,[3H]-mepyramine (radioligand),36.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
55,8903934,hrh1_human,194,T,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.7,nM,=,,0.9,-4.115,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
65,14978232,hrh1_human,194,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.2,,=,,3.7,3.162,,,[3H]-mepyramine (radioligand),36.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
77,8093027,hrh1_human,194,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,16.9,µM,=,,59.9,3.544,,,[3H]-mepyramine (radioligand),122.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
88,11809864,hrh1_human,194,T,A,Loratadine,ChEMBL Compound ID,CHEMBL998,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,7.3,3.162,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
89,8903934,hrh1_human,194,T,A,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.2,,=,,8.5,-1.996,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
90,11809864,hrh1_human,194,T,A,Levocetirizine,ChEMBL Compound ID,CHEMBL1201191,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.5,,=,,8.7,-1.585,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
97,11809864,hrh1_human,194,T,A,(S)-ucb 29992,SMILES,O=C(COCCN1CCN(CC1)[C@@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3)OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,8.1,-7.937,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
99,11809864,hrh1_human,194,T,A,R-hydroxyzine,SMILES,OCCOCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.0,,=,,9.3,-1.996,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
105,11809864,hrh1_human,194,T,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,4.2,nM,=,,0.9,-4.673,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
120,8198587,hrh1_human,194,T,A,L-chlorpheniramine,ChEMBL Compound ID,CHEMBL1554789,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,69.0,nM,=,,36.0,-1.916,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
124,8198587,hrh1_human,194,T,A,2-pyridylethylamine,ChEMBL Compound ID,CHEMBL32813,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,38.0,µM,=,,44.0,1.158,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
129,8198587,hrh1_human,194,T,A,D-chlorpheniramine,ChEMBL Compound ID,CHEMBL1201353,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.79,nM,=,,0.56,-1.41,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
137,14978232,hrh1_human,194,T,A,8R-Lisuride,ChEMBL Compound ID,CHEMBL1528238,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,8.0,-1.259,,,[3H]-mepyramine (radioligand),36.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
140,8198587,hrh1_human,194,T,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.58,nM,=,,0.22,-2.639,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
146,11809864,hrh1_human,194,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.9,,=,,5.2,5.012,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
148,8198587,hrh1_human,194,T,A,2-(3-bromophenyl)histamine,ChEMBL Compound ID,CHEMBL26116,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.67,µM,=,,0.44,-1.522,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
154,14978232,hrh1_human,194,T,A,8R-Terguride,ChEMBL Compound ID,CHEMBL1480516,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.1,1.0,,,[3H]-mepyramine (radioligand),36.7,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
167,8903934,hrh1_human,194,T,A,Chlorpheniramine,ChEMBL Compound ID,CHEMBL505,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.0,-2.513,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
172,8903934,hrh1_human,194,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.9,,=,,5.2,5.012,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
179,9593602,hrh1_human,194,T,A,[3H]-Olopatidine,ChEMBL Compound ID,CHEMBL1189432,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,2.5,nM,=,,3.7,1.48,,,[3H]-Olopatidine,56.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
184,11809864,hrh1_human,194,T,A,(S)-hydroxyzine,ChEMBL Compound ID,CHEMBL1513166,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,8.4,-7.937,,,[3H]-mepyramine (radioligand),24.4,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
234,8198587,hrh1_human,194,T,A,2-thiazolylethylamine,ChEMBL Compound ID,CHEMBL25414,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,24.0,µM,=,,28.0,1.167,,,[3H]-mepyramine (radioligand),126.0,0.0,,0.0,,P35367,-0.271773,TA194A,HRH1
1,15033376,hrh1_human,432,F,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,>,,30.0,23.077,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,3.17079,FA432A,HRH1
5,15626750,hrh1_human,433,I,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.5,-1.585,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
6,15626750,hrh1_human,433,I,V,VUF4669,SMILES,OC(C1=CC=CC=C1)(C2CCN(CCCOC3=CC=C(C(CC(C(O)=O)O4)=O)C4=C3)CC2)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
28,15626750,hrh1_human,433,I,V,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,7.1,-1.996,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
53,15626750,hrh1_human,433,I,V,VUF8401,SMILES,N=C(NCCCC1=CNC=N1)NCCSC(C2=CC=CC=C2)C3=CC=CC=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.1,-1.259,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
71,15626750,hrh1_human,433,I,V,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,8.0,-1.259,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
72,15626750,hrh1_human,433,I,V,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.2,-1.259,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
114,12626648,hrh1_human,433,I,V,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,4.49,nM,=,,53.7,11.96,,,[3H]-mepyramine (radioligand),19.3,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
158,15626750,hrh1_human,433,I,V,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.7,-1.715,,,[3H]-mepyramine (radioligand),81.8,0.0,,0.0,,P35367,0.75659,IA433V,HRH1
9,14978232,hrh1_human,103,W,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,7.8,7.943,,,[3H]-mepyramine (radioligand),23.9,0.0,,0.0,,P35367,4.02148,WA103A,HRH1
64,14978232,hrh1_human,103,W,A,8R-Lisuride,ChEMBL Compound ID,CHEMBL1528238,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,6.4,31.623,,,[3H]-mepyramine (radioligand),23.9,0.0,,0.0,,P35367,4.02148,WA103A,HRH1
185,14978232,hrh1_human,103,W,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,8.7,,=,,7.8,7.943,,,[3H]-mepyramine (radioligand),23.9,0.0,,0.0,,P35367,4.02148,WA103A,HRH1
200,14978232,hrh1_human,103,W,A,8R-Terguride,ChEMBL Compound ID,CHEMBL1480516,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,4.8,19.953,,,[3H]-mepyramine (radioligand),23.9,0.0,,0.0,,P35367,4.02148,WA103A,HRH1
232,14978232,hrh1_human,103,W,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.2,,<,,2.2,100.0,,,[3H]-mepyramine (radioligand),23.9,0.0,,0.0,,P35367,4.02148,WA103A,HRH1
14,15626750,hrh1_human,459,I,L,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,8.0,-1.259,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
17,15626750,hrh1_human,459,I,L,VUF8401,SMILES,N=C(NCCCC1=CNC=N1)NCCSC(C2=CC=CC=C2)C3=CC=CC=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.0,1.0,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
27,15626750,hrh1_human,459,I,L,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.4,-1.259,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
58,15626750,hrh1_human,459,I,L,VUF4669,SMILES,OC(C1=CC=CC=C1)(C2CCN(CCCOC3=CC=C(C(CC(C(O)=O)O4)=O)C4=C3)CC2)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.8,-1.259,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
69,15626750,hrh1_human,459,I,L,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.0,-1.2,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
119,15626750,hrh1_human,459,I,L,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,7.0,-1.585,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
183,15626750,hrh1_human,459,I,L,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.0,1.259,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,-0.638327,IA459L,HRH1
18,11809864,hrh1_human,191,K,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,4.2,nM,=,,1.3,-3.226,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
21,11809864,hrh1_human,191,K,A,(S)-cetirizine,ChEMBL Compound ID,CHEMBL1334217,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,6.3,6.31,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
24,11809864,hrh1_human,191,K,A,Terfenadine,ChEMBL Compound ID,CHEMBL17157,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,8.5,1.585,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
50,15033376,hrh1_human,191,K,A,Methylhistaprodifen,ChEMBL Compound ID,CHEMBL275035,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.1,-1.259,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
70,15033376,hrh1_human,191,K,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,0.6,-2.165,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
73,11809864,hrh1_human,191,K,A,(R)-ucb 29992,SMILES,O=C(COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3)OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.3,1.0,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
76,11809864,hrh1_human,191,K,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.9,,=,,4.7,15.849,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
96,11809864,hrh1_human,191,K,A,Levocetirizine,ChEMBL Compound ID,CHEMBL1201191,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.5,,=,,7.9,3.981,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
103,15033376,hrh1_human,191,K,A,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.8,,=,,6.4,-3.984,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
145,15033376,hrh1_human,191,K,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,3.9,2.512,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
149,15033376,hrh1_human,191,K,A,HP-HP,SMILES,O=C(COCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3)OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,6.6,-2.513,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
163,11809864,hrh1_human,191,K,A,R-hydroxyzine,SMILES,OCCOCCN1CCN(CC1)[C@H](C2=CC=CC=C2)C3=CC=C(Cl)C=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.0,,=,,9.1,-1.259,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
194,11809864,hrh1_human,191,K,A,Loratadine,ChEMBL Compound ID,CHEMBL998,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,7.8,1.0,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
214,11809864,hrh1_human,191,K,A,Fexofenadine,ChEMBL Compound ID,CHEMBL914,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,7.4,3.981,,,[3H]-mepyramine (radioligand),55.2,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
229,15033376,hrh1_human,191,K,A,Histaprodifen,ChEMBL Compound ID,CHEMBL275507,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.9,-1.996,,,[3H]-mepyramine (radioligand),70.3,0.0,,0.0,,P35367,0.656844,KA191A,HRH1
22,15626750,hrh1_human,37,I,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,3.9,2.512,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
43,15626750,hrh1_human,37,I,V,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,5.9,1.585,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
111,15626750,hrh1_human,37,I,V,VUF4669,SMILES,OC(C1=CC=CC=C1)(C2CCN(CCCOC3=CC=C(C(CC(C(O)=O)O4)=O)C4=C3)CC2)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
125,15626750,hrh1_human,37,I,V,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,6.9,-1.259,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
166,15626750,hrh1_human,37,I,V,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.7,1.585,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
198,15626750,hrh1_human,37,I,V,VUF8401,SMILES,N=C(NCCCC1=CNC=N1)NCCSC(C2=CC=CC=C2)C3=CC=CC=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,5.9,1.259,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
211,15626750,hrh1_human,37,I,V,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.7,1.417,,,[3H]-mepyramine (radioligand),94.2,0.0,,0.0,,P35367,0.899927,IA37V,HRH1
29,15626750,hrh1_human,449,L,V,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.0,1.259,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
45,15626750,hrh1_human,449,L,V,VUF4669,SMILES,OC(C1=CC=CC=C1)(C2CCN(CCCOC3=CC=C(C(CC(C(O)=O)O4)=O)C4=C3)CC2)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.1,-2.513,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
85,15626750,hrh1_human,449,L,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.0,1.995,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
169,15626750,hrh1_human,449,L,V,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.9,1.0,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
174,15626750,hrh1_human,449,L,V,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.4,1.167,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
201,15626750,hrh1_human,449,L,V,VUF8401,SMILES,N=C(NCCCC1=CNC=N1)NCCSC(C2=CC=CC=C2)C3=CC=CC=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.0,1.0,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
217,15626750,hrh1_human,449,L,V,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,7.0,-1.585,,,[3H]-mepyramine (radioligand),80.2,0.0,,0.0,,P35367,1.16972,LA449V,HRH1
33,25013351,hrh1_human,435,F,A,"[3H]-(2S,4R)-PAT",ChEMBL Compound ID,CHEMBL127307,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,1.3,nM,=,,9.4,7.231,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
81,25013351,hrh1_human,435,F,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,mM,>,,10.0,3.333,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
101,15033376,hrh1_human,435,F,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,2.7,39.811,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
109,15033376,hrh1_human,435,F,A,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.8,2.512,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
127,15033376,hrh1_human,435,F,A,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.8,,=,,5.5,1.995,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
186,15033376,hrh1_human,435,F,A,Histaprodifen,ChEMBL Compound ID,CHEMBL275507,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.3,1.995,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
213,15033376,hrh1_human,435,F,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,5.7,4.385,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
226,25013351,hrh1_human,435,F,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.84,nM,=,,8.3,9.881,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
230,15033376,hrh1_human,435,F,A,Methylhistaprodifen,ChEMBL Compound ID,CHEMBL275035,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,5.5,3.162,,,[3H]-mepyramine (radioligand),85.1,0.0,,0.0,,P35367,1.01478,FA435A,HRH1
35,15626750,hrh1_human,89,L,H,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,>,,30.0,25.0,Abolished effect,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,1.78257,LA89H,HRH1
41,17959710,hrh1_human,420,I,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand saturation,8.0,,=,,8.2,-1.585,,,[3H]-mepyramine (radioligand),25.0,0.0,,0.0,,P35367,2.40887,IA420A,HRH1
161,17959710,hrh1_human,420,I,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.9,-7.937,,,[3H]-mepyramine (radioligand),25.0,0.0,,0.0,,P35367,2.40887,IA420A,HRH1
42,17959710,hrh1_human,420,I,F,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand saturation,8.0,,=,,8.1,-1.259,,,[3H]-mepyramine (radioligand),52.3,0.0,,0.0,,P35367,5.95757,IA420F,HRH1
218,17959710,hrh1_human,420,I,F,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,5.9,1.259,,,[3H]-mepyramine (radioligand),52.3,0.0,,0.0,,P35367,5.95757,IA420F,HRH1
46,9593602,hrh1_human,107,D,A,[3H]-Olopatidine,ChEMBL Compound ID,CHEMBL1189432,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,2.5,nM,=,,49.0,19.6,,,[3H]-Olopatidine,64.7,0.0,,0.0,,P35367,0.569973,DA107A,HRH1
188,15033376,hrh1_human,107,D,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,>,,30.0,23.077,Abolished effect,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,0.569973,DA107A,HRH1
51,16408006,hrh1_human,111,S,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,4.1,3.154,,,[3H]-mepyramine (radioligand),58.3,0.0,,0.0,,P35367,-0.898856,SA111A,HRH1
133,16408006,hrh1_human,111,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.1,,=,,3.0,12.589,,,[3H]-mepyramine (radioligand),58.3,0.0,,0.0,,P35367,-0.898856,SA111A,HRH1
170,16408006,hrh1_human,111,S,A,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.3,1.0,,,[3H]-mepyramine (radioligand),58.3,0.0,,0.0,,P35367,-0.898856,SA111A,HRH1
54,8903934,hrh1_human,155,S,A,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.2,,=,,7.8,2.512,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
87,8903934,hrh1_human,155,S,A,Chlorpheniramine,ChEMBL Compound ID,CHEMBL505,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.4,1.585,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
131,8903934,hrh1_human,155,S,A,Levocetirizine,ChEMBL Compound ID,CHEMBL1201191,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.5,,=,,8.2,1.995,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
222,8903934,hrh1_human,155,S,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.7,nM,=,,2.6,-1.422,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
223,8903934,hrh1_human,155,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.9,,=,,5.7,1.585,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
237,8903934,hrh1_human,155,S,A,(S)-cetirizine,ChEMBL Compound ID,CHEMBL1334217,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.7,1.995,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-0.897993,SA155A,HRH1
61,15626750,hrh1_human,84,N,S,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.2,1.259,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
93,15626750,hrh1_human,84,N,S,Histaprodifen,ChEMBL Compound ID,CHEMBL275507,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,6.2,1.0,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
98,15626750,hrh1_human,84,N,S,VUF8401,SMILES,N=C(NCCCC1=CNC=N1)NCCSC(C2=CC=CC=C2)C3=CC=CC=C3,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.4,-2.513,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
107,15626750,hrh1_human,84,N,S,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.8,-5.0,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
138,15626750,hrh1_human,84,N,S,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.1,-1.091,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
199,15626750,hrh1_human,84,N,S,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.5,2.512,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
231,15626750,hrh1_human,84,N,S,VUF4669,SMILES,OC(C1=CC=CC=C1)(C2CCN(CCCOC3=CC=C(C(CC(C(O)=O)O4)=O)C4=C3)CC2)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.9,-15.873,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
235,15626750,hrh1_human,84,N,S,HP-HP,SMILES,C1(CCNCCC2=CNC(CCC(C3=CC=CC=C3)C4=CC=CC=C4)=N2)=CN=C(CCC(C5=CC=CC=C5)C6=CC=CC=C6)N1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,7.3,-3.165,,,[3H]-mepyramine (radioligand),53.7,0.0,,0.0,,P35367,0.529214,NA84S,HRH1
84,15626750,hrh1_human,458,Y,A,HP-HA,ChEMBL Compound ID,CHEMBL264491,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.1,,=,,6.8,-5.0,,,[3H]-mepyramine (radioligand),67.8,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
108,25013351,hrh1_human,458,Y,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.84,nM,=,,9.1,10.833,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
135,15626750,hrh1_human,458,Y,A,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.2,nM,=,,3.0,2.5,,,[3H]-mepyramine (radioligand),67.8,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
143,15626750,hrh1_human,458,Y,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.4,-1.259,,,[3H]-mepyramine (radioligand),67.8,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
147,25013351,hrh1_human,458,Y,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,µM,=,,51.0,17.0,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
204,25013351,hrh1_human,458,Y,A,"[3H]-(2S,4R)-PAT",ChEMBL Compound ID,CHEMBL127307,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,1.3,nM,=,,9.0,6.923,,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,4.40244,YA458A,HRH1
104,16408006,hrh1_human,111,S,C,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.1,,=,,4.4,-1.996,,,[3H]-mepyramine (radioligand),55.0,0.0,,0.0,,P35367,-0.296204,SA111C,HRH1
118,16408006,hrh1_human,111,S,C,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,0.4,-3.247,,,[3H]-mepyramine (radioligand),55.0,0.0,,0.0,,P35367,-0.296204,SA111C,HRH1
122,16408006,hrh1_human,111,S,C,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.5,-1.585,,,[3H]-mepyramine (radioligand),55.0,0.0,,0.0,,P35367,-0.296204,SA111C,HRH1
117,17959710,hrh1_human,420,I,S,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,6.0,1.0,,,[3H]-mepyramine (radioligand),22.7,0.0,,0.0,,P35367,2.78851,IA420S,HRH1
236,17959710,hrh1_human,420,I,S,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand saturation,8.0,,=,,7.5,3.162,,,[3H]-mepyramine (radioligand),22.7,0.0,,0.0,,P35367,2.78851,IA420S,HRH1
130,16408006,hrh1_human,111,S,T,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.5,-1.585,,,[3H]-mepyramine (radioligand),63.6,0.0,,0.0,,P35367,-0.158553,SA111T,HRH1
171,16408006,hrh1_human,111,S,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.1,,=,,4.1,1.0,,,[3H]-mepyramine (radioligand),63.6,0.0,,0.0,,P35367,-0.158553,SA111T,HRH1
207,16408006,hrh1_human,111,S,T,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,2.7,2.077,,,[3H]-mepyramine (radioligand),63.6,0.0,,0.0,,P35367,-0.158553,SA111T,HRH1
144,16408006,hrh1_human,460,N,S,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.2,1.259,,,[3H]-mepyramine (radioligand),48.3,0.0,,0.0,,P35367,-0.0816211,NA460S,HRH1
208,16408006,hrh1_human,460,N,S,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.1,,=,,4.9,-6.329,,,[3H]-mepyramine (radioligand),48.3,0.0,,0.0,,P35367,-0.0816211,NA460S,HRH1
220,16408006,hrh1_human,460,N,S,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,2.8,2.154,,,[3H]-mepyramine (radioligand),48.3,0.0,,0.0,,P35367,-0.0816211,NA460S,HRH1
153,16408006,hrh1_human,460,N,C,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,=,,2.7,2.077,,,[3H]-mepyramine (radioligand),39.1,0.0,,0.0,,P35367,-1.03968,NA460C,HRH1
180,16408006,hrh1_human,460,N,C,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.1,,=,,4.7,-3.984,,,[3H]-mepyramine (radioligand),39.1,0.0,,0.0,,P35367,-1.03968,NA460C,HRH1
189,16408006,hrh1_human,460,N,C,Cetirizine,ChEMBL Compound ID,CHEMBL1000,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.1,1.585,,,[3H]-mepyramine (radioligand),39.1,0.0,,0.0,,P35367,-1.03968,NA460C,HRH1
156,17959710,hrh1_human,420,I,G,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.0,,=,,7.2,-15.873,,,[3H]-mepyramine (radioligand),40.9,0.0,,0.0,,P35367,3.93511,IA420G,HRH1
203,17959710,hrh1_human,420,I,G,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand saturation,8.0,,=,,7.6,2.512,,,[3H]-mepyramine (radioligand),40.9,0.0,,0.0,,P35367,3.93511,IA420G,HRH1
193,8093027,hrh1_human,107,D,N,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.04,nM,=,,131.0,125.962,,,[3H]-mepyramine (radioligand),97.4,0.0,,0.0,,P35367,0.86107,DA107N,HRH1
196,16408006,hrh1_human,460,N,L,[3H]-mepyramine,ChEMBL Compound ID,CHEMBL511,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.3,nM,>,,30.0,23.077,Abolished effect,,[3H]-mepyramine (radioligand),0.0,0.0,,0.0,,P35367,-2.87302,NA460L,HRH1
3,10.1016/j.bbrc.2014.08.048,cnr2_human,192,L,A,SR144528,PubChem CID,3081355,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,4.8,4.8,,,H3CP55940,0.0,0.0,,0.0,,P34972,1.14168,LA192A,CNR2
10,10.1016/j.bbrc.2014.08.048,cnr2_human,192,L,A,CP55940,PubChem CID,104895,Full agonist,EC50,Functional - cAMP accumulation,32.0,nM,=,,0.14,-250.0,,,,0.0,0.0,,0.0,,P34972,1.14168,LA192A,CNR2
33,10.1016/j.bbrc.2014.08.048,cnr2_human,192,L,A,CP55940,PubChem CID,104895,Full agonist,K(i),Binding - Radioligand competition/displacement,2.6,nM,=,,2.3,-1.13,,,H3CP55940,0.0,0.0,,0.0,,P34972,1.14168,LA192A,CNR2
39,10.1016/j.bbrc.2014.08.048,cnr2_human,192,L,A,XIE95-26,SMILES,O=C(CC(NC(=O)CC1=CC=CC=C1)C2=CC=C(N(CC)CC)C=C2)CC3=CC=CC=C3,Inverse agonist,K(i),Binding - Radioligand competition/displacement,154.0,nM,=,,6.1,-25.0,,,H3CP55940,0.0,0.0,,0.0,,P34972,1.14168,LA192A,CNR2
11,19133996,adrb3_human,265,T,M,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,306.0,pM,=,,295.0,-1.037,,,,88.4,0.0,,0.0,,P13945,2.6626,TA265M,ADRB3
5,9254607,acm5_human,465,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.48,nM,=,,0.31,-1.548,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.1785,SA465A,CHRM5
396,9254607,acm5_human,465,S,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.8,nM,=,,0.97,-1.855,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.1785,SA465A,CHRM5
7,9521726,acm5_human,440,A,Q,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,263.0,3.704,,,[3H]N-methyl scopolamine (radioligand),207.1,0.0,,0.0,,P08912,-0.451653,AA440Q,CHRM5
22,7852396,acm5_human,441,A,I,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.1,µM,=,,6.3,2.032,,,[3H]N-methyl scopolamine (radioligand),300.0,0.0,,0.0,,P08912,-1.39062,AA441I,CHRM5
36,7852396,acm5_human,441,A,I,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,141.0,pM,=,,339.0,2.404,,,[3H]N-methyl scopolamine (radioligand),300.0,0.0,,0.0,,P08912,-1.39062,AA441I,CHRM5
46,9254607,acm5_human,465,S,F,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.8,nM,=,,1.1,-1.637,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,-0.221375,SA465F,CHRM5
142,9254607,acm5_human,465,S,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.48,nM,=,,0.44,-1.091,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,-0.221375,SA465F,CHRM5
50,9705286,acm5_human,459,N,V,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,200.0,200.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.695671,NA459V,CHRM5
55,9254607,acm5_human,465,S,R,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.8,nM,=,,1.6,-1.125,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.267101,SA465R,CHRM5
328,9254607,acm5_human,465,S,R,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.48,nM,=,,1.5,3.125,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.267101,SA465R,CHRM5
60,7852396,acm5_human,441,A,R,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,141.0,pM,=,,217.0,1.539,,,[3H]N-methyl scopolamine (radioligand),194.4,0.0,,0.0,,P08912,0.252219,AA441R,CHRM5
160,7852396,acm5_human,441,A,R,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.1,µM,=,,5.7,1.839,,,[3H]N-methyl scopolamine (radioligand),194.4,0.0,,0.0,,P08912,0.252219,AA441R,CHRM5
69,8621674,acm5_human,223,R,E,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,497.0,-1.046,,,[3H]N-methyl scopolamine (radioligand),183.9,0.0,,0.0,,P08912,1.77035,RA223E,CHRM5
78,7852396,acm5_human,441,A,P,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.1,µM,=,,11.0,3.548,,,[3H]N-methyl scopolamine (radioligand),155.6,0.0,,0.0,,P08912,3.1366,AA441P,CHRM5
399,7852396,acm5_human,441,A,P,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,141.0,pM,=,,201.0,1.426,,,[3H]N-methyl scopolamine (radioligand),155.6,0.0,,0.0,,P08912,3.1366,AA441P,CHRM5
84,9733718,acm5_human,142,R,H,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.17,-1.176,,,[3H]N-methyl scopolamine (radioligand),101.4,0.0,,0.0,,P08912,1.25127,RA142H,CHRM5
103,9705286,acm5_human,459,N,Y,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,>,,1000.0,1000.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,2.06411,NA459Y,CHRM5
164,9705286,acm5_human,447,I,S,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.9,,=,,9.6,1.995,,,[3H]N-methyl scopolamine (radioligand),87.5,0.0,,0.0,,P08912,2.72983,IA447S,CHRM5
167,9733718,acm5_human,130,F,C,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.2,1.0,,,[3H]N-methyl scopolamine (radioligand),82.4,0.0,,0.0,,P08912,1.89616,FA130C,CHRM5
169,9254607,acm5_human,465,S,G,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.48,nM,=,,1.0,2.083,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.742287,SA465G,CHRM5
204,9254607,acm5_human,465,S,G,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.8,nM,=,,2.5,1.389,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.742287,SA465G,CHRM5
179,8621674,acm5_human,217,Y,S,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,423.0,-1.23,,,[3H]N-methyl scopolamine (radioligand),110.7,0.0,,0.0,,P08912,0.834999,YA217S,CHRM5
193,8621674,acm5_human,220,T,V,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,530.0,1.019,,,[3H]N-methyl scopolamine (radioligand),144.6,0.0,,0.0,,P08912,-0.429843,TA220V,CHRM5
197,9705286,acm5_human,459,N,C,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,1000.0,1000.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.019806,NA459C,CHRM5
201,7852396,acm5_human,441,A,Y,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,141.0,pM,=,,315.0,2.234,,,[3H]N-methyl scopolamine (radioligand),333.3,0.0,,0.0,,P08912,-1.83392,AA441Y,CHRM5
308,7852396,acm5_human,441,A,Y,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.1,µM,=,,5.9,1.903,,,[3H]N-methyl scopolamine (radioligand),333.3,0.0,,0.0,,P08912,-1.83392,AA441Y,CHRM5
212,9254607,acm5_human,465,S,V,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.8,nM,=,,0.73,-2.463,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.813498,SA465V,CHRM5
407,9254607,acm5_human,465,S,V,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.48,nM,=,,0.31,-1.548,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.813498,SA465V,CHRM5
213,8621674,acm5_human,216,I,G,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,388.0,-1.34,,,[3H]N-methyl scopolamine (radioligand),132.1,0.0,,0.0,,P08912,3.9842,IA216G,CHRM5
215,9705286,acm5_human,451,F,C,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.0,nM,=,,60.0,15.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,5.34925,FA451C,CHRM5
224,9705286,acm5_human,459,N,D,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,>,,1000.0,1000.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,1.59188,NA459D,CHRM5
272,9705286,acm5_human,451,F,G,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.0,nM,>,,1000.0,250.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,5.74696,FA451G,CHRM5
283,9521726,acm5_human,440,A,E,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,318.0,4.479,,,[3H]N-methyl scopolamine (radioligand),100.0,0.0,,0.0,,P08912,0.258459,AA440E,CHRM5
284,9705286,acm5_human,451,F,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.0,nM,=,,60.0,15.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,3.52543,FA451A,CHRM5
293,9705286,acm5_human,459,N,H,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.9,,=,,8.5,25.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.454702,NA459H,CHRM5
323,9705286,acm5_human,459,N,H,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,200.0,200.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.454702,NA459H,CHRM5
300,9705286,acm5_human,451,F,W,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.0,nM,=,,1.0,-4.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,1.04367,FA451W,CHRM5
311,7852396,acm5_human,441,A,T,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.1,µM,=,,8.7,2.806,,,[3H]N-methyl scopolamine (radioligand),200.0,0.0,,0.0,,P08912,0.159771,AA441T,CHRM5
385,7852396,acm5_human,441,A,T,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,141.0,pM,=,,208.0,1.475,,,[3H]N-methyl scopolamine (radioligand),200.0,0.0,,0.0,,P08912,0.159771,AA441T,CHRM5
325,8621674,acm5_human,216,I,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,221.0,-2.353,,,[3H]N-methyl scopolamine (radioligand),64.3,0.0,,0.0,,P08912,2.09797,IA216F,CHRM5
327,8621674,acm5_human,220,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,540.0,1.038,,,[3H]N-methyl scopolamine (radioligand),198.2,0.0,,0.0,,P08912,0.0198211,TA220A,CHRM5
331,8621674,acm5_human,223,R,L,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,520.0,pM,=,,1200.0,2.308,,,[3H]N-methyl scopolamine (radioligand),252.7,0.0,,0.0,,P08912,0.714189,RA223L,CHRM5
333,9733718,acm5_human,134,R,E,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.15,-1.333,,,[3H]N-methyl scopolamine (radioligand),58.1,0.0,,0.0,,P08912,1.17953,RA134E,CHRM5
344,9705286,acm5_human,459,N,T,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,200.0,200.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,0.481104,NA459T,CHRM5
348,9521726,acm5_human,439,K,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,149.0,2.099,,,[3H]N-methyl scopolamine (radioligand),107.1,0.0,,0.0,,P08912,-0.0720122,KA439A,CHRM5
351,9705286,acm5_human,451,F,V,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.0,nM,=,,10.0,2.5,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,3.57369,FA451V,CHRM5
352,9521726,acm5_human,439,K,G,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,184.0,2.592,,,[3H]N-methyl scopolamine (radioligand),96.4,0.0,,0.0,,P08912,0.753898,KA439G,CHRM5
372,9733718,acm5_human,138,Y,T,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.18,-1.111,,,[3H]N-methyl scopolamine (radioligand),44.6,0.0,,0.0,,P08912,4.48461,YA138T,CHRM5
375,9705286,acm5_human,459,N,G,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,300.0,300.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,2.60642,NA459G,CHRM5
376,9733718,acm5_human,130,F,M,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.27,1.35,,,[3H]N-methyl scopolamine (radioligand),101.4,0.0,,0.0,,P08912,0.0437891,FA130M,CHRM5
380,9705286,acm5_human,459,N,F,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,200.0,200.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,1.72004,NA459F,CHRM5
386,9521726,acm5_human,439,K,E,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,98.0,1.38,,,[3H]N-methyl scopolamine (radioligand),60.7,0.0,,0.0,,P08912,0.0825522,KA439E,CHRM5
388,9733718,acm5_human,142,R,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.24,1.2,,,[3H]N-methyl scopolamine (radioligand),125.7,0.0,,0.0,,P08912,0.832122,RA142N,CHRM5
394,9705286,acm5_human,459,N,S,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,nM,=,,100.0,100.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08912,1.3928,NA459S,CHRM5
405,9521726,acm5_human,439,K,Q,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL1201268,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,71.0,pM,=,,179.0,2.521,,,[3H]N-methyl scopolamine (radioligand),92.9,0.0,,0.0,,P08912,0.120569,KA439Q,CHRM5
1,8466481,drd1_human,283,C,V,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2340.0,nM,=,,5400.0,2.308,,,[3H]SCH23405,0.0,0.0,,0.0,,P21728,-0.190662,CA283V,DRD1
10,8466481,drd1_human,283,C,V,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,362.0,pM,=,,654.0,1.807,,,,0.0,0.0,,0.0,,P21728,-0.190662,CA283V,DRD1
57,8466481,drd1_human,283,C,V,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,41.0,nM,=,,165.0,4.024,,,[3H]SCH23399,0.0,0.0,,0.0,,P21728,-0.190662,CA283V,DRD1
78,8466481,drd1_human,283,C,V,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.35,nM,=,,0.6,1.714,,,[3H]SCH23393,0.0,0.0,,0.0,,P21728,-0.190662,CA283V,DRD1
2,8910419,drd1_human,264,F,I,[125I]CH23982,ChEMBL Compound ID,CHEMBL290118,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,~,,0.6,1.0,,,,100.0,0.0,,0.0,,P21728,0.647806,FA264I,DRD1
25,8910419,drd1_human,264,F,I,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.3,nM,=,,8.0,-1.163,,,[125I]CH23982,0.0,0.0,,0.0,,P21728,0.647806,FA264I,DRD1
103,8910419,drd1_human,264,F,I,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5610.0,nM,=,,2950.0,-1.901,,,[125I]CH23982,0.0,0.0,,0.0,,P21728,0.647806,FA264I,DRD1
4,8913366,drd1_human,205,I,A,cis-Z-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,0.79,1.756,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.34324,IA205A,DRD1
42,8913366,drd1_human,205,I,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,µM,=,,2.5,1.316,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.34324,IA205A,DRD1
43,8913366,drd1_human,205,I,A,R(+)[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.71,nM,=,,0.37,-1.919,,,,0.0,0.0,,0.0,,P21728,1.34324,IA205A,DRD1
58,8913366,drd1_human,205,I,A,SKF-82958,ChEMBL Compound ID,CHEMBL317741,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,23.0,nM,=,,13.0,-1.77,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.34324,IA205A,DRD1
86,8913366,drd1_human,205,I,A,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,530.0,nM,=,,900.0,1.698,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.34324,IA205A,DRD1
5,7643110,drd1_human,351,C,G,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,40.0,nM,=,,29.0,-1.379,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
12,7643110,drd1_human,351,C,G,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.6,nM,=,,1.6,1.0,,,,63.2,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
17,7643110,drd1_human,351,C,G,cis-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,nM,=,,2.1,-1.429,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
27,7643110,drd1_human,351,C,G,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,42.0,nM,=,,48.0,1.143,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
30,7643110,drd1_human,351,C,G,(+)-Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.7,nM,=,,0.6,-1.167,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
37,7643110,drd1_human,351,C,G,Bulbocapnine,ChEMBL Compound ID,CHEMBL157913,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,155.0,nM,=,,116.0,-1.337,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
73,7643110,drd1_human,351,C,G,(S)-Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10000.0,nM,>,,10000.0,1.0,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
93,7643110,drd1_human,351,C,G,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,174.0,1.582,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
104,7643110,drd1_human,351,C,G,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,nM,=,,1.1,-1.727,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.38762,CA351G,DRD1
6,1355478,drd1_human,202,S,A,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(m),Binding - Radioligand saturation,0.6,nM,=,,0.71,1.183,,,,590.9,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
33,1355478,drd1_human,202,S,A,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.95,nM,=,,0.69,-1.377,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
51,1355478,drd1_human,202,S,A,SKF-82958,ChEMBL Compound ID,CHEMBL317741,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,83.1,nM,=,,100.8,1.213,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
67,1355478,drd1_human,202,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1298.0,nM,=,,62250.0,47.958,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
87,1355478,drd1_human,202,S,A,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,300.0,nM,=,,174.5,-1.718,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
94,1355478,drd1_human,202,S,A,cis-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.06,nM,=,,2.76,1.34,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
118,1355478,drd1_human,202,S,A,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,173.6,nM,=,,332.0,1.912,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.224115,SA202A,DRD1
7,1355478,drd1_human,199,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1298.0,nM,=,,12800.0,9.861,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
24,1355478,drd1_human,199,S,A,cis-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.06,nM,=,,18.8,9.126,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
45,1355478,drd1_human,199,S,A,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,300.0,nM,=,,1648.0,5.493,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
55,1355478,drd1_human,199,S,A,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(m),Binding - Radioligand saturation,0.6,nM,=,,16.6,27.667,,,,427.3,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
72,1355478,drd1_human,199,S,A,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.95,nM,=,,68.0,71.579,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
100,1355478,drd1_human,199,S,A,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,173.6,nM,=,,2187.0,12.598,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
116,1355478,drd1_human,199,S,A,SKF-82958,ChEMBL Compound ID,CHEMBL317741,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,83.1,nM,=,,375.5,4.519,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.608794,SA199A,DRD1
9,7643110,drd1_human,347,C,G,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,40.0,nM,=,,41.0,1.025,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
44,7643110,drd1_human,347,C,G,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.6,nM,=,,1.5,-1.066,,,,21.1,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
59,7643110,drd1_human,347,C,G,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,120.0,1.091,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
60,7643110,drd1_human,347,C,G,(+)-Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.7,nM,=,,0.5,-1.401,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
63,7643110,drd1_human,347,C,G,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,42.0,nM,=,,44.0,1.048,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
75,7643110,drd1_human,347,C,G,Bulbocapnine,ChEMBL Compound ID,CHEMBL157912,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,155.0,nM,=,,140.0,-1.107,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
83,7643110,drd1_human,347,C,G,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,nM,=,,2.3,1.211,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
89,7643110,drd1_human,347,C,G,cis-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,nM,=,,2.0,-1.499,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
115,7643110,drd1_human,347,C,G,(S)-Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10000.0,nM,>,,10000.0,1.0,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.487027,CA347G,DRD1
11,9137920,drd1_human,347,C,A,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,284.2,pM,=,,369.6,1.3,,,,0.0,0.0,,0.0,,P21728,-0.459898,CA347A,DRD1
19,9137920,drd1_human,347,C,A,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,31.75,nM,=,,26.34,-1.205,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.459898,CA347A,DRD1
41,9137920,drd1_human,347,C,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,177.4,nM,=,,159.89,-1.11,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.459898,CA347A,DRD1
91,9137920,drd1_human,347,C,A,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.93,nM,=,,3.13,-1.256,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,-0.459898,CA347A,DRD1
13,8913366,drd1_human,205,I,Y,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,530.0,nM,=,,13000.0,24.528,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.38358,IA205Y,DRD1
34,8913366,drd1_human,205,I,Y,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,µM,=,,94.0,49.474,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.38358,IA205Y,DRD1
40,8913366,drd1_human,205,I,Y,SKF-82958,ChEMBL Compound ID,CHEMBL317741,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,23.0,nM,=,,500.0,21.739,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.38358,IA205Y,DRD1
52,8913366,drd1_human,205,I,Y,R(+)[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.71,nM,=,,5.2,7.324,,,,0.0,0.0,,0.0,,P21728,0.38358,IA205Y,DRD1
74,8913366,drd1_human,205,I,Y,cis-Z-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,0.31,-1.451,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.38358,IA205Y,DRD1
15,8466481,drd1_human,70,D,V,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,703.0,pM,=,,788.0,1.121,,,,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
20,8466481,drd1_human,70,D,V,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,76.0,nM,=,,60.0,-1.267,,,[3H]SCH23397,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
54,8466481,drd1_human,70,D,V,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,362.0,pM,=,,1056.0,2.917,,,,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
62,8466481,drd1_human,70,D,V,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3100.0,nM,=,,14600.0,4.71,,,[3H]SCH23403,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
77,8466481,drd1_human,70,D,V,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.35,nM,=,,1.67,4.771,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
96,8466481,drd1_human,70,D,V,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2340.0,nM,=,,21500.0,9.188,,,[3H]SCH23402,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
97,8466481,drd1_human,70,D,V,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.78,nM,=,,0.86,1.103,,,[3H]SCH23391,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
102,8466481,drd1_human,70,D,V,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,41.0,nM,=,,46.0,1.122,,,[3H]SCH23396,0.0,0.0,,0.0,,P21728,0.929987,DA70V,DRD1
21,8910419,drd1_human,266,R,K,[125I]CH23982,ChEMBL Compound ID,CHEMBL290118,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,~,,0.6,1.0,,,,100.0,0.0,,0.0,,P21728,-0.217709,RA266K,DRD1
53,8910419,drd1_human,266,R,K,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5610.0,nM,=,,4130.0,-1.359,,,[125I]CH23982,0.0,0.0,,0.0,,P21728,-0.217709,RA266K,DRD1
80,8910419,drd1_human,266,R,K,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.3,nM,=,,7.3,-1.274,,,[125I]CH23982,0.0,0.0,,0.0,,P21728,-0.217709,RA266K,DRD1
23,8913366,drd1_human,286,L,A,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,530.0,nM,=,,680.0,1.283,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.53809,LA286A,DRD1
28,8913366,drd1_human,286,L,A,SKF-82958,ChEMBL Compound ID,CHEMBL317741,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,23.0,nM,=,,46.0,2.0,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.53809,LA286A,DRD1
32,8913366,drd1_human,286,L,A,cis-Z-flupentixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,0.7,1.556,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.53809,LA286A,DRD1
79,8913366,drd1_human,286,L,A,R(+)[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.71,nM,=,,1.1,1.549,,,,0.0,0.0,,0.0,,P21728,1.53809,LA286A,DRD1
119,8913366,drd1_human,286,L,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,µM,=,,1.2,-1.582,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,1.53809,LA286A,DRD1
31,8466481,drd1_human,81,K,E,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2340.0,nM,=,,4200.0,1.795,,,[3H]SCH23404,0.0,0.0,,0.0,,P21728,2.01692,KA81E,DRD1
48,8466481,drd1_human,81,K,E,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,362.0,pM,=,,556.0,1.536,,,,0.0,0.0,,0.0,,P21728,2.01692,KA81E,DRD1
66,8466481,drd1_human,81,K,E,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.35,nM,=,,0.65,1.857,,,[3H]SCH23392,0.0,0.0,,0.0,,P21728,2.01692,KA81E,DRD1
106,8466481,drd1_human,81,K,E,SCH-23388,ChEMBL Compound ID,CHEMBL63321,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,41.0,nM,=,,55.0,1.341,,,[3H]SCH23398,0.0,0.0,,0.0,,P21728,2.01692,KA81E,DRD1
65,9137920,drd1_human,351,C,A,[3H]SCH23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,284.2,pM,=,,363.0,1.277,,,,0.0,0.0,,0.0,,P21728,0.199191,CA351A,DRD1
69,9137920,drd1_human,351,C,A,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,31.75,nM,=,,42.52,1.339,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.199191,CA351A,DRD1
82,9137920,drd1_human,351,C,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,177.4,nM,=,,223.75,1.261,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.199191,CA351A,DRD1
95,9137920,drd1_human,351,C,A,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.93,nM,=,,5.91,1.504,,,[3H]SCH23390,0.0,0.0,,0.0,,P21728,0.199191,CA351A,DRD1
0,10940778,acm2_human,409,I,V,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,7.7,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.613082,IA409V,CHRM2
1,8157684,acm2_human,210,S,Y,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,5.6,µM,=,,2.9,-1.931,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.800508,SA210Y,CHRM2
155,8157684,acm2_human,210,S,Y,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,115.0,pM,=,,81.0,-1.42,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.800508,SA210Y,CHRM2
5,10513578,acm2_human,179,Q,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,260.0,pM,=,,180.0,-1.445,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.206337,QA179A,CHRM2
156,10513578,acm2_human,179,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,180.0,pM,=,,190.0,1.056,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,0.206337,QA179A,CHRM2
6,20051519,acm2_human,80,Y,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,6.0,-2.513,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
27,20051519,acm2_human,80,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,4.2,5.012,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
39,20051519,acm2_human,80,Y,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.9,1.995,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
68,20051519,acm2_human,80,Y,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.7,1.995,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
75,20051519,acm2_human,80,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,4.9,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
93,20051519,acm2_human,80,Y,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,7.1,-25.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
98,20051519,acm2_human,80,Y,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.8,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
160,20051519,acm2_human,80,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.4,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
203,20051519,acm2_human,80,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,9.6,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,2.69602,YA80A,CHRM2
7,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-8,ChEMBL Compound ID,CHEMBL86903,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.7,µM,=,,42.0,60.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
18,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-6,ChEMBL Compound ID,CHEMBL87622,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,4.0,µM,=,,50.8,12.7,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
43,23826889,acm2_human,103,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.64,,=,,2.93,512.861,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
53,10188794,acm2_human,103,D,N,"L607,207",ChEMBL Compound ID,CHEMBL314737,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.005,µM,>,,95.0,19000.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
61,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-12,ChEMBL Compound ID,CHEMBL155960,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.1,µM,=,,6.5,65.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
63,20643905,acm2_human,103,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.68,,=,,3.01,467.735,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
95,20643905,acm2_human,103,D,N,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,1.29,%,=,,3.0,-2.326,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
96,10188794,acm2_human,103,D,N,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.2,µM,=,,19.5,97.5,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
113,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-7,ChEMBL Compound ID,CHEMBL434072,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.8,µM,=,,21.2,26.5,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
127,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-11,ChEMBL Compound ID,CHEMBL345415,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,9.2,µM,=,,14.4,1.565,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
133,23826889,acm2_human,103,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.57,,=,,4.12,2.818,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
145,20643905,acm2_human,103,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,,=,,7.93,15.136,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
152,10188794,acm2_human,103,D,N,Arylacetylene oxime-2,ChEMBL Compound ID,CHEMBL84919,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,37.5,µM,=,,25.3,-1.481,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
157,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-9,ChEMBL Compound ID,CHEMBL84726,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.1,µM,=,,10.8,108.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
173,20643905,acm2_human,103,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,7.79,%,=,,79.0,-10.101,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
180,10188794,acm2_human,103,D,N,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,3.3,µM,=,,605.7,183.545,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
182,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-5,ChEMBL Compound ID,CHEMBL160509,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,21.2,µM,=,,71.0,3.349,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
183,10188794,acm2_human,103,D,N,Arylacetylene oxime-3,ChEMBL Compound ID,CHEMBL81878,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,23.4,µM,=,,45.6,1.949,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
195,23826889,acm2_human,103,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.14,,=,,7.86,19.055,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
201,10188794,acm2_human,103,D,N,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,2.1,µM,=,,162.0,77.143,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
202,10188794,acm2_human,103,D,N,Aryl-ene-yne oxime-10,ChEMBL Compound ID,CHEMBL160582,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,0.4,µM,=,,17.2,43.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
219,10188794,acm2_human,103,D,N,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,2.8,µM,>,,950.0,339.286,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
238,10188794,acm2_human,103,D,N,Arylacetylene oxime-1,ChEMBL Compound ID,CHEMBL84893,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,14.4,µM,=,,37.2,2.583,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
248,10188794,acm2_human,103,D,N,Arylacetylene oxime-4,ChEMBL Compound ID,CHEMBL155763,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,31.0,µM,=,,50.8,1.639,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
259,20643905,acm2_human,103,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.59,,=,,4.2,2.455,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
267,10188794,acm2_human,103,D,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,118.0,pM,=,,0.0,30.0,Decreased effect,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
271,10188794,acm2_human,103,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,Kapp,Binding - Radioligand competition/displacement,16.1,µM,=,,27.4,1.702,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.300879,DA103N,CHRM2
10,20051519,acm2_human,99,W,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand saturation,6.2,,=,,6.3,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
65,20051519,acm2_human,99,W,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.7,-2.513,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
76,20051519,acm2_human,99,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,4.3,3.981,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
87,20051519,acm2_human,99,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,9.6,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
151,20051519,acm2_human,99,W,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.6,2.512,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
168,10513578,acm2_human,99,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,260.0,pM,=,,270.0,1.038,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
169,20051519,acm2_human,99,W,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,8.8,-1000.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
184,20051519,acm2_human,99,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,4.5,3.981,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
186,20051519,acm2_human,99,W,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,5.2,-1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
236,20051519,acm2_human,99,W,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,7.4,-62.5,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
252,10513578,acm2_human,99,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,180.0,pM,=,,410.0,2.278,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,3.6289,WA99A,CHRM2
11,20051519,acm2_human,104,Y,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,3.0,100.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
19,20051519,acm2_human,104,Y,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.8,2.512,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
22,20051519,acm2_human,104,Y,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,3.0,100.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
44,20051519,acm2_human,104,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,2.5,251.189,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
62,20051519,acm2_human,104,Y,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,5.2,3.162,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
88,20051519,acm2_human,104,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.3,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
110,20051519,acm2_human,104,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,2.5,398.107,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
116,20051519,acm2_human,104,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,8.4,39.811,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
194,20051519,acm2_human,104,Y,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.2,2.512,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.05196,YA104A,CHRM2
12,20051519,acm2_human,423,T,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.6,-1.996,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
13,20051519,acm2_human,423,T,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.2,2.512,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
15,20051519,acm2_human,423,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,5.5,-2.513,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
32,20051519,acm2_human,423,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,4.9,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
37,20051519,acm2_human,423,T,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,6.0,-1.996,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
64,20051519,acm2_human,423,T,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,9.6,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
172,20051519,acm2_human,423,T,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,6.0,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
178,20051519,acm2_human,423,T,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,5.2,-1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
231,20051519,acm2_human,423,T,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,5.1,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.770791,TA423A,CHRM2
14,8190113,acm2_human,22,E,Q,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,132.0,pM,=,,114.0,-1.157,,,,47.2,0.0,,0.0,,P08172,0.414496,EA22Q,CHRM2
134,8190113,acm2_human,22,E,Q,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.8,µM,=,,6.7,-1.015,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.414496,EA22Q,CHRM2
150,8190113,acm2_human,22,E,Q,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.1,µM,=,,10.7,-1.131,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.414496,EA22Q,CHRM2
17,10940778,acm2_human,417,I,V,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,7.6,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.06712,IA417V,CHRM2
24,10940778,acm2_human,401,A,T,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,8.0,-3.165,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.438,AA401T,CHRM2
147,10940778,acm2_human,401,A,T,AF-DX 116,ChEMBL Compound ID,CHEMBL17045,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.3,,=,,7.3,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.438,AA401T,CHRM2
223,10940778,acm2_human,401,A,T,4-DAMP,ChEMBL Compound ID,CHEMBL76897,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.5,,=,,8.6,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.438,AA401T,CHRM2
262,10940778,acm2_human,401,A,T,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,6.6,,=,,7.3,-5.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.438,AA401T,CHRM2
25,20643905,acm2_human,97,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,,=,,8.86,1.778,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
51,20643905,acm2_human,97,D,N,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,1.29,%,=,,3.0,-2.326,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
85,20643905,acm2_human,97,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.68,,=,,3.65,107.152,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
136,20643905,acm2_human,97,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.59,,=,,4.63,-1.096,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
141,8190113,acm2_human,97,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.1,µM,=,,11.3,-1.071,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
197,8190113,acm2_human,97,D,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,132.0,pM,=,,197.0,1.492,,,,104.4,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
205,8190113,acm2_human,97,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.8,µM,=,,4.7,-1.447,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.417162,DA97N,CHRM2
28,8190113,acm2_human,69,D,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,132.0,pM,=,,58.0,-2.278,,,,13.2,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
45,23826889,acm2_human,69,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.14,,=,,9.35,-1.621,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
82,23826889,acm2_human,69,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.57,,=,,5.15,-3.802,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
103,8190113,acm2_human,69,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.8,µM,=,,21.2,3.118,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
196,23826889,acm2_human,69,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.64,,=,,5.75,-1.289,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
211,8190113,acm2_human,69,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.1,µM,=,,30.4,2.512,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.0380716,DA69N,CHRM2
29,20051519,acm2_human,403,Y,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,6.3,-3.984,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
34,20051519,acm2_human,403,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,3.0,79.433,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
52,20051519,acm2_human,403,Y,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.5,1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
74,20051519,acm2_human,403,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,3.1,100.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
120,20051519,acm2_human,403,Y,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.9,1.995,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
171,20051519,acm2_human,403,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,9.5,3.162,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
175,20051519,acm2_human,403,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.5,-1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
191,20051519,acm2_human,403,Y,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,3.7,19.953,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
230,20051519,acm2_human,403,Y,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,3.4,39.811,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.68745,YA403A,CHRM2
31,20051519,acm2_human,177,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,5.0,1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
115,20051519,acm2_human,177,Y,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.8,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
126,20051519,acm2_human,177,Y,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.8,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
140,18723515,acm2_human,177,Y,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.17,,=,,4.9,18.621,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
146,20051519,acm2_human,177,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.4,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
162,20051519,acm2_human,177,Y,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,6.2,-3.165,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
163,20051519,acm2_human,177,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,4.4,3.162,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
188,20051519,acm2_human,177,Y,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,6.2,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
218,20051519,acm2_human,177,Y,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.5,1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
222,20051519,acm2_human,177,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,10.0,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,1.85727,YA177A,CHRM2
41,8190113,acm2_human,382,E,Q,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,132.0,pM,=,,137.0,1.038,,,,62.9,0.0,,0.0,,P08172,-0.255,EA382Q,CHRM2
241,8190113,acm2_human,382,E,Q,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.1,µM,=,,11.9,-1.017,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.255,EA382Q,CHRM2
255,8190113,acm2_human,382,E,Q,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.8,µM,=,,6.2,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-0.255,EA382Q,CHRM2
42,20643905,acm2_human,103,D,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,7.79,%,=,,70.0,-9.009,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.188355,DA103A,CHRM2
192,20643905,acm2_human,103,D,A,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,1.29,%,=,,15.0,-11.628,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,0.188355,DA103A,CHRM2
46,15937215,acm2_human,419,N,V,W84,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.7,,=,,8.1,-2.513,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.0115555,NA419V,CHRM2
67,10940778,acm2_human,419,N,V,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,7.6,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.0115555,NA419V,CHRM2
84,15937215,acm2_human,419,N,V,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.0,,=,,7.2,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.0115555,NA419V,CHRM2
49,20051519,acm2_human,107,S,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,3.6,19.953,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
60,20051519,acm2_human,107,S,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.8,1.585,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
69,20051519,acm2_human,107,S,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.6,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
79,20051519,acm2_human,107,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,3.8,19.953,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
121,20051519,acm2_human,107,S,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.4,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
148,20051519,acm2_human,107,S,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.7,3.162,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
207,20051519,acm2_human,107,S,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.3,5.012,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
234,20051519,acm2_human,107,S,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,9.7,1.995,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
257,20051519,acm2_human,107,S,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,5.7,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.477639,SA107A,CHRM2
50,10513578,acm2_human,187,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,260.0,pM,=,,730.0,2.808,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.264817,TA187A,CHRM2
66,10513578,acm2_human,187,T,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,180.0,pM,=,,170.0,-1.059,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.264817,TA187A,CHRM2
70,9063897,acm2_human,390,L,S,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,232.0,pM,=,,704.0,3.034,,,[3H]N-methyl scopolamine (radioligand),122.1,0.0,,0.0,,P08172,0.718259,LA390S,CHRM2
200,9063897,acm2_human,390,L,S,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.6,µM,=,,10.9,1.028,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.718259,LA390S,CHRM2
71,8190113,acm2_human,120,D,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,132.0,pM,=,,92.0,-1.435,,,,10.1,0.0,,0.0,,P08172,1.64676,DA120N,CHRM2
149,8190113,acm2_human,120,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.1,µM,=,,9.7,-1.247,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,1.64676,DA120N,CHRM2
199,8190113,acm2_human,120,D,N,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.8,µM,=,,6.2,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08172,1.64676,DA120N,CHRM2
72,15937215,acm2_human,175,E,Q,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.0,,=,,6.7,1.995,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.099348,EA175Q,CHRM2
102,15937215,acm2_human,175,E,Q,W84,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.7,,=,,7.4,1.995,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.099348,EA175Q,CHRM2
73,10940778,acm2_human,410,N,S,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,7.7,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-1.10712,NA410S,CHRM2
80,10513578,acm2_human,190,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,260.0,pM,=,,900.0,3.462,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.0698,TA190A,CHRM2
138,10513578,acm2_human,190,T,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,180.0,pM,=,,800.0,4.444,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,-0.0698,TA190A,CHRM2
91,20051519,acm2_human,100,L,A,77-LH-28-1,SMILES,O=C1N(CCCN2CCC(CCCC)CC2)C3=C(C=CC=C3)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,5.6,1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
123,20051519,acm2_human,100,L,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,3.6,25.119,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
132,20051519,acm2_human,100,L,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.6,,=,,5.7,-1.259,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
135,20051519,acm2_human,100,L,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.9,,=,,3.3,39.811,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
224,20051519,acm2_human,100,L,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,4.0,10.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
237,20051519,acm2_human,100,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,8.7,19.953,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
239,20051519,acm2_human,100,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.1,,=,,3.3,63.096,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
243,20051519,acm2_human,100,L,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.3,,=,,4.3,1.0,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
246,20051519,acm2_human,100,L,A,NDMC,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,5.0,15.849,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,2.52397,LA100A,CHRM2
97,9063897,acm2_human,385,V,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,232.0,pM,=,,428.0,1.845,,,[3H]N-methyl scopolamine (radioligand),127.5,0.0,,0.0,,P08172,-1.25985,VA385A,CHRM2
220,9063897,acm2_human,385,V,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.6,µM,=,,18.7,1.764,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-1.25985,VA385A,CHRM2
99,10570052,acm2_human,419,N,D,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand kinetics (association/dissociation),6.8,,=,,7.4,-3.984,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-1.3812,NA419D,CHRM2
100,9063897,acm2_human,389,I,L,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,232.0,pM,=,,535.0,2.306,,,[3H]N-methyl scopolamine (radioligand),125.3,0.0,,0.0,,P08172,-0.655851,IA389L,CHRM2
226,9063897,acm2_human,389,I,L,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.6,µM,=,,66.1,6.236,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.655851,IA389L,CHRM2
122,15937215,acm2_human,172,E,P,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.0,,=,,6.6,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-1.67288,EA172P,CHRM2
249,15937215,acm2_human,172,E,P,W84,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pKapp,Binding - Radioligand competition/displacement,7.7,,=,,7.3,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-1.67288,EA172P,CHRM2
124,9063897,acm2_human,386,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.6,µM,=,,5.7,-1.859,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,0.425383,TA386A,CHRM2
227,9063897,acm2_human,386,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,232.0,pM,=,,425.0,1.832,,,[3H]N-methyl scopolamine (radioligand),106.4,0.0,,0.0,,P08172,0.425383,TA386A,CHRM2
131,10513578,acm2_human,155,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,180.0,pM,=,,3000.0,16.667,,,[3H]QNB (radioligand),0.0,0.0,,0.0,,P08172,4.9205,WA155A,CHRM2
159,9143344,acm2_human,457,C,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.0,,=,,4.21,-1.621,,,[3H]QNB (radioligand),102.6,0.0,,0.0,,P08172,0.579986,CA457A,CHRM2
258,9143344,acm2_human,457,C,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.73,,=,,6.88,-1.412,,,[3H]QNB (radioligand),102.6,0.0,,0.0,,P08172,0.579986,CA457A,CHRM2
247,10940778,acm2_human,405,V,I,UH-AH 37,SMILES,O=C1C2=CC=CC=C2N(C(CC3CCN(C)CC3)=O)C4=C(Cl)C=CC=C4N1,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,7.5,,=,,7.4,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P08172,-0.719056,VA405I,CHRM2
265,20643905,acm2_human,76,S,A,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,1.29,%,=,,1.29,1.0,,,N-methyl scopolamine,0.0,0.0,,0.0,,P08172,-1.51433,SA76A,CHRM2
0,21948388,cxcr2_human,280,Q,R,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.13,1.862,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.624439,QA280R,CXCR2
64,21948388,cxcr2_human,280,Q,R,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,7.1,1.202,,,radioligand: [125I]-CXCL13,0.0,0.0,,0.0,,P25025,-0.624439,QA280R,CXCR2
98,21948388,cxcr2_human,280,Q,R,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.29,2.455,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.624439,QA280R,CXCR2
1,21948388,cxcr2_human,107,S,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.09,2.042,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.335191,SA107A,CXCR2
83,21948388,cxcr2_human,107,S,A,SB-265611,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.1,3.802,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.335191,SA107A,CXCR2
99,21948388,cxcr2_human,107,S,A,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.73,2.818,,,radioligand: [125I]-CXCL22,0.0,0.0,,0.0,,P25025,-0.335191,SA107A,CXCR2
3,21948388,cxcr2_human,287,E,Q,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.99,1.549,,,radioligand: [125I]-CXCL16,0.0,0.0,,0.0,,P25025,1.20642,EA287Q,CXCR2
116,21948388,cxcr2_human,287,E,Q,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.39,1.95,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,1.20642,EA287Q,CXCR2
124,21948388,cxcr2_human,287,E,Q,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.11,1.95,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,1.20642,EA287Q,CXCR2
4,21948388,cxcr2_human,271,L,A,SB-265615,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,6.76,8.318,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,1.36274,LA271A,CXCR2
9,21948388,cxcr2_human,271,L,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.18,1.66,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,1.36274,LA271A,CXCR2
70,21948388,cxcr2_human,271,L,A,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.22,9.12,,,radioligand: [125I]-CXCL26,0.0,0.0,,0.0,,P25025,1.36274,LA271A,CXCR2
5,12628493,cxcr2_human,304,I,F,SB-225002,ChEMBL ID,CHEMBL239767,Antagonist (neutral/silent),EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,10.9,9.083,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,1.72933,IA304F,CXCR2
71,12628493,cxcr2_human,304,I,F,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,16.3,13.583,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,1.72933,IA304F,CXCR2
94,12628493,cxcr2_human,304,I,F,GROA_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,0.2,-5.988,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,1.72933,IA304F,CXCR2
6,20233217,cxcr2_human,83,T,L,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.14,2.138,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
34,20233217,cxcr2_human,83,T,L,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,0.93,-2.551,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
39,20233217,cxcr2_human,83,T,L,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,7.88,-1.779,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
56,20233217,cxcr2_human,83,T,L,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,1.89,-1.111,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
112,20233217,cxcr2_human,83,T,L,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,2.47,41.864,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
126,20233217,cxcr2_human,83,T,L,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.27,2.015,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
127,20233217,cxcr2_human,83,T,L,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,8.31,1.0,,,,0.0,0.0,,0.0,,P25025,-1.32635,TA83L,CXCR2
7,21948388,cxcr2_human,268,N,H,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.14,3.467,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.227717,NA268H,CXCR2
60,21948388,cxcr2_human,268,N,H,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,<,,5.0,151.356,,,radioligand: [125I]-CXCL10,0.0,0.0,,0.0,,P25025,-0.227717,NA268H,CXCR2
133,21948388,cxcr2_human,268,N,H,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.18,1.66,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.227717,NA268H,CXCR2
10,12628493,cxcr2_human,203,N,D,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,0.1,-12.048,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,-0.041378,NA203D,CXCR2
16,12628493,cxcr2_human,203,N,D,GROA_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,0.3,-4.0,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,-0.041378,NA203D,CXCR2
142,12628493,cxcr2_human,203,N,D,SB-225002,ChEMBL ID,CHEMBL239767,Antagonist (neutral/silent),EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,24.0,20.0,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,-0.041378,NA203D,CXCR2
11,20233217,cxcr2_human,249,A,L,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,16.52,280.0,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
31,20233217,cxcr2_human,249,A,L,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,3.54,1.686,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
35,20233217,cxcr2_human,249,A,L,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.321,2.396,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
51,20233217,cxcr2_human,249,A,L,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,6.54,12.303,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
77,20233217,cxcr2_human,249,A,L,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.05,2.63,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
114,20233217,cxcr2_human,249,A,L,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,33.64,14.194,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
143,20233217,cxcr2_human,249,A,L,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,8.44,-1.35,,,,0.0,0.0,,0.0,,P25025,-1.45502,AA249L,CXCR2
12,20233217,cxcr2_human,84,D,N,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,6.63,10.0,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
21,20233217,cxcr2_human,84,D,N,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.49,-1.047,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
36,20233217,cxcr2_human,84,D,N,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.211,1.575,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
40,20233217,cxcr2_human,84,D,N,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,4.1,69.492,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
104,20233217,cxcr2_human,84,D,N,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,10.79,4.553,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
140,20233217,cxcr2_human,84,D,N,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,6.79,33.113,,,,0.0,0.0,,0.0,,P25025,1.19719,DA84N,CXCR2
15,12628493,cxcr2_human,312,L,I,GROA_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,0.8,-1.499,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,1.03251,LA312I,CXCR2
69,12628493,cxcr2_human,312,L,I,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Binding - Radioligand competition/displacement,1.2,nM,=,,5.4,4.5,,,125I-CXCL8,90.0,0.0,,0.0,,P25025,1.03251,LA312I,CXCR2
17,21948388,cxcr2_human,300,E,Q,SB-265617,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.26,2.63,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
38,20233217,cxcr2_human,300,E,Q,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.032,-1.845,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
41,20233217,cxcr2_human,300,E,Q,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,8.32,-1.024,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
46,20233217,cxcr2_human,300,E,Q,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.238,1.776,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
52,21948388,cxcr2_human,300,E,Q,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.69,3.09,,,radioligand: [125I]-CXCL28,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
59,20233217,cxcr2_human,300,E,Q,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.14,2.138,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
63,20233217,cxcr2_human,300,E,Q,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,3.43,1.447,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
108,20233217,cxcr2_human,300,E,Q,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,7.64,-1.024,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
129,21948388,cxcr2_human,300,E,Q,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.0,2.512,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
137,20233217,cxcr2_human,300,E,Q,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,2.88,1.371,,,,0.0,0.0,,0.0,,P25025,-0.380167,EA300Q,CXCR2
18,21948388,cxcr2_human,300,E,S,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.04,2.291,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.043295,EA300S,CXCR2
20,21948388,cxcr2_human,300,E,S,SB-265616,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.21,2.951,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.043295,EA300S,CXCR2
45,21948388,cxcr2_human,300,E,S,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.79,2.455,,,radioligand: [125I]-CXCL27,0.0,0.0,,0.0,,P25025,0.043295,EA300S,CXCR2
19,21948388,cxcr2_human,130,F,A,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,<,,4.0,1513.561,,,radioligand: [125I]-CXCL23,0.0,0.0,,0.0,,P25025,3.77637,FA130A,CXCR2
115,21948388,cxcr2_human,130,F,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.65,-1.779,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,3.77637,FA130A,CXCR2
117,21948388,cxcr2_human,130,F,A,SB-265612,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.55,1.349,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,3.77637,FA130A,CXCR2
22,20233217,cxcr2_human,147,A,L,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.193,1.44,,,,0.0,0.0,,0.0,,P25025,-0.592495,AA147L,CXCR2
23,20233217,cxcr2_human,147,A,L,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.194,3.288,,,,0.0,0.0,,0.0,,P25025,-0.592495,AA147L,CXCR2
24,20233217,cxcr2_human,147,A,L,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,1.85,-1.28,,,,0.0,0.0,,0.0,,P25025,-0.592495,AA147L,CXCR2
88,20233217,cxcr2_human,147,A,L,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,3.24,1.543,,,,0.0,0.0,,0.0,,P25025,-0.592495,AA147L,CXCR2
25,20233217,cxcr2_human,83,T,A,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,7.22,2.57,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
48,20233217,cxcr2_human,83,T,A,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,11.65,5.548,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
57,20233217,cxcr2_human,83,T,A,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,3.54,1.494,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
89,20233217,cxcr2_human,83,T,A,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,7.39,8.318,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
118,20233217,cxcr2_human,83,T,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.232,1.731,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
123,20233217,cxcr2_human,83,T,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.39,1.202,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
136,20233217,cxcr2_human,83,T,A,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.694,11.763,,,,0.0,0.0,,0.0,,P25025,0.782051,TA83A,CXCR2
27,20233217,cxcr2_human,321,F,A,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,6.29,21.878,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
33,20233217,cxcr2_human,321,F,A,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,7.87,2.754,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
76,20233217,cxcr2_human,321,F,A,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,5.41,2.283,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
91,20233217,cxcr2_human,321,F,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.91,-2.755,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
102,20233217,cxcr2_human,321,F,A,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,3.96,1.886,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
105,20233217,cxcr2_human,321,F,A,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.109,1.847,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
122,20233217,cxcr2_human,321,F,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.211,1.575,,,,0.0,0.0,,0.0,,P25025,4.20011,FA321A,CXCR2
30,20233217,cxcr2_human,314,Y,A,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,18.33,8.729,,,,0.0,0.0,,0.0,,P25025,2.57924,YA314A,CXCR2
42,20233217,cxcr2_human,314,Y,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.289,2.157,,,,0.0,0.0,,0.0,,P25025,2.57924,YA314A,CXCR2
85,20233217,cxcr2_human,314,Y,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.23,1.738,,,,0.0,0.0,,0.0,,P25025,2.57924,YA314A,CXCR2
135,20233217,cxcr2_human,314,Y,A,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.415,7.034,,,,0.0,0.0,,0.0,,P25025,2.57924,YA314A,CXCR2
32,20233217,cxcr2_human,320,K,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.21,1.82,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
47,20233217,cxcr2_human,320,K,A,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.358,2.672,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
61,20233217,cxcr2_human,320,K,A,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,6.54,12.303,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
67,20233217,cxcr2_human,320,K,A,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,38.77,16.359,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
92,20233217,cxcr2_human,320,K,A,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,9.34,4.448,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
106,20233217,cxcr2_human,320,K,A,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,1.82,30.847,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
141,20233217,cxcr2_human,320,K,A,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,7.3,10.233,,,,0.0,0.0,,0.0,,P25025,-0.283395,KA320A,CXCR2
37,20233217,cxcr2_human,143,D,R,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pIC50,Binding - Other,8.31,,=,,7.16,14.125,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
55,20233217,cxcr2_human,143,D,R,Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),pIC50,Binding - Other,7.63,,=,,7.39,1.738,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
81,20233217,cxcr2_human,143,D,R,[3H]Pteridone-1,SMILES,O=C1C=NC2=C(N=C(SCC3=CC=CC(F)=C3F)N=C2N[C@H](C)CO)N1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.37,nM,=,,2.56,1.08,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
82,20233217,cxcr2_human,143,D,R,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,K(d),Binding - Radioligand saturation,0.134,nM,=,,0.149,1.112,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
93,20233217,cxcr2_human,143,D,R,[3H]Sch527123,SMILES,OC1=C(NC2=C(N[C@@H](C3=CC=C(C)O3)CC)C(C2=O)=O)C=CC=C1C(N(C)C)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,0.059,nM,=,,0.804,13.627,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
101,20233217,cxcr2_human,143,D,R,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pEC50,Functional - Other,8.47,,=,,8.13,2.188,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
138,20233217,cxcr2_human,143,D,R,[3H]SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,2.1,nM,=,,25.38,12.086,,,,0.0,0.0,,0.0,,P25025,2.09587,DA143R,CXCR2
49,21948388,cxcr2_human,216,Q,E,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.01,2.455,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.573692,QA216E,CXCR2
68,21948388,cxcr2_human,216,Q,E,SB-265613,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.56,1.318,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.573692,QA216E,CXCR2
87,21948388,cxcr2_human,216,Q,E,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,6.47,5.129,,,radioligand: [125I]-CXCL24,0.0,0.0,,0.0,,P25025,0.573692,QA216E,CXCR2
66,21948388,cxcr2_human,217,S,T,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.2,1.585,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.0970164,SA217T,CXCR2
119,21948388,cxcr2_human,217,S,T,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,5.77,25.704,,,radioligand: [125I]-CXCL9,0.0,0.0,,0.0,,P25025,0.0970164,SA217T,CXCR2
134,21948388,cxcr2_human,217,S,T,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.92,-1.739,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,0.0970164,SA217T,CXCR2
73,21948388,cxcr2_human,294,R,Q,IP8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,pK(d),Binding - Radioligand kinetics (association/dissociation),9.4,,=,,9.15,1.778,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.0557436,RA294Q,CXCR2
97,21948388,cxcr2_human,294,R,Q,SB-265610,SMILES,N#CC1=C(N=NN2)C2=C(NC(NC3=C(Br)C=CC=C3)=O)C=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.24,2.754,,,125I-CXCL8,0.0,0.0,,0.0,,P25025,-0.0557436,RA294Q,CXCR2
107,21948388,cxcr2_human,294,R,Q,imidazolylpyrimidine 1,SMILES,CCCCCCCCSC1=CC(N[C@@H](CCCN2CCCOCC)C2=O)=NC(N3C=NC=C3)=N1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.18,,=,,7.04,1.38,,,radioligand: [125I]-CXCL17,0.0,0.0,,0.0,,P25025,-0.0557436,RA294Q,CXCR2
0,26958838,acm4_human,172,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.99,-1.259,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
42,26958838,acm4_human,172,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.02,3.09,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
56,26958838,acm4_human,172,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.99,-1.259,,,[3H]QNB (radioligand),167.8,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
129,26958838,acm4_human,172,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.02,3.09,,,[3H]QNB (radioligand),167.8,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
197,26958838,acm4_human,172,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.4,1.479,,,[3H]QNB (radioligand),167.8,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
223,26958838,acm4_human,172,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.4,1.479,,,,167.8,0.0,,0.0,,P08173,1.49933,QA172A,CHRM4
1,21300722,acm4_human,116,S,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,10.51,-1.148,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
91,21300722,acm4_human,116,S,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,5.09,-1.202,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
157,21300722,acm4_human,116,S,A,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,5.7,-1.318,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
162,26958838,acm4_human,116,S,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.12,1.23,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
164,21300722,acm4_human,116,S,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.12,1.23,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
190,26958838,acm4_human,116,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.61,19.055,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
195,21300722,acm4_human,116,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.61,19.055,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
229,21300722,acm4_human,116,S,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.07,-1.412,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
295,21300722,acm4_human,116,S,A,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.63,1.072,,,[3H]QNB (radioligand),99.4,0.0,,0.0,,P08173,-0.315007,SA116A,CHRM4
2,26958838,acm4_human,164,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.95,3.631,,,[3H]QNB,0.0,0.0,,0.0,,P08173,4.55551,WA164A,CHRM4
181,26958838,acm4_human,164,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.15,-1.818,,,[3H]QNB (radioligand),50.0,0.0,,0.0,,P08173,4.55551,WA164A,CHRM4
268,26958838,acm4_human,164,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.95,3.631,,,[3H]QNB (radioligand),50.0,0.0,,0.0,,P08173,4.55551,WA164A,CHRM4
292,26958838,acm4_human,164,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.15,-1.818,,,[3H]QNB,0.0,0.0,,0.0,,P08173,4.55551,WA164A,CHRM4
3,26958838,acm4_human,85,S,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.52,1.122,,,[3H]QNB (radioligand),69.5,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
6,26958838,acm4_human,85,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.09,2.63,,,[3H]QNB (radioligand),69.5,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
27,26958838,acm4_human,85,S,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.44,-3.546,,,[3H]QNB (radioligand),69.5,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
168,26958838,acm4_human,85,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.09,2.63,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
186,26958838,acm4_human,85,S,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.44,-3.546,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
289,26958838,acm4_human,85,S,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.52,1.122,,,,69.5,0.0,,0.0,,P08173,-2.6035,SA85A,CHRM4
4,26958838,acm4_human,190,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,9.88,4.898,,,,113.6,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
13,26958838,acm4_human,190,L,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.92,-1.072,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
81,26958838,acm4_human,190,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.2,2.042,,,[3H]QNB (radioligand),113.6,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
105,26958838,acm4_human,190,L,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.92,-1.072,,,[3H]QNB (radioligand),113.6,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
216,26958838,acm4_human,190,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.2,2.042,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
232,26958838,acm4_human,190,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,9.88,4.898,,,[3H]QNB (radioligand),113.6,0.0,,0.0,,P08173,3.32366,LA190A,CHRM4
5,20406819,acm4_human,93,I,T,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,5.23,-2.342,,,[3H]QNB (radioligand),121.7,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
74,20406819,acm4_human,93,I,T,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.76,-2.688,,,[3H]QNB (radioligand),121.7,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
100,26958838,acm4_human,93,I,T,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.36,-1.412,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
140,26958838,acm4_human,93,I,T,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.97,-1.698,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
142,20406819,acm4_human,93,I,T,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.97,-1.698,,,[3H]QNB (radioligand),121.7,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
154,20406819,acm4_human,93,I,T,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.36,-1.412,,,[3H]QNB (radioligand),121.7,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
279,20406819,acm4_human,93,I,T,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,7.22,-3.546,,,[3H]QNB (radioligand),121.7,0.0,,0.0,,P08173,1.2648,IA93T,CHRM4
7,26958838,acm4_human,101,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.37,1.38,,,[3H]QNB (radioligand),57.6,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
77,26958838,acm4_human,101,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.37,1.38,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
148,26958838,acm4_human,101,G,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.46,1.288,,,[3H]QNB (radioligand),57.6,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
158,26958838,acm4_human,101,G,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.03,-1.381,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
173,26958838,acm4_human,101,G,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.46,1.288,,,,57.6,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
264,26958838,acm4_human,101,G,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.03,-1.381,,,[3H]QNB (radioligand),57.6,0.0,,0.0,,P08173,3.5866,GA101A,CHRM4
8,26958838,acm4_human,189,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.44,1.349,,,[3H]QNB (radioligand),84.7,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
18,26958838,acm4_human,189,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.65,-1.381,,,[3H]QNB (radioligand),84.7,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
97,26958838,acm4_human,189,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.09,-1.585,,,[3H]QNB (radioligand),84.7,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
131,26958838,acm4_human,189,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.65,-1.381,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
215,26958838,acm4_human,189,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.09,-1.585,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
284,26958838,acm4_human,189,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.44,1.349,,,,84.7,0.0,,0.0,,P08173,3.02715,FA189A,CHRM4
9,26958838,acm4_human,188,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.6,-1.23,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
80,26958838,acm4_human,188,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.3,1.862,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
96,26958838,acm4_human,188,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.94,-1.122,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
115,26958838,acm4_human,188,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.3,1.862,,,,35.6,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
247,26958838,acm4_human,188,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.6,-1.23,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
281,26958838,acm4_human,188,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.94,-1.122,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.138488,QA188A,CHRM4
10,21300722,acm4_human,112,D,N,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,<,,3.0,102.329,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
65,26958838,acm4_human,112,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.79,-3.802,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
82,26958838,acm4_human,112,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,<,,2.0,776.247,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
104,23826889,acm4_human,112,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.05,,=,,3.84,16.218,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
108,21300722,acm4_human,112,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.79,-3.802,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
122,23826889,acm4_human,112,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.81,,=,,2.06,562.341,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
182,21300722,acm4_human,112,D,N,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,<,,4.0,457.088,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
191,23826889,acm4_human,112,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.62,,=,,8.03,38.905,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
207,21300722,acm4_human,112,D,N,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,8.44,102.329,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
230,21300722,acm4_human,112,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,<,,2.0,776.247,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
278,21300722,acm4_human,112,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,<,,3.0,83.176,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
288,21300722,acm4_human,112,D,N,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,3.64,87.096,,,[3H]QNB (radioligand),115.1,0.0,,0.0,,P08173,1.97316,DA112N,CHRM4
11,26958838,acm4_human,98,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,9.54,10.715,,,,50.8,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
32,26958838,acm4_human,98,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.39,3.162,,,[3H]QNB (radioligand),50.8,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
150,26958838,acm4_human,98,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.39,3.162,,,[3H]QNB,0.0,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
192,26958838,acm4_human,98,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.65,7.244,,,[3H]QNB (radioligand),50.8,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
210,26958838,acm4_human,98,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,9.54,10.715,,,[3H]QNB (radioligand),50.8,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
269,26958838,acm4_human,98,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.65,7.244,,,[3H]QNB,0.0,0.0,,0.0,,P08173,5.38106,WA98A,CHRM4
12,26958838,acm4_human,440,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.01,3.631,,,,61.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
48,26958838,acm4_human,440,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.29,1.66,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
116,26958838,acm4_human,440,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.94,-1.122,,,[3H]QNB (radioligand),61.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
156,26958838,acm4_human,440,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.94,-1.122,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
206,26958838,acm4_human,440,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.29,1.66,,,[3H]QNB (radioligand),61.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
293,26958838,acm4_human,440,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.01,3.631,,,[3H]QNB (radioligand),61.0,0.0,,0.0,,P08173,3.27157,WA440A,CHRM4
14,26958838,acm4_human,173,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.39,1.514,,,[3H]QNB (radioligand),30.5,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
15,26958838,acm4_human,173,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.78,1.288,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
35,26958838,acm4_human,173,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.39,1.514,,,,30.5,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
64,26958838,acm4_human,173,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.09,2.63,,,[3H]QNB (radioligand),30.5,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
234,26958838,acm4_human,173,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.78,1.288,,,[3H]QNB (radioligand),30.5,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
238,26958838,acm4_human,173,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.09,2.63,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.796088,FA173A,CHRM4
16,26958838,acm4_human,170,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.77,-1.818,,,[3H]QNB (radioligand),93.2,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
45,26958838,acm4_human,170,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.61,-1.096,,,[3H]QNB (radioligand),93.2,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
76,26958838,acm4_human,170,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.77,-1.818,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
103,26958838,acm4_human,170,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.53,2.291,,,[3H]QNB (radioligand),93.2,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
124,26958838,acm4_human,170,F,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.53,2.291,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
248,26958838,acm4_human,170,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.61,-1.096,,,,93.2,0.0,,0.0,,P08173,1.56178,FA170A,CHRM4
17,26958838,acm4_human,171,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.91,3.981,,,[3H]QNB (radioligand),71.2,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
37,26958838,acm4_human,171,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.56,2.138,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
51,26958838,acm4_human,171,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.45,1.318,,,,71.2,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
70,26958838,acm4_human,171,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.56,2.138,,,[3H]QNB (radioligand),71.2,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
112,26958838,acm4_human,171,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.45,1.318,,,[3H]QNB (radioligand),71.2,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
187,26958838,acm4_human,171,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.91,3.981,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.825378,WA171A,CHRM4
19,26958838,acm4_human,184,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.36,-2.95,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
40,26958838,acm4_human,184,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.65,-1.202,,,,59.3,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
72,26958838,acm4_human,184,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.25,1.82,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
136,26958838,acm4_human,184,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.36,-2.95,,,[3H]QNB (radioligand),59.3,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
138,26958838,acm4_human,184,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.65,-1.202,,,[3H]QNB (radioligand),59.3,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
214,26958838,acm4_human,184,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.25,1.82,,,[3H]QNB (radioligand),59.3,0.0,,0.0,,P08173,0.298966,QA184A,CHRM4
20,20406819,acm4_human,428,S,P,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.73,-1.148,,,[3H]QNB (radioligand),47.8,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
60,26958838,acm4_human,428,S,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,5.14,-2.513,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
200,20406819,acm4_human,428,S,P,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.17,1.096,,,[3H]QNB (radioligand),47.8,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
201,26958838,acm4_human,428,S,P,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.17,1.096,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
218,20406819,acm4_human,428,S,P,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.77,-2.755,,,[3H]QNB (radioligand),47.8,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
253,20406819,acm4_human,428,S,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,5.14,-2.513,,,[3H]QNB (radioligand),47.8,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
263,20406819,acm4_human,428,S,P,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,5.31,-2.817,,,[3H]QNB (radioligand),47.8,0.0,,0.0,,P08173,-0.100627,SA428P,CHRM4
21,26958838,acm4_human,113,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.97,-1.202,,,[3H]QNB (radioligand),74.6,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
98,26958838,acm4_human,113,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,8.76,64.565,,,[3H]QNB (radioligand),74.6,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
101,26958838,acm4_human,113,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,2.98,33.884,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
135,26958838,acm4_human,113,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.97,-1.202,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
251,26958838,acm4_human,113,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,2.98,33.884,,,[3H]QNB (radioligand),74.6,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
273,26958838,acm4_human,113,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,8.76,64.565,,,,74.6,0.0,,0.0,,P08173,1.87441,YA113A,CHRM4
22,20406819,acm4_human,442,C,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.35,-1.381,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
53,20406819,acm4_human,442,C,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.01,2.089,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
95,26958838,acm4_human,442,C,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.35,-1.381,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
121,20406819,acm4_human,442,C,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.33,2.188,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
166,20406819,acm4_human,442,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.04,5.012,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
274,26958838,acm4_human,442,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.04,5.012,,,[3H]QNB,0.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
277,20406819,acm4_human,442,C,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,4.87,-1.024,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,-0.31303,CA442A,CHRM4
23,26958838,acm4_human,94,I,V,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.71,1.072,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
43,20406819,acm4_human,94,I,V,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.17,1.096,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
69,20406819,acm4_human,94,I,V,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.71,1.072,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
151,20406819,acm4_human,94,I,V,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.47,1.585,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
205,20406819,acm4_human,94,I,V,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,4.85,1.023,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
242,26958838,acm4_human,94,I,V,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.17,1.096,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
246,20406819,acm4_human,94,I,V,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.32,1.023,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,1.36457,IA94V,CHRM4
24,26958838,acm4_human,108,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.01,7.586,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
41,21300722,acm4_human,108,W,A,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,7.08,-2.632,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
61,21300722,acm4_human,108,W,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.88,1.096,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
63,21300722,acm4_human,108,W,A,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,4.83,5.623,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
118,21300722,acm4_human,108,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,4.24,9.333,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
175,21300722,acm4_human,108,W,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.59,2.63,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
176,21300722,acm4_human,108,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,9.77,4.786,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
262,21300722,acm4_human,108,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.01,7.586,,,[3H]QNB (radioligand),69.8,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
290,26958838,acm4_human,108,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,4.24,9.333,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.7095,WA108A,CHRM4
25,26958838,acm4_human,413,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.51,2.399,,,[3H]QNB (radioligand),55.9,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
163,26958838,acm4_human,413,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,8.4,147.911,,,,55.9,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
189,26958838,acm4_human,413,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.47,10.965,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
219,26958838,acm4_human,413,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,8.4,147.911,,,[3H]QNB (radioligand),55.9,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
250,26958838,acm4_human,413,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.47,10.965,,,[3H]QNB (radioligand),55.9,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
267,26958838,acm4_human,413,W,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.51,2.399,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.27222,WA413A,CHRM4
28,21300722,acm4_human,120,V,A,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.07,3.89,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
52,21300722,acm4_human,120,V,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.63,-5.495,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
71,21300722,acm4_human,120,V,A,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,5.27,2.042,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
83,21300722,acm4_human,120,V,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.41,-1.585,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
99,26958838,acm4_human,120,V,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.41,-1.585,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
139,21300722,acm4_human,120,V,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.3,-2.398,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
178,21300722,acm4_human,120,V,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,5.95,-8.696,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
252,26958838,acm4_human,120,V,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.63,-5.495,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
294,21300722,acm4_human,120,V,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,9.41,10.965,,,[3H]QNB (radioligand),166.0,0.0,,0.0,,P08173,1.85542,VA120A,CHRM4
29,23826889,acm4_human,78,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.81,,=,,5.77,-9.091,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,0.935844,DA78N,CHRM4
92,23826889,acm4_human,78,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.62,,=,,10.05,-2.688,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,0.935844,DA78N,CHRM4
172,23826889,acm4_human,78,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.05,,=,,6.16,-12.821,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P08173,0.935844,DA78N,CHRM4
30,20406819,acm4_human,432,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,5.15,-1.949,,,[3H]QNB (radioligand),56.5,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
130,20406819,acm4_human,432,D,N,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.72,-1.122,,,[3H]QNB (radioligand),56.5,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
141,20406819,acm4_human,432,D,N,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.6,-1.862,,,[3H]QNB (radioligand),56.5,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
167,26958838,acm4_human,432,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.21,1.0,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
198,20406819,acm4_human,432,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,5.19,-2.817,,,[3H]QNB (radioligand),56.5,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
199,26958838,acm4_human,432,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,5.19,-2.817,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
204,20406819,acm4_human,432,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.21,1.0,,,[3H]QNB (radioligand),56.5,0.0,,0.0,,P08173,1.0536,DA432N,CHRM4
31,26958838,acm4_human,97,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.25,4.365,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.668023,YA97A,CHRM4
111,26958838,acm4_human,97,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.25,4.365,,,[3H]QNB (radioligand),86.4,0.0,,0.0,,P08173,0.668023,YA97A,CHRM4
123,26958838,acm4_human,97,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.49,1.202,,,[3H]QNB (radioligand),86.4,0.0,,0.0,,P08173,0.668023,YA97A,CHRM4
153,26958838,acm4_human,97,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.49,1.202,,,,86.4,0.0,,0.0,,P08173,0.668023,YA97A,CHRM4
240,26958838,acm4_human,97,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.69,-1.513,,,[3H]QNB (radioligand),86.4,0.0,,0.0,,P08173,0.668023,YA97A,CHRM4
34,26958838,acm4_human,106,D,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.29,-1.202,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
39,26958838,acm4_human,106,D,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.95,8.71,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
93,21300722,acm4_human,106,D,A,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.67,-1.024,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
94,21300722,acm4_human,106,D,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.95,8.71,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
137,21300722,acm4_human,106,D,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,9.7,5.623,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
143,21300722,acm4_human,106,D,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.29,-1.202,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
243,21300722,acm4_human,106,D,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.7,1.66,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
261,21300722,acm4_human,106,D,A,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,5.66,-1.202,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
275,21300722,acm4_human,106,D,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.24,5.888,,,[3H]QNB (radioligand),25.8,0.0,,0.0,,P08173,1.18205,DA106A,CHRM4
36,26958838,acm4_human,92,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.15,2.291,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
87,26958838,acm4_human,92,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.52,1.122,,,,79.7,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
155,26958838,acm4_human,92,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,4.53,2.291,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
209,26958838,acm4_human,92,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,4.53,2.291,,,[3H]QNB (radioligand),79.7,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
249,26958838,acm4_human,92,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.15,2.291,,,[3H]QNB (radioligand),79.7,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
254,26958838,acm4_human,92,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.52,1.122,,,[3H]QNB (radioligand),79.7,0.0,,0.0,,P08173,0.930427,YA92A,CHRM4
38,26958838,acm4_human,187,I,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.16,2.57,,,,140.7,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
59,26958838,acm4_human,187,I,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.46,-3.717,,,[3H]QNB (radioligand),140.7,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
67,26958838,acm4_human,187,I,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.71,6.31,,,[3H]QNB (radioligand),140.7,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
146,26958838,acm4_human,187,I,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.46,-3.717,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
171,26958838,acm4_human,187,I,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.71,6.31,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
208,26958838,acm4_human,187,I,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.16,2.57,,,[3H]QNB (radioligand),140.7,0.0,,0.0,,P08173,3.03378,IA187A,CHRM4
44,21300722,acm4_human,109,L,A,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,4.89,4.898,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
79,26958838,acm4_human,109,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.11,60.256,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
107,21300722,acm4_human,109,L,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.83,1.23,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
113,21300722,acm4_human,109,L,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,4.28,8.511,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
132,21300722,acm4_human,109,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,9.12,21.38,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
170,21300722,acm4_human,109,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.11,60.256,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
217,21300722,acm4_human,109,L,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.22,6.166,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
221,26958838,acm4_human,109,L,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,4.28,8.511,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
260,21300722,acm4_human,109,L,A,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,5.93,5.37,,,[3H]QNB (radioligand),67.3,0.0,,0.0,,P08173,2.32036,LA109A,CHRM4
54,21300722,acm4_human,129,D,N,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,5.08,-1.175,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
73,26958838,acm4_human,129,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.37,-1.445,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
75,21300722,acm4_human,129,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.05,-1.35,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
90,21300722,acm4_human,129,D,N,N-desmethylclozapine,ChEMBL Compound ID,CHEMBL845,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.57,1.23,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
119,26958838,acm4_human,129,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.54,-4.464,,,[3H]QNB,0.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
128,21300722,acm4_human,129,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.54,-4.464,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
159,21300722,acm4_human,129,D,N,C7/3-phth,ChEMBL Compound ID,CHEMBL28407,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.58,,=,,5.16,2.63,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
227,21300722,acm4_human,129,D,N,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.37,-1.445,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
285,21300722,acm4_human,129,D,N,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.45,,=,,10.11,2.188,,,[3H]QNB (radioligand),34.0,0.0,,0.0,,P08173,1.8581,DA129N,CHRM4
57,20406819,acm4_human,439,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.24,1.23,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
89,20406819,acm4_human,439,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,3.33,25.704,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
183,26958838,acm4_human,439,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,5.84,-4.274,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
194,20406819,acm4_human,439,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.3,2.344,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
212,20406819,acm4_human,439,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,5.84,-4.274,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
225,26958838,acm4_human,439,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,3.33,25.704,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
256,20406819,acm4_human,439,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,4.54,2.089,,,[3H]QNB (radioligand),95.7,0.0,,0.0,,P08173,2.46931,YA439A,CHRM4
62,26958838,acm4_human,427,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.43,-3.472,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
161,26958838,acm4_human,427,Q,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.43,-3.472,,,[3H]QNB (radioligand),67.8,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
231,26958838,acm4_human,427,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.73,-1.445,,,[3H]QNB (radioligand),67.8,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
239,26958838,acm4_human,427,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.73,-1.445,,,,67.8,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
270,26958838,acm4_human,427,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.46,1.122,,,[3H]QNB (radioligand),67.8,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
296,26958838,acm4_human,427,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,4.46,1.122,,,[3H]QNB,0.0,0.0,,0.0,,P08173,0.604128,QA427A,CHRM4
68,26958838,acm4_human,416,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,9.86,5.129,,,[3H]QNB (radioligand),16.9,0.0,,0.0,,P08173,2.36812,YA416A,CHRM4
88,26958838,acm4_human,416,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,9.86,5.129,,,,16.9,0.0,,0.0,,P08173,2.36812,YA416A,CHRM4
152,26958838,acm4_human,416,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,2.85,45.709,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.36812,YA416A,CHRM4
272,26958838,acm4_human,416,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,2.85,45.709,,,[3H]QNB (radioligand),16.9,0.0,,0.0,,P08173,2.36812,YA416A,CHRM4
86,20406819,acm4_human,443,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.13,3.467,,,[3H]QNB (radioligand),73.9,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
117,26958838,acm4_human,443,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,3.36,23.988,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
149,20406819,acm4_human,443,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,3.36,23.988,,,[3H]QNB (radioligand),73.9,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
203,20406819,acm4_human,443,Y,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,4.44,2.63,,,[3H]QNB (radioligand),73.9,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
213,20406819,acm4_human,443,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.22,1.288,,,[3H]QNB (radioligand),73.9,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
222,20406819,acm4_human,443,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.21,,=,,6.22,-10.204,,,[3H]QNB (radioligand),73.9,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
236,26958838,acm4_human,443,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,,=,,6.22,-10.204,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.28025,YA443A,CHRM4
127,26958838,acm4_human,186,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.85,-1.289,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.09218,FA186A,CHRM4
147,20406819,acm4_human,186,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.74,,=,,4.85,-1.289,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,2.09218,FA186A,CHRM4
241,20406819,acm4_human,186,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.33,,=,,10.29,1.096,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,2.09218,FA186A,CHRM4
245,20406819,acm4_human,186,F,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.86,,=,,5.3,-2.755,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,2.09218,FA186A,CHRM4
271,20406819,acm4_human,186,F,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.67,,=,,6.5,1.479,,,[3H]QNB (radioligand),113.0,0.0,,0.0,,P08173,2.09218,FA186A,CHRM4
169,26958838,acm4_human,435,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.21,2.291,,,,61.0,0.0,,0.0,,P08173,3.95831,WA435A,CHRM4
211,26958838,acm4_human,435,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.37,13.804,,,[3H]QNB,0.0,0.0,,0.0,,P08173,3.95831,WA435A,CHRM4
258,26958838,acm4_human,435,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.21,2.291,,,[3H]QNB (radioligand),61.0,0.0,,0.0,,P08173,3.95831,WA435A,CHRM4
280,26958838,acm4_human,435,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,3.37,13.804,,,[3H]QNB (radioligand),61.0,0.0,,0.0,,P08173,3.95831,WA435A,CHRM4
179,26958838,acm4_human,89,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,5.07,-3.636,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
180,26958838,acm4_human,89,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.57,,=,,10.43,1.38,,,,35.6,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
224,26958838,acm4_human,89,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.36,-2.95,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
244,26958838,acm4_human,89,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.43,1.38,,,[3H]QNB (radioligand),35.6,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
255,26958838,acm4_human,89,Y,A,LY2033298,PubChem CID,11536903,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.89,,=,,5.36,-2.95,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
265,26958838,acm4_human,89,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.51,,=,,5.07,-3.636,,,[3H]QNB,0.0,0.0,,0.0,,P08173,2.65959,YA89A,CHRM4
1,9855638,5ht1d_human,203,C,V,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,58.0,nM,=,,240.0,4.138,,,[3H]5-CT,0.0,0.0,,0.0,,P28221,-0.468675,CA203V,HTR1D
27,9855638,5ht1d_human,203,C,V,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,43.0,nM,=,,70.0,1.628,,,[3H]GR 125746,0.0,0.0,,0.0,,P28221,-0.468675,CA203V,HTR1D
3,10936201,5ht1d_human,189,L,Q,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.68,nM,=,,7.79,1.371,,,[3H]5-CT,0.0,0.0,,0.0,,P28221,-0.0523829,LA189Q,HTR1D
17,10936201,5ht1d_human,189,L,Q,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.4,nM,=,,61.55,5.918,,,[3H]5-CT,0.0,0.0,,0.0,,P28221,-0.0523829,LA189Q,HTR1D
8,9855638,5ht1d_human,208,I,F,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,43.0,nM,=,,57.0,1.326,,,[3H]GR 125747,0.0,0.0,,0.0,,P28221,-0.278158,IA208F,HTR1D
15,9855638,5ht1d_human,208,I,F,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,58.0,nM,=,,170.0,2.931,,,[3H]5-CT,0.0,0.0,,0.0,,P28221,-0.278158,IA208F,HTR1D
12,9855638,5ht1d_human,199,I,V,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,43.0,nM,=,,45.0,1.047,,,[3H]GR 125745,0.0,0.0,,0.0,,P28221,0.854091,IA199V,HTR1D
19,9855638,5ht1d_human,199,I,V,Ketanserin,ChEMBL Compound ID,ChEMBL51,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,58.0,nM,=,,125.0,2.155,,,[3H]5-CT,0.0,0.0,,0.0,,P28221,0.854091,IA199V,HTR1D
0,1349154,5ht1a_human,386,N,V,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,160.0,-1.499,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
1,9145928,5ht1a_human,386,N,V,Cmp12,PubChem CID,10017756,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3800.0,nM,=,,7200.0,1.895,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
7,9145928,5ht1a_human,386,N,V,Cmp9,PubChem CID,551839,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4000.0,nM,=,,5910.0,1.478,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
8,9145928,5ht1a_human,386,N,V,Cmp10 (isomer S),PubChem CID,10107358,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,150.0,nM,=,,160.0,1.067,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
10,9145928,5ht1a_human,386,N,V,Penbutolol (isomer S),ChEMBL Compound ID,CHEMBL1290,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.3,nM,=,,500.0,151.515,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
11,9145928,5ht1a_human,386,N,V,Cmp10,PubChem CID,10107358,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,170.0,nM,=,,140.0,-1.214,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
17,1349154,5ht1a_human,386,N,V,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,900.0,nM,=,,220.0,-4.098,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
19,1349154,5ht1a_human,386,N,V,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.4,nM,=,,0.74,-1.89,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
22,1349154,5ht1a_human,386,N,V,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,750.0,nM,=,,1000.0,1.333,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
24,9145928,5ht1a_human,386,N,V,8-OH-DPAT (isomer R),ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,0.5,-7.576,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
29,9145928,5ht1a_human,386,N,V,Propranolol (isomer S),ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,160.0,nM,=,,3600.0,22.5,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
31,9145928,5ht1a_human,386,N,V,Propranolol (isomer R),ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2100.0,nM,=,,9800.0,4.667,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
32,1349154,5ht1a_human,386,N,V,Ipsapirone,ChEMBL Compound ID,CHEMBL8412,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,nM,=,,2.5,1.316,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
33,9145928,5ht1a_human,386,N,V,Cmp10 (isomer R),PubChem CID,10107358,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1700.0,nM,=,,1300.0,-1.307,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
42,9145928,5ht1a_human,386,N,V,Penbutolol (isomer R),ChEMBL Compound ID,CHEMBL1290,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,80.0,nM,=,,3400.0,42.5,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
43,1349154,5ht1a_human,386,N,V,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,24.0,nM,=,,2700.0,112.5,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
44,9145928,5ht1a_human,386,N,V,WAY-100635,ChEMBL Compound ID,CHEMBL31354,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,6.5,2.321,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
52,9145928,5ht1a_human,386,N,V,Cmp11,PubChem CID,10085460,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1400.0,nM,=,,2000.0,1.429,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
57,9145928,5ht1a_human,386,N,V,8-OH-DPAT (isomer S),ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.6,nM,=,,9.0,1.957,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
59,1349154,5ht1a_human,386,N,V,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.12,nM,=,,0.27,2.25,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
66,1349154,5ht1a_human,386,N,V,Lisuride,ChEMBL Compound ID,CHEMBL157138,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.76,nM,=,,0.42,-1.808,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
69,9145928,5ht1a_human,386,N,V,Alprenolol (isomer R),ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5400.0,nM,=,,56000.0,10.37,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
74,1349154,5ht1a_human,386,N,V,Buspirone,ChEMBL Compound ID,CHEMBL49,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,23.0,nM,=,,6.5,-3.534,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
77,1349154,5ht1a_human,386,N,V,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,28.0,nM,=,,4100.0,146.429,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
78,1349154,5ht1a_human,386,N,V,Metergoline,ChEMBL Compound ID,CHEMBL19215,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.2,nM,=,,3.2,1.455,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
80,9145928,5ht1a_human,386,N,V,Alprenolol (isomer S),ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,60.0,nM,=,,7200.0,120.0,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
83,1349154,5ht1a_human,386,N,V,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,150.0,nM,=,,6100.0,40.667,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
87,9145928,5ht1a_human,386,N,V,Cmp8,ChEMBL Compound ID,CHEMBL139737,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1500.0,nM,=,,1300.0,-1.153,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
88,9145928,5ht1a_human,386,N,V,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.3,nM,=,,14.0,4.242,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
89,1349154,5ht1a_human,386,N,V,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,37.0,nM,=,,11.0,-3.367,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
91,1349154,5ht1a_human,386,N,V,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.6,nM,=,,4.4,2.75,,,[3H]8-OH-DPAT,0.0,0.0,,0.0,,P08908,-0.126489,NA386V,HTR1A
2,8474430,5ht1a_human,396,N,V,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand saturation,277.5,fmol/mg,=,,1.0,-250.0,,,,0.0,0.0,,0.0,,P08908,0.111534,NA396V,HTR1A
3,1426261,5ht1a_human,199,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.1,nM,=,,250.0,227.273,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,-1.70875,SA199A,HTR1A
48,1426261,5ht1a_human,199,S,A,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.0,nM,=,,32.0,1.778,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,-1.70875,SA199A,HTR1A
90,1426261,5ht1a_human,199,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.8,nM,=,,172.0,95.556,,,,0.0,0.0,,0.0,,P08908,-1.70875,SA199A,HTR1A
4,1426261,5ht1a_human,82,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.8,nM,=,,110.0,61.111,,,,0.0,0.0,,0.0,,P08908,-0.069601,DA82N,HTR1A
26,1426261,5ht1a_human,82,D,N,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.0,nM,=,,21.0,1.167,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,-0.069601,DA82N,HTR1A
65,1426261,5ht1a_human,82,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.1,nM,=,,240.0,218.182,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,-0.069601,DA82N,HTR1A
14,10936212,5ht1a_human,344,V,E,8-OH-DPAT (isomer R),ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.59,,=,,7.8,-1.621,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
28,10936212,5ht1a_human,344,V,E,8-OH-DPAT (isomer R),ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.59,,=,,7.89,-1.996,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
41,10936212,5ht1a_human,344,V,E,Buspirone,ChEMBL Compound ID,CHEMBL49,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.24,,=,,7.19,1.122,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
46,10936212,5ht1a_human,344,V,E,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.15,1.82,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
68,10936212,5ht1a_human,344,V,E,Buspirone,ChEMBL Compound ID,CHEMBL49,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.24,,=,,7.23,1.023,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
76,10936212,5ht1a_human,344,V,E,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.22,1.549,,,[3H]NAD-299,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
85,10936212,5ht1a_human,344,V,E,[3H]NAD-299,PubChem CID,120168990,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.58,,=,,9.34,1.738,,,,0.0,0.0,,0.0,,P08908,0.0583354,VA344E,HTR1A
15,15037200,5ht1a_human,50,A,V,[3H]WAY-100635,ChEMBL Compound ID,CHEMBL31354,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.0,,=,,10.2,-1.585,,,,7.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
38,15037200,5ht1a_human,50,A,V,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,6.8,1.259,,,[3H]WAY-100635,0.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
49,15037200,5ht1a_human,50,A,V,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.1,-1.259,,,[3H]WAY-100636,0.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
54,15037200,5ht1a_human,50,A,V,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.2,,=,,8.5,-1.996,,,[3H]WAY-100636,0.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
58,15037200,5ht1a_human,50,A,V,WAY-100635,ChEMBL Compound ID,CHEMBL31354,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[3H]WAY-100636,0.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
84,15037200,5ht1a_human,50,A,V,(+)8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.9,-3.984,,,[3H]WAY-100635,0.0,0.0,,0.0,,P08908,0.272667,AA50V,HTR1A
18,8474430,5ht1a_human,393,S,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.98,nM,=,,35.5,36.224,,,,0.0,0.0,,0.0,,P08908,0.0851772,SA393A,HTR1A
36,1426261,5ht1a_human,116,D,N,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.0,nM,=,,30.0,1.667,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,0.569343,DA116N,HTR1A
55,1426261,5ht1a_human,116,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.1,nM,=,,198.0,180.0,,,[3H]5-HT,0.0,0.0,,0.0,,P08908,0.569343,DA116N,HTR1A
75,1426261,5ht1a_human,116,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.8,nM,=,,158.0,87.778,,,,0.0,0.0,,0.0,,P08908,0.569343,DA116N,HTR1A
47,8474430,5ht1a_human,391,S,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand saturation,277.5,fmol/mg,=,,274.4,-1.011,,,,0.0,0.0,,0.0,,P08908,-0.127662,SA391A,HTR1A
60,8474430,5ht1a_human,82,D,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand saturation,277.5,fmol/mg,=,,2.4,-111.111,,,,0.0,0.0,,0.0,,P08908,-1.02423,DA82A,HTR1A
71,8474430,5ht1a_human,396,N,F,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand saturation,277.5,fmol/mg,=,,1.2,-250.0,,,,0.0,0.0,,0.0,,P08908,-3.41819,NA396F,HTR1A
0,10.1021/jm801442p,p2ry2_human,180,R,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,63.1,nM,=,,237.0,3.756,,,,0.0,0.0,,104.5454545,,P41231,0.795388,RA180A,P2RY2
8,10.1021/jm801442p,p2ry2_human,180,R,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,167.0,nM,=,,423.0,2.533,,,,0.0,0.0,,68.0,,P41231,0.795388,RA180A,P2RY2
23,10.1021/jm801442p,p2ry2_human,180,R,A,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.7,µM,=,,23.4,1.078,,,,0.0,0.0,,0.0,,P41231,0.795388,RA180A,P2RY2
25,10.1021/jm801442p,p2ry2_human,180,R,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,179.0,nM,=,,419.0,2.341,,,,0.0,0.0,,73.46938776,,P41231,0.795388,RA180A,P2RY2
39,10.1021/jm801442p,p2ry2_human,180,R,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,59.0,nM,=,,138.0,2.339,,,,0.0,0.0,,94.20289855,,P41231,0.795388,RA180A,P2RY2
47,10.1021/jm801442p,p2ry2_human,180,R,A,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.85,µM,=,,2.1,1.135,,,,0.0,0.0,,0.0,,P41231,0.795388,RA180A,P2RY2
3,10.1021/jm801442p,p2ry2_human,118,Y,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,80.4,nM,=,,157.0,1.953,,,,0.0,0.0,,43.0,,P41231,3.08217,YA118A,P2RY2
26,10.1021/jm801442p,p2ry2_human,118,Y,A,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.62,µM,=,,1.57,-1.032,,,,0.0,0.0,,0.0,,P41231,3.08217,YA118A,P2RY2
33,10.1021/jm801442p,p2ry2_human,118,Y,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,145.0,nM,=,,345.0,2.379,,,,0.0,0.0,,22.05882353,,P41231,3.08217,YA118A,P2RY2
49,10.1021/jm801442p,p2ry2_human,118,Y,A,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.9,µM,=,,22.4,1.023,,,,0.0,0.0,,0.0,,P41231,3.08217,YA118A,P2RY2
53,10.1021/jm801442p,p2ry2_human,118,Y,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,112.0,nM,=,,145.0,1.295,,,,0.0,0.0,,34.72222222,,P41231,3.08217,YA118A,P2RY2
56,10.1021/jm801442p,p2ry2_human,118,Y,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,95.8,nM,=,,299.0,3.121,,,,0.0,0.0,,44.56521739,,P41231,3.08217,YA118A,P2RY2
4,10.1021/jm801442p,p2ry2_human,177,R,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,63.1,nM,=,,183.0,2.9,,,,0.0,0.0,,106.3636364,,P41231,0.686619,RA177A,P2RY2
15,10.1021/jm801442p,p2ry2_human,177,R,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,59.0,nM,=,,50.1,-1.178,,,,0.0,0.0,,96.37681159,,P41231,0.686619,RA177A,P2RY2
28,10.1021/jm801442p,p2ry2_human,177,R,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,179.0,nM,=,,572.0,3.196,,,,0.0,0.0,,104.0816327,,P41231,0.686619,RA177A,P2RY2
32,10.1021/jm801442p,p2ry2_human,177,R,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,167.0,nM,=,,1230.0,7.365,,,,0.0,0.0,,86.0,,P41231,0.686619,RA177A,P2RY2
41,10.1021/jm801442p,p2ry2_human,177,R,A,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.85,µM,=,,3.36,1.816,,,,0.0,0.0,,0.0,,P41231,0.686619,RA177A,P2RY2
55,10.1021/jm801442p,p2ry2_human,177,R,A,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.7,µM,=,,30.8,1.419,,,,0.0,0.0,,0.0,,P41231,0.686619,RA177A,P2RY2
6,10.1021/jm801442p,p2ry2_human,198,Y,A,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.62,µM,=,,9.3,5.741,,,,0.0,0.0,,0.0,,P41231,4.24087,YA198A,P2RY2
35,10.1021/jm801442p,p2ry2_human,198,Y,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,80.4,nM,=,,108.0,1.343,,,,0.0,0.0,,128.0,,P41231,4.24087,YA198A,P2RY2
36,10.1021/jm801442p,p2ry2_human,198,Y,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,95.8,nM,=,,120.0,1.253,,,,0.0,0.0,,136.9565217,,P41231,4.24087,YA198A,P2RY2
43,10.1021/jm801442p,p2ry2_human,198,Y,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,145.0,nM,=,,335.0,2.31,,,,0.0,0.0,,172.0588235,,P41231,4.24087,YA198A,P2RY2
50,10.1021/jm801442p,p2ry2_human,198,Y,A,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.9,µM,=,,21.1,-1.038,,,,0.0,0.0,,0.0,,P41231,4.24087,YA198A,P2RY2
52,10.1021/jm801442p,p2ry2_human,198,Y,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,112.0,nM,=,,231.0,2.062,,,,0.0,0.0,,176.3888889,,P41231,4.24087,YA198A,P2RY2
9,10.1021/jm801442p,p2ry2_human,272,R,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,0.167,µM,~,,740.0,4431.138,,,,0.0,0.0,,0.0,,P41231,0.240601,RA272A,P2RY2
18,10.1021/jm801442p,p2ry2_human,272,R,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,0.0631,µM,=,,11.7,185.42,,,,0.0,0.0,,79.09090909,,P41231,0.240601,RA272A,P2RY2
57,10.1021/jm801442p,p2ry2_human,272,R,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,0.179,µM,~,,620.0,3463.687,,,,0.0,0.0,,0.0,,P41231,0.240601,RA272A,P2RY2
59,10.1021/jm801442p,p2ry2_human,272,R,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,0.059,µM,=,,20.6,349.153,,,,0.0,0.0,,71.73913043,,P41231,0.240601,RA272A,P2RY2
10,10.1021/jm801442p,p2ry2_human,114,Y,A,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,63.1,nM,=,,30.1,-2.096,,,,0.0,0.0,,79.09090909,,P41231,2.9813,YA114A,P2RY2
13,10.1021/jm801442p,p2ry2_human,114,Y,A,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.85,µM,>,,100.0,54.054,,,,0.0,0.0,,0.0,,P41231,2.9813,YA114A,P2RY2
29,10.1021/jm801442p,p2ry2_human,114,Y,A,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,167.0,nM,=,,170.0,1.018,,,,0.0,0.0,,128.0,,P41231,2.9813,YA114A,P2RY2
40,10.1021/jm801442p,p2ry2_human,114,Y,A,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,179.0,nM,=,,94.5,-1.894,,,,0.0,0.0,,144.8979592,,P41231,2.9813,YA114A,P2RY2
48,10.1021/jm801442p,p2ry2_human,114,Y,A,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.7,µM,=,,24.6,1.134,,,,0.0,0.0,,0.0,,P41231,2.9813,YA114A,P2RY2
58,10.1021/jm801442p,p2ry2_human,114,Y,A,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,59.0,nM,=,,37.2,-1.585,,,,0.0,0.0,,77.53623188,,P41231,2.9813,YA114A,P2RY2
14,10.1021/jm801442p,p2ry2_human,194,R,H,Ip4U,SMILES,c1cn(c(=O)[nH]c1=O)C2C(C(C(O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OCC3C(C(C(O3)n4cnc5c4nc[nH]c5=O)O)O)O)O,Full agonist,EC50,Ca2+ accumulaion,112.0,nM,=,,216.0,1.929,,,,0.0,0.0,,118.0555556,,P41231,0.612146,RA194H,P2RY2
17,10.1021/jm801442p,p2ry2_human,194,R,H,ATP,CID,5957,Full agonist,EC50,Ca2+ accumulaion,95.8,nM,=,,111.0,1.159,,,,0.0,0.0,,141.3043478,,P41231,0.612146,RA194H,P2RY2
20,10.1021/jm801442p,p2ry2_human,194,R,H,PSB-416,SMILES,COc1ccc(cc1)Nc2cc(c(c3c2C(=O)c4ccccc4C3=O)N)S(=O)(=O)[O-].[Na+],Antagonist,IC50,Ca2+ accumulaion,21.9,µM,=,,17.6,-1.244,,,,0.0,0.0,,0.0,,P41231,0.612146,RA194H,P2RY2
21,10.1021/jm801442p,p2ry2_human,194,R,H,Reactive Blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,IC50,Ca2+ accumulaion,1.62,µM,=,,1.0,-1.621,,,,0.0,0.0,,0.0,,P41231,0.612146,RA194H,P2RY2
24,10.1021/jm801442p,p2ry2_human,194,R,H,UTP,CID,6133,Full agonist,EC50,Ca2+ accumulaion,80.4,nM,=,,121.0,1.505,,,,0.0,0.0,,127.0,,P41231,0.612146,RA194H,P2RY2
60,10.1021/jm801442p,p2ry2_human,194,R,H,Ap4A,CID,25243905,Full agonist,EC50,Ca2+ accumulaion,145.0,nM,=,,185.0,1.276,,,,0.0,0.0,,219.1176471,,P41231,0.612146,RA194H,P2RY2
5,10.1096/fj.10-164319,aa2br_human,74,D,T,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,108.0,1.149,,,,0.0,106.0,=,0.0,,P29275,4.41482,DA74T,ADORA2B
263,10.1096/fj.10-164319,aa2br_human,74,D,T,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,135.0,1.667,,,,0.0,106.0,=,0.0,,P29275,4.41482,DA74T,ADORA2B
6,11093773,aa2br_human,273,N,Y,181873-18-7,PubChem CID,53720188,Full agonist,K(i),Binding - Radioligand competition/displacement,53.0,µM,=,,2.5,-21.277,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
20,11093773,aa2br_human,273,N,Y,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.008,µM,=,,0.003,-2.667,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
31,11093773,aa2br_human,273,N,Y,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,3.8,1.727,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
62,11093773,aa2br_human,273,N,Y,181873-18-7,PubChem CID,53720188,Full agonist,EC50,Functional - cAMP accumulation,5.6,µM,=,,0.56,-10.0,,,,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
75,11093773,aa2br_human,273,N,Y,144348-17-4,PubChem CID,73232013,Full agonist,K(i),Binding - Radioligand competition/displacement,26.0,µM,=,,7.4,-3.509,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
87,11093773,aa2br_human,273,N,Y,Cid13830107(R),PubChem CID,13830107,Full agonist,K(i),Binding - Radioligand competition/displacement,10.0,µM,=,,2.9,-3.448,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
91,11093773,aa2br_human,273,N,Y,2-ClAdo,PubChem CID,235481,Full agonist,K(i),Binding - Radioligand competition/displacement,8.9,µM,=,,26.0,2.921,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
106,11093773,aa2br_human,273,N,Y,Cid13830107(S),PubChem CID,13830107,Full agonist,K(i),Binding - Radioligand competition/displacement,1.7,µM,=,,0.19,-8.929,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
140,11093773,aa2br_human,273,N,Y,ZM241385,PubChem CID,176407,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.026,µM,=,,0.064,2.462,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
150,11093773,aa2br_human,273,N,Y,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.34,µM,=,,0.39,1.147,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
202,11093773,aa2br_human,273,N,Y,2-(1-hexynyl)adenosine,PubChem CID,10020580,Full agonist,K(i),Binding - Radioligand competition/displacement,11.0,µM,=,,0.18,-62.5,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
204,11093773,aa2br_human,273,N,Y,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,300.0,µM,=,,95.0,-3.155,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
208,11093773,aa2br_human,273,N,Y,L005974,PubChem CID,14842876,Full agonist,K(i),Binding - Radioligand competition/displacement,47.0,µM,=,,7.7,-6.098,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
249,11093773,aa2br_human,273,N,Y,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,21.0,µM,=,,13.0,-1.616,,,DPCPX,0.0,0.0,=,0.0,,P29275,-1.47779,NA273Y,ADORA2B
8,10.1016/j.ejphar.2020.173126,aa2br_human,215,R,H,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.57,1.66,,,,86.0,280.0,,94.0,NECA,P29275,0.38115,RA215H,ADORA2B
12,10.1096/fj.10-164319,aa2br_human,74,D,C,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,156.0,1.926,,,,0.0,107.0,=,0.0,,P29275,4.85979,DA74C,ADORA2B
286,10.1096/fj.10-164319,aa2br_human,74,D,C,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,256.0,2.723,,,,0.0,107.0,=,0.0,,P29275,4.85979,DA74C,ADORA2B
13,10.1096/fj.10-164319,aa2br_human,74,D,V,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,242.0,2.988,,,,0.0,100.0,=,0.0,,P29275,5.21415,DA74V,ADORA2B
112,10.1096/fj.10-164319,aa2br_human,74,D,V,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,333.0,3.543,,,,0.0,100.0,=,0.0,,P29275,5.21415,DA74V,ADORA2B
15,10.1016/j.bcp.2013.03.005,aa2br_human,169,V,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,45.1,-3.663,,,,0.0,0.0,,0.0,,P29275,1.6808,VA169A,ADORA2B
72,10.1016/j.bcp.2013.03.005,aa2br_human,169,V,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.884,2.389,,,PSB-603,0.0,0.0,,0.0,,P29275,1.6808,VA169A,ADORA2B
124,10.1016/j.bcp.2013.03.005,aa2br_human,169,V,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,90.1,-2.551,,,,0.0,0.0,,0.0,,P29275,1.6808,VA169A,ADORA2B
200,10.1016/j.bcp.2013.03.005,aa2br_human,169,V,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,1190.0,-1.042,,,PSB-603,0.0,0.0,,0.0,,P29275,1.6808,VA169A,ADORA2B
19,10.1042/BCJ20160272,aa2br_human,301,F,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,23.0,1.15,,,,100.0,0.0,=,0.0,,P29275,3.77783,FA301A,ADORA2B
24,10.1021/bi3012065,aa2br_human,198,M,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,128.0,1.596,,,,0.0,0.0,,90.0,,P29275,3.99908,MA198A,ADORA2B
77,10.1021/bi3012065,aa2br_human,198,M,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,83.5,nM,=,,165.0,1.976,,,,0.0,0.0,,90.0,,P29275,3.99908,MA198A,ADORA2B
119,10.1021/bi3012065,aa2br_human,198,M,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,3.59,nM,=,,2.89,-1.242,,,,0.0,0.0,,0.0,,P29275,3.99908,MA198A,ADORA2B
253,10.1021/bi3012065,aa2br_human,198,M,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,5850.0,nM,=,,5530.0,-1.058,,,PSB-603,0.0,0.0,,0.0,,P29275,3.99908,MA198A,ADORA2B
29,10.1096/fj.10-164319,aa2br_human,71,F,H,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,437.0,4.649,,,,0.0,100.0,=,0.0,,P29275,2.36662,FA71H,ADORA2B
115,10.1096/fj.10-164319,aa2br_human,71,F,H,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,226.0,2.79,,,,0.0,100.0,=,0.0,,P29275,2.36662,FA71H,ADORA2B
39,10.1096/fj.10-164319,aa2br_human,71,F,D,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,442.0,4.702,,,,0.0,95.0,=,0.0,,P29275,2.89723,FA71D,ADORA2B
120,10.1096/fj.10-164319,aa2br_human,71,F,D,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,387.0,4.778,,,,0.0,95.0,=,0.0,,P29275,2.89723,FA71D,ADORA2B
40,10.1021/bi3012065,aa2br_human,279,S,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,12.1,-6.623,,,,0.0,0.0,,0.0,,P29275,-0.70322,SA279A,ADORA2B
94,10.1021/bi3012065,aa2br_human,279,S,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,0.0835,µM,>,,100.0,1197.605,,,,0.0,0.0,,0.0,,P29275,-0.70322,SA279A,ADORA2B
110,10.1021/bi3012065,aa2br_human,279,S,A,adenosine,CID,6083,Full agonist,EC50,cAMP accumulation,0.806,µM,>,,5000.0,6203.474,,,,0.0,0.0,,0.0,,P29275,-0.70322,SA279A,ADORA2B
131,10.1021/bi3012065,aa2br_human,279,S,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,548.0,nM,=,,436.0,-1.256,,,,0.0,0.0,,0.0,,P29275,-0.70322,SA279A,ADORA2B
187,10.1021/bi3012065,aa2br_human,279,S,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,3.59,nM,=,,6.35,1.769,,,,0.0,0.0,,0.0,,P29275,-0.70322,SA279A,ADORA2B
43,10.1096/fj.10-164319,aa2br_human,74,D,Y,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,84.0,-1.119,,,,0.0,104.0,=,0.0,,P29275,4.36207,DA74Y,ADORA2B
165,10.1096/fj.10-164319,aa2br_human,74,D,Y,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,70.0,-1.157,,,,0.0,104.0,=,0.0,,P29275,4.36207,DA74Y,ADORA2B
45,10.1016/j.bcp.2013.03.005,aa2br_human,165,S,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,316.0,1.374,,,,0.0,0.0,,0.0,,P29275,-1.89223,SA165A,ADORA2B
93,10.1016/j.bcp.2013.03.005,aa2br_human,165,S,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,805.0,-1.541,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.89223,SA165A,ADORA2B
105,10.1016/j.bcp.2013.03.005,aa2br_human,165,S,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.253,-1.462,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.89223,SA165A,ADORA2B
123,10.1016/j.bcp.2013.03.005,aa2br_human,165,S,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,186.0,1.127,,,,0.0,0.0,,0.0,,P29275,-1.89223,SA165A,ADORA2B
307,10.1016/j.bcp.2013.03.005,aa2br_human,165,S,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,114.0,nM,=,,275.0,2.412,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.89223,SA165A,ADORA2B
48,10.1096/fj.10-164319,aa2br_human,74,D,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,91.0,-1.033,,,,0.0,108.0,=,0.0,,P29275,3.68809,DA74A,ADORA2B
264,10.1096/fj.10-164319,aa2br_human,74,D,A,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,144.0,1.778,,,,0.0,108.0,=,0.0,,P29275,3.68809,DA74A,ADORA2B
49,10.1016/j.ejphar.2020.173126,aa2br_human,310,L,I,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.4,2.455,,,,124.0,360.0,,88.0,NECA,P29275,1.06082,LA310I,ADORA2B
50,10.1016/j.ejphar.2020.173126,aa2br_human,113,Y,F,BAY 60-6583,PubChem CID,11717831,Partial agonist,pEC50,Functional - Other,7.49,,=,,6.51,9.55,,,,101.0,60.0,,15.0,BAY 60-6583,P29275,1.20185,YA113F,ADORA2B
107,10.1016/j.ejphar.2020.173126,aa2br_human,113,Y,F,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,5.28,32.359,,,,101.0,60.0,,57.0,NECA,P29275,1.20185,YA113F,ADORA2B
51,10.1007/s11302-011-9251-x,aa2br_human,168,L,P,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,137.0,nM,=,,11.0,-12.5,,,,0.0,550.0,=,0.0,,P29275,0.651407,LA168P,ADORA2B
54,10.1124/mol.65.3.702,aa2br_human,84,F,S,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,97.0,nM,=,,15.0,-6.452,,,,0.0,0.0,=,0.0,,P29275,2.9934,FA84S,ADORA2B
56,10.1021/bi3012065,aa2br_human,282,N,D,NECA,CID,448222,Full agonist,K(i),radioligand binding,6.32,nM,>,,100.0,15.823,,,PSB-603,0.0,0.0,,0.0,,P29275,1.29431,NA282D,ADORA2B
111,10.1021/bi3012065,aa2br_human,282,N,D,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,727.0,nM,=,,1800.0,2.476,,,,0.0,0.0,,0.0,,P29275,1.29431,NA282D,ADORA2B
147,10.1021/bi3012065,aa2br_human,282,N,D,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,0.0269,µM,=,,15.5,576.208,,,,0.0,0.0,,0.0,,P29275,1.29431,NA282D,ADORA2B
171,10.1021/bi3012065,aa2br_human,282,N,D,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,37.5,nM,=,,908.0,24.213,,,,0.0,0.0,,0.0,,P29275,1.29431,NA282D,ADORA2B
228,10.1021/bi3012065,aa2br_human,282,N,D,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,2.45,nM,=,,1.38,-1.776,,,,0.0,0.0,,0.0,,P29275,1.29431,NA282D,ADORA2B
57,10.1016/j.ejphar.2020.173126,aa2br_human,310,L,P,BAY 60-6583,PubChem CID,11717831,Partial agonist,pEC50,Functional - Other,7.49,,=,,7.16,2.138,,,,92.0,2600.0,,80.0,BAY 60-6583,P29275,1.66833,LA310P,ADORA2B
198,10.1016/j.ejphar.2020.173126,aa2br_human,310,L,P,PSB603,PubChem CID,44185871,Antagonist (neutral/silent),pK(b),Functional - Other,8.47,,=,,8.27,1.585,,,,92.0,2600.0,Yes,0.0,,P29275,1.66833,LA310P,ADORA2B
270,10.1016/j.ejphar.2020.173126,aa2br_human,310,L,P,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,7.21,-2.632,,,,92.0,2600.0,Yes,95.0,NECA,P29275,1.66833,LA310P,ADORA2B
61,10.1096/fj.10-164319,aa2br_human,71,F,M,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,130.0,1.383,,,,0.0,100.0,=,0.0,,P29275,0.650822,FA71M,ADORA2B
316,10.1096/fj.10-164319,aa2br_human,71,F,M,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,114.0,1.407,,,,0.0,100.0,=,0.0,,P29275,0.650822,FA71M,ADORA2B
63,11093773,aa2br_human,12,A,T,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,21.0,µM,=,,36.0,1.714,,,DPCPX,0.0,0.0,=,0.0,,P29275,0.791008,AA12T,ADORA2B
297,11093773,aa2br_human,12,A,T,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,5.3,2.409,,,DPCPX,0.0,0.0,=,0.0,,P29275,0.791008,AA12T,ADORA2B
305,11093773,aa2br_human,12,A,T,2-ClAdo,PubChem CID,235481,Full agonist,K(i),Binding - Radioligand competition/displacement,8.9,µM,=,,21.0,2.36,,,DPCPX,0.0,0.0,=,0.0,,P29275,0.791008,AA12T,ADORA2B
67,10.1016/j.bcp.2013.03.005,aa2br_human,148,D,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,1140.0,-1.088,,,PSB-603,0.0,0.0,,0.0,,P29275,0.647839,DA148A,ADORA2B
71,10.1016/j.bcp.2013.03.005,aa2br_human,148,D,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,114.0,nM,=,,339.0,2.974,,,PSB-603,0.0,0.0,,0.0,,P29275,0.647839,DA148A,ADORA2B
129,10.1016/j.bcp.2013.03.005,aa2br_human,148,D,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.319,-1.16,,,PSB-603,0.0,0.0,,0.0,,P29275,0.647839,DA148A,ADORA2B
201,10.1016/j.bcp.2013.03.005,aa2br_human,148,D,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,158.0,-1.456,,,,0.0,0.0,,0.0,,P29275,0.647839,DA148A,ADORA2B
257,10.1016/j.bcp.2013.03.005,aa2br_human,148,D,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,72.4,-2.278,,,,0.0,0.0,,0.0,,P29275,0.647839,DA148A,ADORA2B
68,10.1021/bi3012065,aa2br_human,247,W,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,3.59,nM,=,,12.8,3.565,,,,0.0,0.0,,0.0,,P29275,2.2047,WA247A,ADORA2B
255,10.1021/bi3012065,aa2br_human,247,W,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,0.0835,µM,=,,10.4,124.551,,,,0.0,0.0,,150.0,,P29275,2.2047,WA247A,ADORA2B
281,10.1021/bi3012065,aa2br_human,247,W,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,5.85,µM,=,,78.5,13.419,,,PSB-603,0.0,0.0,,0.0,,P29275,2.2047,WA247A,ADORA2B
324,10.1021/bi3012065,aa2br_human,247,W,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,241.0,3.005,,,,0.0,0.0,,110.0,,P29275,2.2047,WA247A,ADORA2B
73,10.1016/j.ejphar.2020.173126,aa2br_human,310,L,F,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.8,-1.024,,,,101.0,200.0,,105.0,NECA,P29275,0.0441504,LA310F,ADORA2B
76,10.1007/s11302-014-9407-6,aa2br_human,235,S,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,0.0,,=,,0.0,1.0,,,,0.0,0.0,=,85.0,NECA,P29275,-0.499207,SA235A,ADORA2B
85,10.1016/j.bcp.2013.03.005,aa2br_human,151,T,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,287.0,1.248,,,,0.0,0.0,,0.0,,P29275,0.121337,TA151A,ADORA2B
117,10.1016/j.bcp.2013.03.005,aa2br_human,151,T,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,121.0,-1.364,,,,0.0,0.0,,0.0,,P29275,0.121337,TA151A,ADORA2B
173,10.1016/j.bcp.2013.03.005,aa2br_human,151,T,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,114.0,nM,=,,257.0,2.254,,,PSB-603,0.0,0.0,,0.0,,P29275,0.121337,TA151A,ADORA2B
248,10.1016/j.bcp.2013.03.005,aa2br_human,151,T,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.431,1.165,,,PSB-603,0.0,0.0,,0.0,,P29275,0.121337,TA151A,ADORA2B
320,10.1016/j.bcp.2013.03.005,aa2br_human,151,T,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,2380.0,1.919,,,PSB-603,0.0,0.0,,0.0,,P29275,0.121337,TA151A,ADORA2B
97,10.1007/s11302-011-9251-x,aa2br_human,202,Y,S,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,48.0,nM,=,,4.9,-9.804,,,,0.0,0.0,=,0.0,,P29275,3.58059,YA202S,ADORA2B
134,10.1007/s11302-011-9251-x,aa2br_human,202,Y,S,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,137.0,nM,=,,13.0,-10.526,,,,0.0,130.0,=,0.0,,P29275,3.58059,YA202S,ADORA2B
101,10.1016/j.bcp.2013.03.005,aa2br_human,164,E,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,62.5,-3.676,,,,0.0,0.0,,0.0,,P29275,-1.34501,EA164A,ADORA2B
143,10.1016/j.bcp.2013.03.005,aa2br_human,164,E,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,114.0,nM,=,,236.0,2.07,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.34501,EA164A,ADORA2B
210,10.1016/j.bcp.2013.03.005,aa2br_human,164,E,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,1420.0,1.145,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.34501,EA164A,ADORA2B
278,10.1016/j.bcp.2013.03.005,aa2br_human,164,E,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,76.0,-2.169,,,,0.0,0.0,,0.0,,P29275,-1.34501,EA164A,ADORA2B
306,10.1016/j.bcp.2013.03.005,aa2br_human,164,E,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.425,1.149,,,PSB-603,0.0,0.0,,0.0,,P29275,-1.34501,EA164A,ADORA2B
118,10.1016/j.bcp.2013.03.005,aa2br_human,149,S,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,0.37,nM,=,,0.44,1.189,,,PSB-603,0.0,0.0,,0.0,,P29275,0.120849,SA149A,ADORA2B
190,10.1016/j.bcp.2013.03.005,aa2br_human,149,S,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,1240.0,nM,=,,4150.0,3.347,,,PSB-603,0.0,0.0,,0.0,,P29275,0.120849,SA149A,ADORA2B
235,10.1016/j.bcp.2013.03.005,aa2br_human,149,S,A,BAY60-6583,CID,11717831,Partial agonist,K(i),radioligand binding,114.0,nM,=,,286.0,2.509,,,PSB-603,0.0,0.0,,0.0,,P29275,0.120849,SA149A,ADORA2B
262,10.1016/j.bcp.2013.03.005,aa2br_human,149,S,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,230.0,nM,=,,183.0,-1.256,,,,0.0,0.0,,0.0,,P29275,0.120849,SA149A,ADORA2B
268,10.1016/j.bcp.2013.03.005,aa2br_human,149,S,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,165.0,nM,=,,126.0,-1.309,,,,0.0,0.0,,0.0,,P29275,0.120849,SA149A,ADORA2B
122,10.1016/j.ejphar.2020.173126,aa2br_human,315,V,G,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.89,-1.259,,,,205.0,140.0,,94.0,NECA,P29275,-0.466192,VA315G,ADORA2B
126,10.1096/fj.10-164319,aa2br_human,71,F,V,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,171.0,2.111,,,,0.0,100.0,=,0.0,,P29275,2.7701,FA71V,ADORA2B
293,10.1096/fj.10-164319,aa2br_human,71,F,V,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,167.0,1.777,,,,0.0,100.0,=,0.0,,P29275,2.7701,FA71V,ADORA2B
132,10.1007/s11302-011-9251-x,aa2br_human,136,I,T,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,137.0,nM,=,,10.0,-13.699,,,,0.0,150.0,=,0.0,,P29275,1.30203,IA136T,ADORA2B
149,10.1096/fj.10-164319,aa2br_human,71,F,I,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,108.0,1.149,,,,0.0,100.0,=,0.0,,P29275,1.21636,FA71I,ADORA2B
226,10.1096/fj.10-164319,aa2br_human,71,F,I,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,132.0,1.63,,,,0.0,100.0,=,0.0,,P29275,1.21636,FA71I,ADORA2B
151,10.1042/BCJ20160272,aa2br_human,296,D,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,29.0,1.45,,,,100.0,0.0,=,0.0,,P29275,0.509128,DA296A,ADORA2B
152,10.1021/bi3012065,aa2br_human,10,Y,A,PSB-603,CID,44185871,Antagonist (neutral/silent),K(i),radioligand binding,3.59,nM,=,,5.73,1.596,,,,0.0,0.0,,0.0,,P29275,3.5563,YA10A,ADORA2B
209,10.1021/bi3012065,aa2br_human,10,Y,A,NECA,CID,448222,Full agonist,K(i),radioligand binding,5.85,µM,=,,11.5,1.966,,,PSB-603,0.0,0.0,,0.0,,P29275,3.5563,YA10A,ADORA2B
223,10.1021/bi3012065,aa2br_human,10,Y,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,83.5,nM,=,,426.0,5.102,,,,0.0,0.0,,120.0,,P29275,3.5563,YA10A,ADORA2B
231,10.1021/bi3012065,aa2br_human,10,Y,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,1160.0,14.464,,,,0.0,0.0,,70.0,,P29275,3.5563,YA10A,ADORA2B
153,10.1096/fj.10-164319,aa2br_human,74,D,N,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,45.0,-1.799,,,,0.0,103.0,=,0.0,,P29275,4.33901,DA74N,ADORA2B
274,10.1096/fj.10-164319,aa2br_human,74,D,N,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,61.0,-1.541,,,,0.0,103.0,=,0.0,,P29275,4.33901,DA74N,ADORA2B
166,10.1096/fj.10-164319,aa2br_human,71,F,C,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,589.0,6.266,,,,0.0,100.0,=,0.0,,P29275,1.82558,FA71C,ADORA2B
290,10.1096/fj.10-164319,aa2br_human,71,F,C,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,312.0,3.852,,,,0.0,100.0,=,0.0,,P29275,1.82558,FA71C,ADORA2B
168,10.1096/fj.10-164319,aa2br_human,71,F,S,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,319.0,3.938,,,,0.0,82.0,=,0.0,,P29275,2.02286,FA71S,ADORA2B
265,10.1096/fj.10-164319,aa2br_human,71,F,S,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,933.0,9.926,,,,0.0,82.0,=,0.0,,P29275,2.02286,FA71S,ADORA2B
175,10.1042/BCJ20160272,aa2br_human,295,R,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,25.0,1.25,,,,100.0,0.0,=,0.0,,P29275,0.0168746,RA295A,ADORA2B
176,10.1096/fj.10-164319,aa2br_human,71,F,Y,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,101.0,1.247,,,,0.0,100.0,=,0.0,,P29275,0.944352,FA71Y,ADORA2B
317,10.1096/fj.10-164319,aa2br_human,71,F,Y,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,147.0,1.564,,,,0.0,100.0,=,0.0,,P29275,0.944352,FA71Y,ADORA2B
179,10.1096/fj.10-164319,aa2br_human,74,D,W,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,197.0,2.096,,,,0.0,103.0,=,0.0,,P29275,5.23591,DA74W,ADORA2B
304,10.1096/fj.10-164319,aa2br_human,74,D,W,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,152.0,1.877,,,,0.0,103.0,=,0.0,,P29275,5.23591,DA74W,ADORA2B
184,10.1021/bi3012065,aa2br_human,250,V,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,164.0,2.045,,,,0.0,0.0,,130.0,,P29275,1.29962,VA250A,ADORA2B
211,10.1021/bi3012065,aa2br_human,250,V,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,0.0835,µM,=,,13.9,166.467,,,,0.0,0.0,,180.0,,P29275,1.29962,VA250A,ADORA2B
191,10.1016/j.ejphar.2020.173126,aa2br_human,148,D,G,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.87,-1.202,,,,90.0,250.0,,98.0,NECA,P29275,1.25499,DA148G,ADORA2B
193,10.1124/mol.65.3.702,aa2br_human,42,T,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,97.0,nM,=,,20.0,-4.854,,,,0.0,0.0,=,0.0,,P29275,1.21076,TA42A,ADORA2B
315,10.1124/mol.65.3.702,aa2br_human,42,T,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - cAMP accumulation,1.3,µM,=,,0.15,-8.696,,,,0.0,0.0,=,0.0,,P29275,1.21076,TA42A,ADORA2B
194,10.1096/fj.10-164319,aa2br_human,74,D,L,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,323.0,3.436,,,,0.0,85.0,=,0.0,,P29275,4.08393,DA74L,ADORA2B
252,10.1096/fj.10-164319,aa2br_human,74,D,L,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,188.0,2.321,,,,0.0,85.0,=,0.0,,P29275,4.08393,DA74L,ADORA2B
196,10.1016/j.ejphar.2020.173126,aa2br_human,259,F,S,BAY 60-6583,PubChem CID,11717831,Partial agonist,pEC50,Functional - Other,7.49,,=,,6.71,6.026,,,,66.0,60.0,,20.0,BAY 60-6583,P29275,2.12816,FA259S,ADORA2B
285,10.1016/j.ejphar.2020.173126,aa2br_human,259,F,S,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,5.44,22.387,,,,66.0,60.0,,57.0,NECA,P29275,2.12816,FA259S,ADORA2B
205,10.1007/s11302-014-9407-6,aa2br_human,213,L,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,0.0,,=,,0.0,-1.667,,,,0.0,0.0,=,100.0,NECA,P29275,1.90779,LA213A,ADORA2B
289,10.1007/s11302-014-9407-6,aa2br_human,213,L,A,NECA,PubChem CID,448222,Full agonist,IC50,Binding - Radioligand competition/displacement,1.85,µM,=,,1.9,1.027,,,PSB-603,0.0,0.0,=,0.0,,P29275,1.90779,LA213A,ADORA2B
214,10.1096/fj.10-164319,aa2br_human,74,D,F,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,159.0,1.963,,,,0.0,71.0,=,0.0,,P29275,4.96734,DA74F,ADORA2B
227,10.1096/fj.10-164319,aa2br_human,74,D,F,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,587.0,6.245,,,,0.0,71.0,=,0.0,,P29275,4.96734,DA74F,ADORA2B
225,10.1007/s11302-014-9407-6,aa2br_human,236,L,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,0.0,,=,,0.0,7.9,,,,0.0,0.0,=,102.0,NECA,P29275,2.89788,LA236A,ADORA2B
233,10.1007/s11302-014-9407-6,aa2br_human,236,L,A,NECA,PubChem CID,448222,Full agonist,IC50,Binding - Radioligand competition/displacement,1.85,µM,=,,1.88,1.016,,,PSB-603,0.0,0.0,=,0.0,,P29275,2.89788,LA236A,ADORA2B
230,10.1096/fj.10-164319,aa2br_human,74,D,R,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,97.0,1.032,,,,0.0,100.0,=,0.0,,P29275,5.28876,DA74R,ADORA2B
258,10.1096/fj.10-164319,aa2br_human,74,D,R,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,83.0,1.025,,,,0.0,100.0,=,0.0,,P29275,5.28876,DA74R,ADORA2B
241,10.1021/bi3012065,aa2br_human,81,L,A,BAY60-6583,CID,11717831,Partial agonist,EC50,cAMP accumulation,80.2,nM,=,,398.0,4.963,,,,0.0,0.0,,100.0,,P29275,2.38626,LA81A,ADORA2B
259,10.1021/bi3012065,aa2br_human,81,L,A,NECA,CID,448222,Full agonist,EC50,cAMP accumulation,83.5,nM,=,,909.0,10.886,,,,0.0,0.0,,100.0,,P29275,2.38626,LA81A,ADORA2B
242,10.1042/BCJ20160272,aa2br_human,293,R,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,28.0,1.4,,,,100.0,0.0,=,0.0,,P29275,1.89946,RA293A,ADORA2B
246,10.1096/fj.10-164319,aa2br_human,74,D,G,Bay60-6583,PubChem CID,11717831,Full agonist,EC50,Functional - Other,81.0,nM,=,,43.0,-1.883,,,,0.0,107.0,=,0.0,,P29275,5.35056,DA74G,ADORA2B
292,10.1096/fj.10-164319,aa2br_human,74,D,G,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,94.0,nM,=,,47.0,-2.0,,,,0.0,107.0,=,0.0,107,P29275,5.35056,DA74G,ADORA2B
275,10.1016/j.ejphar.2020.173126,aa2br_human,202,Y,C,BAY 60-6583,PubChem CID,11717831,Partial agonist,pEC50,Functional - Other,7.49,,=,,7.21,1.905,,,,144.0,4800.0,,74.0,BAY 60-6583,P29275,3.35781,YA202C,ADORA2B
276,10.1016/j.ejphar.2020.173126,aa2br_human,202,Y,C,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.3,3.09,,,,144.0,4800.0,Yes,73.0,NECA,P29275,3.35781,YA202C,ADORA2B
280,10.1124/mol.65.3.702,aa2br_human,36,N,D,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,97.0,nM,=,,42.0,-2.309,,,,0.0,0.0,=,0.0,,P29275,-0.0343429,NA36D,ADORA2B
287,10.1042/BCJ20160272,aa2br_human,302,H,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,19.0,-1.053,,,,100.0,0.0,=,0.0,,P29275,-0.218048,HA302A,ADORA2B
298,10.1042/BCJ20160272,aa2br_human,300,T,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,22.0,1.1,,,,100.0,0.0,=,0.0,,P29275,0.0742036,TA300A,ADORA2B
299,10.1124/mol.65.3.702,aa2br_human,91,S,G,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,97.0,nM,=,,61.0,-1.59,,,,0.0,0.0,=,0.0,,P29275,0.111063,SA91G,ADORA2B
301,10.1042/BCJ20160272,aa2br_human,299,Y,A,NECA,PubChem CID,448222,Full agonist,pmol/mg,Functional - cAMP accumulation,20.0,,=,,20.0,1.0,,,,100.0,0.0,=,0.0,,P29275,-0.262219,YA299A,ADORA2B
318,10.1007/s11302-011-9251-x,aa2br_human,200,V,G,NECA,PubChem CID,448222,Full agonist,EC50,Functional - Other,137.0,nM,=,,13.0,-10.526,,,,500.0,0.0,=,0.0,,P29275,0.44752,VA200G,ADORA2B
319,10.1016/j.ejphar.2020.173126,aa2br_human,167,C,Y,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - Other,6.79,,=,,6.65,1.38,,,,36.0,100.0,,91.0,NECA,P29275,3.60762,CA167Y,ADORA2B
2,17917257,ada1b_human,130,T,A,Tamsulosin,ChEMBL Compound ID,CHEMBL836,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.57,,=,,8.53,10.965,,,[3H]Prazosin,0.0,0.0,,0.0,,P35368,-1.04721,TA130A,ADRA1B
5,17917257,ada1b_human,130,T,A,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.76,,=,,9.8,9.12,,,[3H]Prazosin,0.0,0.0,,0.0,,P35368,-1.04721,TA130A,ADRA1B
10,17917257,ada1b_human,130,T,A,[3H]Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,90.27,pM,=,,674.27,7.469,,,,112.5,0.0,,0.0,,P35368,-1.04721,TA130A,ADRA1B
24,17917257,ada1b_human,125,D,A,[3H]Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,90.27,pM,>,,10000.0,110.779,,,,0.0,0.0,,0.0,,P35368,0.627732,DA125A,ADRA1B
0,10.1074/jbc.M414287200,ts1r3_human,778,F,A,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,1800.0,43.902,,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,3.4534,FA778A,TAS1R3
69,10.1186/1472-6807-7-66,ts1r3_human,778,F,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.5,15.0,,,,0.0,0.0,,0.0,50,Q7RTX0,3.4534,FA778A,TAS1R3
11,10.1186/1472-6807-7-66,ts1r3_human,801,C,I,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.6,16.0,,,,0.0,0.0,,0.0,70,Q7RTX0,-1.29391,CA801I,TAS1R3
127,10.1186/1472-6807-7-66,ts1r3_human,801,C,I,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.3,3.0,,,aspartame,0.0,0.0,,0.0,,Q7RTX0,-1.29391,CA801I,TAS1R3
12,10.1186/1472-6807-7-66,ts1r3_human,621,V,I,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,>,,1.0,10.0,,,,0.0,0.0,,0.0,60,Q7RTX0,1.3425,VA621I,TAS1R3
14,10.1074/jbc.M414287200,ts1r3_human,640,S,A,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,14.0,-2.933,,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,0.0561923,SA640A,TAS1R3
57,10.1186/1472-6807-7-66,ts1r3_human,640,S,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.8,8.0,,,,0.0,0.0,,0.0,63,Q7RTX0,0.0561923,SA640A,TAS1R3
18,10.1186/1472-6807-7-66,ts1r3_human,775,W,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,>,,3.0,30.0,,,,0.0,0.0,,0.0,30,Q7RTX0,2.94323,WA775A,TAS1R3
24,10.1074/jbc.M505255200,ts1r3_human,790,R,Q,cyclamate,PubChem CID,7533,Allosteric agonist,EC50,Functional - Ca2+ accumulation,3.1,mM,>,,40.0,12.903,,,,0.0,0.0,,0.0,,Q7RTX0,1.41803,RA790Q,TAS1R3
39,10.1186/1472-6807-7-66,ts1r3_human,790,R,Q,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.1,1.0,,,,0.0,0.0,,0.0,77,Q7RTX0,1.41803,RA790Q,TAS1R3
110,10.1074/jbc.M414287200,ts1r3_human,790,R,Q,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,170.0,4.146,Decreased effect,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,1.41803,RA790Q,TAS1R3
25,10.1186/1472-6807-7-66,ts1r3_human,620,S,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.3,13.0,,,,0.0,0.0,,0.0,55,Q7RTX0,-0.379477,SA620A,TAS1R3
26,10.1074/jbc.M505255200,ts1r3_human,723,R,A,cyclamate,PubChem CID,7533,Allosteric agonist,EC50,Functional - Ca2+ accumulation,3.1,mM,=,,19.0,6.129,,,,100.0,0.0,,0.0,,Q7RTX0,1.07093,RA723A,TAS1R3
142,10.1186/1472-6807-7-66,ts1r3_human,723,R,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.2,2.0,,,,0.0,0.0,,0.0,69,Q7RTX0,1.07093,RA723A,TAS1R3
27,10.1186/1472-6807-7-66,ts1r3_human,782,L,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,>,,3.0,30.0,,,,0.0,0.0,,0.0,50,Q7RTX0,1.70039,LA782A,TAS1R3
81,10.1074/jbc.M414287200,ts1r3_human,782,L,A,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,12.0,-3.413,,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,1.70039,LA782A,TAS1R3
28,10.1186/1472-6807-7-66,ts1r3_human,726,S,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.9,9.0,,,,0.0,0.0,,0.0,60,Q7RTX0,1.54358,SA726A,TAS1R3
47,10.1186/1472-6807-7-66,ts1r3_human,726,S,A,cyclamate,PubChem CID,7533,Allosteric agonist,EC50,Functional - Ca2+ accumulation,1.9,mM,>,,10.0,5.263,,,,0.0,0.0,,0.0,,Q7RTX0,1.54358,SA726A,TAS1R3
123,10.1186/1472-6807-7-66,ts1r3_human,726,S,A,cyclamate,PubChem CID,7533,Allosteric agonist,EC50,Functional - Ca2+ accumulation,1.9,mM,>,,10.0,5.263,,,,0.0,0.0,,0.0,,Q7RTX0,1.54358,SA726A,TAS1R3
35,10.1186/1472-6807-7-66,ts1r3_human,804,G,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.3,13.0,,,,0.0,0.0,,0.0,53,Q7RTX0,-0.400266,GA804A,TAS1R3
40,10.1186/1472-6807-7-66,ts1r3_human,637,Q,E,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.5,15.0,,,,0.0,0.0,,0.0,51,Q7RTX0,-0.233911,QA637E,TAS1R3
44,10.1186/1472-6807-7-66,ts1r3_human,641,H,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.2,12.0,,,,0.0,0.0,,0.0,57,Q7RTX0,0.285813,HA641A,TAS1R3
45,10.1186/1472-6807-7-66,ts1r3_human,798,L,I,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.2,2.0,,,,0.0,0.0,,0.0,66,Q7RTX0,0.964335,LA798I,TAS1R3
147,10.1074/jbc.M414287200,ts1r3_human,798,L,I,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,220.0,5.366,Decreased effect,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,0.964335,LA798I,TAS1R3
76,10.1186/1472-6807-7-66,ts1r3_human,729,S,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.2,2.0,,,,0.0,0.0,,0.0,80,Q7RTX0,0.242589,SA729A,TAS1R3
83,10.1186/1472-6807-7-66,ts1r3_human,725,R,M,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,1.3,13.0,,,,0.0,0.0,,0.0,64,Q7RTX0,-0.427399,RA725M,TAS1R3
87,10.1186/1472-6807-7-66,ts1r3_human,721,H,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.8,8.0,,,,0.0,0.0,,0.0,66,Q7RTX0,-0.0319049,HA721A,TAS1R3
89,10.1186/1472-6807-7-66,ts1r3_human,779,V,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.2,2.0,,,,0.0,0.0,,0.0,88,Q7RTX0,-0.450475,VA779A,TAS1R3
94,10.1186/1472-6807-7-66,ts1r3_human,636,Q,A,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.3,3.0,,,,0.0,0.0,,0.0,61,Q7RTX0,0.169274,QA636A,TAS1R3
117,10.1186/1472-6807-7-66,ts1r3_human,699,Y,F,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.6,6.0,,,,0.0,0.0,,0.0,72,Q7RTX0,-0.633987,YA699F,TAS1R3
139,10.1186/1472-6807-7-66,ts1r3_human,699,Y,F,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.5,5.0,,,aspartame,0.0,0.0,,0.0,,Q7RTX0,-0.633987,YA699F,TAS1R3
130,10.1186/1472-6807-7-66,ts1r3_human,733,A,V,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.1,1.0,,,,0.0,0.0,,0.0,133,Q7RTX0,-1.13858,AA733V,TAS1R3
154,10.1074/jbc.M414287200,ts1r3_human,733,A,V,lactisole,PubChem CID,23670520,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,41.0,µM,=,,1900.0,46.341,,,D-tryptophan,0.0,0.0,,0.0,,Q7RTX0,-1.13858,AA733V,TAS1R3
153,10.1186/1472-6807-7-66,ts1r3_human,800,L,F,NHDC,PubChem CID,30231,Allosteric agonist,EC50,Functional - Ca2+ accumulation,0.1,mM,=,,0.2,2.0,,,,0.0,0.0,,0.0,91,Q7RTX0,-0.0278815,LA800F,TAS1R3
0,10807903,drd5_human,439,Q,A,"6,7-ADTN",ChEMBL Compound ID,CHEMBL26736,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,568.0,nM,=,,91.0,-6.25,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
3,10807903,drd5_human,439,Q,A,NPA,ChEMBL Compound ID,CHEMBL225230,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,429.0,nM,=,,144.0,-2.976,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
5,10807903,drd5_human,439,Q,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,220.0,nM,=,,62.0,-3.546,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
8,10807903,drd5_human,439,Q,A,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.0,nM,=,,15.0,-1.2,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
12,10807903,drd5_human,439,Q,A,SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.401,nM,=,,0.354,-1.133,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
18,10807903,drd5_human,439,Q,A,[3H]SCH-23390,ChEMBL Compound ID,CHEMBL62,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,415.0,pM,=,,487.0,1.173,,,,138.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
21,10807903,drd5_human,439,Q,A,Apomorphine,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,125.0,nM,=,,56.0,-2.232,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
22,10807903,drd5_human,439,Q,A,Flupenthixol,ChEMBL Compound ID,CHEMBL54661,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.0,nM,=,,6.0,-1.499,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
23,10807903,drd5_human,439,Q,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,81.0,nM,=,,47.0,-1.724,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
26,10807903,drd5_human,439,Q,A,SKF-38393,ChEMBL Compound ID,CHEMBL24077,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,62.0,nM,=,,51.0,-1.215,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
30,10807903,drd5_human,439,Q,A,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,75.0,nM,=,,28.0,-2.681,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
42,10807903,drd5_human,439,Q,A,SKF-82526,ChEMBL Compound ID,CHEMBL588,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.0,nM,=,,4.0,-2.0,,,[3H]SCH23390,0.0,0.0,,0.0,,P21918,0.166285,QA439A,DRD5
1,8910419,drd5_human,290,K,R,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1470.0,nM,=,,1330.0,-1.105,,,[125I]CH23982,0.0,0.0,,0.0,,P21918,0.159951,KA290R,DRD5
13,8910419,drd5_human,290,K,R,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,46.0,nM,=,,45.0,-1.022,,,[125I]CH23982,0.0,0.0,,0.0,,P21918,0.159951,KA290R,DRD5
31,8910419,drd5_human,290,K,R,[125I]CH23982,ChEMBL Compound ID,CHEMBL290118,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,~,,0.6,1.0,,,,100.0,0.0,,0.0,,P21918,0.159951,KA290R,DRD5
15,8910419,drd5_human,288,I,F,Butaclamol,ChEMBL Compound ID,CHEMBL8514,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,46.0,nM,=,,47.0,1.022,,,[125I]CH23982,0.0,0.0,,0.0,,P21918,-0.345906,IA288F,DRD5
20,8910419,drd5_human,288,I,F,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1470.0,nM,=,,4085.0,2.779,,,[125I]CH23982,0.0,0.0,,0.0,,P21918,-0.345906,IA288F,DRD5
24,8910419,drd5_human,288,I,F,[125I]CH23982,ChEMBL Compound ID,CHEMBL290118,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,~,,0.6,1.0,,,,100.0,0.0,,0.0,,P21918,-0.345906,IA288F,DRD5
1,10.1124/jpet.109.156687,p2y12_human,101,S,A,PSB-0739,CID,44583582,Antagonist,pK(d),CRE-luciferase,9.8,,=,,9.4,2.512,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
2,10.1124/jpet.109.156687,p2y12_human,101,S,A,Suramin,CID,5361,Antagonist,pK(b),CRE-luciferase,5.5,,=,,5.5,1.0,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
6,10.1016/j.bcp.2008.08.029,p2y12_human,101,S,A,2-methylthio-ADP,CID,121990,Agonist,EC50,SRE-luciferase,3.5,nM,=,,2.9,-1.206,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
8,10.1016/j.bcp.2008.08.029,p2y12_human,101,S,A,2-methylthio-ADP,CID,121990,Agonist,IC50,CRE-luciferase,1.4,nM,=,,0.8,-1.751,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
11,10.1124/jpet.109.156687,p2y12_human,101,S,A,BAY-9421,SMILES,c1ccc(c(c1)C(=O)Nc2cc(cc3c2c(cc(c3)S(=O)(=O)[O-])O)S(=O)(=O)[O-])Nc4nc(nc(n4)Cl)Nc5ccccc5C(=O)Nc6cc(cc7c6c(cc(c7)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,5.9,,=,,6.2,-1.996,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
12,10.1111/jth.12719,p2y12_human,101,S,A,Ticagrelor,CID,9871419,Antagonist,pK(b),cAMP accumulation,8.59,,=,,8.78,-1.548,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
15,10.1016/j.bcp.2008.08.029,p2y12_human,101,S,A,Cangrelor,CID,9854012,Antagonist,pK(b),cAMP accumulation,9.2,,=,,9.1,1.259,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
20,10.1124/jpet.109.156687,p2y12_human,101,S,A,2-methylthio-ADP,CID,121990,Agonist,pIC50,CRE-luciferase,9.0,,=,,9.2,-1.585,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
25,10.1016/j.bcp.2008.08.029,p2y12_human,101,S,A,Reactive blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,7.4,,=,,7.6,-1.585,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
31,10.1124/jpet.109.156687,p2y12_human,101,S,A,Reactive red,CID,6509445,Antagonist,pK(b),CRE-luciferase,6.5,,=,,6.6,-1.259,,,,0.0,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
36,10.1016/j.bcp.2008.08.029,p2y12_human,101,S,A,2-methylthio-ADP,CID,121990,Agonist,pIC50,cAMP accumulation,9.5,,=,,8.9,3.981,,,,95.5,0.0,,0.0,,Q9H244,-0.559338,SA101A,P2RY12
3,10.1124/jpet.109.156687,p2y12_human,256,R,A,2-methylthio-ADP,CID,121990,Agonist,pIC50,CRE-luciferase,9.0,,=,,8.4,3.981,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
4,10.1124/jpet.109.156687,p2y12_human,256,R,A,PSB-0826,SMILES,c1ccc(cc1)Nc2ccc(cc2)Nc3cc(c(c4c3C(=O)c5ccccc5C4=O)N)S(=O)(=O)[O-].[Na+],Antagonist,pK(b),CRE-luciferase,8.4,,=,,8.3,1.259,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
5,10.1124/jpet.109.156687,p2y12_human,256,R,A,Suramin,CID,5361,Antagonist,pK(b),CRE-luciferase,5.5,,=,,5.2,1.995,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
10,10.1124/jpet.109.156687,p2y12_human,256,R,A,Cangrelor,CID,9854012,Antagonist,pK(b),CRE-luciferase,8.6,,=,,8.5,1.259,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
14,10.1124/jpet.109.156687,p2y12_human,256,R,A,MG 38-1,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])N.[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,5.9,,=,,4.8,12.589,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
16,10.1111/jth.12719,p2y12_human,256,R,A,Ticagrelor,CID,9871419,Antagonist,pK(b),cAMP accumulation,8.59,,=,,8.64,-1.122,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
17,10.1124/jpet.109.156687,p2y12_human,256,R,A,PSB-0801,SMILES,Cc1cc(c2c(c1N)C(=O)c3ccccc3C2=O)Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5ccccc5.[Na+],Antagonist,pK(b),CRE-luciferase,7.4,,=,,6.7,5.012,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
18,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,Cangrelor,CID,9854012,Antagonist,pK(b),cAMP accumulation,9.2,,=,,9.2,1.0,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
22,10.1124/jpet.109.156687,p2y12_human,256,R,A,BAY-9421,SMILES,c1ccc(c(c1)C(=O)Nc2cc(cc3c2c(cc(c3)S(=O)(=O)[O-])O)S(=O)(=O)[O-])Nc4nc(nc(n4)Cl)Nc5ccccc5C(=O)Nc6cc(cc7c6c(cc(c7)S(=O)(=O)[O-])O)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,5.9,,=,,5.9,1.0,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
23,10.1111/jth.12719,p2y12_human,256,R,A,2-methylthio-ADP,CID,121990,Agonist,EC50,cAMP accumulation,1.04,nM,=,,9.4,9.038,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
24,10.1124/jpet.109.156687,p2y12_human,256,R,A,Reactive blue 2 meta,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,7.8,,=,,7.0,6.31,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
26,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,2-methylthio-ADP,CID,121990,Agonist,EC50,SRE-luciferase,3.5,nM,=,,6.2,1.771,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
27,10.1124/jpet.109.156687,p2y12_human,256,R,A,Reactive blue 2 para,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,7.3,,=,,6.7,3.981,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
32,10.1124/jpet.109.156687,p2y12_human,256,R,A,PSB-0739,CID,44583582,Antagonist,pK(d),CRE-luciferase,9.8,,=,,9.1,5.012,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
33,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,2-methylthio-ADP,CID,121990,Agonist,pIC50,cAMP accumulation,9.5,,=,,7.6,79.433,,,,95.5,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
34,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,2-methylthio-ADP,CID,121990,Agonist,IC50,CRE-luciferase,1.4,nM,=,,9.0,6.429,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
35,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,Reactive blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),cAMP accumulation,7.6,,=,,6.7,7.943,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
37,10.1124/jpet.109.156687,p2y12_human,256,R,A,Cibacron blue 3GA,CID,172469,Antagonist,pK(b),CRE-luciferase,7.2,,=,,5.7,31.623,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
38,10.1124/jpet.109.156687,p2y12_human,256,R,A,Reactive red 2,CID,6509445,Antagonist,pK(b),CRE-luciferase,6.5,,=,,6.5,1.0,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
39,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,A,Reactive blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,7.4,,=,,5.9,31.623,,,,0.0,0.0,,0.0,,Q9H244,-0.154099,RA256A,P2RY12
7,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,K,Cangrelor,CID,9854012,Antagonist,pK(b),cAMP accumulation,9.2,,=,,8.9,1.995,,,,0.0,0.0,,0.0,,Q9H244,-2.01054,RA256K,P2RY12
21,10.1016/j.bcp.2008.08.029,p2y12_human,256,R,K,2-methylthio-ADP,CID,121990,Agonist,pIC50,cAMP accumulation,9.5,,=,,9.7,-1.585,,,,94.0,0.0,,0.0,,Q9H244,-2.01054,RA256K,P2RY12
9,10.1111/jth.12719,p2y12_human,194,C,A,2-methylthio-ADP,CID,121990,Agonist,EC50,CRE-luciferase,0.52,nM,=,,1.13,2.173,,,,0.0,0.0,,0.0,,Q9H244,0.198371,CA194A,P2RY12
13,10.1111/jth.12719,p2y12_human,194,C,A,Reactive blue 2,SMILES,c1ccc2c(c1)C(=O)c3c(cc(c(c3C2=O)N)S(=O)(=O)[O-])Nc4ccc(c(c4)S(=O)(=O)[O-])Nc5nc(nc(n5)Cl)Nc6cccc(c6)S(=O)(=O)[O-].[Na+].[Na+].[Na+],Antagonist,pK(b),CRE-luciferase,9.64,,=,,10.2,-3.636,,,,0.0,0.0,,0.0,,Q9H244,0.198371,CA194A,P2RY12
19,10.1111/jth.12719,p2y12_human,194,C,A,PSB-0739,CID,44583582,Antagonist,pK(b),CRE-luciferase,7.72,,=,,8.88,-14.493,,,,0.0,0.0,,0.0,,Q9H244,0.198371,CA194A,P2RY12
28,10.1111/jth.12719,p2y12_human,194,C,A,Ticagrelor,CID,9871419,Antagonist,pK(b),CRE-luciferase,8.95,,=,,8.12,6.761,,,,0.0,0.0,,0.0,,Q9H244,0.198371,CA194A,P2RY12
30,10.1111/jth.12719,p2y12_human,194,C,A,2-methylthio-ADP,CID,121990,Agonist,EC50,cAMP accumulation,1.04,nM,=,,2.5,2.404,,,,97.8,0.0,,0.0,,Q9H244,0.198371,CA194A,P2RY12
29,10.1111/jth.12719,p2y12_human,248,C,A,Ticagrelor,CID,9871419,Antagonist,pK(b),cAMP accumulation,8.59,,=,,8.55,1.096,,,,0.0,0.0,,0.0,,Q9H244,0.134869,CA248A,P2RY12
2,2159799,adrb2_human,190,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,130.0,22.414,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.94316,CA190V,ADRB2
57,2159799,adrb2_human,190,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,153.0,38.432,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.94316,CA190V,ADRB2
129,2159799,adrb2_human,190,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,55.0,152.778,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.94316,CA190V,ADRB2
458,2159799,adrb2_human,190,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,3.4,26.154,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.94316,CA190V,ADRB2
552,2159799,adrb2_human,190,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,124.0,11.273,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.94316,CA190V,ADRB2
4,8101966,adrb2_human,312,N,T,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.47,µM,=,,58.0,123.404,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
101,8101966,adrb2_human,312,N,T,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,79.432823,50.119,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
155,8101966,adrb2_human,312,N,T,Yohimbine,ChEMBL Compound ID,CHEMBL15245,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,81.0,µM,=,,5.4,-14.925,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
204,8101966,adrb2_human,312,N,T,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.398107,nM,=,,794.328235,1995.263,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
510,8101966,adrb2_human,312,N,T,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.9,µM,=,,10.0,5.263,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
523,8101966,adrb2_human,312,N,T,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.29,nM,=,,31.622777,109.044,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.57422,NA312T,ADRB2
5,8799191,adrb2_human,293,N,L,(-)-norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.9,µM,=,,43.0,11.026,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
22,8799191,adrb2_human,293,N,L,(rac)-dobutamine,ChEMBL Compound ID,CHEMBL926,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,66.0,µM,=,,63.0,-1.047,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
51,8799191,adrb2_human,293,N,L,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.6,µM,=,,5.8,-1.828,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
140,8799191,adrb2_human,293,N,L,(rac)-terbutaline,ChEMBL Compound ID,CHEMBL1760,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.4,µM,=,,8.3,1.537,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
195,8799191,adrb2_human,293,N,L,(+)-Epinephrine,ChEMBL Compound ID,CHEMBL42280,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.1,µM,=,,31.0,14.762,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
234,8799191,adrb2_human,293,N,L,dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,400.0,µM,=,,550.0,1.375,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
344,8799191,adrb2_human,293,N,L,(+)-norepinephrine,ChEMBL Compound ID,CHEMBL18824,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,174.0,µM,=,,800.0,4.598,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
436,8799191,adrb2_human,293,N,L,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0071,nM,=,,0.007943,1.119,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
447,8799191,adrb2_human,293,N,L,(+)-clenbuterol,ChEMBL Compound ID,CHEMBL1396140,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,0.3,-1.866,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
474,8799191,adrb2_human,293,N,L,(rac)-clenbuterol,ChEMBL Compound ID,CHEMBL49080,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.024,µM,=,,0.025,1.042,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
524,8799191,adrb2_human,293,N,L,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.28,µM,=,,2.5,8.929,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
566,8799191,adrb2_human,293,N,L,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.17,µM,=,,6.2,36.471,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.81175,NA293L,ADRB2
6,10510435,adrb2_human,204,S,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,24.4,pM,=,,17.9,-1.362,,,[125I]iodocyanopindolol (radioligand),63.1,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
77,10964911,adrb2_human,204,S,A,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.3,4.169,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
82,10964911,adrb2_human,204,S,A,Synephrine,ChEMBL Compound ID,CHEMBL33720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,4.84,-1.024,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
139,9249239,adrb2_human,204,S,A,Salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,21.0,nM,=,,66.2,3.152,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
258,9249239,adrb2_human,204,S,A,Salbutamol,ChEMBL Compound ID,CHEMBL714,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3340.0,nM,=,,8080.0,2.419,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
272,10964911,adrb2_human,204,S,A,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.5,,=,,4.68,6.607,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
319,10510435,adrb2_human,204,S,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.21,µM,=,,6.9,32.857,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
383,9249239,adrb2_human,204,S,A,(-)-Isoprenaline,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,904.0,nM,=,,24100.0,26.659,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
413,10617695,adrb2_human,204,S,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,199.526231,nM,=,,5011.872336,25.119,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
491,10964911,adrb2_human,204,S,A,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,5.37,33.884,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
590,10510435,adrb2_human,204,S,A,Meta-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL327122,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,14.8,6.727,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
634,9249239,adrb2_human,204,S,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,671.0,55.917,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
653,10510435,adrb2_human,204,S,A,Para-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL109378,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,µM,=,,5.6,1.647,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.671674,SA204A,ADRB2
11,9765503,adrb2_human,317,V,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,25.8,1.112,,,[125I]iodocyanopindolol (radioligand),81.8,0.0,,0.0,,P07550,0.404322,VA317A,ADRB2
197,9443940,adrb2_human,317,V,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,5.9,1.372,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.404322,VA317A,ADRB2
212,9765503,adrb2_human,317,V,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,2.2,1.388,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.404322,VA317A,ADRB2
393,9443940,adrb2_human,317,V,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,32.0,1.032,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.404322,VA317A,ADRB2
597,9443940,adrb2_human,317,V,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,310.0,1.292,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.404322,VA317A,ADRB2
13,8799191,adrb2_human,165,S,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.28,µM,=,,0.19,-1.473,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.40657,SA165A,ADRB2
37,8799191,adrb2_human,165,S,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0071,nM,=,,0.012589,1.773,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.40657,SA165A,ADRB2
351,8799191,adrb2_human,165,S,A,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.6,µM,=,,39.8,3.755,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.40657,SA165A,ADRB2
20,7901205,adrb2_human,164,T,I,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.43,nM,=,,1.97,4.581,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
48,7901205,adrb2_human,164,T,I,dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,209.0,nM,=,,238.0,1.139,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
240,7901205,adrb2_human,164,T,I,propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.2,3.333,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
291,7901205,adrb2_human,164,T,I,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,68.2,nM,=,,295.0,4.326,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
316,7901205,adrb2_human,164,T,I,CGP-20712,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1110.0,nM,=,,6580.0,5.928,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
414,7901205,adrb2_human,164,T,I,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,368.0,nM,=,,1450.0,3.94,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
427,7901205,adrb2_human,164,T,I,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.3,nM,=,,9.74,-1.057,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
475,7901205,adrb2_human,164,T,I,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.58,nM,=,,3.48,1.349,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
500,7901205,adrb2_human,164,T,I,alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.11,nM,=,,0.18,1.636,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
535,7901205,adrb2_human,164,T,I,Dobutamine,ChEMBL Compound ID,CHEMBL926,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.31,nM,=,,4.48,1.939,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
581,7901205,adrb2_human,164,T,I,norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10395.0,nM,=,,45000.0,4.329,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.34819,TA164I,ADRB2
21,10652295,adrb2_human,268,E,A,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.36,nM,=,,1.2,3.333,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
125,11375997,adrb2_human,268,E,A,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.2,3.333,,,[3H]CGP-12177 (radioligand),92.4,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
236,11375997,adrb2_human,268,E,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,45.0,nM,=,,16.0,-2.809,,,[3H]CGP-12177 (radioligand),92.4,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
310,10652295,adrb2_human,268,E,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,124.0,nM,=,,70.0,-1.77,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
356,10652295,adrb2_human,268,E,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,nM,=,,1.3,-2.309,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
538,11375997,adrb2_human,268,E,A,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.14,2.333,,,[3H]CGP-12177 (radioligand),92.4,0.0,,0.0,,P07550,0.364894,EA268A,ADRB2
25,7492540,adrb2_human,323,P,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,21.0,nM,=,,48.0,2.286,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.75437,PA323A,ADRB2
449,7492540,adrb2_human,323,P,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,12.0,4.8,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.75437,PA323A,ADRB2
27,9765503,adrb2_human,309,I,A,Salmeterol-derivative 2,SMILES,OCC1=C(O)C=CC([C@@H](CNCCCCCCCCOCCC2=CC=CC=C2)O)=C1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,96.0,nM,=,,281.0,2.927,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
164,9765503,adrb2_human,309,I,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.2,pM,=,,34.0,1.09,,,[125I]iodocyanopindolol (radioligand),115.9,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
188,9443940,adrb2_human,309,I,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,34.0,1.097,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
225,9765503,adrb2_human,309,I,A,Salmeterol-derivative 1,SMILES,OCC1=C(O)C=CC([C@@H](CNCCCCOCCCCCCC2=CC=CC=C2)O)=C1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,50.118723,nM,=,,133.0,2.654,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
238,9765503,adrb2_human,309,I,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,18.7,11.799,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
263,9765503,adrb2_human,309,I,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,24.0,15.143,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
394,9443940,adrb2_human,309,I,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,21.0,4.884,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
440,9765503,adrb2_human,309,I,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,26.6,1.147,,,[125I]iodocyanopindolol (radioligand),75.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
455,9765503,adrb2_human,309,I,A,Salmeterol-derivative 3,ChEMBL Compound ID,CHEMBL1800935,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,220.0,nM,=,,3370.0,15.318,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
645,9443940,adrb2_human,309,I,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,360.0,1.5,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.891215,IA309A,ADRB2
31,10617695,adrb2_human,204,S,C,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,199.526231,nM,=,,6309.573445,31.623,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.533539,SA204C,ADRB2
33,12409304,adrb2_human,269,H,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,7.4,nM,=,,2.0,-3.704,,,,0.0,0.0,,0.0,,P07550,-0.604864,HA269A,ADRB2
198,12409304,adrb2_human,269,H,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,220.0,2.0,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.604864,HA269A,ADRB2
468,12409304,adrb2_human,269,H,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.5,nM,=,,120.0,6.486,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.604864,HA269A,ADRB2
641,12409304,adrb2_human,269,H,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.54,nM,=,,1.182,2.189,,,,0.0,0.0,,0.0,,P07550,-0.604864,HA269A,ADRB2
36,10510435,adrb2_human,207,S,A,Para-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL109378,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,µM,=,,2.5,-1.361,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
153,10510435,adrb2_human,207,S,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,24.4,pM,=,,20.2,-1.208,,,[125I]iodocyanopindolol (radioligand),57.2,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
222,10510435,adrb2_human,207,S,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.21,µM,=,,2.3,10.952,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
391,10617695,adrb2_human,207,S,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,199.526231,nM,=,,3981.071706,19.953,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
529,10617695,adrb2_human,207,S,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,199.526231,nM,=,,3162.27766,15.849,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
595,10510435,adrb2_human,207,S,A,Meta-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL327122,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,1.4,-1.572,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.0517112,SA207A,ADRB2
42,12409304,adrb2_human,225,E,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,7.4,nM,=,,2.2,-3.367,,,,0.0,0.0,,0.0,,P07550,-0.00778806,EA225A,ADRB2
136,12409304,adrb2_human,225,E,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,91.0,-1.209,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.00778806,EA225A,ADRB2
435,12409304,adrb2_human,225,E,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.5,nM,=,,35.0,1.892,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.00778806,EA225A,ADRB2
582,12409304,adrb2_human,225,E,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.54,nM,=,,0.91,1.685,,,,0.0,0.0,,0.0,,P07550,-0.00778806,EA225A,ADRB2
46,9765503,adrb2_human,308,Y,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,184.0,116.096,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
119,9443940,adrb2_human,308,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,1300.0,5.417,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
122,9765503,adrb2_human,308,Y,A,Salmeterol-derivative 1,SMILES,OCC1=C(O)C=CC([C@@H](CNCCCCOCCCCCCC2=CC=CC=C2)O)=C1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,50.118723,nM,=,,542.0,10.814,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
219,9765503,adrb2_human,308,Y,A,Salmeterol-derivative 3,ChEMBL Compound ID,CHEMBL1800935,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,220.0,nM,=,,1300.0,5.909,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
235,9765503,adrb2_human,308,Y,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.2,pM,=,,29.8,-1.047,,,[125I]iodocyanopindolol (radioligand),127.3,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
260,9443940,adrb2_human,308,Y,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,71.0,16.512,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
289,9765503,adrb2_human,308,Y,A,Salmeterol-derivative 2,SMILES,OCC1=C(O)C=CC([C@@H](CNCCCCCCCCOCCC2=CC=CC=C2)O)=C1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,96.0,nM,=,,1400.0,14.583,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
303,9765503,adrb2_human,308,Y,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,24.2,1.043,,,[125I]iodocyanopindolol (radioligand),93.2,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
352,9765503,adrb2_human,308,Y,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,184.0,116.096,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
610,9443940,adrb2_human,308,Y,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,27.0,-1.148,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.81401,YA308A,ADRB2
53,12167654,adrb2_human,285,C,T,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,71.3,nM,=,,13.8,-5.155,,,[3H]CGP-12177,0.0,0.0,,0.0,,P07550,-0.190558,CA285T,ADRB2
361,12167654,adrb2_human,285,C,T,[3H]CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.073,nM,=,,0.081,1.11,,,,0.0,0.0,,0.0,,P07550,-0.190558,CA285T,ADRB2
58,12409304,adrb2_human,265,C,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.54,nM,=,,0.44,-1.227,,,,0.0,0.0,,0.0,,P07550,-0.661045,CA265A,ADRB2
90,12409304,adrb2_human,265,C,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.5,nM,=,,40.0,2.162,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.661045,CA265A,ADRB2
386,12409304,adrb2_human,265,C,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,7.4,nM,=,,0.84,-8.772,,,,0.0,0.0,,0.0,,P07550,-0.661045,CA265A,ADRB2
460,12409304,adrb2_human,265,C,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,60.0,-1.835,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.661045,CA265A,ADRB2
59,2159799,adrb2_human,184,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,47.0,4.273,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.92154,CA184V,ADRB2
67,2159799,adrb2_human,184,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,1.8,13.846,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.92154,CA184V,ADRB2
295,2159799,adrb2_human,184,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,320.0,55.172,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.92154,CA184V,ADRB2
395,2159799,adrb2_human,184,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,55.0,13.815,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.92154,CA184V,ADRB2
609,2159799,adrb2_human,184,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,15.848932,44.025,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.92154,CA184V,ADRB2
61,2540197,adrb2_human,341,C,G,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.6,pM,=,,26.4,-1.198,,,,70.1,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
83,2846532,adrb2_human,341,C,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,441.3,1.087,,,[125I]iodocyanopindolol,105.3,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
177,2540197,adrb2_human,341,C,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,185.0,nM,=,,206.0,1.114,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
196,8702933,adrb2_human,341,C,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,33.0,nM,=,,73.0,2.212,,,[125I]iodocyanopindolol (radioligand),74.4,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
442,8381352,adrb2_human,341,C,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,233.0,nM,=,,287.0,1.232,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
504,2846532,adrb2_human,341,C,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,390.38,-1.04,,,[125I]iodocyanopindolol,105.3,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
537,8702933,adrb2_human,341,C,G,Iodocyanopindolol,PubChem CID,68618,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,51.3,pM,=,,70.0,1.365,,,[125I]iodocyanopindolol (radioligand),74.4,0.0,,0.0,,P07550,-1.17972,CA341G,ADRB2
64,2840663,adrb2_human,130,D,N,(-)-Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,219.0,nM,=,,55.0,-3.984,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
80,11375997,adrb2_human,130,D,N,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.11,1.833,,,[3H]CGP-12177 (radioligand),9.1,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
117,2840663,adrb2_human,130,D,N,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,56.5,nM,=,,4.3,-13.158,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
135,10385699,adrb2_human,130,D,N,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.93,nM,=,,0.92,-1.011,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
144,2840663,adrb2_human,130,D,N,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,36.8,nM,=,,65.0,1.766,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
187,2840663,adrb2_human,130,D,N,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,200.0,nM,=,,32.5,-6.135,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
425,10385699,adrb2_human,130,D,N,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.22,1.1,,,[3H]dihydroalprenolol,7.1,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
499,2840663,adrb2_human,130,D,N,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.22,nM,=,,0.36,1.636,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
511,2840663,adrb2_human,130,D,N,(+)-Epinephrine,ChEMBL Compound ID,CHEMBL42280,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,500.0,nM,=,,75.0,-6.667,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
532,11375997,adrb2_human,130,D,N,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.06,1.0,,,[3H]CGP-12177 (radioligand),9.1,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
542,2840663,adrb2_human,130,D,N,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,17.6,nM,=,,2.5,-7.042,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
557,10385699,adrb2_human,130,D,N,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,278.0,nM,=,,11.5,-24.39,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
570,2840663,adrb2_human,130,D,N,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,120.0,nM,=,,9.3,-12.987,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
626,2840663,adrb2_human,130,D,N,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,21.0,nM,=,,32.0,1.524,,,,0.0,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
640,11375997,adrb2_human,130,D,N,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,45.0,nM,=,,0.398107,-111.111,,,[3H]CGP-12177 (radioligand),9.1,0.0,,0.0,,P07550,3.39411,DA130N,ADRB2
66,9452461,adrb2_human,116,C,F,Dichloroisoproterenol,ChEMBL Compound ID,CHEMBL30816,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,170.0,nM,=,,9.3,-18.182,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
95,9452461,adrb2_human,116,C,F,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,0.67,1.861,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
123,9452461,adrb2_human,116,C,F,Metaproterenol,ChEMBL Compound ID,CHEMBL776,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12000.0,nM,=,,1700.0,-7.042,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
213,9452461,adrb2_human,116,C,F,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.087,nM,=,,2.3,26.437,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
268,9452461,adrb2_human,116,C,F,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.22,nM,=,,8.7,39.545,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
486,9452461,adrb2_human,116,C,F,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.62,nM,=,,0.078,-7.937,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
507,9452461,adrb2_human,116,C,F,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.12,nM,=,,0.44,3.667,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
573,9452461,adrb2_human,116,C,F,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,120.0,nM,=,,1.6,-76.923,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
600,9452461,adrb2_human,116,C,F,Albuterol,ChEMBL Compound ID,CHEMBL714,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,180.0,nM,=,,120.0,-1.499,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
621,9452461,adrb2_human,116,C,F,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,5.6,-50.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,3.96083,CA116F,ADRB2
70,9443940,adrb2_human,320,G,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,480.0,2.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.899674,GA320A,ADRB2
98,9443940,adrb2_human,320,G,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,49.0,1.581,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.899674,GA320A,ADRB2
143,9443940,adrb2_human,320,G,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,9.0,2.093,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.899674,GA320A,ADRB2
362,9765503,adrb2_human,320,G,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,44.7,1.927,,,[125I]iodocyanopindolol (radioligand),140.9,0.0,,0.0,,P07550,-0.899674,GA320A,ADRB2
412,9765503,adrb2_human,320,G,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,3.0,1.893,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.899674,GA320A,ADRB2
72,8832227,adrb2_human,326,Y,F,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,40.9,pM,=,,45.5,1.112,,,,91.5,0.0,,0.0,,P07550,-0.509096,YA326F,ADRB2
94,8832227,adrb2_human,326,Y,F,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,681.0,nM,=,,815.0,1.197,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,-0.509096,YA326F,ADRB2
189,7492540,adrb2_human,326,Y,F,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,15.0,6.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.509096,YA326F,ADRB2
420,7492540,adrb2_human,326,Y,F,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,21.0,nM,=,,57.0,2.714,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.509096,YA326F,ADRB2
571,8832227,adrb2_human,326,Y,F,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,17.0,nM,=,,44.0,2.588,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,-0.509096,YA326F,ADRB2
81,9443940,adrb2_human,311,L,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,12.0,2.791,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.52709,LA311A,ADRB2
320,9443940,adrb2_human,311,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,28.0,-1.107,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.52709,LA311A,ADRB2
376,9765503,adrb2_human,311,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,26.1,1.125,,,[125I]iodocyanopindolol (radioligand),88.6,0.0,,0.0,,P07550,2.52709,LA311A,ADRB2
451,9443940,adrb2_human,311,L,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,360.0,1.5,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.52709,LA311A,ADRB2
624,9765503,adrb2_human,311,L,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,1.6,1.01,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.52709,LA311A,ADRB2
86,2159799,adrb2_human,77,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,0.29,2.231,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.798068,CA77V,ADRB2
116,2159799,adrb2_human,77,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,6.9,1.733,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.798068,CA77V,ADRB2
210,2159799,adrb2_human,77,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,1.1,3.056,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.798068,CA77V,ADRB2
433,2159799,adrb2_human,77,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,13.0,1.182,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.798068,CA77V,ADRB2
555,2159799,adrb2_human,77,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,23.0,3.966,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.798068,CA77V,ADRB2
87,8388251,adrb2_human,350,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,19.0,nM,=,,4.0,-4.739,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.329545,YA350A,ADRB2
214,8388251,adrb2_human,350,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,377.0,nM,=,,289.0,-1.304,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.329545,YA350A,ADRB2
100,10964911,adrb2_human,203,S,C,Synephrine,ChEMBL Compound ID,CHEMBL33720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,5.28,-2.817,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
120,10964911,adrb2_human,203,S,C,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.5,,=,,4.83,4.677,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
121,10964911,adrb2_human,203,S,C,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,5.05,70.795,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
199,10964911,adrb2_human,203,S,C,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.02,-1.259,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
419,10964911,adrb2_human,203,S,C,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.87,,=,,10.6,-5.376,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
466,10964911,adrb2_human,203,S,C,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.88,,=,,8.9,9.55,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
540,10964911,adrb2_human,203,S,C,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.16,,=,,8.35,64.565,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
628,10964911,adrb2_human,203,S,C,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.17,,=,,9.86,2.042,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.844623,SA203C,ADRB2
107,10964911,adrb2_human,203,S,V,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.88,,=,,9.07,6.457,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
251,10964911,adrb2_human,203,S,V,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.17,,=,,10.2,-1.072,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
279,10964911,adrb2_human,203,S,V,Synephrine,ChEMBL Compound ID,CHEMBL33720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,5.37,-3.472,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
304,10964911,adrb2_human,203,S,V,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.5,,=,,5.3,1.585,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
349,10964911,adrb2_human,203,S,V,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.87,,=,,10.22,-2.237,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
370,10964911,adrb2_human,203,S,V,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.16,,=,,8.33,67.608,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
381,10964911,adrb2_human,203,S,V,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,5.3,39.811,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
577,10964911,adrb2_human,203,S,V,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.5,-3.802,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.303498,SA203V,ADRB2
108,2831218,adrb2_human,79,D,N,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,199.526231,nM,=,,12167.0,60.979,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
115,2831218,adrb2_human,79,D,N,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.22,nM,=,,0.22,1.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
128,2831218,adrb2_human,79,D,N,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,36.8,nM,=,,36.8,1.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
134,2831218,adrb2_human,79,D,N,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,17.6,nM,=,,697.0,39.602,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
142,15102946,adrb2_human,79,D,N,Methyldopamine,ChEMBL Compound ID,CHEMBL31088,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.37,,=,,4.46,8.128,,,[3H]CGP-12177,0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
200,15102946,adrb2_human,79,D,N,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.4,,=,,4.21,15.488,,,[3H]CGP-12177,0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
250,2831218,adrb2_human,79,D,N,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,56.5,nM,=,,7800.0,138.053,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
388,15102946,adrb2_human,79,D,N,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.08,,=,,4.32,5.754,,,[3H]CGP-12177,0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
472,2831218,adrb2_human,79,D,N,(-)-norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,219.0,nM,=,,52500.0,239.726,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
493,15102946,adrb2_human,79,D,N,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.16,,=,,5.32,69.183,,,[3H]CGP-12177,0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
643,2831218,adrb2_human,79,D,N,(rac)-iodocyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,21.0,nM,=,,22.0,1.048,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.483982,DA79N,ADRB2
126,9443940,adrb2_human,324,L,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,280.0,1.167,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.252616,LA324A,ADRB2
131,9443940,adrb2_human,324,L,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,21.0,4.884,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.252616,LA324A,ADRB2
275,9765503,adrb2_human,324,L,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,4.7,2.965,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.252616,LA324A,ADRB2
392,9443940,adrb2_human,324,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,36.0,1.161,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.252616,LA324A,ADRB2
604,9765503,adrb2_human,324,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,32.9,1.418,,,[125I]iodocyanopindolol (radioligand),104.5,0.0,,0.0,,P07550,0.252616,LA324A,ADRB2
132,2159799,adrb2_human,191,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,167.0,15.182,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,6.812,CA191V,ADRB2
166,2159799,adrb2_human,191,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,120.0,20.69,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,6.812,CA191V,ADRB2
231,2159799,adrb2_human,191,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,672.0,168.799,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,6.812,CA191V,ADRB2
245,2159799,adrb2_human,191,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,2.9,22.308,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,6.812,CA191V,ADRB2
520,2159799,adrb2_human,191,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,57.0,158.333,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,6.812,CA191V,ADRB2
151,10964911,adrb2_human,203,S,T,Synephrine,ChEMBL Compound ID,CHEMBL33720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,4.97,-1.381,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
163,10964911,adrb2_human,203,S,T,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,6.46,2.754,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
315,10964911,adrb2_human,203,S,T,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.87,,=,,10.01,-1.381,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
339,10964911,adrb2_human,203,S,T,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.16,,=,,9.45,5.129,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
441,10964911,adrb2_human,203,S,T,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.88,,=,,10.11,-1.698,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
601,10964911,adrb2_human,203,S,T,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.17,,=,,9.83,2.188,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
612,10964911,adrb2_human,203,S,T,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.89,1.072,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
617,10964911,adrb2_human,203,S,T,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.5,,=,,5.39,1.288,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.29839,SA203T,ADRB2
157,7507928,adrb2_human,326,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,4.1,nM,=,,0.2,-20.408,,,[125I]-pindolol,0.0,64.3,,0.0,,P07550,3.38986,YA326A,ADRB2
325,8832227,adrb2_human,326,Y,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,681.0,nM,=,,1101.0,1.617,,,[125I]iodocyanopindolol,0.0,0.0,,0.0,,P07550,3.38986,YA326A,ADRB2
608,7507928,adrb2_human,326,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,379.0,nM,=,,327.0,-1.159,,,[125I]-pindolol,0.0,64.3,,0.0,,P07550,3.38986,YA326A,ADRB2
615,8832227,adrb2_human,326,Y,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,40.9,pM,=,,40.1,-1.02,,,,68.9,0.0,,0.0,,P07550,3.38986,YA326A,ADRB2
650,7507928,adrb2_human,326,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,617.0,nM,=,,177.0,-3.484,,,[125I]-pindolol,0.0,64.3,,0.0,,P07550,3.38986,YA326A,ADRB2
160,2846532,adrb2_human,64,L,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,37.59,-10.753,,,[125I]iodocyanopindolol,384.6,0.0,,0.0,,P07550,4.68807,LA64G,ADRB2
167,10510435,adrb2_human,203,S,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.21,µM,=,,2.9,13.81,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
178,10510435,adrb2_human,203,S,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,24.4,pM,=,,46.1,1.889,,,[125I]iodocyanopindolol (radioligand),25.5,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
247,10964911,adrb2_human,203,S,A,Propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.87,,=,,10.92,-11.236,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
254,10964911,adrb2_human,203,S,A,Alprenolol,ChEMBL Compound ID,CHEMBL266195,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.17,,=,,10.33,-1.445,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
261,10964911,adrb2_human,203,S,A,Epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,5.5,25.119,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
266,10964911,adrb2_human,203,S,A,Synephrine,ChEMBL Compound ID,CHEMBL33720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,5.48,-4.464,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
300,10510435,adrb2_human,203,S,A,Para-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL109378,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,µM,=,,2.4,-1.416,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
331,10964911,adrb2_human,203,S,A,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.88,,=,,9.34,3.467,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
373,10964911,adrb2_human,203,S,A,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.5,,=,,4.81,4.898,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
550,10964911,adrb2_human,203,S,A,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.16,,=,,8.77,24.547,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
564,10964911,adrb2_human,203,S,A,Halostachine,ChEMBL Compound ID,CHEMBL1241267,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.51,-3.891,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
625,10510435,adrb2_human,203,S,A,Meta-hydroxyl isoprenaline,ChEMBL Compound ID,CHEMBL327122,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,8.3,3.773,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.927258,SA203A,ADRB2
175,10385699,adrb2_human,130,D,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,278.0,nM,=,,22.2,-12.5,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
294,10652295,adrb2_human,130,D,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,124.0,nM,=,,42.0,-2.95,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
328,10385699,adrb2_human,130,D,A,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.93,nM,=,,0.83,-1.121,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
518,10652295,adrb2_human,130,D,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,nM,=,,1.8,-1.667,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
545,10385699,adrb2_human,130,D,A,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.2,nM,=,,0.2,1.0,,,[3H]dihydroalprenolol,41.4,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
567,10652295,adrb2_human,130,D,A,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.36,nM,=,,1.3,3.611,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.89833,DA130A,ADRB2
184,11375997,adrb2_human,268,E,Q,Pindolol,ChEMBL Compound ID,CHEMBL500,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.36,6.0,,,[3H]CGP-12177 (radioligand),166.7,0.0,,0.0,,P07550,-0.31854,EA268Q,ADRB2
286,11375997,adrb2_human,268,E,Q,CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.06,nM,=,,0.12,2.0,,,[3H]CGP-12177 (radioligand),166.7,0.0,,0.0,,P07550,-0.31854,EA268Q,ADRB2
408,11375997,adrb2_human,268,E,Q,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,45.0,nM,=,,32.0,-1.406,,,[3H]CGP-12177 (radioligand),166.7,0.0,,0.0,,P07550,-0.31854,EA268Q,ADRB2
192,9765503,adrb2_human,306,E,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,22.3,-1.041,,,[125I]iodocyanopindolol (radioligand),4.5,0.0,,0.0,,P07550,0.794616,EA306A,ADRB2
270,9443940,adrb2_human,306,E,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,200.0,-1.2,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.794616,EA306A,ADRB2
343,9443940,adrb2_human,306,E,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,4.7,1.093,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.794616,EA306A,ADRB2
390,9443940,adrb2_human,306,E,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,33.0,1.065,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.794616,EA306A,ADRB2
536,9765503,adrb2_human,306,E,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,3.162278,1.995,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.794616,EA306A,ADRB2
217,2159799,adrb2_human,106,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,110.0,18.966,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,8.14207,CA106V,ADRB2
358,2159799,adrb2_human,106,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,210.0,52.75,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,8.14207,CA106V,ADRB2
492,2159799,adrb2_human,106,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,471.0,1308.333,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,8.14207,CA106V,ADRB2
496,2159799,adrb2_human,106,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,3.5,26.923,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,8.14207,CA106V,ADRB2
579,2159799,adrb2_human,106,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,173.0,15.727,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,8.14207,CA106V,ADRB2
218,2159799,adrb2_human,285,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,0.04,-3.247,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.13828,CA285V,ADRB2
353,2159799,adrb2_human,285,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,19.0,1.727,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.13828,CA285V,ADRB2
369,2159799,adrb2_human,285,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,0.095,-3.788,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.13828,CA285V,ADRB2
494,2159799,adrb2_human,285,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,2.4,-2.415,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.13828,CA285V,ADRB2
637,2159799,adrb2_human,285,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,2.1,-1.898,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.13828,CA285V,ADRB2
228,2159799,adrb2_human,125,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,0.46,3.538,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.466113,CA125V,ADRB2
438,2159799,adrb2_human,125,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,16.0,4.019,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.466113,CA125V,ADRB2
525,2159799,adrb2_human,125,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,27.0,4.655,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.466113,CA125V,ADRB2
531,2159799,adrb2_human,125,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,4.1,11.389,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.466113,CA125V,ADRB2
622,2159799,adrb2_human,125,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,11.0,1.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.466113,CA125V,ADRB2
230,9765503,adrb2_human,314,I,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,2.0,1.262,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.12822,IA314A,ADRB2
265,9443940,adrb2_human,314,I,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,150.0,-1.6,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.12822,IA314A,ADRB2
269,9443940,adrb2_human,314,I,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,3.2,-1.344,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.12822,IA314A,ADRB2
405,9443940,adrb2_human,314,I,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,28.0,-1.107,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.12822,IA314A,ADRB2
432,9765503,adrb2_human,314,I,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,21.5,-1.079,,,[125I]iodocyanopindolol (radioligand),65.9,0.0,,0.0,,P07550,1.12822,IA314A,ADRB2
241,7492540,adrb2_human,322,N,D,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,3.7,1.48,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.550484,NA322D,ADRB2
385,7492540,adrb2_human,322,N,D,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,21.0,nM,=,,29.0,1.381,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.550484,NA322D,ADRB2
243,10652295,adrb2_human,122,E,A,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.36,nM,=,,1.5,4.167,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.141238,EA122A,ADRB2
481,10652295,adrb2_human,122,E,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,nM,=,,5.5,1.833,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.141238,EA122A,ADRB2
495,10652295,adrb2_human,122,E,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,124.0,nM,=,,712.0,5.742,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.141238,EA122A,ADRB2
262,11118431,adrb2_human,269,H,C,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.16,µM,,,0.1,-1.6,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,-0.0596613,HA269C,ADRB2
292,11118431,adrb2_human,269,H,C,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.66,nM,,,0.45,-1.466,,,[3H]dihydroalprenolol,44.9,0.0,,0.0,,P07550,-0.0596613,HA269C,ADRB2
276,9765503,adrb2_human,307,V,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,2.3,1.451,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.47554,VA307A,ADRB2
411,9443940,adrb2_human,307,V,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,35.0,1.129,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.47554,VA307A,ADRB2
478,9765503,adrb2_human,307,V,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,22.8,-1.017,,,[125I]iodocyanopindolol (radioligand),59.1,0.0,,0.0,,P07550,0.47554,VA307A,ADRB2
515,9443940,adrb2_human,307,V,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,6.3,1.465,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.47554,VA307A,ADRB2
633,9443940,adrb2_human,307,V,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,330.0,1.375,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.47554,VA307A,ADRB2
282,9443940,adrb2_human,310,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,31.0,pM,=,,39.0,1.258,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.638896,LA310A,ADRB2
366,9443940,adrb2_human,310,L,A,TA-2005,ChEMBL Compound ID,CHEMBL1094785,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.3,nM,=,,5.5,1.279,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.638896,LA310A,ADRB2
377,9765503,adrb2_human,310,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,23.2,pM,=,,25.7,1.108,,,[125I]iodocyanopindolol (radioligand),79.5,0.0,,0.0,,P07550,0.638896,LA310A,ADRB2
553,9765503,adrb2_human,310,L,A,salmeterol,ChEMBL Compound ID,CHEMBL1263,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.584893,nM,=,,2.0,1.262,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.638896,LA310A,ADRB2
565,9443940,adrb2_human,310,L,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,240.0,nM,=,,280.0,1.167,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.638896,LA310A,ADRB2
296,9356441,adrb2_human,339,L,A,(-)-Isoprenaline,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,323.0,nM,=,,358.0,1.108,,,[125I]iodocyanopindolol (radioligand),181.6,0.0,,0.0,,P07550,2.96623,LA339A,ADRB2
382,9356441,adrb2_human,339,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,44.6,pM,=,,44.0,-1.013,,,[125I]iodocyanopindolol (radioligand),181.6,0.0,,0.0,,P07550,2.96623,LA339A,ADRB2
498,9356441,adrb2_human,339,L,A,(-)-Isoprenaline,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,7.0,nM,=,,7.0,1.0,,,[125I]iodocyanopindolol (radioligand),181.6,0.0,,0.0,,P07550,2.96623,LA339A,ADRB2
606,9356441,adrb2_human,339,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,44.6,pM,=,,44.0,-1.013,,,[125I]iodocyanopindolol (radioligand),181.6,0.0,,0.0,,P07550,2.96623,LA339A,ADRB2
620,9356441,adrb2_human,339,L,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,361.0,nM,=,,421.0,1.166,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,2.96623,LA339A,ADRB2
311,2159799,adrb2_human,116,C,V,epinephrine,ChEMBL Compound ID,CHEMBL1740,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,0.3,-1.2,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.835568,CA116V,ADRB2
400,2159799,adrb2_human,116,C,V,(+)-isoproterenol,ChEMBL Compound ID,CHEMBL460574,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.981072,nM,=,,2.4,-1.658,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.835568,CA116V,ADRB2
416,2159799,adrb2_human,116,C,V,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.13,nM,=,,0.09,-1.445,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.835568,CA116V,ADRB2
543,2159799,adrb2_human,116,C,V,Norepinephrine,ChEMBL Compound ID,CHEMBL432,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,4.2,-1.381,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.835568,CA116V,ADRB2
548,2159799,adrb2_human,116,C,V,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.0,pM,=,,25.0,2.273,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,-0.835568,CA116V,ADRB2
323,11118431,adrb2_human,272,L,C,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.16,µM,,,0.043,-3.717,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,2.42991,LA272C,ADRB2
387,11118431,adrb2_human,272,L,C,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.66,nM,,,0.46,-1.435,,,[3H]dihydroalprenolol,71.4,0.0,,0.0,,P07550,2.42991,LA272C,ADRB2
336,2846532,adrb2_human,138,P,T,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,390.38,-1.04,,,[125I]iodocyanopindolol,128.2,0.0,,0.0,,P07550,1.90922,PA138T,ADRB2
479,2846532,adrb2_human,138,P,T,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,418.56,1.031,,,[125I]iodocyanopindolol,128.2,0.0,,0.0,,P07550,1.90922,PA138T,ADRB2
357,9356441,adrb2_human,340,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,44.6,pM,=,,42.7,-1.045,,,[125I]iodocyanopindolol (radioligand),42.9,0.0,,0.0,,P07550,1.73392,LA340A,ADRB2
422,9356441,adrb2_human,340,L,A,(-)-isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,361.0,nM,=,,441.0,1.222,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,1.73392,LA340A,ADRB2
533,9356441,adrb2_human,340,L,A,(-)-Isoprenaline,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,323.0,nM,=,,413.0,1.279,,,[125I]iodocyanopindolol (radioligand),42.9,0.0,,0.0,,P07550,1.73392,LA340A,ADRB2
636,9356441,adrb2_human,340,L,A,(-)-Isoprenaline,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,7.0,nM,=,,5.0,-1.401,,,[125I]iodocyanopindolol (radioligand),42.9,0.0,,0.0,,P07550,1.73392,LA340A,ADRB2
642,9356441,adrb2_human,340,L,A,[125I]iodocyanopindolol,PubChem CID,73754996,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,44.6,pM,=,,42.7,-1.045,,,[125I]iodocyanopindolol (radioligand),42.9,0.0,,0.0,,P07550,1.73392,LA340A,ADRB2
423,8388251,adrb2_human,354,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,377.0,nM,=,,146.0,-2.584,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.0675447,YA354A,ADRB2
444,8388251,adrb2_human,354,Y,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,19.0,nM,=,,79.432823,4.181,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P07550,0.0675447,YA354A,ADRB2
505,2846532,adrb2_human,268,E,G,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,88.84,-4.566,,,[125I]iodocyanopindolol,70.3,0.0,,0.0,,P07550,1.26506,EA268G,ADRB2
528,2846532,adrb2_human,327,C,R,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,1561.54,3.846,,,[125I]iodocyanopindolol,222.2,0.0,,0.0,,P07550,-0.245218,CA327R,ADRB2
635,2846532,adrb2_human,327,C,R,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,406.0,nM,=,,1268.75,3.125,,,[125I]iodocyanopindolol,222.2,0.0,,0.0,,P07550,-0.245218,CA327R,ADRB2
568,11118431,adrb2_human,271,A,C,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.16,µM,,,0.073,-2.193,,,[3H]dihydroalprenolol,0.0,0.0,,0.0,,P07550,0.415367,AA271C,ADRB2
572,11118431,adrb2_human,271,A,C,[3H]dihydroalprenolol,ChEMBL Compound ID,CHEMBL1159723,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.66,nM,,,0.56,-1.179,,,[3H]dihydroalprenolol,110.2,0.0,,0.0,,P07550,0.415367,AA271C,ADRB2
0,24443568,acm1_human,405,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.95,1.23,,,,63.0,0.0,,0.0,,P11229,3.30256,WA405A,CHRM1
192,24443568,acm1_human,405,W,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,5.7,-16.129,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.30256,WA405A,CHRM1
248,24443568,acm1_human,405,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,5.4,-6.897,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.30256,WA405A,CHRM1
1,20413650,acm1_human,101,W,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.74,,=,,8.64,-76.923,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
70,7838137,acm1_human,101,W,A,Methoctramine,ChEMBL Compound ID,CHEMBL27673,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.83,,=,,6.09,5.495,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
87,9334899,acm1_human,101,W,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.667,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
121,25006252,acm1_human,101,W,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,8.0,-55.556,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
135,7838137,acm1_human,101,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,2.6,11.749,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
163,20413650,acm1_human,101,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,4.46,,=,,3.33,13.49,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
182,9334899,acm1_human,101,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.111,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
201,9334899,acm1_human,101,W,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.429,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
220,25006252,acm1_human,101,W,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,8.57,-32.258,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
232,9334899,acm1_human,101,W,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,19.1,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
238,9334899,acm1_human,101,W,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,13.2,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
241,9334899,acm1_human,101,W,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,28.9,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
247,20413650,acm1_human,101,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.25,,=,,9.36,7.762,,,,171.3,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
285,21685390,acm1_human,101,W,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.79,4.786,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
298,7838137,acm1_human,101,W,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,5.9,154.882,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
308,25006252,acm1_human,101,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.42,17.378,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
319,7838137,acm1_human,101,W,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.89,,=,,7.0,77.625,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
350,7838137,acm1_human,101,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,3.64,23.988,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
351,21685390,acm1_human,101,W,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.29,8.511,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
355,24443568,acm1_human,101,W,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.38,1.288,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
373,25006252,acm1_human,101,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,9.5,18.197,,,,18.9,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
388,25006252,acm1_human,101,W,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,7.99,-50.0,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
393,20413650,acm1_human,101,W,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,5.1,,=,,4.59,3.236,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
429,9334899,acm1_human,101,W,A,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.25,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
518,9334899,acm1_human,101,W,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.429,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
521,24443568,acm1_human,101,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.64,8.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
534,7838137,acm1_human,101,W,A,Himbacine,ChEMBL Compound ID,CHEMBL1993504,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.35,-1.949,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
548,9334899,acm1_human,101,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,9.7,,,,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
688,20413650,acm1_human,101,W,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.14,,=,,7.53,-24.39,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
690,25006252,acm1_human,101,W,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,5.45,21.878,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
698,25006252,acm1_human,101,W,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.39,3.388,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
713,7838137,acm1_human,101,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,3.79,26.303,,,,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
719,7838137,acm1_human,101,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,3.91,21.878,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
751,7838137,acm1_human,101,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,8.97,8.913,,,,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
774,25006252,acm1_human,101,W,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.11,5.623,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
786,24443568,acm1_human,101,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.36,4.786,,,,59.0,0.0,,0.0,,P11229,3.95756,WA101A,CHRM1
2,24443568,acm1_human,85,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.84,5.248,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
3,7838137,acm1_human,85,Y,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.77,2.754,,,,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
35,7838137,acm1_human,85,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.67,1.778,,,,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
36,25006252,acm1_human,85,Y,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.48,2.754,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
69,25006252,acm1_human,85,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.63,4.266,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
172,25006252,acm1_human,85,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.47,2.455,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
176,25326383,acm1_human,85,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,4.65,2.884,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
219,24443568,acm1_human,85,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.82,1.66,,,,132.7,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
233,25006252,acm1_human,85,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.54,13.183,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
243,7838137,acm1_human,85,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.56,2.884,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
257,7838137,acm1_human,85,Y,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.74,-1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
262,25006252,acm1_human,85,Y,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.29,5.888,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
268,25326383,acm1_human,85,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.86,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
303,25006252,acm1_human,85,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.49,1.862,,,,26.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
407,25006252,acm1_human,85,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.33,2.884,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
748,24443568,acm1_human,85,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.32,1.479,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
752,7838137,acm1_human,85,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.92,2.138,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
760,25006252,acm1_human,85,Y,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,4.91,23.988,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
763,25326383,acm1_human,85,Y,A,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,5.37,15.136,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
778,25326383,acm1_human,85,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,9.82,1.259,,,,95.9,0.0,,0.0,,P11229,1.04743,YA85A,CHRM1
4,9334899,acm1_human,411,S,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.5,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.610996,SA411A,CHRM1
49,9334899,acm1_human,411,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,1.6,,,,0.0,0.0,,0.0,,P11229,-0.610996,SA411A,CHRM1
152,9334899,acm1_human,411,S,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.1,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.610996,SA411A,CHRM1
271,9334899,acm1_human,411,S,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.1,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.610996,SA411A,CHRM1
436,9334899,acm1_human,411,S,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.5,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.610996,SA411A,CHRM1
7,20413650,acm1_human,77,F,I,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.14,,=,,6.04,1.259,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
107,25006252,acm1_human,77,F,I,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.83,-1.096,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
149,25006252,acm1_human,77,F,I,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.76,1.259,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
159,25006252,acm1_human,77,F,I,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.48,1.514,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
190,20413650,acm1_human,77,F,I,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.74,,=,,6.41,2.138,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
264,25006252,acm1_human,77,F,I,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.89,1.479,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
311,20413650,acm1_human,77,F,I,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,4.46,,=,,4.13,2.138,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
501,25006252,acm1_human,77,F,I,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.68,4.074,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
599,20413650,acm1_human,77,F,I,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.25,,=,,10.69,-2.755,,,,90.8,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
606,25006252,acm1_human,77,F,I,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.94,-1.047,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
635,25006252,acm1_human,77,F,I,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.99,1.862,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
670,20413650,acm1_human,77,F,I,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,5.1,,=,,5.03,1.175,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
792,25006252,acm1_human,77,F,I,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.83,-1.175,,,,42.3,0.0,,0.0,,P11229,0.124502,FA77I,CHRM1
8,25006252,acm1_human,180,I,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.93,-4.367,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
236,25006252,acm1_human,180,I,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.65,1.622,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
287,24443568,acm1_human,180,I,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,5.03,-3.472,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
327,25006252,acm1_human,180,I,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.91,1.023,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
493,24443568,acm1_human,180,I,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.95,1.23,,,,62.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
506,25006252,acm1_human,180,I,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.57,1.549,,,,33.7,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
601,25006252,acm1_human,180,I,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.58,-3.311,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
640,24443568,acm1_human,180,I,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.07,3.09,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
682,25006252,acm1_human,180,I,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.97,-5.128,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
742,25006252,acm1_human,180,I,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,5.85,8.71,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
772,25006252,acm1_human,180,I,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.8,7.244,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.57421,IA180A,CHRM1
10,25326383,acm1_human,85,Y,F,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,5.86,4.898,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.233891,YA85F,CHRM1
344,25326383,acm1_human,85,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,10.04,-1.318,,,,71.1,0.0,,0.0,,P11229,-0.233891,YA85F,CHRM1
708,25326383,acm1_human,85,Y,F,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.66,1.445,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.233891,YA85F,CHRM1
727,25326383,acm1_human,85,Y,F,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,4.98,1.349,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.233891,YA85F,CHRM1
12,21685390,acm1_human,400,W,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.12,1.259,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
19,7838137,acm1_human,400,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.12,7.943,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
41,25006252,acm1_human,400,W,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.88,-1.23,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
89,7838137,acm1_human,400,W,A,Himbacine,ChEMBL Compound ID,CHEMBL1993504,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,5.83,16.982,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
112,24443568,acm1_human,400,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.18,2.399,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
138,25326383,acm1_human,400,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,9.95,-1.072,,,,33.3,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
147,7838137,acm1_human,400,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,2.68,9.772,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
200,7838137,acm1_human,400,W,A,Methoctramine,ChEMBL Compound ID,CHEMBL27673,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.83,,=,,6.2,4.266,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
234,21685390,acm1_human,400,W,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.43,10.965,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
253,7838137,acm1_human,400,W,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.54,3.548,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
314,25006252,acm1_human,400,W,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.3,9.12,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
347,25006252,acm1_human,400,W,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.53,2.138,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
356,25006252,acm1_human,400,W,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.19,7.413,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
358,25006252,acm1_human,400,W,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.15,13.804,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
385,25326383,acm1_human,400,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,4.62,3.09,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
404,7838137,acm1_human,400,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.75,1.479,,,,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
439,24443568,acm1_human,400,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.95,1.23,,,,46.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
455,25006252,acm1_human,400,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.49,1.862,,,,28.6,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
514,7838137,acm1_human,400,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,3.95,18.197,,,,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
549,7838137,acm1_human,400,W,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.89,,=,,9.0,-1.289,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
622,25006252,acm1_human,400,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.41,17.783,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
653,25006252,acm1_human,400,W,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.6,2.089,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
709,7838137,acm1_human,400,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.29,9.12,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.34644,WA400A,CHRM1
18,25006252,acm1_human,183,L,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.47,-1.621,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
60,25006252,acm1_human,183,L,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.29,3.715,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
315,25006252,acm1_human,183,L,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.48,-1.548,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
343,21685390,acm1_human,183,L,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.0,1.66,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
376,25006252,acm1_human,183,L,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.66,1.82,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
432,24443568,acm1_human,183,L,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.23,1.82,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
467,25006252,acm1_human,183,L,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.64,1.413,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
491,24443568,acm1_human,183,L,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.31,5.37,,,,100.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
557,25006252,acm1_human,183,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.19,2.951,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
561,25006252,acm1_human,183,L,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.33,-1.862,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
572,24443568,acm1_human,183,L,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.51,11.22,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
697,25006252,acm1_human,183,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.2,3.631,,,,65.3,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
732,21685390,acm1_human,183,L,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.44,1.072,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.46983,LA183A,CHRM1
22,9334899,acm1_human,192,T,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.25,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
29,10188986,acm1_human,192,T,A,(-)-N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.022,nM,=,,0.12,5.455,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
61,10188986,acm1_human,192,T,A,CDD-0034,SMILES,COC(=O)C1CNC=NC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,39.0,µM,=,,140.0,3.59,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
62,10188986,acm1_human,192,T,A,[3H](R)-QNB,ChEMBL Compound ID,CHEMBL558910,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.032,nM,=,,0.0222,-1.441,,,,87.4,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
72,10188986,acm1_human,192,T,A,AF-DX 116,ChEMBL Compound ID,CHEMBL17045,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,520.0,nM,=,,1400.0,2.692,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
79,10188986,acm1_human,192,T,A,CDD-0098,SMILES,Cc1noc(n1)C1CNC=NC1,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,8.1,µM,=,,15.0,1.852,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
84,24443568,acm1_human,192,T,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.06,2.692,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
97,10188986,acm1_human,192,T,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.2,µM,=,,5.4,1.286,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
110,10188986,acm1_human,192,T,A,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.18,µM,=,,0.52,2.889,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
144,10188986,acm1_human,192,T,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,1.1,µM,=,,0.76,-1.447,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
156,10188986,acm1_human,192,T,A,Scopolamine,PubChem CID,3000322,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.085,nM,=,,0.12,1.412,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
169,10188986,acm1_human,192,T,A,[3H](R)-QNB,ChEMBL Compound ID,CHEMBL558910,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.027,nM,=,,0.023,-1.174,,,,720.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
186,10188986,acm1_human,192,T,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.2,µM,=,,10.0,4.545,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
267,10188986,acm1_human,192,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,1.6,µM,=,,1.7,1.062,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
310,10188986,acm1_human,192,T,A,p-F-HHSiD,PubChem CID,3603,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.6,nM,=,,2.6,1.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
312,10188986,acm1_human,192,T,A,APE,ChEMBL Compound ID,CHEMBL1255649,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.32,µM,=,,0.57,1.781,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
333,9334899,acm1_human,192,T,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.667,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
336,10188986,acm1_human,192,T,A,CDD-0102,SMILES,CCc1noc(n1)C1CNC=NC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.0,µM,=,,2.3,1.15,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
372,10188986,acm1_human,192,T,A,CDD-0098,SMILES,Cc1noc(n1)C1CNC=NC1,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,0.12,µM,=,,0.24,2.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
417,10188986,acm1_human,192,T,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.4,nM,=,,5.8,1.318,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
420,9334899,acm1_human,192,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,-1.25,,,,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
448,10188986,acm1_human,192,T,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,33.0,µM,=,,18.0,-1.835,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
472,10188986,acm1_human,192,T,A,CDD-0098,SMILES,Cc1noc(n1)C1CNC=NC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.9,µM,=,,8.7,3.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
520,10188986,acm1_human,192,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,83.0,µM,=,,320.0,3.855,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
539,9334899,acm1_human,192,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.5,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
588,10188986,acm1_human,192,T,A,CDD-0078,SMILES,CCOC(=O)C1CNC=NC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.4,µM,=,,9.8,1.815,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
594,10188986,acm1_human,192,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.0,µM,=,,110.0,36.667,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
610,9334899,acm1_human,192,T,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-3.333,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
612,9334899,acm1_human,192,T,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-2.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
619,10188986,acm1_human,192,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.51,µM,=,,44.0,86.275,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
631,10188986,acm1_human,192,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,20.0,µM,=,,190.0,9.5,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
633,24443568,acm1_human,192,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.76,1.905,,,,134.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
644,9334899,acm1_human,192,T,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.3,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
678,24443568,acm1_human,192,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.22,21.878,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
703,9334899,acm1_human,192,T,A,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
718,10188986,acm1_human,192,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,39.0,µM,=,,83.0,2.128,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
722,9334899,acm1_human,192,T,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.7,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
733,10188986,acm1_human,192,T,A,Trihexyphenidyl,ChEMBL Compound ID,CHEMBL1490,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.1,nM,=,,0.063,-1.587,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
739,10188986,acm1_human,192,T,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.19,nM,=,,0.19,1.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
746,10188986,acm1_human,192,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,17.0,µM,=,,1.2,-14.085,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
785,10188986,acm1_human,192,T,A,l-Hyoscyamine,ChEMBL Compound ID,CHEMBL1331216,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.088,nM,=,,0.21,2.386,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.350018,TA192A,CHRM1
23,7838137,acm1_human,184,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.87,2.399,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
55,24443568,acm1_human,184,S,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.7,-1.621,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
173,24443568,acm1_human,184,S,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.35,1.622,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
337,7838137,acm1_human,184,S,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.23,-1.047,,,,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
442,7838137,acm1_human,184,S,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.62,2.512,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
488,7838137,acm1_human,184,S,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.68,-1.024,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
535,24443568,acm1_human,184,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,10.04,1.0,,,,82.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
614,7838137,acm1_human,184,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,10.0,-1.202,,,,0.0,0.0,,0.0,,P11229,-0.00672823,SA184A,CHRM1
25,25326383,acm1_human,179,Y,F,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,5.24,-1.35,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
32,21685390,acm1_human,179,Y,F,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.85,2.344,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
141,25326383,acm1_human,179,Y,F,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,6.15,2.512,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
416,21685390,acm1_human,179,Y,F,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.25,16.596,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
616,25326383,acm1_human,179,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,9.95,-1.072,,,,67.5,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
793,25326383,acm1_human,179,Y,F,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.72,1.259,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.797626,YA179F,CHRM1
26,7706286,acm1_human,209,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,0.28,-1.179,,,[3H]N-methyl scopolamine,0.0,93.1,,0.0,,P11229,-0.0268695,WA209A,CHRM1
27,25006252,acm1_human,392,K,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.98,1.905,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
82,25006252,acm1_human,392,K,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.84,2.818,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
94,21685390,acm1_human,392,K,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.57,-1.259,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
160,21685390,acm1_human,392,K,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.2,1.047,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
224,25006252,acm1_human,392,K,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.7,1.445,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
245,24443568,acm1_human,392,K,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.88,1.445,,,,77.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
279,25006252,acm1_human,392,K,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.21,2.818,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
284,25006252,acm1_human,392,K,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.78,1.905,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
474,25006252,acm1_human,392,K,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.71,1.202,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
511,24443568,acm1_human,392,K,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.4,1.23,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
581,25006252,acm1_human,392,K,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.72,1.585,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
762,25006252,acm1_human,392,K,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.61,1.413,,,,68.9,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
783,24443568,acm1_human,392,K,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.28,1.905,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.0845457,KA392A,CHRM1
30,25006252,acm1_human,381,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,7.01,-1.658,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
106,20413650,acm1_human,381,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.25,,=,,10.26,-1.024,,,,113.9,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
137,20413650,acm1_human,381,Y,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,5.1,,=,,3.56,34.674,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
297,25006252,acm1_human,381,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.02,43.652,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
424,24443568,acm1_human,381,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.67,,=,,2.46,162.181,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
428,20413650,acm1_human,381,Y,A,AC-42,ChEMBL Compound ID,CHEMBL1242950,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.14,,=,,6.53,-2.457,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
458,20413650,acm1_human,381,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,4.46,,=,,2.39,117.49,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
479,25006252,acm1_human,381,Y,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.75,-2.882,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
543,25006252,acm1_human,381,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,6.75,128.825,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
583,25006252,acm1_human,381,Y,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,8.36,-20.0,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
618,24443568,acm1_human,381,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.85,,=,,9.82,1.072,,,,60.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
641,25006252,acm1_human,381,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.94,-4.785,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
702,25006252,acm1_human,381,Y,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.22,-1.996,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
720,25006252,acm1_human,381,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.44,2.089,,,,9.7,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
789,20413650,acm1_human,381,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand competition/displacement,6.74,,=,,7.16,-2.632,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.21189,YA381A,CHRM1
31,25006252,acm1_human,181,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.57,1.23,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
57,7838137,acm1_human,181,Q,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.88,1.096,,,,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
123,7838137,acm1_human,181,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.68,-2.688,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
155,7838137,acm1_human,181,Q,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.08,1.349,,,,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
300,24443568,acm1_human,181,Q,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.92,1.318,,,,92.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
328,24443568,acm1_human,181,Q,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,5.12,-4.274,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
392,7838137,acm1_human,181,Q,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.65,1.047,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
486,25006252,acm1_human,181,Q,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.67,1.549,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
499,25006252,acm1_human,181,Q,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.76,1.445,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
509,25006252,acm1_human,181,Q,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.3,-1.739,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
532,25006252,acm1_human,181,Q,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.64,1.318,,,,33.2,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
604,7838137,acm1_human,181,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,5.33,-2.041,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
625,24443568,acm1_human,181,Q,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,5.42,-7.246,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
630,25006252,acm1_human,181,Q,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.43,-1.479,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
662,25006252,acm1_human,181,Q,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.24,1.122,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
743,25006252,acm1_human,181,Q,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.6,1.549,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.309165,QA181A,CHRM1
33,25006252,acm1_human,82,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.01,5.623,,,,51.5,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
80,25326383,acm1_human,82,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,4.29,6.607,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
136,25006252,acm1_human,82,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.54,13.183,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
168,25326383,acm1_human,82,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.73,1.23,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
221,25006252,acm1_human,82,Y,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,5.97,12.303,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
231,25326383,acm1_human,82,Y,A,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,5.28,18.621,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
242,24443568,acm1_human,82,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.7,-1.621,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
252,24443568,acm1_human,82,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.89,4.677,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
434,25006252,acm1_human,82,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.19,4.677,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
524,25006252,acm1_human,82,Y,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.26,4.571,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
638,25006252,acm1_human,82,Y,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,4.83,28.84,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
663,25006252,acm1_human,82,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.79,2.951,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
680,25006252,acm1_human,82,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.18,4.074,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
684,24443568,acm1_human,82,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.76,1.905,,,,75.0,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
695,25326383,acm1_human,82,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,9.76,1.445,,,,54.2,0.0,,0.0,,P11229,3.15702,YA82A,CHRM1
34,7838137,acm1_human,169,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.22,6.31,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.91799,GA169A,CHRM1
116,7838137,acm1_human,169,G,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.61,3.981,,,,0.0,0.0,,0.0,,P11229,3.91799,GA169A,CHRM1
133,7838137,acm1_human,169,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.61,4.365,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.91799,GA169A,CHRM1
282,7838137,acm1_human,169,G,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.54,2.399,,,,0.0,0.0,,0.0,,P11229,3.91799,GA169A,CHRM1
419,7838137,acm1_human,169,G,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.55,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.91799,GA169A,CHRM1
39,25006252,acm1_human,102,L,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.46,2.884,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
63,25006252,acm1_human,102,L,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,9.37,24.547,,,,31.1,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
88,25006252,acm1_human,102,L,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.36,8.511,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
167,24443568,acm1_human,102,L,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.4,4.365,,,,49.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
288,25006252,acm1_human,102,L,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,7.61,17.783,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
435,25006252,acm1_human,102,L,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.71,3.548,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
516,24443568,acm1_human,102,L,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.21,22.387,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
536,25006252,acm1_human,102,L,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,2.89,58.884,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
570,25006252,acm1_human,102,L,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,5.21,38.019,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
596,25006252,acm1_human,102,L,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.78,1.905,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
627,24443568,acm1_human,102,L,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.12,2.344,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.37067,LA102A,CHRM1
40,10496961,acm1_human,388,S,Y,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,33000.0,nM,=,,1200.0,-27.778,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
73,10496961,acm1_human,388,S,Y,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2200.0,nM,=,,760.0,-2.899,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
98,10496961,acm1_human,388,S,Y,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3000.0,nM,=,,28.0,-111.111,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
108,10496961,acm1_human,388,S,Y,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2200.0,nM,=,,130.0,-16.949,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
185,10496961,acm1_human,388,S,Y,(-)-N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.61,,=,,10.42,1.549,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
202,10496961,acm1_human,388,S,Y,[3H](R)-QNB,ChEMBL Compound ID,CHEMBL558910,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,10.23,2.188,,,,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
211,10496961,acm1_human,388,S,Y,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,39.0,µM,=,,72.0,1.846,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
304,10496961,acm1_human,388,S,Y,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,83.0,µM,=,,360.0,4.337,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
397,10496961,acm1_human,388,S,Y,l-Hyoscyamine,ChEMBL Compound ID,CHEMBL1331216,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.06,,=,,9.59,2.951,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
438,10496961,acm1_human,388,S,Y,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,20000.0,nM,=,,230.0,-90.909,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
463,10496961,acm1_human,388,S,Y,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.37,,=,,7.99,2.399,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
504,10496961,acm1_human,388,S,Y,Trihexyphenidyl,ChEMBL Compound ID,CHEMBL1490,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.02,,=,,9.66,2.291,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
505,10496961,acm1_human,388,S,Y,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,510.0,nM,=,,42.0,-12.195,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
537,10496961,acm1_human,388,S,Y,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,13.0,µM,=,,680.0,52.308,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
578,10496961,acm1_human,388,S,Y,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4200.0,nM,=,,220.0,-19.231,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
649,10496961,acm1_human,388,S,Y,Choline,ChEMBL Compound ID,CHEMBL920,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,µM,=,,230.0,1.15,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
696,10496961,acm1_human,388,S,Y,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,180.0,nM,=,,490.0,2.722,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,0.64211,SA388Y,CHRM1
43,7838137,acm1_human,94,G,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.77,1.413,,,,0.0,0.0,,0.0,,P11229,3.52749,GA94A,CHRM1
117,7838137,acm1_human,94,G,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.31,2.291,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.52749,GA94A,CHRM1
389,7838137,acm1_human,94,G,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.72,3.09,,,,0.0,0.0,,0.0,,P11229,3.52749,GA94A,CHRM1
469,7838137,acm1_human,94,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.6,2.63,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.52749,GA94A,CHRM1
674,7838137,acm1_human,94,G,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.39,-1.381,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.52749,GA94A,CHRM1
44,25006252,acm1_human,401,E,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.66,1.585,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
140,24443568,acm1_human,401,E,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.72,-1.698,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
250,21685390,acm1_human,401,E,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.2,1.862,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
261,25006252,acm1_human,401,E,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.79,1.862,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
283,24443568,acm1_human,401,E,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.6,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
326,21685390,acm1_human,401,E,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.76,2.884,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
349,25006252,acm1_human,401,E,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.67,1.318,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
556,25006252,acm1_human,401,E,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.1,3.631,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
576,25006252,acm1_human,401,E,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.88,2.57,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
600,24443568,acm1_human,401,E,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.97,1.175,,,,78.7,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
634,25006252,acm1_human,401,E,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.98,-1.148,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
700,25006252,acm1_human,401,E,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.16,1.259,,,[3H]QNB,0.0,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
780,25006252,acm1_human,401,E,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.56,1.585,,,,27.6,0.0,,0.0,,P11229,-0.497646,EA401A,CHRM1
47,21685390,acm1_human,171,R,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.76,2.884,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
114,7838137,acm1_human,171,R,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.4,3.311,,,,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
281,21685390,acm1_human,171,R,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.5,9.333,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
430,7838137,acm1_human,171,R,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.12,1.23,,,,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
440,7838137,acm1_human,171,R,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.68,3.715,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
443,7838137,acm1_human,171,R,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.4,4.169,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
495,7838137,acm1_human,171,R,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,4.15,-3.021,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.94233,RA171A,CHRM1
48,25006252,acm1_human,179,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.35,3.236,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
86,25006252,acm1_human,179,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.59,-2.137,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
230,25326383,acm1_human,179,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.68,1.38,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
286,25326383,acm1_human,179,Y,A,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,4.56,97.724,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
361,25006252,acm1_human,179,Y,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.97,-8.13,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
460,25006252,acm1_human,179,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.39,2.344,,,,32.1,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
512,25006252,acm1_human,179,Y,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.33,2.884,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
540,25326383,acm1_human,179,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,5.05,1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
607,24443568,acm1_human,179,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,10.0,1.096,,,,90.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
609,25006252,acm1_human,179,Y,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.6,2.089,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
624,25326383,acm1_human,179,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,10.0,-1.202,,,,65.1,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
648,24443568,acm1_human,179,Y,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.55,-1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
672,24443568,acm1_human,179,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.63,-1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
725,25006252,acm1_human,179,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,3.99,4.677,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
773,25006252,acm1_human,179,Y,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.37,-1.202,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.90684,YA179A,CHRM1
52,24443568,acm1_human,397,E,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.64,-1.202,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.565916,EA397A,CHRM1
78,24443568,acm1_human,397,E,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.82,1.66,,,,79.0,0.0,,0.0,,P11229,0.565916,EA397A,CHRM1
334,24443568,acm1_human,397,E,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.66,-1.479,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.565916,EA397A,CHRM1
451,21685390,acm1_human,397,E,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.54,-1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.565916,EA397A,CHRM1
712,21685390,acm1_human,397,E,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.21,1.023,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.565916,EA397A,CHRM1
53,1488411,acm1_human,82,Y,F,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.43,mM,=,,0.23,-1.869,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
157,1488411,acm1_human,82,Y,F,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.41,mM,=,,0.28,-1.464,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
341,1488411,acm1_human,82,Y,F,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.28,nM,=,,0.3,1.071,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
406,1488411,acm1_human,82,Y,F,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,57.0,nM,=,,146.0,2.561,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
478,25326383,acm1_human,82,Y,F,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,5.24,-1.35,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
529,1488411,acm1_human,82,Y,F,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.44,nM,=,,0.42,-1.047,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
566,1488411,acm1_human,82,Y,F,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.41,mM,=,,0.22,-1.862,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
573,1488411,acm1_human,82,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.85,nM,=,,0.54,-1.575,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
613,1488411,acm1_human,82,Y,F,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,43.0,nM,=,,129.0,3.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
647,25326383,acm1_human,82,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,10.39,-2.95,,,,67.5,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
685,25326383,acm1_human,82,Y,F,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,4.99,-1.479,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
776,25326383,acm1_human,82,Y,F,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,5.67,7.586,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.805868,YA82F,CHRM1
56,7838137,acm1_human,404,Y,A,Methoctramine,ChEMBL Compound ID,CHEMBL27673,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.83,,=,,6.7,1.349,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
77,7838137,acm1_human,404,Y,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.89,,=,,7.9,9.772,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
210,7838137,acm1_human,404,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,3.25,58.884,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
299,7838137,acm1_human,404,Y,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.33,-1.318,,,,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
317,7838137,acm1_human,404,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,3.6,44.668,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
527,7838137,acm1_human,404,Y,A,Himbacine,ChEMBL Compound ID,CHEMBL1993504,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,5.7,22.909,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
749,7838137,acm1_human,404,Y,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.19,7.943,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
794,7838137,acm1_human,404,Y,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,8.19,53.703,,,,0.0,0.0,,0.0,,P11229,3.13229,YA404A,CHRM1
59,1618842,acm1_human,71,D,N,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,55.0,%,=,,91.0,-1.656,,,,85.4,0.0,,0.0,,P11229,0.899908,DA71N,CHRM1
67,25006252,acm1_human,182,F,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.39,2.512,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
101,25006252,acm1_human,182,F,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.62,1.38,,,,41.8,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
115,7838137,acm1_human,182,F,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.73,-1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
161,25006252,acm1_human,182,F,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.36,3.162,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
189,7838137,acm1_human,182,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.78,1.738,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
269,25006252,acm1_human,182,F,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.47,2.818,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
324,24443568,acm1_human,182,F,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.41,1.202,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
401,24443568,acm1_human,182,F,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.68,-1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
423,25006252,acm1_human,182,F,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,6.35,-1.148,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
481,7838137,acm1_human,182,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.01,1.738,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
590,24443568,acm1_human,182,F,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.52,3.311,,,,85.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
591,7838137,acm1_human,182,F,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.19,1.047,,,,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
623,7838137,acm1_human,182,F,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.44,3.02,,,,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
705,25006252,acm1_human,182,F,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.18,-1.318,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
716,25006252,acm1_human,182,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.13,3.388,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
740,25006252,acm1_human,182,F,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.26,1.0,,,[3H]QNB,0.0,0.0,,0.0,,P11229,3.44594,FA182A,CHRM1
68,7838137,acm1_human,394,C,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,10.04,-1.318,,,,0.0,0.0,,0.0,,P11229,0.455219,CA394A,CHRM1
323,7838137,acm1_human,394,C,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.03,1.514,,,,0.0,0.0,,0.0,,P11229,0.455219,CA394A,CHRM1
454,7838137,acm1_human,394,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,5.35,-2.137,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.455219,CA394A,CHRM1
587,7838137,acm1_human,394,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.81,-3.636,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.455219,CA394A,CHRM1
602,7838137,acm1_human,394,C,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.51,1.445,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.455219,CA394A,CHRM1
74,7838137,acm1_human,91,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.93,-1.818,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
207,21685390,acm1_human,91,W,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.3,14.791,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
246,7838137,acm1_human,91,W,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.2,7.762,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
367,7838137,acm1_human,91,W,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.89,,=,,7.33,36.308,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
490,7838137,acm1_human,91,W,A,Himbacine,ChEMBL Compound ID,CHEMBL1993504,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,5.92,13.804,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
502,21685390,acm1_human,91,W,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.23,9.772,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
569,7838137,acm1_human,91,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.02,7.943,,,,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
721,7838137,acm1_human,91,W,A,Methoctramine,ChEMBL Compound ID,CHEMBL27673,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.83,,=,,6.35,3.02,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
741,7838137,acm1_human,91,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,3.36,45.709,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
781,7838137,acm1_human,91,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.65,3.631,,,,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
790,7838137,acm1_human,91,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,3.68,37.154,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,5.30135,WA91A,CHRM1
83,7838137,acm1_human,398,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.94,-1.047,,,,0.0,0.0,,0.0,,P11229,-0.274609,TA398A,CHRM1
354,7838137,acm1_human,398,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.16,1.122,,,,0.0,0.0,,0.0,,P11229,-0.274609,TA398A,CHRM1
679,7838137,acm1_human,398,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.1,1.413,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.274609,TA398A,CHRM1
750,7838137,acm1_human,398,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.87,1.413,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.274609,TA398A,CHRM1
766,7838137,acm1_human,398,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.6,1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.274609,TA398A,CHRM1
85,7838137,acm1_human,164,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.75,1.479,,,,0.0,0.0,,0.0,,P11229,2.31097,WA164A,CHRM1
215,7838137,acm1_human,164,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.28,5.495,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.31097,WA164A,CHRM1
260,7838137,acm1_human,164,W,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,4.43,6.607,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.31097,WA164A,CHRM1
676,7838137,acm1_human,164,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.85,-1.513,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.31097,WA164A,CHRM1
734,7838137,acm1_human,164,W,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.16,1.122,,,,0.0,0.0,,0.0,,P11229,2.31097,WA164A,CHRM1
93,25006252,acm1_human,106,Y,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,2.96,50.119,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
102,25006252,acm1_human,106,Y,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,5.09,-1.479,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
124,25006252,acm1_human,106,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,7.42,27.542,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
177,25006252,acm1_human,106,Y,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.4,4.571,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
203,25006252,acm1_human,106,Y,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.65,4.365,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
380,24443568,acm1_human,106,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.85,,=,,9.15,5.012,,,,75.9,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
384,24443568,acm1_human,106,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.67,,=,,1.73,870.964,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
611,25006252,acm1_human,106,Y,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,5.66,3.981,,,[3H]QNB,0.0,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
729,25006252,acm1_human,106,Y,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,9.22,34.674,,,,24.5,0.0,,0.0,,P11229,1.76204,YA106A,CHRM1
95,7838137,acm1_human,396,P,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.96,1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.29462,PA396A,CHRM1
259,7838137,acm1_human,396,P,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.01,1.585,,,,0.0,0.0,,0.0,,P11229,1.29462,PA396A,CHRM1
274,7838137,acm1_human,396,P,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,10.05,-1.35,,,,0.0,0.0,,0.0,,P11229,1.29462,PA396A,CHRM1
579,7838137,acm1_human,396,P,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.13,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.29462,PA396A,CHRM1
605,7838137,acm1_human,396,P,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.75,-1.202,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.29462,PA396A,CHRM1
99,25006252,acm1_human,90,H,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.84,1.202,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
258,25006252,acm1_human,90,H,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.26,1.0,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
377,25006252,acm1_human,90,H,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.96,2.138,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
410,21685390,acm1_human,90,H,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.2,1.047,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
483,25006252,acm1_human,90,H,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.17,3.09,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
565,25006252,acm1_human,90,H,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.79,1.175,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
584,25006252,acm1_human,90,H,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.66,1.349,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
664,21685390,acm1_human,90,H,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.66,-1.548,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
669,25006252,acm1_human,90,H,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,7.08,-1.047,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
761,25006252,acm1_human,90,H,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.76,1.0,,,,16.8,0.0,,0.0,,P11229,0.402278,HA90A,CHRM1
105,25006252,acm1_human,393,D,A,Xanomeline,ChEMBL Compound ID,CHEMBL21536,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.79,,=,,6.75,1.096,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
273,25006252,acm1_human,393,D,A,VCP813,SMILES,CN(C)C1CCN(Cc2ccccc2C)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.92,,=,,4.81,1.288,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
422,25006252,acm1_human,393,D,A,TBPB,ChEMBL Compound ID,CHEMBL522460,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.82,1.738,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
554,21685390,acm1_human,393,D,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.96,1.82,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
589,25006252,acm1_human,393,D,A,77-LH-28-1,PubChem CID,10236758,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.12,1.38,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
593,25006252,acm1_human,393,D,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,10.66,1.259,,,,48.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
598,25006252,acm1_human,393,D,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.66,,=,,4.42,1.738,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
694,25006252,acm1_human,393,D,A,VCP794,SMILES,O=c1[nH]c2ccccc2n1C1CCN(CC1)C1CCCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.29,,=,,5.92,2.344,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
715,21685390,acm1_human,393,D,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.5,-1.072,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
731,25006252,acm1_human,393,D,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.86,,=,,8.75,1.288,,,[3H]QNB,0.0,0.0,,0.0,,P11229,0.307843,DA393A,CHRM1
109,7706286,acm1_human,211,I,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,0.58,1.758,,,[3H]N-methyl scopolamine,0.0,95.7,,0.0,,P11229,2.52642,IA211A,CHRM1
111,10496961,acm1_human,389,T,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3000.0,nM,=,,2800.0,-1.072,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
254,10496961,acm1_human,389,T,P,(-)-N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.61,,=,,9.55,11.482,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
266,10496961,acm1_human,389,T,P,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,20000.0,nM,=,,4300.0,-4.651,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
293,10496961,acm1_human,389,T,P,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,33.0,µM,=,,64.0,1.939,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
399,10496961,acm1_human,389,T,P,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,83.0,µM,=,,2.8,-29.412,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
519,10496961,acm1_human,389,T,P,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.0,µM,=,,18.0,1.0,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
531,10496961,acm1_human,389,T,P,l-Hyoscyamine,ChEMBL Compound ID,CHEMBL1331216,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.06,,=,,9.42,4.365,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
538,10496961,acm1_human,389,T,P,[3H](R)-QNB,ChEMBL Compound ID,CHEMBL558910,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.57,,=,,9.93,4.365,,,,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
541,10496961,acm1_human,389,T,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,510.0,nM,=,,630.0,1.235,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
558,10496961,acm1_human,389,T,P,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.37,,=,,7.53,6.918,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
737,10496961,acm1_human,389,T,P,Choline,ChEMBL Compound ID,CHEMBL920,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,µM,=,,620.0,3.1,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
753,10496961,acm1_human,389,T,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,39000.0,nM,=,,500.0,-76.923,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
755,10496961,acm1_human,389,T,P,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,13.0,µM,=,,0.23,-55.556,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
758,10496961,acm1_human,389,T,P,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4200.0,nM,=,,380.0,-11.111,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
782,10496961,acm1_human,389,T,P,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,180.0,nM,=,,58.0,-3.106,,,[3H](R)-QNB,0.0,0.0,,0.0,,P11229,2.69196,TA389P,CHRM1
113,20643905,acm1_human,105,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,3.88,,=,,2.2,47.863,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
187,20643905,acm1_human,105,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,3.82,10.233,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
225,23826889,acm1_human,105,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,3.87,,=,,2.12,56.234,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
239,23826889,acm1_human,105,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.2,,=,,7.7,31.623,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
313,20643905,acm1_human,105,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.36,,=,,7.81,35.481,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
485,23826889,acm1_human,105,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.83,,=,,3.76,11.749,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
673,25006252,acm1_human,105,D,N,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.76,,=,,8.19,371.535,,,,26.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
726,20643905,acm1_human,105,D,N,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,21.0,%,=,,73.7,-3.509,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.3346,DA105N,CHRM1
118,9334899,acm1_human,378,W,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,288.2,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
125,9334899,acm1_human,378,W,A,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-10.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
280,9334899,acm1_human,378,W,A,Oxotremorine,ChEMBL Compound ID,CHEMBL7634,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.6,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
289,9334899,acm1_human,378,W,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.25,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
290,9334899,acm1_human,378,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-5.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
459,9334899,acm1_human,378,W,A,Pilocarpine,ChEMBL Compound ID,CHEMBL550,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,4.8,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
559,9334899,acm1_human,378,W,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,115.0,,,,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
632,9334899,acm1_human,378,W,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,34.6,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
756,9334899,acm1_human,378,W,A,Arecoline,ChEMBL Compound ID,CHEMBL7303,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.667,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,2.55807,WA378A,CHRM1
131,21685390,acm1_human,174,L,P,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.15,1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.732972,LA174P,CHRM1
675,21685390,acm1_human,174,L,P,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.37,12.589,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.732972,LA174P,CHRM1
139,25326383,acm1_human,179,Y,W,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.92,,=,,9.85,1.175,,,,73.3,0.0,,0.0,,P11229,0.41072,YA179W,CHRM1
148,25326383,acm1_human,179,Y,W,Benzoquinazolinone 12,SMILES,Cn1cc(cn1)-c1ccc(Cc2cc3C(=O)N(CNc3c3ccccc23)C2CCCC[C@@H]2O)cn1,,pK(b),Binding - Radioligand competition/displacement,6.55,,=,,6.69,-1.381,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.41072,YA179W,CHRM1
256,25326383,acm1_human,179,Y,W,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.11,,=,,5.08,1.072,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.41072,YA179W,CHRM1
747,25326383,acm1_human,179,Y,W,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.82,,=,,5.06,-1.739,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.41072,YA179W,CHRM1
146,7838137,acm1_human,389,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.98,1.698,,,,0.0,0.0,,0.0,,P11229,1.4231,TA389A,CHRM1
150,7838137,acm1_human,389,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.86,1.148,,,,0.0,0.0,,0.0,,P11229,1.4231,TA389A,CHRM1
216,7838137,acm1_human,389,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.51,1.445,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.4231,TA389A,CHRM1
318,7838137,acm1_human,389,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.9,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.4231,TA389A,CHRM1
369,7838137,acm1_human,389,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.03,1.66,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.4231,TA389A,CHRM1
151,21685390,acm1_human,170,E,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.2,1.862,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.348293,EA170A,CHRM1
656,21685390,acm1_human,170,E,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.2,1.047,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.348293,EA170A,CHRM1
154,7838137,acm1_human,83,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.94,-1.047,,,,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
296,7838137,acm1_human,83,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.09,1.318,,,,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
325,7838137,acm1_human,83,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.29,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
409,24443568,acm1_human,83,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.95,1.23,,,,100.7,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
470,7838137,acm1_human,83,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.74,-1.175,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
497,7838137,acm1_human,83,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,5.02,1.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
525,24443568,acm1_human,83,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,4.62,-1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
683,24443568,acm1_human,83,T,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.39,1.259,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.172519,TA83A,CHRM1
165,7838137,acm1_human,404,Y,F,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,3.61,25.704,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
208,7838137,acm1_human,404,Y,F,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,3.89,22.909,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
223,7838137,acm1_human,404,Y,F,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.14,-1.122,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
255,7838137,acm1_human,404,Y,F,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.89,,=,,8.1,6.166,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
425,7838137,acm1_human,404,Y,F,Himbacine,ChEMBL Compound ID,CHEMBL1993504,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.06,,=,,6.71,2.239,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
586,7838137,acm1_human,404,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.06,7.244,,,,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
636,7838137,acm1_human,404,Y,F,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.15,1.148,,,,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
711,7838137,acm1_human,404,Y,F,Methoctramine,ChEMBL Compound ID,CHEMBL27673,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.83,,=,,6.86,-1.072,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
738,7838137,acm1_human,404,Y,F,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.0,4.677,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.01298,YA404F,CHRM1
171,1618842,acm1_human,322,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,52.0,1.058,,,,0.0,0.0,,0.0,,P11229,-0.0746563,SA322A,CHRM1
195,9334899,acm1_human,106,Y,F,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.3,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.409056,YA106F,CHRM1
447,9334899,acm1_human,106,Y,F,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.25,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.409056,YA106F,CHRM1
449,9334899,acm1_human,106,Y,F,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,2.8,,,,0.0,0.0,,0.0,,P11229,-0.409056,YA106F,CHRM1
645,9334899,acm1_human,106,Y,F,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.6,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.409056,YA106F,CHRM1
779,9334899,acm1_human,106,Y,F,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.3,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.409056,YA106F,CHRM1
196,7838137,acm1_human,172,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.16,1.122,,,,0.0,0.0,,0.0,,P11229,-0.70987,TA172A,CHRM1
381,7838137,acm1_human,172,T,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.66,1.023,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.70987,TA172A,CHRM1
391,7838137,acm1_human,172,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.82,1.585,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.70987,TA172A,CHRM1
542,7838137,acm1_human,172,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.85,1.175,,,,0.0,0.0,,0.0,,P11229,-0.70987,TA172A,CHRM1
564,7838137,acm1_human,172,T,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.13,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.70987,TA172A,CHRM1
197,1618842,acm1_human,228,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,52.0,1.058,,,,0.0,0.0,,0.0,,P11229,0.815803,SA228A,CHRM1
199,7838137,acm1_human,165,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.87,1.413,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.48739,QA165A,CHRM1
227,7838137,acm1_human,165,Q,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.55,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.48739,QA165A,CHRM1
330,7838137,acm1_human,165,Q,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.98,1.698,,,,0.0,0.0,,0.0,,P11229,1.48739,QA165A,CHRM1
338,7838137,acm1_human,165,Q,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.33,-1.202,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.48739,QA165A,CHRM1
398,7838137,acm1_human,165,Q,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.84,1.202,,,,0.0,0.0,,0.0,,P11229,1.48739,QA165A,CHRM1
206,7838137,acm1_human,391,C,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.63,1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.34091,CA391A,CHRM1
331,7838137,acm1_human,391,C,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.94,-1.047,,,,0.0,0.0,,0.0,,P11229,-0.34091,CA391A,CHRM1
507,7838137,acm1_human,391,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.53,-1.905,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.34091,CA391A,CHRM1
744,7838137,acm1_human,391,C,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,5.33,-2.041,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.34091,CA391A,CHRM1
754,7838137,acm1_human,391,C,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,4.7,3.236,,,,0.0,0.0,,0.0,,P11229,-0.34091,CA391A,CHRM1
228,1618842,acm1_human,368,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,58.0,-1.055,,,,0.0,0.0,,0.0,,P11229,-0.173408,SA368A,CHRM1
237,24443568,acm1_human,157,W,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.85,,=,,9.32,3.388,,,,103.4,0.0,,0.0,,P11229,4.20642,WA157A,CHRM1
547,24443568,acm1_human,157,W,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.67,,=,,1.85,660.693,,,[3H]QNB,0.0,0.0,,0.0,,P11229,4.20642,WA157A,CHRM1
278,7838137,acm1_human,390,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.96,1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.3903,FA390A,CHRM1
291,7838137,acm1_human,390,F,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,5.21,,=,,5.04,1.479,,,,0.0,0.0,,0.0,,P11229,1.3903,FA390A,CHRM1
368,7838137,acm1_human,390,F,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.92,,=,,9.77,1.413,,,,0.0,0.0,,0.0,,P11229,1.3903,FA390A,CHRM1
396,7838137,acm1_human,390,F,A,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.25,,=,,5.13,1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.3903,FA390A,CHRM1
655,7838137,acm1_human,390,F,A,Gallamine,ChEMBL Compound ID,CHEMBL360055,Binding - unknown pharmacological activity,pK(i),Binding - Other,3.67,,=,,3.76,-1.23,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,1.3903,FA390A,CHRM1
332,24443568,acm1_human,189,T,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,4.68,-1.548,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.305443,TA189A,CHRM1
574,24443568,acm1_human,189,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,3.69,7.413,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.305443,TA189A,CHRM1
735,24443568,acm1_human,189,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.56,3.02,,,,130.0,0.0,,0.0,,P11229,0.305443,TA189A,CHRM1
375,7706286,acm1_human,212,Y,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,0.48,1.455,,,[3H]N-methyl scopolamine,0.0,98.3,,0.0,,P11229,-0.685834,YA212A,CHRM1
378,21685390,acm1_human,185,Q,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.59,-1.318,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.457793,QA185A,CHRM1
681,21685390,acm1_human,185,Q,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.18,1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.457793,QA185A,CHRM1
379,24443568,acm1_human,395,V,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.18,,=,,4.31,-1.35,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.87779,VA395A,CHRM1
452,24443568,acm1_human,395,V,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.67,,=,,2.03,436.516,,,[3H]QNB,0.0,0.0,,0.0,,P11229,2.87779,VA395A,CHRM1
513,24443568,acm1_human,395,V,A,[3H]QNB,ChEMBL Compound ID,CHEMBL12980,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,9.85,,=,,9.3,3.548,,,,108.6,0.0,,0.0,,P11229,2.87779,VA395A,CHRM1
383,9334899,acm1_human,412,T,A,Oxotremorine-M,ChEMBL Compound ID,CHEMBL44674,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.188506,TA412A,CHRM1
426,9334899,acm1_human,412,T,A,Pirenzepine,ChEMBL Compound ID,CHEMBL9967,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.111,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.188506,TA412A,CHRM1
639,9334899,acm1_human,412,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,=,,0.0,-1.429,,,,0.0,0.0,,0.0,,P11229,-0.188506,TA412A,CHRM1
646,9334899,acm1_human,412,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.3,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.188506,TA412A,CHRM1
661,9334899,acm1_human,412,T,A,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-2.0,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.188506,TA412A,CHRM1
390,17540859,acm1_human,254,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.57,,=,,9.15,2.63,,,,106.5,0.0,,0.0,,P11229,-0.624251,TA254A,CHRM1
394,17540859,acm1_human,252,P,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.57,,=,,9.23,2.188,,,,142.2,0.0,,0.0,,P11229,-0.924686,PA252A,CHRM1
413,1618842,acm1_human,428,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,53.0,1.038,,,,0.0,0.0,,0.0,,P11229,2.07681,TA428A,CHRM1
444,20643905,acm1_human,99,D,N,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,21.0,%,=,,7.4,2.838,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.139996,DA99N,CHRM1
453,7706286,acm1_human,360,E,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,0.03,-10.989,,,[3H]N-methyl scopolamine,0.0,187.9,,0.0,,P11229,0.411014,EA360A,CHRM1
456,21685390,acm1_human,177,Q,E,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.08,1.38,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.358494,QA177E,CHRM1
461,21685390,acm1_human,177,Q,E,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.58,-1.289,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.358494,QA177E,CHRM1
457,17540859,acm1_human,263,C,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.57,,=,,9.25,2.089,,,,141.9,0.0,,0.0,,P11229,0.0389766,CA263A,CHRM1
466,1618842,acm1_human,356,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,60.0,-1.091,,,,0.0,0.0,,0.0,,P11229,0.460944,SA356A,CHRM1
482,20643905,acm1_human,407,C,A,BR-384,PubChem CID,3078975,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,21.0,%,=,,1.6,13.125,,,N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.263919,CA407A,CHRM1
487,21685390,acm1_human,174,L,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.21,1.023,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.243759,LA174A,CHRM1
546,21685390,acm1_human,174,L,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.51,-1.096,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-0.243759,LA174A,CHRM1
498,7706286,acm1_human,366,T,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,0.12,-2.747,,,[3H]N-methyl scopolamine,0.0,87.9,,0.0,,P11229,-0.106946,TA366A,CHRM1
522,24443568,acm1_human,374,F,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.56,,=,,5.43,-7.407,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.84054,FA374A,CHRM1
745,24443568,acm1_human,374,F,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(A),Binding - Radioligand saturation,10.04,,=,,9.29,5.623,,,,30.0,0.0,,0.0,,P11229,3.84054,FA374A,CHRM1
770,24443568,acm1_human,374,F,A,BQCA,ChEMBL Compound ID,CHEMBL608112,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.49,,=,,5.38,-7.752,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,3.84054,FA374A,CHRM1
544,1618842,acm1_human,215,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,55.0,1.0,,,,0.0,0.0,,0.0,,P11229,0.736298,TA215A,CHRM1
550,7706286,acm1_human,362,K,A,Carbachol,ChEMBL Compound ID,CHEMBL965,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.33,mM,=,,1.6,4.848,,,[3H]N-methyl scopolamine,0.0,74.1,,0.0,,P11229,0.112727,KA362A,CHRM1
562,21685390,acm1_human,166,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,9.83,2.455,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.723263,YA166A,CHRM1
575,21685390,acm1_human,166,Y,A,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,10.33,1.38,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,0.723263,YA166A,CHRM1
592,8463213,acm1_human,284,S,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,46.0,1.196,,,,0.0,0.0,,0.0,,P11229,1.74918,SA284A,CHRM1
642,21685390,acm1_human,170,E,K,MT7,FASTA sequence (peptide),LTCVKSNSIWFPTSEDCPDGQNLCFKRWQYISPRMYDFTRGCAATCPKAEYRDVINCCGTDKCNK,Binding - unknown pharmacological activity,pKx,Binding - Radioligand competition/displacement,10.47,,=,,9.31,14.454,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-1.36823,EA170K,CHRM1
677,21685390,acm1_human,170,E,K,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.22,,=,,10.16,1.148,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P11229,-1.36823,EA170K,CHRM1
717,1618842,acm1_human,330,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,56.0,-1.018,,,,0.0,0.0,,0.0,,P11229,0.0341867,TA330A,CHRM1
775,1618842,acm1_human,354,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,Single-point,Binding - Other,55.0,%,=,,62.0,-1.127,,,,0.0,0.0,,0.0,,P11229,0.127033,TA354A,CHRM1
5,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-97,FASTA sequence (peptide),Ac-His-DPhe-Arg-(pCl)Phe-NH2,,EC50,Functional - cAMP accumulation,17.0,nM,=,,2096.0,123.294,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
41,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-91,FASTA sequence (peptide),Ac-Arg-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,1.06,nM,=,,124.0,116.981,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
52,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-108,FASTA sequence (peptide),Ac-His-DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,5.3,nM,=,,680.0,128.302,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
73,10.1021/jm500064t,mc4r_human,106,L,P,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,=,,2.6,10.0,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
116,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-93,FASTA sequence (peptide),Ac-Tyr-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,6.2,nM,=,,540.0,87.097,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
160,10.1021/jm500064t,mc4r_human,106,L,P,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,191.0,205.376,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
174,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-109,FASTA sequence (peptide),Ac-His-DPhe-Arg-(pNO2)Phe-NH2,,EC50,Functional - cAMP accumulation,195.0,nM,>,,10000.0,51.282,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
221,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-94,FASTA sequence (peptide),Ac-DArg-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,40.0,nM,=,,1242.0,31.05,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
239,10.1021/jm500064t,mc4r_human,106,L,P,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,10.0,22.222,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
252,10.1021/jm500064t,mc4r_human,106,L,P,Gamma-MSH,PubChem CID,16133814,,EC50,Functional - cAMP accumulation,73.0,nM,=,,2660.0,36.438,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
267,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-96,FASTA sequence (peptide),Ac-His-DPhe-Lys-Trp-NH2,,EC50,Functional - cAMP accumulation,40.0,nM,=,,6240.0,156.0,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
281,10.1093/hmg/ddg057,mc4r_human,106,L,P,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,18.7,5.348,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
287,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-110,FASTA sequence (peptide),Ac-His-DPhe-Arg-Nal(1')-NH2,,EC50,Functional - cAMP accumulation,28.0,nM,=,,4280.0,152.857,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
288,10.1021/jm500064t,mc4r_human,106,L,P,Beta-MSH,PubChem CID,16172929,,EC50,Functional - cAMP accumulation,0.42,nM,=,,365.0,869.048,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
289,10.1021/jm500064t,mc4r_human,106,L,P,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,10.0,41.667,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
291,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-107,FASTA sequence (peptide),Ac-His-DPhe-Arg-Tic-NH2,,EC50,Functional - cAMP accumulation,10000.0,nM,>,,10000.0,1.0,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
303,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-106,FASTA sequence (peptide),Ac-His-DPhe-Tic-Trp-NH2,,EC50,Functional - cAMP accumulation,204.0,nM,>,,10000.0,49.02,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
314,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-105,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,1.3,nM,=,,97.0,74.615,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
339,10.1021/jm500064t,mc4r_human,106,L,P,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,=,,2.9,20.714,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
347,10.1021/jm500064t,mc4r_human,106,L,P,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,2.6,nM,=,,215.0,82.692,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
373,10.1021/jm500064t,mc4r_human,106,L,P,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,15.0,37.5,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
387,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-92,FASTA sequence (peptide),Ac-Trp-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,32.0,nM,=,,170.0,5.312,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
398,10.1021/jm500064t,mc4r_human,106,L,P,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,=,,4.4,15.172,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
415,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-98,FASTA sequence (peptide),Ac-His-DPhe-Arg-(pCl)DPhe-NH2,,EC50,Functional - cAMP accumulation,46.0,nM,=,,8230.0,178.913,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
466,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-99,FASTA sequence (peptide),Ac-Tic-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,15.0,nM,=,,4940.0,329.333,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
467,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-104,FASTA sequence (peptide),Ac-His(pCl)DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.28,nM,=,,48.0,171.429,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
472,10.1021/jm500064t,mc4r_human,106,L,P,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,=,,13.0,68.421,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
474,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-101,FASTA sequence (peptide),Ac-(pCl)DPhe-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,48.0,nM,=,,4440.0,92.5,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
505,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-95,FASTA sequence (peptide),Ac-His-Arg-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,75.0,nM,=,,4940.0,65.867,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
525,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-102,FASTA sequence (peptide),Ac-(pI)DPhe-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,76.0,nM,=,,4910.0,64.605,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
536,10.1021/jm500064t,mc4r_human,106,L,P,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,3.4,16.19,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
541,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-100,FASTA sequence (peptide),Ac-DTic-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,297.0,nM,>,,10000.0,33.67,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
579,10.1021/jm500064t,mc4r_human,106,L,P,EMH4-103,FASTA sequence (peptide),Ac-(3I)Tyr-DPhe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,1.9,nM,=,,43.0,22.632,,,,0.0,0.0,,0.0,,P32245,3.51532,LA106P,MC4R
7,10.1111/j.1582-4934.2009.00726.x,mc4r_human,219,A,V,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,20.11,1.528,,,125-I-NDP-MSH,85.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
47,10.1021/jm500064t,mc4r_human,219,A,V,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,=,,17.0,89.474,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
176,10.1021/jm500064t,mc4r_human,219,A,V,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,=,,6.1,23.462,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
270,10.1021/jm500064t,mc4r_human,219,A,V,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,=,,14.0,48.276,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
277,10.1021/jm500064t,mc4r_human,219,A,V,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,=,,3.2,22.857,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
311,10.1021/jm500064t,mc4r_human,219,A,V,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,4.2,20.0,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
382,10.1021/jm500064t,mc4r_human,219,A,V,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,2.8,7.0,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
425,10.1111/j.1582-4934.2009.00726.x,mc4r_human,219,A,V,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,24.19,19.828,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
439,10.1021/jm500064t,mc4r_human,219,A,V,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,6.1,13.556,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
463,10.1111/j.1582-4934.2009.00726.x,mc4r_human,219,A,V,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,12.83,3.084,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
480,10.1021/jm500064t,mc4r_human,219,A,V,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,4.5,18.75,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
577,10.1021/jm500064t,mc4r_human,219,A,V,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,9.78,10.516,,,,0.0,0.0,,0.0,,P32245,-0.445829,AA219V,MC4R
10,10.1210/jc.2003-030233,mc4r_human,103,V,I,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,29.0,-1.757,,,,0.0,0.0,,0.0,,P32245,-0.87219,VA103I,MC4R
11,10.1677/joe-09-0336,mc4r_human,252,G,S,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,2.3,3.239,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
86,10.1677/joe-09-0336,mc4r_human,252,G,S,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,160.0,6.154,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
152,10.1677/joe-09-0336,mc4r_human,252,G,S,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,8.0,11.429,,,,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
215,10.1677/joe-09-0336,mc4r_human,252,G,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,210.0,7.0,,,,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
336,10.1677/joe-09-0336,mc4r_human,252,G,S,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,13.0,8.667,,,,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
533,10.1210/jc.2003-030233,mc4r_human,252,G,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,37.0,-1.379,,,,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
561,10.1677/joe-09-0336,mc4r_human,252,G,S,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,1.6,2.254,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.426687,GA252S,MC4R
14,10.1021/bi001684q,mc4r_human,49,E,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.42,1.556,,,,0.0,0.0,,0.0,,P32245,1.49312,EA49A,MC4R
137,10.1021/bi001684q,mc4r_human,49,E,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.37,1.769,,,,0.0,0.0,,0.0,,P32245,1.49312,EA49A,MC4R
138,10.1021/bi001684q,mc4r_human,49,E,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.87,1.312,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,1.49312,EA49A,MC4R
142,10.1021/bi001684q,mc4r_human,49,E,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,83.7,2.44,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.49312,EA49A,MC4R
390,10.1021/bi001684q,mc4r_human,49,E,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,2.2,1.429,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.49312,EA49A,MC4R
15,10.1677/joe-09-0336,mc4r_human,50,V,M,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,37.0,1.233,,,,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
63,10.1677/joe-09-0336,mc4r_human,50,V,M,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,22.0,-1.182,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
269,10.1677/joe-09-0336,mc4r_human,50,V,M,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,2.0,1.333,,,,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
343,10.1677/joe-09-0336,mc4r_human,50,V,M,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,0.96,1.371,,,,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
349,10.1677/joe-09-0336,mc4r_human,50,V,M,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.63,-1.127,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
449,10.1677/joe-09-0336,mc4r_human,50,V,M,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.79,1.113,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.24378,VA50M,MC4R
16,10.1021/bi001684q,mc4r_human,261,F,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,1.06,3.926,,,,0.0,0.0,,0.0,,P32245,2.40275,FA261A,MC4R
112,10.1021/bi001684q,mc4r_human,261,F,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,160.0,4.665,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.40275,FA261A,MC4R
218,10.1021/bi001684q,mc4r_human,261,F,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,5.43,4.052,,,,0.0,0.0,,0.0,,P32245,2.40275,FA261A,MC4R
283,10.1021/bi001684q,mc4r_human,261,F,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.98,1.349,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,2.40275,FA261A,MC4R
443,10.1021/bi001684q,mc4r_human,261,F,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,8.31,5.396,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.40275,FA261A,MC4R
17,10.1111/j.1582-4934.2009.00726.x,mc4r_human,7,R,C,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,3.06,2.508,,,,0.0,0.0,,0.0,,P32245,-0.0967706,RA7C,MC4R
114,10.1111/j.1582-4934.2009.00726.x,mc4r_human,7,R,C,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,3.6,-1.156,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.0967706,RA7C,MC4R
389,10.1111/j.1582-4934.2009.00726.x,mc4r_human,7,R,C,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,12.32,-1.068,,,125-I-NDP-MSH,70.0,0.0,,0.0,,P32245,-0.0967706,RA7C,MC4R
18,10.1021/bi001684q,mc4r_human,165,R,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,2.03,1.318,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.328478,RA165A,MC4R
25,10.1021/bi001684q,mc4r_human,165,R,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.12,1.058,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,0.328478,RA165A,MC4R
296,10.1021/bi001684q,mc4r_human,165,R,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,54.5,1.589,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.328478,RA165A,MC4R
306,10.1021/bi001684q,mc4r_human,165,R,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.33,1.222,,,,0.0,0.0,,0.0,,P32245,0.328478,RA165A,MC4R
459,10.1021/bi001684q,mc4r_human,165,R,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,3.1,2.313,,,,0.0,0.0,,0.0,,P32245,0.328478,RA165A,MC4R
19,10.1021/bi001684q,mc4r_human,283,H,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.26,-1.305,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,0.69887,HA283A,MC4R
190,10.1021/bi001684q,mc4r_human,283,H,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,27.0,-1.271,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.69887,HA283A,MC4R
198,10.1021/bi001684q,mc4r_human,283,H,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.11,-1.387,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.69887,HA283A,MC4R
532,10.1021/bi001684q,mc4r_human,283,H,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.54,1.896,,,,0.0,0.0,,0.0,,P32245,0.69887,HA283A,MC4R
547,10.1021/bi001684q,mc4r_human,283,H,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.27,1.0,,,,0.0,0.0,,0.0,,P32245,0.69887,HA283A,MC4R
20,10.1677/joe-09-0336,mc4r_human,127,S,L,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,160.0,6.154,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
91,10.1677/joe-09-0336,mc4r_human,127,S,L,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,17.0,11.333,,,,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
178,10.1111/j.1582-4934.2009.00726.x,mc4r_human,127,S,L,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,18.25,4.387,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
216,10.1111/j.1582-4934.2009.00726.x,mc4r_human,127,S,L,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,1.78,1.459,,,,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
219,10.1677/joe-09-0336,mc4r_human,127,S,L,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,5.2,7.429,,,,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
256,10.1677/joe-09-0336,mc4r_human,127,S,L,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,2.6,3.662,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
421,10.1111/j.1582-4934.2009.00726.x,mc4r_human,127,S,L,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,14.99,1.139,,,125-I-NDP-MSH,100.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
511,10.1210/jc.2003-030233,mc4r_human,127,S,L,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,4003.0,78.49,,,,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
523,10.1677/joe-09-0336,mc4r_human,127,S,L,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,3.3,4.648,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
524,10.1677/joe-09-0336,mc4r_human,127,S,L,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,640.0,21.333,,,,0.0,0.0,,0.0,,P32245,-0.491156,SA127L,MC4R
22,10.1677/joe-09-0336,mc4r_human,305,R,W,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,130.0,5.0,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
24,10.1677/joe-09-0336,mc4r_human,305,R,W,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,15.0,-2.0,,,,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
38,10.1677/joe-09-0336,mc4r_human,305,R,W,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,2.5,3.521,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
129,10.1677/joe-09-0336,mc4r_human,305,R,W,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,0.61,-1.148,,,,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
209,10.1677/joe-09-0336,mc4r_human,305,R,W,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,0.87,-1.724,,,,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
302,10.1677/joe-09-0336,mc4r_human,305,R,W,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,2.2,3.099,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.589799,RA305W,MC4R
23,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,F,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,0.41,-10.101,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,5.12144,SA136F,MC4R
173,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,F,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,3.72,-3.534,,,125-I-NDP-MSH,80.0,0.0,,0.0,,P32245,5.12144,SA136F,MC4R
224,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,F,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,7.61,6.238,,,,0.0,0.0,,0.0,,P32245,5.12144,SA136F,MC4R
31,10.1677/joe-09-0336,mc4r_human,18,R,C,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,34.0,1.133,,,,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
135,10.1677/joe-09-0336,mc4r_human,18,R,C,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,1.9,1.267,,,,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
305,10.1677/joe-09-0336,mc4r_human,18,R,C,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,0.92,1.314,,,,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
328,10.1677/joe-09-0336,mc4r_human,18,R,C,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,16.0,-1.626,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
374,10.1677/joe-09-0336,mc4r_human,18,R,C,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.37,-1.919,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
522,10.1677/joe-09-0336,mc4r_human,18,R,C,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.65,-1.093,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.08914,RA18C,MC4R
33,10.1111/j.1582-4934.2009.00726.x,mc4r_human,317,I,V,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,3.56,-1.168,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.769988,IA317V,MC4R
102,10.1111/j.1582-4934.2009.00726.x,mc4r_human,317,I,V,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,18.44,1.401,,,125-I-NDP-MSH,150.0,0.0,,0.0,,P32245,0.769988,IA317V,MC4R
554,10.1111/j.1582-4934.2009.00726.x,mc4r_human,317,I,V,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,3.6,2.951,,,,0.0,0.0,,0.0,,P32245,0.769988,IA317V,MC4R
35,10.1021/bi001684q,mc4r_human,100,E,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.97,1.346,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.396358,EA100A,MC4R
226,10.1021/bi001684q,mc4r_human,100,E,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,4.45,3.321,,,,0.0,0.0,,0.0,,P32245,-0.396358,EA100A,MC4R
285,10.1021/bi001684q,mc4r_human,100,E,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,6.71,4.357,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.396358,EA100A,MC4R
342,10.1021/bi001684q,mc4r_human,100,E,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,132.0,3.848,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.396358,EA100A,MC4R
461,10.1021/bi001684q,mc4r_human,100,E,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.65,2.407,,,,0.0,0.0,,0.0,,P32245,-0.396358,EA100A,MC4R
37,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,94,S,N,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,7.33,2.262,,,,0.0,0.0,,0.0,,P32245,4.89083,SA94N,MC4R
108,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,94,S,N,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,5.26,2.031,,,,0.0,0.0,,0.0,,P32245,4.89083,SA94N,MC4R
121,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,94,S,N,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,53.7,-31.25,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.89083,SA94N,MC4R
199,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,94,S,N,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,239.64,-6.289,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.89083,SA94N,MC4R
42,10.1021/bi001684q,mc4r_human,298,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,4.54,2.948,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.262541,DA298A,MC4R
168,10.1021/bi001684q,mc4r_human,298,D,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.98,1.01,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.262541,DA298A,MC4R
432,10.1021/bi001684q,mc4r_human,298,D,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,79.4,2.315,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.262541,DA298A,MC4R
45,10.1021/bi001684q,mc4r_human,305,R,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.9,1.234,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.503638,RA305A,MC4R
56,10.1021/bi001684q,mc4r_human,305,R,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.49,1.815,,,,0.0,0.0,,0.0,,P32245,0.503638,RA305A,MC4R
297,10.1021/bi001684q,mc4r_human,305,R,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.7,-1.093,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,0.503638,RA305A,MC4R
484,10.1021/bi001684q,mc4r_human,305,R,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,1.31,-1.022,,,,0.0,0.0,,0.0,,P32245,0.503638,RA305A,MC4R
550,10.1021/bi001684q,mc4r_human,305,R,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,90.4,2.636,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.503638,RA305A,MC4R
46,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,195,I,S,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,329.08,-5.128,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.940075,IA195S,MC4R
149,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,195,I,S,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,4.28,1.321,,,,0.0,0.0,,0.0,,P32245,0.940075,IA195S,MC4R
403,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,195,I,S,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,593.4,-2.538,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.940075,IA195S,MC4R
582,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,195,I,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,3.11,1.201,,,,0.0,0.0,,0.0,,P32245,0.940075,IA195S,MC4R
48,10.1677/joe-09-0336,mc4r_human,58,S,C,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,1.7,2.394,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
113,10.1677/joe-09-0336,mc4r_human,58,S,C,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.97,1.366,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
186,10.1677/joe-09-0336,mc4r_human,58,S,C,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,19.0,27.143,,,,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
187,10.1677/joe-09-0336,mc4r_human,58,S,C,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,53.0,2.038,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
412,10.1677/joe-09-0336,mc4r_human,58,S,C,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,46.0,30.667,,,,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
501,10.1677/joe-09-0336,mc4r_human,58,S,C,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,670.0,22.333,,,,0.0,0.0,,0.0,,P32245,0.495413,SA58C,MC4R
50,10.1021/jm500064t,mc4r_human,271,C,R,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,>,,10000.0,52631.579,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
105,10.1021/jm500064t,mc4r_human,271,C,R,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,>,,10000.0,34482.759,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
126,10.1021/jm500064t,mc4r_human,271,C,R,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,>,,10000.0,71428.571,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
151,10.1021/jm500064t,mc4r_human,271,C,R,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,>,,10000.0,38461.538,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
165,10.1021/jm500064t,mc4r_human,271,C,R,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,1600.0,1720.43,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
191,10.1021/jm500064t,mc4r_human,271,C,R,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,3390.0,16142.857,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
205,10.1021/jm500064t,mc4r_human,271,C,R,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,295.0,1229.167,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
236,10.1021/jm500064t,mc4r_human,271,C,R,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,130.0,325.0,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
381,10.1021/jm500064t,mc4r_human,271,C,R,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,210.0,466.667,,,,0.0,0.0,,0.0,,P32245,2.32132,CA271R,MC4R
51,10.1021/bi001684q,mc4r_human,126,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,>,,10000.0,6493.506,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.40735,DA126A,MC4R
189,10.1021/bi001684q,mc4r_human,126,D,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,>,,10000.0,37037.037,,,,0.0,0.0,,0.0,,P32245,-1.40735,DA126A,MC4R
316,10.1021/bi001684q,mc4r_human,126,D,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,26.4,8.949,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-1.40735,DA126A,MC4R
53,10.1021/bi001684q,mc4r_human,214,H,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.18,-1.499,,,,0.0,0.0,,0.0,,P32245,0.302922,HA214A,MC4R
100,10.1021/bi001684q,mc4r_human,214,H,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.41,-1.092,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.302922,HA214A,MC4R
132,10.1021/bi001684q,mc4r_human,214,H,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.4,1.791,,,,0.0,0.0,,0.0,,P32245,0.302922,HA214A,MC4R
153,10.1021/bi001684q,mc4r_human,214,H,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,42.8,1.248,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.302922,HA214A,MC4R
290,10.1021/bi001684q,mc4r_human,214,H,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.3,1.119,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,0.302922,HA214A,MC4R
54,10.1677/joe-09-0336,mc4r_human,231,G,S,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.68,-1.044,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
156,10.1677/joe-09-0336,mc4r_human,231,G,S,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,28.0,1.077,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
231,10.1677/joe-09-0336,mc4r_human,231,G,S,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,1.9,1.267,,,,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
248,10.1677/joe-09-0336,mc4r_human,231,G,S,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.58,-1.224,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
564,10.1677/joe-09-0336,mc4r_human,231,G,S,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,0.79,1.129,,,,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
566,10.1677/joe-09-0336,mc4r_human,231,G,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,33.0,1.1,,,,0.0,0.0,,0.0,,P32245,4.06397,GA231S,MC4R
55,10.1021/bi001684q,mc4r_human,199,T,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,42.6,1.242,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.12048,TA199A,MC4R
228,10.1021/bi001684q,mc4r_human,199,T,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.5,1.866,,,,0.0,0.0,,0.0,,P32245,-0.12048,TA199A,MC4R
312,10.1021/bi001684q,mc4r_human,199,T,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.6,1.039,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.12048,TA199A,MC4R
395,10.1021/bi001684q,mc4r_human,199,T,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.5,-1.181,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.12048,TA199A,MC4R
573,10.1021/bi001684q,mc4r_human,199,T,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.29,1.074,,,,0.0,0.0,,0.0,,P32245,-0.12048,TA199A,MC4R
57,10.1021/bi001684q,mc4r_human,204,M,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.54,2.0,,,,0.0,0.0,,0.0,,P32245,1.55313,MA204A,MC4R
104,10.1021/bi001684q,mc4r_human,204,M,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.6,-1.135,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,1.55313,MA204A,MC4R
264,10.1021/bi001684q,mc4r_human,204,M,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,5.7,4.254,,,,0.0,0.0,,0.0,,P32245,1.55313,MA204A,MC4R
408,10.1021/bi001684q,mc4r_human,204,M,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,>,,10000.0,291.545,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.55313,MA204A,MC4R
488,10.1021/bi001684q,mc4r_human,204,M,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,2.31,1.5,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.55313,MA204A,MC4R
59,https://doi.org/10.1016/j.jmb.2010.06.028,mc4r_human,264,H,C,NDP-MSH,PubChem CID,16154396,,pEC50,Functional - CRE-luciferase,8.27,nM,=,,5.67,398.107,,,,0.0,0.0,,0.0,,P32245,1.00591,HA264C,MC4R
65,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,186,I,V,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,1.06,-3.058,,,,0.0,0.0,,0.0,,P32245,0.669636,IA186V,MC4R
197,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,186,I,V,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,1084.7,-1.553,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.669636,IA186V,MC4R
330,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,186,I,V,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,0.6,-4.31,,,,0.0,0.0,,0.0,,P32245,0.669636,IA186V,MC4R
361,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,186,I,V,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,1106.9,-1.361,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.669636,IA186V,MC4R
66,10.1093/hmg/ddg057,mc4r_human,62,N,S,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,20.0,5.0,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.98219,NA62S,MC4R
68,10.1021/bi001684q,mc4r_human,164,K,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.5,1.866,,,,0.0,0.0,,0.0,,P32245,-0.232382,KA164A,MC4R
266,10.1021/bi001684q,mc4r_human,164,K,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.44,1.63,,,,0.0,0.0,,0.0,,P32245,-0.232382,KA164A,MC4R
272,10.1021/bi001684q,mc4r_human,164,K,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,35.1,1.023,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.232382,KA164A,MC4R
417,10.1021/bi001684q,mc4r_human,164,K,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.89,1.319,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.232382,KA164A,MC4R
431,10.1021/bi001684q,mc4r_human,164,K,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.73,1.123,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.232382,KA164A,MC4R
70,10.1021/jm500064t,mc4r_human,102,I,S,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,720.0,774.194,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
131,10.1677/joe-09-0336,mc4r_human,102,I,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,>,,10000.0,333.333,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
150,10.1677/joe-09-0336,mc4r_human,102,I,S,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.84,1.183,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
161,10.1021/jm500064t,mc4r_human,102,I,S,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,=,,13.0,68.421,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
201,10.1021/jm500064t,mc4r_human,102,I,S,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,=,,4.0,28.571,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
253,10.1677/joe-09-0336,mc4r_human,102,I,S,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,260.0,10.0,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
358,10.1677/joe-09-0336,mc4r_human,102,I,S,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,21.0,30.0,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
367,10.1677/joe-09-0336,mc4r_human,102,I,S,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,4.7,6.62,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
402,10.1021/jm500064t,mc4r_human,102,I,S,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,20.0,44.444,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
438,10.1021/jm500064t,mc4r_human,102,I,S,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,=,,3.5,12.069,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
452,10.1021/jm500064t,mc4r_human,102,I,S,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,3.0,7.5,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
470,10.1021/jm500064t,mc4r_human,102,I,S,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,4.4,20.952,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
515,10.1021/jm500064t,mc4r_human,102,I,S,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,14.0,58.333,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
544,10.1677/joe-09-0336,mc4r_human,102,I,S,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,100.0,66.667,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
583,10.1021/jm500064t,mc4r_human,102,I,S,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,=,,2.9,11.154,,,,0.0,0.0,,0.0,,P32245,0.417619,IA102S,MC4R
72,10.1021/bi001684q,mc4r_human,264,H,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,>,,10000.0,6493.506,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.898796,HA264A,MC4R
384,10.1021/bi001684q,mc4r_human,264,H,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,134.0,496.296,,,,0.0,0.0,,0.0,,P32245,0.898796,HA264A,MC4R
462,10.1021/bi001684q,mc4r_human,264,H,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,4.1,1.39,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,0.898796,HA264A,MC4R
574,10.1021/bi001684q,mc4r_human,264,H,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,>,,10000.0,7462.687,,,,0.0,0.0,,0.0,,P32245,0.898796,HA264A,MC4R
77,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,T,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.5,nM,=,,2.45,1.633,,,,0.0,0.0,,0.0,,P32245,0.164241,SA136T,MC4R
101,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,T,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,25.21,nM,=,,43.77,1.736,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.164241,SA136T,MC4R
80,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,300,L,P,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,3.3,1.274,,,,0.0,0.0,,0.0,,P32245,1.09575,LA300P,MC4R
282,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,300,L,P,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,342.63,-4.405,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.09575,LA300P,MC4R
493,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,300,L,P,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,53.6,-31.25,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.09575,LA300P,MC4R
543,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,300,L,P,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,5.83,1.799,,,,0.0,0.0,,0.0,,P32245,1.09575,LA300P,MC4R
82,http://doi.org/10.1016/j.domaniend.2007.05.003,mc4r_human,298,D,N,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,7.7,nM,=,,14.07,1.827,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-2.05722,DA298N,MC4R
117,http://doi.org/10.1016/j.domaniend.2007.05.003,mc4r_human,298,D,N,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,5.43,nM,=,,4.02,-1.351,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-2.05722,DA298N,MC4R
207,http://doi.org/10.1016/j.domaniend.2007.05.003,mc4r_human,298,D,N,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.63,nM,=,,12.96,7.951,,,,0.0,0.0,,0.0,,P32245,-2.05722,DA298N,MC4R
84,10.1111/j.1582-4934.2009.00726.x,mc4r_human,230,P,L,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,12.31,10.09,,,,0.0,0.0,,0.0,,P32245,0.835327,PA230L,MC4R
213,10.1111/j.1582-4934.2009.00726.x,mc4r_human,230,P,L,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,4.01,-1.037,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.835327,PA230L,MC4R
423,10.1111/j.1582-4934.2009.00726.x,mc4r_human,230,P,L,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,12.82,-1.027,,,125-I-NDP-MSH,90.0,0.0,,0.0,,P32245,0.835327,PA230L,MC4R
434,10.1210/jc.2003-030233,mc4r_human,230,P,L,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,107.0,2.098,,,,0.0,0.0,,0.0,,P32245,0.835327,PA230L,MC4R
94,10.1021/jm500064t,mc4r_human,69,I,T,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,=,,1.5,10.714,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
124,10.1021/jm500064t,mc4r_human,69,I,T,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,=,,8.2,43.158,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
158,10.1021/jm500064t,mc4r_human,69,I,T,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,2.9,6.444,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
238,10.1021/jm500064t,mc4r_human,69,I,T,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,5.2,24.762,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
321,10.1021/jm500064t,mc4r_human,69,I,T,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,=,,3.4,11.724,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
366,10.1021/jm500064t,mc4r_human,69,I,T,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,4.3,10.75,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
492,10.1021/jm500064t,mc4r_human,69,I,T,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,40.7,43.763,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
546,10.1021/jm500064t,mc4r_human,69,I,T,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,=,,4.1,15.769,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
578,10.1021/jm500064t,mc4r_human,69,I,T,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,3.8,15.833,,,,0.0,0.0,,0.0,,P32245,1.6826,IA69T,MC4R
95,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD6,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.26,nM,>,,10000.0,38461.538,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
144,10.1021/jm500064t,mc4r_human,271,C,Y,JRH887-9,FASTA sequence (peptide),Ac-His-Dphe-Arg-Trp-NH2,,EC50,Functional - cAMP accumulation,0.93,nM,=,,1200.0,1290.323,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
230,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD9,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.45,nM,=,,260.0,577.778,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
251,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD5,FASTA sequence (peptide),Ac-His-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.14,nM,>,,10000.0,71428.571,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
426,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD11,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.19,nM,>,,10000.0,52631.579,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
435,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD4,FASTA sequence (peptide),Ac-His-(pI)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.24,nM,=,,190.0,791.667,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
513,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD7,FASTA sequence (peptide),Ac-Arg-(pI)DPhe-Arg-(pI)Phe-NH2,,EC50,Functional - cAMP accumulation,0.29,nM,>,,10000.0,34482.759,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
530,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD10,FASTA sequence (peptide),Ac-Arg-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.21,nM,=,,470.0,2238.095,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
531,10.1021/jm500064t,mc4r_human,271,C,Y,CMPD8,FASTA sequence (peptide),Ac-His-(pCl)DPhe-Tic-(pNO2)DPhe-NH2,,EC50,Functional - cAMP accumulation,0.4,nM,=,,82.0,205.0,,,,0.0,0.0,,0.0,,P32245,2.84975,CA271Y,MC4R
97,https://doi.org/10.1016/j.jmb.2010.06.028,mc4r_human,125,I,C,NDP-MSH,PubChem CID,16154396,,pEC50,Functional - CRE-luciferase,8.27,nM,=,,7.98,1.95,,,,0.0,0.0,,0.0,,P32245,2.24455,IA125C,MC4R
99,10.1210/jc.2003-030233,mc4r_human,244,A,E,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,425.0,8.333,,,,0.0,0.0,,0.0,,P32245,0.257586,AA244E,MC4R
103,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,R,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,25.21,nM,=,,151.8,6.021,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.38847,SA136R,MC4R
400,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,R,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.5,nM,=,,10.73,7.153,,,,0.0,0.0,,0.0,,P32245,-1.38847,SA136R,MC4R
107,10.1111/j.1582-4934.2009.00726.x,mc4r_human,325,L,F,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,2.62,2.148,,,,0.0,0.0,,0.0,,P32245,0.00728518,LA325F,MC4R
195,10.1111/j.1582-4934.2009.00726.x,mc4r_human,325,L,F,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,6.17,1.483,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.00728518,LA325F,MC4R
468,10.1111/j.1582-4934.2009.00726.x,mc4r_human,325,L,F,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,5.12,-2.571,,,125-I-NDP-MSH,140.0,0.0,,0.0,,P32245,0.00728518,LA325F,MC4R
111,10.1210/jc.2003-030233,mc4r_human,317,I,T,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,57.0,1.118,,,,0.0,0.0,,0.0,,P32245,1.2336,IA317T,MC4R
118,10.1021/bi001684q,mc4r_human,267,F,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,22.0,-1.56,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.12784,FA267A,MC4R
128,10.1021/bi001684q,mc4r_human,267,F,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.37,1.37,,,,0.0,0.0,,0.0,,P32245,2.12784,FA267A,MC4R
157,10.1021/bi001684q,mc4r_human,267,F,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.9,2.164,,,,0.0,0.0,,0.0,,P32245,2.12784,FA267A,MC4R
185,10.1021/bi001684q,mc4r_human,267,F,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.65,1.071,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.12784,FA267A,MC4R
383,10.1021/bi001684q,mc4r_human,267,F,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,1.9,-1.553,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,2.12784,FA267A,MC4R
120,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,146,D,N,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,0.08,-32.258,,,,0.0,0.0,,0.0,,P32245,0.500382,DA146N,MC4R
346,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,146,D,N,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,66.74,-22.727,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.500382,DA146N,MC4R
481,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,146,D,N,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,0.47,-6.897,,,,0.0,0.0,,0.0,,P32245,0.500382,DA146N,MC4R
559,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,146,D,N,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,4.41,-333.333,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.500382,DA146N,MC4R
123,10.1677/joe-09-0336,mc4r_human,18,R,H,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.42,-1.689,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
130,10.1677/joe-09-0336,mc4r_human,18,R,H,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,0.93,-1.613,,,,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
233,10.1677/joe-09-0336,mc4r_human,18,R,H,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,16.0,-1.626,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
310,10.1677/joe-09-0336,mc4r_human,18,R,H,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,0.43,-1.629,,,,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
496,10.1677/joe-09-0336,mc4r_human,18,R,H,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.49,-1.449,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
500,10.1677/joe-09-0336,mc4r_human,18,R,H,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,16.0,-1.876,,,,0.0,0.0,,0.0,,P32245,0.865188,RA18H,MC4R
125,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,C,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,957.03,-1.761,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.111788,YA332C,MC4R
155,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,C,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,1.55,-2.092,,,,0.0,0.0,,0.0,,P32245,-0.111788,YA332C,MC4R
308,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,C,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,0.34,-7.634,,,,0.0,0.0,,0.0,,P32245,-0.111788,YA332C,MC4R
460,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,C,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,832.13,-1.812,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.111788,YA332C,MC4R
133,10.1021/bi001684q,mc4r_human,203,T,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.33,1.222,,,,0.0,0.0,,0.0,,P32245,-0.224009,TA203A,MC4R
217,10.1021/bi001684q,mc4r_human,203,T,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.14,-1.379,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.224009,TA203A,MC4R
235,10.1021/bi001684q,mc4r_human,203,T,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,1.76,1.313,,,,0.0,0.0,,0.0,,P32245,-0.224009,TA203A,MC4R
240,10.1021/bi001684q,mc4r_human,203,T,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,2.11,1.37,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.224009,TA203A,MC4R
576,10.1021/bi001684q,mc4r_human,203,T,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,45.3,1.321,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.224009,TA203A,MC4R
134,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,C,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.5,nM,=,,1.07,-1.403,,,,0.0,0.0,,0.0,,P32245,-0.0738059,SA136C,MC4R
529,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,C,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,25.21,nM,=,,37.37,1.482,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.0738059,SA136C,MC4R
140,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,76,H,R,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,1.18,-2.747,,,,0.0,0.0,,0.0,,P32245,-1.35766,HA76R,MC4R
154,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,76,H,R,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,0.92,-2.817,,,,0.0,0.0,,0.0,,P32245,-1.35766,HA76R,MC4R
508,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,76,H,R,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,111.34,-13.514,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.35766,HA76R,MC4R
585,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,76,H,R,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,41.31,-40.0,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.35766,HA76R,MC4R
141,10.1093/hmg/ddg057,mc4r_human,97,N,D,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,10.5,9.524,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.23308,NA97D,MC4R
143,10.1021/bi001684q,mc4r_human,196,C,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.42,1.556,,,,0.0,0.0,,0.0,,P32245,-0.706863,CA196A,MC4R
194,10.1021/bi001684q,mc4r_human,196,C,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.18,1.078,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.706863,CA196A,MC4R
227,10.1021/bi001684q,mc4r_human,196,C,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,2.36,1.761,,,,0.0,0.0,,0.0,,P32245,-0.706863,CA196A,MC4R
360,10.1021/bi001684q,mc4r_human,196,C,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,30.9,-1.11,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.706863,CA196A,MC4R
571,10.1021/bi001684q,mc4r_human,196,C,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,3.1,2.013,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.706863,CA196A,MC4R
148,10.1677/joe-09-0336,mc4r_human,102,I,T,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,210.0,8.077,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
203,10.1677/joe-09-0336,mc4r_human,102,I,T,IRC-022511,PubChem CID,,,EC50,Functional - cAMP accumulation,0.7,nM,=,,38.0,54.286,,,,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
229,10.1677/joe-09-0336,mc4r_human,102,I,T,IRC-022493,PubChem CID,11993702,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,2.2,3.099,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
245,10.1677/joe-09-0336,mc4r_human,102,I,T,IRC-022493,PubChem CID,11993702,,EC50,Functional - cAMP accumulation,1.5,nM,=,,150.0,100.0,,,,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
465,10.1677/joe-09-0336,mc4r_human,102,I,T,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,30.0,nM,=,,5800.0,193.333,,,,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
519,10.1677/joe-09-0336,mc4r_human,102,I,T,IRC-022511,PubChem CID,,,K(i),Binding - Radioligand competition/displacement,0.71,nM,=,,0.85,1.197,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.65117,IA102T,MC4R
162,10.1021/bi001684q,mc4r_human,122,D,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,4.9,1.661,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
164,10.1021/bi001684q,mc4r_human,122,D,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,1.67,6.185,,,,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
271,10.1021/bi001684q,mc4r_human,122,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,9.32,6.052,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
292,10.1021/bi001684q,mc4r_human,122,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,26.0,21.667,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
479,10.1021/bi001684q,mc4r_human,122,D,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,722.7,21.07,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
516,10.1021/bi001684q,mc4r_human,122,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,9.3,7.154,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
540,10.1021/bi001684q,mc4r_human,122,D,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,>,,10000.0,7462.687,,,,0.0,0.0,,0.0,,P32245,-1.08828,DA122A,MC4R
163,10.1111/j.1582-4934.2009.00726.x,mc4r_human,261,F,S,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,13.16,nM,=,,2.49,-5.291,,,125-I-NDP-MSH,80.0,0.0,,0.0,,P32245,2.83391,FA261S,MC4R
225,10.1111/j.1582-4934.2009.00726.x,mc4r_human,261,F,S,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,IC50,Binding - Radioligand competition/displacement,4.16,nM,=,,1.33,-3.125,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.83391,FA261S,MC4R
485,10.1111/j.1582-4934.2009.00726.x,mc4r_human,261,F,S,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,1.48,1.213,,,,0.0,0.0,,0.0,,P32245,2.83391,FA261S,MC4R
170,10.1111/j.1582-4934.2009.00726.x,mc4r_human,84,C,R,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.22,nM,=,,8.73,7.156,,,,0.0,0.0,,0.0,,P32245,-1.26363,CA84R,MC4R
171,10.1021/bi001684q,mc4r_human,90,D,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.12,1.058,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-2.94083,DA90A,MC4R
380,10.1021/bi001684q,mc4r_human,90,D,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,364.0,10.612,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-2.94083,DA90A,MC4R
413,10.1021/bi001684q,mc4r_human,90,D,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,5.61,3.643,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-2.94083,DA90A,MC4R
180,10.1021/bi001684q,mc4r_human,268,Y,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.5,1.852,,,,0.0,0.0,,0.0,,P32245,1.00516,YA268A,MC4R
220,10.1021/bi001684q,mc4r_human,268,Y,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,90.0,67.164,,,,0.0,0.0,,0.0,,P32245,1.00516,YA268A,MC4R
411,10.1021/bi001684q,mc4r_human,268,Y,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.6,1.22,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,1.00516,YA268A,MC4R
549,10.1021/bi001684q,mc4r_human,268,Y,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,1.87,1.214,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.00516,YA268A,MC4R
575,10.1021/bi001684q,mc4r_human,268,Y,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,16.0,-2.146,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.00516,YA268A,MC4R
181,10.1021/bi001684q,mc4r_human,258,W,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,782.7,22.819,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.47345,WA258A,MC4R
279,10.1021/bi001684q,mc4r_human,258,W,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,4.01,2.604,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.47345,WA258A,MC4R
324,10.1021/bi001684q,mc4r_human,258,W,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.54,2.0,,,,0.0,0.0,,0.0,,P32245,4.47345,WA258A,MC4R
386,10.1021/bi001684q,mc4r_human,258,W,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,2.31,-1.277,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,4.47345,WA258A,MC4R
478,10.1021/bi001684q,mc4r_human,258,W,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,16.0,11.94,,,,0.0,0.0,,0.0,,P32245,4.47345,WA258A,MC4R
182,10.1021/bi001684q,mc4r_human,200,M,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.45,1.667,,,,0.0,0.0,,0.0,,P32245,1.20019,MA200A,MC4R
250,10.1021/bi001684q,mc4r_human,200,M,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,9.1,6.791,,,,0.0,0.0,,0.0,,P32245,1.20019,MA200A,MC4R
320,10.1021/bi001684q,mc4r_human,200,M,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,579.7,16.901,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.20019,MA200A,MC4R
471,10.1021/bi001684q,mc4r_human,200,M,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.1,1.051,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,1.20019,MA200A,MC4R
510,10.1021/bi001684q,mc4r_human,200,M,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,3.02,1.961,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,1.20019,MA200A,MC4R
183,10.1021/bi001684q,mc4r_human,122,D,N,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.69,2.556,,,,0.0,0.0,,0.0,,P32245,-1.17751,DA122N,MC4R
414,10.1021/bi001684q,mc4r_human,122,D,N,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,155.0,115.672,,,,0.0,0.0,,0.0,,P32245,-1.17751,DA122N,MC4R
447,10.1021/bi001684q,mc4r_human,122,D,N,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,129.3,3.77,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.17751,DA122N,MC4R
537,10.1021/bi001684q,mc4r_human,122,D,N,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.98,1.349,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-1.17751,DA122N,MC4R
555,10.1021/bi001684q,mc4r_human,122,D,N,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,5.56,3.61,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-1.17751,DA122N,MC4R
184,10.1021/bi001684q,mc4r_human,61,E,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,4.3,1.458,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.0502928,EA61A,MC4R
376,10.1021/bi001684q,mc4r_human,61,E,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,71.9,2.096,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.0502928,EA61A,MC4R
418,10.1021/bi001684q,mc4r_human,61,E,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.51,1.889,,,,0.0,0.0,,0.0,,P32245,-0.0502928,EA61A,MC4R
487,10.1021/bi001684q,mc4r_human,61,E,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,4.04,2.623,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.0502928,EA61A,MC4R
539,10.1021/bi001684q,mc4r_human,61,E,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,6.12,4.567,,,,0.0,0.0,,0.0,,P32245,-0.0502928,EA61A,MC4R
202,10.1021/bi001684q,mc4r_human,130,C,A,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,1.34,nM,=,,1.23,-1.089,,,,0.0,0.0,,0.0,,P32245,-0.432241,CA130A,MC4R
210,10.1021/bi001684q,mc4r_human,130,C,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.47,1.741,,,,0.0,0.0,,0.0,,P32245,-0.432241,CA130A,MC4R
255,10.1021/bi001684q,mc4r_human,130,C,A,Alpha-MSH,PubChem CID,16133793,,K(i),Binding - Radioligand competition/displacement,34.3,nM,=,,28.3,-1.212,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.432241,CA130A,MC4R
364,10.1021/bi001684q,mc4r_human,130,C,A,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,=,,2.82,1.831,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.432241,CA130A,MC4R
569,10.1021/bi001684q,mc4r_human,130,C,A,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.3,1.119,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.432241,CA130A,MC4R
204,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,231,G,V,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,1450.2,-1.038,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.79346,GA231V,MC4R
309,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,231,G,V,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,1.74,-1.488,,,,0.0,0.0,,0.0,,P32245,4.79346,GA231V,MC4R
348,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,231,G,V,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,1.77,-1.832,,,,0.0,0.0,,0.0,,P32245,4.79346,GA231V,MC4R
362,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,231,G,V,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,745.7,-2.257,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,4.79346,GA231V,MC4R
242,https://doi.org/10.1016/j.bbamem.2012.10.011,mc4r_human,318,C,A,NDP-MSH,PubChem CID,16154396,,K(d),Binding - Radioligand competition/displacement,7.6,nM,=,,7.05,-1.078,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.22471,CA318A,MC4R
246,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,H,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,0.76,-3.413,,,,0.0,0.0,,0.0,,P32245,0.0499495,YA332H,MC4R
378,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,H,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,975.93,-1.543,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.0499495,YA332H,MC4R
396,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,H,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,1674.37,-1.006,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.0499495,YA332H,MC4R
450,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,332,Y,H,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,2.54,-1.276,,,,0.0,0.0,,0.0,,P32245,0.0499495,YA332H,MC4R
258,10.1210/jc.2003-030233,mc4r_human,121,I,T,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,518.0,10.157,,,,0.0,0.0,,0.0,,P32245,0.752841,IA121T,MC4R
259,10.1021/bi001684q,mc4r_human,126,D,N,Ag-RP (86-132),UniProt Entry Code (peptide),O00253 ,,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,15.9,5.39,,,125-I-AGRP,0.0,0.0,,0.0,,P32245,-0.31693,DA126N,MC4R
482,10.1021/bi001684q,mc4r_human,126,D,N,NDP-MSH,PubChem CID,16154396,,K(i),Binding - Radioligand competition/displacement,1.54,nM,>,,10000.0,6493.506,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.31693,DA126N,MC4R
580,10.1021/bi001684q,mc4r_human,126,D,N,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,0.27,nM,=,,342.0,1266.667,,,,0.0,0.0,,0.0,,P32245,-0.31693,DA126N,MC4R
262,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,D,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,25.21,nM,=,,26.74,1.061,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,8.07761,SA136D,MC4R
317,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,D,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.5,nM,=,,2.85,1.9,,,,0.0,0.0,,0.0,,P32245,8.07761,SA136D,MC4R
265,10.1210/jc.2003-030233,mc4r_human,78,P,L,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,570.0,11.176,,,,0.0,0.0,,0.0,,P32245,3.46802,PA78L,MC4R
315,10.1093/hmg/ddg057,mc4r_human,316,I,S,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,28.0,3.571,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,2.27854,IA316S,MC4R
323,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,A,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,25.21,nM,=,,24.84,-1.015,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.496588,SA136A,MC4R
424,10.1111/j.1582-4934.2009.00726.x,mc4r_human,136,S,A,NDP-MSH,PubChem CID,16154396,,EC50,Functional - cAMP accumulation,1.5,nM,=,,8.06,5.373,,,,0.0,0.0,,0.0,,P32245,-0.496588,SA136A,MC4R
385,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,305,R,S,Alpha-MSH,PubChem CID,16133793,,IC50,Binding - Radioligand competition/displacement,1684.23,nM,=,,2263.67,1.344,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.365563,RA305S,MC4R
392,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,305,R,S,Beta-MSH,PubChem CID,16132286,,EC50,Functional - cAMP accumulation,3.24,nM,=,,6.92,2.136,,,,0.0,0.0,,0.0,,P32245,0.365563,RA305S,MC4R
455,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,305,R,S,Beta-MSH,PubChem CID,16132286,,IC50,Binding - Radioligand competition/displacement,1506.32,nM,=,,1327.4,-1.135,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.365563,RA305S,MC4R
581,http://doi.org/10.1016/j.bbadis.2011.06.008,mc4r_human,305,R,S,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,2.59,nM,=,,8.75,3.378,,,,0.0,0.0,,0.0,,P32245,0.365563,RA305S,MC4R
410,10.1093/hmg/ddg057,mc4r_human,165,R,Q,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,29.9,3.344,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.14278,RA165Q,MC4R
441,10.1210/jc.2003-030233,mc4r_human,30,S,F,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,23.0,-2.217,,,,0.0,0.0,,0.0,,P32245,0.0939942,SA30F,MC4R
509,10.1093/hmg/ddg057,mc4r_human,175,A,T,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,60.4,1.656,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,0.596101,AA175T,MC4R
518,10.1093/hmg/ddg057,mc4r_human,253,V,I,Alpha-MSH,PubChem CID,16133793,,,Binding - Radioligand competition/displacement,100.0,%,=,,80.3,1.245,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.604932,VA253I,MC4R
552,https://doi.org/10.1016/j.bbamem.2012.10.011,mc4r_human,84,C,A,NDP-MSH,PubChem CID,16154396,,IC50,Binding - Radioligand competition/displacement,7.98,nM,=,,7.25,-1.1,,,125-I-NDP-MSH,0.0,0.0,,0.0,,P32245,-0.277973,CA84A,MC4R
557,10.1210/jc.2003-030233,mc4r_human,178,T,M,Alpha-MSH,PubChem CID,16133793,,EC50,Functional - cAMP accumulation,51.0,nM,=,,90.0,1.765,,,,0.0,0.0,,0.0,,P32245,-1.15519,TA178M,MC4R
4,10.1111/bph.13065,grm2_human,773,W,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,<,,5.0,60.256,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
5,10.1111/bph.13065,grm2_human,773,W,A,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,<,,5.0,54.954,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
6,10.1111/bph.13065,grm2_human,773,W,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,<,,5.0,93.325,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
54,10.1111/bph.13065,grm2_human,773,W,A,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,<,,5.0,61.66,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
82,10.1111/bph.13065,grm2_human,773,W,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,<,,5.0,79.433,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
155,10.1111/bph.13065,grm2_human,773,W,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,<,,5.0,107.152,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
227,10.1111/bph.13065,grm2_human,773,W,A,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.09,,=,,7.11,9.55,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
318,10.1111/bph.13065,grm2_human,773,W,A,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,<,,5.0,15.488,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
334,10.1111/bph.13065,grm2_human,773,W,A,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,5.9,32.359,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.97176,WA773A,GRM2
9,10.1111/bph.13065,grm2_human,643,F,A,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,<,,5.0,54.954,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
42,10.1111/bph.13065,grm2_human,643,F,A,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.09,,=,,6.32,58.884,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
166,10.1111/bph.13065,grm2_human,643,F,A,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,5.24,147.911,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
261,10.1111/bph.13065,grm2_human,643,F,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,5.64,18.197,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
299,10.1111/bph.13065,grm2_human,643,F,A,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,<,,5.0,61.66,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
311,10.1111/bph.13065,grm2_human,643,F,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,<,,5.0,60.256,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
338,10.1111/bph.13065,grm2_human,643,F,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,5.85,15.136,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
341,10.1111/bph.13065,grm2_human,643,F,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.08,7.762,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.76616,FA643A,GRM2
10,10.1111/bph.13065,grm2_human,723,H,V,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,=,,6.72,1.047,,,,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
71,10.1124/mol.64.4.798,grm2_human,723,H,V,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,62.0,1.258,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
78,10.1111/bph.13065,grm2_human,723,H,V,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,5.79,2.512,,,,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
181,10.1124/jpet.108.138271,grm2_human,723,H,V,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,79.0,1.165,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
187,10.1111/bph.13065,grm2_human,723,H,V,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.56,2.57,,,,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
249,10.1111/bph.13065,grm2_human,723,H,V,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,6.27,4.266,,,,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
336,10.1111/bph.13065,grm2_human,723,H,V,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,=,,6.46,2.138,,,,0.0,0.0,,0.0,,Q14416,-0.527201,HA723V,GRM2
11,10.1124/mol.64.4.798,grm2_human,735,N,D,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,14.0,5.571,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
22,10.1111/bph.13065,grm2_human,735,N,D,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,5.13,79.433,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
25,10.1111/bph.13065,grm2_human,735,N,D,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.09,,=,,6.67,26.303,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
32,10.1111/bph.13065,grm2_human,735,N,D,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,5.97,27.542,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
85,10.1111/bph.13065,grm2_human,735,N,D,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,<,,5.0,54.954,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
112,10.1111/bph.13065,grm2_human,735,N,D,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,<,,5.0,61.66,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
173,10.1111/bph.13065,grm2_human,735,N,D,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,<,,5.0,15.488,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
189,10.1111/bph.13065,grm2_human,735,N,D,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,5.52,23.988,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
205,10.1124/jpet.106.117093,grm2_human,735,N,D,MNI-135,PubChem CID,22224658,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,21.4,nM,=,,24.4,1.14,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
220,10.1124/jpet.108.138271,grm2_human,735,N,D,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,27.0,3.407,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
275,10.1124/jpet.106.117093,grm2_human,735,N,D,MNI137,PubChem CID,25210562,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.4,nM,=,,17.0,1.491,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
313,10.1111/bph.13065,grm2_human,735,N,D,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,<,,5.0,60.256,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
324,10.1111/bph.13065,grm2_human,735,N,D,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,5.53,27.542,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
326,10.1124/jpet.106.117093,grm2_human,735,N,D,MNI-136,SMILES,C1(=CC2=C(C=C1)NC(CC(=N2)C3=CC=CC(=C3)C4=CC=CN=C4)=O)Br,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,17.5,nM,=,,18.3,1.046,,,Glutamate,0.0,0.0,,0.0,,Q14416,1.28405,NA735D,GRM2
14,10.1124/mol.64.4.798,grm2_human,733,A,T,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,85.0,-1.089,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.306944,AA733T,GRM2
222,10.1124/jpet.108.138271,grm2_human,733,A,T,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,88.0,1.045,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.306944,AA733T,GRM2
17,10.1124/jpet.108.138271,grm2_human,688,S,L,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,98.0,-1.065,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
18,10.1124/mol.64.4.798,grm2_human,688,S,L,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,97.0,-1.244,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
34,10.1111/bph.13065,grm2_human,688,S,L,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.36,,=,,6.28,1.202,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
53,10.1111/bph.13065,grm2_human,688,S,L,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.22,,=,,7.69,3.388,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
143,10.1111/bph.13065,grm2_human,688,S,L,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.55,,=,,7.5,1.122,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
152,10.1111/bph.13065,grm2_human,688,S,L,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.75,,=,,6.8,-1.122,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
192,10.1111/bph.13065,grm2_human,688,S,L,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.11,,=,,6.93,1.514,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
241,10.1111/bph.13065,grm2_human,688,S,L,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.83,,=,,6.89,-1.148,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
294,10.1111/bph.13065,grm2_human,688,S,L,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.08,,=,,6.92,1.445,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
298,10.1111/bph.13065,grm2_human,688,S,L,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.91,1.148,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
300,10.1111/bph.13065,grm2_human,688,S,L,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.85,,=,,6.92,-1.175,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.14144,SA688L,GRM2
20,10.1124/mol.64.4.798,grm2_human,681,A,F,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,90.0,-1.153,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.412986,AA681F,GRM2
86,10.1124/jpet.108.138271,grm2_human,681,A,F,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,80.0,1.15,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.412986,AA681F,GRM2
23,10.1111/bph.13065,grm2_human,635,R,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,6.42,3.02,,,Glutamate,0.0,0.0,,0.0,,Q14416,2.38011,RA635A,GRM2
176,10.1111/bph.13065,grm2_human,635,R,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,6.21,6.607,,,Glutamate,0.0,0.0,,0.0,,Q14416,2.38011,RA635A,GRM2
322,10.1111/bph.13065,grm2_human,635,R,A,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,6.07,1.318,,,Glutamate,0.0,0.0,,0.0,,Q14416,2.38011,RA635A,GRM2
29,10.1124/mol.64.4.798,grm2_human,689,G,V,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,90.0,-1.153,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
33,10.1111/bph.13065,grm2_human,689,G,V,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,6.84,3.715,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
70,10.1111/bph.13065,grm2_human,689,G,V,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,6.2,6.761,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
149,10.1111/bph.13065,grm2_human,689,G,V,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.22,5.623,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
150,10.1111/bph.13065,grm2_human,689,G,V,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,6.27,4.266,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
160,10.1111/bph.13065,grm2_human,689,G,V,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,<,,5.0,54.954,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
165,10.1111/bph.13065,grm2_human,689,G,V,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,5.74,2.818,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
193,10.1111/bph.13065,grm2_human,689,G,V,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,=,,6.85,-1.175,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
271,10.1124/jpet.108.138271,grm2_human,689,G,V,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,79.0,1.165,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
307,10.1111/bph.13065,grm2_human,689,G,V,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,=,,6.3,3.09,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
343,10.1111/bph.13065,grm2_human,689,G,V,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.09,,=,,7.21,7.586,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.477499,GA689V,GRM2
38,10.1111/bph.13065,grm2_human,776,F,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,<,,5.0,60.256,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.42901,FA776A,GRM2
41,10.1111/bph.13065,grm2_human,776,F,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,6.71,2.089,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.42901,FA776A,GRM2
128,10.1111/bph.13065,grm2_human,776,F,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.93,1.096,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.42901,FA776A,GRM2
202,10.1111/bph.13065,grm2_human,776,F,A,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,7.16,1.778,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.42901,FA776A,GRM2
228,10.1111/bph.13065,grm2_human,776,F,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,6.38,3.311,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.42901,FA776A,GRM2
47,10.1111/bph.13065,grm2_human,732,L,A,JNJ-41482012 ,PubChem CID,46227786,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.74,,<,,5.0,54.954,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
81,10.1111/bph.13065,grm2_human,732,L,A,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,6.22,-1.072,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
126,10.1111/bph.13065,grm2_human,732,L,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,7.8,-5.882,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
168,10.1111/bph.13065,grm2_human,732,L,A,JNJ-42329001 ,PubChem CID,49801368,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.41,,=,,6.25,14.454,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
174,10.1111/bph.13065,grm2_human,732,L,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.49,3.02,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
240,10.1111/bph.13065,grm2_human,732,L,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,7.03,-1.35,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
266,10.1111/bph.13065,grm2_human,732,L,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,<,,5.0,60.256,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
303,10.1111/bph.13065,grm2_human,732,L,A,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,=,,6.51,1.905,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
323,10.1111/bph.13065,grm2_human,732,L,A,JNJ-46281222 ,PubChem CID,49822115,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,8.09,,=,,7.31,6.026,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.06015,LA732A,GRM2
56,10.1111/bph.13065,grm2_human,639,L,A,JNJ-40068782 ,PubChem CID,59234231,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.9,,=,,6.27,4.266,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
75,10.1111/bph.13065,grm2_human,639,L,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,=,,6.16,4.169,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
148,10.1111/bph.13065,grm2_human,639,L,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.78,1.549,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
199,10.1111/bph.13065,grm2_human,639,L,A,BINA ,PubChem CID,9868580,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,7.03,,=,,5.86,14.791,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
245,10.1111/bph.13065,grm2_human,639,L,A,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,5.83,2.291,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
339,10.1111/bph.13065,grm2_human,639,L,A,JNJ-40297036 ,PubChem CID,46917791,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.79,,=,,6.28,3.236,,,Glutamate,0.0,0.0,,0.0,,Q14416,3.30545,LA639A,GRM2
93,10.1111/bph.13065,grm2_human,731,S,A,JNJ-35814376 ,PubChem CID,11523023,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.19,,=,,5.92,1.862,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.0826916,SA731A,GRM2
153,10.1111/bph.13065,grm2_human,731,S,A,LY487379 ,PubChem CID,9825084,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.78,,=,,6.08,5.012,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.0826916,SA731A,GRM2
210,10.1111/bph.13065,grm2_human,731,S,A,LY2607540 ,PubChem CID,44595851,Positive allosteric modulator,pEC50,Functional - [35S]GPTγS binding,6.97,,=,,6.56,2.57,,,Glutamate,0.0,0.0,,0.0,,Q14416,-0.0826916,SA731A,GRM2
235,10.1124/mol.64.4.798,grm2_human,730,G,I,LY487379,PubChem CID,9825084,Positive allosteric modulator,Single-point,Functional - IP accumulation,78.0,%,=,,73.0,1.068,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.09282,GA730I,GRM2
305,10.1124/jpet.108.138271,grm2_human,730,G,I,MRLSD-650,PubChem CID,11663353,Positive allosteric modulator,Single-point,Functional - IP accumulation,92.0,%,=,,89.0,1.034,,,Glutamate,0.0,0.0,,0.0,,Q14416,-1.09282,GA730I,GRM2
0,16837468,ccr1_human,86,T,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,384.0,38.4,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,1.06281,TA86A,CCR1
12,16837468,ccr1_human,86,T,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,348.0,34.8,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,1.06281,TA86A,CCR1
37,15548526,ccr1_human,86,T,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,50.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,1.06281,TA86A,CCR1
1,16837468,ccr1_human,91,I,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,849.0,84.9,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.31757,IA91A,CCR1
39,16837468,ccr1_human,91,I,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,849.0,84.9,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.31757,IA91A,CCR1
52,15548526,ccr1_human,91,I,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,60.0,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,2.31757,IA91A,CCR1
2,15548526,ccr1_human,203,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.10686,LA203A,CCR1
3,15548526,ccr1_human,207,G,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,90.0,0.0,,0.0,,P32246,0.363369,GA207A,CCR1
5,16837468,ccr1_human,260,L,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,58.0,5.8,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,1.6684,LA260A,CCR1
46,16837468,ccr1_human,260,L,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,58.0,5.8,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,1.6684,LA260A,CCR1
6,15548526,ccr1_human,208,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,110.0,0.0,,0.0,,P32246,2.38312,LA208A,CCR1
7,15548526,ccr1_human,287,E,Q,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,40.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,0.347386,EA287Q,CCR1
40,16837468,ccr1_human,287,E,Q,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,344.0,34.4,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,0.347386,EA287Q,CCR1
50,16837468,ccr1_human,287,E,Q,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,344.0,34.4,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,0.347386,EA287Q,CCR1
9,15548526,ccr1_human,115,T,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,140.0,0.0,,0.0,,P32246,0.362937,TA115A,CCR1
10,15548526,ccr1_human,252,W,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,radioligand: [125I]-CCL3,50.0,0.0,,0.0,,P32246,2.01417,WA252A,CCR1
11,16837468,ccr1_human,291,Y,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,542.0,54.2,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.81557,YA291A,CCR1
17,16837468,ccr1_human,291,Y,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,542.0,54.2,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.81557,YA291A,CCR1
15,15548526,ccr1_human,120,E,Q,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,90.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,-1.89221,EA120Q,CCR1
19,15548526,ccr1_human,80,D,N,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,110.0,0.0,,0.0,,P32246,-3.88113,DA80N,CCR1
20,15548526,ccr1_human,44,V,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,50.0,0.0,,0.0,,P32246,2.07179,VA44A,CCR1
21,15548526,ccr1_human,109,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,3.17965,LA109A,CCR1
22,15548526,ccr1_human,92,D,N,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,85.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,-0.788741,DA92N,CCR1
23,16837468,ccr1_human,259,I,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,>,,10000.0,1000.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.04721,IA259A,CCR1
53,15548526,ccr1_human,259,I,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,radioligand: [125I]-CCL3,90.0,0.0,,0.0,,P32246,2.04721,IA259A,CCR1
67,16837468,ccr1_human,259,I,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,>,,10000.0,1000.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.04721,IA259A,CCR1
26,16837468,ccr1_human,41,Y,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,264.0,26.4,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,3.34051,YA41A,CCR1
58,15548526,ccr1_human,41,Y,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,10.0,,,radioligand: [125I]-CCL3,95.0,0.0,,0.0,,P32246,3.34051,YA41A,CCR1
70,16837468,ccr1_human,41,Y,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,264.0,26.4,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,3.34051,YA41A,CCR1
27,15548526,ccr1_human,37,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,90.0,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,1.93346,LA37A,CCR1
28,15548526,ccr1_human,94,K,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,90.0,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,0.947957,KA94A,CCR1
29,16837468,ccr1_human,113,Y,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,>,,10000.0,1000.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.93912,YA113A,CCR1
34,15548526,ccr1_human,113,Y,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,20.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.93912,YA113A,CCR1
69,16837468,ccr1_human,113,Y,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,>,,10000.0,1000.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,2.93912,YA113A,CCR1
30,15548526,ccr1_human,111,G,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,125.0,0.0,,0.0,,P32246,-1.45342,GA111A,CCR1
31,16837468,ccr1_human,114,Y,A,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,5017.0,501.7,,,radioligand: [125I]-CCL3,50.0,0.0,,0.0,,P32246,1.58383,YA114A,CCR1
33,16837468,ccr1_human,114,Y,A,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,5017.0,501.7,,,radioligand: [125I]-CCL3,55.0,0.0,,0.0,,P32246,1.58383,YA114A,CCR1
54,15548526,ccr1_human,114,Y,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,90.0,0.0,,0.0,,P32246,1.58383,YA114A,CCR1
32,15548526,ccr1_human,160,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,90.0,0.0,,0.0,,P32246,1.12647,LA160A,CCR1
36,15548526,ccr1_human,165,S,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,98.0,,,radioligand: [125I]-CCL3,120.0,0.0,,0.0,,P32246,-0.00406728,SA165A,CCR1
45,16837468,ccr1_human,113,Y,F,BX 471,SMILES,ClC1=CC=C(OCC(N2CCN(CC3=CC=C(F)C=C3)C[C@H]2C)=O)C(NC(C)=O)=C1,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,464.0,46.4,,,radioligand: [125I]-CCL3,105.0,0.0,,0.0,,P32246,0.00569468,YA113F,CCR1
57,16837468,ccr1_human,113,Y,F,BX-471,ChEMBL Compound ID,CHEMBL232656,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,464.0,46.4,,,radioligand: [125I]-CCL3,110.0,0.0,,0.0,,P32246,0.00569468,YA113F,CCR1
48,15548526,ccr1_human,262,S,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,95.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,-0.353937,SA262A,CCR1
56,15548526,ccr1_human,168,G,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,85.0,0.0,,0.0,,P32246,1.88437,GA168A,CCR1
59,15548526,ccr1_human,119,S,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,radioligand: [125I]-CCL3,100.0,0.0,,0.0,,P32246,-1.50444,SA119A,CCR1
61,15548526,ccr1_human,90,W,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,radioligand: [125I]-CCL3,110.0,0.0,,0.0,,P32246,2.08226,WA90A,CCR1
63,15548526,ccr1_human,105,M,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,98.0,,,radioligand: [125I]-CCL3,115.0,0.0,,0.0,,P32246,1.83506,MA105A,CCR1
68,15548526,ccr1_human,255,Y,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,60.0,,,radioligand: [125I]-CCL3,75.0,0.0,,0.0,,P32246,3.28848,YA255A,CCR1
71,15548526,ccr1_human,40,L,A,UCB-35625,SMILES,O=C(NC1CC[N+](CC2CCCCCC2)(CC)CC1)C3C4=C(C=CC=C4)OC5=CC=CC=C53.[I-],Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,100.0,,,radioligand: [125I]-CCL3,95.0,0.0,,0.0,,P32246,1.41884,LA40A,CCR1
1,11306703,aa1r_human,270,T,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,24.1,-3.448,,,,0.0,0.0,=,0.0,,P30542,0.66083,TA270C,ADORA1
78,11306703,aa1r_human,270,T,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,20.2,-3.367,,,,0.0,0.0,=,0.0,,P30542,0.66083,TA270C,ADORA1
94,11306703,aa1r_human,270,T,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,14.1,-4.545,,,,0.0,0.0,=,0.0,,P30542,0.66083,TA270C,ADORA1
608,11306703,aa1r_human,270,T,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.24,1.0,,,,0.0,0.0,=,0.0,,P30542,0.66083,TA270C,ADORA1
2,8967987,aa1r_human,141,T,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.4,-1.499,,,,0.0,0.0,=,0.0,,P30542,0.724401,TA141A,ADORA1
461,8967987,aa1r_human,141,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,0.74,1.057,,,,0.0,0.0,=,0.0,,P30542,0.724401,TA141A,ADORA1
5,10.1021/bi7001828,aa1r_human,278,H,L,CID73014720,PubChem CID,73014720,Full agonist,K(i),Binding - Radioligand competition/displacement,6200.0,nM,=,,290.0,-21.277,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
87,10.1021/bi7001828,aa1r_human,278,H,L,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,90.0,26.471,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
135,10.1021/bi7001828,aa1r_human,278,H,L,CCPA,PubChem CID,123807,Full agonist,K(i),Binding - Radioligand competition/displacement,610.0,nM,=,,820.0,1.344,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
462,10.1021/bi7001828,aa1r_human,278,H,L,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,1600.0,nM,=,,8800.0,5.5,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
512,10.1021/bi7001828,aa1r_human,278,H,L,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,35.0,7.778,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
604,10.1021/bi7001828,aa1r_human,278,H,L,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,2.37,nM,=,,3.94,1.662,,,,0.0,30.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
686,10.1021/bi7001828,aa1r_human,278,H,L,CID73019726,PubChem CID,73019726,Full agonist,K(i),Binding - Radioligand competition/displacement,15000.0,nM,=,,550.0,-27.027,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.382695,HA278L,ADORA1
10,10.1016/S0006-2952(00)00474-3,aa1r_human,255,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,2.58,1.071,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.00116453,CA255A,ADORA1
24,10.1016/S0006-2952(00)00474-3,aa1r_human,255,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,1.5,2.027,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.00116453,CA255A,ADORA1
118,10.1016/S0006-2952(00)00474-3,aa1r_human,255,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.06,1.152,,,,0.0,0.0,=,0.0,,P30542,0.00116453,CA255A,ADORA1
699,10.1016/S0006-2952(00)00474-3,aa1r_human,255,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,94.0,-1.032,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.00116453,CA255A,ADORA1
14,10.1124/mol.116.105007,aa1r_human,166,V,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.05,1.318,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.02871,VA166A,ADORA1
228,10.1016/j.bcp.2012.03.008,aa1r_human,166,V,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.64,6.4,,,,0.0,19.0,=,0.0,,P30542,1.02871,VA166A,ADORA1
376,10.1124/mol.116.105015,aa1r_human,166,V,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.95,-3.472,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.02871,VA166A,ADORA1
655,10.1124/mol.116.105007,aa1r_human,166,V,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.45,1.38,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.02871,VA166A,ADORA1
782,10.1124/mol.116.105015,aa1r_human,166,V,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.8,-1.412,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.02871,VA166A,ADORA1
15,10.1016/j.bcp.2012.03.008,aa1r_human,265,K,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.18,1.8,,,,0.0,37.0,=,0.0,,P30542,1.49358,KA265A,ADORA1
355,10.1124/mol.116.105007,aa1r_human,265,K,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.34,1.778,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.49358,KA265A,ADORA1
381,10.1124/mol.116.105007,aa1r_human,265,K,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.98,1.549,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.49358,KA265A,ADORA1
16,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,DPCPX,PubChem CID,1329,Inverse agonist,,Functional - cAMP accumulation,125.0,%,=,,102.0,1.225,,,,0.0,0.0,=,0.0,,P30542,-0.694654,GA14A,ADORA1
50,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - [35S]GPTγS binding,165.0,,=,,204.0,1.236,,,,0.0,375.0,=,0.0,,P30542,-0.694654,GA14A,ADORA1
81,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.96,,=,,3.7,1.25,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.694654,GA14A,ADORA1
256,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,CPA,PubChem CID,4402,Full agonist,,Functional - cAMP accumulation,49.0,%,=,,69.0,-1.408,,,,0.0,0.0,=,0.0,,P30542,-0.694654,GA14A,ADORA1
315,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,CPT,PubChem CID,1917,Inverse agonist,EC50,Functional - [35S]GPTγS binding,26.0,,=,,23.0,-1.13,,,,0.0,375.0,=,0.0,,P30542,-0.694654,GA14A,ADORA1
344,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,436.0,,=,,459.0,1.053,,,DPCPX,0.0,0.0,,0.0,,P30542,-0.694654,GA14A,ADORA1
17,10.1016/S0006-2952(00)00474-3,aa1r_human,260,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.28,1.391,,,,0.0,0.0,=,0.0,,P30542,0.70108,CA260A,ADORA1
121,10.1016/j.bcp.2012.03.008,aa1r_human,260,C,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.14,1.4,,,,0.0,60.0,=,0.0,,P30542,0.70108,CA260A,ADORA1
421,10.1016/S0006-2952(00)00474-3,aa1r_human,260,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,1.03,-2.342,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.70108,CA260A,ADORA1
499,10.1016/S0006-2952(00)00474-3,aa1r_human,260,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,0.39,-1.898,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.70108,CA260A,ADORA1
753,10.1016/S0006-2952(00)00474-3,aa1r_human,260,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,82.5,-1.175,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.70108,CA260A,ADORA1
23,10.1124/mol.116.105007,aa1r_human,144,F,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.62,-1.072,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.468612,FA144A,ADORA1
141,10.1124/mol.116.105007,aa1r_human,144,F,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.23,-1.148,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.468612,FA144A,ADORA1
200,10.1124/mol.116.105015,aa1r_human,144,F,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.48,1.479,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.468612,FA144A,ADORA1
471,10.1124/mol.116.105015,aa1r_human,144,F,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.73,-2.088,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.468612,FA144A,ADORA1
26,10.1124/mol.116.105007,aa1r_human,172,E,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,5.84,5.623,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0388,EA172A,ADORA1
528,10.1124/mol.116.105015,aa1r_human,172,E,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,4.89,3.311,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0388,EA172A,ADORA1
618,10.1124/mol.116.105007,aa1r_human,172,E,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.66,3.236,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0388,EA172A,ADORA1
741,10.1124/mol.116.105015,aa1r_human,172,E,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.26,2.455,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0388,EA172A,ADORA1
27,8300561,aa1r_human,277,T,S,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.8,nM,=,,1.1,1.375,,,,0.0,0.0,=,0.0,,P30542,1.47292,TA277S,ADORA1
487,8300561,aa1r_human,277,T,S,S-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,1.094,nM,=,,8.16,7.459,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.47292,TA277S,ADORA1
644,8300561,aa1r_human,277,T,S,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,366.0,nM,=,,3.16,-111.111,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.47292,TA277S,ADORA1
789,8300561,aa1r_human,277,T,S,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,210.0,nM,=,,920.0,4.381,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.47292,TA277S,ADORA1
28,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.11,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
40,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.65,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
198,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.73,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
208,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.84,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
322,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.85,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
369,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.16,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
490,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.45,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
603,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.34,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
763,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.83,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
790,10.1016/j.str.2017.06.012,aa1r_human,70,N,S,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.19,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.301634,NA70S,ADORA1
29,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.96,,=,,4.45,1.503,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
46,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,81.0,nM,=,,2.74,-29.412,,,PD81723,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
51,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.2,nM,=,,4.3,1.955,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
65,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,472.0,nM,=,,4.5,-100.0,,,GTP,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
161,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.007,-83.333,,,,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
185,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.93,nM,=,,1.3,1.398,,,,0.0,0.0,,0.0,,P30542,0.0355201,GA14T,ADORA1
216,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,720.0,nM,=,,17.0,-41.667,,,NaCl,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
252,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.1,µM,=,,0.7,-7.299,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
308,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.0,nM,=,,3.08,1.54,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
458,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,,Functional - cAMP accumulation,49.0,%,=,,61.0,-1.245,,,,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
477,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,5.6,µM,=,,0.006,-1000.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
517,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,436.0,,=,,5.04,-83.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
592,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,,Functional - cAMP accumulation,125.0,%,=,,39.0,3.205,,,,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
651,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,130.0,nM,=,,1.2,-111.111,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
660,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,289.0,nM,=,,3.45,-83.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
692,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.08,nM,=,,6.0,1.948,,,PD81723,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
748,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.8,nM,=,,2.2,1.222,,,,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
775,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,370.0,nM,=,,2.7,-142.857,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
796,10.1074/jbc.274.6.3617,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.8,1.143,,,,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
801,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.75,nM,=,,2.98,1.084,,,GTP,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
815,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.87,nM,=,,0.94,1.08,,,NaCl,0.0,0.0,=,0.0,,P30542,0.0355201,GA14T,ADORA1
30,11306703,aa1r_human,295,F,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.42,1.145,,,,0.0,0.0,=,0.0,,P30542,4.94574,FA295C,ADORA1
33,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.149,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
64,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.15,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
163,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.58,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
364,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,8.56,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
416,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
441,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.44,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
571,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.15,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
707,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.08,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
759,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.01,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
822,10.1016/j.str.2017.06.012,aa1r_human,62,V,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.02,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.21097,VA62A,ADORA1
34,10.1074/jbc.274.6.3617,aa1r_human,87,V,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.36,µM,=,,26.0,72.222,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0288,VA87A,ADORA1
241,10.1074/jbc.274.6.3617,aa1r_human,87,V,A,N-0840,PubChem CID,4401,Full agonist,K(i),Binding - Radioligand competition/displacement,0.75,µM,=,,2.3,3.067,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0288,VA87A,ADORA1
335,10.1074/jbc.274.6.3617,aa1r_human,87,V,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,1.3,1.3,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0288,VA87A,ADORA1
432,10.1074/jbc.274.6.3617,aa1r_human,87,V,A,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,0.55,-1.018,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0288,VA87A,ADORA1
722,10.1074/jbc.274.6.3617,aa1r_human,87,V,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.1,µM,=,,4.2,-1.214,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.0288,VA87A,ADORA1
36,10.1124/mol.116.105015,aa1r_human,145,G,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.2,1.622,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.26843,GA145A,ADORA1
91,10.1124/mol.116.105007,aa1r_human,145,G,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.0,1.479,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.26843,GA145A,ADORA1
731,10.1124/mol.116.105015,aa1r_human,145,G,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.32,2.138,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.26843,GA145A,ADORA1
749,10.1124/mol.116.105007,aa1r_human,145,G,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.38,1.622,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.26843,GA145A,ADORA1
37,10.1016/j.bcp.2012.03.008,aa1r_human,161,S,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.41,4.1,,,,0.0,28.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
306,10.1016/j.bcp.2012.03.008,aa1r_human,161,S,A,CPA,PubChem CID,4402,Full agonist,IC50,Binding - Radioligand competition/displacement,167.0,nM,=,,169.0,1.012,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
394,10.1016/j.bcp.2012.03.008,aa1r_human,161,S,A,PD81723,PubChem CID,122028,Allosteric agonist,IC50,Binding - Radioligand competition/displacement,69.0,nM,=,,75.0,1.087,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
400,10.1124/mol.116.105015,aa1r_human,161,S,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,6.18,-5.882,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
474,10.1124/mol.116.105007,aa1r_human,161,S,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.66,3.236,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
513,10.1124/mol.116.105007,aa1r_human,161,S,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.1,3.09,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
800,10.1124/mol.116.105015,aa1r_human,161,S,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.63,1.047,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.808546,SA161A,ADORA1
42,10.1124/mol.116.105007,aa1r_human,149,L,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.35,-1.513,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.45847,LA149A,ADORA1
152,10.1124/mol.116.105015,aa1r_human,149,L,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.77,-2.288,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.45847,LA149A,ADORA1
691,10.1124/mol.116.105007,aa1r_human,149,L,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.94,-2.237,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.45847,LA149A,ADORA1
769,10.1124/mol.116.105015,aa1r_human,149,L,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.67,-1.047,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.45847,LA149A,ADORA1
48,10.1016/S0006-2952(00)00474-3,aa1r_human,46,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,1.43,-1.686,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.419065,CA46A,ADORA1
230,10.1016/S0006-2952(00)00474-3,aa1r_human,46,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,1.19,1.608,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.419065,CA46A,ADORA1
291,10.1016/S0006-2952(00)00474-3,aa1r_human,46,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.15,1.25,,,,0.0,0.0,=,0.0,,P30542,-0.419065,CA46A,ADORA1
310,10.1016/S0006-2952(00)00474-3,aa1r_human,46,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,128.8,1.328,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.419065,CA46A,ADORA1
52,10.1124/mol.116.105015,aa1r_human,174,V,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.91,-3.165,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.03583,VA174A,ADORA1
267,10.1124/mol.116.105007,aa1r_human,174,V,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.12,1.122,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.03583,VA174A,ADORA1
717,10.1124/mol.116.105015,aa1r_human,174,V,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.91,-1.818,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.03583,VA174A,ADORA1
787,10.1124/mol.116.105007,aa1r_human,174,V,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.46,1.349,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.03583,VA174A,ADORA1
56,8967987,aa1r_human,135,S,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,0.72,1.029,,,,0.0,0.0,=,0.0,,P30542,-1.21774,SA135A,ADORA1
776,8967987,aa1r_human,135,S,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.6,1.0,,,,0.0,0.0,=,0.0,,P30542,-1.21774,SA135A,ADORA1
58,10.1124/mol.116.105007,aa1r_human,167,I,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,5.74,7.079,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.80291,IA167A,ADORA1
80,10.1124/mol.116.105007,aa1r_human,167,I,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.42,5.623,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.80291,IA167A,ADORA1
354,10.1124/mol.116.105015,aa1r_human,167,I,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.9,-1.779,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.80291,IA167A,ADORA1
595,10.1016/j.bcp.2012.03.008,aa1r_human,167,I,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,4.5,45.0,,,,0.0,14.0,=,0.0,,P30542,2.80291,IA167A,ADORA1
711,10.1124/mol.116.105015,aa1r_human,167,I,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,6.21,-6.329,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.80291,IA167A,ADORA1
60,10.1021/bi7001828,aa1r_human,278,H,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,160.0,47.059,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
133,10.1021/bi7001828,aa1r_human,278,H,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,40.0,8.889,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
277,10.1021/bi7001828,aa1r_human,278,H,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,1600.0,nM,=,,8800.0,5.5,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
388,10.1021/bi7001828,aa1r_human,278,H,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,2.37,nM,=,,4.72,1.992,,,,0.0,29.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
439,10.1021/bi7001828,aa1r_human,278,H,A,CCPA,PubChem CID,123807,Full agonist,K(i),Binding - Radioligand competition/displacement,610.0,nM,=,,1400.0,2.295,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
599,10.1021/bi7001828,aa1r_human,278,H,A,CID73019726,PubChem CID,73019726,Full agonist,K(i),Binding - Radioligand competition/displacement,15000.0,nM,=,,570.0,-26.316,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
728,10.1021/bi7001828,aa1r_human,278,H,A,CID73014720,PubChem CID,73014720,Full agonist,K(i),Binding - Radioligand competition/displacement,6200.0,nM,=,,220.0,-28.571,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.80794,HA278A,ADORA1
62,11306703,aa1r_human,289,A,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.11,-1.117,,,,0.0,0.0,=,0.0,,P30542,0.563834,AA289C,ADORA1
289,11306703,aa1r_human,289,A,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,2.0,3.5,,,,0.0,0.0,=,0.0,,P30542,0.563834,AA289C,ADORA1
456,11306703,aa1r_human,289,A,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,1.2,2.583,,,,0.0,0.0,=,0.0,,P30542,0.563834,AA289C,ADORA1
564,11306703,aa1r_human,289,A,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,6.4,-1.066,,,,0.0,0.0,=,0.0,,P30542,0.563834,AA289C,ADORA1
63,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.2,nM,=,,3.3,1.5,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
338,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,5.6,µM,=,,22.0,3.929,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
569,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,370.0,nM,=,,1300.0,3.514,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
620,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.7,1.0,,,,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
709,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.1,µM,=,,15.0,2.941,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
746,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.6,nM,=,,1.8,3.0,,,,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
793,10.1074/jbc.274.6.3617,aa1r_human,25,P,L,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,130.0,nM,=,,7900.0,60.769,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59255,PA25L,ADORA1
67,11306703,aa1r_human,288,Y,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.73,-1.698,,,,0.0,0.0,=,0.0,,P30542,3.44476,YA288C,ADORA1
269,11306703,aa1r_human,288,Y,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,20.4,-3.401,,,,0.0,0.0,=,0.0,,P30542,3.44476,YA288C,ADORA1
358,11306703,aa1r_human,288,Y,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,15.5,-5.0,,,,0.0,0.0,=,0.0,,P30542,3.44476,YA288C,ADORA1
558,11306703,aa1r_human,288,Y,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,16.3,-2.331,,,,0.0,0.0,=,0.0,,P30542,3.44476,YA288C,ADORA1
69,10.1016/S0006-2952(00)00474-3,aa1r_human,85,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,0.56,-1.321,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.470368,CA85A,ADORA1
225,10.1016/S0006-2952(00)00474-3,aa1r_human,85,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,3.17,1.315,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.470368,CA85A,ADORA1
654,10.1016/S0006-2952(00)00474-3,aa1r_human,85,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.18,1.283,,,,0.0,0.0,=,0.0,,P30542,0.470368,CA85A,ADORA1
678,10.1016/S0006-2952(00)00474-3,aa1r_human,85,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,55.3,-1.754,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.470368,CA85A,ADORA1
70,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,CPT,PubChem CID,1917,Inverse agonist,EC50,Functional - [35S]GPTγS binding,26.0,,=,,32.0,1.231,,,,0.0,375.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
90,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.96,,=,,5.23,1.767,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
249,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,CPA,PubChem CID,4402,Full agonist,EC50,Functional - [35S]GPTγS binding,165.0,,=,,192.0,1.164,,,,0.0,375.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
264,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,436.0,,=,,551.0,1.264,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
368,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,CPA,PubChem CID,4402,Full agonist,,Functional - cAMP accumulation,49.0,%,=,,43.0,1.14,,,,0.0,0.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
570,10.1016/j.ejphar.2005.01.007,aa1r_human,14,G,L,DPCPX,PubChem CID,1329,Inverse agonist,,Functional - cAMP accumulation,125.0,%,=,,125.0,1.0,,,,0.0,0.0,=,0.0,,P30542,-0.990586,GA14L,ADORA1
71,11306703,aa1r_human,276,L,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,5.7,1.228,,,,0.0,0.0,=,0.0,,P30542,1.61254,LA276C,ADORA1
327,11306703,aa1r_human,276,L,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,10.5,-3.39,,,,0.0,0.0,=,0.0,,P30542,1.61254,LA276C,ADORA1
440,11306703,aa1r_human,276,L,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,24.6,-4.098,,,,0.0,0.0,=,0.0,,P30542,1.61254,LA276C,ADORA1
488,11306703,aa1r_human,276,L,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.23,-1.008,,,,0.0,0.0,=,0.0,,P30542,1.61254,LA276C,ADORA1
72,10.1074/jbc.274.6.3617,aa1r_human,88,L,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.36,µM,=,,180.0,500.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.06172,LA88A,ADORA1
483,10.1074/jbc.274.6.3617,aa1r_human,88,L,A,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,42.0,75.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.06172,LA88A,ADORA1
563,10.1074/jbc.274.6.3617,aa1r_human,88,L,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.1,µM,=,,150.0,29.412,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.06172,LA88A,ADORA1
636,10.1074/jbc.274.6.3617,aa1r_human,88,L,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,1.1,1.1,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.06172,LA88A,ADORA1
73,10.1016/j.bcp.2012.03.008,aa1r_human,154,R,A,CPA,PubChem CID,4402,Full agonist,IC50,Binding - Radioligand competition/displacement,167.0,nM,=,,166.0,-1.006,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
110,10.1016/j.bcp.2012.03.008,aa1r_human,154,R,A,PD81723,PubChem CID,122028,Allosteric agonist,IC50,Binding - Radioligand competition/displacement,69.0,nM,=,,72.0,1.043,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
166,10.1124/mol.116.105007,aa1r_human,154,R,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.06,1.288,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
313,10.1124/mol.116.105015,aa1r_human,154,R,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.91,-1.818,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
429,10.1124/mol.116.105015,aa1r_human,154,R,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.49,-1.202,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
614,10.1016/j.bcp.2012.03.008,aa1r_human,154,R,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.12,1.2,,,,0.0,116.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
816,10.1124/mol.116.105007,aa1r_human,154,R,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.52,1.175,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.117665,RA154A,ADORA1
74,10.1021/bi7001828,aa1r_human,278,H,D,CCPA,PubChem CID,123807,Full agonist,K(i),Binding - Radioligand competition/displacement,610.0,nM,=,,1000.0,1.639,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
77,10.1021/bi7001828,aa1r_human,278,H,D,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,110.0,32.353,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
109,10.1021/bi7001828,aa1r_human,278,H,D,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,2.37,nM,=,,3.11,1.312,,,,0.0,21.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
160,10.1021/bi7001828,aa1r_human,278,H,D,CID73019726,PubChem CID,73019726,Full agonist,K(i),Binding - Radioligand competition/displacement,15000.0,nM,=,,450.0,-33.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
247,10.1021/bi7001828,aa1r_human,278,H,D,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,1600.0,nM,=,,8500.0,5.312,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
258,10.1021/bi7001828,aa1r_human,278,H,D,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,50.0,11.111,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
520,10.1021/bi7001828,aa1r_human,278,H,D,CID73014720,PubChem CID,73014720,Full agonist,K(i),Binding - Radioligand competition/displacement,6200.0,nM,=,,240.0,-25.641,,,DPCPX,0.0,0.0,=,0.0,,P30542,5.77794,HA278D,ADORA1
76,10.1124/mol.116.105007,aa1r_human,165,P,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.05,1.318,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.19329,PA165A,ADORA1
544,10.1124/mol.116.105015,aa1r_human,165,P,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.79,-2.398,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.19329,PA165A,ADORA1
641,10.1124/mol.116.105007,aa1r_human,165,P,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.45,1.38,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.19329,PA165A,ADORA1
727,10.1016/j.bcp.2012.03.008,aa1r_human,165,P,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.61,6.1,,,,0.0,35.0,=,0.0,,P30542,2.19329,PA165A,ADORA1
761,10.1124/mol.116.105015,aa1r_human,165,P,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.95,-1.996,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.19329,PA165A,ADORA1
83,11306703,aa1r_human,279,G,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.65,1.331,,,,0.0,0.0,=,0.0,,P30542,0.306317,GA279C,ADORA1
84,10.1016/j.bcp.2012.03.008,aa1r_human,164,E,A,CPA,PubChem CID,4402,Full agonist,IC50,Binding - Radioligand competition/displacement,167.0,nM,=,,192.0,1.15,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.713533,EA164A,ADORA1
577,10.1016/j.bcp.2012.03.008,aa1r_human,164,E,A,PD81723,PubChem CID,122028,Allosteric agonist,IC50,Binding - Radioligand competition/displacement,69.0,nM,=,,58.0,-1.189,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.713533,EA164A,ADORA1
639,10.1016/j.bcp.2012.03.008,aa1r_human,164,E,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.15,1.5,,,,0.0,107.0,=,0.0,,P30542,0.713533,EA164A,ADORA1
89,10.1016/S0006-2952(00)00474-3,aa1r_human,309,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.04,1.13,,,,0.0,0.0,=,0.0,,P30542,-0.112081,CA309A,ADORA1
576,10.1016/S0006-2952(00)00474-3,aa1r_human,309,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,1.8,-1.339,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.112081,CA309A,ADORA1
594,10.1016/S0006-2952(00)00474-3,aa1r_human,309,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,61.2,-1.585,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.112081,CA309A,ADORA1
596,10.1016/S0006-2952(00)00474-3,aa1r_human,309,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,0.62,-1.193,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.112081,CA309A,ADORA1
95,11306703,aa1r_human,271,Y,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,12.4,-1.77,,,,0.0,0.0,=,0.0,,P30542,1.67819,YA271C,ADORA1
206,11306703,aa1r_human,271,Y,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,1.1,2.818,,,,0.0,0.0,=,0.0,,P30542,1.67819,YA271C,ADORA1
449,11306703,aa1r_human,271,Y,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,1.0,6.0,,,,0.0,0.0,=,0.0,,P30542,1.67819,YA271C,ADORA1
451,11306703,aa1r_human,271,Y,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,2.61,2.105,,,,0.0,0.0,=,0.0,,P30542,1.67819,YA271C,ADORA1
96,10.1124/mol.116.105007,aa1r_human,270,T,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,5.76,6.761,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.0458321,TA270A,ADORA1
143,10.1124/mol.116.105007,aa1r_human,270,T,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.83,2.188,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.0458321,TA270A,ADORA1
98,10.1016/j.bcp.2012.03.008,aa1r_human,162,M,A,PD81723,PubChem CID,122028,Allosteric agonist,IC50,Binding - Radioligand competition/displacement,69.0,nM,=,,55.0,-1.255,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.0702272,MA162A,ADORA1
337,10.1016/j.bcp.2012.03.008,aa1r_human,162,M,A,CPA,PubChem CID,4402,Full agonist,IC50,Binding - Radioligand competition/displacement,167.0,nM,=,,130.0,-1.285,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.0702272,MA162A,ADORA1
347,10.1124/mol.113.088682,aa1r_human,162,M,A,I-ABA,PubChem CID,125348,Full agonist,K(d),Binding - Radioligand saturation,3.401,nM,=,,1.434,-2.37,,,,0.0,0.0,=,0.0,,P30542,-0.0702272,MA162A,ADORA1
384,10.1016/j.bcp.2012.03.008,aa1r_human,162,M,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.12,1.2,,,,0.0,110.0,=,0.0,,P30542,-0.0702272,MA162A,ADORA1
99,10.1021/bi7001828,aa1r_human,277,T,E,CCPA,PubChem CID,123807,Full agonist,K(i),Binding - Radioligand competition/displacement,610.0,nM,=,,7000.0,11.475,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.33954,TA277E,ADORA1
380,10.1021/bi7001828,aa1r_human,277,T,E,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,18.3,4.067,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.33954,TA277E,ADORA1
760,10.1021/bi7001828,aa1r_human,277,T,E,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,8.6,2.529,,,DPCPX,0.0,0.0,=,0.0,,P30542,3.33954,TA277E,ADORA1
794,10.1021/bi7001828,aa1r_human,277,T,E,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,2.37,nM,=,,5.14,2.169,,,,57.0,0.0,=,0.0,,P30542,3.33954,TA277E,ADORA1
101,11306703,aa1r_human,284,N,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,18.1,-5.848,,,,0.0,0.0,=,0.0,,P30542,0.635541,NA284C,ADORA1
196,11306703,aa1r_human,284,N,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.7,-1.77,,,,0.0,0.0,=,0.0,,P30542,0.635541,NA284C,ADORA1
342,11306703,aa1r_human,284,N,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,20.4,-2.915,,,,0.0,0.0,=,0.0,,P30542,0.635541,NA284C,ADORA1
726,11306703,aa1r_human,284,N,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,9.3,-1.55,,,,0.0,0.0,=,0.0,,P30542,0.635541,NA284C,ADORA1
112,8967987,aa1r_human,55,D,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0022,µM,=,,0.0016,-1.376,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
145,8967987,aa1r_human,55,D,A,DPX,PubChem CID,15667089,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.18,µM,=,,0.27,1.5,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
237,8967987,aa1r_human,55,D,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.0,µM,=,,0.007,-1000.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
271,8967987,aa1r_human,55,D,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,0.13,µM,=,,0.00096,-142.857,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
278,8967987,aa1r_human,55,D,A,N6-cyclopentyl-9-methyladenine,PubChem CID,4401,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.3,µM,=,,4.1,3.154,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
406,8967987,aa1r_human,55,D,A,Caffeine,PubChem CID,2519,Inverse agonist,K(i),Binding - Radioligand competition/displacement,750.0,µM,=,,630.0,-1.19,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
489,8967987,aa1r_human,55,D,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.2,-3.003,,,,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
500,8967987,aa1r_human,55,D,A,Aminophylline,PubChem CID,9433,Inverse agonist,K(i),Binding - Radioligand competition/displacement,77.0,µM,=,,52.0,-1.481,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
523,8967987,aa1r_human,55,D,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.37,µM,=,,0.0012,-333.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
657,8967987,aa1r_human,55,D,A,2-ClAdo,PubChem CID,235481,Full agonist,K(i),Binding - Radioligand competition/displacement,8.4,µM,=,,0.15,-55.556,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
675,8967987,aa1r_human,55,D,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,0.5,-1.401,,,,0.0,0.0,=,0.0,,P30542,-0.104373,DA55A,ADORA1
114,8967987,aa1r_human,16,E,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.0,µM,=,,42.0,8.4,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
127,8967987,aa1r_human,16,E,A,Aminophylline,PubChem CID,9433,Inverse agonist,K(i),Binding - Radioligand competition/displacement,77.0,µM,=,,83.0,1.078,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
168,8967987,aa1r_human,16,E,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0022,µM,=,,0.0023,1.045,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
317,8967987,aa1r_human,16,E,A,Caffeine,PubChem CID,2519,Inverse agonist,K(i),Binding - Radioligand competition/displacement,750.0,µM,=,,520.0,-1.443,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
457,8967987,aa1r_human,16,E,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,1.3,1.857,,,,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
550,8967987,aa1r_human,16,E,A,2-ClAdo,PubChem CID,235481,Full agonist,K(i),Binding - Radioligand competition/displacement,8.4,µM,=,,130.0,15.476,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
601,8967987,aa1r_human,16,E,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.37,µM,=,,1.3,3.514,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
680,8967987,aa1r_human,16,E,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,5.3,8.833,,,,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
721,8967987,aa1r_human,16,E,A,N6-cyclopentyl-9-methyladenine,PubChem CID,4401,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.3,µM,=,,38.0,29.231,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
733,8967987,aa1r_human,16,E,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,0.13,µM,=,,5.3,40.769,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.15307,EA16A,ADORA1
119,10.1124/mol.116.105007,aa1r_human,153,E,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.17,1.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.582252,EA153A,ADORA1
122,10.1016/j.bcp.2012.03.008,aa1r_human,153,E,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.43,4.3,,,,0.0,23.0,=,0.0,,P30542,0.582252,EA153A,ADORA1
345,10.1124/mol.116.105007,aa1r_human,153,E,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.58,1.023,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.582252,EA153A,ADORA1
590,10.1124/mol.116.105015,aa1r_human,153,E,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.71,-1.996,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.582252,EA153A,ADORA1
626,10.1124/mol.116.105015,aa1r_human,153,E,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.38,1.862,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.582252,EA153A,ADORA1
131,10.1016/S0006-2952(00)00474-3,aa1r_human,131,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,1.55,2.095,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.339043,CA131A,ADORA1
299,10.1016/S0006-2952(00)00474-3,aa1r_human,131,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,0.91,-1.011,,,,0.0,0.0,=,0.0,,P30542,-0.339043,CA131A,ADORA1
587,10.1016/S0006-2952(00)00474-3,aa1r_human,131,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,2.78,1.154,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.339043,CA131A,ADORA1
825,10.1016/S0006-2952(00)00474-3,aa1r_human,131,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,135.3,1.395,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.339043,CA131A,ADORA1
140,10.1124/mol.116.105007,aa1r_human,156,W,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.07,1.259,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
321,10.1016/j.bcp.2012.03.008,aa1r_human,156,W,A,PD81723,PubChem CID,122028,Allosteric agonist,IC50,Binding - Radioligand competition/displacement,69.0,nM,=,,141.0,2.043,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
366,10.1124/mol.116.105015,aa1r_human,156,W,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.92,-1.862,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
390,10.1016/j.bcp.2012.03.008,aa1r_human,156,W,A,CPA,PubChem CID,4402,Full agonist,IC50,Binding - Radioligand competition/displacement,167.0,nM,=,,161.0,-1.037,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
515,10.1124/mol.116.105015,aa1r_human,156,W,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.4,1.023,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
723,10.1124/mol.116.105007,aa1r_human,156,W,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.5,1.23,,,DPCPX,0.0,0.0,=,0.0,,P30542,-0.421174,WA156A,ADORA1
146,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-4.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
173,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,4.52,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
175,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.724,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
180,10.1016/j.cell.2017.01.042,aa1r_human,270,T,M,DPCPX,PubChem CID,1329,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,8.9,,=,,8.0,7.943,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
287,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-4.545,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
318,10.1016/j.cell.2017.01.042,aa1r_human,270,T,M,ZM241385,PubChem CID,176408,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,6.9,,=,,7.1,-1.585,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
464,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.39,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
514,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-3.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
549,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.333,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
685,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.24,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
768,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.16,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
788,10.1016/j.str.2017.06.012,aa1r_human,270,T,M,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.111,,,DPCPX,0.0,0.0,=,0.0,,P30542,-1.43134,TA270M,ADORA1
158,8300561,aa1r_human,277,T,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,210.0,nM,=,,807.0,3.843,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
174,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Other,0.00311,µM,=,,123.9,39839.228,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
231,10.1021/bi7001828,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,3.5,-1.285,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
234,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,CPA,PubChem CID,4402,Full agonist,,Functional - cAMP accumulation,70.0,%,=,,100.0,-1.429,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
246,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,CPT,PubChem CID,1917,Inverse agonist,K(i),Binding - Radioligand competition/displacement,31.8,nM,=,,70.9,2.23,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
284,8300561,aa1r_human,277,T,A,S-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,1.094,nM,=,,7.49,6.846,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
319,8300561,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.8,nM,=,,0.4,-2.0,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
332,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,PD81723,PubChem CID,122028,Allosteric agonist,,Functional - cAMP accumulation,75.0,%,=,,100.0,-1.333,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
348,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,76.0,nM,=,,8200.0,107.895,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
353,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.59,nM,=,,1.33,-1.196,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
360,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Other,8.8,nM,=,,0.5,-17.544,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
382,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.69,nM,=,,0.75,1.087,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
428,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.007823,µM,=,,176.0,22497.763,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
494,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,,Functional - cAMP accumulation,130.0,%,=,,100.0,1.3,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
506,8300561,aa1r_human,277,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,366.0,µM,=,,160.0,-2.288,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
509,10.1021/bi7001828,aa1r_human,277,T,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,4.6,1.353,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
541,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Other,0.00093,µM,=,,2.36,2537.634,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
579,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,8BCPA,PubChem CID,9887609,Partial agonist,K(i),Binding - Radioligand competition/displacement,7.1,µM,=,,33.2,4.676,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
598,10.1021/bi7001828,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,2.37,nM,=,,1.12,-2.114,,,,140.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
606,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.6,nM,=,,0.2,-8.0,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
623,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,0.00229,µM,=,,11.31,4938.865,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
624,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.00309,µM,=,,1.73,559.871,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
658,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,PD81723,PubChem CID,122028,Allosteric agonist,,Functional - cAMP accumulation,5.0,%,=,,100.0,-20.0,,,CPA,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
663,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Other,0.00117,µM,=,,19.1,16324.786,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
693,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,CPT,PubChem CID,1917,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.0,nM,=,,35.3,3.53,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
701,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,8BCPA,PubChem CID,9887609,Partial agonist,K(i),Binding - Radioligand competition/displacement,4000.0,nM,=,,8300.0,2.075,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
807,10.1016/S0006-2952(98)00202-0,aa1r_human,277,T,A,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,0.01,µM,=,,33.1,3310.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
812,10.1016/S0006-2952(00)00536-0,aa1r_human,277,T,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Other,6.8,nM,=,,2.1,-3.236,,,,0.0,0.0,=,0.0,,P30542,0.787715,TA277A,ADORA1
164,11306703,aa1r_human,272,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.0,-1.241,,,,0.0,0.0,=,0.0,,P30542,1.17931,IA272C,ADORA1
312,11306703,aa1r_human,272,I,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,12.0,-1.715,,,,0.0,0.0,=,0.0,,P30542,1.17931,IA272C,ADORA1
629,11306703,aa1r_human,272,I,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,9.1,-2.933,,,,0.0,0.0,=,0.0,,P30542,1.17931,IA272C,ADORA1
750,11306703,aa1r_human,272,I,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,27.3,-4.545,,,,0.0,0.0,=,0.0,,P30542,1.17931,IA272C,ADORA1
169,11306703,aa1r_human,280,N,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.21,-1.025,,,,0.0,0.0,=,0.0,,P30542,-0.993098,NA280C,ADORA1
182,11306703,aa1r_human,278,H,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,87.5,-28.571,,,,0.0,0.0,=,0.0,,P30542,2.14465,HA278C,ADORA1
205,11306703,aa1r_human,278,H,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,84.4,-14.085,,,,0.0,0.0,=,0.0,,P30542,2.14465,HA278C,ADORA1
379,11306703,aa1r_human,278,H,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,81.4,-11.628,,,,0.0,0.0,=,0.0,,P30542,2.14465,HA278C,ADORA1
785,11306703,aa1r_human,278,H,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.26,1.016,,,,0.0,0.0,=,0.0,,P30542,2.14465,HA278C,ADORA1
187,10.1124/mol.116.105015,aa1r_human,170,E,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,6.0,-3.891,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.242058,EA170A,ADORA1
325,10.1124/mol.116.105015,aa1r_human,170,E,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.72,-1.175,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.242058,EA170A,ADORA1
407,10.1016/j.bcp.2012.03.008,aa1r_human,170,E,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.4,4.0,,,,0.0,23.0,=,0.0,,P30542,0.242058,EA170A,ADORA1
530,10.1124/mol.116.105007,aa1r_human,170,E,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.22,2.344,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.242058,EA170A,ADORA1
820,10.1124/mol.116.105007,aa1r_human,170,E,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.24,-1.175,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.242058,EA170A,ADORA1
210,10.1124/mol.116.105015,aa1r_human,176,S,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.78,-2.342,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.410803,SA176A,ADORA1
399,10.1124/mol.116.105007,aa1r_human,176,S,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.08,1.23,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.410803,SA176A,ADORA1
738,10.1124/mol.116.105007,aa1r_human,176,S,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.38,1.622,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.410803,SA176A,ADORA1
799,10.1124/mol.116.105015,aa1r_human,176,S,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.47,1.514,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.410803,SA176A,ADORA1
214,10.1124/mol.116.105007,aa1r_human,168,K,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.12,1.122,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.580364,KA168A,ADORA1
343,10.1124/mol.116.105015,aa1r_human,168,K,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.86,-2.817,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.580364,KA168A,ADORA1
410,10.1124/mol.116.105007,aa1r_human,168,K,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.43,1.445,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.580364,KA168A,ADORA1
585,10.1124/mol.116.105015,aa1r_human,168,K,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.49,1.445,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.580364,KA168A,ADORA1
215,10.1016/j.bcp.2012.03.008,aa1r_human,262,S,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.19,1.9,,,,0.0,63.0,=,0.0,,P30542,-0.0245769,SA262A,ADORA1
218,10.1124/mol.116.105007,aa1r_human,173,K,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.42,1.479,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.1216,KA173A,ADORA1
242,10.1124/mol.116.105015,aa1r_human,173,K,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,6.2,-6.173,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.1216,KA173A,ADORA1
276,10.1124/mol.116.105007,aa1r_human,173,K,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.21,-1.096,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.1216,KA173A,ADORA1
745,10.1124/mol.116.105015,aa1r_human,173,K,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.37,1.905,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.1216,KA173A,ADORA1
222,10.1124/mol.116.105015,aa1r_human,146,W,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.49,-1.202,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59569,WA146A,ADORA1
223,10.1124/mol.116.105015,aa1r_human,146,W,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.65,1.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59569,WA146A,ADORA1
431,10.1124/mol.116.105007,aa1r_human,146,W,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.97,1.585,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59569,WA146A,ADORA1
568,10.1124/mol.116.105007,aa1r_human,146,W,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.2,2.455,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.59569,WA146A,ADORA1
226,11306703,aa1r_human,286,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.91,-1.362,,,,0.0,0.0,=,0.0,,P30542,1.03616,IA286C,ADORA1
359,11306703,aa1r_human,286,I,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,4.1,1.707,,,,0.0,0.0,=,0.0,,P30542,1.03616,IA286C,ADORA1
453,11306703,aa1r_human,286,I,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,1.3,2.385,,,,0.0,0.0,=,0.0,,P30542,1.03616,IA286C,ADORA1
503,11306703,aa1r_human,286,I,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,5.5,1.091,,,,0.0,0.0,=,0.0,,P30542,1.03616,IA286C,ADORA1
233,10.1016/j.bcp.2012.03.008,aa1r_human,264,H,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.16,1.6,,,,0.0,88.0,=,0.0,,P30542,0.103599,HA264A,ADORA1
235,8967987,aa1r_human,16,E,Q,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.0,µM,=,,150.0,30.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
260,8967987,aa1r_human,16,E,Q,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0022,µM,=,,0.0033,1.5,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
273,8967987,aa1r_human,16,E,Q,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.37,µM,=,,4.1,11.081,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
274,8967987,aa1r_human,16,E,Q,2-ClAdo,PubChem CID,235481,Full agonist,K(i),Binding - Radioligand competition/displacement,8.4,µM,=,,56.0,6.667,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
292,8967987,aa1r_human,16,E,Q,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,0.13,µM,=,,73.0,561.538,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
314,8967987,aa1r_human,16,E,Q,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,9.3,15.5,,,,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
803,8967987,aa1r_human,16,E,Q,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,1.7,2.429,,,,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
809,8967987,aa1r_human,16,E,Q,N6-cyclopentyl-9-methyladenine,PubChem CID,4401,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.3,µM,=,,14.0,10.769,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.2061,EA16Q,ADORA1
243,10.1124/mol.116.105007,aa1r_human,175,I,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.45,5.248,,,DPCPX,0.0,0.0,=,0.0,,P30542,4.10292,IA175A,ADORA1
547,10.1124/mol.116.105015,aa1r_human,175,I,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,6.49,-12.048,,,DPCPX,0.0,0.0,=,0.0,,P30542,4.10292,IA175A,ADORA1
681,10.1124/mol.116.105015,aa1r_human,175,I,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.83,-1.513,,,DPCPX,0.0,0.0,=,0.0,,P30542,4.10292,IA175A,ADORA1
704,10.1124/mol.116.105007,aa1r_human,175,I,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,5.56,10.715,,,DPCPX,0.0,0.0,=,0.0,,P30542,4.10292,IA175A,ADORA1
293,11306703,aa1r_human,287,V,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,4.6,1.522,,,,0.0,0.0,=,0.0,,P30542,2.00338,VA287C,ADORA1
385,11306703,aa1r_human,287,V,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.39,1.121,,,,0.0,0.0,=,0.0,,P30542,2.00338,VA287C,ADORA1
412,11306703,aa1r_human,287,V,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,8.9,-2.874,,,,0.0,0.0,=,0.0,,P30542,2.00338,VA287C,ADORA1
557,11306703,aa1r_human,287,V,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,8.5,-1.416,,,,0.0,0.0,=,0.0,,P30542,2.00338,VA287C,ADORA1
297,10.1016/j.bcp.2012.03.008,aa1r_human,263,C,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.1,1.0,,,,0.0,72.0,=,0.0,,P30542,1.56105,CA263A,ADORA1
311,10.1016/S0006-2952(00)00474-3,aa1r_human,263,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.74,µM,=,,0.65,-1.139,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.56105,CA263A,ADORA1
373,10.1016/S0006-2952(00)00474-3,aa1r_human,263,C,A,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.41,µM,=,,2.52,1.046,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.56105,CA263A,ADORA1
405,10.1016/S0006-2952(00)00474-3,aa1r_human,263,C,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,97.0,nM,=,,71.1,-1.364,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.56105,CA263A,ADORA1
484,10.1016/S0006-2952(00)00474-3,aa1r_human,263,C,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.92,nM,=,,1.94,2.109,,,,0.0,0.0,=,0.0,,P30542,1.56105,CA263A,ADORA1
303,10.1124/mol.116.105015,aa1r_human,177,M,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.73,-2.088,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.17767,MA177A,ADORA1
329,10.1124/mol.116.105015,aa1r_human,177,M,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.69,-1.096,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.17767,MA177A,ADORA1
383,10.1124/mol.116.105007,aa1r_human,177,M,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,8.39,6.026,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.17767,MA177A,ADORA1
621,10.1124/mol.116.105007,aa1r_human,177,M,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,5.81,6.026,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.17767,MA177A,ADORA1
305,11306703,aa1r_human,282,A,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.08,-1.148,,,,0.0,0.0,=,0.0,,P30542,0.239963,AA282C,ADORA1
307,11306703,aa1r_human,273,A,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,42.8,-13.889,,,,0.0,0.0,=,0.0,,P30542,1.46044,AA273C,ADORA1
414,11306703,aa1r_human,273,A,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.09,-1.138,,,,0.0,0.0,=,0.0,,P30542,1.46044,AA273C,ADORA1
612,11306703,aa1r_human,273,A,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,43.1,-6.173,,,,0.0,0.0,=,0.0,,P30542,1.46044,AA273C,ADORA1
797,11306703,aa1r_human,273,A,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,96.8,-16.129,,,,0.0,0.0,=,0.0,,P30542,1.46044,AA273C,ADORA1
326,11306703,aa1r_human,274,I,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,54.3,-17.544,,,,0.0,0.0,=,0.0,,P30542,1.52116,IA274C,ADORA1
403,11306703,aa1r_human,274,I,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,85.1,-14.085,,,,0.0,0.0,=,0.0,,P30542,1.52116,IA274C,ADORA1
469,11306703,aa1r_human,274,I,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,83.8,-11.905,,,,0.0,0.0,=,0.0,,P30542,1.52116,IA274C,ADORA1
640,11306703,aa1r_human,274,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,3.55,2.863,,,,0.0,0.0,=,0.0,,P30542,1.52116,IA274C,ADORA1
339,11306703,aa1r_human,264,H,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.36,1.097,,,,0.0,0.0,=,0.0,,P30542,0.131358,HA264C,ADORA1
351,11306703,aa1r_human,285,P,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,5.9,1.017,,,,0.0,0.0,=,0.0,,P30542,2.87193,PA285C,ADORA1
643,11306703,aa1r_human,285,P,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,4.8,1.458,,,,0.0,0.0,=,0.0,,P30542,2.87193,PA285C,ADORA1
689,11306703,aa1r_human,285,P,C,MTS-TEAH,PubChem CID,46783166,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,3.1,%,=,,6.1,-1.969,,,,0.0,0.0,=,0.0,,P30542,2.87193,PA285C,ADORA1
817,11306703,aa1r_human,285,P,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.1,-1.127,,,,0.0,0.0,=,0.0,,P30542,2.87193,PA285C,ADORA1
356,10.1074/jbc.274.6.3617,aa1r_human,91,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,5.1,µM,=,,770.0,150.98,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.16942,TA91A,ADORA1
631,10.1074/jbc.274.6.3617,aa1r_human,91,T,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.36,µM,=,,72.0,200.0,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.16942,TA91A,ADORA1
744,10.1074/jbc.274.6.3617,aa1r_human,91,T,A,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,9.7,17.321,,,DPCPX,0.0,0.0,=,0.0,,P30542,0.16942,TA91A,ADORA1
397,8967987,aa1r_human,50,S,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,0.5,-1.401,,,,0.0,0.0,=,0.0,,P30542,-0.552315,SA50A,ADORA1
714,8967987,aa1r_human,50,S,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,1.1,1.833,,,,0.0,0.0,=,0.0,,P30542,-0.552315,SA50A,ADORA1
415,11306703,aa1r_human,275,F,C,MTSEA,PubChem CID,53443082,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,6.0,%,=,,0.9,6.667,,,,0.0,0.0,=,0.0,,P30542,3.69254,FA275C,ADORA1
475,11306703,aa1r_human,275,F,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.68,-1.825,,,,0.0,0.0,=,0.0,,P30542,3.69254,FA275C,ADORA1
730,11306703,aa1r_human,275,F,C,MTSET,PubChem CID,107933,Binding - unknown pharmacological activity,Specific binding,Binding - Radioligand competition/displacement,7.0,%,=,,1.8,3.889,,,,0.0,0.0,=,0.0,,P30542,3.69254,FA275C,ADORA1
417,11306703,aa1r_human,267,S,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.29,1.04,,,,0.0,0.0,=,0.0,,P30542,0.52712,SA267C,ADORA1
418,10.1074/jbc.274.6.3617,aa1r_human,92,Q,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.36,µM,=,,2600.0,7222.222,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.16928,QA92A,ADORA1
694,10.1074/jbc.274.6.3617,aa1r_human,92,Q,A,N-0840,PubChem CID,657378,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,13.0,23.214,,,DPCPX,0.0,0.0,=,0.0,,P30542,1.16928,QA92A,ADORA1
420,11306703,aa1r_human,266,P,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.97,-1.279,,,,0.0,0.0,=,0.0,,P30542,1.56508,PA266C,ADORA1
424,10.1074/jbc.274.6.3617,aa1r_human,31,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.8,1.143,,,,0.0,0.0,=,0.0,,P30542,2.16574,IA31C,ADORA1
602,10.1074/jbc.274.6.3617,aa1r_human,31,I,C,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.7,1.167,,,,0.0,0.0,=,0.0,,P30542,2.16574,IA31C,ADORA1
444,10.1074/jbc.274.6.3617,aa1r_human,65,L,F,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.6,1.0,,,,0.0,0.0,=,0.0,,P30542,0.310221,LA65F,ADORA1
742,10.1074/jbc.274.6.3617,aa1r_human,65,L,F,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.7,1.0,,,,0.0,0.0,=,0.0,,P30542,0.310221,LA65F,ADORA1
448,8967987,aa1r_human,93,S,A,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.7,nM,=,,0.4,-1.751,,,,0.0,0.0,=,0.0,,P30542,-0.903534,SA93A,ADORA1
567,8967987,aa1r_human,93,S,A,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,1.0,1.667,,,,0.0,0.0,=,0.0,,P30542,-0.903534,SA93A,ADORA1
504,10.1016/j.bcp.2012.03.008,aa1r_human,266,P,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.36,3.6,,,,0.0,49.0,=,0.0,,P30542,1.68191,PA266A,ADORA1
505,10.1124/mol.116.105007,aa1r_human,160,G,A,NECA,PubChem CID,448222,Full agonist,pK(i),Binding - Radioligand competition/displacement,6.59,,=,,6.8,-1.621,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.317,GA160A,ADORA1
575,10.1016/j.bcp.2012.03.008,aa1r_human,160,G,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.71,7.1,,,,0.0,21.0,=,0.0,,P30542,2.317,GA160A,ADORA1
647,10.1124/mol.116.105007,aa1r_human,160,G,A,DPCPX,PubChem CID,1329,Inverse agonist,pK(d),Binding - Radioligand competition/displacement,9.17,,=,,9.3,-1.35,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.317,GA160A,ADORA1
774,10.1124/mol.116.105015,aa1r_human,160,G,A,PD81723,PubChem CID,122028,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.41,,=,,5.76,-2.237,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.317,GA160A,ADORA1
808,10.1124/mol.116.105015,aa1r_human,160,G,A,VCP171,PubChem CID,24873485,Allosteric agonist,pK(b),Binding - Radioligand competition/displacement,5.65,,=,,5.96,-2.041,,,DPCPX,0.0,0.0,=,0.0,,P30542,2.317,GA160A,ADORA1
525,10.1124/mol.113.088682,aa1r_human,150,S,A,I-ABA,PubChem CID,125348,Full agonist,K(d),Binding - Radioligand saturation,3.401,nM,=,,1.475,-2.304,,,,0.0,0.0,=,0.0,,P30542,-0.321735,SA150A,ADORA1
531,10.1074/jbc.274.6.3617,aa1r_human,125,A,K,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.7,1.0,,,,0.0,0.0,=,0.0,,P30542,-0.114793,AA125K,ADORA1
605,10.1074/jbc.274.6.3617,aa1r_human,125,A,K,CCPA,PubChem CID,123807,Full agonist,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.7,1.167,,,,0.0,0.0,=,0.0,,P30542,-0.114793,AA125K,ADORA1
532,11306703,aa1r_human,292,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.62,1.306,,,,0.0,0.0,=,0.0,,P30542,2.57645,IA292C,ADORA1
597,10.1016/j.bcp.2012.03.008,aa1r_human,163,G,S,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,2.1,21.0,,,,0.0,7.0,=,0.0,,P30542,3.91318,GA163S,ADORA1
616,11306703,aa1r_human,269,L,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,0.95,-1.305,,,,0.0,0.0,=,0.0,,P30542,0.896453,LA269C,ADORA1
645,11306703,aa1r_human,291,R,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.44,1.161,,,,0.0,0.0,=,0.0,,P30542,1.05367,RA291C,ADORA1
656,11306703,aa1r_human,268,I,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.7,1.371,,,,0.0,0.0,=,0.0,,P30542,1.14931,IA268C,ADORA1
670,10.1016/j.bcp.2012.03.008,aa1r_human,267,S,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.22,2.2,,,,0.0,37.0,=,0.0,,P30542,0.168332,SA267A,ADORA1
762,11306703,aa1r_human,296,R,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.11,-1.117,,,,0.0,0.0,=,0.0,,P30542,2.66752,RA296C,ADORA1
806,11306703,aa1r_human,290,F,C,DPCPX,PubChem CID,1329,Inverse agonist,K(d),Binding - Radioligand saturation,1.24,nM,=,,1.4,1.129,,,,0.0,0.0,=,0.0,,P30542,0.372385,FA290C,ADORA1
829,10.1016/j.bcp.2012.03.008,aa1r_human,261,P,A,CPA,PubChem CID,4402,Full agonist,EC50,Functional - Other,0.1,nM,=,,0.25,2.5,,,,0.0,63.0,=,0.0,,P30542,1.71785,PA261A,ADORA1
9,8034699,cxcr1_human,272,V,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.9998,-1.515,,,125I-IL-8,93.0,0.0,,0.0,,P25024,-0.1932,VA272A,CXCR1
13,8034699,cxcr1_human,22,P,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.909,-3.333,,,125I-IL-8,106.0,0.0,,0.0,,P25024,0.573143,PA22A,CXCR1
16,12077146,cxcr1_human,265,D,H,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,EC50,Calcium mobilization assay,4.3,nM,=,,4.6,1.07,,,,113.3333333,0.0,,0.0,,P25024,0.89183,DA265H,CXCR1
130,12077146,cxcr1_human,265,D,H,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,IC50,Binding - Radioligand competition/displacement,10.4,nM,=,,7.9,-1.316,,,125I-IL-8,113.3333333,0.0,,0.0,,P25024,0.89183,DA265H,CXCR1
17,8034699,cxcr1_human,179,H,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,3.8178,1.26,,,125I-IL-8,114.0,0.0,,0.0,,P25024,0.662758,HA179A,CXCR1
19,8034699,cxcr1_human,36,T,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,3.19,1.053,,,125I-IL-8,101.0,0.0,,0.0,,P25024,0.159732,TA36A,CXCR1
20,8034699,cxcr1_human,20,M,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,3.4845,1.15,,,125I-IL-8,94.0,0.0,,0.0,,P25024,0.780507,MA20A,CXCR1
25,8103045,cxcr1_human,117,K,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.3,1.34,,,125I-IL-8,60.75949367,0.0,,0.0,,P25024,1.25859,KA117A,CXCR1
26,8034699,cxcr1_human,102,G,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.0908,-2.778,,,125I-IL-8,70.0,0.0,,0.0,,P25024,4.91767,GA102A,CXCR1
34,8034699,cxcr1_human,19,G,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.818,-1.667,,,125I-IL-8,101.0,0.0,,0.0,,P25024,0.399316,GA19A,CXCR1
37,8034699,cxcr1_human,200,M,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.0606,-50.0,,,125I-IL-8,103.0,0.0,,0.0,,P25024,1.35013,MA200A,CXCR1
40,25834784,cxcr1_human,251,F,H,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,5.55,nM,=,,4.86,-1.142,,,125I-IL-8,256.9,0.0,,0.0,,P25024,3.25311,FA251H,CXCR1
41,25834784,cxcr1_human,241,M,V,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,5.55,nM,=,,1.53,-3.623,,,125I-IL-8,160.8,0.0,,0.0,,P25024,1.72461,MA241V,CXCR1
42,25834784,cxcr1_human,251,F,Y,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,5.55,nM,=,,3.478,-1.595,,,125I-IL-8,213.0,0.0,,0.0,,P25024,1.76444,FA251Y,CXCR1
43,8103045,cxcr1_human,265,D,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,2.5,2.577,,,125I-IL-8,13.92405063,0.0,,0.0,,P25024,-0.887545,DA265A,CXCR1
44,8103045,cxcr1_human,118,E,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,4.1,4.227,,,125I-IL-8,73.41772152,0.0,,0.0,,P25024,1.32396,EA118A,CXCR1
56,8903513,cxcr1_human,139,I,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,1.54,1.02,,,125I-IL-8,100.0,0.0,,0.0,,P25024,2.62707,IA139A,CXCR1
58,8103045,cxcr1_human,288,D,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.07,1.103,,,125I-IL-8,108.8607595,0.0,,0.0,,P25024,-0.963039,DA288A,CXCR1
59,8903513,cxcr1_human,140,V,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,1.48,-1.02,,,125I-IL-8,98.94736842,0.0,,0.0,,P25024,1.58662,VA140A,CXCR1
60,8034699,cxcr1_human,107,T,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.7272,-4.167,,,125I-IL-8,81.0,0.0,,0.0,,P25024,-0.0437529,TA107A,CXCR1
65,25834784,cxcr1_human,251,F,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,5.55,nM,=,,1.026,-5.405,,,125I-IL-8,30.2,0.0,,0.0,,P25024,3.75475,FA251A,CXCR1
68,25834784,cxcr1_human,132,S,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,5.55,nM,=,,4.15,-1.337,,,125I-IL-8,179.6,0.0,,0.0,,P25024,-0.855145,SA132A,CXCR1
73,22936990,cxcr1_human,128,L,Q,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,4.87,nM,=,,1.35,-3.61,,,125I-IL-8,189.4,0.0,,0.0,,P25024,3.59084,LA128Q,CXCR1
75,8034699,cxcr1_human,191,L,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.2727,-11.111,,,125I-IL-8,106.0,0.0,,0.0,,P25024,3.17759,LA191A,CXCR1
78,8034699,cxcr1_human,202,L,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.4241,-2.128,,,125I-IL-8,113.0,0.0,,0.0,,P25024,3.55255,LA202A,CXCR1
82,22936990,cxcr1_human,247,V,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,4.87,nM,=,,0.55,-8.85,,,125I-IL-8,109.9,0.0,,0.0,,P25024,1.86488,VA247A,CXCR1
85,8903513,cxcr1_human,241,M,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,0.9,-1.678,,,125I-IL-8,95.78947368,0.0,,0.0,,P25024,2.96405,MA241A,CXCR1
86,8034699,cxcr1_human,21,P,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.3636,-8.333,,,125I-IL-8,106.0,0.0,,0.0,,P25024,1.15462,PA21A,CXCR1
87,8034699,cxcr1_human,192,G,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.303,-10.0,,,125I-IL-8,85.0,0.0,,0.0,,P25024,2.12234,GA192A,CXCR1
88,8103045,cxcr1_human,189,E,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.45,1.495,,,125I-IL-8,77.21518987,0.0,,0.0,,P25024,1.83814,EA189A,CXCR1
94,8103045,cxcr1_human,278,E,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,3.6,3.711,,,125I-IL-8,74.6835443,0.0,,0.0,,P25024,0.777584,EA278A,CXCR1
96,8034699,cxcr1_human,104,I,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,2.1816,-1.389,,,125I-IL-8,90.0,0.0,,0.0,,P25024,0.778094,IA104A,CXCR1
97,8034699,cxcr1_human,271,Q,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,3.3936,1.12,,,125I-IL-8,90.0,0.0,,0.0,,P25024,0.0232312,QA271A,CXCR1
98,8903513,cxcr1_human,242,R,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,0.58,-2.604,,,125I-IL-8,98.94736842,0.0,,0.0,,P25024,0.34964,RA242A,CXCR1
109,8103045,cxcr1_human,291,E,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.2,1.237,,,125I-IL-8,30.37974684,0.0,,0.0,,P25024,0.505857,EA291A,CXCR1
110,22936990,cxcr1_human,247,V,Y,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,4.87,nM,=,,0.693,-7.042,,,125I-IL-8,126.2,0.0,,0.0,,P25024,12.4894,VA247Y,CXCR1
111,8034699,cxcr1_human,105,F,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.909,-3.333,,,125I-IL-8,71.0,0.0,,0.0,,P25024,3.08298,FA105A,CXCR1
114,8034699,cxcr1_human,267,L,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.7574,-1.724,,,125I-IL-8,101.0,0.0,,0.0,,P25024,1.59546,LA267A,CXCR1
120,8034699,cxcr1_human,273,I,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.0909,-33.333,,,125I-IL-8,93.0,0.0,,0.0,,P25024,1.94826,IA273A,CXCR1
124,8103045,cxcr1_human,194,D,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.25,1.289,,,125I-IL-8,81.01265823,0.0,,0.0,,P25024,1.68623,DA194A,CXCR1
125,8034699,cxcr1_human,190,V,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.7877,-1.695,,,125I-IL-8,91.0,0.0,,0.0,,P25024,0.545692,VA190A,CXCR1
126,8034699,cxcr1_human,178,Y,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.1212,-25.0,,,125I-IL-8,93.0,0.0,,0.0,,P25024,1.59659,YA178A,CXCR1
127,8034699,cxcr1_human,27,Y,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.1212,-25.0,,,125I-IL-8,98.0,0.0,,0.0,,P25024,0.923899,YA27A,CXCR1
128,8034699,cxcr1_human,12,F,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,4.82,1.591,,,125I-IL-8,121.0,0.0,,0.0,,P25024,-0.0826994,FA12A,CXCR1
132,8034699,cxcr1_human,269,R,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.2121,-14.286,,,125I-IL-8,103.0,0.0,,0.0,,P25024,-0.424432,RA269A,CXCR1
134,8034699,cxcr1_human,266,T,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.0605,-2.857,,,125I-IL-8,81.0,0.0,,0.0,,P25024,-1.10386,TA266A,CXCR1
137,8903513,cxcr1_human,136,Y,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,2.0,1.325,,,125I-IL-8,98.94736842,0.0,,0.0,,P25024,3.29102,YA136A,CXCR1
140,8103045,cxcr1_human,279,R,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,1.25,1.289,,,125I-IL-8,72.15189873,0.0,,0.0,,P25024,0.764852,RA279A,CXCR1
142,8034699,cxcr1_human,201,V,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.3332,-2.273,,,125I-IL-8,129.0,0.0,,0.0,,P25024,0.0686911,VA201A,CXCR1
143,8034699,cxcr1_human,274,Q,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,4.9389,1.63,,,125I-IL-8,88.0,0.0,,0.0,,P25024,0.358806,QA274A,CXCR1
147,8034699,cxcr1_human,188,Y,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,>,,25.0,8.251,,,125I-IL-8,100.0,0.0,,0.0,,P25024,1.0465,YA188A,CXCR1
149,8034699,cxcr1_human,180,P,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,1.4847,-2.041,,,125I-IL-8,75.0,0.0,,0.0,,P25024,1.70761,PA180A,CXCR1
156,22936990,cxcr1_human,128,L,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,4.87,nM,=,,0.535,-9.091,,,125I-IL-8,86.8,0.0,,0.0,,P25024,3.37906,LA128A,CXCR1
157,22936990,cxcr1_human,247,V,N,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,4.87,nM,=,,3.14,-1.55,,,125I-IL-8,328.5,0.0,,0.0,,P25024,2.00949,VA247N,CXCR1
159,8903513,cxcr1_human,137,L,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,1.51,nM,=,,2.0,1.325,,,125I-IL-8,97.89473684,0.0,,0.0,,P25024,1.02639,LA137A,CXCR1
162,8034699,cxcr1_human,34,T,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,4.98,1.644,,,125I-IL-8,100.0,0.0,,0.0,,P25024,-0.377082,TA34A,CXCR1
167,8034699,cxcr1_human,270,T,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.5454,-5.556,,,125I-IL-8,84.0,0.0,,0.0,,P25024,0.312787,TA270A,CXCR1
169,8103045,cxcr1_human,6,D,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,0.97,nM,=,,0.89,-1.089,,,125I-IL-8,54.43037975,0.0,,0.0,,P25024,0.0903765,DA6A,CXCR1
170,8034699,cxcr1_human,268,M,A,IL8_HUMAN,UniProt Entry Code (peptide),P10145,Full agonist,Kd,Binding - Radioligand competition/displacement,3.03,nM,=,,0.0606,-50.0,,,125I-IL-8,105.0,0.0,,0.0,,P25024,1.61106,MA268A,CXCR1
0,21775441,ccr5_human,37,Y,F,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.111,,,[125I]-CCL3,86.0,0.0,,0.0,,P51681,0.344975,YA37F,CCR5
782,21775441,ccr5_human,37,Y,F,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,78.0,1.282,,,[125I]-CCL3,86.0,0.0,,0.0,,P51681,0.344975,YA37F,CCR5
1,24628038,ccr5_human,108,Y,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,94.0,13.239,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
16,21775441,ccr5_human,108,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,75.5,,,[125I]-CCL3,65.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
195,12411445,ccr5_human,108,Y,A,CCL8_HUMAN,UniProt entry code,P80075,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,8.73,7.244,,,[125I]-CCL4,40.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
338,16476734,ccr5_human,108,Y,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,11.8,-1.355,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
344,18096812,ccr5_human,108,Y,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,12.0,-1.416,,,[125I]-CCL5,89.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
394,18096812,ccr5_human,108,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,113.0,28.25,,,[125I]-CCL5,89.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
424,18096812,ccr5_human,108,Y,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,840.0,60.0,,,[125I]-CCL5,89.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
449,24628038,ccr5_human,108,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,200.0,54.054,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
535,12411445,ccr5_human,108,Y,A,CCL4_HUMAN,UniProt entry code,P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.78,-1.548,,,[125I]-CCL4,40.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
539,18096812,ccr5_human,108,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,630.0,70.0,,,[125I]-CCL5,89.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
606,18590744/16476734,ccr5_human,108,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,19.8,5.5,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
701,18590744,ccr5_human,108,Y,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
721,16476734,ccr5_human,108,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,200.0,6.623,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
759,24628038,ccr5_human,108,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,13.0,10.0,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
785,12411445,ccr5_human,108,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.42,M,=,,9.39,1.072,,,[125I]-CCL4,40.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
834,18590744,ccr5_human,108,Y,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,60.7,43.357,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
873,21775441,ccr5_human,108,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,44.0,2.273,,,[125I]-CCL3,65.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
882,18096812,ccr5_human,108,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,57.0,5.7,,,[125I]-CCL5,89.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
926,12411445,ccr5_human,108,Y,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.64,M,=,,9.92,-1.905,,,[125I]-CCL4,40.0,0.0,,0.0,,P51681,1.96508,YA108A,CCR5
3,12411445,ccr5_human,89,Y,S,CCL8_HUMAN,UniProt entry code,P80075,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.88,-1.949,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
215,12411445,ccr5_human,89,Y,S,CCL4_HUMAN,UniProt entry code,P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,8.75,M,=,,8.62,1.349,,,[125I]-CCL5,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
267,12411445,ccr5_human,89,Y,S,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.64,M,=,,9.31,2.138,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
295,12411445,ccr5_human,89,Y,S,CCL4_HUMAN,UniProt entry code,P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.63,-1.096,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
345,12411445,ccr5_human,89,Y,S,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.13,M,=,,9.29,-1.445,,,[125I]-CCL5,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
689,12411445,ccr5_human,89,Y,S,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.42,M,=,,9.56,-1.381,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.33663,YA89S,CCR5
9,18096812,ccr5_human,248,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,20.0,1.429,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
179,18096812,ccr5_human,248,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,13.0,1.444,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
272,18096812,ccr5_human,248,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,7.0,-1.429,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
310,24628038,ccr5_human,248,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,3.1,-1.193,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
317,18096812,ccr5_human,248,W,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,4.0,-4.255,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
351,21775441,ccr5_human,248,W,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,<,,10.0,10.0,,,[125I]-CCL3,3.6,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
377,18096812,ccr5_human,248,W,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,28.0,7.0,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
399,18590744,ccr5_human,248,W,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
400,24628038,ccr5_human,248,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,0.51,-2.551,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
440,18590744,ccr5_human,248,W,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,43.4,31.0,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
712,24628038,ccr5_human,248,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,5.1,-1.393,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
794,18590744/16476734,ccr5_human,248,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,29.8,8.278,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
817,18096812,ccr5_human,248,W,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.6,1.0,,,[125I]-CCL5,98.7,0.0,,0.0,,P51681,3.61734,WA248A,CCR5
10,24628038,ccr5_human,198,I,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,17.0,13.077,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
217,18096812,ccr5_human,198,I,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,932.0,54.824,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
299,21775441,ccr5_human,198,I,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,131.0,,,[125I]-CCL3,124.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
304,18590744,ccr5_human,198,I,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
311,24628038,ccr5_human,198,I,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,109.0,29.459,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
361,18096812,ccr5_human,198,I,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.4,-1.499,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
393,18590744,ccr5_human,198,I,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,9.8,7.0,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
441,18096812,ccr5_human,198,I,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,350.0,25.0,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
471,18590744/16476734,ccr5_human,198,I,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,24.6,6.833,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
509,24628038,ccr5_human,198,I,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,14.5,2.042,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
662,18096812,ccr5_human,198,I,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,810.0,90.0,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
765,18096812,ccr5_human,198,I,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,26.0,6.5,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
788,18096812,ccr5_human,198,I,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,354.0,35.4,,,[125I]-CCL5,78.1,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
814,21775441,ccr5_human,198,I,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,130.0,-1.3,,,[125I]-CCL3,124.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
870,16476734,ccr5_human,198,I,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,52.4,3.275,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
879,16476734,ccr5_human,198,I,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,54.9,1.818,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,2.09616,IA198A,CCR5
11,24628038,ccr5_human,86,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,4400.0,619.718,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
12,18096812,ccr5_human,86,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,90.0,10.0,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
91,18096812,ccr5_human,86,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,387.0,38.7,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
102,18096812,ccr5_human,86,W,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,211.0,52.75,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
374,24628038,ccr5_human,86,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,1150.0,310.811,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
549,18096812,ccr5_human,86,W,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,3.0,5.0,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
571,18096812,ccr5_human,86,W,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,30.0,1.765,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
609,18096812,ccr5_human,86,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,91.0,6.5,,,[125I]-CCL5,55.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
709,24628038,ccr5_human,86,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,16.0,12.308,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
891,21775441,ccr5_human,86,W,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,40.0,2.5,,,[125I]-CCL3,117.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
930,21775441,ccr5_human,86,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,42.9,,,[125I]-CCL3,117.0,0.0,,0.0,,P51681,2.25239,WA86A,CCR5
13,18590744/16476734,ccr5_human,197,K,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,10.7,2.972,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.4464,KA197A,CCR5
124,18590744,ccr5_human,197,K,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,7.6,5.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.4464,KA197A,CCR5
359,16476734,ccr5_human,197,K,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,14.7,-2.053,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,1.4464,KA197A,CCR5
778,16476734,ccr5_human,197,K,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,16.8,1.05,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,1.4464,KA197A,CCR5
881,18590744,ccr5_human,197,K,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,58.3,3.491,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.4464,KA197A,CCR5
14,18096812,ccr5_human,283,E,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,43.0,10.75,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
125,24628038,ccr5_human,283,E,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,18000.0,13846.154,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
355,18590744,ccr5_human,283,E,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
380,18096812,ccr5_human,283,E,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,18400.0,2044.444,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
453,18096812,ccr5_human,283,E,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,13.0,21.667,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
487,18590744/16476734,ccr5_human,283,E,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,200.0,55.556,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
543,18096812,ccr5_human,283,E,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,9800.0,700.0,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
601,24628038,ccr5_human,283,E,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,603.0,162.973,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
638,18096812,ccr5_human,283,E,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,603.0,60.3,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
664,18590744,ccr5_human,283,E,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,19.1,13.643,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
676,21775441,ccr5_human,283,E,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,>,,0.0,10.0,,,[125I]-CCL3,70.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
823,24628038,ccr5_human,283,E,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,98000.0,13802.817,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
884,16476734,ccr5_human,283,E,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,200.0,6.623,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
886,18096812,ccr5_human,283,E,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,11000.0,647.059,,,[125I]-CCL5,87.5,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
904,21775441,ccr5_human,283,E,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,21.0,4.762,,,[125I]-CCL3,70.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
946,16476734,ccr5_human,283,E,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,200.0,12.5,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.577064,EA283A,CCR5
17,12411445,ccr5_human,109,F,H,CCL4_HUMAN,UniProt entry code,P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.89,-1.996,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
167,21775441,ccr5_human,109,F,H,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.5,,,[125I]-CCL3,106.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
194,12411445,ccr5_human,109,F,H,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.42,M,=,,9.67,-1.779,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
255,21775441,ccr5_human,109,F,H,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,179.0,-1.789,,,[125I]-CCL3,106.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
289,12411445,ccr5_human,109,F,H,CCL8_HUMAN,UniProt entry code,P80075,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.74,-1.412,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
878,12411445,ccr5_human,109,F,H,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.64,M,=,,9.55,1.23,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,1.20207,FA109H,CCR5
23,16476734,ccr5_human,113,F,Y,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,45.3,2.831,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.362227,FA113Y,CCR5
82,18590744,ccr5_human,113,F,Y,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,48.2,2.886,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.362227,FA113Y,CCR5
287,16476734,ccr5_human,113,F,Y,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,32.4,1.073,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.362227,FA113Y,CCR5
306,18590744/16476734,ccr5_human,113,F,Y,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,12.9,3.583,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.362227,FA113Y,CCR5
704,18590744,ccr5_human,113,F,Y,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,2.8,2.0,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.362227,FA113Y,CCR5
24,21775441,ccr5_human,104,L,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.111,,,[125I]-CCL3,131.0,0.0,,0.0,,P51681,2.70461,LA104A,CCR5
212,21775441,ccr5_human,104,L,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,81.0,1.235,,,[125I]-CCL3,131.0,0.0,,0.0,,P51681,2.70461,LA104A,CCR5
367,21775441,ccr5_human,104,L,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.07,,,[3H]-Maraviroc,131.0,0.0,,0.0,,P51681,2.70461,LA104A,CCR5
29,18590744,ccr5_human,178,C,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
163,18590744/16476734,ccr5_human,178,C,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,200.0,55.556,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
170,18590744,ccr5_human,178,C,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
181,16476734,ccr5_human,178,C,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,34.5,1.142,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
222,21775441,ccr5_human,178,C,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,<,,10.0,10.0,,,[125I]-CCL3,0.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
352,16476734,ccr5_human,178,C,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,27.1,1.694,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,4.81499,CA178A,CCR5
33,18096812,ccr5_human,109,F,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,6.0,10.0,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
50,18590744,ccr5_human,109,F,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
67,18096812,ccr5_human,109,F,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,26.0,1.857,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
103,24628038,ccr5_human,109,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,0.66,-1.969,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
276,24628038,ccr5_human,109,F,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,40.0,5.634,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
312,24628038,ccr5_human,109,F,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,>,,10000.0,2702.703,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
417,21775441,ccr5_human,109,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.43,,,[3H]-Maraviroc,91.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
422,21775441,ccr5_human,109,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.4,,,[125I]-CCL3,91.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
491,18096812,ccr5_human,109,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,7.9,-1.139,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
570,18590744,ccr5_human,109,F,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
603,21775441,ccr5_human,109,F,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,159.0,-1.59,,,[125I]-CCL3,91.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
667,18096812,ccr5_human,109,F,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,1577.0,157.7,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
668,18590744/16476734,ccr5_human,109,F,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,100.0,27.778,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
714,18096812,ccr5_human,109,F,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,5.0,-3.401,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
729,18096812,ccr5_human,109,F,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,9.0,2.25,,,[125I]-CCL5,59.8,0.0,,0.0,,P51681,1.86746,FA109A,CCR5
38,21775441,ccr5_human,145,G,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,103.0,-1.03,,,[125I]-CCL3,137.0,0.0,,0.0,,P51681,-1.68984,GA145A,CCR5
406,21775441,ccr5_human,145,G,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.667,,,[3H]-Maraviroc,145.0,0.0,,0.0,,P51681,-1.68984,GA145A,CCR5
654,21775441,ccr5_human,145,G,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.3,,,[125I]-CCL3,137.0,0.0,,0.0,,P51681,-1.68984,GA145A,CCR5
46,18096812,ccr5_human,287,M,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,29.0,1.706,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
77,24628038,ccr5_human,287,M,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,4.5,1.216,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
152,18590744/16476734,ccr5_human,287,M,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,6.8,1.889,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
293,24628038,ccr5_human,287,M,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,0.56,-2.32,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
486,18590744,ccr5_human,287,M,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,16.1,-1.037,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
626,18096812,ccr5_human,287,M,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,5.0,1.25,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
695,18096812,ccr5_human,287,M,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,66.0,6.6,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
703,18096812,ccr5_human,287,M,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,3.3,-2.725,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
711,18096812,ccr5_human,287,M,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,55.0,3.929,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
754,18590744,ccr5_human,287,M,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,2.4,1.714,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
775,16476734,ccr5_human,287,M,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,39.8,1.318,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
876,24628038,ccr5_human,287,M,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,60.0,8.451,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
883,16476734,ccr5_human,287,M,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,28.0,1.75,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
937,18096812,ccr5_human,287,M,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,1.0,1.667,,,[125I]-CCL5,112.2,0.0,,0.0,,P51681,2.88939,MA287A,CCR5
54,10602038,ccr5_human,167,T,W,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,IC50,Binding - Radioligand competition/displacement,0.67,nM,=,,2.49,3.716,,,[125I]-CCL4,85.04672897,0.0,,0.0,,P51681,1.72034,TA167W,CCR5
62,18590744/16476734,ccr5_human,195,T,P,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,100.0,27.778,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,4.44933,TA195P,CCR5
300,18590744,ccr5_human,195,T,P,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,4.44933,TA195P,CCR5
925,18590744,ccr5_human,195,T,P,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,4.44933,TA195P,CCR5
64,18096812,ccr5_human,94,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,33.0,3.3,,,[125I]-CCL5,119.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
146,18096812,ccr5_human,94,W,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,24.0,1.412,,,[125I]-CCL5,119.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
192,21775441,ccr5_human,94,W,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,<,,10.0,10.0,,,[125I]-CCL3,140.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
375,21775441,ccr5_human,94,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.266,,,[3H]-Maraviroc,140.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
559,24628038,ccr5_human,94,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,0.6,-2.165,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
614,24628038,ccr5_human,94,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,3.5,-2.028,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
641,18096812,ccr5_human,94,W,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,11.0,2.75,,,[125I]-CCL5,119.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
857,18096812,ccr5_human,94,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,10.0,1.111,,,[125I]-CCL5,119.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
920,18096812,ccr5_human,94,W,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,30.0,2.143,,,[125I]-CCL5,119.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
936,24628038,ccr5_human,94,W,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,100.0,27.027,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,5.49344,WA94A,CCR5
65,16920949,ccr5_human,9,I,T,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,2.7,1.0,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.149631,IA9T,CCR5
813,16920949,ccr5_human,9,I,T,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,240.0,1.2,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.149631,IA9T,CCR5
916,16920949,ccr5_human,9,I,T,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,18.0,-2.667,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.149631,IA9T,CCR5
69,16920949,ccr5_human,171,K,R,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,42.0,-1.143,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.013018,KA171R,CCR5
246,16920949,ccr5_human,171,K,R,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,4.6,1.704,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.013018,KA171R,CCR5
532,16920949,ccr5_human,171,K,R,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,190.0,-1.053,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.013018,KA171R,CCR5
75,18590744,ccr5_human,84,P,H,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.31916,PA84H,CCR5
546,18590744/16476734,ccr5_human,84,P,H,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,100.0,27.778,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.31916,PA84H,CCR5
833,18590744,ccr5_human,84,P,H,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,37.3,26.643,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.31916,PA84H,CCR5
88,16920949,ccr5_human,130,V,I,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,220.0,1.1,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.107642,VA130I,CCR5
257,16920949,ccr5_human,130,V,I,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,12.0,-4.0,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.107642,VA130I,CCR5
875,16920949,ccr5_human,130,V,I,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,3.2,1.185,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.107642,VA130I,CCR5
99,18096812,ccr5_human,195,T,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,122.0,12.2,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
122,24628038,ccr5_human,195,T,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,11.0,1.549,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
335,18096812,ccr5_human,195,T,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,5.0,-3.401,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
382,18096812,ccr5_human,195,T,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.7,1.167,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
425,18590744/16476734,ccr5_human,195,T,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,48.1,13.361,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
459,18096812,ccr5_human,195,T,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,22.0,1.571,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
757,18096812,ccr5_human,195,T,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,20.0,5.0,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
809,18590744,ccr5_human,195,T,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,14.7,-1.136,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
820,18590744,ccr5_human,195,T,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,5.6,4.0,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
839,24628038,ccr5_human,195,T,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,4.5,1.216,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
887,24628038,ccr5_human,195,T,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,2.1,1.615,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
941,18096812,ccr5_human,195,T,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,14.0,1.556,,,[125I]-CCL5,71.1,0.0,,0.0,,P51681,1.11665,TA195A,CCR5
100,21775441,ccr5_human,258,N,M,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.27,,,[3H]-Maraviroc,85.0,0.0,,0.0,,P51681,-2.26795,NA258M,CCR5
366,21775441,ccr5_human,258,N,M,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.429,,,[125I]-CCL3,85.0,0.0,,0.0,,P51681,-2.26795,NA258M,CCR5
551,21775441,ccr5_human,258,N,M,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,71.0,1.408,,,[125I]-CCL3,85.0,0.0,,0.0,,P51681,-2.26795,NA258M,CCR5
104,21775441,ccr5_human,283,E,Q,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,>,,0.0,10.0,,,[125I]-CCL3,92.0,0.0,,0.0,,P51681,0.709892,EA283Q,CCR5
472,21775441,ccr5_human,283,E,Q,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,33.0,3.03,,,[125I]-CCL3,92.0,0.0,,0.0,,P51681,0.709892,EA283Q,CCR5
105,18096812,ccr5_human,251,Y,A,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.2,-3.003,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
109,16476734,ccr5_human,251,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,43.0,1.424,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
110,18590744,ccr5_human,251,Y,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
155,24628038,ccr5_human,251,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,1.1,-3.367,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
235,24628038,ccr5_human,251,Y,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,2.9,-2.451,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
244,16476734,ccr5_human,251,Y,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,21.5,1.344,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
274,18096812,ccr5_human,251,Y,A,TAK-220,ChEMBL Compound ID,CHEMBL207004,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,17.0,nM,=,,11.0,-1.546,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
357,18096812,ccr5_human,251,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,9.0,nM,=,,113.0,12.556,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
492,21775441,ccr5_human,251,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,7.7,,,[125I]-CCL3,10.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
522,18096812,ccr5_human,251,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,10.0,nM,=,,25.0,2.5,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
583,18590744/16476734,ccr5_human,251,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,36.5,10.139,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
661,21775441,ccr5_human,251,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,13.0,7.692,,,[125I]-CCL3,10.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
780,18096812,ccr5_human,251,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,11.0,2.75,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
816,24628038,ccr5_human,251,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,3.9,3.0,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
848,18096812,ccr5_human,251,Y,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,14.0,nM,=,,255.0,18.214,,,[125I]-CCL5,63.7,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
874,18590744,ccr5_human,251,Y,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.86966,YA251A,CCR5
114,21775441,ccr5_human,280,Q,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.1,,,[125I]-CCL3,106.0,0.0,,0.0,,P51681,0.206211,QA280A,CCR5
132,21775441,ccr5_human,280,Q,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.351,,,[3H]-Maraviroc,106.0,0.0,,0.0,,P51681,0.206211,QA280A,CCR5
552,21775441,ccr5_human,280,Q,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,84.0,1.19,,,[125I]-CCL3,106.0,0.0,,0.0,,P51681,0.206211,QA280A,CCR5
117,10574939,ccr5_human,4,Q,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.18,1.288,,,[125I]-CCL4,116.7630058,0.0,,0.0,,P51681,0.283922,QA4A,CCR5
118,21775441,ccr5_human,251,Y,F,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,3.3,,,[125I]-CCL3,68.0,0.0,,0.0,,P51681,-0.445637,YA251F,CCR5
806,21775441,ccr5_human,251,Y,F,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,88.0,1.136,,,[125I]-CCL3,68.0,0.0,,0.0,,P51681,-0.445637,YA251F,CCR5
126,21775441,ccr5_human,180,S,P,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,58.0,1.724,,,[125I]-CCL3,85.0,0.0,,0.0,,P51681,-0.472251,SA180P,CCR5
673,21775441,ccr5_human,180,S,P,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.111,,,[125I]-CCL3,85.0,0.0,,0.0,,P51681,-0.472251,SA180P,CCR5
750,21775441,ccr5_human,180,S,P,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.786,,,[3H]-Maraviroc,85.0,0.0,,0.0,,P51681,-0.472251,SA180P,CCR5
127,16476734,ccr5_human,112,F,Y,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,35.8,2.237,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
142,21775441,ccr5_human,112,F,Y,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,104.0,-1.04,,,[125I]-CCL3,125.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
318,18590744,ccr5_human,112,F,Y,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,21.1,1.263,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
489,18590744,ccr5_human,112,F,Y,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,5.2,3.714,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
681,16476734,ccr5_human,112,F,Y,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,28.5,-1.059,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
715,21775441,ccr5_human,112,F,Y,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.1,,,[125I]-CCL3,125.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
811,18590744/16476734,ccr5_human,112,F,Y,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,6.8,1.889,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
912,12411445,ccr5_human,112,F,Y,CCL4_HUMAN,UniProt entry code,P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.59,M,=,,9.76,-1.479,,,[125I]-CCL4,80.0,0.0,,0.0,,P51681,0.0065512,FA112Y,CCR5
128,18590744,ccr5_human,287,M,E,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,62.7,44.786,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.47375,MA287E,CCR5
207,16476734,ccr5_human,287,M,E,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,32.2,2.013,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,3.47375,MA287E,CCR5
416,18590744,ccr5_human,287,M,E,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,87.1,5.216,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.47375,MA287E,CCR5
584,18590744/16476734,ccr5_human,287,M,E,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,14.8,4.111,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.47375,MA287E,CCR5
608,16476734,ccr5_human,287,M,E,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,53.1,1.758,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,3.47375,MA287E,CCR5
129,21775441,ccr5_human,184,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,33.0,3.03,,,[125I]-CCL3,160.0,0.0,,0.0,,P51681,-0.0819845,YA184A,CCR5
390,21775441,ccr5_human,184,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,2.1,,,[125I]-CCL3,160.0,0.0,,0.0,,P51681,-0.0819845,YA184A,CCR5
143,18590744/16476734,ccr5_human,188,Q,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,6.6,1.833,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.406764,QA188A,CCR5
598,16476734,ccr5_human,188,Q,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,23.8,1.488,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.406764,QA188A,CCR5
660,18590744,ccr5_human,188,Q,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,1.9,1.357,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.406764,QA188A,CCR5
802,16476734,ccr5_human,188,Q,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,37.9,1.255,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.406764,QA188A,CCR5
863,18590744,ccr5_human,188,Q,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,14.6,-1.144,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.406764,QA188A,CCR5
154,18590744,ccr5_human,191,K,R,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,22.2,1.329,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,-0.702933,KA191R,CCR5
308,18590744,ccr5_human,191,K,R,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,5.2,3.714,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,-0.702933,KA191R,CCR5
713,16476734,ccr5_human,191,K,R,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,34.1,2.131,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,-0.702933,KA191R,CCR5
773,18590744/16476734,ccr5_human,191,K,R,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,9.0,2.5,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,-0.702933,KA191R,CCR5
819,16476734,ccr5_human,191,K,R,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,47.1,1.56,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,-0.702933,KA191R,CCR5
177,21775441,ccr5_human,37,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.25,,,[3H]-Maraviroc,115.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
392,16476734,ccr5_human,37,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,98.9,3.275,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
402,18590744,ccr5_human,37,Y,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
554,18590744/16476734,ccr5_human,37,Y,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,12.8,3.556,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
572,21775441,ccr5_human,37,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,14.0,7.143,,,[125I]-CCL3,115.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
644,16476734,ccr5_human,37,Y,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,200.0,12.5,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
666,18590744,ccr5_human,37,Y,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
726,21775441,ccr5_human,37,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,2.2,,,[125I]-CCL3,115.0,0.0,,0.0,,P51681,3.37105,YA37A,CCR5
205,21775441,ccr5_human,260,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.25,,,[125I]-CCL3,40.0,0.0,,0.0,,P51681,2.04234,FA260A,CCR5
389,21775441,ccr5_human,260,F,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,46.0,2.174,,,[125I]-CCL3,40.0,0.0,,0.0,,P51681,2.04234,FA260A,CCR5
208,16476734,ccr5_human,168,R,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,43.0,1.424,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
369,18590744/16476734,ccr5_human,168,R,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,14.1,3.917,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
373,21775441,ccr5_human,168,R,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.3,,,[125I]-CCL3,77.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
548,18590744,ccr5_human,168,R,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,2.2,1.571,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
732,21775441,ccr5_human,168,R,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,47.0,2.128,,,[125I]-CCL3,77.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
797,16476734,ccr5_human,168,R,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,21.0,1.312,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
860,18590744,ccr5_human,168,R,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,24.6,1.473,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,2.07889,RA168A,CCR5
223,16476734,ccr5_human,113,F,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,43.8,2.737,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,3.99638,FA113A,CCR5
596,18590744,ccr5_human,113,F,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,2.4,1.714,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.99638,FA113A,CCR5
637,16476734,ccr5_human,113,F,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,32.7,1.083,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,3.99638,FA113A,CCR5
655,18590744/16476734,ccr5_human,113,F,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,13.3,3.694,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.99638,FA113A,CCR5
658,18590744,ccr5_human,113,F,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,43.3,2.593,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.99638,FA113A,CCR5
229,16476734,ccr5_human,163,G,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,24.0,-1.258,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,-0.510569,GA163A,CCR5
320,18590744/16476734,ccr5_human,163,G,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,8.0,2.222,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,-0.510569,GA163A,CCR5
343,18590744,ccr5_human,163,G,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,14.7,-1.136,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,-0.510569,GA163A,CCR5
485,18590744,ccr5_human,163,G,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,5.9,4.214,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,-0.510569,GA163A,CCR5
804,16476734,ccr5_human,163,G,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,25.0,1.562,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,-0.510569,GA163A,CCR5
233,21775441,ccr5_human,100,M,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.0,,,[125I]-CCL3,114.0,0.0,,0.0,,P51681,2.06086,MA100A,CCR5
520,21775441,ccr5_human,100,M,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,95.0,1.053,,,[125I]-CCL3,114.0,0.0,,0.0,,P51681,2.06086,MA100A,CCR5
237,16476734,ccr5_human,180,S,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,18.2,-1.658,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
245,21775441,ccr5_human,180,S,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,85.0,1.176,,,[125I]-CCL3,124.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
277,18590744,ccr5_human,180,S,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,34.5,2.066,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
675,21775441,ccr5_human,180,S,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.111,,,[125I]-CCL3,124.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
705,21775441,ccr5_human,180,S,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.1,,,[3H]-Maraviroc,124.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
748,18590744,ccr5_human,180,S,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,7.4,5.286,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
779,18590744/16476734,ccr5_human,180,S,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,5.7,1.583,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
908,16476734,ccr5_human,180,S,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,31.8,1.988,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
910,24628038,ccr5_human,180,S,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,3.0,2.308,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,0.0517085,SA180A,CCR5
239,10574939,ccr5_human,7,S,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.44,-1.412,,,[125I]-CCL4,84.20038536,0.0,,0.0,,P51681,-0.143673,SA7A,CCR5
253,10574939,ccr5_human,9,I,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.56,-1.862,,,[125I]-CCL4,95.37572254,0.0,,0.0,,P51681,-0.205721,IA9A,CCR5
254,21775441,ccr5_human,100,M,T,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.3,,,[125I]-CCL3,79.0,0.0,,0.0,,P51681,3.03411,MA100T,CCR5
617,21775441,ccr5_human,100,M,T,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-1.587,,,[3H]-Maraviroc,79.0,0.0,,0.0,,P51681,3.03411,MA100T,CCR5
859,21775441,ccr5_human,100,M,T,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,42.0,2.381,,,[125I]-CCL3,79.0,0.0,,0.0,,P51681,3.03411,MA100T,CCR5
256,21775441,ccr5_human,255,L,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.111,,,[125I]-CCL3,39.0,0.0,,0.0,,P51681,2.11469,LA255A,CCR5
749,21775441,ccr5_human,255,L,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,49.0,2.041,,,[125I]-CCL3,39.0,0.0,,0.0,,P51681,2.11469,LA255A,CCR5
830,21775441,ccr5_human,255,L,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,2.3,,,[3H]-Maraviroc,39.0,0.0,,0.0,,P51681,2.11469,LA255A,CCR5
278,16476734,ccr5_human,11,D,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,12.4,-1.29,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,-0.0210338,DA11A,CCR5
558,18590744/16476734,ccr5_human,11,D,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,3.0,-1.2,,,[3H]-Aplaviroc,0.0,0.0,,0.0,,P51681,-0.0210338,DA11A,CCR5
624,16476734,ccr5_human,11,D,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,24.5,-1.233,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,-0.0210338,DA11A,CCR5
635,18590744,ccr5_human,11,D,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,1.1,-1.272,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,-0.0210338,DA11A,CCR5
693,18590744,ccr5_human,11,D,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,14.6,-1.144,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,-0.0210338,DA11A,CCR5
280,24628038,ccr5_human,177,T,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,3.7,2.846,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,0.793232,TA177A,CCR5
457,21775441,ccr5_human,177,T,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.7,,,[3H]-Maraviroc,92.0,0.0,,0.0,,P51681,0.793232,TA177A,CCR5
462,21775441,ccr5_human,177,T,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.4,,,[125I]-CCL3,92.0,0.0,,0.0,,P51681,0.793232,TA177A,CCR5
547,21775441,ccr5_human,177,T,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,13.0,7.692,,,[125I]-CCL3,92.0,0.0,,0.0,,P51681,0.793232,TA177A,CCR5
284,16476734,ccr5_human,191,K,A,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,26.5,1.656,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,1.10392,KA191A,CCR5
398,18590744/16476734,ccr5_human,191,K,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,200.0,55.556,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,1.10392,KA191A,CCR5
636,18590744,ccr5_human,191,K,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,6.0,4.286,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,1.10392,KA191A,CCR5
803,18590744,ccr5_human,191,K,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,1.10392,KA191A,CCR5
909,16476734,ccr5_human,191,K,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,35.0,1.159,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,1.10392,KA191A,CCR5
290,16920949,ccr5_human,52,I,V,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,24.0,-2.0,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.972609,IA52V,CCR5
772,16920949,ccr5_human,52,I,V,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,200.0,1.0,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.972609,IA52V,CCR5
861,16920949,ccr5_human,52,I,V,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,2.1,-1.285,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.972609,IA52V,CCR5
307,21775441,ccr5_human,194,Q,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-1.667,,,[125I]-CCL3,105.0,0.0,,0.0,,P51681,0.433495,QA194A,CCR5
401,21775441,ccr5_human,194,Q,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,84.0,1.19,,,[125I]-CCL3,105.0,0.0,,0.0,,P51681,0.433495,QA194A,CCR5
656,21775441,ccr5_human,194,Q,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-2.326,,,[3H]-Maraviroc,105.0,0.0,,0.0,,P51681,0.433495,QA194A,CCR5
309,16920949,ccr5_human,13,N,D,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,4.1,1.519,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.307854,NA13D,CCR5
536,16920949,ccr5_human,13,N,D,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,210.0,1.05,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.307854,NA13D,CCR5
602,16920949,ccr5_human,13,N,D,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,52.0,1.083,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,0.307854,NA13D,CCR5
321,24628038,ccr5_human,199,V,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.3,nM,=,,4.0,3.077,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.01247,VA199A,CCR5
725,24628038,ccr5_human,199,V,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.7,nM,=,,19.0,5.135,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.01247,VA199A,CCR5
850,24628038,ccr5_human,199,V,A,Vicriviroc,ChEMBL Compound ID,CHEMBL82301,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,7.1,nM,=,,23.0,3.239,,,[3H]-Maraviroc,100.0,0.0,,0.0,,P51681,1.01247,VA199A,CCR5
323,16476734,ccr5_human,180,S,T,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,30.2,nM,=,,41.0,1.358,,,[3H]-TAK-779,100.0,0.0,,0.0,,P51681,0.109235,SA180T,CCR5
445,18590744,ccr5_human,180,S,T,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,=,,14.9,-1.121,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,0.109235,SA180T,CCR5
496,16476734,ccr5_human,180,S,T,Ancriviroc,ChEMBL Compound ID,CHEMBL78535,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.0,nM,=,,25.4,1.587,,,[3H]-Ancriviroc,100.0,0.0,,0.0,,P51681,0.109235,SA180T,CCR5
503,18590744/16476734,ccr5_human,180,S,T,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,=,,1.5,-2.398,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,0.109235,SA180T,CCR5
945,18590744,ccr5_human,180,S,T,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,=,,1.4,1.0,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,0.109235,SA180T,CCR5
328,21775441,ccr5_human,252,N,I,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,-2.273,,,[3H]-Maraviroc,141.0,0.0,,0.0,,P51681,-2.60098,NA252I,CCR5
468,21775441,ccr5_human,252,N,I,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,16.0,6.25,,,[125I]-CCL3,141.0,0.0,,0.0,,P51681,-2.60098,NA252I,CCR5
822,21775441,ccr5_human,252,N,I,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.2,,,[125I]-CCL3,141.0,0.0,,0.0,,P51681,-2.60098,NA252I,CCR5
341,18590744,ccr5_human,195,T,S,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,2.23849,TA195S,CCR5
574,18590744,ccr5_human,195,T,S,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,2.23849,TA195S,CCR5
745,18590744/16476734,ccr5_human,195,T,S,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,100.0,27.778,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,2.23849,TA195S,CCR5
348,16920949,ccr5_human,198,I,M,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,K(i),Binding - Radioligand competition/displacement,200.0,pM,=,,220.0,1.1,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.104571,IA198M,CCR5
419,16920949,ccr5_human,198,I,M,YM-370749,SMILES,Cl/C(Cl)=C(NC=O)/[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3.O=Cl(=O)([O-])=O,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,19.0,7.037,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.104571,IA198M,CCR5
815,16920949,ccr5_human,198,I,M,CCL5_HUMAN,UniProt entry code,P13501,Full agonist,K(i),Binding - Radioligand competition/displacement,48.0,pM,=,,49.0,1.021,,,[125I]-CCL3,100.0,0.0,,0.0,,P51681,-0.104571,IA198M,CCR5
370,10574939,ccr5_human,6,S,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.66,-2.342,,,[125I]-CCL4,62.04238921,0.0,,0.0,,P51681,-0.0686118,SA6A,CCR5
371,21775441,ccr5_human,187,Y,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.19,,,[3H]-Maraviroc,88.0,0.0,,0.0,,P51681,0.562648,YA187A,CCR5
518,21775441,ccr5_human,187,Y,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,<,,10.0,10.0,,,[125I]-CCL3,88.0,0.0,,0.0,,P51681,0.562648,YA187A,CCR5
420,10602038,ccr5_human,180,S,V,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,IC50,Binding - Radioligand competition/displacement,0.67,nM,=,,2.7,4.03,,,[125I]-CCL4,88.78504673,0.0,,0.0,,P51681,-0.0584891,SA180V,CCR5
429,10602038,ccr5_human,31,R,G,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,IC50,Binding - Radioligand competition/displacement,0.67,nM,=,,8.33,12.433,,,[125I]-CCL4,93.45794393,0.0,,0.0,,P51681,0.564955,RA31G,CCR5
450,21775441,ccr5_human,251,Y,I,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,19.9,,,[125I]-CCL3,4.8,0.0,,0.0,,P51681,2.2194,YA251I,CCR5
538,21775441,ccr5_human,251,Y,I,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,14.0,7.143,,,[125I]-CCL3,4.8,0.0,,0.0,,P51681,2.2194,YA251I,CCR5
507,18590744,ccr5_human,101,C,A,AK530,SMILES,O=C([C@@H]1[C@@H](O)C2CCCCC2)N(CC#CC)C3(CCN(CC4=C(C)N(C5=CC=CC=C5)N=C4C)CC3)C(N1)=O,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,1.4,nM,>,,100.0,71.429,,,[3H]-AK530,100.0,0.0,,0.0,,P51681,3.78172,CA101A,CCR5
710,18590744,ccr5_human,101,C,A,AK317,ChEMBL Compound ID,CHEMBL1170878,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,16.7,nM,>,,100.0,5.988,,,[3H]-AK317,100.0,0.0,,0.0,,P51681,3.78172,CA101A,CCR5
942,18590744/16476734,ccr5_human,101,C,A,Aplaviroc,ChEMBL Compound ID,CHEMBL1255794,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,3.6,nM,>,,100.0,27.778,,,[3H]-Aplaviroc,100.0,0.0,,0.0,,P51681,3.78172,CA101A,CCR5
537,21775441,ccr5_human,190,W,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,16.0,6.25,,,[125I]-CCL3,22.0,0.0,,0.0,,P51681,2.60878,WA190A,CCR5
588,21775441,ccr5_human,190,W,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.6,,,[125I]-CCL3,22.0,0.0,,0.0,,P51681,2.60878,WA190A,CCR5
678,10574939,ccr5_human,5,V,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.49,-1.585,,,[125I]-CCL4,88.63198459,0.0,,0.0,,P51681,-0.284497,VA5A,CCR5
686,21775441,ccr5_human,94,W,M,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,<,,10.0,10.0,,,[125I]-CCL3,103.0,0.0,,0.0,,P51681,3.03392,WA94M,CCR5
771,21775441,ccr5_human,94,W,M,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),K(d),Binding - Radioligand kinetics (association/dissociation),0.69,nM,=,,0.0,1.18,,,[3H]-Maraviroc,103.0,0.0,,0.0,,P51681,3.03392,WA94M,CCR5
690,10574939,ccr5_human,8,P,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.27,1.047,,,[125I]-CCL4,76.10789981,0.0,,0.0,,P51681,0.191403,PA8A,CCR5
723,10602038,ccr5_human,6,S,P,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,IC50,Binding - Radioligand competition/displacement,0.67,nM,=,,2.71,4.045,,,[125I]-CCL4,110.2803738,0.0,,0.0,,P51681,0.188599,SA6P,CCR5
790,10574939,ccr5_human,12,I,A,CCL4_HUMAN,UniProt Entry Code (peptide),P13236,Full agonist,pIC50,Binding - Radioligand competition/displacement,9.29,M,=,,9.35,-1.148,,,[125I]-CCL4,94.02697495,0.0,,0.0,,P51681,-0.457747,IA12A,CCR5
853,21775441,ccr5_human,189,F,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,71.0,1.408,,,[125I]-CCL3,57.0,0.0,,0.0,,P51681,1.3087,FA189A,CCR5
911,21775441,ccr5_human,189,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,1.5,,,[125I]-CCL3,57.0,0.0,,0.0,,P51681,1.3087,FA189A,CCR5
917,21775441,ccr5_human,112,F,A,CCL3_HUMAN,UniProt entry code,P10147,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,23.0,4.348,,,[125I]-CCL3,21.0,0.0,,0.0,,P51681,3.11852,FA112A,CCR5
923,21775441,ccr5_human,112,F,A,Maraviroc,ChEMBL Compound ID,CHEMBL1201187,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,1.05,nM,=,,0.0,-2.5,,,[125I]-CCL3,21.0,0.0,,0.0,,P51681,3.11852,FA112A,CCR5
0,20434910,5ht6r_human,196,T,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.2,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.776343,TA196A,HTR6
20,20434910,5ht6r_human,196,T,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,10.1,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.776343,TA196A,HTR6
22,20434910,5ht6r_human,196,T,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,10.3,-1.585,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.776343,TA196A,HTR6
31,20434910,5ht6r_human,196,T,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,10.4,-3.165,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.776343,TA196A,HTR6
38,20434910,5ht6r_human,196,T,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.9,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.776343,TA196A,HTR6
1,20434910,5ht6r_human,110,C,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,10.3,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.217598,CA110A,HTR6
6,20434910,5ht6r_human,110,C,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,10.0,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.217598,CA110A,HTR6
17,20434910,5ht6r_human,110,C,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,10.4,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.217598,CA110A,HTR6
25,20434910,5ht6r_human,110,C,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.9,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.217598,CA110A,HTR6
40,20434910,5ht6r_human,110,C,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.2,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P50406,0.217598,CA110A,HTR6
2,20434910,5ht6r_human,284,F,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,9.2,5.012,,,[3H]LSD,0.0,0.0,,0.0,,P50406,2.2472,FA284A,HTR6
13,20434910,5ht6r_human,284,F,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,8.0,31.623,,,[3H]LSD,0.0,0.0,,0.0,,P50406,2.2472,FA284A,HTR6
16,20434910,5ht6r_human,284,F,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,8.2,31.623,,,[3H]LSD,0.0,0.0,,0.0,,P50406,2.2472,FA284A,HTR6
18,20434910,5ht6r_human,284,F,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.1,50.119,,,[3H]LSD,0.0,0.0,,0.0,,P50406,2.2472,FA284A,HTR6
30,20434910,5ht6r_human,284,F,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,8.9,15.849,,,[3H]LSD,0.0,0.0,,0.0,,P50406,2.2472,FA284A,HTR6
3,20434910,5ht6r_human,281,W,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,7.5,100.0,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
7,20434910,5ht6r_human,281,W,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,9.4,3.162,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
10,20434910,5ht6r_human,281,W,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,8.3,25.119,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
12,20078106,5ht6r_human,281,W,A,SB-258585,ChEMBL Compound ID,CHEMBL60264,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.75,nM,=,,0.32,-2.342,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
14,20434910,5ht6r_human,281,W,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,8.1,100.0,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
39,20434910,5ht6r_human,281,W,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.9,7.943,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.00828,WA281A,HTR6
4,20434910,5ht6r_human,106,D,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.3,31.623,,,[3H]LSD,0.0,0.0,,0.0,,P50406,1.09285,DA106A,HTR6
5,20434910,5ht6r_human,106,D,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.3,1.585,,,[3H]LSD,0.0,0.0,,0.0,,P50406,1.09285,DA106A,HTR6
21,20434910,5ht6r_human,106,D,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,9.7,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P50406,1.09285,DA106A,HTR6
26,20434910,5ht6r_human,106,D,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,9.2,5.012,,,[3H]LSD,0.0,0.0,,0.0,,P50406,1.09285,DA106A,HTR6
37,20434910,5ht6r_human,106,D,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,9.0,12.589,,,[3H]LSD,0.0,0.0,,0.0,,P50406,1.09285,DA106A,HTR6
15,20434910,5ht6r_human,193,S,A,Cmp16d,ChEMBL Compound ID,CHEMBL1086326,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.1,,=,,10.2,-1.259,,,[3H]LSD,0.0,0.0,,0.0,,P50406,-1.20132,SA193A,HTR6
19,20434910,5ht6r_human,193,S,A,Cmp16j,ChEMBL Compound ID,CHEMBL1085617,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,0.4,2511886432.0,,,[3H]LSD,0.0,0.0,,0.0,,P50406,-1.20132,SA193A,HTR6
24,20434910,5ht6r_human,193,S,A,Cmp21d,SMILES,CC(=O)NC[C@@H]1CCCc2cc(cc(F)c12)S(=O)(=O)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.1,2.512,,,[3H]LSD,0.0,0.0,,0.0,,P50406,-1.20132,SA193A,HTR6
29,20434910,5ht6r_human,193,S,A,Cmp17l,ChEMBL Compound ID,CHEMBL1082508,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,9.3,2.512,,,[3H]LSD,0.0,0.0,,0.0,,P50406,-1.20132,SA193A,HTR6
33,20434910,5ht6r_human,193,S,A,Cmp17e,ChEMBL Compound ID,CHEMBL1085037,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.9,,=,,10.0,-1.259,,,[3H]LSD,0.0,0.0,,0.0,,P50406,-1.20132,SA193A,HTR6
34,20078106,5ht6r_human,285,F,A,SB-258585,ChEMBL Compound ID,CHEMBL60264,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.75,nM,=,,114.0,152.0,,,[3H]LSD,0.0,0.0,,0.0,,P50406,3.61253,FA285A,HTR6
0,17881091,5ht5a_human,21,N,S,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,8.64,,=,,8.35,1.95,,,,0.0,0.0,,0.0,,P47898,-0.571068,NA21S,HTR5A
1,17881091,5ht5a_human,6,N,S,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,8.64,,=,,8.21,2.692,,,,0.0,0.0,,0.0,,P47898,-0.0641488,NA6S,HTR5A
10,10570038,drd2_human,411,F,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,200.0,-1.401,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.42965,FA411V,DRD2
194,10570038,drd2_human,411,F,V,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,790.0,-1.164,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.42965,FA411V,DRD2
351,10570038,drd2_human,411,F,V,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,102.0,1.291,,,,0.0,0.0,,0.0,,P14416,1.42965,FA411V,DRD2
11,7595496,drd2_human,387,L,A,Bromocriptine,ChEMBL Compound ID,CHEMBL493,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,5.9,-1.389,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
39,7595496,drd2_human,387,L,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,10.0,10.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
55,7595496,drd2_human,387,L,A,[3H]N-0437,ChEMBL Compound ID,CHEMBL1303,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.7,nM,=,,1.2,-1.416,,,,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
94,7595496,drd2_human,387,L,A,NPA,ChEMBL Compound ID,CHEMBL225230,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,34.0,1.545,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
96,7595496,drd2_human,387,L,A,Apomorphine,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,nM,=,,220.0,1.1,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
113,7595496,drd2_human,387,L,A,[3H]Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.083,nM,=,,0.085,1.024,,,,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
130,7595496,drd2_human,387,L,A,[3H]Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.98,nM,=,,0.4,-2.451,,,,0.0,0.0,,0.0,,P14416,2.0006,LA387A,DRD2
15,22416052,drd2_human,193,S,A,DHX,ChEMBL Compound ID,CHEMBL25856,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,490.0,nM,=,,7400.0,15.102,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.932462,SA193A,DRD2
158,22416052,drd2_human,193,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,µM,=,,80.0,177.778,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.932462,SA193A,DRD2
198,22416052,drd2_human,193,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,365.0,nM,=,,1040.0,2.849,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.932462,SA193A,DRD2
268,22416052,drd2_human,193,S,A,DNX,PubChem CID,9819126,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,83.0,nM,=,,2700.0,32.53,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.932462,SA193A,DRD2
291,22416052,drd2_human,193,S,A,DNS,ChEMBL Compound ID,CHEMBL124561,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,144.0,nM,=,,660.0,4.583,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.932462,SA193A,DRD2
16,21163968,drd2_human,393,H,A,FAUC346,SMILES,COc1ccccc1N1CCN(CCCCNC(=O)C2=CSC3C=CC=CC23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.61,,=,,7.77,-14.493,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
24,21163968,drd2_human,393,H,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.35,,=,,5.24,12.882,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
48,21163968,drd2_human,393,H,A,FAUC321,SMILES,COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.43,,=,,9.11,-4.785,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
65,21163968,drd2_human,393,H,A,Buspirone,ChEMBL Compound ID,CHEMBL49,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.64,,=,,7.0,-2.288,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
89,21163968,drd2_human,393,H,A,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.26,,=,,8.51,-1.779,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
114,21163968,drd2_human,393,H,A,CPD1,SMILES,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccccc2)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.43,,=,,9.0,-37.037,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
119,21163968,drd2_human,393,H,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,8.96,,=,,7.89,11.749,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
136,21163968,drd2_human,393,H,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,5.68,,=,,4.42,18.197,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
137,21163968,drd2_human,393,H,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,8.08,,=,,6.64,27.542,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
140,21163968,drd2_human,393,H,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,6.72,,=,,5.55,14.791,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
184,21163968,drd2_human,393,H,A,FAUC350,SMILES,O=C(NCCCN1CCN(CC1)c1cccc2CCOc12)c1cnn2ccccc12,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.41,,=,,8.3,-7.752,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
212,21163968,drd2_human,393,H,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,9.41,,=,,9.6,-1.548,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
216,21163968,drd2_human,393,H,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.16,,=,,5.92,17.378,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
232,21163968,drd2_human,393,H,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,5.7,,=,,4.52,15.136,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
247,21163968,drd2_human,393,H,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,7.89,,=,,6.09,63.096,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
300,21163968,drd2_human,393,H,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.21,,=,,4.96,17.783,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
315,21163968,drd2_human,393,H,A,FAUC335,SMILES,CSc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.85,,=,,9.35,-3.165,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.166906,HA393A,DRD2
20,10570038,drd2_human,111,V,M,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,370.0,1.321,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.567171,VA111M,DRD2
207,10570038,drd2_human,111,V,M,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,910.0,11.519,,,,0.0,0.0,,0.0,,P14416,-0.567171,VA111M,DRD2
305,10570038,drd2_human,111,V,M,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,1650.0,1.793,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.567171,VA111M,DRD2
21,22778805,drd2_human,390,F,W,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(0.5),Binding - Radioligand competition/displacement,610.0,nM,=,,2500.0,4.098,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
25,22778805,drd2_human,390,F,W,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.41,nM,=,,0.6,1.463,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
123,22778805,drd2_human,390,F,W,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(0.5),Binding - Radioligand competition/displacement,69.0,nM,=,,2200.0,31.884,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
157,22778805,drd2_human,390,F,W,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(0.5),Binding - Radioligand competition/displacement,0.45,µM,>,,20.0,44.444,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
205,22778805,drd2_human,390,F,W,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.09,nM,=,,0.14,1.556,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
213,22778805,drd2_human,390,F,W,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,2.0,µM,>,,20.0,10.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
251,22778805,drd2_human,390,F,W,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,190.0,nM,=,,5600.0,29.474,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
295,22778805,drd2_human,390,F,W,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(l),Binding - Radioligand competition/displacement,2100.0,nM,=,,5000.0,2.381,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
297,22778805,drd2_human,390,F,W,Nemonapride,ChEMBL Compound ID,CHEMBL2261102,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.14,nM,=,,1.5,10.714,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
334,22778805,drd2_human,390,F,W,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,1.1,nM,=,,21.0,19.091,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
340,22778805,drd2_human,390,F,W,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(h),Binding - Radioligand competition/displacement,13.0,nM,=,,22.0,1.692,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.132552,FA390W,DRD2
22,29466326,drd2_human,184,I,A,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.018,nM,=,,0.048,2.667,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.61922,IA184A,DRD2
178,29466326,drd2_human,184,I,A,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),9.43,nM,=,,15.5,1.644,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.61922,IA184A,DRD2
275,29466326,drd2_human,184,I,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.031,nM,=,,0.07,2.258,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.61922,IA184A,DRD2
337,29466326,drd2_human,184,I,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),2.51,nM,=,,0.54,-4.651,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.61922,IA184A,DRD2
23,29466326,drd2_human,382,F,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,57.7,12.822,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.93021,FA382A,DRD2
54,29466326,drd2_human,382,F,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.3,1.429,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.93021,FA382A,DRD2
26,10570038,drd2_human,118,C,M,[3H]N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,~,,0.0,5.0,,,,0.0,0.0,,0.0,,P14416,-2.87461,CA118M,DRD2
27,7595496,drd2_human,198,F,A,[3H]Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.083,nM,=,,0.091,1.096,,,,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
105,7595496,drd2_human,198,F,A,Bromocriptine,ChEMBL Compound ID,CHEMBL493,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,6.3,-1.302,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
132,29466326,drd2_human,198,F,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,41.95,9.322,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
165,7595496,drd2_human,198,F,A,Apomorphine,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,nM,=,,39.0,-5.128,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
246,7595496,drd2_human,198,F,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,1.6,1.6,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
269,7595496,drd2_human,198,F,A,[3H]Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.98,nM,=,,1.4,1.429,,,,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
278,29466326,drd2_human,198,F,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.76,3.619,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
318,7595496,drd2_human,198,F,A,NPA,ChEMBL Compound ID,CHEMBL225230,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,23.0,1.045,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,5.29239,FA198A,DRD2
30,29466326,drd2_human,100,W,L,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),2.51,nM,=,,6.77,2.697,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.77224,WA100L,DRD2
106,29466326,drd2_human,100,W,L,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.031,nM,=,,0.2,6.452,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.77224,WA100L,DRD2
151,29466326,drd2_human,100,W,L,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),9.43,nM,=,,387.0,41.039,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.77224,WA100L,DRD2
215,29466326,drd2_human,100,W,L,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.018,nM,=,,0.29,16.111,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.77224,WA100L,DRD2
32,22416052,drd2_human,197,S,A,DNX,PubChem CID,9819126,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,83.0,nM,=,,580.0,6.988,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
56,22416052,drd2_human,197,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,450.0,nM,=,,3500.0,7.778,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
149,22416052,drd2_human,197,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,365.0,nM,=,,2900.0,7.945,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
211,22416052,drd2_human,197,S,A,DHX,ChEMBL Compound ID,CHEMBL25856,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,490.0,nM,=,,1600.0,3.265,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
235,29466326,drd2_human,197,S,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.43,2.048,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
323,22416052,drd2_human,197,S,A,DNS,ChEMBL Compound ID,CHEMBL124561,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,144.0,nM,=,,330.0,2.292,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
329,29466326,drd2_human,197,S,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,1.22,-3.69,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.799788,SA197A,DRD2
34,29466326,drd2_human,119,T,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.43,2.048,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,1.36568,TA119A,DRD2
352,29466326,drd2_human,119,T,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,177.19,39.376,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,1.36568,TA119A,DRD2
37,22416052,drd2_human,194,S,A,DNS,ChEMBL Compound ID,CHEMBL124561,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,144.0,nM,=,,750.0,5.208,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.393069,SA194A,DRD2
163,22416052,drd2_human,194,S,A,DNX,PubChem CID,9819126,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,83.0,nM,=,,770.0,9.277,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.393069,SA194A,DRD2
166,22416052,drd2_human,194,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.365,µM,=,,27.0,73.973,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.393069,SA194A,DRD2
267,22416052,drd2_human,194,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,µM,=,,31.0,68.889,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.393069,SA194A,DRD2
296,22416052,drd2_human,194,S,A,DHX,ChEMBL Compound ID,CHEMBL25856,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,490.0,nM,=,,2600.0,5.306,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.393069,SA194A,DRD2
40,29466326,drd2_human,408,Y,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.18,-1.167,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.59675,YA408A,DRD2
196,29466326,drd2_human,408,Y,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,13.63,3.029,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.59675,YA408A,DRD2
41,26258690,drd2_human,95,E,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,6.26,µM,=,,5.31,8.913,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.87045,EA95A,DRD2
74,26258690,drd2_human,95,E,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,4.35,µM,=,,6.38,-111.111,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.87045,EA95A,DRD2
219,26258690,drd2_human,95,E,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,nM,=,,5.3,-1.23,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.87045,EA95A,DRD2
45,10570038,drd2_human,189,F,Y,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,51.0,-5.495,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,2.19918,FA189Y,DRD2
121,10570038,drd2_human,189,F,Y,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,340.0,-2.703,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,2.19918,FA189Y,DRD2
162,10570038,drd2_human,189,F,Y,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,33.0,-2.392,,,,0.0,0.0,,0.0,,P14416,2.19918,FA189Y,DRD2
49,10570038,drd2_human,196,V,C,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,110.0,1.392,,,,0.0,0.0,,0.0,,P14416,1.18088,VA196C,DRD2
69,10570038,drd2_human,196,V,C,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,370.0,1.321,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.18088,VA196C,DRD2
139,10570038,drd2_human,196,V,C,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,550.0,-1.672,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.18088,VA196C,DRD2
51,21163968,drd2_human,393,H,F,FAUC350,SMILES,O=C(NCCCN1CCN(CC1)c1cccc2CCOc12)c1cnn2ccccc12,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.41,,=,,7.7,-1.949,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
62,21163968,drd2_human,393,H,F,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,8.96,,=,,8.77,1.549,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
124,21163968,drd2_human,393,H,F,FAUC335,SMILES,CSc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.85,,=,,8.72,1.349,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
150,21163968,drd2_human,393,H,F,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.16,,=,,7.05,1.288,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
164,21163968,drd2_human,393,H,F,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.21,,=,,6.51,-1.996,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
170,21163968,drd2_human,393,H,F,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.35,,=,,5.4,8.913,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
189,21163968,drd2_human,393,H,F,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,5.68,,=,,5.96,-1.905,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
199,21163968,drd2_human,393,H,F,FAUC346,SMILES,COc1ccccc1N1CCN(CCCCNC(=O)C2=CSC3C=CC=CC23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.61,,=,,6.76,-1.412,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
201,21163968,drd2_human,393,H,F,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,7.89,,=,,7.96,-1.175,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
233,21163968,drd2_human,393,H,F,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(h),Binding - Radioligand competition/displacement,8.08,,=,,6.82,18.197,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
255,21163968,drd2_human,393,H,F,Buspirone,ChEMBL Compound ID,CHEMBL49,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,6.64,,=,,7.7,-11.494,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
287,21163968,drd2_human,393,H,F,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,6.72,,=,,6.62,1.259,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
288,21163968,drd2_human,393,H,F,CPD1,SMILES,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccccc2)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,7.43,,=,,6.89,3.467,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
299,21163968,drd2_human,393,H,F,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.26,,=,,8.89,-4.274,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
322,21163968,drd2_human,393,H,F,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(l),Binding - Radioligand competition/displacement,5.7,,=,,4.66,10.965,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
342,21163968,drd2_human,393,H,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,9.41,,=,,9.46,-1.122,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
350,21163968,drd2_human,393,H,F,FAUC321,SMILES,COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1,Binding - unknown pharmacological activity,pK(0.5),Binding - Radioligand competition/displacement,8.43,,=,,8.0,2.692,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,-1.64273,HA393F,DRD2
52,10570038,drd2_human,90,W,L,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,106.0,-2.639,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.172404,WA90L,DRD2
112,10570038,drd2_human,90,W,L,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,330.0,-2.786,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.172404,WA90L,DRD2
206,10570038,drd2_human,90,W,L,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,150.0,1.899,,,,0.0,0.0,,0.0,,P14416,-0.172404,WA90L,DRD2
59,29466326,drd2_human,110,F,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,36.89,8.198,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.55688,FA110A,DRD2
355,29466326,drd2_human,110,F,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.17,-1.235,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.55688,FA110A,DRD2
67,7595496,drd2_human,411,F,A,Bromocriptine,ChEMBL Compound ID,CHEMBL493,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,6.6,-1.242,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
117,7595496,drd2_human,411,F,A,Apomorphine,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,nM,=,,250.0,1.25,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
274,7595496,drd2_human,411,F,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,0.89,-1.124,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
310,7595496,drd2_human,411,F,A,[3H]N-0437,ChEMBL Compound ID,CHEMBL1303,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.7,nM,=,,1.2,-1.416,,,,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
312,7595496,drd2_human,411,F,A,NPA,ChEMBL Compound ID,CHEMBL225230,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,25.0,1.136,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
332,7595496,drd2_human,411,F,A,[3H]Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.083,nM,=,,0.061,-1.361,,,,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
338,7595496,drd2_human,411,F,A,[3H]Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.98,nM,=,,0.4,-2.451,,,,0.0,0.0,,0.0,,P14416,1.9362,FA411A,DRD2
75,29466326,drd2_human,412,T,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,4.92,23.429,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.248238,TA412A,DRD2
214,29466326,drd2_human,412,T,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,102.68,22.818,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.248238,TA412A,DRD2
76,29466326,drd2_human,122,I,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,13.87,3.082,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.60006,IA122A,DRD2
353,29466326,drd2_human,122,I,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.3,1.429,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.60006,IA122A,DRD2
82,24061855,drd2_human,181,E,V,NAPS,SMILES,C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCC4=CC(=C(C=C4)N=[N+]=[N-])I)CCCC(=O)C5=CC=C(C=C5)F,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.13,,=,,9.49,-2.288,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.589466,EA181V,DRD2
109,24061855,drd2_human,181,E,V,R-22,SMILES,O[C@H](CCNC(=O)c1cc2ccccc2[nH]1)CN1CCN(CC1)c1cccc(Cl)c1Cl,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.69,,=,,6.28,2.57,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.589466,EA181V,DRD2
88,29466326,drd2_human,390,F,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,1.3,6.19,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.86614,FA390A,DRD2
349,29466326,drd2_human,390,F,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,31.2,6.933,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.86614,FA390A,DRD2
95,29466326,drd2_human,100,W,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,1.97,9.381,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
144,29466326,drd2_human,100,W,A,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.018,nM,=,,0.31,17.222,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
252,29466326,drd2_human,100,W,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),2.51,nM,=,,6.74,2.685,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
264,29466326,drd2_human,100,W,A,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),9.43,nM,=,,273.0,28.95,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
306,29466326,drd2_human,100,W,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,8.14,1.809,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
325,29466326,drd2_human,100,W,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.031,nM,=,,0.19,6.129,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,2.86952,WA100A,DRD2
99,29466326,drd2_human,115,V,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,3.07,-1.466,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.948107,VA115A,DRD2
183,29466326,drd2_human,115,V,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.84,4.0,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.948107,VA115A,DRD2
104,10570038,drd2_human,408,Y,V,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,280.0,-3.289,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,0.69218,YA408V,DRD2
209,10570038,drd2_human,408,Y,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,60.0,-4.673,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,0.69218,YA408V,DRD2
239,10570038,drd2_human,408,Y,V,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,310.0,3.924,,,,0.0,0.0,,0.0,,P14416,0.69218,YA408V,DRD2
125,10570038,drd2_human,94,L,S,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,540.0,-1.704,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,2.0537,LA94S,DRD2
190,10570038,drd2_human,94,L,S,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,300.0,3.797,,,,0.0,0.0,,0.0,,P14416,2.0537,LA94S,DRD2
339,10570038,drd2_human,94,L,S,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,780.0,2.786,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,2.0537,LA94S,DRD2
129,26258690,drd2_human,91,V,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,5.21,nM,=,,4.07,13.804,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.53779,VA91A,DRD2
301,26258690,drd2_human,91,V,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(b),Binding - Radioligand competition/displacement,6.26,µM,=,,6.26,1.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.53779,VA91A,DRD2
133,29466326,drd2_human,94,L,A,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.018,nM,=,,0.062,3.444,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,1.9648,LA94A,DRD2
169,29466326,drd2_human,94,L,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),0.031,nM,=,,0.13,4.194,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,1.9648,LA94A,DRD2
243,29466326,drd2_human,94,L,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),2.51,nM,=,,0.48,-5.236,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,1.9648,LA94A,DRD2
271,29466326,drd2_human,94,L,A,Aripiprazole,ChEMBL Compound ID,CHEMBL1112,Binding - unknown pharmacological activity,K(d),Binding - Radioligand kinetics (association/dissociation),9.43,nM,=,,49.8,5.281,,,[3H]-N-methylspiperone,0.0,0.0,,0.0,,P14416,1.9648,LA94A,DRD2
135,29466326,drd2_human,389,F,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,2992.0,664.889,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
174,7595496,drd2_human,389,F,A,Bromocriptine,ChEMBL Compound ID,CHEMBL493,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,850.0,103.659,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
192,7595496,drd2_human,389,F,A,Apomorphine,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,200.0,nM,=,,16000.0,80.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
263,29466326,drd2_human,389,F,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,4.7,22.381,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
292,7595496,drd2_human,389,F,A,NPA,ChEMBL Compound ID,CHEMBL225230,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,7200.0,327.273,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
319,7595496,drd2_human,389,F,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.0,µM,=,,59.0,59.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
359,7595496,drd2_human,389,F,A,[3H]Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.083,nM,=,,2.8,33.735,,,,0.0,0.0,,0.0,,P14416,1.91462,FA389A,DRD2
155,29466326,drd2_human,118,C,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,4.84,1.076,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.0289836,CA118A,DRD2
175,29466326,drd2_human,118,C,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.4,1.905,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,-0.0289836,CA118A,DRD2
257,10570038,drd2_human,118,C,A,[3H]N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.0,,~,,0.0,2.0,,,,0.0,0.0,,0.0,,P14416,-0.0289836,CA118A,DRD2
161,29466326,drd2_human,416,Y,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,0.88,4.19,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,5.18316,YA416A,DRD2
231,29466326,drd2_human,416,Y,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,=,,2772.0,616.0,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,5.18316,YA416A,DRD2
172,10570038,drd2_human,392,T,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,280.0,1.0,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.674369,TA392V,DRD2
176,10570038,drd2_human,392,T,V,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,110.0,1.392,,,,0.0,0.0,,0.0,,P14416,-0.674369,TA392V,DRD2
356,10570038,drd2_human,392,T,V,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,750.0,-1.227,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.674369,TA392V,DRD2
200,10570038,drd2_human,91,V,F,CPPMA,SMILES,Clc1ccc(cc1)N1CCN(Cc2c[nH]c3ncccc23)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,920.0,nM,=,,9.5,-100.0,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.33151,VA91F,DRD2
227,10570038,drd2_human,91,V,F,N-methylspiperone,ChEMBL Compound ID,CHEMBL267932,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,79.0,pM,=,,28.0,-2.825,,,,0.0,0.0,,0.0,,P14416,1.33151,VA91F,DRD2
284,10570038,drd2_human,91,V,F,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,280.0,nM,=,,5.7,-50.0,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,1.33151,VA91F,DRD2
210,29466326,drd2_human,386,W,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,4.02,19.143,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.29989,WA386A,DRD2
316,29466326,drd2_human,386,W,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,>,,10000.0,2222.222,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,3.29989,WA386A,DRD2
317,29466326,drd2_human,114,D,A,Risperidone,ChEMBL Compound ID,CHEMBL85,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,4.5,nM,>,,10000.0,2222.222,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.917145,DA114A,DRD2
321,29466326,drd2_human,114,D,A,Nemonapride,ChEMBL Compound ID,CHEMBL20734,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.21,nM,=,,8.1,38.571,,,[3H]-nemonapride,0.0,0.0,,0.0,,P14416,0.917145,DA114A,DRD2
320,24061855,drd2_human,99,E,V,NAPS,SMILES,C1CN(CCC12C(=O)N(CN2C3=CC=CC=C3)CCC4=CC(=C(C=C4)N=[N+]=[N-])I)CCCC(=O)C5=CC=C(C=C5)F,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.13,,=,,9.53,-2.513,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.526803,EA99V,DRD2
347,24061855,drd2_human,99,E,V,R-22,SMILES,O[C@H](CCNC(=O)c1cc2ccccc2[nH]1)CN1CCN(CC1)c1cccc(Cl)c1Cl,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.69,,=,,6.33,2.291,,,[3H]N-methylspiperone,0.0,0.0,,0.0,,P14416,-0.526803,EA99V,DRD2
327,18550344,drd2_human,311,S,C,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,654.0,nM,=,,429.0,-1.524,,,[3H]Spiperone,0.0,0.0,,0.0,,P14416,0.0341139,SA311C,DRD2
2,9178745,pth2r_human,365,T,P,PTH,PubChem CID,16133850,Full agonist,Single-point,Functional - cAMP accumulation,0.0,,=,,0.0,-3.333,,,PTH,0.0,130.0,,0.0,,P49190,4.62799,TA365P,PTH2R
5,9178745,pth2r_human,180,H,R,PTH,PubChem CID,16133850,Full agonist,Single-point,Functional - cAMP accumulation,0.0,,=,,0.0,-3.333,,,PTH,0.0,30.0,,0.0,,P49190,-0.0203383,HA180R,PTH2R
1,20736161,lshr_human,77,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,143.0,-1.431,,,,0.0,0.0,,0.0,,P22888,0.752114,KA77A,LHCGR
183,20736161,lshr_human,77,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,143.0,-1.431,,,,0.0,0.0,,0.0,,P22888,0.752114,KA77A,LHCGR
1090,10880516,lshr_human,77,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P22888,0.752114,KA77A,LHCGR
2,17872379,lshr_human,564,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P22888,1.2013,DA564A,LHCGR
392,9584216,lshr_human,564,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,127.0,-1.271,,,,0.0,0.0,,0.0,,P22888,1.2013,DA564A,LHCGR
755,9584216,lshr_human,564,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P22888,1.2013,DA564A,LHCGR
871,17872379,lshr_human,564,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P22888,1.2013,DA564A,LHCGR
875,9584216,lshr_human,564,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P22888,1.2013,DA564A,LHCGR
6,20835841,lshr_human,400,N,W,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P22888,1.45542,NA400W,LHCGR
632,20835841,lshr_human,400,N,W,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P22888,1.45542,NA400W,LHCGR
9,11134146,lshr_human,368,L,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P22888,1.74286,LA368P,LHCGR
1004,11134146,lshr_human,368,L,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P22888,1.74286,LA368P,LHCGR
21,17872379,lshr_human,467,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,181.0,-1.812,,,,0.0,0.0,,0.0,,P22888,0.387884,TA467A,LHCGR
921,17872379,lshr_human,467,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,124.0,-1.241,,,,0.0,0.0,,0.0,,P22888,0.387884,TA467A,LHCGR
27,10967122,lshr_human,645,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P22888,0.202379,KA645A,LHCGR
393,10967122,lshr_human,645,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,113.0,-1.13,,,,0.0,0.0,,0.0,,P22888,0.202379,KA645A,LHCGR
33,12444891,lshr_human,194,F,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,15.0,6.667,,,,0.0,0.0,,0.0,,P22888,5.56235,FA194V,LHCGR
39,17872379,lshr_human,563,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,125.0,-1.25,,,,0.0,0.0,,0.0,,P22888,-0.0322141,KA563A,LHCGR
212,17872379,lshr_human,563,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P22888,-0.0322141,KA563A,LHCGR
42,16901970,lshr_human,331,Y,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P22888,-0.0733704,YA331F,LHCGR
45,17872379,lshr_human,561,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P22888,1.09224,TA561A,LHCGR
614,17872379,lshr_human,561,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,170.0,-1.701,,,,0.0,0.0,,0.0,,P22888,1.09224,TA561A,LHCGR
48,9497355,lshr_human,509,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P22888,-0.0650703,MA509A,LHCGR
51,10967122,lshr_human,640,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P22888,0.250286,KA640A,LHCGR
1097,10967122,lshr_human,640,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P22888,0.250286,KA640A,LHCGR
53,17872379,lshr_human,550,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P22888,0.389868,YA550A,LHCGR
661,17872379,lshr_human,550,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P22888,0.389868,YA550A,LHCGR
54,17872379,lshr_human,462,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P22888,1.48813,LA462A,LHCGR
431,17872379,lshr_human,462,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P22888,1.48813,LA462A,LHCGR
56,10967122,lshr_human,566,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P22888,-0.251991,KA566A,LHCGR
1007,10967122,lshr_human,566,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P22888,-0.251991,KA566A,LHCGR
57,9973249,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
108,9973249,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
312,9973249,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,184.0,-1.842,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
466,10889210,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
472,7892197,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
669,10889210,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
848,9584216,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
981,9584216,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
986,9584216,lshr_human,564,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P22888,2.56837,DA564G,LHCGR
62,10889210,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
209,9584216,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,166.0,-1.661,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
251,9973550,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
337,9584216,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,134.0,-1.34,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
476,10580072,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,300.0,-3.003,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
546,9584216,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,146.0,-1.46,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
591,8943222,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
607,10889210,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
1169,8943222,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
1172,8943222,lshr_human,578,D,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,135.0,-1.35,,,,0.0,0.0,,0.0,,P22888,-1.88221,DA578Y,LHCGR
64,17872379,lshr_human,551,F,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,131.0,-1.311,,,,0.0,0.0,,0.0,,P22888,0.410016,FA551A,LHCGR
98,17872379,lshr_human,551,F,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,155.0,-1.55,,,,0.0,0.0,,0.0,,P22888,0.410016,FA551A,LHCGR
66,17872379,lshr_human,469,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,207.0,-2.07,,,,0.0,0.0,,0.0,,P22888,-0.211139,TA469A,LHCGR
1176,17872379,lshr_human,469,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,200.0,-2.0,,,,0.0,0.0,,0.0,,P22888,-0.211139,TA469A,LHCGR
67,10967122,lshr_human,632,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,116.0,-1.16,,,,0.0,0.0,,0.0,,P22888,1.48365,RA632A,LHCGR
533,10967122,lshr_human,632,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P22888,1.48365,RA632A,LHCGR
69,17872379,lshr_human,466,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P22888,0.133343,HA466A,LHCGR
814,17872379,lshr_human,466,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P22888,0.133343,HA466A,LHCGR
76,20835841,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,116.0,-1.16,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
295,17872379,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,533.0,-5.319,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
413,12356766,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,123.0,-1.23,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
841,12356766,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
1059,10580072,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,400.0,-4.0,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
1155,21490077,lshr_human,578,D,H,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,-1.15602,DA578H,LHCGR
77,20835841,lshr_human,405,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,143.0,-1.431,,,,0.0,0.0,,0.0,,P22888,0.2496,DA405N,LHCGR
671,20835841,lshr_human,405,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P22888,0.2496,DA405N,LHCGR
803,19616090,lshr_human,405,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P22888,0.2496,DA405N,LHCGR
86,17872379,lshr_human,564,D,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P22888,0.917886,DA564R,LHCGR
311,17872379,lshr_human,564,D,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,156.0,-1.56,,,,0.0,0.0,,0.0,,P22888,0.917886,DA564R,LHCGR
89,11118455,lshr_human,521,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,1.21927,TA521A,LHCGR
882,9497355,lshr_human,521,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P22888,1.21927,TA521A,LHCGR
984,11118455,lshr_human,521,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P22888,1.21927,TA521A,LHCGR
100,17872379,lshr_human,558,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,133.0,-1.33,,,,0.0,0.0,,0.0,,P22888,0.975891,LA558A,LHCGR
423,17872379,lshr_human,558,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P22888,0.975891,LA558A,LHCGR
102,17872379,lshr_human,472,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,187.0,-1.869,,,,0.0,0.0,,0.0,,P22888,-0.0641439,IA472A,LHCGR
332,17872379,lshr_human,472,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P22888,-0.0641439,IA472A,LHCGR
103,20736161,lshr_human,127,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P22888,3.89119,YA127A,LHCGR
548,10884391,lshr_human,127,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P22888,3.89119,YA127A,LHCGR
678,20736161,lshr_human,127,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P22888,3.89119,YA127A,LHCGR
116,12444891,lshr_human,193,A,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P22888,1.96319,AA193V,LHCGR
120,8943222,lshr_human,578,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P22888,-3.32734,DA578L,LHCGR
348,8943222,lshr_human,578,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P22888,-3.32734,DA578L,LHCGR
1146,8943222,lshr_human,578,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,11.0,9.091,,,,0.0,0.0,,0.0,,P22888,-3.32734,DA578L,LHCGR
125,8943222,lshr_human,578,D,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P22888,2.82037,DA578P,LHCGR
670,8943222,lshr_human,578,D,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P22888,2.82037,DA578P,LHCGR
126,15016840,lshr_human,398,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P22888,3.37292,MA398A,LHCGR
833,15016840,lshr_human,398,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,203.0,-2.028,,,,0.0,0.0,,0.0,,P22888,3.37292,MA398A,LHCGR
128,9253338,lshr_human,576,F,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P22888,-0.0435469,FA576Y,LHCGR
658,9253338,lshr_human,576,F,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P22888,-0.0435469,FA576Y,LHCGR
760,9253338,lshr_human,576,F,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P22888,-0.0435469,FA576Y,LHCGR
129,20835841,lshr_human,619,N,D,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P22888,3.74896,NA619D,LHCGR
314,20835841,lshr_human,619,N,D,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P22888,3.74896,NA619D,LHCGR
131,10889210,lshr_human,276,P,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,174.0,-1.739,,,,0.0,0.0,,0.0,,P22888,1.61906,PA276A,LHCGR
938,10889210,lshr_human,276,P,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,23.0,4.348,,,,0.0,0.0,,0.0,,P22888,1.61906,PA276A,LHCGR
133,10884391,lshr_human,130,I,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P22888,0.485656,IA130L,LHCGR
139,10884391,lshr_human,135,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P22888,2.5815,IA135A,LHCGR
150,20835841,lshr_human,615,N,D,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P22888,0.831745,NA615D,LHCGR
1021,20835841,lshr_human,615,N,D,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P22888,0.831745,NA615D,LHCGR
154,19616090,lshr_human,546,Y,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P22888,-0.335262,YA546F,LHCGR
156,9584216,lshr_human,564,D,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P22888,0.309438,DA564V,LHCGR
475,9584216,lshr_human,564,D,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P22888,0.309438,DA564V,LHCGR
1095,9584216,lshr_human,564,D,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P22888,0.309438,DA564V,LHCGR
160,12356766,lshr_human,277,S,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P22888,-0.138011,SA277N,LHCGR
991,12356766,lshr_human,277,S,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P22888,-0.138011,SA277N,LHCGR
161,9973550,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
236,9584216,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
341,8943222,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
588,21490077,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
606,21490077,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,125.0,-1.25,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
702,9584216,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
807,8943222,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
868,8943222,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
887,9584216,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
997,7692306,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
1073,7892197,lshr_human,578,D,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,-0.563778,DA578G,LHCGR
169,9973249,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,237.0,-2.37,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
188,9973249,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
386,9584216,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,121.0,-1.211,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
424,9973249,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
549,9584216,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,154.0,-1.541,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
879,9584216,lshr_human,564,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P22888,1.57119,DA564N,LHCGR
203,20736161,lshr_human,77,K,E,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,228.0,-2.278,,,,0.0,0.0,,0.0,,P22888,1.72836,KA77E,LHCGR
899,20736161,lshr_human,77,K,E,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,159.0,-1.59,,,,0.0,0.0,,0.0,,P22888,1.72836,KA77E,LHCGR
213,17872379,lshr_human,556,P,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,157.0,-1.57,,,,0.0,0.0,,0.0,,P22888,1.2981,PA556A,LHCGR
226,17872379,lshr_human,556,P,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P22888,1.2981,PA556A,LHCGR
219,10889210,lshr_human,276,P,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P22888,2.75074,PA276G,LHCGR
788,10889210,lshr_human,276,P,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P22888,2.75074,PA276G,LHCGR
221,17872379,lshr_human,478,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P22888,2.79357,LA478A,LHCGR
582,17872379,lshr_human,478,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,54.0,1.852,,,,0.0,0.0,,0.0,,P22888,2.79357,LA478A,LHCGR
229,8943222,lshr_human,578,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,165.0,-1.65,,,,0.0,0.0,,0.0,,P22888,0.0310757,DA578N,LHCGR
355,8943222,lshr_human,578,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P22888,0.0310757,DA578N,LHCGR
499,8943222,lshr_human,578,D,N,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P22888,0.0310757,DA578N,LHCGR
235,17872379,lshr_human,477,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,9.0,11.111,,,,0.0,0.0,,0.0,,P22888,0.135769,KA477A,LHCGR
802,17872379,lshr_human,477,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P22888,0.135769,KA477A,LHCGR
1033,9973249,lshr_human,477,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,0.135769,KA477A,LHCGR
240,10967122,lshr_human,570,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P22888,1.2495,KA570A,LHCGR
684,10967122,lshr_human,570,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P22888,1.2495,KA570A,LHCGR
243,17872379,lshr_human,474,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P22888,-0.183688,LA474A,LHCGR
570,17872379,lshr_human,474,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P22888,-0.183688,LA474A,LHCGR
246,10967122,lshr_human,569,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,138.0,-1.379,,,,0.0,0.0,,0.0,,P22888,0.182868,KA569A,LHCGR
585,10967122,lshr_human,569,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P22888,0.182868,KA569A,LHCGR
250,9497355,lshr_human,519,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P22888,0.865127,VA519A,LHCGR
704,11118455,lshr_human,519,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P22888,0.865127,VA519A,LHCGR
898,11118455,lshr_human,519,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P22888,0.865127,VA519A,LHCGR
256,10884391,lshr_human,137,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P22888,0.429746,KA137A,LHCGR
260,10967122,lshr_human,388,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P22888,0.580534,RA388A,LHCGR
830,10967122,lshr_human,388,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P22888,0.580534,RA388A,LHCGR
264,17872379,lshr_human,459,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P22888,1.91451,VA459A,LHCGR
333,17872379,lshr_human,459,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P22888,1.91451,VA459A,LHCGR
267,9973249,lshr_human,482,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P22888,-0.457295,HA482A,LHCGR
838,17872379,lshr_human,482,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P22888,-0.457295,HA482A,LHCGR
861,17872379,lshr_human,482,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,124.0,-1.241,,,,0.0,0.0,,0.0,,P22888,-0.457295,HA482A,LHCGR
282,17872379,lshr_human,465,W,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P22888,1.54639,WA465A,LHCGR
359,17872379,lshr_human,465,W,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,26.0,3.846,,,,0.0,0.0,,0.0,,P22888,1.54639,WA465A,LHCGR
285,9253338,lshr_human,576,F,I,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,0.166421,FA576I,LHCGR
433,9253338,lshr_human,576,F,I,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P22888,0.166421,FA576I,LHCGR
1062,9253338,lshr_human,576,F,I,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P22888,0.166421,FA576I,LHCGR
289,17872379,lshr_human,559,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P22888,-1.10784,MA559A,LHCGR
1143,17872379,lshr_human,559,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P22888,-1.10784,MA559A,LHCGR
290,15016840,lshr_human,398,M,K,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,4.0,25.0,,,,0.0,0.0,,0.0,,P22888,2.21719,MA398K,LHCGR
293,15016840,lshr_human,398,M,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P22888,1.08219,MA398R,LHCGR
762,15016840,lshr_human,398,M,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,3.0,33.333,,,,0.0,0.0,,0.0,,P22888,1.08219,MA398R,LHCGR
301,9497355,lshr_human,515,F,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P22888,2.76981,FA515A,LHCGR
672,11118455,lshr_human,515,F,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P22888,2.76981,FA515A,LHCGR
931,11118455,lshr_human,515,F,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,2.76981,FA515A,LHCGR
305,20736161,lshr_human,228,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P22888,2.15737,DA228A,LHCGR
430,20736161,lshr_human,228,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P22888,2.15737,DA228A,LHCGR
309,17872379,lshr_human,473,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,169.0,-1.689,,,,0.0,0.0,,0.0,,P22888,-0.144527,HA473A,LHCGR
776,17872379,lshr_human,473,H,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,183.0,-1.832,,,,0.0,0.0,,0.0,,P22888,-0.144527,HA473A,LHCGR
310,9973550,lshr_human,578,D,W,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P22888,-4.30529,DA578W,LHCGR
313,20736161,lshr_human,230,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P22888,0.831307,SA230A,LHCGR
718,20736161,lshr_human,230,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,244.0,-2.439,,,,0.0,0.0,,0.0,,P22888,0.831307,SA230A,LHCGR
320,20835841,lshr_human,623,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P22888,2.51352,YA623A,LHCGR
322,17872379,lshr_human,475,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,178.0,-1.779,,,,0.0,0.0,,0.0,,P22888,0.156574,DA475A,LHCGR
751,17872379,lshr_human,475,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,160.0,-1.6,,,,0.0,0.0,,0.0,,P22888,0.156574,DA475A,LHCGR
324,9626653,lshr_human,625,I,K,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P22888,1.01849,IA625K,LHCGR
652,9626653,lshr_human,625,I,K,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P22888,1.01849,IA625K,LHCGR
326,10884391,lshr_human,134,G,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P22888,0.436605,GA134A,LHCGR
339,9973249,lshr_human,464,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P22888,1.35979,RA464A,LHCGR
801,17872379,lshr_human,464,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,6.0,16.667,,,,0.0,0.0,,0.0,,P22888,1.35979,RA464A,LHCGR
818,17872379,lshr_human,464,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P22888,1.35979,RA464A,LHCGR
345,10880516,lshr_human,66,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P22888,0.248562,SA66A,LHCGR
361,17872379,lshr_human,554,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P22888,0.818816,RA554A,LHCGR
963,17872379,lshr_human,554,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P22888,0.818816,RA554A,LHCGR
362,18162522,lshr_human,476,Q,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,-0.524085,QA476R,LHCGR
368,7757065,lshr_human,577,T,I,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P22888,-1.39843,TA577I,LHCGR
373,20736161,lshr_human,81,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,217.0,-2.169,,,,0.0,0.0,,0.0,,P22888,-0.639621,SA81A,LHCGR
396,10880516,lshr_human,81,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P22888,-0.639621,SA81A,LHCGR
1089,20736161,lshr_human,81,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,165.0,-1.65,,,,0.0,0.0,,0.0,,P22888,-0.639621,SA81A,LHCGR
380,18641392,lshr_human,304,C,A,lutropin,IUPHAR/BPS Guide to pharmacology,1159,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,2.92198,CA304A,LHCGR
394,10880516,lshr_human,56,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,21.0,4.762,,,,0.0,0.0,,0.0,,P22888,4.25677,LA56A,LHCGR
411,10967122,lshr_human,548,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P22888,0.512851,KA548A,LHCGR
445,17872379,lshr_human,548,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,123.0,-1.23,,,,0.0,0.0,,0.0,,P22888,0.512851,KA548A,LHCGR
467,10967122,lshr_human,548,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,142.0,-1.42,,,,0.0,0.0,,0.0,,P22888,0.512851,KA548A,LHCGR
969,17872379,lshr_human,548,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P22888,0.512851,KA548A,LHCGR
412,15016840,lshr_human,398,M,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,21.0,4.762,,,,0.0,0.0,,0.0,,P22888,2.81802,MA398G,LHCGR
774,15016840,lshr_human,398,M,G,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,6.0,16.667,,,,0.0,0.0,,0.0,,P22888,2.81802,MA398G,LHCGR
414,9584216,lshr_human,564,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P22888,-0.834654,DA564F,LHCGR
422,9584216,lshr_human,564,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,-0.834654,DA564F,LHCGR
771,9584216,lshr_human,564,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P22888,-0.834654,DA564F,LHCGR
418,8943222,lshr_human,578,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P22888,-3.33889,DA578F,LHCGR
874,8943222,lshr_human,578,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P22888,-3.33889,DA578F,LHCGR
952,8943222,lshr_human,578,D,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P22888,-3.33889,DA578F,LHCGR
429,9584216,lshr_human,564,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P22888,-0.589032,DA564L,LHCGR
657,9584216,lshr_human,564,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P22888,-0.589032,DA564L,LHCGR
1019,9584216,lshr_human,564,D,L,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P22888,-0.589032,DA564L,LHCGR
435,17872379,lshr_human,557,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,175.0,-1.751,,,,0.0,0.0,,0.0,,P22888,0.228931,EA557A,LHCGR
935,17872379,lshr_human,557,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,126.0,-1.259,,,,0.0,0.0,,0.0,,P22888,0.228931,EA557A,LHCGR
436,16433250,lshr_human,392,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,46.0,2.174,,,,0.0,0.0,,0.0,,P22888,0.172187,TA392I,LHCGR
443,7719343,lshr_human,593,A,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P22888,3.22028,AA593P,LHCGR
446,17872379,lshr_human,553,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P22888,0.684361,VA553A,LHCGR
743,17872379,lshr_human,553,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P22888,0.684361,VA553A,LHCGR
455,17872379,lshr_human,481,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P22888,-0.0101541,RA481A,LHCGR
798,17872379,lshr_human,481,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P22888,-0.0101541,RA481A,LHCGR
1118,9973249,lshr_human,481,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P22888,-0.0101541,RA481A,LHCGR
461,10880516,lshr_human,74,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P22888,0.00272848,EA74A,LHCGR
471,10884391,lshr_human,131,C,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P22888,4.49461,CA131A,LHCGR
483,8559204,lshr_human,616,S,Y,human lutropin,IUPHAR/BPS Guide to pharmacology,1159,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,3.0,33.333,,,,0.0,0.0,,0.0,,P22888,1.01902,SA616Y,LHCGR
768,9626653,lshr_human,616,S,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P22888,1.01902,SA616Y,LHCGR
782,9626653,lshr_human,616,S,Y,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P22888,1.01902,SA616Y,LHCGR
490,10967122,lshr_human,646,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P22888,-0.33379,RA646A,LHCGR
1168,10967122,lshr_human,646,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P22888,-0.33379,RA646A,LHCGR
491,17872379,lshr_human,468,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P22888,2.30301,IA468A,LHCGR
572,17872379,lshr_human,468,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P22888,2.30301,IA468A,LHCGR
500,10967122,lshr_human,395,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P22888,0.502148,RA395A,LHCGR
856,10967122,lshr_human,395,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P22888,0.502148,RA395A,LHCGR
506,10880516,lshr_human,88,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P22888,0.852744,RA88A,LHCGR
508,17872379,lshr_human,549,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P22888,3.06551,IA549A,LHCGR
1011,17872379,lshr_human,549,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P22888,3.06551,IA549A,LHCGR
509,10884391,lshr_human,130,I,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P22888,5.2526,IA130F,LHCGR
525,15372531,lshr_human,502,L,P,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P22888,0.0303769,LA502P,LHCGR
547,17872379,lshr_human,480,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P22888,2.48356,LA480A,LHCGR
736,17872379,lshr_human,480,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,44.0,2.273,,,,0.0,0.0,,0.0,,P22888,2.48356,LA480A,LHCGR
550,10880516,lshr_human,84,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P22888,-0.180396,DA84A,LHCGR
551,17872379,lshr_human,461,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P22888,0.613528,TA461A,LHCGR
958,17872379,lshr_human,461,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P22888,0.613528,TA461A,LHCGR
564,17872379,lshr_human,479,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P22888,-0.593507,RA479A,LHCGR
725,9973249,lshr_human,479,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,-0.593507,RA479A,LHCGR
795,17872379,lshr_human,479,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P22888,-0.593507,RA479A,LHCGR
580,10967122,lshr_human,628,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P22888,0.191877,KA628A,LHCGR
675,10967122,lshr_human,628,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P22888,0.191877,KA628A,LHCGR
594,15016840,lshr_human,398,M,T,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P22888,3.11266,MA398T,LHCGR
716,15016840,lshr_human,398,M,T,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P22888,3.11266,MA398T,LHCGR
816,7593421,lshr_human,398,M,T,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P22888,3.11266,MA398T,LHCGR
599,15016840,lshr_human,398,M,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P22888,2.53059,MA398V,LHCGR
808,15016840,lshr_human,398,M,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,2.53059,MA398V,LHCGR
602,20736161,lshr_human,157,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P22888,0.306724,DA157A,LHCGR
605,9497355,lshr_human,524,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P22888,-0.422609,SA524A,LHCGR
622,17872379,lshr_human,470,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,159.0,-1.59,,,,0.0,0.0,,0.0,,P22888,1.25795,YA470A,LHCGR
1140,17872379,lshr_human,470,Y,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,136.0,-1.361,,,,0.0,0.0,,0.0,,P22888,1.25795,YA470A,LHCGR
626,10880516,lshr_human,155,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P22888,4.53016,IA155A,LHCGR
627,9497355,lshr_human,520,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P22888,-0.470645,EA520A,LHCGR
631,17872379,lshr_human,460,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P22888,2.76312,IA460A,LHCGR
749,17872379,lshr_human,460,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P22888,2.76312,IA460A,LHCGR
643,9497355,lshr_human,510,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,129.0,-1.29,,,,0.0,0.0,,0.0,,P22888,0.193623,KA510A,LHCGR
648,10880516,lshr_human,63,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P22888,1.82712,VA63A,LHCGR
662,10880516,lshr_human,70,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,55.0,1.818,,,,0.0,0.0,,0.0,,P22888,0.834477,RA70A,LHCGR
685,16709601,lshr_human,114,I,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P22888,1.56309,IA114V,LHCGR
753,16709601,lshr_human,114,I,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P22888,1.56309,IA114V,LHCGR
692,10880516,lshr_human,229,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,44.0,2.273,,,,0.0,0.0,,0.0,,P22888,3.40569,IA229A,LHCGR
695,10880516,lshr_human,76,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P22888,0.278501,IA76A,LHCGR
708,10884391,lshr_human,129,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P22888,-0.13145,SA129A,LHCGR
720,20736161,lshr_human,133,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P22888,1.68023,TA133A,LHCGR
947,10884391,lshr_human,133,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P22888,1.68023,TA133A,LHCGR
1112,20736161,lshr_human,133,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P22888,1.68023,TA133A,LHCGR
734,16709601,lshr_human,114,I,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P22888,4.57382,IA114F,LHCGR
1038,16709601,lshr_human,114,I,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,15.0,6.667,,,,0.0,0.0,,0.0,,P22888,4.57382,IA114F,LHCGR
746,18641392,lshr_human,336,C,A,lutropin,IUPHAR/BPS Guide to pharmacology,1159,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P22888,3.57477,CA336A,LHCGR
763,9497355,lshr_human,523,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P22888,0.87034,LA523A,LHCGR
764,9497355,lshr_human,512,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P22888,-0.677199,SA512A,LHCGR
806,11118455,lshr_human,512,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P22888,-0.677199,SA512A,LHCGR
1075,11118455,lshr_human,512,S,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P22888,-0.677199,SA512A,LHCGR
777,9497355,lshr_human,513,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P22888,2.60628,IA513A,LHCGR
804,15016840,lshr_human,398,M,W,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P22888,1.27038,MA398W,LHCGR
946,15016840,lshr_human,398,M,W,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P22888,1.27038,MA398W,LHCGR
809,10967122,lshr_human,390,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P22888,-0.0991921,KA390A,LHCGR
930,10967122,lshr_human,390,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,41.0,2.439,,,,0.0,0.0,,0.0,,P22888,-0.0991921,KA390A,LHCGR
829,9497355,lshr_human,511,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,129.0,-1.29,,,,0.0,0.0,,0.0,,P22888,2.33161,VA511A,LHCGR
840,9497355,lshr_human,518,D,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,122.0,-1.22,,,,0.0,0.0,,0.0,,P22888,0.0584706,DA518A,LHCGR
852,10880516,lshr_human,181,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P22888,3.95037,LA181A,LHCGR
859,10880516,lshr_human,83,I,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P22888,3.54749,IA83A,LHCGR
869,16433250,lshr_human,374,I,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P22888,2.40882,IA374T,LHCGR
876,9497355,lshr_human,522,T,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P22888,-0.159091,TA522A,LHCGR
877,10884391,lshr_human,126,K,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P22888,1.051,KA126A,LHCGR
914,10884391,lshr_human,130,I,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P22888,1.43894,IA130V,LHCGR
957,9215288,lshr_human,131,C,R,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P22888,4.89677,CA131R,LHCGR
959,7714085,lshr_human,572,A,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P22888,0.137739,AA572V,LHCGR
978,7714085,lshr_human,572,A,V,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P22888,0.137739,AA572V,LHCGR
962,10880516,lshr_human,67,Q,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P22888,1.69159,QA67A,LHCGR
968,20736161,lshr_human,154,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,33.0,3.03,,,,0.0,0.0,,0.0,,P22888,3.70332,EA154A,LHCGR
979,10880516,lshr_human,72,L,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,23.0,4.348,,,,0.0,0.0,,0.0,,P22888,3.60092,LA72A,LHCGR
1018,20736161,lshr_human,154,E,K,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P22888,2.57055,EA154K,LHCGR
1026,17872379,lshr_human,476,Q,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P22888,0.232411,QA476A,LHCGR
1091,17872379,lshr_human,476,Q,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P22888,0.232411,QA476A,LHCGR
1035,10880516,lshr_human,71,G,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P22888,3.12514,GA71A,LHCGR
1047,12444891,lshr_human,195,N,I,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P22888,-0.404694,NA195I,LHCGR
1061,9497355,lshr_human,525,Q,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P22888,0.678558,QA525A,LHCGR
1064,9497355,lshr_human,517,M,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P22888,3.27548,MA517A,LHCGR
1068,10880516,lshr_human,75,V,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P22888,2.53514,VA75A,LHCGR
1080,9100567,lshr_human,588,F,S,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P22888,3.46708,FA588S,LHCGR
1092,10884391,lshr_human,136,R,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P22888,0.212748,RA136A,LHCGR
1093,20736161,lshr_human,154,E,Q,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Specific-binding,binding,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P22888,3.25252,EA154Q,LHCGR
1105,10880516,lshr_human,79,E,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P22888,0.668904,EA79A,LHCGR
1130,16901970,lshr_human,333,Y,F,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P22888,-0.209908,YA333F,LHCGR
1138,10880516,lshr_human,65,P,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P22888,2.81432,PA65A,LHCGR
1166,10880516,lshr_human,82,Q,A,human choriogonadotropin,IUPHAR/BPS Guide to pharmacology,1160,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P22888,0.810549,QA82A,LHCGR
3,23519210,5ht2b_human,225,A,S,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.24,-4.785,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
29,10.1038/s41594-018-0116-7,5ht2b_human,225,A,S,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,3.2,nM,=,,1.4,-2.288,,,,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
30,10.1038/s41594-018-0116-7,5ht2b_human,225,A,S,Methylergonovine,PubChem CID,8226,Partial agonist,EC50,Functional - Ca2+ accumulation,23.0,nM,=,,15.0,-1.534,,,,0.0,0.0,,91.0,,P41595,0.291087,AA225S,HTR2B
42,10.1038/s41594-018-0116-7,5ht2b_human,225,A,S,LSD,PubChem CID,5761,Partial agonist,K(d),Binding - Radioligand competition/displacement,0.58,nM,=,,0.28,-2.07,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
44,23519210,5ht2b_human,225,A,S,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.44,-1.072,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
66,10.1038/s41594-018-0116-7,5ht2b_human,225,A,S,Methylergonovine,PubChem CID,8226,Partial agonist,K(i),Binding - Radioligand competition/displacement,0.37,nM,=,,0.3,-1.233,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
104,23519210,5ht2b_human,225,A,S,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.81,-2.688,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
141,10.1038/s41594-018-0116-7,5ht2b_human,225,A,S,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,1.77,11.062,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,0.291087,AA225S,HTR2B
4,23519210,5ht2b_human,217,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.02,24.547,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.76515,FA217A,HTR2B
37,23519210,5ht2b_human,217,F,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.69,4.898,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.76515,FA217A,HTR2B
122,23519210,5ht2b_human,217,F,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,9.03,-29.412,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.76515,FA217A,HTR2B
5,23519210,5ht2b_human,208,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.32,1.148,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.0615116,VA208A,HTR2B
57,23519210,5ht2b_human,208,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.33,1.202,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.0615116,VA208A,HTR2B
121,23519210,5ht2b_human,208,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.54,1.047,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.0615116,VA208A,HTR2B
7,23519210,5ht2b_human,348,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.4,-1.047,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.25383,VA348A,HTR2B
63,23519210,5ht2b_human,348,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.3,1.82,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.25383,VA348A,HTR2B
146,23519210,5ht2b_human,348,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.52,-1.289,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.25383,VA348A,HTR2B
10,10.1038/s41594-018-0116-7,5ht2b_human,140,T,V,Methylergonovine,PubChem CID,8226,Partial agonist,K(i),Binding - Radioligand competition/displacement,0.37,nM,=,,8.03,21.703,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-1.40265,TA140V,HTR2B
17,10.1038/s41594-018-0116-7,5ht2b_human,140,T,V,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.3,1.875,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-1.40265,TA140V,HTR2B
49,10.1038/s41594-018-0116-7,5ht2b_human,140,T,V,LSD,PubChem CID,5761,Partial agonist,K(d),Binding - Radioligand competition/displacement,0.58,nM,=,,1.33,2.293,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-1.40265,TA140V,HTR2B
140,10.1038/s41594-018-0116-7,5ht2b_human,140,T,V,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,5.2,nM,=,,93.0,17.885,,,,0.0,0.0,,0.0,,P41595,-1.40265,TA140V,HTR2B
11,11859080,5ht2b_human,376,N,D,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,120.0,13.333,,,,37.0,0.0,,0.0,,P41595,0.929522,NA376D,HTR2B
123,11859080,5ht2b_human,376,N,D,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,141.0,11.75,,,,0.0,0.0,,0.0,,P41595,0.929522,NA376D,HTR2B
13,23519210,5ht2b_human,362,L,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.9,3.236,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.16658,LA362A,HTR2B
54,10.1038/s41594-018-0116-7,5ht2b_human,362,L,A,LSD,PubChem CID,5761,Partial agonist,EC50,Functional - Ca2+ accumulation,37.0,nM,=,,340.0,9.189,,,,0.0,0.0,,85.0,,P41595,3.16658,LA362A,HTR2B
112,23519210,5ht2b_human,362,L,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.3,1.202,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.16658,LA362A,HTR2B
133,23519210,5ht2b_human,362,L,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.74,-1.513,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.16658,LA362A,HTR2B
14,23519210,5ht2b_human,209,L,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.49,-8.547,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.21147,LA209A,HTR2B
70,23519210,5ht2b_human,209,L,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.78,4.266,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.21147,LA209A,HTR2B
111,23519210,5ht2b_human,209,L,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.94,2.754,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.21147,LA209A,HTR2B
15,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.39,2.438,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
23,23519210,5ht2b_human,140,T,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.72,-1.445,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
31,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,5.2,nM,=,,73.0,14.038,,,,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
51,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,Methylergonovine,PubChem CID,8226,Partial agonist,K(i),Binding - Radioligand competition/displacement,0.37,nM,=,,4.18,11.297,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
64,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - β-arrestin recruitment,3.6,nM,=,,178.0,49.444,,,,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
90,23519210,5ht2b_human,140,T,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.9,3.02,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
109,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,LSD,PubChem CID,5761,Partial agonist,K(d),Binding - Radioligand competition/displacement,0.58,nM,=,,1.41,2.431,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
124,23519210,5ht2b_human,140,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,6.35,114.815,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
151,10.1038/s41594-018-0116-7,5ht2b_human,140,T,A,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,5.2,nM,=,,130.0,25.0,,,,0.0,0.0,,0.0,,P41595,-0.461827,TA140A,HTR2B
16,23519210,5ht2b_human,370,Y,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.22,2.188,,,[3H]LSD,0.0,0.0,,0.0,,P41595,4.83653,YA370A,HTR2B
47,23519210,5ht2b_human,370,Y,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.04,21.878,,,[3H]LSD,0.0,0.0,,0.0,,P41595,4.83653,YA370A,HTR2B
95,23519210,5ht2b_human,370,Y,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,6.46,89.125,,,[3H]LSD,0.0,0.0,,0.0,,P41595,4.83653,YA370A,HTR2B
19,23519210,5ht2b_human,366,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.65,-1.862,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.05878,VA366A,HTR2B
85,23519210,5ht2b_human,366,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.16,2.512,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.05878,VA366A,HTR2B
156,23519210,5ht2b_human,366,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.49,-1.202,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.05878,VA366A,HTR2B
20,23519210,5ht2b_human,139,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.12,19.498,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.987766,SA139A,HTR2B
38,11859080,5ht2b_human,139,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,17.0,1.889,,,,98.0,0.0,,0.0,,P41595,-0.987766,SA139A,HTR2B
67,23519210,5ht2b_human,139,S,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.39,1.479,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.987766,SA139A,HTR2B
108,11859080,5ht2b_human,139,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,347.0,28.917,,,,0.0,0.0,,0.0,,P41595,-0.987766,SA139A,HTR2B
150,23519210,5ht2b_human,139,S,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.38,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P41595,-0.987766,SA139A,HTR2B
22,11859080,5ht2b_human,363,E,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,11.0,1.222,,,,99.0,0.0,,0.0,,P41595,0.0871549,EA363A,HTR2B
81,23519210,5ht2b_human,363,E,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.54,-1.445,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.0871549,EA363A,HTR2B
93,23519210,5ht2b_human,363,E,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.57,-10.204,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.0871549,EA363A,HTR2B
105,23519210,5ht2b_human,363,E,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.69,-1.905,,,[3H]LSD,0.0,0.0,,0.0,,P41595,0.0871549,EA363A,HTR2B
134,11859080,5ht2b_human,363,E,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,58.0,4.833,,,,0.0,0.0,,0.0,,P41595,0.0871549,EA363A,HTR2B
25,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,Methylergonovine,PubChem CID,8226,Partial agonist,EC50,Functional - Ca2+ accumulation,23.0,nM,=,,12.0,-1.916,,,,0.0,0.0,,86.0,,P41595,1.12223,AA225G,HTR2B
96,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.24,1.5,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
98,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,2.2,nM,=,,1.5,-1.466,,,,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
102,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,Methylergonovine,PubChem CID,8226,Partial agonist,K(i),Binding - Radioligand competition/displacement,0.37,nM,=,,0.96,2.595,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
107,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - β-arrestin recruitment,3.6,nM,=,,4.6,1.278,,,,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
117,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,LSD,PubChem CID,5761,Partial agonist,K(d),Binding - Radioligand competition/displacement,0.58,nM,=,,1.31,2.259,,,[3H]-LSD,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
142,10.1038/s41594-018-0116-7,5ht2b_human,225,A,G,5-HT,PubChem CID,5202,Full agonist,EC50,Functional - Ca2+ accumulation,3.2,nM,=,,1.5,-2.132,,,,0.0,0.0,,0.0,,P41595,1.12223,AA225G,HTR2B
27,23519210,5ht2b_human,340,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,6.22,154.882,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.94461,FA340A,HTR2B
77,23519210,5ht2b_human,340,F,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.61,5.888,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.94461,FA340A,HTR2B
120,23519210,5ht2b_human,340,F,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.23,-4.673,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.94461,FA340A,HTR2B
34,11859080,5ht2b_human,231,A,T,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,93.0,7.75,,,,0.0,0.0,,0.0,,P41595,0.399348,AA231T,HTR2B
88,11859080,5ht2b_human,231,A,T,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,56.0,6.222,,,,23.0,0.0,,0.0,,P41595,0.399348,AA231T,HTR2B
41,23519210,5ht2b_human,218,M,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.42,-1.096,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.94487,MA218A,HTR2B
62,23519210,5ht2b_human,218,M,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.51,-8.929,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.94487,MA218A,HTR2B
127,23519210,5ht2b_human,218,M,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.75,4.571,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.94487,MA218A,HTR2B
46,23519210,5ht2b_human,347,L,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,7.85,-1.949,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.83351,LA347A,HTR2B
65,23519210,5ht2b_human,347,L,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,8.18,1.698,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.83351,LA347A,HTR2B
82,23519210,5ht2b_human,347,L,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.54,-1.445,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.83351,LA347A,HTR2B
55,11859080,5ht2b_human,187,A,S,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,9.0,-1.333,,,,0.0,0.0,,0.0,,P41595,0.12221,AA187S,HTR2B
94,11859080,5ht2b_human,187,A,S,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,9.0,1.0,,,,100.0,0.0,,0.0,,P41595,0.12221,AA187S,HTR2B
58,23519210,5ht2b_human,136,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.0,-2.755,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.01862,VA136A,HTR2B
74,23519210,5ht2b_human,136,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.51,7.413,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.01862,VA136A,HTR2B
83,23519210,5ht2b_human,136,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,6.91,31.623,,,[3H]LSD,0.0,0.0,,0.0,,P41595,1.01862,VA136A,HTR2B
59,11859080,5ht2b_human,135,D,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,>,,10000.0,1111.111,,,,0.0,0.0,,0.0,,P41595,1.48761,DA135A,HTR2B
89,11859080,5ht2b_human,135,D,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,>,,10000.0,833.333,,,,0.0,0.0,,0.0,,P41595,1.48761,DA135A,HTR2B
60,11859080,5ht2b_human,337,W,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,132.0,11.0,,,,0.0,0.0,,0.0,,P41595,3.56317,WA337A,HTR2B
86,23519210,5ht2b_human,337,W,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,7.41,9.333,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.56317,WA337A,HTR2B
106,23519210,5ht2b_human,337,W,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.21,-4.464,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.56317,WA337A,HTR2B
113,23519210,5ht2b_human,337,W,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.16,17.783,,,[3H]LSD,0.0,0.0,,0.0,,P41595,3.56317,WA337A,HTR2B
149,11859080,5ht2b_human,337,W,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,13.0,1.444,,,,98.0,0.0,,0.0,,P41595,3.56317,WA337A,HTR2B
68,11859080,5ht2b_human,229,P,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,7.0,-1.285,,,,101.0,0.0,,0.0,,P41595,2.62129,PA229A,HTR2B
132,11859080,5ht2b_human,229,P,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,10.0,-1.2,,,,0.0,0.0,,0.0,,P41595,2.62129,PA229A,HTR2B
71,11859080,5ht2b_human,341,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,14.0,1.556,,,,98.0,0.0,,0.0,,P41595,3.22569,FA341A,HTR2B
100,11859080,5ht2b_human,341,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,174.0,14.5,,,,0.0,0.0,,0.0,,P41595,3.22569,FA341A,HTR2B
80,11859080,5ht2b_human,100,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,120.0,13.333,,,,45.0,0.0,,0.0,,P41595,-0.33507,DA100N,HTR2B
144,11859080,5ht2b_human,100,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,148.0,12.333,,,,0.0,0.0,,0.0,,P41595,-0.33507,DA100N,HTR2B
87,11859080,5ht2b_human,222,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,11.0,1.222,,,,99.0,0.0,,0.0,,P41595,-1.99838,SA222A,HTR2B
130,11859080,5ht2b_human,222,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,11.0,-1.091,,,,0.0,0.0,,0.0,,P41595,-1.99838,SA222A,HTR2B
92,23519210,5ht2b_human,132,L,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.56,,=,,8.39,-6.757,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.65049,LA132A,HTR2B
103,23519210,5ht2b_human,132,L,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.41,,=,,7.75,4.571,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.65049,LA132A,HTR2B
114,23519210,5ht2b_human,132,L,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.38,,=,,8.58,-1.585,,,[3H]LSD,0.0,0.0,,0.0,,P41595,2.65049,LA132A,HTR2B
129,11859080,5ht2b_human,228,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.0,nM,=,,1096.0,91.333,,,,0.0,0.0,,0.0,,P41595,0.0603811,TA228A,HTR2B
147,11859080,5ht2b_human,228,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,186.0,20.667,,,,21.0,0.0,,0.0,,P41595,0.0603811,TA228A,HTR2B
5,9671119,5ht1b_human,185,F,A,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,4.6,-1.412,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
10,9671119,5ht1b_human,185,F,A,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,1.1,-1.364,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
20,9671119,5ht1b_human,185,F,A,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.17,-1.176,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
27,9671119,5ht1b_human,185,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.1,-1.096,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
45,9671119,5ht1b_human,185,F,A,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,5.5,-3.401,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
50,11399261,5ht1b_human,185,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,565.0,5.65,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
59,11399261,5ht1b_human,185,F,A,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,1.0,1.429,,,,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
74,11399261,5ht1b_human,185,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.1,-1.096,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
78,9671119,5ht1b_human,185,F,A,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,2.4,-3.623,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
102,11399261,5ht1b_human,185,F,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.3,-1.06,,,,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
125,9671119,5ht1b_human,185,F,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,2.5,-1.241,,,,16.7,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
145,9671119,5ht1b_human,185,F,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,747.0,nM,=,,291.0,-2.564,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
218,9671119,5ht1b_human,185,F,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Full agonist,EC50,Functional - cAMP accumulation,1098.0,nM,=,,1730.0,1.576,,,Forskolin,0.0,0.0,,0.0,,P28222,0.55482,FA185A,HTR1B
6,11399261,5ht1b_human,185,F,M,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,279.0,2.79,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
76,9671119,5ht1b_human,185,F,M,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Full agonist,EC50,Functional - cAMP accumulation,1098.0,nM,=,,1034.0,-1.062,,,Forskolin,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
83,9671119,5ht1b_human,185,F,M,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,747.0,nM,=,,425.0,-1.757,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
89,9671119,5ht1b_human,185,F,M,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,1.7,-1.825,,,,15.7,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
114,11399261,5ht1b_human,185,F,M,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,1.2,1.714,,,,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
122,9671119,5ht1b_human,185,F,M,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,2.4,-2.71,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
150,11399261,5ht1b_human,185,F,M,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,2.4,-1.458,,,,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
170,9671119,5ht1b_human,185,F,M,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,3.2,-2.717,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
180,9671119,5ht1b_human,185,F,M,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.34,1.7,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
192,9671119,5ht1b_human,185,F,M,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,9.9,-1.89,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
194,9671119,5ht1b_human,185,F,M,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,4.2,1.235,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
199,11399261,5ht1b_human,185,F,M,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,4.2,1.235,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
212,9671119,5ht1b_human,185,F,M,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,1.1,-1.364,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.127657,FA185M,HTR1B
11,23519210,5ht1b_human,209,T,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.9,-1.585,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.385364,TA209A,HTR1B
21,23519210,5ht1b_human,209,T,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.44,-1.318,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.385364,TA209A,HTR1B
52,23519210,5ht1b_human,209,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.22,-1.35,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.385364,TA209A,HTR1B
13,9671119,5ht1b_human,334,S,A,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,5.8,-1.499,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
39,11399261,5ht1b_human,334,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,414.0,4.14,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
40,11399261,5ht1b_human,334,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.8,1.118,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
53,9671119,5ht1b_human,334,S,A,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,4.8,-1.355,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
62,23519210,5ht1b_human,334,S,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.29,1.072,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
96,9671119,5ht1b_human,334,S,A,8-OH-DPAT,ChEMBL Compound ID,CHEMBL56,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,747.0,nM,=,,151.0,-4.95,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
100,23519210,5ht1b_human,334,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.31,6.026,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
126,9671119,5ht1b_human,334,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.8,1.118,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
135,9671119,5ht1b_human,334,S,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,3.0,-1.033,,,,18.1,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
137,11399261,5ht1b_human,334,S,A,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.2,-3.497,,,,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
141,23519210,5ht1b_human,334,S,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
149,9671119,5ht1b_human,334,S,A,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,13.7,-1.364,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
173,9671119,5ht1b_human,334,S,A,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.25,1.25,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
209,11399261,5ht1b_human,334,S,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.6,1.029,,,,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
211,9671119,5ht1b_human,334,S,A,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,0.6,-2.5,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.371057,SA334A,HTR1B
15,9671119,5ht1b_human,354,F,Y,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,2.5,-1.361,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
17,9671119,5ht1b_human,354,F,Y,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,0.9,-1.667,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
43,9671119,5ht1b_human,354,F,Y,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.42,2.1,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
66,11399261,5ht1b_human,354,F,Y,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,1.2,1.714,,,,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
101,9671119,5ht1b_human,354,F,Y,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,18.0,-1.038,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
106,11399261,5ht1b_human,354,F,Y,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,2.2,-1.59,,,,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
116,9671119,5ht1b_human,354,F,Y,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,10.5,1.207,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
120,9671119,5ht1b_human,354,F,Y,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,1.6,-1.938,,,,20.2,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
124,9671119,5ht1b_human,354,F,Y,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,2.3,-2.825,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
156,11399261,5ht1b_human,354,F,Y,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,46.5,-2.151,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
206,11399261,5ht1b_human,354,F,Y,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,2.5,-1.361,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.0339136,FA354Y,HTR1B
16,23519210,5ht1b_human,201,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.09,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.808212,VA201A,HTR1B
111,23519210,5ht1b_human,201,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.61,-1.949,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.808212,VA201A,HTR1B
205,23519210,5ht1b_human,201,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.2,-3.165,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.808212,VA201A,HTR1B
23,23519210,5ht1b_human,337,M,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.1,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P28222,2.18988,MA337A,HTR1B
148,23519210,5ht1b_human,337,M,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.13,-1.096,,,[3H]LSD,0.0,0.0,,0.0,,P28222,2.18988,MA337A,HTR1B
222,23519210,5ht1b_human,337,M,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.39,-1.175,,,[3H]LSD,0.0,0.0,,0.0,,P28222,2.18988,MA337A,HTR1B
28,23519210,5ht1b_human,134,T,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.4,-1.202,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.0716319,TA134A,HTR1B
30,23519210,5ht1b_human,134,T,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.1,3.981,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.0716319,TA134A,HTR1B
224,23519210,5ht1b_human,134,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,6.75,21.878,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.0716319,TA134A,HTR1B
29,9671119,5ht1b_human,181,S,A,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.14,-1.429,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
46,9671119,5ht1b_human,181,S,A,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,12.3,1.414,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
49,9671119,5ht1b_human,181,S,A,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,22.0,1.176,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
69,9671119,5ht1b_human,181,S,A,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,1.9,1.267,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
80,9671119,5ht1b_human,181,S,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,2.0,-1.55,,,,43.9,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
200,9671119,5ht1b_human,181,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.8,1.118,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
210,9671119,5ht1b_human,181,S,A,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,5.9,-1.101,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-0.292316,SA181A,HTR1B
31,23519210,5ht1b_human,351,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.79,1.995,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.85119,FA351A,HTR1B
71,23519210,5ht1b_human,351,F,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.26,1.148,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.85119,FA351A,HTR1B
161,23519210,5ht1b_human,351,F,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.85119,FA351A,HTR1B
38,23519210,5ht1b_human,355,T,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.39,-1.175,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.632927,TA355A,HTR1B
115,23519210,5ht1b_human,355,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.81,1.905,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.632927,TA355A,HTR1B
197,23519210,5ht1b_human,355,T,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.8,-1.259,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.632927,TA355A,HTR1B
42,23519210,5ht1b_human,126,L,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.5,-1.513,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.95208,LA126A,HTR1B
162,23519210,5ht1b_human,126,L,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.95208,LA126A,HTR1B
220,23519210,5ht1b_human,126,L,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.47,4.169,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.95208,LA126A,HTR1B
54,9879059,5ht1b_human,331,F,A,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,1.6,-2.123,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
55,9879059,5ht1b_human,331,F,A,5-CT,PubChem CID,1809,Full agonist,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,0.8,-1.876,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
110,9879059,5ht1b_human,331,F,A,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,8.7,-2.151,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
119,23519210,5ht1b_human,331,F,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.7,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
127,9879059,5ht1b_human,331,F,A,Methiothepin,PubChem CID,4106,Inverse agonist,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,110.0,16.923,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
131,11399261,5ht1b_human,331,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,1.6,-2.123,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
133,11399261,5ht1b_human,331,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,9.3,-10.753,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
134,23519210,5ht1b_human,331,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.96,1.349,,,[3H]LSD,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
158,11399261,5ht1b_human,331,F,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,1.2,-2.915,,,,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
186,23519210,5ht1b_human,331,F,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.13,1.549,,,[3H]LSD,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
189,9879059,5ht1b_human,331,F,A,Sumatriptan,PubChem CID,5358,Partial agonist,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,5.6,-1.553,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
195,11399261,5ht1b_human,331,F,A,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.3,-2.331,,,,0.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
216,9879059,5ht1b_human,331,F,A,[3H]5-HT,PubChem CID,53317992,Full agonist,K(d),Binding - Radioligand saturation,3.1,nM,=,,1.2,-2.584,,,,61.0,0.0,,0.0,,P28222,3.58463,FA331A,HTR1B
60,11399261,5ht1b_human,354,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,1.9,-1.789,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
64,9671119,5ht1b_human,354,F,A,"L-694,247",ChEMBL Compound ID,CHEMBL39317,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.2,nM,=,,0.12,-1.667,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
67,9671119,5ht1b_human,354,F,A,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,8.4,-1.035,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
75,9671119,5ht1b_human,354,F,A,5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,1.0,-1.499,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
104,11399261,5ht1b_human,354,F,A,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.9,1.286,,,,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
108,9671119,5ht1b_human,354,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,1.9,-1.789,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
123,11399261,5ht1b_human,354,F,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.0,-1.167,,,,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
155,9671119,5ht1b_human,354,F,A,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,3.2,-2.033,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
177,9671119,5ht1b_human,354,F,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.1,nM,=,,1.8,-1.721,,,,97.9,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
191,9671119,5ht1b_human,354,F,A,Methysergide,ChEMBL Compound ID,CHEMBL1065,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,21.1,1.128,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
203,11399261,5ht1b_human,354,F,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,60.1,-1.664,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,2.24826,FA354A,HTR1B
65,23519210,5ht1b_human,212,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.98,1.288,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
73,9879059,5ht1b_human,212,S,A,Methysergide,PubChem CID,9681,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,18.7,nM,=,,7.0,-2.674,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
84,23519210,5ht1b_human,212,S,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.7,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
93,9879059,5ht1b_human,212,S,A,Sumatriptan,PubChem CID,5358,Partial agonist,K(i),Binding - Radioligand competition/displacement,8.7,nM,=,,7.1,-1.225,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
95,9879059,5ht1b_human,212,S,A,Methiothepin,PubChem CID,4106,Inverse agonist,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,1.4,-4.651,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
112,9879059,5ht1b_human,212,S,A,[3H]5-HT,PubChem CID,53317992,Full agonist,K(d),Binding - Radioligand saturation,3.1,nM,=,,2.2,-1.408,,,,30.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
138,11399261,5ht1b_human,212,S,A,[3H]5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,3.5,nM,=,,2.2,-1.59,,,,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
142,11399261,5ht1b_human,212,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.3,-1.03,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
160,23519210,5ht1b_human,212,S,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.24,1.202,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
169,11399261,5ht1b_human,212,S,A,[3H]GR125743,ChEMBL Compound ID,CHEMBL1908856,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.7,nM,=,,0.6,-1.167,,,,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
184,9879059,5ht1b_human,212,S,A,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.3,-1.03,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
214,9879059,5ht1b_human,212,S,A,5-CT,PubChem CID,1809,Full agonist,K(i),Binding - Radioligand competition/displacement,1.5,nM,=,,22.7,15.133,,,[3H]5-HT,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
219,11399261,5ht1b_human,212,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,97.3,-1.028,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,-1.62855,SA212A,HTR1B
88,23519210,5ht1b_human,216,A,S,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.1,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.275391,AA216S,HTR1B
97,23519210,5ht1b_human,216,A,S,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.85,1.738,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.275391,AA216S,HTR1B
201,23519210,5ht1b_human,216,A,S,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.44,-1.318,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.275391,AA216S,HTR1B
98,23519210,5ht1b_human,359,Y,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.45,-2.288,,,[3H]LSD,0.0,0.0,,0.0,,P28222,4.70083,YA359A,HTR1B
129,23519210,5ht1b_human,359,Y,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.81,-3.086,,,[3H]LSD,0.0,0.0,,0.0,,P28222,4.70083,YA359A,HTR1B
151,23519210,5ht1b_human,359,Y,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.6,1.259,,,[3H]LSD,0.0,0.0,,0.0,,P28222,4.70083,YA359A,HTR1B
99,23519210,5ht1b_human,203,T,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.03,1.148,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.0606661,TA203A,HTR1B
139,23519210,5ht1b_human,203,T,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.09,1.698,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.0606661,TA203A,HTR1B
179,23519210,5ht1b_human,203,T,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.7,1.0,,,[3H]LSD,0.0,0.0,,0.0,,P28222,-0.0606661,TA203A,HTR1B
136,23519210,5ht1b_human,352,D,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.42,-1.259,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.76939,DA352A,HTR1B
144,23519210,5ht1b_human,352,D,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,8.42,-2.137,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.76939,DA352A,HTR1B
196,23519210,5ht1b_human,352,D,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.1,-2.513,,,[3H]LSD,0.0,0.0,,0.0,,P28222,1.76939,DA352A,HTR1B
146,23519210,5ht1b_human,200,V,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,8.0,-1.996,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.304473,VA200A,HTR1B
152,23519210,5ht1b_human,200,V,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.09,,=,,7.98,1.288,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.304473,VA200A,HTR1B
164,23519210,5ht1b_human,200,V,A,Ergotamine,ChEMBL Compound ID,CHEMBL442,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.32,,=,,8.33,-1.024,,,[3H]LSD,0.0,0.0,,0.0,,P28222,0.304473,VA200A,HTR1B
198,10513577,5ht1b_human,327,W,A,Sumatriptan,ChEMBL Compound ID,CHEMBL128,Binding - unknown pharmacological activity,,Binding - Radioligand competition/displacement,0.0,,,,0.0,60.0,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,2.89904,WA327A,HTR1B
202,10513577,5ht1b_human,327,W,A,Methiothepin,ChEMBL Compound ID,CHEMBL122536,Binding - unknown pharmacological activity,,Binding - Radioligand competition/displacement,0.0,,,,0.0,300.0,,,[3H]GR125743,0.0,0.0,,0.0,,P28222,2.89904,WA327A,HTR1B
2,24903527,hrh4_human,169,F,V,UR-PI376,ChEMBL Compound ID,CHEMBL1078642,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.27,,=,,6.33,8.71,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
9,24903527,hrh4_human,169,F,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.18,,=,,5.51,4.677,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
21,18635748,hrh4_human,169,F,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.12,5.888,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
32,18635748,hrh4_human,169,F,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.35,,=,,5.52,6.761,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
36,24903527,hrh4_human,169,F,V,UR-PI294,ChEMBL Compound ID,CHEMBL475621,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.83,1.023,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
50,24903527,hrh4_human,169,F,V,Thioperamide,ChEMBL Compound ID,CHEMBL260374,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.75,,=,,6.98,-1.698,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
67,24903527,hrh4_human,169,F,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.59,1.995,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
78,24903527,hrh4_human,169,F,V,Immepip,ChEMBL Compound ID,CHEMBL18661,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.47,1.82,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
100,24903527,hrh4_human,169,F,V,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.83,2.138,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
101,18635748,hrh4_human,169,F,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,9.0,nM,=,,42.4,4.711,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
103,18635748,hrh4_human,169,F,V,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.46,,=,,7.05,2.57,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
143,24903527,hrh4_human,169,F,V,Isoloxapine,ChEMBL Compound ID,CHEMBL7828,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.93,,=,,6.05,7.586,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
161,24903527,hrh4_human,169,F,V,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.21,3.311,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
181,24903527,hrh4_human,169,F,V,[3H]-histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,11.16,nM,=,,20.15,1.806,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
184,24903527,hrh4_human,169,F,V,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.44,2.512,,,[3H]-histamine (radioligand),99.5,0.0,,0.0,,Q9H3N8,1.38943,FA169V,HRH4
3,20103609,hrh4_human,179,S,L,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.7,1.585,,,[3H]-histamine (radioligand),106.5,0.0,,0.0,,Q9H3N8,0.16072,SA179L,HRH4
34,20103609,hrh4_human,179,S,L,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.0,nM,=,,12.0,1.333,,,[3H]-histamine (radioligand),106.5,0.0,,0.0,,Q9H3N8,0.16072,SA179L,HRH4
93,20103609,hrh4_human,179,S,L,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.3,1.585,,,[3H]-histamine (radioligand),106.5,0.0,,0.0,,Q9H3N8,0.16072,SA179L,HRH4
96,20103609,hrh4_human,179,S,L,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.4,,=,,6.6,-1.585,,,[3H]-histamine (radioligand),106.5,0.0,,0.0,,Q9H3N8,0.16072,SA179L,HRH4
177,20103609,hrh4_human,179,S,L,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.8,3.162,,,[3H]-histamine (radioligand),106.5,0.0,,0.0,,Q9H3N8,0.16072,SA179L,HRH4
4,22003888,hrh4_human,147,N,Y,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,6.5,10.0,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,2.85887,NA147Y,HRH4
183,22003888,hrh4_human,147,N,Y,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,7.8,1.995,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,2.85887,NA147Y,HRH4
5,20103609,hrh4_human,175,L,V,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.1,15.849,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
31,20103609,hrh4_human,175,L,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.4,,=,,7.0,-3.984,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
48,10.1039/C2MD20212C,hrh4_human,175,L,V,1H-indol-2-yl-(4-methylpiperazin-1-yl)methanone,ChEMBL Compound ID,CHEMBL129199,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,6.5,3.981,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
54,20103609,hrh4_human,175,L,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,8.0,-1.259,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
74,20103609,hrh4_human,175,L,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.0,nM,=,,10.0,1.111,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
75,10.1039/C2MD20212C,hrh4_human,175,L,V,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,6.4,19.953,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
87,10.1039/C2MD20212C,hrh4_human,175,L,V,4-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine,ChEMBL Compound ID,CHEMBL493720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,7.2,31.623,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
99,10.1039/C2MD20212C,hrh4_human,175,L,V,VUF10460,ChEMBL Compound ID,CHEMBL492884,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.7,3.981,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,1.9221,LA175V,HRH4
7,20103609,hrh4_human,174,I,V,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.3,1.0,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,0.519501,IA174V,HRH4
73,20103609,hrh4_human,174,I,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.4,,=,,6.2,1.585,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,0.519501,IA174V,HRH4
129,20103609,hrh4_human,174,I,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.9,1.0,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,0.519501,IA174V,HRH4
149,20103609,hrh4_human,174,I,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.0,nM,=,,10.0,1.111,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,0.519501,IA174V,HRH4
150,20103609,hrh4_human,174,I,V,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.4,1.259,,,[3H]-histamine (radioligand),112.9,0.0,,0.0,,Q9H3N8,0.519501,IA174V,HRH4
8,24903527,hrh4_human,179,S,A,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.18,,=,,6.59,-2.571,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
10,24903527,hrh4_human,179,S,A,Immepip,ChEMBL Compound ID,CHEMBL18661,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.44,1.95,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
42,24903527,hrh4_human,179,S,A,Isoloxapine,ChEMBL Compound ID,CHEMBL7828,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.93,,=,,7.47,-3.472,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
45,24903527,hrh4_human,179,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.61,1.905,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
56,24903527,hrh4_human,179,S,A,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.81,1.072,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
71,24903527,hrh4_human,179,S,A,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.56,1.479,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
81,12065753,hrh4_human,179,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,15.3,nM,=,,34.4,2.248,,,[3H]-histamine (radioligand),135.9,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
83,24903527,hrh4_human,179,S,A,[3H]-histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,11.16,nM,=,,14.81,1.327,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
92,24903527,hrh4_human,179,S,A,Thioperamide,ChEMBL Compound ID,CHEMBL260374,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.75,,=,,7.34,-3.891,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
115,24903527,hrh4_human,179,S,A,UR-PI376,ChEMBL Compound ID,CHEMBL1078642,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.27,,=,,7.6,-2.137,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
122,24903527,hrh4_human,179,S,A,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.16,,=,,7.78,-4.167,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
126,24903527,hrh4_human,179,S,A,UR-PI294,ChEMBL Compound ID,CHEMBL475621,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.9,-1.148,,,[3H]-histamine (radioligand),116.6,0.0,,0.0,,Q9H3N8,-1.10466,SA179A,HRH4
11,24903527,hrh4_human,179,S,M,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.49,2.512,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
29,24903527,hrh4_human,179,S,M,Isoloxapine,ChEMBL Compound ID,CHEMBL7828,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.93,,=,,7.02,-1.23,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
44,24903527,hrh4_human,179,S,M,[3H]-histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,11.16,nM,=,,17.81,1.596,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
51,18635748,hrh4_human,179,S,M,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.35,,=,,6.27,1.202,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
68,18635748,hrh4_human,179,S,M,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,9.0,nM,=,,18.0,2.0,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
82,24903527,hrh4_human,179,S,M,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.16,,=,,7.23,-1.175,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
88,18635748,hrh4_human,179,S,M,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.57,2.089,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
90,24903527,hrh4_human,179,S,M,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.18,,=,,6.36,-1.513,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
110,24903527,hrh4_human,179,S,M,Immepip,ChEMBL Compound ID,CHEMBL18661,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.49,1.738,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
128,18635748,hrh4_human,179,S,M,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.46,,=,,7.52,-1.148,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
135,24903527,hrh4_human,179,S,M,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.73,,=,,7.14,3.89,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
159,24903527,hrh4_human,179,S,M,Thioperamide,ChEMBL Compound ID,CHEMBL260374,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.75,,=,,6.67,1.202,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
166,24903527,hrh4_human,179,S,M,UR-PI376,ChEMBL Compound ID,CHEMBL1078642,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.27,,=,,7.1,1.479,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
169,24903527,hrh4_human,179,S,M,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.55,1.95,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
178,24903527,hrh4_human,179,S,M,UR-PI294,ChEMBL Compound ID,CHEMBL475621,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.84,,=,,7.93,-1.23,,,[3H]-histamine (radioligand),107.8,0.0,,0.0,,Q9H3N8,-1.05941,SA179M,HRH4
12,10.1039/C2MD20212C,hrh4_human,182,E,Q,VUF10460,ChEMBL Compound ID,CHEMBL492884,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.2,12.589,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
19,22003888,hrh4_human,182,E,Q,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,7.3,6.31,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
24,18553960,hrh4_human,182,E,Q,[3H]-JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.5,nM,=,,7.5,-1.267,,,[3H]-JNJ 7777120 (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
37,18553960,hrh4_human,182,E,Q,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.74,,=,,4.95,616.595,,,[3H]-JNJ 7777120 (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
43,10.1039/C2MD20212C,hrh4_human,182,E,Q,4-(4-chlorophenyl)-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine,ChEMBL Compound ID,CHEMBL493720,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,6.7,100.0,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
65,10.1039/C2MD20212C,hrh4_human,182,E,Q,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.5,1.585,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
79,10.1039/C2MD20212C,hrh4_human,182,E,Q,1H-indol-2-yl-(4-methylpiperazin-1-yl)methanone,ChEMBL Compound ID,CHEMBL129199,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,6.7,2.512,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
86,18553960,hrh4_human,182,E,Q,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.25,,=,,6.15,1.259,,,[3H]-JNJ 7777120 (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
102,18553960,hrh4_human,182,E,Q,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.57,,=,,5.04,338.844,,,[3H]-JNJ 7777120 (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
119,22003888,hrh4_human,182,E,Q,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,6.8,5.012,,,[3H]-JNJ 7777120 (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.261733,EA182Q,HRH4
16,20103609,hrh4_human,150,M,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.0,nM,=,,14.0,1.556,,,[3H]-histamine (radioligand),77.4,0.0,,0.0,,Q9H3N8,1.01744,MA150V,HRH4
72,20103609,hrh4_human,150,M,V,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.2,1.995,,,[3H]-histamine (radioligand),77.4,0.0,,0.0,,Q9H3N8,1.01744,MA150V,HRH4
136,20103609,hrh4_human,150,M,V,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.2,1.259,,,[3H]-histamine (radioligand),77.4,0.0,,0.0,,Q9H3N8,1.01744,MA150V,HRH4
144,20103609,hrh4_human,150,M,V,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.4,,=,,6.2,1.585,,,[3H]-histamine (radioligand),77.4,0.0,,0.0,,Q9H3N8,1.01744,MA150V,HRH4
155,20103609,hrh4_human,150,M,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.8,1.259,,,[3H]-histamine (radioligand),77.4,0.0,,0.0,,Q9H3N8,1.01744,MA150V,HRH4
17,18635748,hrh4_human,176,A,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.76,1.349,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.537569,AA176T,HRH4
105,18635748,hrh4_human,176,A,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,9.0,nM,=,,8.5,-1.059,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.537569,AA176T,HRH4
125,18635748,hrh4_human,176,A,T,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.46,,=,,7.52,-1.148,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.537569,AA176T,HRH4
158,18635748,hrh4_human,176,A,T,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.35,,=,,6.18,1.479,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.537569,AA176T,HRH4
28,18635748,hrh4_human,170,S,T,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.35,,=,,6.02,2.138,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-0.168047,SA170T,HRH4
30,18635748,hrh4_human,170,S,T,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.46,,=,,7.6,-1.381,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-0.168047,SA170T,HRH4
41,18635748,hrh4_human,170,S,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.82,1.175,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-0.168047,SA170T,HRH4
98,18635748,hrh4_human,170,S,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,9.0,nM,=,,11.9,1.322,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,-0.168047,SA170T,HRH4
33,22003888,hrh4_human,323,T,M,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,8.8,-5.0,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,-1.1393,TA323M,HRH4
133,22003888,hrh4_human,323,T,M,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.9,-2.513,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,-1.1393,TA323M,HRH4
38,20103609,hrh4_human,147,N,H,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.4,3.162,,,[3H]-histamine (radioligand),71.0,0.0,,0.0,,Q9H3N8,1.171,NA147H,HRH4
94,20103609,hrh4_human,147,N,H,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,9.0,nM,=,,51.0,5.667,,,[3H]-histamine (radioligand),71.0,0.0,,0.0,,Q9H3N8,1.171,NA147H,HRH4
112,20103609,hrh4_human,147,N,H,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.7,3.981,,,[3H]-histamine (radioligand),71.0,0.0,,0.0,,Q9H3N8,1.171,NA147H,HRH4
139,20103609,hrh4_human,147,N,H,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,6.8,5.012,,,[3H]-histamine (radioligand),71.0,0.0,,0.0,,Q9H3N8,1.171,NA147H,HRH4
172,20103609,hrh4_human,147,N,H,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.4,,=,,4.7,50.119,,,[3H]-histamine (radioligand),71.0,0.0,,0.0,,Q9H3N8,1.171,NA147H,HRH4
46,22003888,hrh4_human,347,Q,L,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.9,-2.513,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,-1.19434,QA347L,HRH4
140,22003888,hrh4_human,347,Q,L,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,9.0,-7.937,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,-1.19434,QA347L,HRH4
53,20103609,hrh4_human,156,S,A,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.5,1.0,,,[3H]-histamine (radioligand),6.5,0.0,,0.0,,Q9H3N8,-1.04774,SA156A,HRH4
80,20103609,hrh4_human,156,S,A,JNJ-7777120,ChEMBL Compound ID,CHEMBL129198,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.2,1.259,,,[3H]-histamine (radioligand),6.5,0.0,,0.0,,Q9H3N8,-1.04774,SA156A,HRH4
153,20103609,hrh4_human,156,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.9,,=,,7.8,1.259,Abolished effect,,[3H]-histamine (radioligand),6.5,0.0,,0.0,,Q9H3N8,-1.04774,SA156A,HRH4
57,22003888,hrh4_human,102,V,A,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.2,1.995,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.990582,VA102A,HRH4
180,22003888,hrh4_human,102,V,A,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,8.0,1.259,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.990582,VA102A,HRH4
60,18635748,hrh4_human,153,V,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,9.0,nM,=,,12.9,1.433,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.287332,VA153A,HRH4
91,18635748,hrh4_human,153,V,A,Clozapine,ChEMBL Compound ID,CHEMBL42,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.35,,=,,6.23,1.318,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.287332,VA153A,HRH4
117,18635748,hrh4_human,153,V,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.89,,=,,7.72,1.479,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.287332,VA153A,HRH4
141,18635748,hrh4_human,153,V,A,VUF8430,ChEMBL Compound ID,CHEMBL1196470,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.46,,=,,7.46,1.0,,,[3H]-histamine (radioligand),0.0,0.0,,0.0,,Q9H3N8,0.287332,VA153A,HRH4
69,12065753,hrh4_human,320,S,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,15.3,nM,=,,32.1,2.098,,,[3H]-histamine (radioligand),58.7,0.0,,0.0,,Q9H3N8,-1.61638,SA320A,HRH4
95,12065753,hrh4_human,178,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,15.3,nM,=,,47.9,3.131,,,[3H]-histamine (radioligand),68.5,0.0,,0.0,,Q9H3N8,0.980641,TA178A,HRH4
104,22003888,hrh4_human,178,T,A,VUF5228,ChEMBL Compound ID,CHEMBL43934,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.5,,=,,7.9,-2.513,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.980641,TA178A,HRH4
170,22003888,hrh4_human,178,T,A,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,,=,,8.6,-3.165,,,[3H]-histamine (radioligand),100.0,0.0,,0.0,,Q9H3N8,0.980641,TA178A,HRH4
124,12065753,hrh4_human,147,N,T,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,15.3,nM,=,,31.4,2.052,,,[3H]-histamine (radioligand),126.1,0.0,,0.0,,Q9H3N8,1.35879,NA147T,HRH4
131,12065753,hrh4_human,320,S,F,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,15.3,nM,=,,76.1,4.974,,,[3H]-histamine (radioligand),42.4,0.0,,0.0,,Q9H3N8,4.43162,SA320F,HRH4
0,24088171,acm3_human,504,W,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,8.5,50.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
14,24088171,acm3_human,504,W,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,9.2,39.811,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
107,24088171,acm3_human,504,W,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,7.9,79.433,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
139,24088171,acm3_human,504,W,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,8.5,63.096,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
142,24088171,acm3_human,504,W,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,8.1,19.953,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
151,24088171,acm3_human,504,W,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,9.2,199.526,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,1.91564,WA504A,CHRM3
1,24088171,acm3_human,149,Y,A,Cpd7,ChEMBL Compound ID,CHEMBL3140016,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.8,,=,,6.4,251.189,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
19,24088171,acm3_human,149,Y,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,8.6,158.489,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
42,24088171,acm3_human,149,Y,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,6.6,630.957,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
46,24088171,acm3_human,149,Y,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,8.4,79.433,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
83,24088171,acm3_human,149,Y,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,8.8,501.187,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
93,24088171,acm3_human,149,Y,A,Cpd3,ChEMBL Compound ID,CHEMBL3140032,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,7.2,199.526,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
112,24088171,acm3_human,149,Y,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,8.7,31.623,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
123,24088171,acm3_human,149,Y,A,Cpd9,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.0,,=,,7.3,501.187,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
140,24088171,acm3_human,149,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,7.9,79.433,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.47943,YA149A,CHRM3
2,24088171,acm3_human,530,Y,A,Cpd9,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.0,,=,,8.9,12.589,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
22,24088171,acm3_human,530,Y,A,Cpd3,ChEMBL Compound ID,CHEMBL3140032,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,8.6,7.943,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
29,24088171,acm3_human,530,Y,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.2,3.981,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
57,24088171,acm3_human,530,Y,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,9.2,12.589,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
143,24088171,acm3_human,530,Y,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,10.2,19.953,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
150,24088171,acm3_human,530,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.1,50.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
171,24088171,acm3_human,530,Y,A,Cpd7,ChEMBL Compound ID,CHEMBL3140016,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.8,,=,,7.3,31.623,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.88023,YA530A,CHRM3
6,24088171,acm3_human,523,K,A,Cpd7,ChEMBL Compound ID,CHEMBL3140016,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.8,,=,,9.1,-1.996,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
16,24088171,acm3_human,523,K,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
43,24088171,acm3_human,523,K,A,Cpd3,ChEMBL Compound ID,CHEMBL3140032,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.8,-1.996,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
108,24088171,acm3_human,523,K,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.6,-1.259,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
126,24088171,acm3_human,523,K,A,Cpd9,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.0,,=,,10.1,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
165,24088171,acm3_human,523,K,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,10.7,-2.513,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
172,24088171,acm3_human,523,K,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.650975,KA523A,CHRM3
7,24088171,acm3_human,241,Y,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.9,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.36102,YA241A,CHRM3
61,24088171,acm3_human,241,Y,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,9.6,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.36102,YA241A,CHRM3
70,24088171,acm3_human,241,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.36102,YA241A,CHRM3
73,24088171,acm3_human,241,Y,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,10.7,-2.513,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.36102,YA241A,CHRM3
154,24088171,acm3_human,241,Y,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,10.0,1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.36102,YA241A,CHRM3
11,24088171,acm3_human,206,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.44239,FA206A,CHRM3
40,24088171,acm3_human,206,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.44239,FA206A,CHRM3
12,24088171,acm3_human,148,D,N,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,9.1,50.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.46855,DA148N,CHRM3
28,24088171,acm3_human,148,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,7.9,79.433,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.46855,DA148N,CHRM3
53,23826889,acm3_human,148,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.05,,=,,7.69,22.909,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,3.46855,DA148N,CHRM3
135,23826889,acm3_human,148,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,3.7,15.488,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,3.46855,DA148N,CHRM3
175,23826889,acm3_human,148,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.4,,=,,2.04,229.087,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,3.46855,DA148N,CHRM3
13,24088171,acm3_human,225,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.49127,FA225A,CHRM3
26,24088171,acm3_human,225,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.49127,FA225A,CHRM3
168,24088171,acm3_human,225,F,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.3,1.585,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,4.49127,FA225A,CHRM3
17,24088171,acm3_human,525,F,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.5,1.0,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,1.0443,FA525A,CHRM3
75,24088171,acm3_human,525,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.1,-1.996,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.0443,FA525A,CHRM3
97,24088171,acm3_human,525,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.1,-1.996,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.0443,FA525A,CHRM3
20,24088171,acm3_human,507,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,6.9,794.328,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
31,24088171,acm3_human,507,Y,A,Scopolamine,ChEMBL Compound ID,CHEMBL569713,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,7.2,199.526,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
39,24088171,acm3_human,507,Y,A,Cpd7,ChEMBL Compound ID,CHEMBL3140016,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.8,,=,,6.7,125.893,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
44,24088171,acm3_human,507,Y,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,8.1,158.489,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
71,24088171,acm3_human,507,Y,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,9.4,25.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
80,24088171,acm3_human,507,Y,A,Cpd6,SMILES,C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.4,,=,,9.0,25.119,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
86,24088171,acm3_human,507,Y,A,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.1,,=,,7.0,125.893,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
94,24088171,acm3_human,507,Y,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,9.2,10.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
100,24088171,acm3_human,507,Y,A,Cpd3,ChEMBL Compound ID,CHEMBL3140032,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,7.9,39.811,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
125,24088171,acm3_human,507,Y,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,9.2,199.526,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
132,24088171,acm3_human,507,Y,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,7.3,125.893,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
134,24088171,acm3_human,507,Y,A,Cpd1,ChEMBL Compound ID,CHEMBL3139993,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,6.1,158.489,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
141,24088171,acm3_human,507,Y,A,Cpd9,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.0,,=,,8.1,79.433,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.00204,YA507A,CHRM3
23,24088171,acm3_human,200,W,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,8.3,1584.893,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
59,24088171,acm3_human,200,W,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,6.9,794.328,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
76,24088171,acm3_human,200,W,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,8.2,398.107,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
78,24088171,acm3_human,200,W,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,5.6,6309.573,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
84,24088171,acm3_human,200,W,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,7.4,630.957,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
98,24088171,acm3_human,200,W,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,7.6,501.187,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,5.73665,WA200A,CHRM3
33,24088171,acm3_human,240,F,A,Cpd4,ChEMBL Compound ID,CHEMBL3139994,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,10.2,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
37,24088171,acm3_human,240,F,A,Cpd9,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(c1cccs1)c1cccs1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.0,,=,,9.3,5.012,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
38,24088171,acm3_human,240,F,A,Cpd7,ChEMBL Compound ID,CHEMBL3140016,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.8,,=,,9.7,-7.937,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
49,24088171,acm3_human,240,F,A,Cpd10,SMILES,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(C1CCCC1)C1CCCC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.4,,=,,9.2,1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
65,24088171,acm3_human,240,F,A,Cpd2,ChEMBL Compound ID,CHEMBL3140031,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,7.8,7.943,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
67,24088171,acm3_human,240,F,A,Cpd5,ChEMBL Compound ID,CHEMBL3139995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.3,,=,,10.4,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
88,24088171,acm3_human,240,F,A,Cpd1,ChEMBL Compound ID,CHEMBL3139993,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,7.6,5.012,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
90,24088171,acm3_human,240,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.2,3.981,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
104,24088171,acm3_human,240,F,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,10.3,15.849,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
163,24088171,acm3_human,240,F,A,Cpd3,ChEMBL Compound ID,CHEMBL3140032,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.5,,=,,9.1,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
173,24088171,acm3_human,240,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.6,15.849,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.83266,FA240A,CHRM3
41,24088171,acm3_human,197,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.25442,FA197A,CHRM3
157,24088171,acm3_human,197,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.25442,FA197A,CHRM3
45,24088171,acm3_human,148,D,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,7.7,125.893,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.94971,DA148A,CHRM3
169,24088171,acm3_human,148,D,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,9.2,39.811,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.94971,DA148A,CHRM3
54,24088171,acm3_human,213,K,V,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.618538,KA213V,CHRM3
136,24088171,acm3_human,213,K,V,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.9,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.618538,KA213V,CHRM3
58,24088171,acm3_human,222,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.23913,FA222A,CHRM3
111,24088171,acm3_human,222,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.23913,FA222A,CHRM3
60,16489127,acm3_human,514,N,Y,Atropine,ChEMBL Compound ID,CHEMBL517712,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.2,,=,,8.9,1.995,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-1.68282,NA514Y,CHRM3
92,16489127,acm3_human,514,N,Y,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,169.0,pM,=,,269.0,1.592,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-1.68282,NA514Y,CHRM3
146,16489127,acm3_human,514,N,Y,4-DAMP,ChEMBL Compound ID,CHEMBL168067,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.0,,=,,8.6,2.512,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-1.68282,NA514Y,CHRM3
63,24088171,acm3_human,156,V,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.0,6.31,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.54627,VA156A,CHRM3
81,24088171,acm3_human,156,V,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.1,5.012,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.54627,VA156A,CHRM3
66,11562438,acm3_human,213,K,T,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.29,nM,=,,0.33,1.138,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.386353,KA213T,CHRM3
68,8264552,acm3_human,550,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,110.0,pM,=,,100.0,-1.1,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-0.0543177,TA550A,CHRM3
69,8264552,acm3_human,553,T,A,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,110.0,pM,=,,124.0,1.127,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-0.147,TA553A,CHRM3
89,24088171,acm3_human,233,F,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.9,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.983499,FA233A,CHRM3
131,24088171,acm3_human,233,F,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.983499,FA233A,CHRM3
110,24088171,acm3_human,518,D,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.272933,DA518A,CHRM3
153,24088171,acm3_human,518,D,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.272933,DA518A,CHRM3
116,11562438,acm3_human,217,P,D,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.29,nM,=,,0.31,1.069,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,2.35851,PA217D,CHRM3
118,24088171,acm3_human,220,E,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.328541,EA220A,CHRM3
128,24088171,acm3_human,220,E,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.328541,EA220A,CHRM3
147,24088171,acm3_human,220,E,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.5,1.0,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,0.328541,EA220A,CHRM3
121,24088171,acm3_human,142,D,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.1,5.012,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.499733,DA142A,CHRM3
127,24088171,acm3_human,142,D,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,9.9,7.943,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.499733,DA142A,CHRM3
122,24088171,acm3_human,133,R,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.610383,RA133A,CHRM3
138,24088171,acm3_human,133,R,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,0.610383,RA133A,CHRM3
124,24088171,acm3_human,228,E,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.9,-1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.03735,EA228A,CHRM3
170,24088171,acm3_human,228,E,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.03735,EA228A,CHRM3
129,24088171,acm3_human,511,V,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,11.1,-1.996,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.64246,VA511A,CHRM3
148,24088171,acm3_human,511,V,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,10.0,-1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.64246,VA511A,CHRM3
166,24088171,acm3_human,511,V,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.3,1.585,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,1.64246,VA511A,CHRM3
133,24088171,acm3_human,534,Y,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.1,5.012,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.99236,YA534A,CHRM3
158,24088171,acm3_human,534,Y,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,8.0,63.096,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,3.99236,YA534A,CHRM3
144,24088171,acm3_human,224,Q,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-0.0526898,QA224A,CHRM3
159,24088171,acm3_human,224,Q,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.6,1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,-0.0526898,QA224A,CHRM3
161,24088171,acm3_human,224,Q,A,[3H]Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,11.5,,=,,11.4,1.259,,,[3H]Tiotropium (radioligand),0.0,0.0,,0.0,,P20309,-0.0526898,QA224A,CHRM3
145,23826889,acm3_human,114,D,N,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.05,,=,,9.37,-2.088,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,0.0363422,DA114N,CHRM3
156,23826889,acm3_human,114,D,N,Acetylcholine,ChEMBL Compound ID,CHEMBL667,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.4,,=,,5.49,-12.346,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,0.0363422,DA114N,CHRM3
178,23826889,acm3_human,114,D,N,McN-A343,ChEMBL Compound ID,CHEMBL40554,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.89,,=,,5.8,-8.13,,,[3H]N-methyl scopolamine,0.0,0.0,,0.0,,P20309,0.0363422,DA114N,CHRM3
149,24088171,acm3_human,204,I,A,N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.7,1.259,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.17279,IA204A,CHRM3
176,24088171,acm3_human,204,I,A,Tiotropium,ChEMBL Compound ID,CHEMBL1900528,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.8,,=,,10.6,1.585,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,4.17279,IA204A,CHRM3
167,11562438,acm3_human,133,R,G,[3H]N-methyl scopolamine,ChEMBL Compound ID,CHEMBL376897,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.29,nM,=,,0.49,1.69,,,[3H]N-methyl scopolamine (radioligand),0.0,0.0,,0.0,,P20309,1.52202,RA133G,CHRM3
0,27315480,glp1r_human,215,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.4,1.995,,,,0.0,0.0,,104.0,,P43220,0.214044,DA215A,GLP1R
75,27315480,glp1r_human,215,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.5,1.445,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.214044,DA215A,GLP1R
107,27315480,glp1r_human,215,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.83,-1.047,,,,0.0,0.0,,125.0,,P43220,0.214044,DA215A,GLP1R
187,27315480,glp1r_human,215,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.49,1.479,,,,0.0,0.0,,105.0,,P43220,0.214044,DA215A,GLP1R
622,27315480,glp1r_human,215,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.65,63.096,,,,0.0,0.0,,105.0,,P43220,0.214044,DA215A,GLP1R
651,27315480,glp1r_human,215,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.34,2.63,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.214044,DA215A,GLP1R
905,27315480,glp1r_human,215,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.75,3.802,,,,0.0,0.0,,109.0,,P43220,0.214044,DA215A,GLP1R
913,27315480,glp1r_human,215,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.08,-1.381,,,,0.0,0.0,,117.0,,P43220,0.214044,DA215A,GLP1R
964,27315480,glp1r_human,215,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.92,1.549,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.214044,DA215A,GLP1R
1082,27315480,glp1r_human,215,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.02,2.692,,,,0.0,0.0,,107.0,,P43220,0.214044,DA215A,GLP1R
1089,27315480,glp1r_human,215,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.4,-5.882,,,,0.0,0.0,,7.74,,P43220,0.214044,DA215A,GLP1R
1164,27315480,glp1r_human,215,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.9,1.148,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.214044,DA215A,GLP1R
1,26598711,glp1r_human,374,H,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.32,1.072,,,[125I]-exendin(9-39) (radioligand),22.01834862,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
40,27315480,glp1r_human,374,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.08,1.66,,,[125I]-exendin(9-39) (radioligand),82.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
158,27315480,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.69,1.514,,,,0.0,0.0,,97.0,,P43220,0.451149,HA374A,GLP1R
163,27315480,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,8.62,-2.188,,,,0.0,0.0,,88.0,,P43220,0.451149,HA374A,GLP1R
193,26598711,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.43,1.004,,,,22.01834862,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
195,27315480,glp1r_human,374,H,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.35,7.413,,,[125I]-exendin(9-39) (radioligand),82.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
377,27059958,glp1r_human,374,H,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,5.2,-1.326,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),76.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
412,27315480,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,10.11,-1.289,,,,0.0,0.0,,102.0,,P43220,0.451149,HA374A,GLP1R
507,27315480,glp1r_human,374,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,7.98,1.023,,,,0.0,0.0,,92.0,,P43220,0.451149,HA374A,GLP1R
592,27315480,glp1r_human,374,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.49,-1.148,,,,0.0,0.0,,93.0,,P43220,0.451149,HA374A,GLP1R
632,27059958,glp1r_human,374,H,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,14.0,1.4,,,,76.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
715,27315480,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.59,1.445,,,[125I]-exendin(9-39) (radioligand),82.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
774,27315480,glp1r_human,374,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,9.1,1.318,,,[125I]-exendin(9-39) (radioligand),82.0,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
825,26598711,glp1r_human,374,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.23,1.66,,,[125I]-exendin(9-39) (radioligand),22.01834862,0.0,,0.0,,P43220,0.451149,HA374A,GLP1R
836,27315480,glp1r_human,374,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.7,-1.259,,,,0.0,0.0,,101.0,,P43220,0.451149,HA374A,GLP1R
862,27315480,glp1r_human,374,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.49,-8.333,,,,0.0,0.0,,7.71,,P43220,0.451149,HA374A,GLP1R
922,27315480,glp1r_human,374,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,9.01,38.905,,,,0.0,0.0,,64.0,,P43220,0.451149,HA374A,GLP1R
2,27315480,glp1r_human,203,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.43,1.047,,,,0.0,0.0,,94.0,,P43220,1.74391,WA203A,GLP1R
47,27315480,glp1r_human,203,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.89,1.122,,,,0.0,0.0,,74.0,,P43220,1.74391,WA203A,GLP1R
64,27315480,glp1r_human,203,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,9.0,1.288,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
106,27059958,glp1r_human,203,W,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,11.0,1.594,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),113.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
179,27315480,glp1r_human,203,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.79,3.467,,,,0.0,0.0,,74.0,,P43220,1.74391,WA203A,GLP1R
215,27315480,glp1r_human,203,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.39,1148.154,,,,0.0,0.0,,55.0,,P43220,1.74391,WA203A,GLP1R
271,27059958,glp1r_human,203,W,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,14.0,1.4,,,,113.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
300,27315480,glp1r_human,203,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.13,3.388,,,,0.0,0.0,,96.0,,P43220,1.74391,WA203A,GLP1R
673,27315480,glp1r_human,203,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.81,-15.152,,,,0.0,0.0,,6.87,,P43220,1.74391,WA203A,GLP1R
757,27315480,glp1r_human,203,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.31,3.162,,,,0.0,0.0,,51.0,,P43220,1.74391,WA203A,GLP1R
759,27315480,glp1r_human,203,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.5,1.445,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
926,27315480,glp1r_human,203,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.52,1.738,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
951,27315480,glp1r_human,203,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.89,1.175,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.74391,WA203A,GLP1R
1169,27315480,glp1r_human,203,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.81,-1.289,,,,0.0,0.0,,90.0,,P43220,1.74391,WA203A,GLP1R
3,27315480,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,8.65,22.387,,,,0.0,0.0,,91.0,,P43220,0.972251,LA384A,GLP1R
95,27315480,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.69,11.482,,,[125I]-exendin(9-39) (radioligand),74.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
337,27059958,glp1r_human,384,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,60.0,5.0,,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
345,27059958,glp1r_human,384,L,A,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,97.0,-1.072,,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
351,27059958,glp1r_human,384,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,718.0,47.867,,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
353,27059958,glp1r_human,384,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,8.0,-3.247,,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
359,27315480,glp1r_human,384,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.47,6.761,,,[125I]-exendin(9-39) (radioligand),74.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
395,27315480,glp1r_human,384,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.89,2.138,,,[125I]-exendin(9-39) (radioligand),74.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
448,26598711,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.66,6.166,,,[125I]-exendin(9-39) (radioligand),77.52293578,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
476,27315480,glp1r_human,384,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,7.34,1.698,,,,0.0,0.0,,6.63,,P43220,0.972251,LA384A,GLP1R
530,27315480,glp1r_human,384,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,7.34,12.303,,,,0.0,0.0,,92.0,,P43220,0.972251,LA384A,GLP1R
558,27315480,glp1r_human,384,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.06,14.454,,,[125I]-exendin(9-39) (radioligand),74.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
652,27059958,glp1r_human,384,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,407.0,40.7,,,,105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
675,27059958,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,191.0,31.311,,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
736,27315480,glp1r_human,384,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,6.89,12.589,,,,0.0,0.0,,75.0,,P43220,0.972251,LA384A,GLP1R
837,27059958,glp1r_human,384,L,A,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,209.0,-1.12,Abolished effect,,[125I]-exendin(9-39) (radioligand),105.0,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
915,26598711,glp1r_human,384,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.42,-1.175,,,[125I]-exendin(9-39) (radioligand),77.52293578,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
965,27315480,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.47,2.512,,,,0.0,0.0,,82.0,,P43220,0.972251,LA384A,GLP1R
1006,27315480,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.06,16.596,,,,0.0,0.0,,99.0,,P43220,0.972251,LA384A,GLP1R
1021,27315480,glp1r_human,384,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,7.8,630.957,,,,0.0,0.0,,108.0,,P43220,0.972251,LA384A,GLP1R
1084,27315480,glp1r_human,384,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.0,3.981,,,,0.0,0.0,,82.0,,P43220,0.972251,LA384A,GLP1R
1129,26598711,glp1r_human,384,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.81,-1.053,,,,77.52293578,0.0,,0.0,,P43220,0.972251,LA384A,GLP1R
4,27315480,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.15,39.811,,,[125I]-exendin(9-39) (radioligand),86.0,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
55,27315480,glp1r_human,372,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,6.63,63.096,,,,0.0,0.0,,75.0,,P43220,-0.0214156,DA372A,GLP1R
201,27315480,glp1r_human,372,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.12,12.589,,,[125I]-exendin(9-39) (radioligand),86.0,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
370,26598711,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.85,3.981,,,[125I]-exendin(9-39) (radioligand),13.30275229,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
426,27315480,glp1r_human,372,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.63,3.89,,,[125I]-exendin(9-39) (radioligand),86.0,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
613,27315480,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,6.45,67.608,,,,0.0,0.0,,99.0,,P43220,-0.0214156,DA372A,GLP1R
807,27315480,glp1r_human,372,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,7.88,524.807,,,,0.0,0.0,,60.0,,P43220,-0.0214156,DA372A,GLP1R
819,27315480,glp1r_human,372,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,6.63,8.71,,,,0.0,0.0,,6.01,,P43220,-0.0214156,DA372A,GLP1R
904,27315480,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,6.83,10.965,,,,0.0,0.0,,35.0,,P43220,-0.0214156,DA372A,GLP1R
943,27315480,glp1r_human,372,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,6.79,15.849,,,,0.0,0.0,,18.0,,P43220,-0.0214156,DA372A,GLP1R
1019,27315480,glp1r_human,372,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.81,3.09,,,[125I]-exendin(9-39) (radioligand),86.0,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
1092,27315480,glp1r_human,372,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,9.1,31.623,,,,0.0,0.0,,99.0,,P43220,-0.0214156,DA372A,GLP1R
1105,26598711,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,9.65,-1.179,,,,13.30275229,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
1109,26598711,glp1r_human,372,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.25,1.259,,,[125I]-exendin(9-39) (radioligand),13.30275229,0.0,,0.0,,P43220,-0.0214156,DA372A,GLP1R
1115,27315480,glp1r_human,372,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,7.82,151.356,,,,0.0,0.0,,80.0,,P43220,-0.0214156,DA372A,GLP1R
5,22147710,glp1r_human,285,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,8.1,-1.996,,,,0.0,0.0,,86.79245283,,P43220,-0.838203,GA285A,GLP1R
799,22147710,glp1r_human,285,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,9.1,-2.513,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,-0.838203,GA285A,GLP1R
815,22147710,glp1r_human,285,G,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.1,1.259,,,,0.0,0.0,,145.6140351,,P43220,-0.838203,GA285A,GLP1R
864,22147710,glp1r_human,285,G,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.7,1.0,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,-0.838203,GA285A,GLP1R
870,22147710,glp1r_human,285,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,9.1,-1.259,,,,0.0,0.0,,92.71206691,,P43220,-0.838203,GA285A,GLP1R
1046,22147710,glp1r_human,285,G,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.7,-2.513,,,,0.0,0.0,,83.44331134,,P43220,-0.838203,GA285A,GLP1R
6,26598711,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.03,-1.032,,,,42.66055046,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
27,27315480,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.9,1.259,,,,0.0,0.0,,108.0,,P43220,-0.700128,EA387A,GLP1R
28,27315480,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.55,1.585,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
126,21868452,glp1r_human,387,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,9.77,2.455,,,,0.0,0.0,,172.0,,P43220,-0.700128,EA387A,GLP1R
335,21868452,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.09,1.349,,,[125I]-exendin(9-39) (radioligand),102.6909091,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
343,27315480,glp1r_human,387,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,7.23,2.188,,,,0.0,0.0,,6.96,,P43220,-0.700128,EA387A,GLP1R
365,27315480,glp1r_human,387,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.86,2.754,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
453,27315480,glp1r_human,387,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.14,288.403,,,,0.0,0.0,,72.0,,P43220,-0.700128,EA387A,GLP1R
490,27315480,glp1r_human,387,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,7.23,15.849,,,,0.0,0.0,,61.0,,P43220,-0.700128,EA387A,GLP1R
510,27315480,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.79,3.09,,,,0.0,0.0,,45.0,,P43220,-0.700128,EA387A,GLP1R
515,27315480,glp1r_human,387,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,8.12,-1.35,,,,0.0,0.0,,106.0,,P43220,-0.700128,EA387A,GLP1R
536,27315480,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.69,1.514,,,,0.0,0.0,,98.0,,P43220,-0.700128,EA387A,GLP1R
842,27315480,glp1r_human,387,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.83,2.455,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
882,26598711,glp1r_human,387,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.91,-2.882,,,[125I]-exendin(9-39) (radioligand),42.66055046,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
1042,27315480,glp1r_human,387,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.3,1.995,,,,0.0,0.0,,106.0,,P43220,-0.700128,EA387A,GLP1R
1104,21868452,glp1r_human,387,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,9.77,2.455,,,,102.6909091,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
1108,26598711,glp1r_human,387,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.08,1.862,,,[125I]-exendin(9-39) (radioligand),42.66055046,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
1138,21868452,glp1r_human,387,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.56,3.89,,,[125I]-exendin(9-39) (radioligand),102.6909091,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
1178,27315480,glp1r_human,387,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.03,1.549,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,-0.700128,EA387A,GLP1R
7,23479653,glp1r_human,247,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.29,-1.513,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,1.53208,EA247A,GLP1R
205,23479653,glp1r_human,247,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.19,3.02,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,1.53208,EA247A,GLP1R
467,23479653,glp1r_human,247,E,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,8.64,2.138,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,1.53208,EA247A,GLP1R
894,23479653,glp1r_human,247,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.43,-1.479,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,1.53208,EA247A,GLP1R
8,22147710,glp1r_human,297,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,6.5,316.228,,,,0.0,0.0,,27.12066906,,P43220,5.44429,WA297A,GLP1R
88,22147710,glp1r_human,297,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,6.9,63.096,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,5.44429,WA297A,GLP1R
92,22147710,glp1r_human,297,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.9,-1.585,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,5.44429,WA297A,GLP1R
474,22147710,glp1r_human,297,W,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.9,-5.0,,,,0.0,0.0,,38.59649123,,P43220,5.44429,WA297A,GLP1R
552,22147710,glp1r_human,297,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.3,3.162,,,,0.0,0.0,,56.60377358,,P43220,5.44429,WA297A,GLP1R
9,22147710,glp1r_human,288,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,6.7,12.589,,,,0.0,0.0,,54.71698113,,P43220,1.69049,KA288A,GLP1R
177,26598711,glp1r_human,288,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,7.66,-1.486,,,,83.02752294,0.0,,0.0,,P43220,1.69049,KA288A,GLP1R
196,26598711,glp1r_human,288,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.2,1.413,,,[125I]-exendin(9-39) (radioligand),83.02752294,0.0,,0.0,,P43220,1.69049,KA288A,GLP1R
756,22147710,glp1r_human,288,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,8.0,-1.996,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,1.69049,KA288A,GLP1R
780,22147710,glp1r_human,288,K,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,6.6,3.981,,,,0.0,0.0,,57.89473684,,P43220,1.69049,KA288A,GLP1R
967,22147710,glp1r_human,288,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,6.6,125.893,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,1.69049,KA288A,GLP1R
1128,26598711,glp1r_human,288,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.09,22.909,,,[125I]-exendin(9-39) (radioligand),83.02752294,0.0,,0.0,,P43220,1.69049,KA288A,GLP1R
10,19861722,glp1r_human,123,L,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,9.5,1.727,,,,47.27272727,0.0,,0.0,,P43220,1.82325,LA123A,GLP1R
414,19861722,glp1r_human,123,L,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.33,-2.304,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),47.27272727,0.0,,0.0,,P43220,1.82325,LA123A,GLP1R
509,19861722,glp1r_human,123,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,1.1,1.1,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),47.27272727,0.0,,0.0,,P43220,1.82325,LA123A,GLP1R
573,19861722,glp1r_human,123,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,17.0,1.545,,,,47.27272727,0.0,,0.0,,P43220,1.82325,LA123A,GLP1R
12,27315480,glp1r_human,373,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,6.78,31.623,,,,0.0,0.0,,59.0,,P43220,0.0543497,EA373A,GLP1R
60,27315480,glp1r_human,373,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,6.97,1071.519,,,,0.0,0.0,,64.0,,P43220,0.0543497,EA373A,GLP1R
79,27315480,glp1r_human,373,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,8.81,61.66,,,,0.0,0.0,,80.0,,P43220,0.0543497,EA373A,GLP1R
121,27315480,glp1r_human,373,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.15,1.175,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
156,27315480,glp1r_human,373,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,7.27,2137.962,,,,0.0,0.0,,42.0,,P43220,0.0543497,EA373A,GLP1R
326,27315480,glp1r_human,373,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.43,7.413,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
419,27315480,glp1r_human,373,E,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,7.95,18.621,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
463,27315480,glp1r_human,373,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,6.92,32.359,,,,0.0,0.0,,40.0,,P43220,0.0543497,EA373A,GLP1R
785,26598711,glp1r_human,373,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.46,-1.024,,,[125I]-exendin(9-39) (radioligand),27.52293578,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
849,27315480,glp1r_human,373,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.08,46.774,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
896,26598711,glp1r_human,373,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.39,-1.096,,,[125I]-exendin(9-39) (radioligand),27.52293578,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
919,26598711,glp1r_human,373,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.16,-1.019,,,,27.52293578,0.0,,0.0,,P43220,0.0543497,EA373A,GLP1R
1070,27315480,glp1r_human,373,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,6.92,4.467,,,,0.0,0.0,,6.48,,P43220,0.0543497,EA373A,GLP1R
14,27315480,glp1r_human,383,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.29,8.511,,,[125I]-exendin(9-39) (radioligand),78.0,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
221,26598711,glp1r_human,383,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.92,3.388,,,[125I]-exendin(9-39) (radioligand),123.853211,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
252,26598711,glp1r_human,383,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.17,1.514,,,[125I]-exendin(9-39) (radioligand),123.853211,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
625,27315480,glp1r_human,383,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,6.89,1288.25,,,,0.0,0.0,,87.0,,P43220,0.322937,KA383A,GLP1R
737,26598711,glp1r_human,383,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,9.67,-1.176,,,,123.853211,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
762,27315480,glp1r_human,383,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,8.7,79.433,,,,0.0,0.0,,73.0,,P43220,0.322937,KA383A,GLP1R
779,27315480,glp1r_human,383,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,7.22,16.218,,,,0.0,0.0,,32.0,,P43220,0.322937,KA383A,GLP1R
860,27315480,glp1r_human,383,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.17,11.22,,,[125I]-exendin(9-39) (radioligand),78.0,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
892,27315480,glp1r_human,383,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,6.68,39.811,,,,0.0,0.0,,38.0,,P43220,0.322937,KA383A,GLP1R
979,27315480,glp1r_human,383,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.76,9.772,,,[125I]-exendin(9-39) (radioligand),78.0,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
1074,27315480,glp1r_human,383,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.4,7.943,,,[125I]-exendin(9-39) (radioligand),78.0,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
1111,27315480,glp1r_human,383,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,7.22,2.239,,,,0.0,0.0,,0.0,,P43220,0.322937,KA383A,GLP1R
15,27315480,glp1r_human,214,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.02,269.153,,,,0.0,0.0,,105.0,,P43220,2.75948,WA214A,GLP1R
39,27315480,glp1r_human,214,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.44,1.66,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.75948,WA214A,GLP1R
49,27315480,glp1r_human,214,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.24,2.884,,,,0.0,0.0,,92.0,,P43220,2.75948,WA214A,GLP1R
410,27315480,glp1r_human,214,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.2,3.631,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.75948,WA214A,GLP1R
597,27315480,glp1r_human,214,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.29,1.445,,,,0.0,0.0,,104.0,,P43220,2.75948,WA214A,GLP1R
642,27315480,glp1r_human,214,W,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.24,-4.082,,,,0.0,0.0,,7.65,,P43220,2.75948,WA214A,GLP1R
686,27315480,glp1r_human,214,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,6.8,10.233,,,,0.0,0.0,,97.0,,P43220,2.75948,WA214A,GLP1R
691,27315480,glp1r_human,214,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.78,1.514,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.75948,WA214A,GLP1R
751,27315480,glp1r_human,214,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,8.95,5.129,,,,0.0,0.0,,97.0,,P43220,2.75948,WA214A,GLP1R
829,27315480,glp1r_human,214,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.62,5.129,,,,0.0,0.0,,106.0,,P43220,2.75948,WA214A,GLP1R
914,27315480,glp1r_human,214,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.9,1.622,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.75948,WA214A,GLP1R
990,27315480,glp1r_human,214,W,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.68,1.82,,,,0.0,0.0,,90.0,,P43220,2.75948,WA214A,GLP1R
16,22147710,glp1r_human,291,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.8,1.0,,,,0.0,0.0,,77.35849057,,P43220,1.83767,YA291A,GLP1R
38,22147710,glp1r_human,291,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.3,2.512,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),84.0,0.0,,0.0,,P43220,1.83767,YA291A,GLP1R
144,22147710,glp1r_human,291,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.6,2.512,,,,0.0,0.0,,75.80645161,,P43220,1.83767,YA291A,GLP1R
633,22147710,glp1r_human,291,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.2,1.259,,,,0.0,0.0,,71.56568686,,P43220,1.83767,YA291A,GLP1R
710,22147710,glp1r_human,291,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,6.9,1.995,,,,0.0,0.0,,100.0,,P43220,1.83767,YA291A,GLP1R
716,22147710,glp1r_human,291,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.8,-1.259,,,[125I]-exendin(9-39) (radioligand),84.0,0.0,,0.0,,P43220,1.83767,YA291A,GLP1R
17,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,28.84,nM,=,,91.2,3.162,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
21,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.78,µM,>,,10.0,5.618,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
70,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,µM,>,,10.0,10.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
104,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.33,nM,=,,47.86,145.03,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
105,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.29,µM,=,,4.68,16.138,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
111,25561730,glp1r_human,379,L,R,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,0.31,nM,=,,43.65,140.806,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
170,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,190.55,nM,>,,1000.0,5.248,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
274,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,123.03,nM,>,,1000.0,8.128,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
388,25561730,glp1r_human,379,L,R,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.05,µM,=,,0.59,11.8,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
415,25561730,glp1r_human,379,L,R,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,45.71,nM,>,,1000.0,21.877,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
444,25561730,glp1r_human,379,L,R,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.29,µM,>,,10.0,7.752,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
497,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.82,µM,>,,10.0,5.495,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
523,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,1000.0,nM,>,,1000.0,1.0,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
639,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.83,µM,=,,1.41,1.699,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
666,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.0,µM,>,,10.0,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
712,25561730,glp1r_human,379,L,R,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,85.11,nM,=,,851.14,10.0,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
1023,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,52.48,nM,=,,186.21,3.548,,,,83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
1123,25561730,glp1r_human,379,L,R,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.41,µM,=,,1.02,-1.383,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),83.3,0.0,,0.0,,P43220,0.929858,LA379R,GLP1R
20,26598711,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.17,-1.018,,,,17.88990826,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
96,27315480,glp1r_human,386,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.23,1.175,,,[125I]-exendin(9-39) (radioligand),128.0,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
102,26598711,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.91,3.467,,,[125I]-exendin(9-39) (radioligand),17.88990826,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
113,27315480,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,10.0,1.0,,,,0.0,0.0,,101.0,,P43220,-0.0556473,TA386A,GLP1R
290,27315480,glp1r_human,386,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.56,-9.804,,,,0.0,0.0,,7.26,,P43220,-0.0556473,TA386A,GLP1R
296,27315480,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.41,2.188,,,[125I]-exendin(9-39) (radioligand),128.0,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
501,27315480,glp1r_human,386,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.34,181.97,,,,0.0,0.0,,74.0,,P43220,-0.0556473,TA386A,GLP1R
684,27315480,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.76,3.311,,,,0.0,0.0,,88.0,,P43220,-0.0556473,TA386A,GLP1R
753,27315480,glp1r_human,386,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.66,3.631,,,[125I]-exendin(9-39) (radioligand),128.0,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
944,27315480,glp1r_human,386,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.56,-1.35,,,,0.0,0.0,,101.0,,P43220,-0.0556473,TA386A,GLP1R
1059,27315480,glp1r_human,386,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.22,1.0,,,[125I]-exendin(9-39) (radioligand),128.0,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
1072,27315480,glp1r_human,386,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,7.29,5.012,,,,0.0,0.0,,73.0,,P43220,-0.0556473,TA386A,GLP1R
1130,27315480,glp1r_human,386,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.7,-1.259,,,,0.0,0.0,,98.0,,P43220,-0.0556473,TA386A,GLP1R
1165,26598711,glp1r_human,386,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.36,-1.024,,,[125I]-exendin(9-39) (radioligand),17.88990826,0.0,,0.0,,P43220,-0.0556473,TA386A,GLP1R
1167,27315480,glp1r_human,386,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.78,1.23,,,,0.0,0.0,,95.0,,P43220,-0.0556473,TA386A,GLP1R
23,27315480,glp1r_human,201,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,6.76,15.136,,,,0.0,0.0,,17.0,,P43220,0.987467,LA201A,GLP1R
80,27315480,glp1r_human,201,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.66,1.995,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.987467,LA201A,GLP1R
281,27315480,glp1r_human,201,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.94,323.594,,,,0.0,0.0,,78.0,,P43220,0.987467,LA201A,GLP1R
312,27315480,glp1r_human,201,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,8.47,15.488,,,,0.0,0.0,,92.0,,P43220,0.987467,LA201A,GLP1R
390,27315480,glp1r_human,201,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.3,14.125,,,,0.0,0.0,,100.0,,P43220,0.987467,LA201A,GLP1R
397,27315480,glp1r_human,201,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,7.43,18.621,,,,0.0,0.0,,61.0,,P43220,0.987467,LA201A,GLP1R
471,27315480,glp1r_human,201,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,7.43,1.585,,,,0.0,0.0,,7.93,,P43220,0.987467,LA201A,GLP1R
472,27315480,glp1r_human,201,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.05,5.129,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.987467,LA201A,GLP1R
631,27315480,glp1r_human,201,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,6.74,8.318,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.987467,LA201A,GLP1R
750,27315480,glp1r_human,201,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.83,1.905,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.987467,LA201A,GLP1R
1173,27315480,glp1r_human,201,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.37,9.12,,,,0.0,0.0,,82.0,,P43220,0.987467,LA201A,GLP1R
24,22147710,glp1r_human,293,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,7.8,15.849,,,,0.0,0.0,,70.48984468,,P43220,1.68315,DA293A,GLP1R
93,22147710,glp1r_human,293,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.5,1.995,,,,0.0,0.0,,50.94339623,,P43220,1.68315,DA293A,GLP1R
393,22147710,glp1r_human,293,D,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.2,1.0,,,,0.0,0.0,,70.1754386,,P43220,1.68315,DA293A,GLP1R
494,22147710,glp1r_human,293,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.3,25.119,,,[125I]-exendin(9-39) (radioligand),62.0,0.0,,0.0,,P43220,1.68315,DA293A,GLP1R
535,22147710,glp1r_human,293,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.9,-1.585,,,[125I]-exendin(9-39) (radioligand),62.0,0.0,,0.0,,P43220,1.68315,DA293A,GLP1R
1080,22147710,glp1r_human,293,D,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,6.8,3.162,,,,0.0,0.0,,38.45230954,,P43220,1.68315,DA293A,GLP1R
25,27315480,glp1r_human,207,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.65,1.95,,,,0.0,0.0,,13.0,,P43220,-0.361772,TA207A,GLP1R
153,27315480,glp1r_human,207,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,7.92,6.026,,,,0.0,0.0,,94.0,,P43220,-0.361772,TA207A,GLP1R
160,27315480,glp1r_human,207,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.81,1.0,,,,0.0,0.0,,22.0,,P43220,-0.361772,TA207A,GLP1R
319,27315480,glp1r_human,207,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.1,3.631,,,,0.0,0.0,,102.0,,P43220,-0.361772,TA207A,GLP1R
338,27315480,glp1r_human,207,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,7.92,-1.949,,,,0.0,0.0,,7.61,,P43220,-0.361772,TA207A,GLP1R
643,27315480,glp1r_human,207,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.89,1.175,,,[125I]-exendin(9-39) (radioligand),75.0,0.0,,0.0,,P43220,-0.361772,TA207A,GLP1R
660,27315480,glp1r_human,207,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.85,1.82,,,[125I]-exendin(9-39) (radioligand),75.0,0.0,,0.0,,P43220,-0.361772,TA207A,GLP1R
741,27315480,glp1r_human,207,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.65,1.023,,,[125I]-exendin(9-39) (radioligand),75.0,0.0,,0.0,,P43220,-0.361772,TA207A,GLP1R
765,27315480,glp1r_human,207,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.26,154.882,,,,0.0,0.0,,36.0,,P43220,-0.361772,TA207A,GLP1R
940,27315480,glp1r_human,207,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.34,1.288,,,,0.0,0.0,,102.0,,P43220,-0.361772,TA207A,GLP1R
953,27315480,glp1r_human,207,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.67,1.23,,,[125I]-exendin(9-39) (radioligand),75.0,0.0,,0.0,,P43220,-0.361772,TA207A,GLP1R
1094,27315480,glp1r_human,207,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.85,3.02,,,,0.0,0.0,,58.0,,P43220,-0.361772,TA207A,GLP1R
26,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,123.03,nM,=,,16.6,-7.407,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
43,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.82,µM,>,,0.65,-2.801,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
164,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.33,nM,=,,17.78,53.879,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
167,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.41,µM,=,,0.14,-10.101,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
189,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,µM,>,,0.52,-1.923,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
295,25561730,glp1r_human,380,R,G,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Binding - Radioligand competition/displacement,0.31,nM,=,,12.3,39.677,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
346,25561730,glp1r_human,380,R,G,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.29,µM,>,,0.45,-2.865,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
350,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,190.55,nM,=,,575.44,3.02,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
511,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.83,µM,=,,0.23,-3.61,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
576,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,28.84,nM,=,,7.59,-3.802,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
656,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.78,µM,=,,0.15,-11.905,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
827,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,85.11,nM,=,,616.6,7.245,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
908,25561730,glp1r_human,380,R,G,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,45.71,nM,=,,141.25,3.09,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
928,25561730,glp1r_human,380,R,G,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.05,µM,=,,0.21,4.2,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
933,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,52.48,nM,=,,19.05,-2.755,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
963,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.0,µM,>,,0.68,-14.706,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
996,25561730,glp1r_human,380,R,G,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.29,µM,=,,0.27,-1.074,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
1134,25561730,glp1r_human,380,R,G,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,1000.0,nM,=,,575.44,-1.739,,,,202.6,0.0,,0.0,,P43220,1.02657,RA380G,GLP1R
29,22147710,glp1r_human,294,E,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.4,-1.259,,,,0.0,0.0,,86.56268746,,P43220,0.817266,EA294A,GLP1R
97,22147710,glp1r_human,294,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.3,25.119,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),81.0,0.0,,0.0,,P43220,0.817266,EA294A,GLP1R
437,22147710,glp1r_human,294,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.8,1.0,,,,0.0,0.0,,75.47169811,,P43220,0.817266,EA294A,GLP1R
742,22147710,glp1r_human,294,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.9,-1.585,,,[125I]-exendin(9-39) (radioligand),81.0,0.0,,0.0,,P43220,0.817266,EA294A,GLP1R
872,22147710,glp1r_human,294,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,9.1,-1.259,,,,0.0,0.0,,73.17801673,,P43220,0.817266,EA294A,GLP1R
984,22147710,glp1r_human,294,E,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.1,1.259,,,,0.0,0.0,,105.2631579,,P43220,0.817266,EA294A,GLP1R
30,27315480,glp1r_human,211,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.71,4.169,,,,0.0,0.0,,117.0,,P43220,0.293387,QA211A,GLP1R
61,27315480,glp1r_human,211,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.2,3.162,,,,0.0,0.0,,101.0,,P43220,0.293387,QA211A,GLP1R
154,27315480,glp1r_human,211,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.51,-1.148,,,,0.0,0.0,,104.0,,P43220,0.293387,QA211A,GLP1R
267,27315480,glp1r_human,211,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.73,2.399,,,[125I]-exendin(9-39) (radioligand),112.0,0.0,,0.0,,P43220,0.293387,QA211A,GLP1R
289,27315480,glp1r_human,211,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.17,190.546,,,,0.0,0.0,,95.0,,P43220,0.293387,QA211A,GLP1R
464,27315480,glp1r_human,211,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.2,-3.717,,,,0.0,0.0,,7.89,,P43220,0.293387,QA211A,GLP1R
521,27315480,glp1r_human,211,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.14,3.311,,,,0.0,0.0,,98.0,,P43220,0.293387,QA211A,GLP1R
657,27315480,glp1r_human,211,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.66,1.259,,,[125I]-exendin(9-39) (radioligand),112.0,0.0,,0.0,,P43220,0.293387,QA211A,GLP1R
713,27315480,glp1r_human,211,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.83,-1.047,,,,0.0,0.0,,135.0,,P43220,0.293387,QA211A,GLP1R
947,27315480,glp1r_human,211,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.63,1.072,,,[125I]-exendin(9-39) (radioligand),112.0,0.0,,0.0,,P43220,0.293387,QA211A,GLP1R
972,27315480,glp1r_human,211,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,8.05,-1.23,,,[125I]-exendin(9-39) (radioligand),112.0,0.0,,0.0,,P43220,0.293387,QA211A,GLP1R
1146,27315480,glp1r_human,211,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.06,-1.318,,,,0.0,0.0,,123.0,,P43220,0.293387,QA211A,GLP1R
31,24199154,glp1r_human,128,E,A,compound 2,PubChem CID,16007289,Allosteric agonist,EC50,Functional - cAMP accumulation,300.0,nM,=,,570.0,1.9,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
146,24199154,glp1r_human,128,E,A,Chimer 2,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAAKEFIAWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.038,nM,=,,0.051,1.342,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
169,24199154,glp1r_human,128,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,0.017,nM,=,,0.026,1.529,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
204,19861722,glp1r_human,128,E,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,25.0,4.545,,,,109.0909091,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
299,24199154,glp1r_human,128,E,A,Chimer 2,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAAKEFIAWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.038,nM,=,,0.04,1.053,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
407,24199154,glp1r_human,128,E,A,glucagon-(Ser22Glu/Gln26Lys),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAEDFVKWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.083,nM,=,,0.14,1.687,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
484,24199154,glp1r_human,128,E,A,glucagon-(Ser22Glu),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAQDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.06,nM,=,,0.059,-1.017,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
486,24199154,glp1r_human,128,E,A,GLP-1-(Ala8Gly/Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HGEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.011,nM,=,,0.017,1.545,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
690,19861722,glp1r_human,128,E,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,1.8,2.368,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),109.0909091,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
700,24199154,glp1r_human,128,E,A,exendin-4(1-30),FASTA sequence (peptide),HGEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.012,1.714,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
708,24199154,glp1r_human,128,E,A,GLP-1-(Ala8Gly),FASTA sequence (peptide),HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.25,nM,=,,0.49,1.96,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
747,24199154,glp1r_human,128,E,A,Chimer 2X,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAVRLFIEWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.076,nM,=,,0.078,1.026,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
818,19861722,glp1r_human,128,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,28.0,2.545,,,,109.0909091,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
840,24199154,glp1r_human,128,E,A,GLP-1-(Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HAEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.008,1.143,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
867,24199154,glp1r_human,128,E,A,exendin-4(1-30)(Gly2Ala),FASTA sequence (peptide),HAEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.005,nM,=,,0.007,1.4,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
966,24199154,glp1r_human,128,E,A,Chimer 2X,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAVRLFIEWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.076,nM,=,,0.084,1.105,,,,100.0,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
1117,19861722,glp1r_human,128,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,2.7,2.7,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),109.0909091,0.0,,0.0,,P43220,-0.383567,EA128A,GLP1R
33,26598711,glp1r_human,379,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.08,-1.027,,,,31.19266055,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
57,27315480,glp1r_human,379,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.08,46.774,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
416,27315480,glp1r_human,379,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,6.61,23.988,,,,0.0,0.0,,38.0,,P43220,0.794636,LA379A,GLP1R
422,27315480,glp1r_human,379,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.3,-1.202,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
489,26598711,glp1r_human,379,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.17,1.514,,,[125I]-exendin(9-39) (radioligand),31.19266055,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
596,27315480,glp1r_human,379,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.0,3.981,,,,0.0,0.0,,78.0,,P43220,0.794636,LA379A,GLP1R
645,27315480,glp1r_human,379,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.87,2.57,,,,0.0,0.0,,52.0,,P43220,0.794636,LA379A,GLP1R
669,26598711,glp1r_human,379,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.08,2.344,,,[125I]-exendin(9-39) (radioligand),31.19266055,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
677,27315480,glp1r_human,379,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,6.95,4.169,,,,0.0,0.0,,6.89,,P43220,0.794636,LA379A,GLP1R
711,27315480,glp1r_human,379,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,7.7,794.328,,,,0.0,0.0,,87.0,,P43220,0.794636,LA379A,GLP1R
812,27315480,glp1r_human,379,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,6.95,30.2,,,,0.0,0.0,,62.0,,P43220,0.794636,LA379A,GLP1R
924,27315480,glp1r_human,379,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,8.23,58.884,,,,0.0,0.0,,80.0,,P43220,0.794636,LA379A,GLP1R
997,27315480,glp1r_human,379,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.47,5.623,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
1002,27315480,glp1r_human,379,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.45,7.079,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.794636,LA379A,GLP1R
34,24199154,glp1r_human,32,L,A,GLP-1-(Ala8Gly),FASTA sequence (peptide),HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.25,nM,=,,2.4,9.6,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
54,19861722,glp1r_human,32,L,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,5.4,7.105,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),109.0909091,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
94,24199154,glp1r_human,32,L,A,GLP-1-(Ala8Gly/Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HGEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.011,nM,=,,0.095,8.636,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
123,19861722,glp1r_human,32,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,12.0,1.091,,,,109.0909091,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
140,24199154,glp1r_human,32,L,A,compound 2,PubChem CID,16007289,Allosteric agonist,EC50,Functional - cAMP accumulation,300.0,nM,=,,450.0,1.5,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
149,19861722,glp1r_human,32,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,1.1,1.1,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),109.0909091,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
191,19861722,glp1r_human,32,L,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,52.0,9.455,,,,109.0909091,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
217,24199154,glp1r_human,32,L,A,glucagon-(Ser22Glu/Gln26Lys),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAEDFVKWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.076,nM,=,,0.17,2.237,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
238,24199154,glp1r_human,32,L,A,GLP-1-(Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HAEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.014,2.0,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
273,24199154,glp1r_human,32,L,A,exendin-4(1-30),FASTA sequence (peptide),HGEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.044,6.286,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
562,24199154,glp1r_human,32,L,A,glucagon-(Ser22Glu),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAQDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.06,nM,=,,0.43,7.167,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
605,24199154,glp1r_human,32,L,A,exendin-4(1-30)(Gly2Ala),FASTA sequence (peptide),HAEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.005,nM,=,,0.01,2.0,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
755,24199154,glp1r_human,32,L,A,Chimer 2,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAAKEFIAWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.083,nM,=,,0.076,-1.092,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
992,24199154,glp1r_human,32,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,0.017,nM,=,,0.037,2.176,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
1022,24199154,glp1r_human,32,L,A,Chimer 2X,FASTA sequence (peptide),HSQGTFTSDYSKYLDEEAVRLFIEWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.038,nM,=,,0.076,2.0,,,,100.0,0.0,,0.0,,P43220,2.75315,LA32A,GLP1R
35,22147710,glp1r_human,296,C,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,6.9,7.943,,,,0.0,0.0,,88.67924528,,P43220,5.2788,CA296A,GLP1R
181,22147710,glp1r_human,296,C,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.6,12.589,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,5.2788,CA296A,GLP1R
401,22147710,glp1r_human,296,C,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.8,-1.259,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,5.2788,CA296A,GLP1R
609,22147710,glp1r_human,296,C,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,6.9,125.893,,,,0.0,0.0,,59.37873357,,P43220,5.2788,CA296A,GLP1R
977,22147710,glp1r_human,296,C,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.8,-3.984,,,,0.0,0.0,,35.0877193,,P43220,5.2788,CA296A,GLP1R
36,27315480,glp1r_human,220,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.49,1.862,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.49921,YA220A,GLP1R
223,27315480,glp1r_human,220,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.33,2.138,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.49921,YA220A,GLP1R
334,27315480,glp1r_human,220,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.36,3.802,,,,0.0,0.0,,90.0,,P43220,1.49921,YA220A,GLP1R
384,27315480,glp1r_human,220,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,9.23,-1.318,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.49921,YA220A,GLP1R
531,27315480,glp1r_human,220,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.13,1.585,,,,0.0,0.0,,90.0,,P43220,1.49921,YA220A,GLP1R
544,27315480,glp1r_human,220,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.88,1.202,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,1.49921,YA220A,GLP1R
570,27315480,glp1r_human,220,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.12,213.796,,,,0.0,0.0,,100.0,,P43220,1.49921,YA220A,GLP1R
723,27315480,glp1r_human,220,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.05,-2.632,,,,0.0,0.0,,7.48,,P43220,1.49921,YA220A,GLP1R
834,27315480,glp1r_human,220,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.73,1.202,,,,0.0,0.0,,118.0,,P43220,1.49921,YA220A,GLP1R
956,27315480,glp1r_human,220,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.05,4.467,,,,0.0,0.0,,95.0,,P43220,1.49921,YA220A,GLP1R
1018,27315480,glp1r_human,220,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.53,-1.202,,,,0.0,0.0,,104.0,,P43220,1.49921,YA220A,GLP1R
1158,27315480,glp1r_human,220,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.47,1.549,,,,0.0,0.0,,105.0,,P43220,1.49921,YA220A,GLP1R
37,22147710,glp1r_human,303,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.8,1.0,,,,0.0,0.0,,103.7735849,,P43220,0.621275,MA303A,GLP1R
147,22147710,glp1r_human,303,M,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,8.1,-2.513,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,0.621275,MA303A,GLP1R
241,22147710,glp1r_human,303,M,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.2,1.0,,,,0.0,0.0,,96.49122807,,P43220,0.621275,MA303A,GLP1R
268,22147710,glp1r_human,303,M,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.3,1.0,,,,0.0,0.0,,60.16796641,,P43220,0.621275,MA303A,GLP1R
550,22147710,glp1r_human,303,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.1,3.981,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,0.621275,MA303A,GLP1R
1127,22147710,glp1r_human,303,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.5,3.162,,,,0.0,0.0,,71.14695341,,P43220,0.621275,MA303A,GLP1R
41,27315480,glp1r_human,217,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.55,1.288,,,,0.0,0.0,,97.0,,P43220,3.77074,LA217A,GLP1R
48,27315480,glp1r_human,217,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.91,1.122,,,[125I]-exendin(9-39) (radioligand),109.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
98,27315480,glp1r_human,217,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.66,-10.753,,,,0.0,0.0,,7.43,,P43220,3.77074,LA217A,GLP1R
152,27315480,glp1r_human,217,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.03,263.027,,,,0.0,0.0,,64.0,,P43220,3.77074,LA217A,GLP1R
171,27315480,glp1r_human,217,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.4,2.57,,,,0.0,0.0,,84.0,,P43220,3.77074,LA217A,GLP1R
194,27315480,glp1r_human,217,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.47,1.549,,,[125I]-exendin(9-39) (radioligand),109.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
381,27315480,glp1r_human,217,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.25,1.585,,,,0.0,0.0,,112.0,,P43220,3.77074,LA217A,GLP1R
428,27315480,glp1r_human,217,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.37,9.12,,,,0.0,0.0,,108.0,,P43220,3.77074,LA217A,GLP1R
447,27315480,glp1r_human,217,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.66,1.096,,,,0.0,0.0,,106.0,,P43220,3.77074,LA217A,GLP1R
729,27059958,glp1r_human,217,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,7.0,1.014,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),112.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
733,27315480,glp1r_human,217,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.72,1.096,,,[125I]-exendin(9-39) (radioligand),109.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
771,27315480,glp1r_human,217,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.69,2.63,,,[125I]-exendin(9-39) (radioligand),109.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
869,27059958,glp1r_human,217,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,25.0,2.5,,,,112.0,0.0,,0.0,,P43220,3.77074,LA217A,GLP1R
952,27315480,glp1r_human,217,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.13,-1.548,,,,0.0,0.0,,78.0,,P43220,3.77074,LA217A,GLP1R
42,27315480,glp1r_human,385,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,8.12,-1.35,,,,0.0,0.0,,99.0,,P43220,0.983285,FA385A,GLP1R
134,27315480,glp1r_human,385,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,7.84,3.89,,,,0.0,0.0,,101.0,,P43220,0.983285,FA385A,GLP1R
226,27315480,glp1r_human,385,F,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.29,-1.175,,,[125I]-exendin(9-39) (radioligand),110.0,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
265,27315480,glp1r_human,385,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,7.84,-1.862,,,,0.0,0.0,,7.24,,P43220,0.983285,FA385A,GLP1R
309,26598711,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.94,3.236,,,[125I]-exendin(9-39) (radioligand),84.86238532,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
470,27315480,glp1r_human,385,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,9.0,1.66,,,[125I]-exendin(9-39) (radioligand),110.0,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
533,26598711,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.42,1.004,,,,84.86238532,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
555,26598711,glp1r_human,385,F,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.32,1.072,,,[125I]-exendin(9-39) (radioligand),84.86238532,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
699,27315480,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.41,3.89,,,,0.0,0.0,,91.0,,P43220,0.983285,FA385A,GLP1R
734,27315480,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.94,2.188,,,,0.0,0.0,,91.0,,P43220,0.983285,FA385A,GLP1R
907,27315480,glp1r_human,385,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.3,1.995,,,,0.0,0.0,,90.0,,P43220,0.983285,FA385A,GLP1R
920,27315480,glp1r_human,385,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.47,134.896,,,,0.0,0.0,,93.0,,P43220,0.983285,FA385A,GLP1R
986,27315480,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.97,-1.658,,,[125I]-exendin(9-39) (radioligand),110.0,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
1077,27315480,glp1r_human,385,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.81,1.148,,,,0.0,0.0,,85.0,,P43220,0.983285,FA385A,GLP1R
1126,27315480,glp1r_human,385,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.17,1.349,,,[125I]-exendin(9-39) (radioligand),110.0,0.0,,0.0,,P43220,0.983285,FA385A,GLP1R
44,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,µM,>,,10.0,10.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
129,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.33,nM,=,,104.71,317.303,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
210,25561730,glp1r_human,380,R,D,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.05,µM,=,,1.05,21.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
250,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.29,µM,=,,0.41,1.414,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
284,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.83,µM,=,,0.19,-4.367,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
307,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,123.03,nM,=,,64.57,-1.905,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
354,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.78,µM,=,,0.35,-5.076,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
518,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.41,µM,=,,0.15,-9.434,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
587,25561730,glp1r_human,380,R,D,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,45.71,nM,>,,1000.0,21.877,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
594,25561730,glp1r_human,380,R,D,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.29,µM,>,,10.0,7.752,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
630,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,190.55,nM,>,,1000.0,5.248,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
640,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,28.84,nM,=,,4.79,-6.024,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
704,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.0,µM,>,,10.0,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
748,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.82,µM,>,,10.0,5.495,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
764,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,1000.0,nM,>,,1000.0,1.0,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
945,25561730,glp1r_human,380,R,D,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,52.48,nM,=,,12.88,-4.082,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
1020,25561730,glp1r_human,380,R,D,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Binding - Radioligand competition/displacement,0.31,nM,=,,574.44,1853.032,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
1112,25561730,glp1r_human,380,R,D,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,85.11,nM,>,,1000.0,11.75,,,,95.0,0.0,,0.0,,P43220,1.0437,RA380D,GLP1R
45,26598711,glp1r_human,306,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,7.41,109.648,,,[125I]-exendin(9-39) (radioligand),41.28440367,0.0,,0.0,,P43220,0.715549,WA306A,GLP1R
184,26598711,glp1r_human,306,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,9.1,-1.25,,,,41.28440367,0.0,,0.0,,P43220,0.715549,WA306A,GLP1R
387,22147710,glp1r_human,306,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.9,-1.585,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.715549,WA306A,GLP1R
958,26598711,glp1r_human,306,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.61,-1.818,,,[125I]-exendin(9-39) (radioligand),41.28440367,0.0,,0.0,,P43220,0.715549,WA306A,GLP1R
999,22147710,glp1r_human,306,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.3,25.119,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.715549,WA306A,GLP1R
51,27315480,glp1r_human,223,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.86,3.89,,,,0.0,0.0,,103.0,,P43220,0.860554,SA223A,GLP1R
256,27315480,glp1r_human,223,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.06,1.862,,,,0.0,0.0,,141.0,,P43220,0.860554,SA223A,GLP1R
285,27315480,glp1r_human,223,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.68,2.692,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.860554,SA223A,GLP1R
450,27315480,glp1r_human,223,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,8.07,-1.289,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.860554,SA223A,GLP1R
611,27315480,glp1r_human,223,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.45,2.291,,,,0.0,0.0,,74.0,,P43220,0.860554,SA223A,GLP1R
696,27315480,glp1r_human,223,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.12,3.802,,,,0.0,0.0,,102.0,,P43220,0.860554,SA223A,GLP1R
721,27315480,glp1r_human,223,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.32,2.754,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.860554,SA223A,GLP1R
839,27315480,glp1r_human,223,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.99,-1.122,,,,0.0,0.0,,71.0,,P43220,0.860554,SA223A,GLP1R
887,27315480,glp1r_human,223,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.12,-3.086,,,,0.0,0.0,,7.76,,P43220,0.860554,SA223A,GLP1R
1116,27315480,glp1r_human,223,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.64,64.565,,,,0.0,0.0,,100.0,,P43220,0.860554,SA223A,GLP1R
1150,27315480,glp1r_human,223,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.36,1.995,,,,0.0,0.0,,98.0,,P43220,0.860554,SA223A,GLP1R
1159,27315480,glp1r_human,223,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.32,2.188,,,[125I]-exendin(9-39) (radioligand),90.0,0.0,,0.0,,P43220,0.860554,SA223A,GLP1R
53,27315480,glp1r_human,218,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.85,398.107,,,,0.0,0.0,,82.0,,P43220,2.51878,LA218A,GLP1R
190,27315480,glp1r_human,218,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,8.92,5.495,,,,0.0,0.0,,99.0,,P43220,2.51878,LA218A,GLP1R
254,27315480,glp1r_human,218,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.69,4.365,,,,0.0,0.0,,83.0,,P43220,2.51878,LA218A,GLP1R
303,27315480,glp1r_human,218,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,7.59,1.096,,,,0.0,0.0,,7.26,,P43220,2.51878,LA218A,GLP1R
304,27315480,glp1r_human,218,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,7.91,7.079,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,2.51878,LA218A,GLP1R
372,27315480,glp1r_human,218,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.03,6.026,,,,0.0,0.0,,95.0,,P43220,2.51878,LA218A,GLP1R
488,27315480,glp1r_human,218,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.51,8.71,,,,0.0,0.0,,100.0,,P43220,2.51878,LA218A,GLP1R
532,27315480,glp1r_human,218,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.64,1.995,,,,0.0,0.0,,85.0,,P43220,2.51878,LA218A,GLP1R
565,27315480,glp1r_human,218,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.15,3.236,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,2.51878,LA218A,GLP1R
787,27315480,glp1r_human,218,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.64,2.089,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,2.51878,LA218A,GLP1R
946,27315480,glp1r_human,218,L,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.14,9.333,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,2.51878,LA218A,GLP1R
1137,27315480,glp1r_human,218,L,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,7.59,12.882,,,,0.0,0.0,,94.0,,P43220,2.51878,LA218A,GLP1R
56,20407008,glp1r_human,82,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,26.0,pM,=,,61.0,2.346,,,,84.72222222,0.0,,0.0,,P43220,-0.988294,NA82L,GLP1R
253,20407008,glp1r_human,82,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - unknown pharmacological activity,2.8,nM,=,,1.7,-1.647,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),84.72222222,0.0,,0.0,,P43220,-0.988294,NA82L,GLP1R
58,27315480,glp1r_human,205,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.26,3.548,,,,0.0,0.0,,14.0,,P43220,1.05663,YA205A,GLP1R
85,27315480,glp1r_human,205,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.32,13.49,,,,0.0,0.0,,47.0,,P43220,1.05663,YA205A,GLP1R
86,27315480,glp1r_human,205,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.87,2.884,,,,0.0,0.0,,44.0,,P43220,1.05663,YA205A,GLP1R
180,27315480,glp1r_human,205,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.18,8.511,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,1.05663,YA205A,GLP1R
242,27315480,glp1r_human,205,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.55,794.328,,,,0.0,0.0,,24.0,,P43220,1.05663,YA205A,GLP1R
249,27315480,glp1r_human,205,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.33,2.138,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,1.05663,YA205A,GLP1R
318,27315480,glp1r_human,205,Y,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,6.84,12.589,,,,0.0,0.0,,22.0,,P43220,1.05663,YA205A,GLP1R
542,27315480,glp1r_human,205,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,8.9,5.754,,,,0.0,0.0,,30.0,,P43220,1.05663,YA205A,GLP1R
580,27315480,glp1r_human,205,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,7.9,-1.862,,,,0.0,0.0,,6.15,,P43220,1.05663,YA205A,GLP1R
629,27315480,glp1r_human,205,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.25,3.236,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,1.05663,YA205A,GLP1R
735,27315480,glp1r_human,205,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.9,1.148,,,[125I]-exendin(9-39) (radioligand),68.0,0.0,,0.0,,P43220,1.05663,YA205A,GLP1R
879,27059958,glp1r_human,205,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,617.0,61.7,,,,99.0,0.0,,0.0,,P43220,1.05663,YA205A,GLP1R
969,27315480,glp1r_human,205,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,7.9,6.31,,,,0.0,0.0,,40.0,,P43220,1.05663,YA205A,GLP1R
59,21308878,glp1r_human,68,E,K,glucagon-(Ser22Glu),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAQDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.022,nM,=,,0.039,1.773,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
73,21308878,glp1r_human,68,E,K,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,EC50,Functional - cAMP accumulation,0.15,nM,=,,1.6,10.667,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
294,21308878,glp1r_human,68,E,K,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,0.0089,nM,=,,0.075,8.427,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
301,21308878,glp1r_human,68,E,K,glucagon-like peptide 1-(Gln22Glu)-(7-35),FASTA sequence (peptide),HAEGTFTSDVSSYLEEQAAKEFIAWLVKR,Full agonist,EC50,Functional - cAMP accumulation,0.0024,nM,=,,0.011,4.583,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
1067,21308878,glp1r_human,68,E,K,glucagon-like peptide 1-(7-35),FASTA sequence (peptide),HAEGTFTSDVSSYLEGQAAKEFIAWLVKR,Full agonist,EC50,Functional - cAMP accumulation,0.0084,nM,=,,0.036,4.286,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
1085,21308878,glp1r_human,68,E,K,glucagon,PubChem CID,44278361,Full agonist,EC50,Functional - cAMP accumulation,0.061,nM,=,,0.12,1.967,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
1095,21308878,glp1r_human,68,E,K,glucagon-like peptide 1-(Arg36Gly),FASTA sequence (peptide),HAEGTFTSDVSSYLEGQAAKEFIAWLVKGG,Full agonist,EC50,Functional - cAMP accumulation,0.0049,nM,=,,0.022,4.49,,,,0.0,0.0,,0.0,,P43220,-0.581141,EA68K,GLP1R
62,22147710,glp1r_human,292,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.2,3.981,,,,0.0,0.0,,37.73584906,,P43220,1.03753,EA292A,GLP1R
213,27059958,glp1r_human,292,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,332.0,33.2,,,,39.0,0.0,,0.0,,P43220,1.03753,EA292A,GLP1R
270,22147710,glp1r_human,292,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.7,1.0,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,1.03753,EA292A,GLP1R
689,22147710,glp1r_human,292,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,6.7,100.0,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,1.03753,EA292A,GLP1R
803,22147710,glp1r_human,292,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,6.9,125.893,,,,0.0,0.0,,56.69056153,,P43220,1.03753,EA292A,GLP1R
1055,22147710,glp1r_human,292,E,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,6.7,3.162,,,,0.0,0.0,,68.42105263,,P43220,1.03753,EA292A,GLP1R
63,21868452,glp1r_human,197,K,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.36,630.957,,,,57.34545455,0.0,,0.0,,P43220,1.0031,KA197A,GLP1R
74,21868452,glp1r_human,197,K,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.36,630.957,,,,0.0,0.0,,85.0,,P43220,1.0031,KA197A,GLP1R
135,21868452,glp1r_human,197,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.67,3.02,,,[125I]-exendin(9-39) (radioligand),57.34545455,0.0,,0.0,,P43220,1.0031,KA197A,GLP1R
329,21868452,glp1r_human,197,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.86,22.909,,,[125I]-exendin(9-39) (radioligand),57.34545455,0.0,,0.0,,P43220,1.0031,KA197A,GLP1R
65,26598711,glp1r_human,376,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.13,1.66,,,[125I]-exendin(9-39) (radioligand),137.1559633,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
84,27315480,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.58,2.63,,,,0.0,0.0,,101.0,,P43220,0.16193,RA376A,GLP1R
185,27315480,glp1r_human,376,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.79,2.692,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
197,27315480,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,8.09,1.549,,,,0.0,0.0,,77.0,,P43220,0.16193,RA376A,GLP1R
283,27315480,glp1r_human,376,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.33,186.209,,,,0.0,0.0,,79.0,,P43220,0.16193,RA376A,GLP1R
443,27315480,glp1r_human,376,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.4,1.585,,,,0.0,0.0,,97.0,,P43220,0.16193,RA376A,GLP1R
522,26598711,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.23,1.66,,,[125I]-exendin(9-39) (radioligand),137.1559633,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
564,27315480,glp1r_human,376,R,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.29,-5.236,,,,0.0,0.0,,6.99,,P43220,0.16193,RA376A,GLP1R
568,27315480,glp1r_human,376,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.9,2.089,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
591,27315480,glp1r_human,376,R,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.29,1.38,,,,0.0,0.0,,92.0,,P43220,0.16193,RA376A,GLP1R
595,27315480,glp1r_human,376,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,8.01,-1.047,,,,0.0,0.0,,95.0,,P43220,0.16193,RA376A,GLP1R
703,27315480,glp1r_human,376,R,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.14,1.445,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
781,27315480,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.15,3.981,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
817,27315480,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.88,-1.024,,,,0.0,0.0,,102.0,,P43220,0.16193,RA376A,GLP1R
1017,26598711,glp1r_human,376,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.32,-1.005,,,,137.1559633,0.0,,0.0,,P43220,0.16193,RA376A,GLP1R
66,27315480,glp1r_human,204,M,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,6.21,28.184,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.79284,MA204A,GLP1R
116,27315480,glp1r_human,204,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,6.98,22.387,,,,0.0,0.0,,67.0,,P43220,2.79284,MA204A,GLP1R
282,27315480,glp1r_human,204,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,7.93,53.703,,,,0.0,0.0,,105.0,,P43220,2.79284,MA204A,GLP1R
355,27315480,glp1r_human,204,M,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.78,1.514,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.79284,MA204A,GLP1R
380,27315480,glp1r_human,204,M,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.71,5.495,,,,0.0,0.0,,107.0,,P43220,2.79284,MA204A,GLP1R
465,27315480,glp1r_human,204,M,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,7.98,13.49,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.79284,MA204A,GLP1R
610,27315480,glp1r_human,204,M,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.61,691.831,,,,0.0,0.0,,77.0,,P43220,2.79284,MA204A,GLP1R
676,27315480,glp1r_human,204,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,7.09,46.774,,,[125I]-exendin(9-39) (radioligand),99.0,0.0,,0.0,,P43220,2.79284,MA204A,GLP1R
693,27315480,glp1r_human,204,M,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,7.58,13.183,,,,0.0,0.0,,100.0,,P43220,2.79284,MA204A,GLP1R
702,27315480,glp1r_human,204,M,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,7.58,1.122,,,,0.0,0.0,,7.35,,P43220,2.79284,MA204A,GLP1R
784,27059958,glp1r_human,204,M,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,3341.0,334.1,,,,109.0,0.0,,0.0,,P43220,2.79284,MA204A,GLP1R
67,21868452,glp1r_human,310,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.06,1258.925,,,,0.0,0.0,,130.0,,P43220,0.357812,RA310A,GLP1R
132,21868452,glp1r_human,310,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.81,2.188,,,[125I]-exendin(9-39) (radioligand),17.2,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
151,26598711,glp1r_human,310,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.37,-1.047,,,[125I]-exendin(9-39) (radioligand),18.80733945,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
461,26598711,glp1r_human,310,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,8.31,-1.37,,,,18.80733945,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
679,21868452,glp1r_human,310,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.22,10.0,,,[125I]-exendin(9-39) (radioligand),17.2,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
906,21868452,glp1r_human,310,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.06,1258.925,,,,17.2,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
942,26598711,glp1r_human,310,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.91,3.467,,,[125I]-exendin(9-39) (radioligand),18.80733945,0.0,,0.0,,P43220,0.357812,RA310A,GLP1R
68,27315480,glp1r_human,381,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.18,13.183,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
69,27315480,glp1r_human,381,F,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.86,22.909,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
103,27315480,glp1r_human,381,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.5,125.893,,,,0.0,0.0,,125.0,,P43220,2.27288,FA381A,GLP1R
143,27315480,glp1r_human,381,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,7.96,2.951,,,,0.0,0.0,,80.0,,P43220,2.27288,FA381A,GLP1R
150,27315480,glp1r_human,381,F,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,7.96,-2.457,,,,0.0,0.0,,6.92,,P43220,2.27288,FA381A,GLP1R
405,27315480,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.42,2.138,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
423,27315480,glp1r_human,381,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,7.58,2.57,,,,0.0,0.0,,110.0,,P43220,2.27288,FA381A,GLP1R
644,26598711,glp1r_human,381,F,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.31,1.096,,,[125I]-exendin(9-39) (radioligand),16.05504587,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
661,27315480,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.71,1.95,,,,0.0,0.0,,74.0,,P43220,2.27288,FA381A,GLP1R
788,27315480,glp1r_human,381,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.97,1.778,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
814,27315480,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,8.98,-5.0,,,,0.0,0.0,,115.0,,P43220,2.27288,FA381A,GLP1R
846,27315480,glp1r_human,381,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.5,1.259,,,,0.0,0.0,,88.0,,P43220,2.27288,FA381A,GLP1R
901,26598711,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.18,-1.018,,,,16.05504587,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
939,27315480,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.16,5.129,,,,0.0,0.0,,83.0,,P43220,2.27288,FA381A,GLP1R
1076,26598711,glp1r_human,381,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.23,1.66,,,[125I]-exendin(9-39) (radioligand),16.05504587,0.0,,0.0,,P43220,2.27288,FA381A,GLP1R
71,19861722,glp1r_human,35,T,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,23.0,4.182,,,,6.909090909,0.0,,0.0,,P43220,0.488268,TA35A,GLP1R
468,19861722,glp1r_human,35,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,30.0,2.727,,,,6.909090909,0.0,,0.0,,P43220,0.488268,TA35A,GLP1R
1079,19861722,glp1r_human,35,T,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.44,-1.727,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),6.909090909,0.0,,0.0,,P43220,0.488268,TA35A,GLP1R
1132,19861722,glp1r_human,35,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,3.1,3.1,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),6.909090909,0.0,,0.0,,P43220,0.488268,TA35A,GLP1R
72,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.29,µM,>,,10.0,34.483,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
235,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.0,µM,>,,10.0,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
240,25561730,glp1r_human,379,L,E,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Binding - Radioligand competition/displacement,0.31,nM,=,,51.29,165.452,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
480,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.83,µM,>,,10.0,12.048,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
514,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.82,µM,>,,10.0,5.495,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
662,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.33,nM,=,,104.71,317.303,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
674,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,123.03,nM,>,,1000.0,8.128,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
706,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,1000.0,nM,>,,1000.0,1.0,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
795,25561730,glp1r_human,379,L,E,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.05,µM,=,,0.54,10.8,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
800,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.78,µM,>,,10.0,5.618,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
804,25561730,glp1r_human,379,L,E,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.29,µM,>,,10.0,7.752,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
822,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,µM,>,,10.0,10.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
859,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,52.48,nM,>,,1000.0,19.055,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
911,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.41,µM,>,,10.0,7.092,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
962,25561730,glp1r_human,379,L,E,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,45.71,nM,>,,1000.0,21.877,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
973,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,190.55,nM,>,,1000.0,5.248,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
1004,25561730,glp1r_human,379,L,E,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,28.84,nM,>,,1000.0,34.674,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
1099,25561730,glp1r_human,379,L,E,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,85.11,nM,>,,1000.0,11.75,,,,80.5,0.0,,0.0,,P43220,0.442531,LA379E,GLP1R
76,27315480,glp1r_human,202,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,6.77,7.762,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.566259,KA202A,GLP1R
330,27315480,glp1r_human,202,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,8.39,18.621,,,,0.0,0.0,,97.0,,P43220,0.566259,KA202A,GLP1R
475,27315480,glp1r_human,202,K,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.59,2.344,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.566259,KA202A,GLP1R
482,27315480,glp1r_human,202,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,6.76,15.136,,,,0.0,0.0,,39.0,,P43220,0.566259,KA202A,GLP1R
547,27315480,glp1r_human,202,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.88,1.698,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.566259,KA202A,GLP1R
858,27315480,glp1r_human,202,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.8,4.467,,,,0.0,0.0,,104.0,,P43220,0.566259,KA202A,GLP1R
916,27315480,glp1r_human,202,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.32,1.023,,,,0.0,0.0,,111.0,,P43220,0.566259,KA202A,GLP1R
921,27315480,glp1r_human,202,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.14,-3.236,,,,0.0,0.0,,7.62,,P43220,0.566259,KA202A,GLP1R
1012,27315480,glp1r_human,202,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,6.86,8.913,,,,0.0,0.0,,40.0,,P43220,0.566259,KA202A,GLP1R
1100,27315480,glp1r_human,202,K,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.42,2.188,,,[125I]-exendin(9-39) (radioligand),94.0,0.0,,0.0,,P43220,0.566259,KA202A,GLP1R
1120,27315480,glp1r_human,202,K,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.72,53.703,,,,0.0,0.0,,129.0,,P43220,0.566259,KA202A,GLP1R
1131,27315480,glp1r_human,202,K,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.14,3.631,,,,0.0,0.0,,98.0,,P43220,0.566259,KA202A,GLP1R
77,22147710,glp1r_human,305,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.5,1.995,,,,0.0,0.0,,62.26415094,,P43220,1.66017,YA305A,GLP1R
174,22147710,glp1r_human,305,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,7.4,39.811,,,,0.0,0.0,,81.24253286,,P43220,1.66017,YA305A,GLP1R
200,22147710,glp1r_human,305,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,6.9,2.512,,,,0.0,0.0,,26.93461308,,P43220,1.66017,YA305A,GLP1R
276,22147710,glp1r_human,305,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.7,1.0,,,[125I]-exendin(9-39) (radioligand),52.0,0.0,,0.0,,P43220,1.66017,YA305A,GLP1R
446,22147710,glp1r_human,305,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,6.8,79.433,,,[125I]-exendin(9-39) (radioligand),52.0,0.0,,0.0,,P43220,1.66017,YA305A,GLP1R
541,26598711,glp1r_human,305,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.7,-1.064,,,,22.47706422,0.0,,0.0,,P43220,1.66017,YA305A,GLP1R
791,26598711,glp1r_human,305,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.26,1.549,,,[125I]-exendin(9-39) (radioligand),22.47706422,0.0,,0.0,,P43220,1.66017,YA305A,GLP1R
797,22147710,glp1r_human,305,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.5,-1.996,,,,0.0,0.0,,59.64912281,,P43220,1.66017,YA305A,GLP1R
1145,26598711,glp1r_human,305,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.29,1.148,,,[125I]-exendin(9-39) (radioligand),22.47706422,0.0,,0.0,,P43220,1.66017,YA305A,GLP1R
78,20407008,glp1r_human,115,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,26.0,pM,=,,56.0,2.154,,,,86.80555556,0.0,,0.0,,P43220,0.277301,NA115L,GLP1R
118,20407008,glp1r_human,115,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - unknown pharmacological activity,2.8,nM,=,,2.8,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),86.80555556,0.0,,0.0,,P43220,0.277301,NA115L,GLP1R
87,27315480,glp1r_human,213,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.88,371.535,,,,0.0,0.0,,80.0,,P43220,-0.858468,QA213A,GLP1R
305,27315480,glp1r_human,213,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.38,1.175,,,,0.0,0.0,,100.0,,P43220,-0.858468,QA213A,GLP1R
363,27315480,glp1r_human,213,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.88,-1.318,,,[125I]-exendin(9-39) (radioligand),101.0,0.0,,0.0,,P43220,-0.858468,QA213A,GLP1R
386,27315480,glp1r_human,213,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.7,-11.765,,,,0.0,0.0,,7.25,,P43220,-0.858468,QA213A,GLP1R
557,27315480,glp1r_human,213,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.72,2.455,,,[125I]-exendin(9-39) (radioligand),101.0,0.0,,0.0,,P43220,-0.858468,QA213A,GLP1R
560,27315480,glp1r_human,213,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.83,1.288,,,,0.0,0.0,,85.0,,P43220,-0.858468,QA213A,GLP1R
650,27315480,glp1r_human,213,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.7,1.0,,,,0.0,0.0,,102.0,,P43220,-0.858468,QA213A,GLP1R
746,27315480,glp1r_human,213,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.42,1.738,,,,0.0,0.0,,100.0,,P43220,-0.858468,QA213A,GLP1R
761,27315480,glp1r_human,213,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.96,1.0,,,[125I]-exendin(9-39) (radioligand),101.0,0.0,,0.0,,P43220,-0.858468,QA213A,GLP1R
816,27315480,glp1r_human,213,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.39,2.63,,,,0.0,0.0,,74.0,,P43220,-0.858468,QA213A,GLP1R
857,27315480,glp1r_human,213,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.74,-1.202,,,[125I]-exendin(9-39) (radioligand),101.0,0.0,,0.0,,P43220,-0.858468,QA213A,GLP1R
1036,27315480,glp1r_human,213,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.79,3.467,,,,0.0,0.0,,45.0,,P43220,-0.858468,QA213A,GLP1R
89,23479653,glp1r_human,402,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.45,-2.188,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,4.34019,YA402A,GLP1R
430,23479653,glp1r_human,402,Y,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.09,1.479,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,4.34019,YA402A,GLP1R
575,23479653,glp1r_human,402,Y,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,8.72,1.778,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,4.34019,YA402A,GLP1R
602,23479653,glp1r_human,402,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.42,1.778,,,[125I]-exendin(9-39) (radioligand),0.0,0.0,,0.0,,P43220,4.34019,YA402A,GLP1R
90,26598711,glp1r_human,375,A,G,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,7.67,4.786,,,[125I]-exendin(9-39) (radioligand),185.7798165,0.0,,0.0,,P43220,1.01364,AA375G,GLP1R
584,26598711,glp1r_human,375,A,G,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.46,9.772,,,[125I]-exendin(9-39) (radioligand),185.7798165,0.0,,0.0,,P43220,1.01364,AA375G,GLP1R
705,26598711,glp1r_human,375,A,G,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.52,-1.082,,,,185.7798165,0.0,,0.0,,P43220,1.01364,AA375G,GLP1R
108,22147710,glp1r_human,299,R,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.2,1.259,,,,0.0,0.0,,9.358128374,,P43220,0.768179,RA299A,GLP1R
279,26598711,glp1r_human,299,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.87,-2.632,,,[125I]-exendin(9-39) (radioligand),40.36697248,0.0,,0.0,,P43220,0.768179,RA299A,GLP1R
452,22147710,glp1r_human,299,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.4,1.995,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.768179,RA299A,GLP1R
512,26598711,glp1r_human,299,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.5,-1.083,,,,40.36697248,0.0,,0.0,,P43220,0.768179,RA299A,GLP1R
900,22147710,glp1r_human,299,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,7.6,25.119,,,,0.0,0.0,,55.19713262,,P43220,0.768179,RA299A,GLP1R
932,22147710,glp1r_human,299,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.2,31.623,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.768179,RA299A,GLP1R
959,26598711,glp1r_human,299,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.59,-1.739,,,[125I]-exendin(9-39) (radioligand),40.36697248,0.0,,0.0,,P43220,0.768179,RA299A,GLP1R
1160,22147710,glp1r_human,299,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.5,1.995,,,,0.0,0.0,,79.24528302,,P43220,0.768179,RA299A,GLP1R
1168,22147710,glp1r_human,299,R,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.5,-1.996,,,,0.0,0.0,,94.73684211,,P43220,0.768179,RA299A,GLP1R
109,19861722,glp1r_human,127,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,1.7,1.7,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),101.8181818,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
230,24199154,glp1r_human,127,E,A,GLP-1-(Ala8Gly),FASTA sequence (peptide),HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.25,nM,=,,0.46,1.84,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
364,24199154,glp1r_human,127,E,A,exendin-4(1-30)(Gly2Ala),FASTA sequence (peptide),HAEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.005,nM,=,,0.006,1.2,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
398,24199154,glp1r_human,127,E,A,glucagon-(Ser22Glu/Gln26Lys),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAEDFVKWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.083,nM,=,,0.1,1.205,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
431,19861722,glp1r_human,127,E,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,5.2,6.842,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),101.8181818,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
654,19861722,glp1r_human,127,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,13.0,1.182,,,,101.8181818,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
698,24199154,glp1r_human,127,E,A,exendin-4(1-30),FASTA sequence (peptide),HGEGTFTSDLSKQMEEEAVRLFIEWLKNGG,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.011,1.571,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
739,24199154,glp1r_human,127,E,A,compound 2,PubChem CID,16007289,Allosteric agonist,EC50,Functional - cAMP accumulation,300.0,nM,=,,420.0,1.4,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
744,24199154,glp1r_human,127,E,A,glucagon-(Ser22Glu),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAQDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.06,nM,=,,0.072,1.2,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
845,19861722,glp1r_human,127,E,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,11.0,2.0,,,,101.8181818,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
955,24199154,glp1r_human,127,E,A,GLP-1-(Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HAEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.007,nM,=,,0.008,1.143,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
1047,24199154,glp1r_human,127,E,A,GLP-1-(Ala8Gly/Gly16Glu/Glu21Leu/Ala24Glu),FASTA sequence (peptide),HGEGTFTSDVSSYLEEQAAKLFIEWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.011,nM,=,,0.014,1.273,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
1062,24199154,glp1r_human,127,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,0.017,nM,=,,0.021,1.235,,,,100.0,0.0,,0.0,,P43220,-0.0518758,EA127A,GLP1R
112,25561730,glp1r_human,381,F,R,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.05,µM,=,,0.06,1.2,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
391,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.41,µM,=,,0.59,-2.392,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
462,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,123.03,nM,=,,125.89,1.023,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
589,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,85.11,nM,=,,87.1,1.023,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
607,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,1000.0,nM,=,,398.11,-2.513,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
624,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Lys),FASTA sequence (peptide),HAEGTFTSKVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,52.48,nM,=,,34.67,-1.513,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
658,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,28.84,nM,=,,30.2,1.047,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
768,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,0.33,nM,=,,3.39,10.273,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
775,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Glu),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.82,µM,=,,1.0,-1.821,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
821,25561730,glp1r_human,381,F,R,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,45.71,nM,=,,24.55,-1.862,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
847,25561730,glp1r_human,381,F,R,GLP-1-(Gly10His),FASTA sequence (peptide),HAEHTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.29,µM,=,,0.8,-1.613,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
898,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,µM,=,,1.0,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
931,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Glu),FASTA sequence (peptide),HAEGTFTSEVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.29,µM,=,,0.47,1.621,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
934,25561730,glp1r_human,381,F,R,GLP-1-(Asp15Arg),FASTA sequence (peptide),HAEGTFTSKVSSYLRGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.83,µM,=,,1.32,1.59,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
937,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Arg),FASTA sequence (peptide),HAEETFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.78,µM,=,,2.14,1.202,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
941,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Lys),FASTA sequence (peptide),HAEKTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,10.0,µM,=,,2.88,-3.472,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
1015,25561730,glp1r_human,381,F,R,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Binding - Radioligand competition/displacement,0.31,nM,=,,0.15,-2.066,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
1102,25561730,glp1r_human,381,F,R,GLP-1-(Gly10Asp),FASTA sequence (peptide),HAEDTFTSDVSSYLEGQAAKEFIAWLVKGR,Full agonist,EC50,Functional - cAMP accumulation,190.55,nM,=,,302.0,1.585,,,,218.2,0.0,,0.0,,P43220,2.57974,FA381R,GLP1R
117,27315480,glp1r_human,221,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.39,-5.747,,,,0.0,0.0,,7.81,,P43220,0.221352,QA221A,GLP1R
218,27315480,glp1r_human,221,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.96,-1.047,,,,0.0,0.0,,93.0,,P43220,0.221352,QA221A,GLP1R
220,27315480,glp1r_human,221,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.53,1.698,,,[125I]-exendin(9-39) (radioligand),97.0,0.0,,0.0,,P43220,0.221352,QA221A,GLP1R
269,27315480,glp1r_human,221,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.85,-1.548,,,,0.0,0.0,,108.0,,P43220,0.221352,QA221A,GLP1R
280,27315480,glp1r_human,221,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.39,2.042,,,,0.0,0.0,,92.0,,P43220,0.221352,QA221A,GLP1R
322,27315480,glp1r_human,221,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,9.75,5.012,,,,0.0,0.0,,102.0,,P43220,0.221352,QA221A,GLP1R
339,27315480,glp1r_human,221,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.46,2.239,,,,0.0,0.0,,94.0,,P43220,0.221352,QA221A,GLP1R
572,27315480,glp1r_human,221,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.14,1.549,,,,0.0,0.0,,86.0,,P43220,0.221352,QA221A,GLP1R
603,27315480,glp1r_human,221,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.91,1.585,,,[125I]-exendin(9-39) (radioligand),97.0,0.0,,0.0,,P43220,0.221352,QA221A,GLP1R
678,27315480,glp1r_human,221,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.14,204.174,,,,0.0,0.0,,89.0,,P43220,0.221352,QA221A,GLP1R
902,27315480,glp1r_human,221,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.81,-1.412,,,[125I]-exendin(9-39) (radioligand),97.0,0.0,,0.0,,P43220,0.221352,QA221A,GLP1R
960,27315480,glp1r_human,221,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.69,1.862,,,[125I]-exendin(9-39) (radioligand),97.0,0.0,,0.0,,P43220,0.221352,QA221A,GLP1R
122,27059958,glp1r_human,145,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,3.4,-2.028,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),47.0,0.0,,0.0,,P43220,1.12406,YA145A,GLP1R
626,27059958,glp1r_human,145,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,13.0,1.3,,,,47.0,0.0,,0.0,,P43220,1.12406,YA145A,GLP1R
124,27315480,glp1r_human,222,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.35,2.042,,,[125I]-exendin(9-39) (radioligand),102.0,0.0,,0.0,,P43220,-0.300306,DA222A,GLP1R
178,27315480,glp1r_human,222,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.48,-7.092,,,,0.0,0.0,,7.39,,P43220,-0.300306,DA222A,GLP1R
246,27315480,glp1r_human,222,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.13,1.585,,,,0.0,0.0,,108.0,,P43220,-0.300306,DA222A,GLP1R
262,27315480,glp1r_human,222,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.99,-1.072,,,[125I]-exendin(9-39) (radioligand),102.0,0.0,,0.0,,P43220,-0.300306,DA222A,GLP1R
347,27315480,glp1r_human,222,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.3,141.254,,,,0.0,0.0,,104.0,,P43220,-0.300306,DA222A,GLP1R
406,27315480,glp1r_human,222,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.84,-1.072,,,,0.0,0.0,,97.0,,P43220,-0.300306,DA222A,GLP1R
478,27315480,glp1r_human,222,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.95,1.445,,,[125I]-exendin(9-39) (radioligand),102.0,0.0,,0.0,,P43220,-0.300306,DA222A,GLP1R
543,27315480,glp1r_human,222,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.94,-1.905,,,,0.0,0.0,,99.0,,P43220,-0.300306,DA222A,GLP1R
813,27315480,glp1r_human,222,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.73,-1.905,,,,0.0,0.0,,103.0,,P43220,-0.300306,DA222A,GLP1R
832,27315480,glp1r_human,222,D,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.85,1.23,,,,0.0,0.0,,101.0,,P43220,-0.300306,DA222A,GLP1R
868,27315480,glp1r_human,222,D,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.48,1.66,,,,0.0,0.0,,101.0,,P43220,-0.300306,DA222A,GLP1R
983,27315480,glp1r_human,222,D,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.62,1.38,,,[125I]-exendin(9-39) (radioligand),102.0,0.0,,0.0,,P43220,-0.300306,DA222A,GLP1R
125,27315480,glp1r_human,378,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,11.0,-2.513,,,,0.0,0.0,,108.0,,P43220,0.465595,TA378A,GLP1R
188,27315480,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,10.6,-3.984,,,,0.0,0.0,,101.0,,P43220,0.465595,TA378A,GLP1R
287,26598711,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.19,-1.017,,,,12.3853211,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
369,27315480,glp1r_human,378,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.1,1.318,,,[125I]-exendin(9-39) (radioligand),173.0,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
600,27315480,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,8.42,-3.546,,,,0.0,0.0,,179.0,,P43220,0.465595,TA378A,GLP1R
667,27315480,glp1r_human,378,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.67,4.266,,,[125I]-exendin(9-39) (radioligand),173.0,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
719,27315480,glp1r_human,378,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,9.05,35.481,,,,0.0,0.0,,136.0,,P43220,0.465595,TA378A,GLP1R
728,26598711,glp1r_human,378,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.31,1.096,,,[125I]-exendin(9-39) (radioligand),12.3853211,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
835,26598711,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.5,-1.122,,,[125I]-exendin(9-39) (radioligand),12.3853211,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
861,27315480,glp1r_human,378,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.44,-7.407,,,,0.0,0.0,,7.64,,P43220,0.465595,TA378A,GLP1R
1011,27315480,glp1r_human,378,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,8.55,-3.636,,,,0.0,0.0,,157.0,,P43220,0.465595,TA378A,GLP1R
1041,27315480,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,8.77,-3.086,,,,0.0,0.0,,136.0,,P43220,0.465595,TA378A,GLP1R
1043,27315480,glp1r_human,378,T,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.44,-1.024,,,,0.0,0.0,,105.0,,P43220,0.465595,TA378A,GLP1R
1051,27315480,glp1r_human,378,T,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.71,3.236,,,[125I]-exendin(9-39) (radioligand),173.0,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
1140,27315480,glp1r_human,378,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.79,-1.096,,,[125I]-exendin(9-39) (radioligand),173.0,0.0,,0.0,,P43220,0.465595,TA378A,GLP1R
127,19861722,glp1r_human,128,E,Q,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,8.0,1.455,,,,94.54545455,0.0,,0.0,,P43220,-0.213093,EA128Q,GLP1R
317,19861722,glp1r_human,128,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,0.66,-1.515,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),94.54545455,0.0,,0.0,,P43220,-0.213093,EA128Q,GLP1R
539,19861722,glp1r_human,128,E,Q,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.45,-1.689,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),94.54545455,0.0,,0.0,,P43220,-0.213093,EA128Q,GLP1R
1060,19861722,glp1r_human,128,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,10.0,-1.1,,,,94.54545455,0.0,,0.0,,P43220,-0.213093,EA128Q,GLP1R
128,27315480,glp1r_human,382,I,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.18,1.096,,,[125I]-exendin(9-39) (radioligand),115.0,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
332,27315480,glp1r_human,382,I,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,7.83,1.445,,,,0.0,0.0,,85.0,,P43220,0.653015,IA382A,GLP1R
349,27315480,glp1r_human,382,I,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.02,2.57,,,,0.0,0.0,,86.0,,P43220,0.653015,IA382A,GLP1R
399,27315480,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,8.82,-1.175,,,[125I]-exendin(9-39) (radioligand),115.0,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
403,26598711,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.1,2.239,,,[125I]-exendin(9-39) (radioligand),22.93577982,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
411,27315480,glp1r_human,382,I,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,9.1,1.318,,,[125I]-exendin(9-39) (radioligand),115.0,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
435,27315480,glp1r_human,382,I,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.2,2.512,,,,0.0,0.0,,86.0,,P43220,0.653015,IA382A,GLP1R
487,27315480,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.55,2.818,,,,0.0,0.0,,96.0,,P43220,0.653015,IA382A,GLP1R
619,27315480,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.21,4.571,,,,0.0,0.0,,79.0,,P43220,0.653015,IA382A,GLP1R
727,27315480,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,8.71,-2.688,,,,0.0,0.0,,117.0,,P43220,0.653015,IA382A,GLP1R
884,27315480,glp1r_human,382,I,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.02,-2.817,,,,0.0,0.0,,7.54,,P43220,0.653015,IA382A,GLP1R
982,26598711,glp1r_human,382,I,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.46,-1.289,,,[125I]-exendin(9-39) (radioligand),22.93577982,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
1027,27315480,glp1r_human,382,I,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.37,-1.175,,,[125I]-exendin(9-39) (radioligand),115.0,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
1154,26598711,glp1r_human,382,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.09,-1.026,,,,22.93577982,0.0,,0.0,,P43220,0.653015,IA382A,GLP1R
1155,27315480,glp1r_human,382,I,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.51,123.027,,,,0.0,0.0,,125.0,,P43220,0.653015,IA382A,GLP1R
130,27059958,glp1r_human,211,Q,R,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,7.0,1.014,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),173.0,0.0,,0.0,,P43220,-0.548892,QA211R,GLP1R
477,27059958,glp1r_human,211,Q,R,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,28.0,2.8,,,,173.0,0.0,,0.0,,P43220,-0.548892,QA211R,GLP1R
131,27315480,glp1r_human,210,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.78,-2.137,,,,0.0,0.0,,99.0,,P43220,0.166093,QA210A,GLP1R
175,27315480,glp1r_human,210,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.17,3.388,,,,0.0,0.0,,92.0,,P43220,0.166093,QA210A,GLP1R
333,27315480,glp1r_human,210,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.02,4.365,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,0.166093,QA210A,GLP1R
438,27315480,glp1r_human,210,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.63,1.072,,,,0.0,0.0,,96.0,,P43220,0.166093,QA210A,GLP1R
567,27315480,glp1r_human,210,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.22,169.824,,,,0.0,0.0,,78.0,,P43220,0.166093,QA210A,GLP1R
638,27315480,glp1r_human,210,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.64,1.318,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,0.166093,QA210A,GLP1R
701,27315480,glp1r_human,210,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.93,1.072,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,0.166093,QA210A,GLP1R
809,27315480,glp1r_human,210,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.71,-2.398,,,,0.0,0.0,,96.0,,P43220,0.166093,QA210A,GLP1R
897,27315480,glp1r_human,210,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.81,1.995,,,[125I]-exendin(9-39) (radioligand),88.0,0.0,,0.0,,P43220,0.166093,QA210A,GLP1R
998,27315480,glp1r_human,210,Q,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,7.78,1.445,,,,0.0,0.0,,83.0,,P43220,0.166093,QA210A,GLP1R
1030,27315480,glp1r_human,210,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.62,1.549,,,,0.0,0.0,,113.0,,P43220,0.166093,QA210A,GLP1R
1110,27315480,glp1r_human,210,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.17,-3.472,,,,0.0,0.0,,7.71,,P43220,0.166093,QA210A,GLP1R
133,27059958,glp1r_human,152,Y,H,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,9.0,-1.111,,,,88.0,0.0,,0.0,,P43220,1.36444,YA152H,GLP1R
373,27059958,glp1r_human,152,Y,H,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,3.8,-1.815,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),88.0,0.0,,0.0,,P43220,1.36444,YA152H,GLP1R
136,27059958,glp1r_human,190,R,K,GLP-1(Glu9Gln),FASTA sequence (peptide),HAQGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,36.0,nM,=,,25.0,-1.441,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
157,27059958,glp1r_human,190,R,K,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,61.0,5.083,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
263,27059958,glp1r_human,190,R,K,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,270.0,1.154,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
404,27059958,glp1r_human,190,R,K,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,173.0,28.361,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
432,27059958,glp1r_human,190,R,K,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,474.0,31.6,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
635,27059958,glp1r_human,190,R,K,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,110.0,1.058,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
778,27059958,glp1r_human,190,R,K,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,168.0,16.8,,,,87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
909,27059958,glp1r_human,190,R,K,GLP-1-(Ala8Ser),FASTA sequence (peptide),HSEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,61.0,nM,=,,109.0,1.787,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
1096,27059958,glp1r_human,190,R,K,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,12.0,-2.165,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,1.35686,RA190K,GLP1R
138,27315480,glp1r_human,212,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.87,-1.148,,,,0.0,0.0,,109.0,,P43220,-0.124007,HA212A,GLP1R
234,27315480,glp1r_human,212,H,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,7.96,1.0,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
277,27315480,glp1r_human,212,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.81,-1.122,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
315,27059958,glp1r_human,212,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,5.7,-1.754,,,,135.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
540,27315480,glp1r_human,212,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.45,1.0,,,,0.0,0.0,,96.0,,P43220,-0.124007,HA212A,GLP1R
559,27315480,glp1r_human,212,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.62,1.096,,,,0.0,0.0,,99.0,,P43220,-0.124007,HA212A,GLP1R
585,27315480,glp1r_human,212,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.64,-10.204,,,,0.0,0.0,,7.6,,P43220,-0.124007,HA212A,GLP1R
601,27315480,glp1r_human,212,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.84,-1.513,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
615,27315480,glp1r_human,212,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.24,-1.996,,,,0.0,0.0,,87.0,,P43220,-0.124007,HA212A,GLP1R
877,27315480,glp1r_human,212,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.64,1.148,,,,0.0,0.0,,100.0,,P43220,-0.124007,HA212A,GLP1R
1054,27315480,glp1r_human,212,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,9.43,-2.088,,,[125I]-exendin(9-39) (radioligand),103.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
1071,27315480,glp1r_human,212,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,7.97,2.291,,,,0.0,0.0,,109.0,,P43220,-0.124007,HA212A,GLP1R
1124,27059958,glp1r_human,212,H,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,12.0,1.739,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),135.0,0.0,,0.0,,P43220,-0.124007,HA212A,GLP1R
1135,27315480,glp1r_human,212,H,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.6,70.795,,,,0.0,0.0,,105.0,,P43220,-0.124007,HA212A,GLP1R
139,21868452,glp1r_human,364,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.99,14.791,,,,42.14545455,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
216,26700562,glp1r_human,364,E,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,7.1,1.585,,,[125I]-exendin(9-39) (radioligand),41.0,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
237,21868452,glp1r_human,364,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,7.28,74.131,,,[125I]-exendin(9-39) (radioligand),42.14545455,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
320,21868452,glp1r_human,364,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.99,14.791,,,,0.0,0.0,,44.0,,P43220,-0.189469,EA364A,GLP1R
537,26700562,glp1r_human,364,E,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.1,M,=,,7.5,3.981,,,[125I]-exendin(9-39) (radioligand),41.0,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
769,26700562,glp1r_human,364,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.3,25.119,,,[125I]-exendin(9-39) (radioligand),41.0,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
878,26700562,glp1r_human,364,E,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.0,M,=,,7.5,31.623,,,[125I]-exendin(9-39) (radioligand),41.0,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
1125,21868452,glp1r_human,364,E,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.46,57.544,,,[125I]-exendin(9-39) (radioligand),42.14545455,0.0,,0.0,,P43220,-0.189469,EA364A,GLP1R
141,27059958,glp1r_human,381,F,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,15.0,2.174,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),127.0,0.0,,0.0,,P43220,2.49211,FA381S,GLP1R
356,27059958,glp1r_human,381,F,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,24.0,2.4,,,,127.0,0.0,,0.0,,P43220,2.49211,FA381S,GLP1R
142,27315480,glp1r_human,377,G,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,10.5,1.259,,,,0.0,0.0,,92.0,,P43220,3.00169,GA377A,GLP1R
366,27315480,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.8,3.02,,,,0.0,0.0,,87.0,,P43220,3.00169,GA377A,GLP1R
519,27315480,glp1r_human,377,G,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,8.78,66.069,,,,0.0,0.0,,94.0,,P43220,3.00169,GA377A,GLP1R
549,27315480,glp1r_human,377,G,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.18,1.096,,,[125I]-exendin(9-39) (radioligand),96.0,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
582,27315480,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.85,7.943,,,[125I]-exendin(9-39) (radioligand),96.0,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
616,27315480,glp1r_human,377,G,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.57,M,=,,8.09,-3.311,,,,0.0,0.0,,7.05,,P43220,3.00169,GA377A,GLP1R
641,27315480,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.87,M,=,,7.47,2.512,,,,0.0,0.0,,89.0,,P43220,3.00169,GA377A,GLP1R
681,26598711,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.03,2.63,,,[125I]-exendin(9-39) (radioligand),18.80733945,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
841,26598711,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,11.01,-1.034,,,,18.80733945,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
910,27315480,glp1r_human,377,G,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.45,3.548,,,,0.0,0.0,,98.0,,P43220,3.00169,GA377A,GLP1R
938,26598711,glp1r_human,377,G,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.32,1.072,,,[125I]-exendin(9-39) (radioligand),18.80733945,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
991,27315480,glp1r_human,377,G,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.43,M,=,,8.09,2.188,,,,0.0,0.0,,88.0,,P43220,3.00169,GA377A,GLP1R
1053,27315480,glp1r_human,377,G,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,8.79,2.692,,,[125I]-exendin(9-39) (radioligand),96.0,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
1171,27315480,glp1r_human,377,G,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.99,M,=,,7.94,1.122,,,,0.0,0.0,,86.0,,P43220,3.00169,GA377A,GLP1R
1175,27315480,glp1r_human,377,G,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.89,2.57,,,[125I]-exendin(9-39) (radioligand),96.0,0.0,,0.0,,P43220,3.00169,GA377A,GLP1R
155,22147710,glp1r_human,298,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,8.1,-2.513,,,[125I]-exendin(9-39) (radioligand),85.0,0.0,,0.0,,P43220,0.0750895,TA298A,GLP1R
222,22147710,glp1r_human,298,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,9.1,-2.513,,,[125I]-exendin(9-39) (radioligand),85.0,0.0,,0.0,,P43220,0.0750895,TA298A,GLP1R
578,22147710,glp1r_human,298,T,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.8,-3.165,,,,0.0,0.0,,76.12477504,,P43220,0.0750895,TA298A,GLP1R
745,22147710,glp1r_human,298,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,9.7,-5.0,,,,0.0,0.0,,69.41457587,,P43220,0.0750895,TA298A,GLP1R
824,22147710,glp1r_human,298,T,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.8,-3.984,,,,0.0,0.0,,121.0526316,,P43220,0.0750895,TA298A,GLP1R
880,22147710,glp1r_human,298,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,8.0,-1.585,,,,0.0,0.0,,115.0943396,,P43220,0.0750895,TA298A,GLP1R
159,19861722,glp1r_human,127,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,12.0,1.091,,,,111.0909091,0.0,,0.0,,P43220,-0.260864,EA127Q,GLP1R
228,19861722,glp1r_human,127,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,1.1,1.1,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),111.0909091,0.0,,0.0,,P43220,-0.260864,EA127Q,GLP1R
649,19861722,glp1r_human,127,E,Q,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,6.8,1.236,,,,111.0909091,0.0,,0.0,,P43220,-0.260864,EA127Q,GLP1R
1081,19861722,glp1r_human,127,E,Q,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.82,1.079,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),111.0909091,0.0,,0.0,,P43220,-0.260864,EA127Q,GLP1R
162,22147710,glp1r_human,301,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,8.1,-2.513,,,[125I]-exendin(9-39) (radioligand),63.0,0.0,,0.0,,P43220,-0.366629,SA301A,GLP1R
247,22147710,glp1r_human,301,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.8,1.0,,,,0.0,0.0,,84.90566038,,P43220,-0.366629,SA301A,GLP1R
418,22147710,glp1r_human,301,S,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.3,-1.259,,,,0.0,0.0,,84.21052632,,P43220,-0.366629,SA301A,GLP1R
466,22147710,glp1r_human,301,S,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.5,-1.585,,,,0.0,0.0,,61.72765447,,P43220,-0.366629,SA301A,GLP1R
793,22147710,glp1r_human,301,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,9.0,1.0,,,,0.0,0.0,,63.26164875,,P43220,-0.366629,SA301A,GLP1R
1040,22147710,glp1r_human,301,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.8,-1.259,,,[125I]-exendin(9-39) (radioligand),63.0,0.0,,0.0,,P43220,-0.366629,SA301A,GLP1R
166,27315480,glp1r_human,206,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,8.12,-1.445,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,-0.118478,SA206A,GLP1R
445,27315480,glp1r_human,206,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.84,-2.457,,,,0.0,0.0,,120.0,,P43220,-0.118478,SA206A,GLP1R
454,27315480,glp1r_human,206,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.76,-1.259,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,-0.118478,SA206A,GLP1R
628,27315480,glp1r_human,206,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,7.98,295.121,,,,0.0,0.0,,72.0,,P43220,-0.118478,SA206A,GLP1R
777,27315480,glp1r_human,206,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.01,2.089,,,,0.0,0.0,,83.0,,P43220,-0.118478,SA206A,GLP1R
808,27315480,glp1r_human,206,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.83,-1.35,,,,0.0,0.0,,109.0,,P43220,-0.118478,SA206A,GLP1R
838,27315480,glp1r_human,206,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,8.83,1.905,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,-0.118478,SA206A,GLP1R
843,27315480,glp1r_human,206,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.83,-15.873,,,,0.0,0.0,,7.68,,P43220,-0.118478,SA206A,GLP1R
1066,27315480,glp1r_human,206,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.64,1.318,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,-0.118478,SA206A,GLP1R
1090,27315480,glp1r_human,206,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.78,-1.318,,,,0.0,0.0,,112.0,,P43220,-0.118478,SA206A,GLP1R
1151,27315480,glp1r_human,206,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,7.92,-1.289,,,,0.0,0.0,,97.0,,P43220,-0.118478,SA206A,GLP1R
1157,27315480,glp1r_human,206,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.25,-2.041,,,,0.0,0.0,,82.0,,P43220,-0.118478,SA206A,GLP1R
168,23479653,glp1r_human,394,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.45,-2.188,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,0.355506,QA394A,GLP1R
367,23479653,glp1r_human,394,Q,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,8.72,1.778,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,0.355506,QA394A,GLP1R
664,23479653,glp1r_human,394,Q,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.42,1.778,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,0.355506,QA394A,GLP1R
1001,23479653,glp1r_human,394,Q,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.09,1.479,,,[125I]-exendin(9-39) (radioligand),111.0,0.0,,0.0,,P43220,0.355506,QA394A,GLP1R
183,27059958,glp1r_human,148,Y,F,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,70.0,-1.486,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
255,27059958,glp1r_human,148,Y,F,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,147.0,9.8,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
427,27059958,glp1r_human,148,Y,F,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,6.1,-4.255,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
440,27059958,glp1r_human,148,Y,F,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,144.0,14.4,,,,89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
457,27059958,glp1r_human,148,Y,F,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,87.0,7.25,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
831,27059958,glp1r_human,148,Y,F,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,72.0,11.803,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
1153,27059958,glp1r_human,148,Y,F,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,169.0,-1.385,,,[125I]-exendin(9-39) (radioligand),89.0,0.0,,0.0,,P43220,1.30856,YA148F,GLP1R
199,27059958,glp1r_human,148,Y,N,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,80.0,8.0,,,,84.0,0.0,,0.0,,P43220,3.18858,YA148N,GLP1R
707,27059958,glp1r_human,148,Y,N,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,102.0,14.783,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),84.0,0.0,,0.0,,P43220,3.18858,YA148N,GLP1R
206,22147710,glp1r_human,287,V,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,6.9,1.995,,,,0.0,0.0,,119.2982456,,P43220,0.340387,VA287A,GLP1R
429,22147710,glp1r_human,287,V,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.7,1.0,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.340387,VA287A,GLP1R
646,22147710,glp1r_human,287,V,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.2,1.259,,,,0.0,0.0,,80.62387522,,P43220,0.340387,VA287A,GLP1R
1007,22147710,glp1r_human,287,V,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.6,1.585,,,,0.0,0.0,,100.0,,P43220,0.340387,VA287A,GLP1R
1035,22147710,glp1r_human,287,V,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.4,3.981,,,,0.0,0.0,,82.01911589,,P43220,0.340387,VA287A,GLP1R
1152,22147710,glp1r_human,287,V,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.5,1.585,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,0.340387,VA287A,GLP1R
207,23479653,glp1r_human,190,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,7.37,19.953,,,[125I]-exendin(9-39) (radioligand),44.0,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
257,23479653,glp1r_human,190,R,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.6,-2.188,,,[125I]-exendin(9-39) (radioligand),44.0,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
449,21868452,glp1r_human,190,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.93,169.824,,,,0.0,0.0,,112.0,,P43220,2.77991,RA190A,GLP1R
551,21868452,glp1r_human,190,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.93,169.824,,,,6.690909091,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
612,23479653,glp1r_human,190,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.64,-3.39,,,[125I]-exendin(9-39) (radioligand),44.0,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
671,21868452,glp1r_human,190,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.36,6.166,,,[125I]-exendin(9-39) (radioligand),6.690909091,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
720,23479653,glp1r_human,190,R,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,7.43,34.674,,,[125I]-exendin(9-39) (radioligand),44.0,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
1143,21868452,glp1r_human,190,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.78,27.542,,,[125I]-exendin(9-39) (radioligand),6.690909091,0.0,,0.0,,P43220,2.77991,RA190A,GLP1R
208,22147710,glp1r_human,286,I,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.6,-1.996,,,,0.0,0.0,,76.60467906,,P43220,0.781792,IA286A,GLP1R
379,22147710,glp1r_human,286,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.8,-1.259,,,[125I]-exendin(9-39) (radioligand),79.0,0.0,,0.0,,P43220,0.781792,IA286A,GLP1R
400,22147710,glp1r_human,286,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.8,1.585,,,,0.0,0.0,,92.71206691,,P43220,0.781792,IA286A,GLP1R
517,22147710,glp1r_human,286,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.8,1.0,,,,0.0,0.0,,107.5471698,,P43220,0.781792,IA286A,GLP1R
709,22147710,glp1r_human,286,I,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.2,1.0,,,,0.0,0.0,,114.0350877,,P43220,0.781792,IA286A,GLP1R
1048,22147710,glp1r_human,286,I,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.7,1.0,,,[125I]-exendin(9-39) (radioligand),79.0,0.0,,0.0,,P43220,0.781792,IA286A,GLP1R
211,21868452,glp1r_human,234,Q,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.51,44.668,,,,26.61818182,0.0,,0.0,,P43220,0.0888805,QA234A,GLP1R
383,21868452,glp1r_human,234,Q,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,7.12,12.589,,,[125I]-exendin(9-39) (radioligand),26.61818182,0.0,,0.0,,P43220,0.0888805,QA234A,GLP1R
458,21868452,glp1r_human,234,Q,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.63,3.311,,,[125I]-exendin(9-39) (radioligand),26.61818182,0.0,,0.0,,P43220,0.0888805,QA234A,GLP1R
571,21868452,glp1r_human,234,Q,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.51,44.668,,,,0.0,0.0,,179.0,,P43220,0.0888805,QA234A,GLP1R
1013,27059958,glp1r_human,234,Q,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,1506.0,150.6,,,,35.0,0.0,,0.0,,P43220,0.0888805,QA234A,GLP1R
214,22147710,glp1r_human,290,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.6,1.259,,,[125I]-exendin(9-39) (radioligand),77.0,0.0,,0.0,,P43220,1.10925,LA290A,GLP1R
528,22147710,glp1r_human,290,L,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.0,1.585,,,,0.0,0.0,,96.49122807,,P43220,1.10925,LA290A,GLP1R
682,22147710,glp1r_human,290,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.9,-1.585,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),77.0,0.0,,0.0,,P43220,1.10925,LA290A,GLP1R
794,22147710,glp1r_human,290,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.9,-1.259,,,,0.0,0.0,,64.1509434,,P43220,1.10925,LA290A,GLP1R
820,22147710,glp1r_human,290,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.7,1.995,,,,0.0,0.0,,80.10752688,,P43220,1.10925,LA290A,GLP1R
1075,22147710,glp1r_human,290,L,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.3,1.0,,,,0.0,0.0,,61.54769046,,P43220,1.10925,LA290A,GLP1R
219,27059958,glp1r_human,149,T,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,817.0,81.7,,,,123.0,0.0,,0.0,,P43220,0.299939,TA149S,GLP1R
1056,27059958,glp1r_human,149,T,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,10.0,1.449,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),123.0,0.0,,0.0,,P43220,0.299939,TA149S,GLP1R
224,27059958,glp1r_human,234,Q,E,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,38.0,3.167,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
293,27059958,glp1r_human,234,Q,E,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,6.3,-4.132,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
378,27059958,glp1r_human,234,Q,E,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,244.0,16.267,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
659,27059958,glp1r_human,234,Q,E,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,268.0,1.145,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
752,27059958,glp1r_human,234,Q,E,GLP-1-(Ala8Ser),FASTA sequence (peptide),HSEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,61.0,nM,=,,118.0,1.934,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
981,27059958,glp1r_human,234,Q,E,GLP-1(Glu9Gln),FASTA sequence (peptide),HAQGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,36.0,nM,=,,8.0,-4.505,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
1025,27059958,glp1r_human,234,Q,E,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,139.0,1.337,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
1118,27059958,glp1r_human,234,Q,E,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,88.0,14.426,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
1163,27059958,glp1r_human,234,Q,E,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,294.0,29.4,,,,69.0,0.0,,0.0,,P43220,0.221862,QA234E,GLP1R
225,26598711,glp1r_human,380,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,7.34,128.825,,,[125I]-exendin(9-39) (radioligand),67.88990826,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
288,27315480,glp1r_human,380,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.75,M,=,,7.65,12.589,,,[125I]-exendin(9-39) (radioligand),73.0,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
581,27315480,glp1r_human,380,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.6,M,=,,6.94,4570.882,,,,0.0,0.0,,69.0,,P43220,-0.0867194,RA380A,GLP1R
598,27315480,glp1r_human,380,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.6,M,=,,8.33,186.209,,,,0.0,0.0,,69.0,,P43220,-0.0867194,RA380A,GLP1R
668,27315480,glp1r_human,380,R,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,M,=,,7.75,29.512,,,[125I]-exendin(9-39) (radioligand),73.0,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
685,27315480,glp1r_human,380,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.28,M,=,,7.15,13.49,,,,0.0,0.0,,25.0,,P43220,-0.0867194,RA380A,GLP1R
717,26598711,glp1r_human,380,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,7.92,2.692,,,[125I]-exendin(9-39) (radioligand),67.88990826,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
823,27315480,glp1r_human,380,R,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,M,=,,6.71,3.89,,,[125I]-exendin(9-39) (radioligand),73.0,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
1024,27315480,glp1r_human,380,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,6.73,1862.087,,,,0.0,0.0,,74.0,,P43220,-0.0867194,RA380A,GLP1R
1139,26598711,glp1r_human,380,R,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,9.0,-1.264,,,,67.88990826,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
1148,27315480,glp1r_human,380,R,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,8.03,1.549,,,[125I]-exendin(9-39) (radioligand),73.0,0.0,,0.0,,P43220,-0.0867194,RA380A,GLP1R
227,27315480,glp1r_human,219,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.76,-1.259,,,,0.0,0.0,,101.0,,P43220,0.152924,SA219A,GLP1R
292,27315480,glp1r_human,219,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,8.33,M,=,,8.43,-1.259,,,,0.0,0.0,,125.0,,P43220,0.152924,SA219A,GLP1R
314,27315480,glp1r_human,219,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - cAMP accumulation,10.45,M,=,,10.23,1.66,,,,0.0,0.0,,108.0,,P43220,0.152924,SA219A,GLP1R
352,27315480,glp1r_human,219,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.96,M,=,,8.23,-1.862,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,0.152924,SA219A,GLP1R
485,27315480,glp1r_human,219,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - ERK activation,7.63,M,=,,8.55,-8.333,,,,0.0,0.0,,7.86,,P43220,0.152924,SA219A,GLP1R
524,27315480,glp1r_human,219,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - Ca2+ accumulation,7.94,M,=,,8.26,-2.088,,,,0.0,0.0,,90.0,,P43220,0.152924,SA219A,GLP1R
732,27315480,glp1r_human,219,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Full agonist,pEC50,Functional - ERK activation,10.45,M,=,,8.77,47.863,,,,0.0,0.0,,91.0,,P43220,0.152924,SA219A,GLP1R
802,27315480,glp1r_human,219,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - Ca2+ accumulation,7.81,M,=,,8.14,-2.137,,,,0.0,0.0,,101.0,,P43220,0.152924,SA219A,GLP1R
970,27315480,glp1r_human,219,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Full agonist,pEC50,Functional - cAMP accumulation,8.7,M,=,,8.55,1.413,,,,0.0,0.0,,97.0,,P43220,0.152924,SA219A,GLP1R
1031,27315480,glp1r_human,219,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.66,M,=,,7.79,-1.35,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,0.152924,SA219A,GLP1R
1061,27315480,glp1r_human,219,S,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.11,M,=,,9.05,1.148,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,0.152924,SA219A,GLP1R
1073,27315480,glp1r_human,219,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.76,M,=,,8.82,-1.148,,,[125I]-exendin(9-39) (radioligand),104.0,0.0,,0.0,,P43220,0.152924,SA219A,GLP1R
232,22147710,glp1r_human,307,L,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,8.0,-1.996,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.889767,LA307A,GLP1R
310,22147710,glp1r_human,307,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,7.6,12.589,,,[125I]-exendin(9-39) (radioligand),60.0,0.0,,0.0,,P43220,0.889767,LA307A,GLP1R
566,22147710,glp1r_human,307,L,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.4,-1.585,,,,0.0,0.0,,49.12280702,,P43220,0.889767,LA307A,GLP1R
796,22147710,glp1r_human,307,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.6,1.585,,,,0.0,0.0,,58.49056604,,P43220,0.889767,LA307A,GLP1R
1026,22147710,glp1r_human,307,L,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,7.6,25.119,,,,0.0,0.0,,60.33452808,,P43220,0.889767,LA307A,GLP1R
1028,22147710,glp1r_human,307,L,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.0,1.995,,,,0.0,0.0,,31.43371326,,P43220,0.889767,LA307A,GLP1R
244,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,2.2,-3.135,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
260,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,22.0,-10.638,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
340,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,0.3,-50.0,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
361,27059958,glp1r_human,364,E,Q,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,13.0,-2.0,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
371,27059958,glp1r_human,364,E,Q,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,0.3,-40.0,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
394,27059958,glp1r_human,364,E,Q,GLP-1-(Ala8Ser),FASTA sequence (peptide),HSEGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,61.0,nM,=,,0.4,-142.857,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
413,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,0.3,-20.408,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
424,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,21.0,-4.95,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
434,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,0.3,-50.0,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
520,27059958,glp1r_human,364,E,Q,GLP-1(Glu9Gln),FASTA sequence (peptide),HAQGTFTSDVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,36.0,nM,=,,0.3,-125.0,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
593,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,8.7,-1.149,,,,45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
806,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,0.3,-20.408,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
866,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,22.0,-10.638,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
1033,27059958,glp1r_human,364,E,Q,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,0.3,-40.0,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
1087,27059958,glp1r_human,364,E,Q,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,21.0,-4.95,,,[125I]-exendin(9-39) (radioligand),45.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
1091,27059958,glp1r_human,364,E,Q,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,13.0,-2.0,,,[125I]-exendin(9-39) (radioligand),87.0,0.0,,0.0,,P43220,0.155166,EA364Q,GLP1R
245,22134089,glp1r_human,241,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,2182.1,pM,=,,3387.4,1.552,,,,0.0,0.0,,0.0,,P43220,2.09627,YA241A,GLP1R
342,27059958,glp1r_human,241,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,6.6,-1.045,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),78.0,0.0,,0.0,,P43220,2.09627,YA241A,GLP1R
848,22134089,glp1r_human,241,Y,A,compound 3,PubChem CID,16133830,Allosteric agonist,EC50,Functional - cAMP accumulation,1.9,µM,=,,4.2,2.211,,,,0.0,0.0,,25.0,glucagon-like peptide 1-(7-37),P43220,2.09627,YA241A,GLP1R
1177,27059958,glp1r_human,241,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,22.0,2.2,,,,78.0,0.0,,0.0,,P43220,2.09627,YA241A,GLP1R
258,22134089,glp1r_human,391,T,A,compound 3,PubChem CID,16133830,Allosteric agonist,EC50,Functional - cAMP accumulation,1.9,µM,=,,6.3,3.316,,,,0.0,0.0,,15.0,glucagon-like peptide 1-(7-37),P43220,-0.788999,TA391A,GLP1R
577,22134089,glp1r_human,391,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,2182.1,pM,=,,2689.7,1.233,,,,0.0,0.0,,0.0,,P43220,-0.788999,TA391A,GLP1R
738,21868452,glp1r_human,391,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,10.21,-1.122,,,,0.0,0.0,,93.0,,P43220,-0.788999,TA391A,GLP1R
891,21868452,glp1r_human,391,T,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,8.22,M,=,,7.22,-1.139,,,[125I]-exendin(9-39) (radioligand),64.54545455,0.0,,0.0,,P43220,-0.788999,TA391A,GLP1R
1038,21868452,glp1r_human,391,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,10.21,-1.122,,,,64.54545455,0.0,,0.0,,P43220,-0.788999,TA391A,GLP1R
1063,21868452,glp1r_human,391,T,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.7,2.818,,,[125I]-exendin(9-39) (radioligand),64.54545455,0.0,,0.0,,P43220,-0.788999,TA391A,GLP1R
259,27059958,glp1r_human,220,Y,D,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,1045.0,104.5,,,,100.0,0.0,,0.0,,P43220,2.85814,YA220D,GLP1R
261,21868452,glp1r_human,152,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.72,31.623,,,[125I]-exendin(9-39) (radioligand),6.690909091,0.0,,0.0,,P43220,2.26928,YA152A,GLP1R
264,21868452,glp1r_human,152,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.92,17.378,,,,6.690909091,0.0,,0.0,,P43220,2.26928,YA152A,GLP1R
291,21868452,glp1r_human,152,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.13,10.471,,,[125I]-exendin(9-39) (radioligand),6.690909091,0.0,,0.0,,P43220,2.26928,YA152A,GLP1R
360,21868452,glp1r_human,152,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.92,17.378,,,,0.0,0.0,,96.0,,P43220,2.26928,YA152A,GLP1R
275,21868452,glp1r_human,235,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.82,21.878,,,,0.0,0.0,,80.0,,P43220,3.35737,YA235A,GLP1R
653,21868452,glp1r_human,235,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,8.82,21.878,,,,11.96363636,0.0,,0.0,,P43220,3.35737,YA235A,GLP1R
655,21868452,glp1r_human,235,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.84,23.988,,,[125I]-exendin(9-39) (radioligand),11.96363636,0.0,,0.0,,P43220,3.35737,YA235A,GLP1R
726,21868452,glp1r_human,235,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,7.88,18.621,,,[125I]-exendin(9-39) (radioligand),11.96363636,0.0,,0.0,,P43220,3.35737,YA235A,GLP1R
298,23479653,glp1r_human,392,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.45,-2.188,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,-0.724379,SA392A,GLP1R
328,23479653,glp1r_human,392,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.09,1.479,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,-0.724379,SA392A,GLP1R
672,23479653,glp1r_human,392,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.42,1.778,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,-0.724379,SA392A,GLP1R
766,23479653,glp1r_human,392,S,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,8.72,1.778,,,[125I]-exendin(9-39) (radioligand),92.0,0.0,,0.0,,P43220,-0.724379,SA392A,GLP1R
302,27059958,glp1r_human,233,M,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,46.0,3.833,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
442,27059958,glp1r_human,233,M,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,235.0,15.667,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
479,27059958,glp1r_human,233,M,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,11.0,-2.364,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
606,27059958,glp1r_human,233,M,A,glucagon-like peptide 1-(9-36),PubChem CID,90488821,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,234.0,nM,=,,220.0,-1.064,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
692,27059958,glp1r_human,233,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,134.0,21.967,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
954,27059958,glp1r_human,233,M,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,697.0,69.7,,,,125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
1044,27059958,glp1r_human,233,M,A,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,120.0,1.154,,,[125I]-exendin(9-39) (radioligand),125.0,0.0,,0.0,,P43220,1.31249,MA233A,GLP1R
308,19861722,glp1r_human,36,V,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.98,1.289,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,1.43606,VA36A,GLP1R
923,19861722,glp1r_human,36,V,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,2.8,2.8,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,1.43606,VA36A,GLP1R
1034,19861722,glp1r_human,36,V,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,36.0,6.545,,,,103.6363636,0.0,,0.0,,P43220,1.43606,VA36A,GLP1R
1093,19861722,glp1r_human,36,V,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,57.0,5.182,,,,103.6363636,0.0,,0.0,,P43220,1.43606,VA36A,GLP1R
311,26598711,glp1r_human,289,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.48,-1.35,,,[125I]-exendin(9-39) (radioligand),19.72477064,0.0,,0.0,,P43220,0.433405,YA289A,GLP1R
392,22147710,glp1r_human,289,Y,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,M,=,,7.6,1.259,,,[125I]-exendin(9-39) (radioligand),84.0,0.0,,0.0,,P43220,0.433405,YA289A,GLP1R
506,22147710,glp1r_human,289,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,9.0,M,=,,8.9,1.259,,,,0.0,0.0,,66.24850657,,P43220,0.433405,YA289A,GLP1R
695,26598711,glp1r_human,289,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.38,-1.096,,,,19.72477064,0.0,,0.0,,P43220,0.433405,YA289A,GLP1R
767,26598711,glp1r_human,289,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,9.33,1.318,,,[125I]-exendin(9-39) (radioligand),19.72477064,0.0,,0.0,,P43220,0.433405,YA289A,GLP1R
895,22147710,glp1r_human,289,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - ERK activation,7.2,M,=,,7.3,-1.259,,,,0.0,0.0,,85.96491228,,P43220,0.433405,YA289A,GLP1R
1009,22147710,glp1r_human,289,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.7,M,=,,8.9,-1.585,,,[125I]-exendin(9-39) (radioligand),84.0,0.0,,0.0,,P43220,0.433405,YA289A,GLP1R
1050,22147710,glp1r_human,289,Y,A,glucagon-like peptide 1-(1-36),PubChem CID,16131070,Full agonist,pEC50,Functional - cAMP accumulation,7.3,M,=,,7.6,-1.996,,,,0.0,0.0,,71.56568686,,P43220,0.433405,YA289A,GLP1R
1098,22147710,glp1r_human,289,Y,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - ERK activation,7.8,M,=,,7.4,2.512,,,,0.0,0.0,,94.33962264,,P43220,0.433405,YA289A,GLP1R
316,27059958,glp1r_human,192,L,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,3.1,-3.226,,,,82.0,0.0,,0.0,,P43220,1.49324,LA192S,GLP1R
402,22134089,glp1r_human,192,L,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,2182.1,pM,=,,1981.4,-1.101,,,,0.0,0.0,,0.0,,P43220,1.49324,LA192S,GLP1R
617,27059958,glp1r_human,192,L,S,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,8.5,1.232,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),82.0,0.0,,0.0,,P43220,1.49324,LA192S,GLP1R
912,22134089,glp1r_human,192,L,S,compound 3,PubChem CID,22341103,Allosteric agonist,EC50,Functional - cAMP accumulation,1.9,µM,=,,2.1,1.105,,,,0.0,0.0,,44.0,glucagon-like peptide 1-(7-37),P43220,1.49324,LA192S,GLP1R
323,23479653,glp1r_human,363,H,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,7.41,5.012,,,[125I]-exendin(9-39) (radioligand),53.0,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
376,21868452,glp1r_human,363,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.23,97.724,,,[125I]-exendin(9-39) (radioligand),24.18181818,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
473,23479653,glp1r_human,363,H,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,7.31,22.909,,,[125I]-exendin(9-39) (radioligand),53.0,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
574,23479653,glp1r_human,363,H,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,6.46,6.31,,,[125I]-exendin(9-39) (radioligand),53.0,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
798,21868452,glp1r_human,363,H,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,7.53,41.687,,,[125I]-exendin(9-39) (radioligand),24.18181818,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
874,23479653,glp1r_human,363,H,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,7.54,26.915,,,[125I]-exendin(9-39) (radioligand),53.0,0.0,,0.0,,P43220,-0.0239171,HA363A,GLP1R
324,21308878,glp1r_human,128,E,M,glucagon-(Ser22Glu),FASTA sequence (peptide),HSQGTFTSDYSKYLDERRAQDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.022,nM,=,,0.026,1.182,,,,0.0,0.0,,0.0,,P43220,-1.26337,EA128M,GLP1R
844,21308878,glp1r_human,128,E,M,glucagon-(Ser26Lys),FASTA sequence (peptide),HSQGTFTSDYSKYLDSRRAKDFVQWLMNT,Full agonist,EC50,Functional - cAMP accumulation,0.045,nM,=,,0.03,-1.499,,,,0.0,0.0,,0.0,,P43220,-1.26337,EA128M,GLP1R
1068,21308878,glp1r_human,128,E,M,glucagon,PubChem CID,44278361,Full agonist,EC50,Functional - cAMP accumulation,0.061,nM,=,,0.096,1.574,,,,0.0,0.0,,0.0,,P43220,-1.26337,EA128M,GLP1R
1156,21308878,glp1r_human,128,E,M,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,0.0056,nM,=,,0.015,2.679,,,,0.0,0.0,,0.0,,P43220,-1.26337,EA128M,GLP1R
358,27059958,glp1r_human,367,F,H,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,53.0,7.681,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),108.0,0.0,,0.0,,P43220,1.81015,FA367H,GLP1R
853,27059958,glp1r_human,367,F,H,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,1314.0,131.4,,,,108.0,0.0,,0.0,,P43220,1.81015,FA367H,GLP1R
362,27059958,glp1r_human,149,T,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,594.0,59.4,,,,131.0,0.0,,0.0,,P43220,-0.24778,TA149A,GLP1R
382,26598711,glp1r_human,309,I,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.31,1.096,,,[125I]-exendin(9-39) (radioligand),75.2293578,0.0,,0.0,,P43220,2.74678,IA309A,GLP1R
504,26598711,glp1r_human,309,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.93,3.311,,,[125I]-exendin(9-39) (radioligand),75.2293578,0.0,,0.0,,P43220,2.74678,IA309A,GLP1R
1166,26598711,glp1r_human,309,I,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.2,-1.116,,,,75.2293578,0.0,,0.0,,P43220,2.74678,IA309A,GLP1R
385,27059958,glp1r_human,376,R,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,6.3,-1.095,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),138.0,0.0,,0.0,,P43220,-0.176052,RA376Q,GLP1R
548,27059958,glp1r_human,376,R,Q,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,28.0,2.8,,,,138.0,0.0,,0.0,,P43220,-0.176052,RA376Q,GLP1R
389,27059958,glp1r_human,198,D,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,892.0,89.2,,,,124.0,0.0,,0.0,,P43220,0.907409,DA198A,GLP1R
586,21868452,glp1r_human,198,D,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.17,977.237,,,,0.0,0.0,,77.0,,P43220,0.907409,DA198A,GLP1R
856,21868452,glp1r_human,198,D,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.74,2.57,,,[125I]-exendin(9-39) (radioligand),66.10909091,0.0,,0.0,,P43220,0.907409,DA198A,GLP1R
976,21868452,glp1r_human,198,D,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.59,42.658,,,[125I]-exendin(9-39) (radioligand),66.10909091,0.0,,0.0,,P43220,0.907409,DA198A,GLP1R
1121,21868452,glp1r_human,198,D,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.17,977.237,,,,66.10909091,0.0,,0.0,,P43220,0.907409,DA198A,GLP1R
408,23479653,glp1r_human,155,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.28,-1.047,,,[125I]-exendin(9-39) (radioligand),48.0,0.0,,0.0,,P43220,0.59017,SA155A,GLP1R
516,23479653,glp1r_human,155,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.29,2.399,,,[125I]-exendin(9-39) (radioligand),48.0,0.0,,0.0,,P43220,0.59017,SA155A,GLP1R
971,23479653,glp1r_human,155,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,8.08,1.072,,,[125I]-exendin(9-39) (radioligand),48.0,0.0,,0.0,,P43220,0.59017,SA155A,GLP1R
1032,23479653,glp1r_human,155,S,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,8.43,3.467,,,[125I]-exendin(9-39) (radioligand),48.0,0.0,,0.0,,P43220,0.59017,SA155A,GLP1R
425,27059958,glp1r_human,233,M,T,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,618.0,61.8,,,,98.0,0.0,,0.0,,P43220,2.12173,MA233T,GLP1R
439,22134089,glp1r_human,278,L,M,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,2182.1,pM,=,,2687.5,1.232,,,,0.0,0.0,,0.0,,P43220,-0.437174,LA278M,GLP1R
513,22134089,glp1r_human,278,L,M,compound 3,PubChem CID,16133830,Allosteric agonist,EC50,Functional - cAMP accumulation,1.9,µM,=,,1.8,-1.056,,,,0.0,0.0,,37.0,glucagon-like peptide 1-(7-37),P43220,-0.437174,LA278M,GLP1R
469,27059958,glp1r_human,367,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,719.0,71.9,,,,118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
636,27059958,glp1r_human,367,F,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.1,nM,=,,219.0,35.902,,,[125I]-exendin(9-39) (radioligand),118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
670,27059958,glp1r_human,367,F,A,exendin 4,FASTA sequence (peptide),DVSSYLEGQAAKEFIAWLVKGR,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,12.0,nM,=,,130.0,10.833,,,[125I]-exendin(9-39) (radioligand),118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
760,27059958,glp1r_human,367,F,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,15.0,nM,=,,482.0,32.133,,,[125I]-exendin(9-39) (radioligand),118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
811,27059958,glp1r_human,367,F,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,26.0,nM,=,,69.0,2.654,,,[125I]-exendin(9-39) (radioligand),118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
854,27059958,glp1r_human,367,F,A,glucagon-like peptide 1-(15-36),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,104.0,nM,=,,517.0,4.971,,,[125I]-exendin(9-39) (radioligand),118.0,0.0,,0.0,,P43220,2.24603,FA367A,GLP1R
481,19861722,glp1r_human,68,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,15.0,1.364,,,,103.6363636,0.0,,0.0,,P43220,0.244739,EA68A,GLP1R
569,19861722,glp1r_human,68,E,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,0.48,-1.582,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,0.244739,EA68A,GLP1R
886,19861722,glp1r_human,68,E,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,1.9,1.9,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,0.244739,EA68A,GLP1R
930,19861722,glp1r_human,68,E,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,9.5,1.727,,,,103.6363636,0.0,,0.0,,P43220,0.244739,EA68A,GLP1R
563,27059958,glp1r_human,367,F,I,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,196.0,19.6,,,,93.0,0.0,,0.0,,P43220,0.886028,FA367I,GLP1R
604,27059958,glp1r_human,388,L,F,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,9.3,1.348,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),114.0,0.0,,0.0,,P43220,0.204965,LA388F,GLP1R
758,27059958,glp1r_human,388,L,F,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,40.0,4.0,,,,114.0,0.0,,0.0,,P43220,0.204965,LA388F,GLP1R
623,26598711,glp1r_human,371,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,EC50,Functional - cAMP accumulation,11.38,M,=,,10.88,-1.046,,,,54.12844037,0.0,,0.0,,P43220,2.08919,MA371A,GLP1R
828,26598711,glp1r_human,371,M,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.45,M,=,,8.65,6.31,,,[125I]-exendin(9-39) (radioligand),54.12844037,0.0,,0.0,,P43220,2.08919,MA371A,GLP1R
1101,26598711,glp1r_human,371,M,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.35,M,=,,8.26,1.23,,,[125I]-exendin(9-39) (radioligand),54.12844037,0.0,,0.0,,P43220,2.08919,MA371A,GLP1R
634,27059958,glp1r_human,194,V,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,37.0,3.7,,,,89.0,0.0,,0.0,,P43220,1.18407,VA194A,GLP1R
1008,27059958,glp1r_human,194,V,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,9.1,1.319,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),89.0,0.0,,0.0,,P43220,1.18407,VA194A,GLP1R
637,23479653,glp1r_human,186,S,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.67,M,=,,8.6,1.175,,,[125I]-exendin(9-39) (radioligand),114.0,0.0,,0.0,,P43220,-0.793249,SA186A,GLP1R
850,23479653,glp1r_human,186,S,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.11,M,=,,7.94,1.479,,,[125I]-exendin(9-39) (radioligand),114.0,0.0,,0.0,,P43220,-0.793249,SA186A,GLP1R
1065,23479653,glp1r_human,186,S,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.97,M,=,,9.02,-1.122,,,[125I]-exendin(9-39) (radioligand),114.0,0.0,,0.0,,P43220,-0.793249,SA186A,GLP1R
1144,23479653,glp1r_human,186,S,A,Oxyntomodulin(30-37),PubChem CID,11766473,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.26,M,=,,7.26,1.0,,,[125I]-exendin(9-39) (radioligand),114.0,0.0,,0.0,,P43220,-0.793249,SA186A,GLP1R
647,19861722,glp1r_human,90,P,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,1.6,2.105,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),101.8181818,0.0,,0.0,,P43220,2.07494,PA90A,GLP1R
917,19861722,glp1r_human,90,P,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,55.0,5.0,,,,101.8181818,0.0,,0.0,,P43220,2.07494,PA90A,GLP1R
1016,19861722,glp1r_human,90,P,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,2.8,2.8,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),101.8181818,0.0,,0.0,,P43220,2.07494,PA90A,GLP1R
1176,19861722,glp1r_human,90,P,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,30.0,5.455,,,,101.8181818,0.0,,0.0,,P43220,2.07494,PA90A,GLP1R
665,27059958,glp1r_human,214,W,V,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,36.0,3.6,,,,152.0,0.0,,0.0,,P43220,2.27512,WA214V,GLP1R
1069,27059958,glp1r_human,214,W,V,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,16.0,2.319,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),152.0,0.0,,0.0,,P43220,2.27512,WA214V,GLP1R
749,27059958,glp1r_human,388,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,2083.0,208.3,,,,95.0,0.0,,0.0,,P43220,1.63179,LA388A,GLP1R
786,19861722,glp1r_human,121,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,2.3,2.3,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,0.495157,RA121A,GLP1R
830,19861722,glp1r_human,121,R,A,exendin 4,PubChem CID,56927919,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.76,nM,=,,1.2,1.579,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),103.6363636,0.0,,0.0,,P43220,0.495157,RA121A,GLP1R
873,19861722,glp1r_human,121,R,A,exendin 4,PubChem CID,56927919,Full agonist,EC50,Functional - cAMP accumulation,5.5,pM,=,,44.0,8.0,,,,103.6363636,0.0,,0.0,,P43220,0.495157,RA121A,GLP1R
1113,19861722,glp1r_human,121,R,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,11.0,pM,=,,51.0,4.636,,,,103.6363636,0.0,,0.0,,P43220,0.495157,RA121A,GLP1R
810,27059958,glp1r_human,148,Y,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,259.0,25.9,,,,88.0,0.0,,0.0,,P43220,2.34745,YA148A,GLP1R
852,21868452,glp1r_human,284,W,A,exendin(9-39),PubChem CID,16198321,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.15,M,=,,8.49,4.571,,,[125I]-exendin(9-39) (radioligand),33.92727273,0.0,,0.0,,P43220,3.93621,WA284A,GLP1R
875,21868452,glp1r_human,284,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,M,=,,6.77,28.184,,,[125I]-exendin(9-39) (radioligand),33.92727273,0.0,,0.0,,P43220,3.93621,WA284A,GLP1R
903,21868452,glp1r_human,284,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.03,1348.963,,,,0.0,0.0,,183.0,,P43220,3.93621,WA284A,GLP1R
1078,21868452,glp1r_human,284,W,A,glucagon-like peptide 1-(7-36),PubChem CID,16135499,Full agonist,pEC50,Functional - cAMP accumulation,10.16,M,=,,7.03,1348.963,,,,33.92727273,0.0,,0.0,,P43220,3.93621,WA284A,GLP1R
863,27059958,glp1r_human,384,L,V,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,164.0,16.4,,,,114.0,0.0,,0.0,,P43220,0.648756,LA384V,GLP1R
888,20407008,glp1r_human,63,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,26.0,pM,=,,63.0,2.423,,,,79.16666667,0.0,,0.0,,P43220,-1.23561,NA63L,GLP1R
1142,20407008,glp1r_human,63,N,L,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.8,nM,=,,2.9,1.036,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),79.16666667,0.0,,0.0,,P43220,-1.23561,NA63L,GLP1R
889,27059958,glp1r_human,388,L,I,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,35.0,5.072,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),93.0,0.0,,0.0,,P43220,0.0365919,LA388I,GLP1R
927,27059958,glp1r_human,388,L,I,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,807.0,80.7,,,,93.0,0.0,,0.0,,P43220,0.0365919,LA388I,GLP1R
987,27059958,glp1r_human,204,M,R,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,927.0,92.7,,,,138.0,0.0,,0.0,,P43220,2.57969,MA204R,GLP1R
1003,27059958,glp1r_human,141,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,36.0,3.6,,,,67.0,0.0,,0.0,,P43220,0.400775,LA141A,GLP1R
1039,27059958,glp1r_human,141,L,A,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.9,nM,=,,6.9,1.0,,,[125I]-glucagon-like peptide 1-(7-36) (radioligand),67.0,0.0,,0.0,,P43220,0.400775,LA141A,GLP1R
1174,27059958,glp1r_human,197,K,R,glucagon-like peptide 1-(7-37),PubChem CID,16133830,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,227.0,22.7,,,,130.0,0.0,,0.0,,P43220,0.249122,KA197R,GLP1R
0,22964305,sctr_human,210,A,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,2.2,110.0,,,secretin,0.0,0.0,,94.17989418,secretin,P47872,0.567491,AA210C,SCTR
26,22964305,sctr_human,210,A,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,3.9,3.25,,,[125]secretin (radioligand),4.297224709,0.0,,0.0,,P47872,0.567491,AA210C,SCTR
1,22964305,sctr_human,289,N,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,5.9,4.917,,,[125]secretin (radioligand),20.68039391,0.0,,0.0,,P47872,0.247405,NA289C,SCTR
42,22964305,sctr_human,289,N,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.3,15.0,,,secretin,0.0,0.0,,94.17989418,secretin,P47872,0.247405,NA289C,SCTR
4,22964305,sctr_human,218,V,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,6.6,5.5,,,[125]secretin (radioligand),47.71709937,0.0,,0.0,,P47872,-2.07004,VA218C,SCTR
60,22964305,sctr_human,218,V,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.04,2.0,,,secretin,0.0,0.0,,87.83068783,secretin,P47872,-2.07004,VA218C,SCTR
5,22964305,sctr_human,365,A,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.06,3.0,,,secretin,0.0,0.0,,105.8201058,secretin,P47872,0.121938,AA365C,SCTR
12,22964305,sctr_human,365,A,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,5.2,4.333,,,[125]secretin (radioligand),19.57923008,0.0,,0.0,,P47872,0.121938,AA365C,SCTR
6,22964305,sctr_human,360,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,10.0,8.333,,,[125]secretin (radioligand),40.10743062,0.0,,0.0,,P47872,0.756754,FA360C,SCTR
30,22964305,sctr_human,360,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.1,5.0,,,secretin,0.0,0.0,,97.88359788,secretin,P47872,0.756754,FA360C,SCTR
7,22964305,sctr_human,283,V,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,2.7,2.25,,,[125]secretin (radioligand),6.177260519,0.0,,0.0,,P47872,-0.104671,VA283C,SCTR
10,22964305,sctr_human,283,V,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.2,10.0,,,secretin,0.0,0.0,,88.35978836,secretin,P47872,-0.104671,VA283C,SCTR
11,22964305,sctr_human,222,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,19.7,16.417,,,[125]secretin (radioligand),50.04476276,0.0,,0.0,,P47872,1.28946,FA222C,SCTR
112,22964305,sctr_human,222,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,1.5,75.0,,,secretin,0.0,0.0,,87.83068783,secretin,P47872,1.28946,FA222C,SCTR
14,22964305,sctr_human,211,H,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,2.1,105.0,,,secretin,0.0,0.0,,93.12169312,secretin,P47872,-0.17206,HA211C,SCTR
16,22964305,sctr_human,358,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,3.2,160.0,,,secretin,0.0,0.0,,82.53968254,secretin,P47872,2.65893,FA358C,SCTR
61,22964305,sctr_human,358,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,23.1,19.25,,,[125]secretin (radioligand),79.31960609,0.0,,0.0,,P47872,2.65893,FA358C,SCTR
18,22964305,sctr_human,279,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.04,2.0,,,secretin,0.0,0.0,,110.5820106,secretin,P47872,0.321352,FA279C,SCTR
87,22964305,sctr_human,279,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,9.0,7.5,,,[125]secretin (radioligand),80.30438675,0.0,,0.0,,P47872,0.321352,FA279C,SCTR
20,11517171,sctr_human,342,R,A,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,14.1,nM,=,,32.5,2.305,,,[125]secretin (radioligand),0.0,0.0,,0.0,,P47872,0.526959,RA342A,SCTR
25,11517171,sctr_human,342,R,A,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,0.6,-5.0,,,,0.0,0.0,,0.0,,P47872,0.526959,RA342A,SCTR
22,22964305,sctr_human,214,G,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,4.8,4.0,,,[125]secretin (radioligand),19.78513876,0.0,,0.0,,P47872,0.78781,GA214C,SCTR
51,22964305,sctr_human,214,G,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.08,4.0,,,secretin,0.0,0.0,,106.3492063,secretin,P47872,0.78781,GA214C,SCTR
23,22964305,sctr_human,291,N,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.03,1.5,,,secretin,0.0,0.0,,104.2328042,secretin,P47872,0.807397,NA291C,SCTR
43,22964305,sctr_human,291,N,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,6.5,5.417,,,[125]secretin (radioligand),41.00268577,0.0,,0.0,,P47872,0.807397,NA291C,SCTR
24,22964305,sctr_human,294,I,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,9.2,7.667,,,[125]secretin (radioligand),36.61593554,0.0,,0.0,,P47872,2.65844,IA294C,SCTR
73,22964305,sctr_human,294,I,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.2,10.0,,,secretin,0.0,0.0,,99.47089947,secretin,P47872,2.65844,IA294C,SCTR
31,22964305,sctr_human,288,I,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.5,25.0,,,secretin,0.0,0.0,,104.2328042,secretin,P47872,0.262324,IA288C,SCTR
65,22964305,sctr_human,288,I,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,7.9,6.583,,,[125]secretin (radioligand),20.85944494,0.0,,0.0,,P47872,0.262324,IA288C,SCTR
33,11517171,sctr_human,330,R,I,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,3.0,1.0,,,,0.0,0.0,,0.0,,P47872,1.61569,RA330I,SCTR
105,11517171,sctr_human,330,R,I,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,14.1,nM,=,,10.7,-1.318,,,[125]secretin (radioligand),0.0,0.0,,0.0,,P47872,1.61569,RA330I,SCTR
34,22964305,sctr_human,209,D,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,2.7,2.25,,,[125]secretin (radioligand),6.177260519,0.0,,0.0,,P47872,0.637065,DA209C,SCTR
62,22964305,sctr_human,209,D,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.3,15.0,,,secretin,0.0,0.0,,100.5291005,secretin,P47872,0.637065,DA209C,SCTR
35,22964305,sctr_human,368,I,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,5.0,4.167,,,[125]secretin (radioligand),24.79856759,0.0,,0.0,,P47872,0.847239,IA368C,SCTR
88,22964305,sctr_human,368,I,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.1,5.0,,,secretin,0.0,0.0,,106.8783069,secretin,P47872,0.847239,IA368C,SCTR
38,11517171,sctr_human,323,K,I,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,14.1,nM,=,,3.8,-3.704,,,[125]secretin (radioligand),0.0,0.0,,0.0,,P47872,-0.624224,KA323I,SCTR
98,11517171,sctr_human,323,K,I,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,17.0,5.667,,,,0.0,0.0,,0.0,,P47872,-0.624224,KA323I,SCTR
48,11517171,sctr_human,339,R,A,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,0.5,-5.988,,,,0.0,0.0,,0.0,,P47872,0.818946,RA339A,SCTR
66,11517171,sctr_human,339,R,A,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,14.1,nM,=,,49.7,3.525,,,[125]secretin (radioligand),0.0,0.0,,0.0,,P47872,0.818946,RA339A,SCTR
49,22964305,sctr_human,297,I,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,5.5,4.583,,,[125]secretin (radioligand),32.1396598,0.0,,0.0,,P47872,1.42484,IA297C,SCTR
76,22964305,sctr_human,297,I,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.04,2.0,,,secretin,0.0,0.0,,103.7037037,secretin,P47872,1.42484,IA297C,SCTR
53,22964305,sctr_human,371,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.03,1.5,,,secretin,0.0,0.0,,89.94708995,secretin,P47872,2.33494,FA371C,SCTR
94,22964305,sctr_human,371,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,3.7,3.083,,,[125]secretin (radioligand),23.72426141,0.0,,0.0,,P47872,2.33494,FA371C,SCTR
57,22964305,sctr_human,282,D,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.3,15.0,Abolished effect,,secretin,0.0,0.0,,105.2910053,secretin,P47872,2.5769,DA282C,SCTR
71,22964305,sctr_human,372,F,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,11.0,9.167,,,[125]secretin (radioligand),32.94538944,0.0,,0.0,,P47872,1.70655,FA372C,SCTR
115,22964305,sctr_human,372,F,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.2,10.0,,,secretin,0.0,0.0,,89.41798942,secretin,P47872,1.70655,FA372C,SCTR
78,11517171,sctr_human,339,R,I,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,0.4,-7.519,,,,0.0,0.0,,0.0,,P47872,-0.367257,RA339I,SCTR
80,11517171,sctr_human,339,R,I,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,14.1,nM,=,,26.8,1.901,,,[125]secretin (radioligand),0.0,0.0,,0.0,,P47872,-0.367257,RA339I,SCTR
83,22964305,sctr_human,361,S,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,12.3,10.25,,,[125]secretin (radioligand),57.11727842,0.0,,0.0,,P47872,-0.582588,SA361C,SCTR
99,22964305,sctr_human,361,S,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.05,2.5,,,secretin,0.0,0.0,,98.94179894,secretin,P47872,-0.582588,SA361C,SCTR
84,22964305,sctr_human,287,D,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.8,40.0,,,secretin,0.0,0.0,,93.65079365,secretin,P47872,-0.304077,DA287C,SCTR
111,22964305,sctr_human,287,D,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,2.5,2.083,,,[125]secretin (radioligand),2.506714414,0.0,,0.0,,P47872,-0.304077,DA287C,SCTR
85,22964305,sctr_human,364,D,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,9.2,7.667,,,[125]secretin (radioligand),31.7905103,0.0,,0.0,,P47872,-0.257839,DA364C,SCTR
95,22964305,sctr_human,364,D,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.06,3.0,,,secretin,0.0,0.0,,95.76719577,secretin,P47872,-0.257839,DA364C,SCTR
89,22964305,sctr_human,290,A,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,3.4,2.833,,,[125]secretin (radioligand),9.489704566,0.0,,0.0,,P47872,0.203332,AA290C,SCTR
90,22964305,sctr_human,290,A,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.1,5.0,,,secretin,0.0,0.0,,93.65079365,secretin,P47872,0.203332,AA290C,SCTR
91,22964305,sctr_human,359,A,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,7.6,6.333,,,[125]secretin (radioligand),47.80662489,0.0,,0.0,,P47872,0.233611,AA359C,SCTR
117,22964305,sctr_human,359,A,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.07,3.5,,,secretin,0.0,0.0,,92.59259259,secretin,P47872,0.233611,AA359C,SCTR
92,22964305,sctr_human,293,S,C,secretin,PubChem CID,16129665,Full agonist,EC50,Functional - cAMP accumulation,0.02,nM,=,,0.1,5.0,,,secretin,0.0,0.0,,93.12169312,secretin,P47872,-0.203123,SA293C,SCTR
106,22964305,sctr_human,293,S,C,secretin,PubChem CID,16129665,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,9.3,7.75,,,[125]secretin (radioligand),47.00089526,0.0,,0.0,,P47872,-0.203123,SA293C,SCTR
1,21703310,calrl_human,198,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.86,M,=,,8.07,6.166,,,calcitonin gene-related peptide 1,133.4,0.0,,0.0,,Q16602,2.66635,VA198A,CALCRL
134,21703310,calrl_human,198,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.67,M,=,,8.87,6.31,,,calcitonin gene-related peptide 1,133.4,0.0,,0.0,,Q16602,2.66635,VA198A,CALCRL
2,12630808,calrl_human,282,C,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,EC50,Functional - cAMP accumulation,1.6,nM,=,,22.0,13.75,,,adrenomedullin 2,100.0,0.0,,0.0,,Q16602,4.93425,CA282A,CALCRL
3,21703310,calrl_human,211,S,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,EC50,Functional - cAMP accumulation,9.49,M,=,,9.6,1.012,,,calcitonin gene-related peptide 1,92.62,0.0,,0.0,,Q16602,-0.00954846,SA211A,CALCRL
50,21703310,calrl_human,211,S,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.49,M,=,,9.6,-1.289,,,calcitonin gene-related peptide 1,92.62,0.0,,0.0,,Q16602,-0.00954846,SA211A,CALCRL
4,24199627,calrl_human,42,M,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.82,M,=,,8.61,1.622,,,adrenomedullin 2,0.0,0.0,,262.8,,Q16602,0.596686,MA42A,CALCRL
33,24199627,calrl_human,42,M,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.66,M,=,,9.52,1.38,,,adrenomedullin,0.0,0.0,,150.1,,Q16602,0.596686,MA42A,CALCRL
89,24199627,calrl_human,42,M,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.21,M,=,,7.86,2.239,,,adrenomedullin 2,0.0,0.0,,89.9,,Q16602,0.596686,MA42A,CALCRL
105,24199627,calrl_human,42,M,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.11,M,=,,8.48,4.266,,,adrenomedullin,0.0,0.0,,139.6,,Q16602,0.596686,MA42A,CALCRL
121,24199627,calrl_human,42,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.36,M,=,,7.33,1.072,,,calcitonin gene-related peptide 1,0.0,0.0,,67.4,,Q16602,0.596686,MA42A,CALCRL
5,21703310,calrl_human,359,K,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.76,M,=,,9.94,-1.513,,,calcitonin gene-related peptide 1,71.8,0.0,,0.0,,Q16602,1.00844,KA359A,CALCRL
30,21703310,calrl_human,359,K,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.76,M,=,,9.94,-1.513,,,calcitonin gene-related peptide 1,0.0,0.0,,121.7,,Q16602,1.00844,KA359A,CALCRL
116,21703310,calrl_human,359,K,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.76,M,=,,9.94,-1.513,,,calcitonin gene-related peptide 1,0.0,12.6,,0.0,,Q16602,1.00844,KA359A,CALCRL
6,21703310,calrl_human,365,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.2,M,=,,10.33,-1.35,,,calcitonin gene-related peptide 1,0.0,0.0,,119.7,,Q16602,2.96314,YA365A,CALCRL
32,21703310,calrl_human,365,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.2,M,=,,10.33,-1.35,,,calcitonin gene-related peptide 1,0.0,22.5,,0.0,,Q16602,2.96314,YA365A,CALCRL
156,21703310,calrl_human,365,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.2,M,=,,10.33,-1.35,,,calcitonin gene-related peptide 1,60.0,0.0,,0.0,,Q16602,2.96314,YA365A,CALCRL
7,21703310,calrl_human,350,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.89,M,=,,9.74,1.413,,,calcitonin gene-related peptide 1,0.0,19.3,,0.0,,Q16602,1.32395,VA350A,CALCRL
62,21703310,calrl_human,350,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.89,M,=,,9.74,1.413,,,calcitonin gene-related peptide 1,78.9,0.0,,0.0,,Q16602,1.32395,VA350A,CALCRL
79,21703310,calrl_human,350,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.89,M,=,,9.74,1.413,,,calcitonin gene-related peptide 1,0.0,0.0,,142.3,,Q16602,1.32395,VA350A,CALCRL
8,21703310,calrl_human,358,G,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.68,M,=,,9.46,1.66,,,calcitonin gene-related peptide 1,61.4,0.0,,0.0,,Q16602,3.17883,GA358A,CALCRL
9,21703310,calrl_human,206,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.43,M,=,,10.37,-8.696,,,calcitonin gene-related peptide 1,114.5,0.0,,0.0,,Q16602,-1.32308,AA206L,CALCRL
114,21703310,calrl_human,206,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.0,M,,,9.19,-1.548,,,calcitonin gene-related peptide 1,114.5,0.0,,0.0,,Q16602,-1.32308,AA206L,CALCRL
10,24199627,calrl_human,33,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.12,M,=,,7.89,1.698,,,adrenomedullin 2,0.0,0.0,,281.0,,Q16602,0.019571,QA33A,CALCRL
26,24199627,calrl_human,33,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.46,M,=,,9.61,-1.412,,,adrenomedullin,0.0,0.0,,127.2,,Q16602,0.019571,QA33A,CALCRL
29,24199627,calrl_human,33,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.06,M,=,,9.15,-1.23,,,adrenomedullin,0.0,0.0,,269.4,,Q16602,0.019571,QA33A,CALCRL
151,24199627,calrl_human,33,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.68,M,=,,7.42,1.82,,,calcitonin gene-related peptide 1,0.0,0.0,,196.6,,Q16602,0.019571,QA33A,CALCRL
169,24199627,calrl_human,33,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.59,M,=,,8.56,1.072,,,adrenomedullin 2,0.0,0.0,,155.2,,Q16602,0.019571,QA33A,CALCRL
11,21703310,calrl_human,209,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.85,M,=,,9.91,-1.148,,,calcitonin gene-related peptide 1,0.0,0.0,,122.5,,Q16602,1.87624,PA209A,CALCRL
67,21703310,calrl_human,209,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.85,M,=,,9.91,-1.148,,,calcitonin gene-related peptide 1,0.0,41.5,,0.0,,Q16602,1.87624,PA209A,CALCRL
126,21703310,calrl_human,209,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.85,M,=,,9.91,-1.148,,,calcitonin gene-related peptide 1,133.0,0.0,,0.0,,Q16602,1.87624,PA209A,CALCRL
12,21703310,calrl_human,349,F,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.59,M,=,,10.72,-1.35,,,calcitonin gene-related peptide 1,69.0,0.0,,0.0,,Q16602,1.40886,FA349A,CALCRL
15,21703310,calrl_human,349,F,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.59,M,=,,10.72,-1.35,,,calcitonin gene-related peptide 1,0.0,10.3,,0.0,,Q16602,1.40886,FA349A,CALCRL
25,21703310,calrl_human,349,F,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.59,M,=,,10.72,-1.35,,,calcitonin gene-related peptide 1,0.0,0.0,,122.1,,Q16602,1.40886,FA349A,CALCRL
13,15615699,calrl_human,263,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.66,M,=,,8.8,-1.381,,,[I125]calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,3.28672,PA263A,CALCRL
71,15615699,calrl_human,263,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.15,M,=,,8.79,2.291,,,calcitonin gene-related peptide 1,0.0,0.0,,97.0,,Q16602,3.28672,PA263A,CALCRL
16,21703310,calrl_human,216,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.63,M,=,,9.94,-2.041,,,calcitonin gene-related peptide 1,0.0,22.7,,0.0,,Q16602,-0.0319098,QA216A,CALCRL
61,21703310,calrl_human,216,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.63,M,=,,9.94,-2.041,,,calcitonin gene-related peptide 1,107.3,0.0,,0.0,,Q16602,-0.0319098,QA216A,CALCRL
159,21703310,calrl_human,216,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.63,M,=,,9.94,-2.041,,,calcitonin gene-related peptide 1,0.0,0.0,,144.0,,Q16602,-0.0319098,QA216A,CALCRL
17,24199627,calrl_human,52,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.05,M,=,,8.66,2.455,,,adrenomedullin,0.0,0.0,,136.1,,Q16602,1.59676,IA52A,CALCRL
41,24199627,calrl_human,52,I,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.29,M,=,,9.12,1.479,,,adrenomedullin 2,0.0,0.0,,71.8,,Q16602,1.59676,IA52A,CALCRL
46,24199627,calrl_human,52,I,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.03,M,=,,8.11,-1.202,,,adrenomedullin 2,0.0,0.0,,94.6,,Q16602,1.59676,IA52A,CALCRL
64,24199627,calrl_human,52,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.42,M,=,,6.91,3.236,,,calcitonin gene-related peptide 1,0.0,0.0,,108.8,,Q16602,1.59676,IA52A,CALCRL
117,24199627,calrl_human,52,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.55,M,=,,9.36,1.549,,,adrenomedullin,0.0,0.0,,97.5,,Q16602,1.59676,IA52A,CALCRL
18,21703310,calrl_human,353,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.79,M,=,,9.06,5.37,,,calcitonin gene-related peptide 1,133.3,0.0,,0.0,,Q16602,0.868446,PA353A,CALCRL
84,15615699,calrl_human,353,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.18,M,=,,8.65,3.388,,,[I125]calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,0.868446,PA353A,CALCRL
136,21703310,calrl_human,353,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.18,M,=,,8.65,3.388,,,calcitonin gene-related peptide 1,133.3,0.0,,0.0,,Q16602,0.868446,PA353A,CALCRL
167,15615699,calrl_human,353,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.57,M,=,,8.54,10.715,,,calcitonin gene-related peptide 1,0.0,0.0,,121.0,,Q16602,0.868446,PA353A,CALCRL
19,24199627,calrl_human,45,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.03,M,=,,8.45,3.802,,,adrenomedullin,0.0,0.0,,26.1,,Q16602,0.100924,QA45A,CALCRL
85,24199627,calrl_human,45,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.5,M,=,,7.21,1.95,,,calcitonin gene-related peptide 1,0.0,0.0,,112.2,,Q16602,0.100924,QA45A,CALCRL
106,24199627,calrl_human,45,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.95,M,=,,8.94,1.023,,,adrenomedullin 2,0.0,0.0,,104.6,,Q16602,0.100924,QA45A,CALCRL
157,24199627,calrl_human,45,Q,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.61,M,=,,9.4,1.622,,,adrenomedullin,0.0,0.0,,138.3,,Q16602,0.100924,QA45A,CALCRL
20,15615699,calrl_human,343,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.84,M,=,,7.69,14.125,,,[I125]calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,2.3818,PA343A,CALCRL
97,15615699,calrl_human,343,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.18,M,=,,6.86,208.93,,,calcitonin gene-related peptide 1,0.0,0.0,,59.0,,Q16602,2.3818,PA343A,CALCRL
22,12630808,calrl_human,212,C,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,EC50,Functional - cAMP accumulation,1.6,nM,=,,68.0,42.5,,,adrenomedullin 2,100.0,0.0,,0.0,,Q16602,5.0699,CA212A,CALCRL
95,21703310,calrl_human,212,C,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.71,M,=,,8.78,8.511,,,calcitonin gene-related peptide 1,0.0,-6.7,,0.0,,Q16602,5.0699,CA212A,CALCRL
109,21703310,calrl_human,212,C,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.04,M,=,,6.94,125.893,,,calcitonin gene-related peptide 1,69.71,0.0,,0.0,,Q16602,5.0699,CA212A,CALCRL
132,21703310,calrl_human,212,C,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.71,M,=,,8.78,8.511,,,calcitonin gene-related peptide 1,0.0,0.0,,130.2,,Q16602,5.0699,CA212A,CALCRL
23,21703310,calrl_human,360,I,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.77,M,=,,7.83,8.71,,,calcitonin gene-related peptide 1,107.7,0.0,,0.0,,Q16602,-0.0454696,IA360L,CALCRL
24,24199627,calrl_human,32,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.07,M,=,,9.21,-1.381,,,adrenomedullin,0.0,0.0,,133.9,,Q16602,1.16025,IA32A,CALCRL
36,24199627,calrl_human,32,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.54,M,=,,9.36,1.514,,,adrenomedullin,0.0,0.0,,135.2,,Q16602,1.16025,IA32A,CALCRL
39,24199627,calrl_human,32,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.2,M,=,,7.33,-1.35,,,calcitonin gene-related peptide 1,0.0,0.0,,72.7,,Q16602,1.16025,IA32A,CALCRL
98,24199627,calrl_human,32,I,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.23,M,=,,8.24,-1.024,,,adrenomedullin 2,0.0,0.0,,110.7,,Q16602,1.16025,IA32A,CALCRL
108,24199627,calrl_human,32,I,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.83,M,=,,9.47,2.291,,,adrenomedullin 2,0.0,0.0,,129.3,,Q16602,1.16025,IA32A,CALCRL
27,12630808,calrl_human,225,C,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,EC50,Functional - cAMP accumulation,1.6,nM,=,,0.62,-2.584,,,adrenomedullin 2,100.0,0.0,,0.0,,Q16602,0.106456,CA225A,CALCRL
31,24199627,calrl_human,34,L,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.42,M,=,,9.13,1.95,,,adrenomedullin 2,0.0,0.0,,104.5,,Q16602,0.224857,LA34A,CALCRL
65,24199627,calrl_human,34,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.13,M,=,,7.24,-1.289,,,calcitonin gene-related peptide 1,0.0,0.0,,99.8,,Q16602,0.224857,LA34A,CALCRL
119,24199627,calrl_human,34,L,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.59,M,=,,8.88,5.129,,,adrenomedullin,0.0,0.0,,139.5,,Q16602,0.224857,LA34A,CALCRL
139,24199627,calrl_human,34,L,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.25,M,=,,7.64,4.074,,,adrenomedullin 2,0.0,0.0,,117.9,,Q16602,0.224857,LA34A,CALCRL
140,24199627,calrl_human,34,L,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.89,M,=,,8.5,2.455,,,adrenomedullin,0.0,0.0,,104.7,,Q16602,0.224857,LA34A,CALCRL
34,15615699,calrl_human,297,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.8,M,=,,9.56,1.738,,,calcitonin gene-related peptide 1,0.0,0.0,,97.0,,Q16602,1.77629,PA297A,CALCRL
49,15615699,calrl_human,297,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.86,M,=,,8.91,-1.122,,,[I125]calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,1.77629,PA297A,CALCRL
37,21703310,calrl_human,362,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.7,M,=,,9.65,1.122,,,calcitonin gene-related peptide 1,83.8,0.0,,0.0,,Q16602,-0.246205,EA362A,CALCRL
59,21703310,calrl_human,362,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.05,M,=,,8.74,2.042,,,calcitonin gene-related peptide 1,83.8,0.0,,0.0,,Q16602,-0.246205,EA362A,CALCRL
38,21703310,calrl_human,203,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.33,M,=,,9.77,-2.755,,,calcitonin gene-related peptide 1,112.4,0.0,,0.0,,Q16602,-0.82601,AA203L,CALCRL
43,21703310,calrl_human,203,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.75,M,=,,10.77,-10.526,,,calcitonin gene-related peptide 1,112.4,0.0,,0.0,,Q16602,-0.82601,AA203L,CALCRL
40,21703310,calrl_human,352,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.33,4.677,,,calcitonin gene-related peptide 1,0.0,25.8,,0.0,,Q16602,0.523454,IA352A,CALCRL
96,21703310,calrl_human,352,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.33,4.677,,,calcitonin gene-related peptide 1,70.5,0.0,,0.0,,Q16602,0.523454,IA352A,CALCRL
149,21703310,calrl_human,352,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.0,M,=,,9.33,4.677,,,calcitonin gene-related peptide 1,0.0,0.0,,121.1,,Q16602,0.523454,IA352A,CALCRL
42,21703310,calrl_human,222,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.95,M,=,,10.75,-6.329,,,calcitonin gene-related peptide 1,94.33,0.0,,0.0,,Q16602,2.60047,LA222A,CALCRL
141,21703310,calrl_human,222,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.84,M,=,,10.76,-8.333,,,calcitonin gene-related peptide 1,94.33,0.0,,0.0,,Q16602,2.60047,LA222A,CALCRL
44,24199627,calrl_human,36,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.16,M,=,,6.91,1.778,,,calcitonin gene-related peptide 1,0.0,0.0,,70.5,,Q16602,-0.302538,VA36A,CALCRL
45,24199627,calrl_human,36,V,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.22,M,=,,7.89,2.138,,,adrenomedullin 2,0.0,0.0,,153.9,,Q16602,-0.302538,VA36A,CALCRL
100,24199627,calrl_human,36,V,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.07,M,=,,8.92,1.413,,,adrenomedullin,0.0,0.0,,138.2,,Q16602,-0.302538,VA36A,CALCRL
129,24199627,calrl_human,36,V,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.09,M,=,,8.62,2.951,,,adrenomedullin 2,0.0,0.0,,121.0,,Q16602,-0.302538,VA36A,CALCRL
142,24199627,calrl_human,36,V,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.29,M,=,,9.06,1.698,,,adrenomedullin,0.0,0.0,,89.9,,Q16602,-0.302538,VA36A,CALCRL
47,21703310,calrl_human,221,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.73,M,=,,9.01,5.248,,,calcitonin gene-related peptide 1,107.3,0.0,,0.0,,Q16602,3.21766,YA221A,CALCRL
51,21703310,calrl_human,371,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.84,M,=,,10.16,-2.088,,,calcitonin gene-related peptide 1,70.5,0.0,,0.0,,Q16602,1.26008,IA371A,CALCRL
144,21703310,calrl_human,371,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.96,M,=,,10.18,-1.658,,,calcitonin gene-related peptide 1,70.5,0.0,,0.0,,Q16602,1.26008,IA371A,CALCRL
52,21703310,calrl_human,368,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.13,M,=,,10.3,-1.479,,,calcitonin gene-related peptide 1,129.0,0.0,,0.0,,Q16602,0.642758,IA368A,CALCRL
53,21703310,calrl_human,355,R,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.86,M,=,,9.55,2.042,,,calcitonin gene-related peptide 1,66.2,0.0,,0.0,,Q16602,1.47313,RA355A,CALCRL
103,21703310,calrl_human,355,R,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.86,M,=,,9.55,2.042,,,calcitonin gene-related peptide 1,0.0,0.0,,151.5,,Q16602,1.47313,RA355A,CALCRL
162,21703310,calrl_human,355,R,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.86,M,=,,9.55,2.042,,,calcitonin gene-related peptide 1,0.0,39.7,,0.0,,Q16602,1.47313,RA355A,CALCRL
54,21703310,calrl_human,370,H,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.42,M,=,,9.19,1.698,,,calcitonin gene-related peptide 1,141.1,0.0,,0.0,,Q16602,0.696111,HA370A,CALCRL
55,21703310,calrl_human,210,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.95,M,=,,10.44,-3.086,,,calcitonin gene-related peptide 1,0.0,33.7,,0.0,,Q16602,0.00849212,VA210A,CALCRL
77,21703310,calrl_human,210,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.95,M,=,,9.95,1.0,,,calcitonin gene-related peptide 1,0.0,0.0,,117.9,,Q16602,0.00849212,VA210A,CALCRL
86,21703310,calrl_human,210,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.95,M,=,,10.44,-3.086,,,calcitonin gene-related peptide 1,111.9,0.0,,0.0,,Q16602,0.00849212,VA210A,CALCRL
57,21703310,calrl_human,207,T,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.98,M,=,,10.5,-3.311,,,calcitonin gene-related peptide 1,0.0,0.0,,122.5,,Q16602,-0.187002,TA207A,CALCRL
111,21703310,calrl_human,207,T,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.98,M,=,,10.5,-3.311,,,calcitonin gene-related peptide 1,0.0,0.4,,0.0,,Q16602,-0.187002,TA207A,CALCRL
58,21703310,calrl_human,366,D,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.54,M,=,,9.72,-1.513,,,calcitonin gene-related peptide 1,85.9,0.0,,0.0,,Q16602,-0.52075,DA366A,CALCRL
60,21703310,calrl_human,214,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.83,M,=,,9.97,-1.381,,,calcitonin gene-related peptide 1,88.17,0.0,,0.0,,Q16602,-0.281755,VA214A,CALCRL
63,21703310,calrl_human,363,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.32,M,=,,9.8,3.311,,,calcitonin gene-related peptide 1,0.0,7.6,,0.0,,Q16602,0.686411,EA363A,CALCRL
118,21703310,calrl_human,363,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.32,M,=,,9.8,3.311,,,calcitonin gene-related peptide 1,0.0,0.0,,127.5,,Q16602,0.686411,EA363A,CALCRL
152,21703310,calrl_human,363,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.32,M,=,,9.8,3.311,,,calcitonin gene-related peptide 1,89.6,0.0,,0.0,,Q16602,0.686411,EA363A,CALCRL
68,24199627,calrl_human,35,G,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.15,M,=,,6.5,4.467,,,calcitonin gene-related peptide 1,0.0,0.0,,53.3,,Q16602,-0.479574,GA35A,CALCRL
82,24199627,calrl_human,35,G,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.29,M,=,,8.77,3.311,,,adrenomedullin,0.0,0.0,,71.0,,Q16602,-0.479574,GA35A,CALCRL
110,24199627,calrl_human,35,G,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.07,M,=,,8.91,1.445,,,adrenomedullin,0.0,0.0,,139.9,,Q16602,-0.479574,GA35A,CALCRL
125,24199627,calrl_human,35,G,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.09,M,=,,8.78,2.042,,,adrenomedullin 2,0.0,0.0,,97.9,,Q16602,-0.479574,GA35A,CALCRL
128,24199627,calrl_human,35,G,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.22,M,=,,7.92,1.995,,,adrenomedullin 2,0.0,0.0,,92.9,,Q16602,-0.479574,GA35A,CALCRL
69,21703310,calrl_human,357,E,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.44,M,=,,8.92,33.113,,,calcitonin gene-related peptide 1,11.0,0.0,,0.0,,Q16602,0.213041,EA357A,CALCRL
70,15615699,calrl_human,266,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.05,M,=,,9.01,1.096,,,calcitonin gene-related peptide 1,0.0,0.0,,112.0,,Q16602,2.93604,PA266A,CALCRL
127,15615699,calrl_human,266,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.31,M,=,,8.64,-2.137,,,[I125]calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,2.93604,PA266A,CALCRL
72,21703310,calrl_human,369,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.92,M,=,,10.53,-4.082,,,calcitonin gene-related peptide 1,0.0,0.0,,139.5,,Q16602,2.39675,MA369A,CALCRL
91,21703310,calrl_human,369,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.92,M,=,,10.53,-4.082,,,calcitonin gene-related peptide 1,0.0,19.2,,0.0,,Q16602,2.39675,MA369A,CALCRL
112,21703310,calrl_human,369,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.92,M,=,,10.53,-4.082,,,calcitonin gene-related peptide 1,99.9,0.0,,0.0,,Q16602,2.39675,MA369A,CALCRL
73,21703310,calrl_human,199,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.2,M,=,,8.87,21.38,,,calcitonin gene-related peptide 1,130.2,0.0,,0.0,,Q16602,-1.13359,AA199L,CALCRL
78,21703310,calrl_human,199,A,L,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,8.88,M,=,,7.26,41.687,,,calcitonin gene-related peptide 1,130.2,0.0,,0.0,,Q16602,-1.13359,AA199L,CALCRL
76,24199627,calrl_human,41,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.14,M,=,,7.91,16.982,,,adrenomedullin,0.0,0.0,,33.7,,Q16602,2.0317,IA41A,CALCRL
150,24199627,calrl_human,41,I,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.8,M,=,,8.51,19.498,,,adrenomedullin,0.0,0.0,,77.6,,Q16602,2.0317,IA41A,CALCRL
154,24199627,calrl_human,41,I,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.32,M,=,,8.47,7.079,,,adrenomedullin 2,0.0,0.0,,87.4,,Q16602,2.0317,IA41A,CALCRL
81,21703310,calrl_human,372,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.93,M,=,,10.08,-1.412,,,calcitonin gene-related peptide 1,102.3,0.0,,0.0,,Q16602,0.728456,LA372A,CALCRL
137,21703310,calrl_human,372,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.93,M,=,,10.08,-1.412,,,calcitonin gene-related peptide 1,102.3,0.0,,0.0,,Q16602,0.728456,LA372A,CALCRL
83,21703310,calrl_human,219,H,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.41,M,=,,8.35,11.482,,,calcitonin gene-related peptide 1,68.81,0.0,,0.0,,Q16602,0.973694,HA219A,CALCRL
158,21703310,calrl_human,219,H,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.01,M,=,,7.91,12.589,,,calcitonin gene-related peptide 1,68.81,0.0,,0.0,,Q16602,0.973694,HA219A,CALCRL
87,21703310,calrl_human,204,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.73,M,=,,9.68,1.122,,,calcitonin gene-related peptide 1,0.0,37.3,,0.0,,Q16602,0.632517,LA204A,CALCRL
88,21703310,calrl_human,204,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.73,M,=,,9.68,1.122,,,calcitonin gene-related peptide 1,0.0,0.0,,142.3,,Q16602,0.632517,LA204A,CALCRL
90,24199627,calrl_human,37,T,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.12,M,=,,6.99,13.49,,,adrenomedullin 2,0.0,0.0,,70.6,,Q16602,0.209136,TA37A,CALCRL
113,24199627,calrl_human,37,T,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,7.21,M,=,,7.17,1.096,,,calcitonin gene-related peptide 1,0.0,0.0,,59.1,,Q16602,0.209136,TA37A,CALCRL
131,24199627,calrl_human,37,T,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,8.94,M,=,,8.25,4.898,,,adrenomedullin,0.0,0.0,,89.0,,Q16602,0.209136,TA37A,CALCRL
146,24199627,calrl_human,37,T,A,adrenomedullin,UniProt Entry Code (peptide),ADML_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.61,M,=,,8.63,9.55,,,adrenomedullin,0.0,0.0,,90.1,,Q16602,0.209136,TA37A,CALCRL
170,24199627,calrl_human,37,T,A,adrenomedullin,UniProt Entry Code (peptide),ADM2_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.13,M,=,,7.7,26.915,,,adrenomedullin 2,0.0,0.0,,68.5,,Q16602,0.209136,TA37A,CALCRL
92,21703310,calrl_human,367,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.64,M,=,,9.92,-1.905,,,calcitonin gene-related peptide 1,0.0,16.9,,0.0,,Q16602,2.51511,YA367A,CALCRL
93,21703310,calrl_human,367,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.92,M,=,,9.64,1.905,,,calcitonin gene-related peptide 1,0.0,0.0,,123.2,,Q16602,2.51511,YA367A,CALCRL
107,21703310,calrl_human,367,Y,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.64,M,=,,9.92,-1.905,,,calcitonin gene-related peptide 1,56.6,0.0,,0.0,,Q16602,2.51511,YA367A,CALCRL
99,21703310,calrl_human,351,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.36,M,=,,9.54,-1.513,,,calcitonin gene-related peptide 1,27.2,0.0,,0.0,,Q16602,1.46718,LA351A,CALCRL
101,21703310,calrl_human,373,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.21,M,=,,10.51,-1.996,,,calcitonin gene-related peptide 1,0.0,0.0,,0.0,,Q16602,0.593361,MA373A,CALCRL
102,21703310,calrl_human,220,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.53,M,=,,10.93,-25.0,,,calcitonin gene-related peptide 1,79.21,0.0,,0.0,,Q16602,1.81292,LA220A,CALCRL
133,21703310,calrl_human,220,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.36,M,=,,10.21,-7.092,,,calcitonin gene-related peptide 1,79.21,0.0,,0.0,,Q16602,1.81292,LA220A,CALCRL
104,21703310,calrl_human,196,T,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.73,M,=,,10.18,-2.817,,,calcitonin gene-related peptide 1,96.0,0.0,,0.0,,Q16602,0.234761,TA196A,CALCRL
115,21703310,calrl_human,215,S,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.39,M,=,,9.41,-1.047,,,calcitonin gene-related peptide 1,101.6,0.0,,0.0,,Q16602,-0.477769,SA215A,CALCRL
122,21703310,calrl_human,205,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.62,M,=,,10.04,-2.632,,,calcitonin gene-related peptide 1,81.3,0.0,,0.0,,Q16602,1.08859,VA205A,CALCRL
124,21703310,calrl_human,223,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.71,M,=,,9.65,1.148,,,calcitonin gene-related peptide 1,0.0,0.0,,128.8,,Q16602,1.94846,MA223A,CALCRL
148,21703310,calrl_human,223,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.71,M,=,,9.65,1.148,,,calcitonin gene-related peptide 1,58.97,0.0,,0.0,,Q16602,1.94846,MA223A,CALCRL
165,21703310,calrl_human,223,M,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.71,M,=,,9.65,1.148,,,calcitonin gene-related peptide 1,0.0,13.2,,0.0,,Q16602,1.94846,MA223A,CALCRL
135,21703310,calrl_human,356,P,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.39,M,=,,9.95,2.754,,,calcitonin gene-related peptide 1,85.0,0.0,,0.0,,Q16602,2.23713,PA356A,CALCRL
138,21703310,calrl_human,202,Q,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.49,M,=,,9.17,2.089,,,calcitonin gene-related peptide 1,81.4,0.0,,0.0,,Q16602,0.338072,QA202A,CALCRL
143,21703310,calrl_human,213,K,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.49,M,=,,8.78,5.129,,,calcitonin gene-related peptide 1,94.54,0.0,,0.0,,Q16602,0.123003,KA213A,CALCRL
145,21703310,calrl_human,217,F,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.94,M,=,,9.37,3.715,,,calcitonin gene-related peptide 1,72.78,0.0,,0.0,,Q16602,1.95946,FA217A,CALCRL
147,21703310,calrl_human,194,H,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.97,M,=,,9.41,3.631,,,calcitonin gene-related peptide 1,106.5,0.0,,0.0,,Q16602,0.306794,HA194A,CALCRL
153,21703310,calrl_human,360,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.26,M,=,,8.4,7.244,,,calcitonin gene-related peptide 1,107.7,0.0,,0.0,,Q16602,0.00152687,IA360A,CALCRL
155,21703310,calrl_human,354,W,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Binding - unknown pharmacological activity,pIC50,Binding - Radioligand competition/displacement,9.01,M,=,,8.75,1.82,,,calcitonin gene-related peptide 1,88.1,0.0,,0.0,,Q16602,0.642077,WA354A,CALCRL
163,21703310,calrl_human,354,W,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.08,M,=,,8.91,1.479,,,calcitonin gene-related peptide 1,88.1,0.0,,0.0,,Q16602,0.642077,WA354A,CALCRL
160,21703310,calrl_human,218,I,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.27,M,=,,9.6,-2.137,,,calcitonin gene-related peptide 1,73.05,0.0,,0.0,,Q16602,1.33144,IA218A,CALCRL
161,21703310,calrl_human,364,V,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,9.78,M,=,,9.94,-1.445,,,calcitonin gene-related peptide 1,135.3,0.0,,0.0,,Q16602,-0.244085,VA364A,CALCRL
164,21703310,calrl_human,195,L,A,calcitonin gene-related peptide 1,UniProt Entry Code (peptide),CALCA_HUMAN,Full agonist,pEC50,Functional - cAMP accumulation,10.36,M,=,,8.87,30.903,,,calcitonin gene-related peptide 1,92.7,0.0,,0.0,,Q16602,1.91381,LA195A,CALCRL
0,26043830,gipr_human,339,L,S,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,2.59,5.286,,,GIP,0.0,0.0,,100.0,,P48546,2.45672,LA339S,GIPR
44,26043830,gipr_human,339,L,S,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,1.43,-4.202,,,[125I]GIP-(Tyr1Phe) (radioligand),23.4,0.0,,0.0,,P48546,2.45672,LA339S,GIPR
1,26043830,gipr_human,169,R,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,7.2,1.198,,,[125I]GIP-(Tyr1Phe) (radioligand),70.9,0.0,,0.0,,P48546,0.461239,RA169A,GIPR
34,26043830,gipr_human,169,R,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,3.33,6.796,,,GIP,0.0,0.0,,100.0,,P48546,0.461239,RA169A,GIPR
2,20061446,gipr_human,357,F,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,30.8,15.714,,,[125I]-GIP (radioligand),77.0,0.0,,0.0,,P48546,0.49593,FA357A,GIPR
4,26043830,gipr_human,343,T,S,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,0.22,-2.227,,,GIP,0.0,0.0,,100.0,,P48546,0.909204,TA343S,GIPR
28,26043830,gipr_human,343,T,S,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,1.27,-4.739,,,[125I]GIP-(Tyr1Phe) (radioligand),64.3,0.0,,0.0,,P48546,0.909204,TA343S,GIPR
5,26043830,gipr_human,381,S,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,0.3,-1.634,,,GIP,0.0,0.0,,100.0,,P48546,-0.275937,SA381A,GIPR
21,26043830,gipr_human,381,S,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,3.33,-1.805,,,[125I]GIP-(Tyr1Phe) (radioligand),57.1,0.0,,0.0,,P48546,-0.275937,SA381A,GIPR
6,26043830,gipr_human,343,T,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,0.9,-6.667,,,[125I]GIP-(Tyr1Phe) (radioligand),57.3,0.0,,0.0,,P48546,-0.0227421,TA343A,GIPR
33,26043830,gipr_human,343,T,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,0.08,-6.135,,,GIP,0.0,0.0,,100.0,,P48546,-0.0227421,TA343A,GIPR
7,20061446,gipr_human,231,Y,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,4.2,2.143,,,[125I]-GIP (radioligand),103.0,0.0,,0.0,,P48546,2.66765,YA231A,GIPR
8,26043830,gipr_human,392,Y,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,1.2,-5.0,,,[125I]GIP-(Tyr1Phe) (radioligand),37.6,0.0,,0.0,,P48546,1.21573,YA392A,GIPR
19,26043830,gipr_human,392,Y,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,1.46,2.98,,,GIP,0.0,0.0,,100.0,,P48546,1.21573,YA392A,GIPR
39,20061446,gipr_human,392,Y,A,GIP,PubChem CID,90488736,,EC50,Functional - cAMP accumulation,1.96,nM,=,,9.5,4.847,,,,90.0,0.0,,0.0,,P48546,1.21573,YA392A,GIPR
9,20061446,gipr_human,384,Q,A,GIP,PubChem CID,90488736,,EC50,Functional - cAMP accumulation,1.96,nM,=,,5.2,2.653,,,,115.0,0.0,,0.0,,P48546,1.19881,QA384A,GIPR
36,20061446,gipr_human,384,Q,A,GIP,PubChem CID,90488736,,EC50,Functional - cAMP accumulation,1.96,nM,=,,3.2,1.633,,,,109.0,0.0,,0.0,,P48546,1.19881,QA384A,GIPR
10,26043830,gipr_human,173,H,N,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,2.01,4.102,,,GIP,0.0,0.0,,79.0,,P48546,1.12941,HA173N,GIPR
26,26043830,gipr_human,173,H,N,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,6.4,1.065,,,[125I]GIP-(Tyr1Phe) (radioligand),48.2,0.0,,0.0,,P48546,1.12941,HA173N,GIPR
13,26043830,gipr_human,245,L,S,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,1.23,2.51,,,GIP,0.0,0.0,,100.0,,P48546,1.38893,LA245S,GIPR
42,26043830,gipr_human,245,L,S,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,0.85,-7.092,,,[125I]GIP-(Tyr1Phe) (radioligand),105.9,0.0,,0.0,,P48546,1.38893,LA245S,GIPR
14,20061446,gipr_human,220,Q,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,9.2,4.694,,,[125I]-GIP (radioligand),110.0,0.0,,0.0,,P48546,-0.233152,QA220A,GIPR
15,26043830,gipr_human,320,I,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,4.12,-1.458,,,[125I]GIP-(Tyr1Phe) (radioligand),176.9,0.0,,0.0,,P48546,1.29342,IA320A,GIPR
17,26043830,gipr_human,320,I,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,0.95,1.939,,,GIP,0.0,0.0,,100.0,,P48546,1.29342,IA320A,GIPR
16,26043830,gipr_human,317,I,S,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,3.25,6.633,,,GIP,0.0,0.0,,100.0,,P48546,3.06686,IA317S,GIPR
23,26043830,gipr_human,317,I,S,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,3.0,-2.004,,,[125I]GIP-(Tyr1Phe) (radioligand),55.7,0.0,,0.0,,P48546,3.06686,IA317S,GIPR
18,20061446,gipr_human,190,R,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,139.3,71.071,,,[125I]-GIP (radioligand),85.0,0.0,,0.0,,P48546,0.29651,RA190A,GIPR
20,26043830,gipr_human,354,E,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,0.1,-4.902,,,GIP,0.0,0.0,,100.0,,P48546,0.448019,EA354A,GIPR
24,26043830,gipr_human,354,E,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,6.01,nM,=,,2.23,-2.695,,,[125I]GIP-(Tyr1Phe) (radioligand),134.8,0.0,,0.0,,P48546,0.448019,EA354A,GIPR
22,20061446,gipr_human,183,R,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Binding - Radioligand competition/displacement,1.96,nM,=,,149.7,76.378,,,[125I]-GIP (radioligand),76.0,0.0,,0.0,,P48546,4.32628,RA183A,GIPR
25,20061446,gipr_human,300,R,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,82.3,41.99,,,[125I]-GIP (radioligand),75.0,0.0,,0.0,,P48546,-0.089116,RA300A,GIPR
29,26043830,gipr_human,237,E,A,GIP,PubChem CID,90488736,Full agonist,EC50,Functional - cAMP accumulation,0.49,nM,=,,4.98,10.163,,,GIP,0.0,0.0,,34.0,,P48546,-0.891501,EA237A,GIPR
35,20061446,gipr_human,353,H,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,2.5,1.276,,,[125I]-GIP (radioligand),97.0,0.0,,0.0,,P48546,-0.644126,HA353A,GIPR
38,20061446,gipr_human,224,Q,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,11.0,5.612,,,[125I]-GIP (radioligand),77.0,0.0,,0.0,,P48546,0.0317966,QA224A,GIPR
40,20061446,gipr_human,223,T,A,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,6.7,3.418,,,[125I]-GIP (radioligand),116.0,0.0,,0.0,,P48546,-0.199226,TA223A,GIPR
43,20061446,gipr_human,231,Y,F,GIP,PubChem CID,90488736,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,1.96,nM,=,,7.9,4.031,,,[125I]-GIP (radioligand),96.0,0.0,,0.0,,P48546,-0.632607,YA231F,GIPR
3,12947048,pth1r_human,240,K,A,[M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,61.0,nM,=,,360.0,5.902,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
9,12947048,pth1r_human,240,K,A,[I125][M]PTH(1–20) A-V-A-E-I-Q-L-M-H-Q-Har-A-K-W-L-N-S-M-R-R-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,220.0,4.4,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
17,12947048,pth1r_human,240,K,A,[M]PTH(1–14) A-V-A-E-I-Q-L-M-H-Q-Har-A-K-W-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20000.0,nM,=,,4500.0,-4.444,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
21,12947048,pth1r_human,240,K,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,101.0,-1.01,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
70,12947048,pth1r_human,240,K,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,59.0,1.695,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
74,12947048,pth1r_human,240,K,A,[M3]PTH(1–19) Aib-V-Aib-E-I-Q-L-M-H-Q-Har-A-K-W-L-N-S-M-R-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,16.0,nM,=,,270.0,16.875,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
76,12947048,pth1r_human,240,K,A,[I125][M]PTH(1–20) A-V-A-E-I-Q-L-M-H-Q-Har-A-K-W-L-N-S-M-E-R-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,850.0,nM,=,,5500.0,6.471,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
88,12947048,pth1r_human,240,K,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,145.0,-1.449,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.944998,KA240A,PTH1R
6,12947048,pth1r_human,237,I,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,68.0,1.471,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,2.00529,IA237A,PTH1R
51,12947048,pth1r_human,237,I,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,47.0,2.128,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,2.00529,IA237A,PTH1R
59,12947048,pth1r_human,237,I,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,2.0,50.0,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,2.00529,IA237A,PTH1R
8,12947048,pth1r_human,234,A,V,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,76.0,1.316,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,-1.78352,AA234V,PTH1R
89,12947048,pth1r_human,234,A,V,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,20.0,5.0,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,-1.78352,AA234V,PTH1R
26,12947048,pth1r_human,232,L,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,97.0,1.031,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,1.55575,LA232A,PTH1R
46,12947048,pth1r_human,232,L,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,96.0,1.042,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,1.55575,LA232A,PTH1R
106,12947048,pth1r_human,232,L,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,98.0,1.02,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,1.55575,LA232A,PTH1R
29,12947048,pth1r_human,236,S,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,89.0,1.124,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,-0.624443,SA236A,PTH1R
30,12947048,pth1r_human,236,S,A,[I125][M]PTH(1–20) A-V-A-E-I-Q-L-M-H-Q-Har-A-K-W-L-N-S-M-R-R-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,47.0,-1.064,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,-0.624443,SA236A,PTH1R
64,12947048,pth1r_human,236,S,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,109.0,-1.091,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,-0.624443,SA236A,PTH1R
71,12947048,pth1r_human,236,S,A,[I125][M]PTH(1–20) A-V-A-E-I-Q-L-M-H-Q-Har-A-K-W-L-N-S-M-E-R-NH2,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,850.0,nM,=,,920.0,1.082,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,-0.624443,SA236A,PTH1R
77,12947048,pth1r_human,236,S,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,194.0,-1.942,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,-0.624443,SA236A,PTH1R
34,12947048,pth1r_human,238,F,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,30.0,3.333,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,1.97899,FA238A,PTH1R
38,12947048,pth1r_human,238,F,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,1.0,100.0,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,1.97899,FA238A,PTH1R
66,12947048,pth1r_human,238,F,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,66.0,1.515,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,1.97899,FA238A,PTH1R
39,12947048,pth1r_human,239,V,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,87.0,1.149,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,-0.171267,VA239A,PTH1R
81,12947048,pth1r_human,239,V,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,74.0,1.351,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,-0.171267,VA239A,PTH1R
98,12947048,pth1r_human,239,V,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,89.0,1.124,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,-0.171267,VA239A,PTH1R
47,12947048,pth1r_human,233,R,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,15.0,6.667,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,0.836638,RA233A,PTH1R
72,12947048,pth1r_human,233,R,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,92.0,1.087,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,0.836638,RA233A,PTH1R
49,12947048,pth1r_human,235,V,A,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,PubChem CID,16129665,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,131.0,-1.311,,,[I125][M3]PTH(1–15) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-Y*-NH2,100.0,0.0,,0.0,,Q03431,0.22272,VA235A,PTH1R
68,12947048,pth1r_human,235,V,A,[I125]PTHrP[5-36],FASTA sequence (peptide),IQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEY,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,72.0,1.389,,,[125I]PTHrP[5-36] (radioligand),100.0,0.0,,0.0,,Q03431,0.22272,VA235A,PTH1R
84,12947048,pth1r_human,235,V,A,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,,,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand saturation,100.0,%,=,,93.0,1.075,,,[I125][M3]PTH(1–21) Aib-V-Aib-E-I-Q-L-Nle-H-Q-Har-A-K-W-L-A-S-V-R-R-Y,100.0,0.0,,0.0,,Q03431,0.22272,VA235A,PTH1R
0,15629146,ccr2_human,290,T,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,0.65,-6.757,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
46,12954060,ccr2_human,290,T,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.98,1.514,,,radioligand: [125I]-CXCL2,94.7380082,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
70,12954060,ccr2_human,290,T,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.1,1.202,,,,94.7380082,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
96,12954060,ccr2_human,290,T,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,7.67,3.09,,,radioligand: [125I]-CXCL2,94.7380082,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
131,12954060,ccr2_human,290,T,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.89,1.288,,,radioligand: [125I]-CXCL2,94.7380082,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
154,12954060,ccr2_human,290,T,A,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.28,2.399,,,radioligand: [125I]-CXCL2,94.7380082,0.0,,0.0,,P41597,0.478423,TA290A,CCR2
1,12954060,ccr2_human,288,Q,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,9.78,2.512,,,,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
52,12954060,ccr2_human,288,Q,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.64,3.311,,,radioligand: [125I]-CXCL2,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
130,12954060,ccr2_human,288,Q,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.77,1.698,,,radioligand: [125I]-CXCL2,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
158,12954060,ccr2_human,288,Q,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,8.01,1.413,,,radioligand: [125I]-CXCL2,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
169,12954060,ccr2_human,288,Q,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,6.5,-1.072,,,radioligand: [125I]-CXCL2,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
174,12954060,ccr2_human,288,Q,A,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.76,-1.259,,,radioligand: [125I]-CXCL2,137.8087958,0.0,,0.0,,P41597,0.0475315,QA288A,CCR2
2,19297521,ccr2_human,292,T,V,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,663.74,13.463,,,125I-CCL2,98.0,0.0,,0.0,,P41597,-0.82083,TA292V,CCR2
33,19297521,ccr2_human,292,T,V,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,663.74,13.463,,,125I-CCL2,98.0,0.0,,0.0,,P41597,-0.82083,TA292V,CCR2
120,19297521,ccr2_human,292,T,V,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,9.18,-1.046,,,125I-CCL2,98.0,0.0,,0.0,,P41597,-0.82083,TA292V,CCR2
160,19297521,ccr2_human,292,T,V,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,9.18,-1.046,,,125I-CCL2,98.0,0.0,,0.0,,P41597,-0.82083,TA292V,CCR2
6,15629146,ccr2_human,278,E,K,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,0.74,-5.952,,,125I-CCL2,100.0,0.0,,0.0,,P41597,1.29786,EA278K,CCR2
9,15629146,ccr2_human,286,A,V,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,2.5,-1.761,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.413154,AA286V,CCR2
13,12954060,ccr2_human,120,Y,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.25,5.623,,,radioligand: [125I]-CXCL2,52.70854104,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
14,12954060,ccr2_human,120,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,6.98,15.136,,,radioligand: [125I]-CXCL2,52.70854104,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
44,12954060,ccr2_human,120,Y,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,9.99,1.549,,,,52.70854104,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
60,12954060,ccr2_human,120,Y,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,5.74,5.37,,,radioligand: [125I]-CXCL2,52.70854104,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
118,15629146,ccr2_human,120,Y,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,6.7,1.523,,,125I-CCL2,100.0,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
119,12954060,ccr2_human,120,Y,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,5.59,37.154,,,radioligand: [125I]-CXCL2,52.70854104,0.0,,0.0,,P41597,1.5294,YA120A,CCR2
15,12954060,ccr2_human,292,T,A,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,5.2,28.84,,,radioligand: [125I]-CXCL2,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
47,12954060,ccr2_human,292,T,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.12,10.965,,,radioligand: [125I]-CXCL2,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
56,12954060,ccr2_human,292,T,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.14,7.244,,,radioligand: [125I]-CXCL2,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
100,12954060,ccr2_human,292,T,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.09,1.23,,,,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
105,12954060,ccr2_human,292,T,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,7.54,4.169,,,radioligand: [125I]-CXCL2,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
106,12954060,ccr2_human,292,T,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,5.11,22.909,,,radioligand: [125I]-CXCL2,114.8665116,0.0,,0.0,,P41597,0.050353,TA292A,CCR2
18,15629146,ccr2_human,49,Y,F,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,48.0,10.909,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
68,12954060,ccr2_human,49,Y,F,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.01,1.479,,,,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
75,12954060,ccr2_human,49,Y,F,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,6.5,-1.072,,,radioligand: [125I]-CXCL2,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
93,12954060,ccr2_human,49,Y,F,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,7.78,-6.024,,,radioligand: [125I]-CXCL2,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
129,12954060,ccr2_human,49,Y,F,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,7.23,-3.717,,,radioligand: [125I]-CXCL2,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
153,12954060,ccr2_human,49,Y,F,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.82,2.188,,,radioligand: [125I]-CXCL2,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
161,12954060,ccr2_human,49,Y,F,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,7.56,3.981,,,radioligand: [125I]-CXCL2,76.9801706,0.0,,0.0,,P41597,0.371553,YA49F,CCR2
21,12954060,ccr2_human,284,D,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.03,1.413,,,,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
83,12954060,ccr2_human,284,D,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,7.9,1.82,,,radioligand: [125I]-CXCL2,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
97,12954060,ccr2_human,284,D,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.23,8.511,,,radioligand: [125I]-CXCL2,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
101,12954060,ccr2_human,284,D,A,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.07,3.89,,,radioligand: [125I]-CXCL2,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
138,12954060,ccr2_human,284,D,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,6.1,2.344,,,radioligand: [125I]-CXCL2,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
159,12954060,ccr2_human,284,D,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.64,2.291,,,radioligand: [125I]-CXCL2,79.89365238,0.0,,0.0,,P41597,-0.674551,DA284A,CCR2
27,19297521,ccr2_human,263,I,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,12.85,-3.831,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
31,19297521,ccr2_human,263,I,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,405.51,nM,=,,787.05,1.941,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
58,19297521,ccr2_human,263,I,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,3.18,-3.021,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
62,19297521,ccr2_human,263,I,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,12.85,-3.831,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
98,19297521,ccr2_human,263,I,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,3.18,-3.021,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
166,19297521,ccr2_human,263,I,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,405.51,nM,=,,787.05,1.941,,,125I-CCL2,60.0,0.0,,0.0,,P41597,2.06129,IA263A,CCR2
37,19297521,ccr2_human,121,H,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,19.9,-2.475,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
38,12954060,ccr2_human,121,H,A,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,5.6,11.482,,,radioligand: [125I]-CXCL2,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
77,12954060,ccr2_human,121,H,A,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.22,-1.096,,,,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
80,12954060,ccr2_human,121,H,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,7.75,2.57,,,radioligand: [125I]-CXCL2,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
87,19297521,ccr2_human,121,H,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,49.3,nM,=,,19.9,-2.475,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
117,12954060,ccr2_human,121,H,A,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,6.52,4.365,,,radioligand: [125I]-CXCL2,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
125,19297521,ccr2_human,121,H,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,405.51,nM,=,,1127.2,2.78,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
139,12954060,ccr2_human,121,H,A,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,5.6,25.119,,,radioligand: [125I]-CXCL2,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
140,19297521,ccr2_human,121,H,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,405.51,nM,=,,1127.2,2.78,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
141,19297521,ccr2_human,121,H,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,4.18,-2.299,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
164,19297521,ccr2_human,121,H,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,IC50,Binding - Radioligand competition/displacement,9.6,nM,=,,4.18,-2.299,,,125I-CCL2,85.0,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
168,12954060,ccr2_human,121,H,A,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,5.59,7.586,,,radioligand: [125I]-CXCL2,110.6015287,0.0,,0.0,,P41597,1.16779,HA121A,CCR2
50,12954060,ccr2_human,291,E,Q,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,6.83,21.38,,,radioligand: [125I]-CXCL2,104.0212695,0.0,,0.0,,P41597,0.960658,EA291Q,CCR2
144,12954060,ccr2_human,291,E,Q,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,5.69,29.512,,,radioligand: [125I]-CXCL2,104.0212695,0.0,,0.0,,P41597,0.960658,EA291Q,CCR2
151,12954060,ccr2_human,291,E,Q,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,9.02,14.454,,,,104.0212695,0.0,,0.0,,P41597,0.960658,EA291Q,CCR2
59,12954060,ccr2_human,121,H,F,RS-504393,SMILES,CC1=CC=C(NC(OC23CCN(CCC4=C(C)OC(C5=CC=CC=C5)=N4)CC3)=O)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.66,,=,,6.35,2.042,,,radioligand: [125I]-CXCL2,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
73,12954060,ccr2_human,121,H,F,SB-282241,SMILES,OC1=CC=C(NC=C2C3CCN(CCCCCNC(/C=C/C4=CC(Cl)=C(Cl)C=C4)=O)CC3)C2=C1,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.0,,=,,6.78,1.66,,,radioligand: [125I]-CXCL2,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
76,12954060,ccr2_human,121,H,F,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,8.16,,=,,8.58,-2.632,,,radioligand: [125I]-CXCL2,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
89,12954060,ccr2_human,121,H,F,[125I]-CCL2,UniProt Entry Code (peptide),P13500,Full agonist,pK(d),Binding - Radioligand saturation,10.18,,=,,10.47,-1.949,,,,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
94,12954060,ccr2_human,121,H,F,Teijin,SMILES,O=C(NCC(N[C@@H]1CCN(CC2=CC=C(C)C=C2C)C1)=O)C3=CC=CC(C(F)(F)F)=C3,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,6.47,,=,,6.18,1.95,,,radioligand: [125I]-CXCL2,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
112,12954060,ccr2_human,121,H,F,TAK-779 BASE,ChEMBL Compound ID,CHEMBL131243,Antagonist (neutral/silent),pK(i),Binding - Radioligand competition/displacement,7.16,,=,,7.62,-2.882,,,radioligand: [125I]-CXCL2,56.41963,0.0,,0.0,,P41597,-1.62223,HA121F,CCR2
66,15629146,ccr2_human,278,E,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,2.8,-1.572,,,125I-CCL2,100.0,0.0,,0.0,,P41597,1.25525,EA278A,CCR2
85,15629146,ccr2_human,297,H,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,1.3,-3.39,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.289836,HA297A,CCR2
109,15629146,ccr2_human,117,T,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,18.0,4.091,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.352966,TA117A,CCR2
113,15629146,ccr2_human,95,L,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,17.1,3.886,,,125I-CCL2,100.0,0.0,,0.0,,P41597,3.52961,LA95A,CCR2
137,15629146,ccr2_human,291,E,A,CCL2_HUMAN,UniProt Entry Code (peptide),P13500,Full agonist,Kd,Binding - Radioligand competition/displacement,4.4,nM,=,,5.4,1.227,,,125I-CCL2,100.0,0.0,,0.0,,P41597,0.0711561,EA291A,CCR2
0,10.1038/nature12393,glr_human,239,Y,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.6,1.03,,,[125I]-glucagon (radioligand),50.3,0.0,,0.0,,P47871,1.55952,YA239A,GCGR
332,23863937,glr_human,239,Y,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.6,1.03,,,[125I]-glucagon (radioligand),50.3,0.0,,0.0,,P47871,1.55952,YA239A,GCGR
366,10085108,glr_human,239,Y,A,"L168,049",PubChem CID,5311276,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.3,nM,=,,4.5,3.462,,,[125I]-glucagon (radioligand),0.0,0.0,,0.0,,P47871,1.55952,YA239A,GCGR
3,23863937,glr_human,349,K,A,Mk-0893,PubChem CID,11570626,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.21,M,=,,8.7,3.236,,,[125I]-Mk-0893 (radioligand),100.0,0.0,,0.0,,P47871,0.203647,KA349A,GCGR
4,23863937,glr_human,349,K,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.9,M,=,,8.86,1.096,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,0.203647,KA349A,GCGR
337,23863937,glr_human,349,K,A,Mk-0893,PubChem CID,11570626,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - cAMP accumulation,7.3,M,=,,6.5,6.31,,,glucagon,100.0,0.0,,0.0,,P47871,0.203647,KA349A,GCGR
7,10.1038/nature12393,glr_human,154,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.6,1.03,,,[125I]-glucagon (radioligand),55.2,0.0,,0.0,,P47871,-0.797,GA154S,GCGR
21,23863937,glr_human,154,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.6,1.03,,,[125I]-glucagon (radioligand),55.2,0.0,,0.0,,P47871,-0.797,GA154S,GCGR
13,23863937,glr_human,198,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,56.4,2.82,,,[125I]-glucagon (radioligand),175.9,0.0,,0.0,,P47871,1.58536,LA198V,GCGR
333,10.1038/nature12393,glr_human,198,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,56.4,2.82,,,[125I]-glucagon (radioligand),175.9,0.0,,0.0,,P47871,1.58536,LA198V,GCGR
15,10.1038/nature12393,glr_human,304,W,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,280.7,14.035,,,[125I]-glucagon (radioligand),125.1,0.0,,0.0,,P47871,-0.0995697,WA304A,GCGR
188,23863937,glr_human,304,W,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,280.7,14.035,,,[125I]-glucagon (radioligand),125.1,0.0,,0.0,,P47871,-0.0995697,WA304A,GCGR
16,23863937,glr_human,297,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,22.8,1.14,,,[125I]-glucagon (radioligand),66.9,0.0,,0.0,,P47871,-0.571865,SA297A,GCGR
257,10.1038/nature12393,glr_human,297,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,22.8,1.14,,,[125I]-glucagon (radioligand),66.9,0.0,,0.0,,P47871,-0.571865,SA297A,GCGR
17,12029097,glr_human,374,Q,R,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,12.0,1.091,,,,100.0,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
36,10.1038/nature12393,glr_human,374,Q,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,13.7,-1.46,,,[125I]-glucagon (radioligand),62.9,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
48,12029097,glr_human,374,Q,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.4,-1.499,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
217,23863937,glr_human,374,Q,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,13.7,-1.46,,,[125I]-glucagon (radioligand),62.9,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
265,12029097,glr_human,374,Q,R,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,230.0,1.438,,,,100.0,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
396,12029097,glr_human,374,Q,R,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,36.0,1.2,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,0.321761,QA374R,GCGR
19,23863937,glr_human,140,S,F,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,28.6,1.43,,,[125I]-glucagon (radioligand),77.8,0.0,,0.0,,P47871,-1.27395,SA140F,GCGR
277,10.1038/nature12393,glr_human,140,S,F,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,28.6,1.43,,,[125I]-glucagon (radioligand),77.8,0.0,,0.0,,P47871,-1.27395,SA140F,GCGR
20,21704096,glr_human,212,V,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.4,10.0,,,,100.0,0.0,,0.0,,P47871,1.24355,VA212C,GCGR
23,10.1038/nature12393,glr_human,389,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,30.0,1.5,,,[125I]-glucagon (radioligand),49.4,0.0,,0.0,,P47871,-0.0439801,SA389A,GCGR
164,23863937,glr_human,389,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,30.0,1.5,,,[125I]-glucagon (radioligand),49.4,0.0,,0.0,,P47871,-0.0439801,SA389A,GCGR
25,10.1038/nature12393,glr_human,184,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,19.1,-1.047,,,[125I]-glucagon (radioligand),33.9,0.0,,0.0,,P47871,4.26065,FA184A,GCGR
63,10085108,glr_human,184,F,A,"L168,049",PubChem CID,5311276,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.3,nM,=,,46.0,35.385,,,[125I]-glucagon (radioligand),0.0,0.0,,0.0,,P47871,4.26065,FA184A,GCGR
252,23863937,glr_human,184,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,19.1,-1.047,,,[125I]-glucagon (radioligand),33.9,0.0,,0.0,,P47871,4.26065,FA184A,GCGR
27,23863937,glr_human,131,Q,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,29.8,1.49,,,[125I]-glucagon (radioligand),82.5,0.0,,0.0,,P47871,0.376907,QA131R,GCGR
411,10.1038/nature12393,glr_human,131,Q,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,29.8,1.49,,,[125I]-glucagon (radioligand),82.5,0.0,,0.0,,P47871,0.376907,QA131R,GCGR
29,23863937,glr_human,231,M,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,19.3,-1.036,,,[125I]-glucagon (radioligand),48.8,0.0,,0.0,,P47871,1.87445,MA231A,GCGR
338,10.1038/nature12393,glr_human,231,M,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,19.3,-1.036,,,[125I]-glucagon (radioligand),48.8,0.0,,0.0,,P47871,1.87445,MA231A,GCGR
30,10.1038/nature12393,glr_human,389,S,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,32.1,1.605,,,[125I]-glucagon (radioligand),86.9,0.0,,0.0,,P47871,-0.338313,SA389T,GCGR
162,23863937,glr_human,389,S,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,32.1,1.605,,,[125I]-glucagon (radioligand),86.9,0.0,,0.0,,P47871,-0.338313,SA389T,GCGR
31,23863937,glr_human,350,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.9,M,=,,8.86,1.096,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.323404,SA350A,GCGR
281,23863937,glr_human,350,S,A,Mk-0893,PubChem CID,11570626,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.21,M,=,,9.18,1.072,,,[125I]-Mk-0893 (radioligand),100.0,0.0,,0.0,,P47871,-0.323404,SA350A,GCGR
34,10.1038/nature12393,glr_human,308,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,88.1,4.405,,,[125I]-glucagon (radioligand),35.6,0.0,,0.0,,P47871,-0.938924,RA308A,GCGR
210,23863937,glr_human,308,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,88.1,4.405,,,[125I]-glucagon (radioligand),35.6,0.0,,0.0,,P47871,-0.938924,RA308A,GCGR
35,23863937,glr_human,349,K,M,Mk-0893,PubChem CID,11570626,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.21,M,=,,8.91,1.995,,,[125I]-Mk-0893 (radioligand),100.0,0.0,,0.0,,P47871,-0.863556,KA349M,GCGR
230,23863937,glr_human,349,K,M,Mk-0893,PubChem CID,11570626,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - cAMP accumulation,7.3,M,=,,6.3,10.0,,,glucagon,100.0,0.0,,0.0,,P47871,-0.863556,KA349M,GCGR
331,23863937,glr_human,349,K,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.9,M,=,,8.86,1.096,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.863556,KA349M,GCGR
37,10.1038/nature12393,glr_human,228,A,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,56.8,2.84,,,[125I]-glucagon (radioligand),119.6,0.0,,0.0,,P47871,1.89664,AA228V,GCGR
103,23863937,glr_human,228,A,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,56.8,2.84,,,[125I]-glucagon (radioligand),119.6,0.0,,0.0,,P47871,1.89664,AA228V,GCGR
39,21704096,glr_human,209,D,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.6,6.31,,,,100.0,0.0,,0.0,,P47871,1.44072,DA209C,GCGR
40,23863937,glr_human,387,F,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,46.8,2.34,,,[125I]-glucagon (radioligand),60.5,0.0,,0.0,,P47871,2.51262,FA387S,GCGR
328,10.1038/nature12393,glr_human,387,F,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,46.8,2.34,,,[125I]-glucagon (radioligand),60.5,0.0,,0.0,,P47871,2.51262,FA387S,GCGR
41,23863937,glr_human,217,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,18.7,-1.07,,,[125I]-glucagon (radioligand),115.6,0.0,,0.0,,P47871,-0.225868,SA217A,GCGR
374,10.1038/nature12393,glr_human,217,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,18.7,-1.07,,,[125I]-glucagon (radioligand),115.6,0.0,,0.0,,P47871,-0.225868,SA217A,GCGR
42,10.1038/nature12393,glr_human,240,C,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,23.0,1.15,,,[125I]-glucagon (radioligand),102.7,0.0,,0.0,,P47871,-0.303964,CA240Y,GCGR
105,23863937,glr_human,240,C,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,23.0,1.15,,,[125I]-glucagon (radioligand),102.7,0.0,,0.0,,P47871,-0.303964,CA240Y,GCGR
43,10.1038/nature12393,glr_human,362,E,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,133.0,6.65,,,[125I]-glucagon (radioligand),67.0,0.0,,0.0,,P47871,-0.54289,EA362A,GCGR
370,23863937,glr_human,362,E,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,133.0,6.65,,,[125I]-glucagon (radioligand),67.0,0.0,,0.0,,P47871,-0.54289,EA362A,GCGR
44,23863937,glr_human,306,I,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,82.3,4.115,,,[125I]-glucagon (radioligand),49.2,0.0,,0.0,,P47871,1.22532,IA306A,GCGR
50,10.1038/nature12393,glr_human,306,I,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,82.3,4.115,,,[125I]-glucagon (radioligand),49.2,0.0,,0.0,,P47871,1.22532,IA306A,GCGR
46,20647307,glr_human,71,T,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.5,M,=,,7.0,31.623,,,,100.0,0.0,,0.0,,P47871,1.23734,TA71C,GCGR
49,10.1038/nature12393,glr_human,278,F,C,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.2,-1.235,,,[125I]-glucagon (radioligand),82.4,0.0,,0.0,,P47871,2.42801,FA278C,GCGR
98,23863937,glr_human,278,F,C,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.2,-1.235,,,[125I]-glucagon (radioligand),82.4,0.0,,0.0,,P47871,2.42801,FA278C,GCGR
51,10.1038/nature12393,glr_human,201,R,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,50.0,2.5,,,[125I]-glucagon (radioligand),75.7,0.0,,0.0,,P47871,0.922244,RA201M,GCGR
287,23863937,glr_human,201,R,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,50.0,2.5,,,[125I]-glucagon (radioligand),75.7,0.0,,0.0,,P47871,0.922244,RA201M,GCGR
52,21704096,glr_human,217,S,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.9,31.623,,,,100.0,0.0,,0.0,,P47871,-0.16755,SA217C,GCGR
57,21704096,glr_human,203,S,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.7,5.012,,,,100.0,0.0,,0.0,,P47871,-0.314554,SA203C,GCGR
61,23863937,glr_human,304,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,93.0,4.65,,,[125I]-glucagon (radioligand),136.3,0.0,,0.0,,P47871,-0.610932,WA304L,GCGR
189,10.1038/nature12393,glr_human,304,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,93.0,4.65,,,[125I]-glucagon (radioligand),136.3,0.0,,0.0,,P47871,-0.610932,WA304L,GCGR
65,23863937,glr_human,194,I,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.3,-1.227,,,[125I]-glucagon (radioligand),34.3,0.0,,0.0,,P47871,3.11,IA194A,GCGR
271,10.1038/nature12393,glr_human,194,I,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.3,-1.227,,,[125I]-glucagon (radioligand),34.3,0.0,,0.0,,P47871,3.11,IA194A,GCGR
67,10.1038/nature12393,glr_human,145,Y,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,215.4,10.77,,,[125I]-glucagon (radioligand),114.4,0.0,,0.0,,P47871,2.94977,YA145N,GCGR
140,23863937,glr_human,145,Y,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,215.4,10.77,,,[125I]-glucagon (radioligand),114.4,0.0,,0.0,,P47871,2.94977,YA145N,GCGR
68,22908259,glr_human,113,Q,E,glucagon,PubChem CID,44278361,Full agonist,EC50,Functional - cAMP accumulation,0.0,,=,,0.0,4.0,,,,0.0,0.0,,0.0,,P47871,-0.758132,QA113E,GCGR
70,27059958,glr_human,379,S,F,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,29.0,1.45,,,[125I]-glucagon (radioligand),121.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
96,12029097,glr_human,379,S,F,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,35.0,1.167,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
183,12029097,glr_human,379,S,F,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,2.1,1.0,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
196,12029097,glr_human,379,S,F,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,210.0,1.312,,,,100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
308,12029097,glr_human,379,S,F,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,19.0,1.727,,,,100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
336,12029097,glr_human,379,S,F,glucagon-(Gln9Glu),FASTA sequence (peptide),HSEGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,640.0,nM,=,,130.0,-4.926,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
373,12029097,glr_human,379,S,F,glucagon-(Lys19Ser),FASTA sequence (peptide),HSQGTFTSDYSSYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,150.0,nM,=,,140.0,-1.072,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
412,12029097,glr_human,379,S,F,glucagon-(Lys19Ser),FASTA sequence (peptide),HSQGTFTSDYSSYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,310.0,pM,=,,570.0,1.839,,,,100.0,0.0,,0.0,,P47871,-1.67302,SA379F,GCGR
75,23863937,glr_human,235,I,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,21.6,1.08,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.6441,IA235V,GCGR
294,10.1038/nature12393,glr_human,235,I,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,21.6,1.08,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.6441,IA235V,GCGR
76,10.1038/nature12393,glr_human,30,D,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,17.0,-1.176,,,[125I]-glucagon (radioligand),71.9,0.0,,0.0,,P47871,-1.97502,DA30L,GCGR
408,23863937,glr_human,30,D,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,17.0,-1.176,,,[125I]-glucagon (radioligand),71.9,0.0,,0.0,,P47871,-1.97502,DA30L,GCGR
79,23863937,glr_human,187,K,R,glucagon,PubChem CID,44278361,Full agonist,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,21.3,1.065,,,[125I]-glucagon (radioligand),81.9,0.0,,0.0,,P47871,0.778853,KA187R,GCGR
134,10.1038/nature12393,glr_human,187,K,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,21.3,1.065,,,[125I]-glucagon (radioligand),81.9,0.0,,0.0,,P47871,0.778853,KA187R,GCGR
85,10.1038/nature12393,glr_human,200,T,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,10.3,-1.942,,,[125I]-glucagon (radioligand),160.5,0.0,,0.0,,P47871,-0.374867,TA200W,GCGR
141,23863937,glr_human,200,T,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,10.3,-1.942,,,[125I]-glucagon (radioligand),160.5,0.0,,0.0,,P47871,-0.374867,TA200W,GCGR
86,10.1038/nature12393,glr_human,205,K,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,15.1,-1.325,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.243695,KA205A,GCGR
278,23863937,glr_human,205,K,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,15.1,-1.325,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.243695,KA205A,GCGR
87,23863937,glr_human,361,H,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,43.7,2.185,,,[125I]-glucagon (radioligand),33.8,0.0,,0.0,,P47871,-0.228873,HA361A,GCGR
406,10.1038/nature12393,glr_human,361,H,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,43.7,2.185,,,[125I]-glucagon (radioligand),33.8,0.0,,0.0,,P47871,-0.228873,HA361A,GCGR
88,23863937,glr_human,378,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,129.5,6.475,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.633435,RA378A,GCGR
381,10.1038/nature12393,glr_human,378,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,129.5,6.475,,,[125I]-glucagon (radioligand),108.0,0.0,,0.0,,P47871,0.633435,RA378A,GCGR
91,10.1038/nature12393,glr_human,295,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,28.1,1.405,,,[125I]-glucagon (radioligand),39.0,0.0,,0.0,,P47871,0.626439,WA295L,GCGR
377,23863937,glr_human,295,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,28.1,1.405,,,[125I]-glucagon (radioligand),39.0,0.0,,0.0,,P47871,0.626439,WA295L,GCGR
92,23863937,glr_human,204,Q,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.9,-1.183,,,[125I]-glucagon (radioligand),77.3,0.0,,0.0,,P47871,0.261538,QA204T,GCGR
391,10.1038/nature12393,glr_human,204,Q,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.9,-1.183,,,[125I]-glucagon (radioligand),77.3,0.0,,0.0,,P47871,0.261538,QA204T,GCGR
93,23863937,glr_human,369,T,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,11.2,-1.786,,,[125I]-glucagon (radioligand),34.8,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
212,12029097,glr_human,369,T,M,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,24.0,-1.25,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
329,12029097,glr_human,369,T,M,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,69.0,-2.32,,,,100.0,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
355,12029097,glr_human,369,T,M,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,8.2,-1.342,,,,100.0,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
401,10.1038/nature12393,glr_human,369,T,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,11.2,-1.786,,,[125I]-glucagon (radioligand),34.8,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
407,12029097,glr_human,369,T,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.4,-1.499,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-1.88245,TA369M,GCGR
95,10.1038/nature12393,glr_human,208,D,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,100.8,5.04,,,[125I]-glucagon (radioligand),150.9,0.0,,0.0,,P47871,3.39362,DA208R,GCGR
165,23863937,glr_human,208,D,R,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,100.8,5.04,,,[125I]-glucagon (radioligand),150.9,0.0,,0.0,,P47871,3.39362,DA208R,GCGR
102,23863937,glr_human,303,F,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,25.3,1.265,,,[125I]-glucagon (radioligand),68.3,0.0,,0.0,,P47871,0.532602,FA303Y,GCGR
353,10.1038/nature12393,glr_human,303,F,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,25.3,1.265,,,[125I]-glucagon (radioligand),68.3,0.0,,0.0,,P47871,0.532602,FA303Y,GCGR
106,21704096,glr_human,211,S,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.6,6.31,,,,100.0,0.0,,0.0,,P47871,1.01845,SA211C,GCGR
107,10.1038/nature12393,glr_human,302,G,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,33.8,1.69,,,[125I]-glucagon (radioligand),74.7,0.0,,0.0,,P47871,-0.602674,GA302N,GCGR
335,23863937,glr_human,302,G,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,33.8,1.69,,,[125I]-glucagon (radioligand),74.7,0.0,,0.0,,P47871,-0.602674,GA302N,GCGR
108,12029097,glr_human,360,V,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.9,-1.105,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,2.10249,VA360T,GCGR
116,12029097,glr_human,360,V,T,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,11.0,1.0,,,,100.0,0.0,,0.0,,P47871,2.10249,VA360T,GCGR
253,12029097,glr_human,360,V,T,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,240.0,1.5,,,,100.0,0.0,,0.0,,P47871,2.10249,VA360T,GCGR
405,12029097,glr_human,360,V,T,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,69.0,2.3,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,2.10249,VA360T,GCGR
110,12029097,glr_human,384,F,T,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,90.0,8.182,,,,100.0,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
154,12029097,glr_human,384,F,T,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,14.0,-2.141,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
203,12029097,glr_human,384,F,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.3,-1.616,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
213,10.1038/nature12393,glr_human,384,F,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,71.6,3.58,,,[125I]-glucagon (radioligand),54.2,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
225,23863937,glr_human,384,F,T,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,71.6,3.58,,,[125I]-glucagon (radioligand),54.2,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
233,12029097,glr_human,384,F,T,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,600.0,3.75,,,,100.0,0.0,,0.0,,P47871,0.730022,FA384T,GCGR
112,23863937,glr_human,305,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,35.7,1.785,,,[125I]-glucagon (radioligand),68.1,0.0,,0.0,,P47871,0.126081,WA305L,GCGR
251,10.1038/nature12393,glr_human,305,W,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,35.7,1.785,,,[125I]-glucagon (radioligand),68.1,0.0,,0.0,,P47871,0.126081,WA305L,GCGR
113,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,10.3,nM,=,,32.0,3.107,,,[125I]-glucagon (radioligand),160.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
142,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,0.2,nM,=,,0.8,-3.984,,,,100.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
190,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,10.3,nM,=,,39.0,3.786,,,[125I]-glucagon (radioligand),160.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
209,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,2.0,pM,=,,5.0,-1000.0,,,,160.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
223,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.9,nM,=,,88.7,6.876,,,[125I]-glucagon (radioligand),160.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
339,8635644,glr_human,40,G,S,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,12.9,nM,=,,69.5,5.388,,,[125I]-glucagon (radioligand),160.0,0.0,,0.0,,P47871,-0.10417,GA40S,GCGR
114,21704096,glr_human,223,G,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.8,3.981,,,,100.0,0.0,,0.0,,P47871,-0.0509149,GA223C,GCGR
117,20647307,glr_human,61,T,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.5,M,=,,5.9,398.107,,,,0.0,0.0,,0.0,,P47871,0.244869,TA61C,GCGR
119,21704096,glr_human,206,I,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.7,50.119,,,,100.0,0.0,,0.0,,P47871,0.537564,IA206C,GCGR
120,23863937,glr_human,362,E,Q,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,213.8,10.69,,,[125I]-glucagon (radioligand),83.3,0.0,,0.0,,P47871,-1.39164,EA362Q,GCGR
167,10.1038/nature12393,glr_human,362,E,Q,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,213.8,10.69,,,[125I]-glucagon (radioligand),83.3,0.0,,0.0,,P47871,-1.39164,EA362Q,GCGR
121,10.1038/nature12393,glr_human,298,N,D,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,82.4,4.12,,,[125I]-glucagon (radioligand),105.7,0.0,,0.0,,P47871,0.299324,NA298D,GCGR
387,23863937,glr_human,298,N,D,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,82.4,4.12,,,[125I]-glucagon (radioligand),105.7,0.0,,0.0,,P47871,0.299324,NA298D,GCGR
122,23863937,glr_human,381,K,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,73.3,3.665,,,[125I]-glucagon (radioligand),165.7,0.0,,0.0,,P47871,1.19142,KA381A,GCGR
206,10.1038/nature12393,glr_human,381,K,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,73.3,3.665,,,[125I]-glucagon (radioligand),165.7,0.0,,0.0,,P47871,1.19142,KA381A,GCGR
126,23863937,glr_human,232,Q,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,148.3,7.415,,,[125I]-glucagon (radioligand),147.1,0.0,,0.0,,P47871,-0.32504,QA232A,GCGR
371,10.1038/nature12393,glr_human,232,Q,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,148.3,7.415,,,[125I]-glucagon (radioligand),147.1,0.0,,0.0,,P47871,-0.32504,QA232A,GCGR
131,23863937,glr_human,303,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,101.1,5.055,,,[125I]-glucagon (radioligand),95.2,0.0,,0.0,,P47871,2.48219,FA303A,GCGR
290,10.1038/nature12393,glr_human,303,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,101.1,5.055,,,[125I]-glucagon (radioligand),95.2,0.0,,0.0,,P47871,2.48219,FA303A,GCGR
132,20647307,glr_human,108,R,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.5,M,=,,6.5,100.0,,,,100.0,0.0,,0.0,,P47871,0.948464,RA108C,GCGR
144,10.1038/nature12393,glr_human,366,A,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.5,-1.212,,,[125I]-glucagon (radioligand),101.8,0.0,,0.0,,P47871,-2.56412,AA366M,GCGR
204,23863937,glr_human,366,A,M,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,16.5,-1.212,,,[125I]-glucagon (radioligand),101.8,0.0,,0.0,,P47871,-2.56412,AA366M,GCGR
152,23863937,glr_human,308,R,Q,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,46.5,2.325,,,[125I]-glucagon (radioligand),45.6,0.0,,0.0,,P47871,0.0673909,RA308Q,GCGR
318,10.1038/nature12393,glr_human,308,R,Q,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,46.5,2.325,,,[125I]-glucagon (radioligand),45.6,0.0,,0.0,,P47871,0.0673909,RA308Q,GCGR
155,23863937,glr_human,382,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,107.2,5.36,,,[125I]-glucagon (radioligand),108.4,0.0,,0.0,,P47871,0.683889,LA382V,GCGR
388,10.1038/nature12393,glr_human,382,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,107.2,5.36,,,[125I]-glucagon (radioligand),108.4,0.0,,0.0,,P47871,0.683889,LA382V,GCGR
159,23863937,glr_human,201,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,131.8,6.59,,,[125I]-glucagon (radioligand),39.8,0.0,,0.0,,P47871,2.61913,RA201A,GCGR
205,10.1038/nature12393,glr_human,201,R,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,131.8,6.59,,,[125I]-glucagon (radioligand),39.8,0.0,,0.0,,P47871,2.61913,RA201A,GCGR
160,27059958,glr_human,386,L,I,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,64.0,3.2,,,[125I]-glucagon (radioligand),143.0,0.0,,0.0,,P47871,1.81635,LA386I,GCGR
163,23863937,glr_human,127,E,K,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,23.9,1.195,,,[125I]-glucagon (radioligand),203.0,0.0,,0.0,,P47871,0.213083,EA127K,GCGR
362,10.1038/nature12393,glr_human,127,E,K,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,23.9,1.195,,,[125I]-glucagon (radioligand),203.0,0.0,,0.0,,P47871,0.213083,EA127K,GCGR
169,23863937,glr_human,218,D,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,30.6,1.53,,,[125I]-glucagon (radioligand),184.4,0.0,,0.0,,P47871,0.84285,DA218Y,GCGR
379,10.1038/nature12393,glr_human,218,D,Y,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,30.6,1.53,,,[125I]-glucagon (radioligand),184.4,0.0,,0.0,,P47871,0.84285,DA218Y,GCGR
173,23863937,glr_human,122,Q,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,27.6,1.38,,,[125I]-glucagon (radioligand),125.0,0.0,,0.0,,P47871,0.0464412,QA122A,GCGR
300,10.1038/nature12393,glr_human,122,Q,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,27.6,1.38,,,[125I]-glucagon (radioligand),125.0,0.0,,0.0,,P47871,0.0464412,QA122A,GCGR
176,12029097,glr_human,364,V,I,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,530.0,3.312,,,,100.0,0.0,,0.0,,P47871,-0.269945,VA364I,GCGR
187,12029097,glr_human,364,V,I,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,22.0,-1.364,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.269945,VA364I,GCGR
226,12029097,glr_human,364,V,I,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,21.0,1.909,,,,100.0,0.0,,0.0,,P47871,-0.269945,VA364I,GCGR
261,12029097,glr_human,364,V,I,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.4,-1.499,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.269945,VA364I,GCGR
177,21704096,glr_human,198,L,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.3,125.893,,,,100.0,0.0,,0.0,,P47871,1.79258,LA198C,GCGR
179,23863937,glr_human,123,M,E,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.5,1.025,,,[125I]-glucagon (radioligand),105.3,0.0,,0.0,,P47871,0.873653,MA123E,GCGR
400,10.1038/nature12393,glr_human,123,M,E,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,20.5,1.025,,,[125I]-glucagon (radioligand),105.3,0.0,,0.0,,P47871,0.873653,MA123E,GCGR
181,21704096,glr_human,218,D,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.8,39.811,,,,100.0,0.0,,0.0,,P47871,1.04768,DA218C,GCGR
184,10.1038/nature12393,glr_human,365,F,I,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,550.0,27.5,,,[125I]-glucagon (radioligand),49.5,0.0,,0.0,,P47871,1.83003,FA365I,GCGR
314,23863937,glr_human,365,F,I,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,550.0,27.5,,,[125I]-glucagon (radioligand),49.5,0.0,,0.0,,P47871,1.83003,FA365I,GCGR
185,20647307,glr_human,45,H,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.5,M,=,,6.5,100.0,,,,100.0,0.0,,0.0,,P47871,0.751207,HA45C,GCGR
194,10.1038/nature12393,glr_human,386,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,47.4,2.37,,,[125I]-glucagon (radioligand),155.7,0.0,,0.0,,P47871,1.75493,LA386V,GCGR
229,23863937,glr_human,386,L,V,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,47.4,2.37,,,[125I]-glucagon (radioligand),155.7,0.0,,0.0,,P47871,1.75493,LA386V,GCGR
197,27059958,glr_human,385,D,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,170.0,8.5,,,[125I]-glucagon (radioligand),78.0,0.0,,0.0,,P47871,-0.480294,DA385N,GCGR
199,23863937,glr_human,149,Y,H,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,128.0,6.4,,,[125I]-glucagon (radioligand),108.9,0.0,,0.0,,P47871,1.28011,YA149H,GCGR
227,10.1038/nature12393,glr_human,149,Y,H,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,128.0,6.4,,,[125I]-glucagon (radioligand),108.9,0.0,,0.0,,P47871,1.28011,YA149H,GCGR
201,27059958,glr_human,145,Y,F,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,43.0,2.15,,,[125I]-glucagon (radioligand),120.0,0.0,,0.0,,P47871,1.09393,YA145F,GCGR
211,20647307,glr_human,94,R,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.5,M,=,,5.3,1584.893,,,,100.0,0.0,,0.0,,P47871,1.88086,RA94C,GCGR
214,10.1038/nature12393,glr_human,386,L,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,182.5,9.125,,,[125I]-glucagon (radioligand),156.1,0.0,,0.0,,P47871,1.70382,LA386A,GCGR
292,23863937,glr_human,386,L,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,182.5,9.125,,,[125I]-glucagon (radioligand),156.1,0.0,,0.0,,P47871,1.70382,LA386A,GCGR
216,12029097,glr_human,380,A,I,glucagon,PubChem CID,44278361,Full agonist,EC50,Binding - Radioligand competition/displacement,11.0,pM,=,,8.6,-1.279,,,,100.0,0.0,,0.0,,P47871,-0.639539,AA380I,GCGR
220,12029097,glr_human,380,A,I,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Full agonist,EC50,Binding - Radioligand competition/displacement,160.0,pM,=,,250.0,1.562,,,,100.0,0.0,,0.0,,P47871,-0.639539,AA380I,GCGR
296,12029097,glr_human,380,A,I,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.1,nM,=,,1.4,-1.499,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.639539,AA380I,GCGR
399,12029097,glr_human,380,A,I,glucagon-(Ser8Ala),FASTA sequence (peptide),HAQGTFTSDYSKYLDSRRAQDFVQWLMNT,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,30.0,nM,=,,38.0,1.267,,,[125I]-glucagon (radioligand),100.0,0.0,,0.0,,P47871,-0.639539,AA380I,GCGR
219,10.1038/nature12393,glr_human,189,S,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.7,-1.361,,,[125I]-glucagon (radioligand),99.9,0.0,,0.0,,P47871,-1.81404,SA189L,GCGR
386,23863937,glr_human,189,S,L,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.7,-1.361,,,[125I]-glucagon (radioligand),99.9,0.0,,0.0,,P47871,-1.81404,SA189L,GCGR
221,10.1038/nature12393,glr_human,31,F,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,13.2,-1.515,,,[125I]-glucagon (radioligand),147.9,0.0,,0.0,,P47871,0.0160112,FA31W,GCGR
345,23863937,glr_human,31,F,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,13.2,-1.515,,,[125I]-glucagon (radioligand),147.9,0.0,,0.0,,P47871,0.0160112,FA31W,GCGR
224,23863937,glr_human,122,Q,E,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.9,-1.342,,,[125I]-glucagon (radioligand),56.7,0.0,,0.0,,P47871,-0.285906,QA122E,GCGR
376,10.1038/nature12393,glr_human,122,Q,E,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.9,-1.342,,,[125I]-glucagon (radioligand),56.7,0.0,,0.0,,P47871,-0.285906,QA122E,GCGR
232,10.1038/nature12393,glr_human,305,W,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,73.1,3.655,,,[125I]-glucagon (radioligand),45.1,0.0,,0.0,,P47871,0.817649,WA305A,GCGR
275,23863937,glr_human,305,W,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,73.1,3.655,,,[125I]-glucagon (radioligand),45.1,0.0,,0.0,,P47871,0.817649,WA305A,GCGR
260,21704096,glr_human,222,A,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,8.2,1.585,,,,100.0,0.0,,0.0,,P47871,0.750152,AA222C,GCGR
267,10.1038/nature12393,glr_human,195,D,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,111.1,5.555,,,[125I]-glucagon (radioligand),50.5,0.0,,0.0,,P47871,0.29349,DA195N,GCGR
324,23863937,glr_human,195,D,N,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,111.1,5.555,,,[125I]-glucagon (radioligand),50.5,0.0,,0.0,,P47871,0.29349,DA195N,GCGR
270,10.1038/nature12393,glr_human,195,D,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,170.9,8.545,,,[125I]-glucagon (radioligand),54.1,0.0,,0.0,,P47871,1.23509,DA195A,GCGR
403,23863937,glr_human,195,D,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,170.9,8.545,,,[125I]-glucagon (radioligand),54.1,0.0,,0.0,,P47871,1.23509,DA195A,GCGR
283,21704096,glr_human,200,T,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.4,10.0,,,,100.0,0.0,,0.0,,P47871,0.566983,TA200C,GCGR
288,10.1038/nature12393,glr_human,133,E,P,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,59.1,2.955,,,[125I]-glucagon (radioligand),186.1,0.0,,0.0,,P47871,2.11274,EA133P,GCGR
334,23863937,glr_human,133,E,P,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,59.1,2.955,,,[125I]-glucagon (radioligand),186.1,0.0,,0.0,,P47871,2.11274,EA133P,GCGR
297,23863937,glr_human,383,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,6.3,-3.175,,,[125I]-glucagon (radioligand),52.7,0.0,,0.0,,P47871,1.66509,FA383A,GCGR
359,10.1038/nature12393,glr_human,383,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,6.3,-3.175,,,[125I]-glucagon (radioligand),52.7,0.0,,0.0,,P47871,1.66509,FA383A,GCGR
298,21704096,glr_human,210,L,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,8.6,-1.585,,,,100.0,0.0,,0.0,,P47871,0.605388,LA210C,GCGR
301,10.1038/nature12393,glr_human,150,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.5,-1.379,,,[125I]-glucagon (radioligand),57.9,0.0,,0.0,,P47871,-0.0960383,SA150A,GCGR
343,23863937,glr_human,150,S,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,14.5,-1.379,,,[125I]-glucagon (radioligand),57.9,0.0,,0.0,,P47871,-0.0960383,SA150A,GCGR
304,10.1038/nature12393,glr_human,212,V,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,8.5,-2.353,,,[125I]-glucagon (radioligand),52.3,0.0,,0.0,,P47871,1.15275,VA212W,GCGR
398,23863937,glr_human,212,V,W,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,8.5,-2.353,,,[125I]-glucagon (radioligand),52.3,0.0,,0.0,,P47871,1.15275,VA212W,GCGR
316,21704096,glr_human,201,R,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.5,79.433,,,,100.0,0.0,,0.0,,P47871,3.28214,RA201C,GCGR
320,21704096,glr_human,214,T,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,7.6,6.31,,,,100.0,0.0,,0.0,,P47871,0.346902,TA214C,GCGR
321,21704096,glr_human,207,G,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,8.2,1.585,,,,100.0,0.0,,0.0,,P47871,2.41516,GA207C,GCGR
323,10.1038/nature12393,glr_human,191,V,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,107.1,5.355,,,[125I]-glucagon (radioligand),124.9,0.0,,0.0,,P47871,1.43905,VA191A,GCGR
364,23863937,glr_human,191,V,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,107.1,5.355,,,[125I]-glucagon (radioligand),124.9,0.0,,0.0,,P47871,1.43905,VA191A,GCGR
327,23863937,glr_human,291,N,D,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,40.3,2.015,,,[125I]-glucagon (radioligand),63.0,0.0,,0.0,,P47871,0.0594274,NA291D,GCGR
390,10.1038/nature12393,glr_human,291,N,D,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,40.3,2.015,,,[125I]-glucagon (radioligand),63.0,0.0,,0.0,,P47871,0.0594274,NA291D,GCGR
342,21704096,glr_human,202,Y,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,5.9,316.228,,,,100.0,0.0,,0.0,,P47871,0.752898,YA202C,GCGR
358,23863937,glr_human,365,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,67.7,3.385,,,[125I]-glucagon (radioligand),80.1,0.0,,0.0,,P47871,2.70772,FA365A,GCGR
414,10.1038/nature12393,glr_human,365,F,A,glucagon,PubChem CID,44278361,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,67.7,3.385,,,[125I]-glucagon (radioligand),80.1,0.0,,0.0,,P47871,2.70772,FA365A,GCGR
367,21704096,glr_human,213,S,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.7,50.119,,,,100.0,0.0,,0.0,,P47871,0.108938,SA213C,GCGR
369,21704096,glr_human,216,L,C,glucagon,PubChem CID,44278361,Full agonist,pEC50,Functional - cAMP accumulation,8.4,M,=,,6.5,79.433,,,,100.0,0.0,,0.0,,P47871,2.26398,LA216C,GCGR
0,29343833,drd3_human,189,V,I,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,9.8,1.508,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
6,29343833,drd3_human,189,V,I,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,8.2,2.412,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
47,29343833,drd3_human,189,V,I,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,6.5,1.912,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
49,29343833,drd3_human,189,V,I,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,10.7,4.28,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
108,29343833,drd3_human,189,V,I,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.8,1.6,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
197,29343833,drd3_human,189,V,I,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,14.2,2.185,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
229,29343833,drd3_human,189,V,I,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,1.2,2.4,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
256,29343833,drd3_human,189,V,I,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,6.3,2.52,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,0.312248,VA189I,DRD3
5,10349875,drd3_human,193,S,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,16.6,nM,=,,15.1,-1.099,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.445096,SA193A,DRD3
111,10349875,drd3_human,193,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,36.1,nM,=,,74.9,2.075,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.445096,SA193A,DRD3
171,10349875,drd3_human,193,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,69.8,nM,=,,73.6,1.054,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.445096,SA193A,DRD3
217,10349875,drd3_human,193,S,A,[3H]spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.18,nM,=,,0.065,-2.77,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.445096,SA193A,DRD3
8,9651882,drd3_human,102,C,H,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.9,-3.984,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
22,9651882,drd3_human,102,C,H,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.6,-3.984,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
71,9651882,drd3_human,102,C,H,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,8.2,1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
114,9651882,drd3_human,102,C,H,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.1,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
189,9651882,drd3_human,102,C,H,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,7.1,1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
232,9651882,drd3_human,102,C,H,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.8,-1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
262,9651882,drd3_human,102,C,H,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.3,1.995,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-0.154156,CA102H,DRD3
9,29343833,drd3_human,90,E,Q,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.6,1.2,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
95,29343833,drd3_human,90,E,Q,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,30.9,12.36,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
103,29343833,drd3_human,90,E,Q,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,25.0,10.0,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
121,29343833,drd3_human,90,E,Q,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.5,1.0,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
183,29343833,drd3_human,90,E,Q,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,5.4,1.588,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
206,29343833,drd3_human,90,E,Q,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,36.5,5.615,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
208,29343833,drd3_human,90,E,Q,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,43.6,6.708,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
245,29343833,drd3_human,90,E,Q,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,6.0,1.765,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.405246,EA90Q,DRD3
15,9651882,drd3_human,368,T,V,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.1,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
33,9651882,drd3_human,368,T,V,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.7,-1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
41,9651882,drd3_human,368,T,V,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.4,-2.513,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
80,9651882,drd3_human,368,T,V,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,6.9,1.995,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
141,9651882,drd3_human,368,T,V,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,8.3,1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
150,9651882,drd3_human,368,T,V,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.8,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
200,9651882,drd3_human,368,T,V,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.8,-1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.14194,TA368V,DRD3
21,19606869,drd3_human,349,H,A,paper-1a,ChEMBL Compound ID,CHEMBL310843,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8300.0,nM,=,,46.0,-166.667,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
60,19606869,drd3_human,349,H,A,paper-2b,ChEMBL Compound ID,CHEMBL561763,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,12.0,-2.165,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
74,19606869,drd3_human,349,H,A,paper-1c,SMILES,COC1=CC=CC=C1N1CCN(CC2=C3C=CC=CN3N=C2)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,770.0,nM,=,,61.0,-12.658,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
89,19606869,drd3_human,349,H,A,[3H]spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.54,nM,=,,1.0,1.852,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
98,19606869,drd3_human,349,H,A,paper-3a,ChEMBL Compound ID,CHEMBL142020,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,7.4,nM,=,,2.0,-3.704,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
190,19606869,drd3_human,349,H,A,paper-2a,ChEMBL Compound ID,CHEMBL140612,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,320.0,nM,=,,56.0,-5.714,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
196,19606869,drd3_human,349,H,A,paper-3b,ChEMBL Compound ID,CHEMBL550222,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.63,1.26,,,[3H]Spiperone,75.0,0.0,,0.0,,P35462,0.217397,HA349A,DRD3
26,29343833,drd3_human,36,Y,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.2,-2.5,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
88,29343833,drd3_human,36,Y,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.3,-1.667,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
102,29343833,drd3_human,36,Y,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.2,-1.063,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
138,29343833,drd3_human,36,Y,F,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,13.0,5.2,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
139,29343833,drd3_human,36,Y,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,3.6,-1.805,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
160,29343833,drd3_human,36,Y,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,4.0,-1.626,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
191,29343833,drd3_human,36,Y,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,2.5,-1.361,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
252,29343833,drd3_human,36,Y,F,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,4.5,1.8,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.755703,YA36F,DRD3
27,9651882,drd3_human,361,S,A,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.2,-1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
54,9651882,drd3_human,361,S,A,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.1,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
65,9651882,drd3_human,361,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,7.1,1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
134,9651882,drd3_human,361,S,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,8.2,1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
142,9651882,drd3_human,361,S,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.6,-1.996,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
152,9651882,drd3_human,361,S,A,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.5,1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
185,9651882,drd3_human,361,S,A,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.7,-1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,0.493394,SA361A,DRD3
30,10349875,drd3_human,192,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,69.8,nM,=,,81.2,1.163,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
43,20833147,drd3_human,192,S,A,D237,ChEMBL Compound ID,CHEMBL457024,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.65,nM,=,,40.0,10.959,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
61,10349875,drd3_human,192,S,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,16.6,nM,=,,53.2,3.205,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
75,10349875,drd3_human,192,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,36.1,nM,=,,2234.0,61.884,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
100,20833147,drd3_human,192,S,A,D315,ChEMBL Compound ID,CHEMBL456825,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.503,nM,=,,3.16,6.282,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
106,20833147,drd3_human,192,S,A,D264,ChEMBL Compound ID,CHEMBL514885,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.81,nM,=,,15.5,2.668,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
168,20833147,drd3_human,192,S,A,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.329,nM,=,,0.332,1.009,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
175,20833147,drd3_human,192,S,A,5-OH-DPAT (D323),ChEMBL Compound ID,CHEMBL269004,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.94,nM,=,,110.0,18.519,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
192,20833147,drd3_human,192,S,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.64,nM,=,,28.1,4.982,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
266,10349875,drd3_human,192,S,A,[3H]spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.18,nM,=,,0.13,-1.385,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.03071,SA192A,DRD3
31,29343833,drd3_human,373,Y,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,23.0,3.538,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
45,29343833,drd3_human,373,Y,F,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,136.8,54.72,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
93,29343833,drd3_human,373,Y,F,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,98.4,39.36,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
109,29343833,drd3_human,373,Y,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,26.7,4.108,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
115,29343833,drd3_human,373,Y,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,1.4,2.8,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
116,29343833,drd3_human,373,Y,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,14.8,4.353,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
188,29343833,drd3_human,373,Y,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,15.8,4.647,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
248,29343833,drd3_human,373,Y,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.7,1.4,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.13415,YA373F,DRD3
35,29343833,drd3_human,183,I,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,55.0,16.176,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
77,29343833,drd3_human,183,I,F,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,43.0,12.647,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
99,29343833,drd3_human,183,I,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,18.0,2.769,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
104,29343833,drd3_human,183,I,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.9,1.8,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
147,29343833,drd3_human,183,I,F,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,100.0,15.385,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
148,29343833,drd3_human,183,I,F,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.6,1.2,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
177,29343833,drd3_human,183,I,F,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,6.6,2.64,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.8895,IA183F,DRD3
37,9651882,drd3_human,369,T,V,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,8.8,-2.513,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
53,20833147,drd3_human,369,T,V,Spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.329,nM,=,,0.203,-1.621,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
64,9651882,drd3_human,369,T,V,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,7.9,-5.0,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
73,20833147,drd3_human,369,T,V,D264,ChEMBL Compound ID,CHEMBL514885,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.81,nM,=,,9.14,1.573,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
119,9651882,drd3_human,369,T,V,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,9.3,-10.0,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
120,20833147,drd3_human,369,T,V,D237,ChEMBL Compound ID,CHEMBL457024,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.65,nM,=,,3.28,-1.112,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
170,20833147,drd3_human,369,T,V,5-OH-DPAT (D323),ChEMBL Compound ID,CHEMBL269004,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.94,nM,=,,5.29,-1.122,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
198,9651882,drd3_human,369,T,V,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.4,-6.329,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
203,9651882,drd3_human,369,T,V,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.5,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
226,20833147,drd3_human,369,T,V,D315,ChEMBL Compound ID,CHEMBL456825,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.503,nM,=,,0.31,-1.623,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
235,9651882,drd3_human,369,T,V,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.6,1.0,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
249,9651882,drd3_human,369,T,V,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,9.1,-3.165,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
255,20833147,drd3_human,369,T,V,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.64,nM,=,,2.4,-2.347,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-1.05846,TA369V,DRD3
38,29343833,drd3_human,182,S,I,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,1.9,-1.316,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
42,29343833,drd3_human,182,S,I,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.2,-2.5,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
68,29343833,drd3_human,182,S,I,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,0.8,-3.125,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
130,29343833,drd3_human,182,S,I,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,2.1,-1.618,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
172,29343833,drd3_human,182,S,I,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,34.1,5.246,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
201,29343833,drd3_human,182,S,I,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.5,1.0,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
211,29343833,drd3_human,182,S,I,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,3.6,1.059,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
260,29343833,drd3_human,182,S,I,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,21.8,3.354,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,-0.470604,SA182I,DRD3
55,9651882,drd3_human,349,H,L,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,8.5,-1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
84,9651882,drd3_human,349,H,L,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.5,1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
113,9651882,drd3_human,349,H,L,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.3,-1.996,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
136,9651882,drd3_human,349,H,L,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,7.9,5.012,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
151,9651882,drd3_human,349,H,L,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,7.6,10.0,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
207,9651882,drd3_human,349,H,L,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.4,-1.259,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
223,9651882,drd3_human,349,H,L,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,6.0,15.849,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-1.33541,HA349L,DRD3
58,9651882,drd3_human,361,S,P,Raclopride,ChEMBL Compound ID,CHEMBL8809,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.4,1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
78,9651882,drd3_human,361,S,P,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.3,,=,,8.5,-1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
82,9651882,drd3_human,361,S,P,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.4,,=,,7.7,5.012,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
158,9651882,drd3_human,361,S,P,GR103691,ChEMBL Compound ID,CHEMBL294747,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.6,,=,,9.1,3.162,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
194,9651882,drd3_human,361,S,P,Chlorpromazine,ChEMBL Compound ID,CHEMBL71,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.0,,=,,8.0,1.0,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
218,9651882,drd3_human,361,S,P,GR218231,ChEMBL Compound ID,CHEMBL334529,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.6,,=,,8.8,-1.585,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
270,9651882,drd3_human,361,S,P,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.2,,=,,6.6,3.981,,,[3H]Spiperone,100.0,0.0,,0.0,,P35462,-2.1612,SA361P,DRD3
96,18834111,drd3_human,345,F,W,paper-5c,ChEMBL Compound ID,CHEMBL484202,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,33.0,13.2,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
126,18834111,drd3_human,345,F,W,[3H]spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.52,nM,=,,0.23,-2.262,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
132,18834111,drd3_human,345,F,W,FAUC73,ChEMBL Compound ID,CHEMBL162762,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,190.0,nM,=,,5700.0,30.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
144,18834111,drd3_human,345,F,W,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,72.0,nM,>,,80000.0,1111.111,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
176,18834111,drd3_human,345,F,W,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.6,nM,=,,270.0,75.0,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
240,18834111,drd3_human,345,F,W,paper-4c,ChEMBL Compound ID,CHEMBL484358,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.78,nM,=,,20.0,25.641,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.829926,FA345W,DRD3
112,10349875,drd3_human,196,S,A,7-OH-DPAT,ChEMBL Compound ID,CHEMBL285755,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,16.6,nM,=,,9.5,-1.748,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.214942,SA196A,DRD3
118,10349875,drd3_human,196,S,A,Dopamine,ChEMBL Compound ID,CHEMBL59,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,36.1,nM,=,,30.8,-1.172,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.214942,SA196A,DRD3
195,10349875,drd3_human,196,S,A,Quinpirole,ChEMBL Compound ID,CHEMBL240773,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,69.8,nM,=,,56.9,-1.227,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.214942,SA196A,DRD3
261,10349875,drd3_human,196,S,A,[3H]spiperone,ChEMBL Compound ID,CHEMBL267930,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.18,nM,=,,0.11,-1.637,,,[3H]Spiperone,0.0,0.0,,0.0,,P35462,-0.214942,SA196A,DRD3
157,29343833,drd3_human,189,V,A,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.5,1.0,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
165,29343833,drd3_human,189,V,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,8.5,1.308,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
173,29343833,drd3_human,189,V,A,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,3.6,1.44,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
174,29343833,drd3_human,189,V,A,Eticlopride,ChEMBL Compound ID,CHEMBL8946,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.5,nM,=,,0.7,1.4,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
214,29343833,drd3_human,189,V,A,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,24.0,7.059,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
221,29343833,drd3_human,189,V,A,PF-4363467,SMILES,CCN1CCO[C@H](C1)c1ccc(NS(=O)(=O)c2ccc(cc2)C(C)C)c(C)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.4,nM,=,,30.0,8.824,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
224,29343833,drd3_human,189,V,A,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.5,nM,=,,8.1,1.246,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
267,29343833,drd3_human,189,V,A,GSK598809 ,ChEMBL Compound ID,CHEMBL1081023,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.5,nM,=,,4.0,1.6,,,[3H]7-OH-DPAT,0.0,0.0,,0.0,,P35462,1.67897,VA189A,DRD3
7,10.1111/bph.15756,5ht2a_human,242,S,A,"(2S,4R)-2k",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=C(N(C)C)C=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,7.91,,=,,7.95,-1.096,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
18,8700116,5ht2a_human,242,S,A,Ergonovine,ChEMBL Compound ID,CHEMBL119443,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.46,nM,=,,9.9,21.522,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
22,10.1111/bph.15756,5ht2a_human,242,S,A,"(2R,4R)-3h",SMILES,CN(C)[C@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=CC(F)=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,6.85,1.318,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
26,1644189,5ht2a_human,242,S,A,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,129.0,nM,=,,4.2,-30.303,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
33,10.1111/bph.15756,5ht2a_human,242,S,A,"(2S,4R)-2a",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC=CC(Br)=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,6.9,1.175,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
47,8700116,5ht2a_human,242,S,A,Ketanserin,ChEMBL Compound ID,CHEMBL51,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.75,nM,=,,0.49,-1.531,,,,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
52,10.1111/bph.15756,5ht2a_human,242,S,A,5-HT,SMILES,C1=CC2=C(C=C1O)C(=CN2)CCN,Full agonist,pEC50,Functional - IP accumulation,7.53,,=,,7.29,1.738,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
58,10.1111/bph.15756,5ht2a_human,242,S,A,pimavanserin,SMILES,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,Inverse agonist,pK(b),Functional - IP accumulation,8.24,,=,,8.22,1.047,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
65,8700116,5ht2a_human,242,S,A,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.0,nM,=,,51.0,3.4,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
67,8700116,5ht2a_human,242,S,A,Tryptamine,ChEMBL Compound ID,CHEMBL6640,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,929.0,nM,=,,3493.0,3.76,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
73,8700116,5ht2a_human,242,S,A,Psilocin,ChEMBL Compound ID,CHEMBL65547,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,81.0,nM,=,,259.0,3.198,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
108,8700116,5ht2a_human,242,S,A,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,28.0,nM,=,,3.9,-7.194,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
111,8700116,5ht2a_human,242,S,A,Bufotenine,ChEMBL Compound ID,CHEMBL416526,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,473.0,2.599,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
123,1644189,5ht2a_human,242,S,A,[3H]Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,174.0,nM,=,,2.6,-66.667,,,,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
132,8700116,5ht2a_human,242,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,316.0,nM,=,,1150.0,3.639,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
154,8700116,5ht2a_human,242,S,A,4-HT,ChEMBL Compound ID,CHEMBL18845,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,410.0,nM,=,,1023.0,2.495,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
155,8700116,5ht2a_human,242,S,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.24,nM,=,,2.1,8.75,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
162,8700116,5ht2a_human,242,S,A,Lisuride,ChEMBL Compound ID,CHEMBL157138,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.33,nM,=,,2.0,6.061,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
163,10.1111/bph.15756,5ht2a_human,242,S,A,risperidone,SMILES,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Inverse agonist,pK(b),Functional - IP accumulation,8.88,,=,,8.95,-1.175,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.0682902,SA242A,HTR2A
10,10.1111/bph.15756,5ht2a_human,210,I,V,risperidone,SMILES,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Inverse agonist,pK(b),Functional - IP accumulation,8.88,,=,,8.81,1.175,,,Functional,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
41,10.1111/bph.15756,5ht2a_human,210,I,V,"(2S,4R)-2a",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC=CC(Br)=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,7.1,-1.35,,,Inhibition,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
53,10.1111/bph.15756,5ht2a_human,210,I,V,"(2S,4R)-2k",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=C(N(C)C)C=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,7.91,,=,,8.06,-1.412,,,Inhibition,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
115,10.1111/bph.15756,5ht2a_human,210,I,V,pimavanserin,SMILES,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,Inverse agonist,pK(b),Functional - IP accumulation,8.24,,=,,8.25,-1.024,,,Inhibition,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
120,10.1111/bph.15756,5ht2a_human,210,I,V,5-HT,SMILES,C1=CC2=C(C=C1O)C(=CN2)CCN,Full agonist,pEC50,Functional - IP accumulation,7.53,,=,,7.44,1.23,,,Inhibition,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
121,10.1111/bph.15756,5ht2a_human,210,I,V,"(2R,4R)-3h",SMILES,CN(C)[C@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=CC(F)=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,7.18,-1.621,,,Inhibition,0.0,0.0,,0.0,,P28223,1.32204,IA210V,HTR2A
16,10.1111/bph.15756,5ht2a_human,235,V,M,"(2S,4R)-2k",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=C(N(C)C)C=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,7.91,,=,,8.35,-2.755,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
36,10.1111/bph.15756,5ht2a_human,235,V,M,5-HT,SMILES,C1=CC2=C(C=C1O)C(=CN2)CCN,Full agonist,pEC50,Functional - IP accumulation,7.53,,=,,7.34,1.549,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
59,10.1111/bph.15756,5ht2a_human,235,V,M,"(2R,4R)-3h",SMILES,CN(C)[C@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=CC(F)=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,7.02,-1.122,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
60,10.1111/bph.15756,5ht2a_human,235,V,M,"(2S,4R)-2a",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC=CC(Br)=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,7.25,-1.905,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
99,10.1111/bph.15756,5ht2a_human,235,V,M,pimavanserin,SMILES,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,Inverse agonist,pK(b),Functional - IP accumulation,8.24,,=,,8.62,-2.398,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
143,10.1111/bph.15756,5ht2a_human,235,V,M,risperidone,SMILES,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Inverse agonist,pK(b),Functional - IP accumulation,8.88,,=,,8.93,-1.122,,,Inhibition,0.0,0.0,,0.0,,P28223,-0.318684,VA235M,HTR2A
19,10.1111/bph.15756,5ht2a_human,238,G,S,"(2R,4R)-3h",SMILES,CN(C)[C@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=CC(F)=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,4.59,239.883,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
23,10.1111/bph.15756,5ht2a_human,238,G,S,"(2S,4R)-2k",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC(C4=CC=C(N(C)C)C=C4)=CC=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,7.91,,=,,4.92,977.237,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
80,10.1111/bph.15756,5ht2a_human,238,G,S,risperidone,SMILES,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Inverse agonist,pK(b),Functional - IP accumulation,8.88,,=,,8.69,1.549,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
118,10.1111/bph.15756,5ht2a_human,238,G,S,pimavanserin,SMILES,CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C,Inverse agonist,pK(b),Functional - IP accumulation,8.24,,=,,4.61,4265.795,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
152,10.1111/bph.15756,5ht2a_human,238,G,S,"(2S,4R)-2a",SMILES,CN(C)[C@@H]1CC2=C(C=CC=C2)[C@@H](C3=CC=CC(Br)=C3)C1,Inverse agonist,pK(b),Functional - IP accumulation,6.97,,=,,5.87,12.589,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
153,10.1111/bph.15756,5ht2a_human,238,G,S,5-HT,SMILES,C1=CC2=C(C=C1O)C(=CN2)CCN,Full agonist,pEC50,Functional - IP accumulation,7.53,,=,,6.37,14.454,,,Inhibition,0.0,0.0,,0.0,,P28223,1.02908,GA238S,HTR2A
29,8663249,5ht2a_human,159,S,A,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.38,nM,=,,0.54,1.421,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.11348,SA159A,HTR2A
35,8663249,5ht2a_human,159,S,A,Ketanserin,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.84,nM,=,,1.1,1.31,,,,0.0,0.0,,0.0,,P28223,0.11348,SA159A,HTR2A
61,8663249,5ht2a_human,159,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,396.0,nM,=,,6960.0,17.576,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.11348,SA159A,HTR2A
94,8663249,5ht2a_human,159,S,A,Bufotenine,ChEMBL Compound ID,CHEMBL416526,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,162.0,nM,=,,645.0,3.981,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.11348,SA159A,HTR2A
45,7622478,5ht2a_human,120,D,A,Ketanserin,ChEMBL Compound ID,CHEMBL52,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.64,nM,=,,0.55,-1.164,,,,0.0,0.0,,0.0,,P28223,-2.19362,DA120A,HTR2A
88,7622478,5ht2a_human,120,D,N,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.0,nM,=,,24.0,1.6,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
100,7622478,5ht2a_human,120,D,N,Ketanserin,ChEMBL Compound ID,CHEMBL51,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.64,nM,=,,0.92,1.438,,,,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
126,7622478,5ht2a_human,120,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,296.0,nM,=,,556.0,1.878,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
131,7622478,5ht2a_human,120,D,N,5-Metoxygramine,PubChem CID,27965,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1012.0,nM,=,,703.0,-1.439,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
133,7622478,5ht2a_human,120,D,N,Haloperidol,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,66.0,nM,=,,74.0,1.121,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
140,7622478,5ht2a_human,120,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,296.0,nM,=,,353.0,1.193,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
158,7622478,5ht2a_human,120,D,N,Mianserin,ChEMBL Compound ID,CHEMBL6437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.95,nM,=,,3.75,1.271,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
165,7622478,5ht2a_human,120,D,N,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.25,nM,=,,0.17,-1.471,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.494051,DA120N,HTR2A
102,8663249,5ht2a_human,159,S,C,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,396.0,nM,=,,1947.0,4.917,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.163191,SA159C,HTR2A
114,8663249,5ht2a_human,159,S,C,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.38,nM,=,,0.33,-1.152,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.163191,SA159C,HTR2A
144,8663249,5ht2a_human,159,S,C,Ketanserin,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.84,nM,=,,0.66,-1.272,,,,0.0,0.0,,0.0,,P28223,0.163191,SA159C,HTR2A
159,8663249,5ht2a_human,159,S,C,Bufotenine,ChEMBL Compound ID,CHEMBL416526,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,162.0,nM,=,,224.0,1.383,,,[3H]Ketanserin,0.0,0.0,,0.0,,P28223,0.163191,SA159C,HTR2A
104,7622478,5ht2a_human,376,N,D,Ketanserin,ChEMBL Compound ID,CHEMBL53,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.64,nM,=,,0.77,1.203,,,,0.0,0.0,,0.0,,P28223,1.75946,NA376D,HTR2A
0,24174496,cxcr3_human,128,G,H,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,5.2,100.0,,,[125I]-CXCL11,80.0,0.0,,0.0,,P49682,2.95168,GA128H,CXCR3
57,17170198,cxcr3_human,128,G,H,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,4.3,-25.0,,,,0.0,0.0,,0.0,,P49682,2.95168,GA128H,CXCR3
63,17170198,cxcr3_human,128,G,H,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,22.0,23.479,,,,0.0,0.0,,347.0,,P49682,2.95168,GA128H,CXCR3
76,24174496,cxcr3_human,128,G,H,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,4.9,794.328,,,[125I]-CXCL11,80.0,0.0,,0.0,,P49682,2.95168,GA128H,CXCR3
124,24174496,cxcr3_human,128,G,H,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.0,5.012,,,[125I]-CXCL11,80.0,0.0,,0.0,,P49682,2.95168,GA128H,CXCR3
198,17170198,cxcr3_human,128,G,H,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,15.0,8.824,,,,0.0,0.0,,39.52205882,,P49682,2.95168,GA128H,CXCR3
208,24174496,cxcr3_human,128,G,H,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,4.8,15.849,,,[125I]-CXCL11,80.0,0.0,,0.0,,P49682,2.95168,GA128H,CXCR3
1,17170198,cxcr3_human,268,W,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,50.0,53.362,,,,0.0,0.0,,313.0,,P49682,3.53155,WA268A,CXCR3
128,17170198,cxcr3_human,268,W,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,3.7,-6.329,,,,0.0,0.0,,0.0,,P49682,3.53155,WA268A,CXCR3
159,17170198,cxcr3_human,268,W,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,27.0,15.882,,,,0.0,0.0,,12.5,,P49682,3.53155,WA268A,CXCR3
2,24174496,cxcr3_human,131,F,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,6.5,19.953,,,[125I]-CXCL11,74.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
44,25425280,cxcr3_human,131,F,A,VUF10085,SMILES,O=C(CC1=CC=C(OC(F)(F)F)C=C1)N(C(C(N2C3=CC=C(OCC)C=C3)=NC4=NC=CC=C4C2=O)C)CC5=CC=CN=C5,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.241,µM,=,,0.161,-1.497,,,[125I]-CXCL11,77.6,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
50,24174496,cxcr3_human,131,F,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,74.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
78,17170198,cxcr3_human,131,F,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,1415.0,1510.139,,,,0.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
91,17170198,cxcr3_human,131,F,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,35.0,20.588,,,,0.0,0.0,,13.23529412,,P49682,1.73964,FA131A,CXCR3
101,25425280,cxcr3_human,131,F,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,7.7,nM,=,,1.1,-6.993,,,[125I]-CXCL11,77.6,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
149,17170198,cxcr3_human,131,F,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,3.0,-1.259,,,,0.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
156,24174496,cxcr3_human,131,F,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,4.5,31.623,,,[125I]-CXCL11,74.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
195,24174496,cxcr3_human,131,F,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.3,7.943,,,[125I]-CXCL11,74.0,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
197,25425280,cxcr3_human,131,F,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,31.3,µM,=,,23.3,-1.344,,,[125I]-CXCL11,77.6,0.0,,0.0,,P49682,1.73964,FA131A,CXCR3
3,25425280,cxcr3_human,275,V,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,7.7,nM,=,,7.4,-1.041,,,[125I]-CXCL11,66.3,0.0,,0.0,,P49682,1.27366,VA275A,CXCR3
4,24174496,cxcr3_human,304,S,E,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,<,,4.0,100.0,,,[125I]-CXCL11,91.0,0.0,,0.0,,P49682,-0.769684,SA304E,CXCR3
29,24174496,cxcr3_human,304,S,E,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,91.0,0.0,,0.0,,P49682,-0.769684,SA304E,CXCR3
112,24174496,cxcr3_human,304,S,E,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,5.3,79.433,,,[125I]-CXCL11,91.0,0.0,,0.0,,P49682,-0.769684,SA304E,CXCR3
162,24174496,cxcr3_human,304,S,E,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.6,1.585,,,[125I]-CXCL11,91.0,0.0,,0.0,,P49682,-0.769684,SA304E,CXCR3
5,24174496,cxcr3_human,195,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.1,1.259,,,[125I]-CXCL11,94.0,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
7,24174496,cxcr3_human,195,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.8,-1.259,,,[125I]-CXCL11,94.0,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
52,21895630,cxcr3_human,195,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,16.0,1.468,,,[125I]-CXCL11,74.2,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
92,21895630,cxcr3_human,195,D,N,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,4.7,1.0,,,[125I]-CXCL11,74.2,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
168,24174496,cxcr3_human,195,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,6.2,-1.585,,,[125I]-CXCL11,94.0,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
199,24174496,cxcr3_human,195,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,8.0,-1.585,,,[125I]-CXCL11,94.0,0.0,,0.0,,P49682,0.187528,DA195N,CXCR3
6,24174496,cxcr3_human,109,W,Q,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,<,,5.0,630.957,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,1.33315,WA109Q,CXCR3
79,24174496,cxcr3_human,109,W,Q,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,<,,4.5,31.623,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,1.33315,WA109Q,CXCR3
95,24174496,cxcr3_human,109,W,Q,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.9,-1.585,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,1.33315,WA109Q,CXCR3
155,24174496,cxcr3_human,109,W,Q,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,<,,4.5,501.187,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,1.33315,WA109Q,CXCR3
9,24174496,cxcr3_human,308,Y,F,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,4.9,12.589,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,-0.190572,YA308F,CXCR3
144,24174496,cxcr3_human,308,Y,F,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.7,3.162,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,-0.190572,YA308F,CXCR3
184,24174496,cxcr3_human,308,Y,F,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.3,2.512,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,-0.190572,YA308F,CXCR3
218,24174496,cxcr3_human,308,Y,F,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.3,3.162,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,-0.190572,YA308F,CXCR3
10,17170198,cxcr3_human,186,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,9.0,5.294,,,,0.0,0.0,,12.31617647,,P49682,0.146867,DA186N,CXCR3
15,17170198,cxcr3_human,186,D,N,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,885.0,944.504,,,,0.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
43,24174496,cxcr3_human,186,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.7,1.995,,,[125I]-CXCL11,68.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
117,24174496,cxcr3_human,186,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.7,-3.165,,,[125I]-CXCL11,68.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
119,24174496,cxcr3_human,186,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,6.8,10.0,,,[125I]-CXCL11,68.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
178,17170198,cxcr3_human,186,D,N,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,2.9,1.0,,,,0.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
189,24174496,cxcr3_human,186,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.8,-1.259,,,[125I]-CXCL11,68.0,0.0,,0.0,,P49682,0.146867,DA186N,CXCR3
11,21895630,cxcr3_human,278,D,N,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,30.9,6.574,,,[125I]-CXCL11,92.6,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
54,17170198,cxcr3_human,278,D,N,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,55.0,58.698,,,,0.0,0.0,,195.0,,P49682,-0.474245,DA278N,CXCR3
77,17170198,cxcr3_human,278,D,N,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,3.7,-6.329,,,,0.0,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
93,21895630,cxcr3_human,278,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,2.6,-4.184,,,[125I]-CXCL11,92.6,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
110,24174496,cxcr3_human,278,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.9,-1.259,,,[125I]-CXCL11,84.0,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
120,17170198,cxcr3_human,278,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,13.0,7.647,,,,0.0,0.0,,13.41911765,,P49682,-0.474245,DA278N,CXCR3
173,24174496,cxcr3_human,278,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.7,-3.165,,,[125I]-CXCL11,84.0,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
179,24174496,cxcr3_human,278,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,6.2,-1.585,,,[125I]-CXCL11,84.0,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
180,24174496,cxcr3_human,278,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,84.0,0.0,,0.0,,P49682,-0.474245,DA278N,CXCR3
12,17170198,cxcr3_human,202,H,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,17.0,10.0,,,,0.0,0.0,,15.625,,P49682,1.30531,HA202A,CXCR3
14,25425280,cxcr3_human,202,H,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,7.7,nM,=,,2.9,-2.653,,,[125I]-CXCL11,95.3,0.0,,0.0,,P49682,1.30531,HA202A,CXCR3
135,25425280,cxcr3_human,202,H,A,VUF10085,SMILES,O=C(CC1=CC=C(OC(F)(F)F)C=C1)N(C(C(N2C3=CC=C(OCC)C=C3)=NC4=NC=CC=C4C2=O)C)CC5=CC=CN=C5,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.241,µM,=,,0.299,1.241,,,[125I]-CXCL11,95.3,0.0,,0.0,,P49682,1.30531,HA202A,CXCR3
157,17170198,cxcr3_human,202,H,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,58.0,61.9,,,,0.0,0.0,,153.0,,P49682,1.30531,HA202A,CXCR3
214,25425280,cxcr3_human,202,H,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,31.3,µM,=,,25.3,-1.238,,,[125I]-CXCL11,95.3,0.0,,0.0,,P49682,1.30531,HA202A,CXCR3
13,24174496,cxcr3_human,46,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.8,1.0,,,[125I]-CXCL11,100.0,0.0,,0.0,,P49682,0.417296,DA46N,CXCR3
114,24174496,cxcr3_human,46,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,6.0,1.0,,,[125I]-CXCL11,100.0,0.0,,0.0,,P49682,0.417296,DA46N,CXCR3
115,24174496,cxcr3_human,46,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.3,2.512,,,[125I]-CXCL11,100.0,0.0,,0.0,,P49682,0.417296,DA46N,CXCR3
204,24174496,cxcr3_human,46,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.2,1.0,,,[125I]-CXCL11,100.0,0.0,,0.0,,P49682,0.417296,DA46N,CXCR3
17,24174496,cxcr3_human,304,S,L,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,6.5,19.953,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,1.53262,SA304L,CXCR3
84,24174496,cxcr3_human,304,S,L,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.1,7.943,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,1.53262,SA304L,CXCR3
169,24174496,cxcr3_human,304,S,L,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,5.9,19.953,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,1.53262,SA304L,CXCR3
181,24174496,cxcr3_human,304,S,L,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.5,1.585,,,[125I]-CXCL11,95.0,0.0,,0.0,,P49682,1.53262,SA304L,CXCR3
18,17170198,cxcr3_human,271,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,1.7,1.0,,,,0.0,0.0,,7.904411765,,P49682,1.63496,YA271A,CXCR3
21,24174496,cxcr3_human,271,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,41.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
87,17170198,cxcr3_human,271,Y,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,2.9,1.0,,,,0.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
89,24174496,cxcr3_human,271,Y,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.4,6.31,,,[125I]-CXCL11,41.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
107,24174496,cxcr3_human,271,Y,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.7,1.995,,,[125I]-CXCL11,41.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
188,17170198,cxcr3_human,271,Y,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,794.0,847.385,,,,0.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
191,24174496,cxcr3_human,271,Y,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,6.8,10.0,,,[125I]-CXCL11,41.0,0.0,,0.0,,P49682,1.63496,YA271A,CXCR3
19,24174496,cxcr3_human,60,Y,F,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.5,1.585,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,-0.667212,YA60F,CXCR3
40,24174496,cxcr3_human,60,Y,F,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.5,1.995,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,-0.667212,YA60F,CXCR3
136,24174496,cxcr3_human,60,Y,F,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,4.9,12.589,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,-0.667212,YA60F,CXCR3
174,24174496,cxcr3_human,60,Y,F,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.3,-1.259,,,[125I]-CXCL11,81.0,0.0,,0.0,,P49682,-0.667212,YA60F,CXCR3
22,21895630,cxcr3_human,293,E,Q,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,3.7,-2.95,,,[125I]-CXCL11,134.8,0.0,,0.0,,P49682,-0.311805,EA293Q,CXCR3
150,21895630,cxcr3_human,293,E,Q,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,1.2,-3.922,,,[125I]-CXCL11,134.8,0.0,,0.0,,P49682,-0.311805,EA293Q,CXCR3
23,17170198,cxcr3_human,300,K,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,4.3,-25.0,,,,0.0,0.0,,0.0,,P49682,1.47076,KA300A,CXCR3
130,17170198,cxcr3_human,300,K,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,20.0,21.345,,,,0.0,0.0,,151.0,,P49682,1.47076,KA300A,CXCR3
138,17170198,cxcr3_human,300,K,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,4.2,2.471,,,,0.0,0.0,,18.56617647,,P49682,1.47076,KA300A,CXCR3
24,24174496,cxcr3_human,60,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.8,-1.259,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
33,24174496,cxcr3_human,60,Y,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.9,1.995,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
34,25425280,cxcr3_human,60,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,31.3,µM,=,,14.0,-2.237,,,[125I]-CXCL11,49.8,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
51,25425280,cxcr3_human,60,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,7.7,nM,=,,1.8,-4.274,,,[125I]-CXCL11,49.8,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
132,25425280,cxcr3_human,60,Y,A,VUF10085,SMILES,O=C(CC1=CC=C(OC(F)(F)F)C=C1)N(C(C(N2C3=CC=C(OCC)C=C3)=NC4=NC=CC=C4C2=O)C)CC5=CC=CN=C5,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.241,µM,=,,0.236,-1.021,,,[125I]-CXCL11,49.8,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
153,24174496,cxcr3_human,60,Y,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.5,1.995,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
186,24174496,cxcr3_human,60,Y,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.0,10.0,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,3.07512,YA60A,CXCR3
25,24174496,cxcr3_human,301,S,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,8.1,-1.996,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,0.631561,SA301A,CXCR3
42,24174496,cxcr3_human,301,S,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.9,1.995,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,0.631561,SA301A,CXCR3
103,24174496,cxcr3_human,301,S,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.2,3.162,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,0.631561,SA301A,CXCR3
146,24174496,cxcr3_human,301,S,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.8,1.585,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,0.631561,SA301A,CXCR3
26,16847335,cxcr3_human,21,E,K,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,IC50,Binding - Radioligand competition/displacement,0.062,nM,=,,0.108,1.742,,,[125I]-CXCL10,125.0,0.0,,0.0,,P49682,-0.520226,EA21K,CXCR3
102,16847335,cxcr3_human,21,E,K,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,IC50,Binding - Radioligand competition/displacement,0.5,nM,=,,1.82,3.64,,,[125I]-CXCL11,125.0,0.0,,0.0,,P49682,-0.520226,EA21K,CXCR3
28,24174496,cxcr3_human,297,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,110.0,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
85,21895630,cxcr3_human,297,D,N,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,7.1,1.511,,,[125I]-CXCL11,90.2,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
99,24174496,cxcr3_human,297,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,8.1,-1.996,,,[125I]-CXCL11,110.0,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
127,24174496,cxcr3_human,297,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.6,-2.513,,,[125I]-CXCL11,110.0,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
142,24174496,cxcr3_human,297,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,6.9,-7.937,,,[125I]-CXCL11,110.0,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
161,21895630,cxcr3_human,297,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,26.3,2.413,,,[125I]-CXCL11,90.2,0.0,,0.0,,P49682,-0.00388528,DA297N,CXCR3
30,17170198,cxcr3_human,308,Y,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,3.2,-1.996,,,,0.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
53,25425280,cxcr3_human,308,Y,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,31.3,µM,=,,14.2,-2.203,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
55,24174496,cxcr3_human,308,Y,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,6.9,7.943,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
66,17170198,cxcr3_human,308,Y,A,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,631.0,673.426,,,,0.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
75,24174496,cxcr3_human,308,Y,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.0,10.0,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
81,24174496,cxcr3_human,308,Y,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,5.7,31.623,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
165,24174496,cxcr3_human,308,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.5,1.585,,,[125I]-CXCL11,75.0,0.0,,0.0,,P49682,1.18505,YA308A,CXCR3
182,17170198,cxcr3_human,308,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,7.4,4.353,,,,0.0,0.0,,15.25735294,,P49682,1.18505,YA308A,CXCR3
39,24174496,cxcr3_human,135,F,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.5,-1.996,,,[125I]-CXCL11,106.0,0.0,,0.0,,P49682,3.26655,FA135A,CXCR3
80,24174496,cxcr3_human,135,F,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.4,1.995,,,[125I]-CXCL11,106.0,0.0,,0.0,,P49682,3.26655,FA135A,CXCR3
86,24174496,cxcr3_human,135,F,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,<,,4.5,31.623,,,[125I]-CXCL11,106.0,0.0,,0.0,,P49682,3.26655,FA135A,CXCR3
125,24174496,cxcr3_human,135,F,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.5,1.995,,,[125I]-CXCL11,106.0,0.0,,0.0,,P49682,3.26655,FA135A,CXCR3
41,16847335,cxcr3_human,4,E,K,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,IC50,Binding - Radioligand competition/displacement,0.062,nM,=,,0.049,-1.266,,,[125I]-CXCL10,140.0,0.0,,0.0,,P49682,-0.406526,EA4K,CXCR3
65,16847335,cxcr3_human,4,E,K,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,IC50,Binding - Radioligand competition/displacement,0.5,nM,=,,1.2,2.4,,,[125I]-CXCL11,140.0,0.0,,0.0,,P49682,-0.406526,EA4K,CXCR3
45,21895630,cxcr3_human,196,E,Q,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,0.4,-27.027,,,[125I]-CXCL11,188.0,0.0,,0.0,,P49682,0.000377965,EA196Q,CXCR3
113,21895630,cxcr3_human,196,E,Q,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,7.6,1.617,,,[125I]-CXCL11,188.0,0.0,,0.0,,P49682,0.000377965,EA196Q,CXCR3
46,24174496,cxcr3_human,268,W,Q,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.6,2.512,,,[125I]-CXCL11,60.0,0.0,,0.0,,P49682,2.83902,WA268Q,CXCR3
97,24174496,cxcr3_human,268,W,Q,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.8,-1.259,,,[125I]-CXCL11,60.0,0.0,,0.0,,P49682,2.83902,WA268Q,CXCR3
170,24174496,cxcr3_human,268,W,Q,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.4,-1.585,,,[125I]-CXCL11,60.0,0.0,,0.0,,P49682,2.83902,WA268Q,CXCR3
216,24174496,cxcr3_human,268,W,Q,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.0,6.31,,,[125I]-CXCL11,60.0,0.0,,0.0,,P49682,2.83902,WA268Q,CXCR3
56,25425280,cxcr3_human,279,I,A,VUF10085,SMILES,O=C(CC1=CC=C(OC(F)(F)F)C=C1)N(C(C(N2C3=CC=C(OCC)C=C3)=NC4=NC=CC=C4C2=O)C)CC5=CC=CN=C5,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.241,µM,=,,0.483,2.004,,,[125I]-CXCL11,70.2,0.0,,0.0,,P49682,2.72872,IA279A,CXCR3
160,25425280,cxcr3_human,279,I,A,TAK-779,ChEMBL Compound ID,CHEMBL1178786,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,31.3,µM,=,,39.4,1.259,,,[125I]-CXCL11,70.2,0.0,,0.0,,P49682,2.72872,IA279A,CXCR3
60,16847335,cxcr3_human,216,R,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,IC50,Binding - Radioligand competition/displacement,0.5,nM,=,,1.35,2.7,,,[125I]-CXCL11,121.0,0.0,,0.0,,P49682,0.453194,RA216A,CXCR3
187,16847335,cxcr3_human,216,R,A,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,IC50,Binding - Radioligand competition/displacement,0.062,nM,=,,0.016,-3.876,,,[125I]-CXCL10,121.0,0.0,,0.0,,P49682,0.453194,RA216A,CXCR3
64,24174496,cxcr3_human,131,F,H,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.2,3.981,,,[125I]-CXCL11,55.0,0.0,,0.0,,P49682,0.992002,FA131H,CXCR3
82,24174496,cxcr3_human,131,F,H,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.0,1.585,,,[125I]-CXCL11,55.0,0.0,,0.0,,P49682,0.992002,FA131H,CXCR3
210,24174496,cxcr3_human,131,F,H,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,55.0,0.0,,0.0,,P49682,0.992002,FA131H,CXCR3
215,24174496,cxcr3_human,131,F,H,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.1,7.943,,,[125I]-CXCL11,55.0,0.0,,0.0,,P49682,0.992002,FA131H,CXCR3
68,21895630,cxcr3_human,282,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,1.4,-7.812,,,[125I]-CXCL11,62.1,0.0,,0.0,,P49682,0.6977,DA282N,CXCR3
131,21895630,cxcr3_human,282,D,N,CXL10_HUMAN,UniProt Entry Code (peptide),P02778,Full agonist,K(d),Binding - Radioligand competition/displacement,4.7,nM,=,,2.9,-1.621,,,[125I]-CXCL11,62.1,0.0,,0.0,,P49682,0.6977,DA282N,CXCR3
69,17170198,cxcr3_human,212,R,A,Zn(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Zn],Full agonist,pEC50,,2.9,,=,,4.5,-40.0,,,,0.0,0.0,,0.0,,P49682,0.975793,RA212A,CXCR3
74,24174496,cxcr3_human,112,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,5.5,3.162,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,-0.323916,DA112N,CXCR3
139,24174496,cxcr3_human,112,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.8,1.0,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,-0.323916,DA112N,CXCR3
154,21895630,cxcr3_human,112,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,10.9,nM,=,,3.8,-2.865,,,[125I]-CXCL11,76.8,0.0,,0.0,,P49682,-0.323916,DA112N,CXCR3
190,24174496,cxcr3_human,112,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,-0.323916,DA112N,CXCR3
192,24174496,cxcr3_human,112,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,6.1,12.589,,,[125I]-CXCL11,96.0,0.0,,0.0,,P49682,-0.323916,DA112N,CXCR3
104,17170198,cxcr3_human,271,Y,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,5.6,3.294,,,,0.0,0.0,,7.169117647,,P49682,1.88219,YA271N,CXCR3
164,17170198,cxcr3_human,271,Y,N,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,693.0,739.594,,,,0.0,0.0,,0.0,,P49682,1.88219,YA271N,CXCR3
122,24174496,cxcr3_human,304,S,A,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.3,-1.259,,,[125I]-CXCL11,111.0,0.0,,0.0,,P49682,-0.761846,SA304A,CXCR3
133,24174496,cxcr3_human,304,S,A,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,7.7,1.259,,,[125I]-CXCL11,111.0,0.0,,0.0,,P49682,-0.761846,SA304A,CXCR3
134,24174496,cxcr3_human,304,S,A,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,<,,4.5,31.623,,,[125I]-CXCL11,111.0,0.0,,0.0,,P49682,-0.761846,SA304A,CXCR3
212,24174496,cxcr3_human,304,S,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.0,5.012,,,[125I]-CXCL11,111.0,0.0,,0.0,,P49682,-0.761846,SA304A,CXCR3
145,17170198,cxcr3_human,271,Y,F,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,7.6,4.471,,,,0.0,0.0,,29.59558824,,P49682,-0.339297,YA271F,CXCR3
176,17170198,cxcr3_human,271,Y,F,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,51.0,54.429,,,,0.0,0.0,,263.0,,P49682,-0.339297,YA271F,CXCR3
171,17170198,cxcr3_human,212,R,H,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,16.0,9.412,,,,0.0,0.0,,42.64705882,,P49682,2.41899,RA212H,CXCR3
172,17170198,cxcr3_human,212,R,H,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,19.0,20.277,,,,0.0,0.0,,526.0,,P49682,2.41899,RA212H,CXCR3
177,25425280,cxcr3_human,205,Y,A,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,K(d),Binding - Radioligand competition/displacement,7.7,nM,=,,10.4,1.351,,,[125I]-CXCL11,82.0,0.0,,0.0,,P49682,3.38377,YA205A,CXCR3
193,17170198,cxcr3_human,271,Y,H,Cu(II)-Bipyridine,SMILES,C1=CC=NC(=C1)C2=CC=CC=N2.C1=CC=NC(=C1)C2=CC=CC=N2.[Cu],Full agonist,EC50,Functional - IP accumulation,0.937,µM,=,,108.0,115.261,,,,0.0,0.0,,196.0,,P49682,1.44443,YA271H,CXCR3
202,17170198,cxcr3_human,271,Y,H,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,EC50,,1.7,nM,=,,9.6,5.647,,,,0.0,0.0,,18.93382353,,P49682,1.44443,YA271H,CXCR3
194,24174496,cxcr3_human,52,D,N,NBI-74330,ChEMBL Compound ID,CHEMBL1077819,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.2,,=,,7.5,-1.996,,,[125I]-CXCL11,121.0,0.0,,0.0,,P49682,0.582583,DA52N,CXCR3
196,24174496,cxcr3_human,52,D,N,CXL11_HUMAN,UniProt Entry Code (peptide),O14625,Full agonist,pK(d),Binding - Radioligand competition/displacement,9.7,,=,,9.6,1.259,,,[125I]-CXCL11,121.0,0.0,,0.0,,P49682,0.582583,DA52N,CXCR3
205,24174496,cxcr3_human,52,D,N,VUF10661,ChEMBL Compound ID,CHEMBL2181467,Full agonist,pIC50,Binding - Radioligand competition/displacement,6.0,,=,,6.9,-7.937,,,[125I]-CXCL11,121.0,0.0,,0.0,,P49682,0.582583,DA52N,CXCR3
207,24174496,cxcr3_human,52,D,N,VUF11211,SMILES,CC[C@H]1CN(C2=NC=C(C(NCC)=O)C=C2Cl)CCN1C3CCN(CC4=CC=C(Cl)C=C4)CC3,Antagonist (neutral/silent),pIC50,Binding - Radioligand competition/displacement,7.8,,=,,8.1,-1.996,,,[125I]-CXCL11,121.0,0.0,,0.0,,P49682,0.582583,DA52N,CXCR3
3,10471797,adrb1_human,323,L,C,Atenolol,ChEMBL Compound ID,CHEMBL24,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.78,-3.311,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
27,10471797,adrb1_human,323,L,C,Practolol,ChEMBL Compound ID,CHEMBL6995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.77,,=,,5.86,-1.23,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
31,10471797,adrb1_human,323,L,C,CGP-20712A,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.69,,=,,7.93,-1.739,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
52,10471797,adrb1_human,323,L,C,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.55,,=,,7.23,-4.785,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
57,10471797,adrb1_human,323,L,C,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.15,,=,,6.05,1.259,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
59,10471797,adrb1_human,323,L,C,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.47,,=,,8.72,-1.779,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
88,10471797,adrb1_human,323,L,C,(-)-timolol,ChEMBL Compound ID,CHEMBL499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.19,,=,,8.12,1.175,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
101,10471797,adrb1_human,323,L,C,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.36,,=,,6.25,1.288,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
107,10471797,adrb1_human,323,L,C,Sotalol,ChEMBL Compound ID,CHEMBL471,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.28,,=,,5.57,-1.949,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
130,10471797,adrb1_human,323,L,C,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.84,,=,,5.55,-5.128,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
149,10471797,adrb1_human,323,L,C,Betaxolol,ChEMBL Compound ID,CHEMBL423,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,7.88,-1.202,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
151,10471797,adrb1_human,323,L,C,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.17,,=,,8.18,-1.024,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
174,10471797,adrb1_human,323,L,C,(rac)-Metoprolol,ChEMBL Compound ID,CHEMBL13,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.74,,=,,6.98,-1.739,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
175,10471797,adrb1_human,323,L,C,(rac)-propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,,=,,8.4,-1.513,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
183,10471797,adrb1_human,323,L,C,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.13,,=,,7.19,-1.148,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.22842,LA323C,ADRB1
7,10471797,adrb1_human,323,L,T,CGP-20712A,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.69,,=,,8.05,-2.288,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
15,10471797,adrb1_human,323,L,T,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.55,,=,,6.96,-2.571,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
16,10471797,adrb1_human,323,L,T,(rac)-propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,,=,,8.58,-2.288,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
21,10471797,adrb1_human,323,L,T,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.47,,=,,8.67,-1.585,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
32,10471797,adrb1_human,323,L,T,Atenolol,ChEMBL Compound ID,CHEMBL24,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.52,-1.818,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
66,10471797,adrb1_human,323,L,T,(-)-timolol,ChEMBL Compound ID,CHEMBL499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.19,,=,,8.29,-1.259,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
82,10471797,adrb1_human,323,L,T,(rac)-Metoprolol,ChEMBL Compound ID,CHEMBL13,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.74,,=,,7.05,-2.041,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
90,10471797,adrb1_human,323,L,T,Practolol,ChEMBL Compound ID,CHEMBL6995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.77,,=,,5.94,-1.479,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
117,10471797,adrb1_human,323,L,T,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.15,,=,,6.15,1.0,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
125,10471797,adrb1_human,323,L,T,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.36,,=,,6.33,1.072,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
128,10471797,adrb1_human,323,L,T,Sotalol,ChEMBL Compound ID,CHEMBL471,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.28,,=,,5.72,-2.755,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
133,10471797,adrb1_human,323,L,T,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.13,,=,,7.26,-1.35,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
135,10471797,adrb1_human,323,L,T,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.17,,=,,8.18,-1.024,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
147,10471797,adrb1_human,323,L,T,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.84,,=,,5.44,-3.984,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
168,10471797,adrb1_human,323,L,T,Betaxolol,ChEMBL Compound ID,CHEMBL423,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,8.08,-1.905,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,1.83161,LA323T,ADRB1
9,10471797,adrb1_human,323,L,F,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.84,,=,,5.61,-5.882,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
25,10471797,adrb1_human,323,L,F,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.17,,=,,8.24,-1.175,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
28,10471797,adrb1_human,323,L,F,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.15,,=,,6.09,1.148,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
56,10471797,adrb1_human,323,L,F,(rac)-Metoprolol,ChEMBL Compound ID,CHEMBL13,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.74,,=,,7.04,-1.996,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
76,10471797,adrb1_human,323,L,F,Atenolol,ChEMBL Compound ID,CHEMBL24,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.77,-3.236,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
84,10471797,adrb1_human,323,L,F,Sotalol,ChEMBL Compound ID,CHEMBL471,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.28,,=,,5.66,-2.398,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
97,10471797,adrb1_human,323,L,F,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.47,,=,,8.84,-2.342,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
102,10471797,adrb1_human,323,L,F,(rac)-propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,,=,,8.46,-1.739,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
114,10471797,adrb1_human,323,L,F,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.13,,=,,7.24,-1.289,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
119,10471797,adrb1_human,323,L,F,(-)-timolol,ChEMBL Compound ID,CHEMBL499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.19,,=,,8.22,-1.072,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
122,10471797,adrb1_human,323,L,F,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.55,,=,,7.39,-6.897,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
124,10471797,adrb1_human,323,L,F,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.36,,=,,6.3,1.148,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
153,10471797,adrb1_human,323,L,F,CGP-20712A,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.69,,=,,8.06,-2.342,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
154,10471797,adrb1_human,323,L,F,Practolol,ChEMBL Compound ID,CHEMBL6995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.77,,=,,5.89,-1.318,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
163,10471797,adrb1_human,323,L,F,Betaxolol,ChEMBL Compound ID,CHEMBL423,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,8.07,-1.862,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.475536,LA323F,ADRB1
12,11907156,adrb1_human,102,S,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,24.0,1.091,,,[125I]iodocyanopindolol (radioligand),255.3,0.0,,0.0,,P08588,-0.973352,SA102A,ADRB1
144,11907156,adrb1_human,102,S,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,60.0,1.053,,,[125I]iodocyanopindolol (radioligand),255.3,0.0,,0.0,,P08588,-0.973352,SA102A,ADRB1
14,10471797,adrb1_human,323,L,A,CGP-20712A,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.69,,=,,8.12,-2.688,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
20,10471797,adrb1_human,323,L,A,Practolol,ChEMBL Compound ID,CHEMBL6995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.77,,=,,6.0,-1.698,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
33,10471797,adrb1_human,323,L,A,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.47,,=,,8.65,-1.513,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
34,10471797,adrb1_human,323,L,A,Betaxolol,ChEMBL Compound ID,CHEMBL423,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,8.07,-1.862,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
63,10471797,adrb1_human,323,L,A,Atenolol,ChEMBL Compound ID,CHEMBL24,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.59,-2.137,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
98,10471797,adrb1_human,323,L,A,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.36,,=,,6.35,1.023,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
99,10471797,adrb1_human,323,L,A,(rac)-Metoprolol,ChEMBL Compound ID,CHEMBL13,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.74,,=,,7.16,-2.632,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
118,10471797,adrb1_human,323,L,A,(rac)-propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,,=,,8.35,-1.35,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
126,10471797,adrb1_human,323,L,A,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.15,,=,,6.25,-1.259,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
134,10471797,adrb1_human,323,L,A,(-)-timolol,ChEMBL Compound ID,CHEMBL499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.19,,=,,8.67,-3.021,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
138,10471797,adrb1_human,323,L,A,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.17,,=,,8.29,-1.318,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
155,10471797,adrb1_human,323,L,A,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.84,,=,,5.9,-11.494,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
164,10471797,adrb1_human,323,L,A,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.55,,=,,7.52,-9.346,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
167,10471797,adrb1_human,323,L,A,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.13,,=,,7.32,-1.548,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
172,10471797,adrb1_human,323,L,A,Sotalol,ChEMBL Compound ID,CHEMBL471,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.28,,=,,5.65,-2.342,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,2.32511,LA323A,ADRB1
17,11907156,adrb1_human,355,P,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,27.0,-2.11,,,[125I]iodocyanopindolol (radioligand),9.7,0.0,,0.0,,P08588,1.68413,PA355A,ADRB1
140,11907156,adrb1_human,355,P,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,22.0,1.0,,,[125I]iodocyanopindolol (radioligand),9.7,0.0,,0.0,,P08588,1.68413,PA355A,ADRB1
26,11907156,adrb1_human,110,L,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,140.0,6.364,,,[125I]iodocyanopindolol (radioligand),44.7,0.0,,0.0,,P08588,2.21022,LA110A,ADRB1
67,11907156,adrb1_human,110,L,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,65.0,1.14,,,[125I]iodocyanopindolol (radioligand),44.7,0.0,,0.0,,P08588,2.21022,LA110A,ADRB1
29,11907156,adrb1_human,119,V,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,20.0,-1.1,,,[125I]iodocyanopindolol (radioligand),63.2,0.0,,0.0,,P08588,0.674635,VA119A,ADRB1
35,11907156,adrb1_human,119,V,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,49.0,-1.163,,,[125I]iodocyanopindolol (radioligand),63.2,0.0,,0.0,,P08588,0.674635,VA119A,ADRB1
30,10471797,adrb1_human,323,L,I,(-)-timolol,ChEMBL Compound ID,CHEMBL499,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.19,,=,,8.33,-1.381,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
50,10471797,adrb1_human,323,L,I,Labetalol,ChEMBL Compound ID,CHEMBL429,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.13,,=,,7.12,1.023,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
65,10471797,adrb1_human,323,L,I,Sotalol,ChEMBL Compound ID,CHEMBL471,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.28,,=,,5.39,-1.289,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
68,10471797,adrb1_human,323,L,I,(+)-propranolol,ChEMBL Compound ID,CHEMBL275742,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.36,,=,,6.29,1.175,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
75,10471797,adrb1_human,323,L,I,(-)-alprenolol,ChEMBL Compound ID,CHEMBL1160734,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.17,,=,,8.21,-1.096,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
81,10471797,adrb1_human,323,L,I,Isoproterenol,ChEMBL Compound ID,CHEMBL434,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.55,,=,,6.33,1.66,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
83,10471797,adrb1_human,323,L,I,(-)-propranolol,ChEMBL Compound ID,CHEMBL452861,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.47,,=,,8.52,-1.122,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
85,10471797,adrb1_human,323,L,I,Practolol,ChEMBL Compound ID,CHEMBL6995,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.77,,=,,5.58,1.549,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
95,10471797,adrb1_human,323,L,I,Betaxolol,ChEMBL Compound ID,CHEMBL423,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.8,,=,,7.66,1.38,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
96,10471797,adrb1_human,323,L,I,(rac)-propranolol,ChEMBL Compound ID,CHEMBL27,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.22,,=,,8.47,-1.779,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
103,10471797,adrb1_human,323,L,I,"ICI118,551",ChEMBL Compound ID,CHEMBL513389,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.15,,=,,5.99,1.445,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
121,10471797,adrb1_human,323,L,I,(rac)-Metoprolol,ChEMBL Compound ID,CHEMBL13,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.74,,=,,6.69,1.122,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
129,10471797,adrb1_human,323,L,I,Atenolol,ChEMBL Compound ID,CHEMBL24,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.26,,=,,6.43,-1.479,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
165,10471797,adrb1_human,323,L,I,CGP-20712A,ChEMBL Compound ID,CHEMBL280822,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.69,,=,,7.86,-1.479,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
166,10471797,adrb1_human,323,L,I,(-)-Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.84,,=,,4.68,1.445,,,[125I]iodocyanopindolol (radioligand),0.0,0.0,,0.0,,P08588,-0.233375,LA323I,ADRB1
42,11907156,adrb1_human,98,M,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,78.0,1.368,,,[125I]iodocyanopindolol (radioligand),86.8,0.0,,0.0,,P08588,1.64344,MA98A,ADRB1
170,11907156,adrb1_human,98,M,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,20.0,-1.1,,,[125I]iodocyanopindolol (radioligand),86.8,0.0,,0.0,,P08588,1.64344,MA98A,ADRB1
44,11907156,adrb1_human,375,I,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,31.0,-1.838,,,[125I]iodocyanopindolol (radioligand),31.6,0.0,,0.0,,P08588,1.16671,IA375A,ADRB1
157,11907156,adrb1_human,375,I,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,19.0,-1.157,,,[125I]iodocyanopindolol (radioligand),31.6,0.0,,0.0,,P08588,1.16671,IA375A,ADRB1
45,11907156,adrb1_human,362,F,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,27.0,-2.11,,,[125I]iodocyanopindolol (radioligand),6.6,0.0,,0.0,,P08588,2.41719,FA362A,ADRB1
137,11907156,adrb1_human,362,F,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,23.0,1.045,,,[125I]iodocyanopindolol (radioligand),6.6,0.0,,0.0,,P08588,2.41719,FA362A,ADRB1
46,11907156,adrb1_human,120,V,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,28.0,1.273,,,[125I]iodocyanopindolol (radioligand),52.6,0.0,,0.0,,P08588,1.45993,VA120A,ADRB1
176,11907156,adrb1_human,120,V,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,79.0,1.386,,,[125I]iodocyanopindolol (radioligand),52.6,0.0,,0.0,,P08588,1.45993,VA120A,ADRB1
54,11907156,adrb1_human,359,F,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,90.0,4.091,,,[125I]iodocyanopindolol (radioligand),34.2,0.0,,0.0,,P08588,2.8264,FA359A,ADRB1
70,11907156,adrb1_human,359,F,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,50.0,-1.14,,,[125I]iodocyanopindolol (radioligand),34.2,0.0,,0.0,,P08588,2.8264,FA359A,ADRB1
58,11907156,adrb1_human,356,D,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,47.0,-1.212,,,[125I]iodocyanopindolol (radioligand),12.1,0.0,,0.0,,P08588,1.18126,DA356A,ADRB1
62,11907156,adrb1_human,356,D,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,36.0,1.636,,,[125I]iodocyanopindolol (radioligand),12.1,0.0,,0.0,,P08588,1.18126,DA356A,ADRB1
89,11907156,adrb1_human,121,W,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,20.0,-1.1,,,[125I]iodocyanopindolol (radioligand),92.1,0.0,,0.0,,P08588,0.759687,WA121A,ADRB1
136,11907156,adrb1_human,121,W,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,59.0,1.035,,,[125I]iodocyanopindolol (radioligand),92.1,0.0,,0.0,,P08588,0.759687,WA121A,ADRB1
91,11907156,adrb1_human,360,V,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,37.0,-1.541,,,[125I]iodocyanopindolol (radioligand),50.0,0.0,,0.0,,P08588,0.0846628,VA360A,ADRB1
150,11907156,adrb1_human,360,V,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,40.0,1.818,,,[125I]iodocyanopindolol (radioligand),50.0,0.0,,0.0,,P08588,0.0846628,VA360A,ADRB1
93,11907156,adrb1_human,357,R,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,40.0,-1.425,,,[125I]iodocyanopindolol (radioligand),65.8,0.0,,0.0,,P08588,0.0651486,RA357A,ADRB1
171,11907156,adrb1_human,357,R,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,32.0,1.455,,,[125I]iodocyanopindolol (radioligand),65.8,0.0,,0.0,,P08588,0.0651486,RA357A,ADRB1
106,11907156,adrb1_human,117,T,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,54.0,2.455,,,[125I]iodocyanopindolol (radioligand),34.2,0.0,,0.0,,P08588,-0.0257873,TA117A,ADRB1
115,11907156,adrb1_human,117,T,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,75.0,1.316,,,[125I]iodocyanopindolol (radioligand),34.2,0.0,,0.0,,P08588,-0.0257873,TA117A,ADRB1
120,19580817,adrb1_human,104,D,A,(-)-Isoproterenol,ChEMBL Compound ID,CHEMBL1160723,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.8,,=,,5.7,12.589,,,[3H]CGP-12177,0.0,0.0,,0.0,,P08588,-2.12104,DA104A,ADRB1
142,19580817,adrb1_human,104,D,A,[3H]CGP-12177,ChEMBL Compound ID,CHEMBL420746,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,127.4,pM,=,,228.4,1.793,,,,698.1,0.0,,0.0,,P08588,-2.12104,DA104A,ADRB1
131,11907156,adrb1_human,365,L,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,22.0,1.0,,,[125I]iodocyanopindolol (radioligand),22.6,0.0,,0.0,,P08588,1.25501,LA365A,ADRB1
158,11907156,adrb1_human,365,L,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,26.0,-2.193,,,[125I]iodocyanopindolol (radioligand),22.6,0.0,,0.0,,P08588,1.25501,LA365A,ADRB1
156,11907156,adrb1_human,358,L,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,25.0,1.136,,,[125I]iodocyanopindolol (radioligand),9.7,0.0,,0.0,,P08588,1.82748,LA358A,ADRB1
177,11907156,adrb1_human,358,L,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,25.0,-2.278,,,[125I]iodocyanopindolol (radioligand),9.7,0.0,,0.0,,P08588,1.82748,LA358A,ADRB1
159,11907156,adrb1_human,118,I,A,[125I]Cyanopindolol,ChEMBL Compound ID,CHEMBL210309,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,57.0,pM,=,,56.0,-1.018,,,[125I]iodocyanopindolol (radioligand),157.9,0.0,,0.0,,P08588,0.879465,IA118A,ADRB1
160,11907156,adrb1_human,118,I,A,(-)-RO363,SMILES,COc1c(OC)ccc(CCNC[C@@H](O)COc2cc(O)c(O)cc2)c1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,22.0,nM,=,,20.0,-1.1,,,[125I]iodocyanopindolol (radioligand),157.9,0.0,,0.0,,P08588,0.879465,IA118A,ADRB1
1,16102831,ccr3_human,28,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,11.35,1.277,,,125I-CCL11,72.60753241,0.0,,0.0,,P51677,0.614807,DA28A,CCR3
3,16102831,ccr3_human,272,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,4.4,-2.02,,,125I-CCL11,88.94834328,0.0,,0.0,,P51677,5.47918,DA272A,CCR3
4,16102831,ccr3_human,6,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,12.33,1.387,,,125I-CCL11,94.95781025,0.0,,0.0,,P51677,0.378024,DA6A,CCR3
5,16102831,ccr3_human,19,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,6.76,-1.316,,,125I-CCL11,94.69026549,0.0,,0.0,,P51677,-0.011354,DA19A,CCR3
6,16102831,ccr3_human,275,R,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,4.81,-1.848,,,125I-CCL11,98.51821362,0.0,,0.0,,P51677,0.788067,RA275A,CCR3
7,16102831,ccr3_human,196,R,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,14.16,1.593,,,125I-CCL11,94.69026549,0.0,,0.0,,P51677,0.609342,RA196A,CCR3
8,16102831,ccr3_human,25,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,11.94,1.343,,,125I-CCL11,89.5451739,0.0,,0.0,,P51677,0.982153,EA25A,CCR3
11,16102831,ccr3_human,277,K,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,5.39,-1.65,,,125I-CCL11,97.63325787,0.0,,0.0,,P51677,0.45395,KA277A,CCR3
12,16102831,ccr3_human,9,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,12.16,1.368,,,125I-CCL11,95.49289977,0.0,,0.0,,P51677,0.403351,EA9A,CCR3
14,16102831,ccr3_human,189,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,14.77,1.661,,,125I-CCL11,94.79316732,0.0,,0.0,,P51677,0.223985,EA189A,CCR3
15,16102831,ccr3_human,26,K,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,9.12,1.026,,,125I-CCL11,89.09240584,0.0,,0.0,,P51677,0.892227,KA26A,CCR3
17,16102831,ccr3_human,180,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,10.89,1.225,,,125I-CCL11,91.37682651,0.0,,0.0,,P51677,-0.279649,EA180A,CCR3
18,16102831,ccr3_human,179,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,9.91,1.115,,,125I-CCL11,67.99753036,0.0,,0.0,,P51677,0.186939,EA179A,CCR3
19,16102831,ccr3_human,30,R,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,14.13,1.589,,,125I-CCL11,94.93722988,0.0,,0.0,,P51677,0.0697563,RA30A,CCR3
20,16102831,ccr3_human,173,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,11.71,1.317,,,125I-CCL11,95.10187281,0.0,,0.0,,P51677,-0.582606,EA173A,CCR3
22,16102831,ccr3_human,190,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,19.17,2.156,,,125I-CCL11,108.5202717,0.0,,0.0,,P51677,0.470549,DA190A,CCR3
23,16102831,ccr3_human,274,E,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,4.91,-1.812,,,125I-CCL11,88.94834328,0.0,,0.0,,P51677,0.0893076,EA274A,CCR3
24,16102831,ccr3_human,18,D,A,CCL11_HUMAN,UniProt Entry Code (peptide),P51671,Full agonist,IC50,Binding - Radioligand competition/displacement,8.89,nM,=,,8.07,-1.101,,,125I-CCL11,91.10928175,0.0,,0.0,,P51677,0.394251,DA18A,CCR3
0,11961043,hrh3_human,206,E,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,42100.0,54675.325,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
4,11961043,hrh3_human,206,E,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,295.15,19.017,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
7,11961043,hrh3_human,206,E,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,32550.0,2052.333,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
13,11961043,hrh3_human,206,E,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,888.3,95.107,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
16,11961043,hrh3_human,206,E,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,42100.0,3304.553,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
19,11961043,hrh3_human,206,E,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,888.3,1974.0,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,0.456676,EA206A,HRH3
2,11961043,hrh3_human,208,F,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,70.0,7.495,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
3,11961043,hrh3_human,208,F,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,2.17,2.818,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
17,11961043,hrh3_human,208,F,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,36.81,2.321,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
31,11961043,hrh3_human,208,F,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,70.0,155.556,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
46,11961043,hrh3_human,208,F,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,2.17,-5.882,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
56,11961043,hrh3_human,208,F,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,14.16,-1.096,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,1.34159,FA208A,HRH3
6,11961043,hrh3_human,199,L,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,28.34,3.034,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
10,11961043,hrh3_human,199,L,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,28.34,62.978,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
11,11961043,hrh3_human,199,L,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,10.2,-1.522,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
34,11961043,hrh3_human,199,L,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,18.69,1.178,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
47,11961043,hrh3_human,199,L,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,2.77,-4.608,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
61,11961043,hrh3_human,199,L,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,2.77,3.597,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.10413,LA199A,HRH3
9,12681376,hrh3_human,122,A,V,[3H]N-alpha-methylhistamine,ChEMBL Compound ID,CHEMBL268490,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.34,nM,=,,0.53,1.559,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
27,12681376,hrh3_human,122,A,V,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,0.61,1.089,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
33,12681376,hrh3_human,122,A,V,GT-2331,ChEMBL Compound ID,CHEMBL354374,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.9,nM,=,,1.7,-2.294,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
36,12681376,hrh3_human,122,A,V,A-304121,ChEMBL Compound ID,CHEMBL302196,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,727.0,nM,=,,39.0,-18.519,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
50,12681376,hrh3_human,122,A,V,Imoproxifan,ChEMBL Compound ID,CHEMBL1180120,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,42.0,nM,=,,4.0,-10.526,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
57,12681376,hrh3_human,122,A,V,Thioperamide,ChEMBL Compound ID,CHEMBL260374,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,66.0,nM,=,,2.8,-23.81,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
58,12681376,hrh3_human,122,A,V,Ciproxifan,ChEMBL Compound ID,CHEMBL14638,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,65.0,nM,=,,4.4,-14.706,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
65,12681376,hrh3_human,122,A,V,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,3.2,1.143,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
72,12681376,hrh3_human,122,A,V,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,0.03,-12.048,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,3.75468,AA122V,HRH3
12,12681376,hrh3_human,119,T,A,A-304121,ChEMBL Compound ID,CHEMBL302196,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,727.0,nM,=,,23.0,-31.25,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
20,12681376,hrh3_human,119,T,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,0.49,-1.143,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
22,12681376,hrh3_human,119,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,2.3,-1.218,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
25,12681376,hrh3_human,119,T,A,[3H]N-alpha-methylhistamine,ChEMBL Compound ID,CHEMBL268490,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,0.34,nM,=,,0.32,-1.063,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
35,12681376,hrh3_human,119,T,A,Clobenpropit,ChEMBL Compound ID,CHEMBL14690,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.36,nM,=,,0.78,2.167,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
73,12681376,hrh3_human,119,T,A,GT-2331,ChEMBL Compound ID,CHEMBL354374,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,3.9,nM,=,,0.7,-5.587,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
74,12681376,hrh3_human,119,T,A,Imoproxifan,ChEMBL Compound ID,CHEMBL1180120,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,42.0,nM,=,,15.0,-2.801,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
75,12681376,hrh3_human,119,T,A,Ciproxifan,ChEMBL Compound ID,CHEMBL14638,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,65.0,nM,=,,6.5,-10.0,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
83,12681376,hrh3_human,119,T,A,Thioperamide,ChEMBL Compound ID,CHEMBL260374,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,66.0,nM,=,,32.0,-2.062,,,[3H]N-alpha-methylhistamine (radioligand),0.0,0.0,,0.0,,Q9Y5N1,-0.158524,TA119A,HRH3
14,11961043,hrh3_human,204,T,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,13.94,18.104,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
32,11961043,hrh3_human,204,T,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,35.38,2.28,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
48,11961043,hrh3_human,204,T,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,13.94,1.094,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
64,11961043,hrh3_human,204,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,91.0,5.738,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
81,11961043,hrh3_human,204,T,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,86.63,9.275,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
84,11961043,hrh3_human,204,T,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,86.63,192.511,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.597207,TA204A,HRH3
26,11961043,hrh3_human,201,T,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,6.61,8.584,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
28,11961043,hrh3_human,201,T,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,56.07,6.003,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
38,11961043,hrh3_human,201,T,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,56.07,124.6,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
45,11961043,hrh3_human,201,T,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,6.61,-1.927,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
54,11961043,hrh3_human,201,T,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,14.36,-1.081,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
87,11961043,hrh3_human,201,T,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,17.91,1.129,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,-0.103099,TA201A,HRH3
39,11961043,hrh3_human,196,W,A,Impentamine,ChEMBL Compound ID,CHEMBL417096,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.52,nM,=,,11.06,-1.403,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
40,11961043,hrh3_human,196,W,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.34,nM,=,,68.1,7.291,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
42,11961043,hrh3_human,196,W,A,Histamine,ChEMBL Compound ID,CHEMBL90,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,15.86,nM,=,,25.38,1.6,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
63,11961043,hrh3_human,196,W,A,Imetit,ChEMBL Compound ID,CHEMBL19439,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.45,nM,=,,68.1,151.333,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
69,11961043,hrh3_human,196,W,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,12.74,nM,=,,5.68,-2.242,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
85,11961043,hrh3_human,196,W,A,R-alfa methylhistamine,ChEMBL Compound ID,CHEMBL268229,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.77,nM,=,,5.68,7.377,,,[125I]-iodoproxyfan,0.0,0.0,,0.0,,Q9Y5N1,2.63901,WA196A,HRH3
0,26005408,5ht7r_human,374,Y,F,[3H]5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.55,9.12,,,,0.0,0.0,,0.0,,P34969,1.35056,YA374F,HTR7
23,26005408,5ht7r_human,374,Y,F,[3H]SB269970,ChEMBL Compound ID,CHEMBL282199,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.98,3.388,,,,0.0,0.0,,0.0,,P34969,1.35056,YA374F,HTR7
1,26005408,5ht7r_human,364,W,V,[3H]SB269970,ChEMBL Compound ID,CHEMBL282199,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,9.3,1.622,,,,0.0,0.0,,0.0,,P34969,0.710916,WA364V,HTR7
7,26005408,5ht7r_human,364,W,V,[3H]5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,9.57,-1.148,,,,0.0,0.0,,0.0,,P34969,0.710916,WA364V,HTR7
3,26005408,5ht7r_human,374,Y,T,[3H]5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.55,9.12,,,,0.0,0.0,,0.0,,P34969,5.00587,YA374T,HTR7
22,26005408,5ht7r_human,374,Y,T,[3H]SB269970,ChEMBL Compound ID,CHEMBL282199,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.56,8.913,,,,0.0,0.0,,0.0,,P34969,5.00587,YA374T,HTR7
8,26005408,5ht7r_human,374,Y,A,[3H]SB269970,ChEMBL Compound ID,CHEMBL282199,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,9.77,-1.818,,,,0.0,0.0,,0.0,,P34969,4.59383,YA374A,HTR7
17,26005408,5ht7r_human,374,Y,A,[3H]5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.17,21.878,,,,0.0,0.0,,0.0,,P34969,4.59383,YA374A,HTR7
10,26005408,5ht7r_human,366,E,A,[3H]5-CT,ChEMBL Compound ID,CHEMBL18840,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,8.74,5.888,,,,0.0,0.0,,0.0,,P34969,1.19271,EA366A,HTR7
12,26005408,5ht7r_human,366,E,A,[3H]SB269970,ChEMBL Compound ID,CHEMBL282199,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.51,,=,,9.41,1.259,,,,0.0,0.0,,0.0,,P34969,1.19271,EA366A,HTR7
0,17652183,ccr8_human,193,K,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,17.0,1.133,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.155987,KA193A,CCR8
83,17652183,ccr8_human,193,K,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,31.0,1.069,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.155987,KA193A,CCR8
84,17652183,ccr8_human,193,K,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,8.5,-1.294,,,[125I]-CCL1,0.0,92.55617978,,0.0,,P51685,0.155987,KA193A,CCR8
120,17652183,ccr8_human,193,K,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,30.0,1.0,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.155987,KA193A,CCR8
159,17652183,ccr8_human,193,K,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,4.7,-1.916,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.155987,KA193A,CCR8
165,17652183,ccr8_human,193,K,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,22.0,2.529,,,[125I]-CCL1,0.0,92.55617978,,0.0,,P51685,0.155987,KA193A,CCR8
1,17652183,ccr8_human,110,S,W,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,>,,10000.0,666.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.95572,SA110W,CCR8
7,17652183,ccr8_human,110,S,W,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,>,,10000.0,344.828,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.95572,SA110W,CCR8
50,17652183,ccr8_human,110,S,W,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,>,,1000.0,114.943,,,[125I]-CCL1,0.0,56.17977528,,0.0,,P51685,2.95572,SA110W,CCR8
107,17652183,ccr8_human,110,S,W,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,>,,10000.0,333.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.95572,SA110W,CCR8
112,17652183,ccr8_human,110,S,W,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,>,,10000.0,909.091,,,[125I]-CCL1,0.0,56.17977528,,0.0,,P51685,2.95572,SA110W,CCR8
166,17652183,ccr8_human,110,S,W,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,>,,10000.0,1111.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.95572,SA110W,CCR8
2,17652183,ccr8_human,91,Q,W,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,368.0,12.69,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.56386,QA91W,CCR8
10,17652183,ccr8_human,91,Q,W,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,69.0,7.931,,,[125I]-CCL1,0.0,93.3988764,,0.0,,P51685,-1.56386,QA91W,CCR8
43,17652183,ccr8_human,91,Q,W,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,180.0,12.0,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.56386,QA91W,CCR8
72,17652183,ccr8_human,91,Q,W,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,161.0,17.889,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.56386,QA91W,CCR8
81,17652183,ccr8_human,91,Q,W,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,201.0,6.7,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.56386,QA91W,CCR8
143,17652183,ccr8_human,91,Q,W,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,108.0,9.818,,,[125I]-CCL1,0.0,93.3988764,,0.0,,P51685,-1.56386,QA91W,CCR8
3,17652183,ccr8_human,262,S,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,8.9,-1.011,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.614859,SA262A,CCR8
63,17652183,ccr8_human,262,S,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,5.2,-1.672,,,[125I]-CCL1,0.0,87.21910112,,0.0,,P51685,-0.614859,SA262A,CCR8
76,17652183,ccr8_human,262,S,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,21.0,1.909,,,[125I]-CCL1,0.0,87.21910112,,0.0,,P51685,-0.614859,SA262A,CCR8
77,17652183,ccr8_human,262,S,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,39.0,1.3,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.614859,SA262A,CCR8
113,17652183,ccr8_human,262,S,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,61.0,2.103,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.614859,SA262A,CCR8
115,17652183,ccr8_human,262,S,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,13.0,-1.153,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.614859,SA262A,CCR8
4,17652183,ccr8_human,290,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,6.0,-1.449,,,[125I]-CCL1,0.0,350.7022472,,0.0,,P51685,2.30847,FA290A,CCR8
29,17652183,ccr8_human,290,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,29.0,-1.034,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.30847,FA290A,CCR8
80,17652183,ccr8_human,290,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,41.0,1.414,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.30847,FA290A,CCR8
117,17652183,ccr8_human,290,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,20.0,1.818,,,[125I]-CCL1,0.0,350.7022472,,0.0,,P51685,2.30847,FA290A,CCR8
146,17652183,ccr8_human,290,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,21.0,2.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.30847,FA290A,CCR8
147,17652183,ccr8_human,290,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,26.0,1.733,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.30847,FA290A,CCR8
5,17652183,ccr8_human,84,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,14.0,1.273,,,[125I]-CCL1,0.0,141.7134831,,0.0,,P51685,2.73585,FA84A,CCR8
54,17652183,ccr8_human,84,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,12.0,-1.25,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.73585,FA84A,CCR8
100,17652183,ccr8_human,84,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,7.0,-4.149,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.73585,FA84A,CCR8
102,17652183,ccr8_human,84,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,4.0,-2.174,,,[125I]-CCL1,0.0,141.7134831,,0.0,,P51685,2.73585,FA84A,CCR8
145,17652183,ccr8_human,84,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,133.0,4.433,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.73585,FA84A,CCR8
158,17652183,ccr8_human,84,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,4.8,-1.876,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.73585,FA84A,CCR8
6,17652183,ccr8_human,42,Y,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,172.0,19.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.30676,YA42A,CCR8
95,17652183,ccr8_human,42,Y,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,199.0,6.633,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.30676,YA42A,CCR8
121,17652183,ccr8_human,42,Y,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,11.0,1.264,,,[125I]-CCL1,0.0,110.3932584,,0.0,,P51685,3.30676,YA42A,CCR8
155,17652183,ccr8_human,42,Y,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,178.0,11.867,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.30676,YA42A,CCR8
157,17652183,ccr8_human,42,Y,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,158.0,14.364,,,[125I]-CCL1,0.0,110.3932584,,0.0,,P51685,3.30676,YA42A,CCR8
170,17652183,ccr8_human,42,Y,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,131.0,4.517,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.30676,YA42A,CCR8
8,17652183,ccr8_human,254,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,0.57,-19.231,,,[125I]-CCL1,0.0,117.2752809,,0.0,,P51685,2.56672,FA254A,CCR8
37,17652183,ccr8_human,254,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,42.0,1.4,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.56672,FA254A,CCR8
62,17652183,ccr8_human,254,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,109.0,12.529,,,[125I]-CCL1,0.0,117.2752809,,0.0,,P51685,2.56672,FA254A,CCR8
116,17652183,ccr8_human,254,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,10.0,1.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.56672,FA254A,CCR8
122,17652183,ccr8_human,254,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,278.0,9.586,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.56672,FA254A,CCR8
127,17652183,ccr8_human,254,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,80.0,5.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.56672,FA254A,CCR8
9,17652183,ccr8_human,194,W,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,12.0,-2.415,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.03123,WA194A,CCR8
27,17652183,ccr8_human,194,W,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,4.0,-3.745,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.03123,WA194A,CCR8
28,17652183,ccr8_human,194,W,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,32.0,1.067,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.03123,WA194A,CCR8
40,17652183,ccr8_human,194,W,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,128.0,14.713,,,[125I]-CCL1,0.0,94.52247191,,0.0,,P51685,1.03123,WA194A,CCR8
41,17652183,ccr8_human,194,W,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,7.6,-1.447,,,[125I]-CCL1,0.0,94.52247191,,0.0,,P51685,1.03123,WA194A,CCR8
109,17652183,ccr8_human,194,W,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,6.0,-1.499,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.03123,WA194A,CCR8
11,17652183,ccr8_human,195,K,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,30.0,1.0,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.487468,KA195A,CCR8
21,17652183,ccr8_human,195,K,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,7.0,-2.141,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.487468,KA195A,CCR8
55,17652183,ccr8_human,195,K,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,0.22,-41.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.487468,KA195A,CCR8
101,17652183,ccr8_human,195,K,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,20.0,-1.449,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.487468,KA195A,CCR8
141,17652183,ccr8_human,195,K,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,6.2,-1.773,,,[125I]-CCL1,0.0,93.53932584,,0.0,,P51685,0.487468,KA195A,CCR8
152,17652183,ccr8_human,195,K,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,7.5,-1.16,,,[125I]-CCL1,0.0,93.53932584,,0.0,,P51685,0.487468,KA195A,CCR8
12,17652183,ccr8_human,112,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,>,,37.0,1.233,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.44147,FA112A,CCR8
35,17652183,ccr8_human,112,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,>,,7.1,-1.267,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.44147,FA112A,CCR8
53,17652183,ccr8_human,112,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,4.6,-1.89,,,[125I]-CCL1,0.0,91.43258427,,0.0,,P51685,1.44147,FA112A,CCR8
97,17652183,ccr8_human,112,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,>,,13.0,-1.153,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.44147,FA112A,CCR8
124,17652183,ccr8_human,112,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,51.0,1.759,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.44147,FA112A,CCR8
137,17652183,ccr8_human,112,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,11.0,1.0,,,[125I]-CCL1,0.0,91.43258427,,0.0,,P51685,1.44147,FA112A,CCR8
13,17652183,ccr8_human,172,Y,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,21.0,1.909,,,[125I]-CCL1,0.0,184.6910112,,0.0,,P51685,2.70818,YA172A,CCR8
16,17652183,ccr8_human,172,Y,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,11.0,1.264,,,[125I]-CCL1,0.0,184.6910112,,0.0,,P51685,2.70818,YA172A,CCR8
20,17652183,ccr8_human,172,Y,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,93.0,3.1,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.70818,YA172A,CCR8
24,17652183,ccr8_human,172,Y,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,28.0,3.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.70818,YA172A,CCR8
47,17652183,ccr8_human,172,Y,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,31.0,2.067,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.70818,YA172A,CCR8
169,17652183,ccr8_human,172,Y,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,56.0,1.931,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.70818,YA172A,CCR8
14,17652183,ccr8_human,258,L,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,13.0,1.182,,,[125I]-CCL1,0.0,83.00561798,,0.0,,P51685,0.947209,LA258A,CCR8
33,17652183,ccr8_human,258,L,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,35.0,2.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.947209,LA258A,CCR8
36,17652183,ccr8_human,258,L,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,64.0,2.133,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.947209,LA258A,CCR8
79,17652183,ccr8_human,258,L,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,27.0,3.103,,,[125I]-CCL1,0.0,83.00561798,,0.0,,P51685,0.947209,LA258A,CCR8
96,17652183,ccr8_human,258,L,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,329.0,11.345,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.947209,LA258A,CCR8
126,17652183,ccr8_human,258,L,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,65.0,7.222,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.947209,LA258A,CCR8
15,17652183,ccr8_human,283,H,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,12.0,1.379,,,[125I]-CCL1,0.0,99.01685393,,0.0,,P51685,-0.202675,HA283A,CCR8
18,17652183,ccr8_human,283,H,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,34.0,2.267,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.202675,HA283A,CCR8
65,17652183,ccr8_human,283,H,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,30.0,1.034,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.202675,HA283A,CCR8
66,17652183,ccr8_human,283,H,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,17.0,1.889,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.202675,HA283A,CCR8
103,17652183,ccr8_human,283,H,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,46.0,1.533,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.202675,HA283A,CCR8
118,17652183,ccr8_human,283,H,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,24.0,2.182,,,[125I]-CCL1,0.0,99.01685393,,0.0,,P51685,-0.202675,HA283A,CCR8
19,17652183,ccr8_human,251,W,Q,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,22.0,-1.318,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.775152,WA251Q,CCR8
64,17652183,ccr8_human,251,W,Q,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,44.0,4.0,,,[125I]-CCL1,0.0,154.0730337,,0.0,,P51685,-0.775152,WA251Q,CCR8
70,17652183,ccr8_human,251,W,Q,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,15.0,1.0,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.775152,WA251Q,CCR8
88,17652183,ccr8_human,251,W,Q,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,10.0,1.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.775152,WA251Q,CCR8
134,17652183,ccr8_human,251,W,Q,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,29.0,-1.034,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.775152,WA251Q,CCR8
140,17652183,ccr8_human,251,W,Q,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,6.6,-1.318,,,[125I]-CCL1,0.0,154.0730337,,0.0,,P51685,-0.775152,WA251Q,CCR8
22,17652183,ccr8_human,206,G,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,2.0,-4.505,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.76739,GA206A,CCR8
25,17652183,ccr8_human,206,G,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,19.0,1.727,,,[125I]-CCL1,0.0,71.34831461,,0.0,,P51685,2.76739,GA206A,CCR8
78,17652183,ccr8_human,206,G,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,67.0,7.701,,,[125I]-CCL1,0.0,71.34831461,,0.0,,P51685,2.76739,GA206A,CCR8
92,17652183,ccr8_human,206,G,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,12.0,-1.25,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.76739,GA206A,CCR8
144,17652183,ccr8_human,206,G,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,62.0,2.067,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.76739,GA206A,CCR8
160,17652183,ccr8_human,206,G,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,47.0,1.621,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.76739,GA206A,CCR8
23,17652183,ccr8_human,286,E,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,10000.0,666.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.836032,EA286A,CCR8
75,17652183,ccr8_human,286,E,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,>,,10000.0,909.091,,,[125I]-CCL1,0.0,130.6179775,,0.0,,P51685,0.836032,EA286A,CCR8
108,17652183,ccr8_human,286,E,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,12.0,1.379,,,[125I]-CCL1,0.0,130.6179775,,0.0,,P51685,0.836032,EA286A,CCR8
114,17652183,ccr8_human,286,E,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,10000.0,1111.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.836032,EA286A,CCR8
150,17652183,ccr8_human,286,E,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,10000.0,333.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.836032,EA286A,CCR8
163,17652183,ccr8_human,286,E,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,10000.0,344.828,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.836032,EA286A,CCR8
26,17652183,ccr8_human,110,S,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,2.0,-7.519,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.864139,SA110A,CCR8
51,17652183,ccr8_human,110,S,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,1.6,-5.618,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.864139,SA110A,CCR8
99,17652183,ccr8_human,110,S,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,3.6,-8.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.864139,SA110A,CCR8
128,17652183,ccr8_human,110,S,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,1.5,-7.353,,,[125I]-CCL1,0.0,120.9269663,,0.0,,P51685,-0.864139,SA110A,CCR8
138,17652183,ccr8_human,110,S,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,6.0,-4.831,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.864139,SA110A,CCR8
168,17652183,ccr8_human,110,S,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,1.6,-5.435,,,[125I]-CCL1,0.0,120.9269663,,0.0,,P51685,-0.864139,SA110A,CCR8
30,17652183,ccr8_human,251,W,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,29.0,-1.034,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.32001,WA251A,CCR8
59,17652183,ccr8_human,251,W,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,44.0,4.0,,,[125I]-CCL1,0.0,160.9550562,,0.0,,P51685,-1.32001,WA251A,CCR8
60,17652183,ccr8_human,251,W,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,4.7,-3.195,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.32001,WA251A,CCR8
106,17652183,ccr8_human,251,W,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,20.0,-1.449,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.32001,WA251A,CCR8
131,17652183,ccr8_human,251,W,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,42.0,4.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-1.32001,WA251A,CCR8
171,17652183,ccr8_human,251,W,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,3.4,-2.558,,,[125I]-CCL1,0.0,160.9550562,,0.0,,P51685,-1.32001,WA251A,CCR8
31,17652183,ccr8_human,123,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,19.0,-1.58,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,4.01403,FA123A,CCR8
52,17652183,ccr8_human,123,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,5.0,-1.799,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,4.01403,FA123A,CCR8
74,17652183,ccr8_human,123,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,4.4,-1.976,,,[125I]-CCL1,0.0,59.83146067,,0.0,,P51685,4.01403,FA123A,CCR8
104,17652183,ccr8_human,123,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,7.0,-1.572,,,[125I]-CCL1,0.0,59.83146067,,0.0,,P51685,4.01403,FA123A,CCR8
133,17652183,ccr8_human,123,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,21.0,-1.381,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,4.01403,FA123A,CCR8
151,17652183,ccr8_human,123,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,12.0,-1.25,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,4.01403,FA123A,CCR8
38,17652183,ccr8_human,113,Y,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,>,,10000.0,344.828,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.57097,YA113A,CCR8
48,17652183,ccr8_human,113,Y,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,10000.0,333.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.57097,YA113A,CCR8
89,17652183,ccr8_human,113,Y,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,10000.0,1111.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.57097,YA113A,CCR8
135,17652183,ccr8_human,113,Y,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,>,,10000.0,909.091,,,[125I]-CCL1,0.0,80.05617978,,0.0,,P51685,2.57097,YA113A,CCR8
139,17652183,ccr8_human,113,Y,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,10000.0,666.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.57097,YA113A,CCR8
167,17652183,ccr8_human,113,Y,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,323.0,37.126,,,[125I]-CCL1,0.0,80.05617978,,0.0,,P51685,2.57097,YA113A,CCR8
42,17652183,ccr8_human,88,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,31.0,3.444,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.90025,FA88A,CCR8
91,17652183,ccr8_human,88,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,197.0,13.133,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.90025,FA88A,CCR8
142,17652183,ccr8_human,88,F,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,10.0,1.149,,,[125I]-CCL1,0.0,112.2191011,,0.0,,P51685,3.90025,FA88A,CCR8
148,17652183,ccr8_human,88,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,251.0,8.655,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.90025,FA88A,CCR8
149,17652183,ccr8_human,88,F,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,108.0,9.818,,,[125I]-CCL1,0.0,112.2191011,,0.0,,P51685,3.90025,FA88A,CCR8
161,17652183,ccr8_human,88,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,94.0,3.133,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.90025,FA88A,CCR8
44,17652183,ccr8_human,282,T,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,77.0,2.655,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.222207,TA282A,CCR8
57,17652183,ccr8_human,282,T,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,40.0,4.444,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.222207,TA282A,CCR8
98,17652183,ccr8_human,282,T,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,31.0,2.067,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.222207,TA282A,CCR8
153,17652183,ccr8_human,282,T,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,93.0,3.1,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,0.222207,TA282A,CCR8
45,17652183,ccr8_human,109,V,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,34.0,1.172,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.60533,VA109A,CCR8
90,17652183,ccr8_human,109,V,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,8.2,-1.06,,,[125I]-CCL1,0.0,132.0224719,,0.0,,P51685,1.60533,VA109A,CCR8
110,17652183,ccr8_human,109,V,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,2.6,-3.46,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.60533,VA109A,CCR8
154,17652183,ccr8_human,109,V,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,8.0,-1.876,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.60533,VA109A,CCR8
156,17652183,ccr8_human,109,V,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,7.7,-1.429,,,[125I]-CCL1,0.0,132.0224719,,0.0,,P51685,1.60533,VA109A,CCR8
164,17652183,ccr8_human,109,V,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,33.0,1.1,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,1.60533,VA109A,CCR8
46,17652183,ccr8_human,114,Y,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,430.0,14.828,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.82361,YA114A,CCR8
67,17652183,ccr8_human,114,Y,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,>,,579.0,64.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.82361,YA114A,CCR8
68,17652183,ccr8_human,114,Y,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,>,,191.0,12.733,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.82361,YA114A,CCR8
71,17652183,ccr8_human,114,Y,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,42.0,3.818,,,[125I]-CCL1,0.0,130.1966292,,0.0,,P51685,3.82361,YA114A,CCR8
87,17652183,ccr8_human,114,Y,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,>,,945.0,31.5,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,3.82361,YA114A,CCR8
105,17652183,ccr8_human,114,Y,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,131.0,15.057,,,[125I]-CCL1,0.0,130.1966292,,0.0,,P51685,3.82361,YA114A,CCR8
49,17652183,ccr8_human,289,S,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,>,,211.0,7.276,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.550382,SA289A,CCR8
61,17652183,ccr8_human,289,S,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,>,,17.0,1.889,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.550382,SA289A,CCR8
86,17652183,ccr8_human,289,S,A,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,=,,18.0,2.069,,,[125I]-CCL1,0.0,118.258427,,0.0,,P51685,-0.550382,SA289A,CCR8
94,17652183,ccr8_human,289,S,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,>,,34.0,2.267,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.550382,SA289A,CCR8
125,17652183,ccr8_human,289,S,A,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,=,,16.0,1.455,,,[125I]-CCL1,0.0,118.258427,,0.0,,P51685,-0.550382,SA289A,CCR8
130,17652183,ccr8_human,289,S,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,>,,36.0,1.2,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,-0.550382,SA289A,CCR8
56,17652183,ccr8_human,110,S,H,CCL1,UniProt Entry Code,P22362,Full agonist,EC50,Functional - IP accumulation,8.7,nM,>,,1000.0,114.943,,,[125I]-CCL1,0.0,78.08988764,,0.0,,P51685,6.37035,SA110H,CCR8
73,17652183,ccr8_human,110,S,H,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,10000.0,333.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,6.37035,SA110H,CCR8
85,17652183,ccr8_human,110,S,H,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,10000.0,666.667,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,6.37035,SA110H,CCR8
111,17652183,ccr8_human,110,S,H,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,>,,10000.0,344.828,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,6.37035,SA110H,CCR8
129,17652183,ccr8_human,110,S,H,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,10000.0,1111.111,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,6.37035,SA110H,CCR8
162,17652183,ccr8_human,110,S,H,LMD-009,SMILES,COC1=CC=CC=C1OC2=CC=CC(CN3CCC4(C(NCN4CCC5=CC=CC=C5)=O)CC3)=C2,Full agonist,EC50,Functional - IP accumulation,11.0,nM,>,,10000.0,909.091,,,[125I]-CCL1,0.0,78.08988764,,0.0,,P51685,6.37035,SA110H,CCR8
93,17652183,ccr8_human,46,F,A,LMD-902,SMILES,CCNS(C1=CC=C(OC)C=C1C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)(=O)=O,Full agonist,EC50,Functional - IP accumulation,15.0,nM,=,,50.0,3.333,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.25512,FA46A,CCR8
123,17652183,ccr8_human,46,F,A,LMD-174,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C4CC(NC5=C4C=CC=C5)=O,Full agonist,EC50,Functional - IP accumulation,30.0,nM,=,,52.0,1.733,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.25512,FA46A,CCR8
132,17652183,ccr8_human,46,F,A,LMD-584,SMILES,OC(C1=C(C2(O)CCN(CC3=CC(OC4=C(OC)C=CC=C4)=CC=C3)CC2)C=CC=C1)=O,Full agonist,EC50,Functional - IP accumulation,29.0,nM,=,,126.0,4.345,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.25512,FA46A,CCR8
136,17652183,ccr8_human,46,F,A,LMD-268,SMILES,O=C(NC1CCN(CC2=CC(OC3=C(OC)C=CC=C3)=CC=C2)CC1)C(CCN4CCCC4)C5=CC=CC=C5,Full agonist,EC50,Functional - IP accumulation,9.0,nM,=,,43.0,4.778,,,[125I]-CCL1,0.0,0.0,,0.0,,P51685,2.25512,FA46A,CCR8
1,11502843,ghrhr_human,137,H,Y,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,1.0,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-1.75892,HA137Y,GHRHR
40,11502843,ghrhr_human,137,H,Y,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,1.0,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-1.75892,HA137Y,GHRHR
6,11502843,ghrhr_human,113,P,L,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,-2.0,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.953966,PA113L,GHRHR
51,11502843,ghrhr_human,113,P,L,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-1.667,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.953966,PA113L,GHRHR
8,11502843,ghrhr_human,254,V,M,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,1.0,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-1.02308,VA254M,GHRHR
44,11502843,ghrhr_human,254,V,M,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,1.6,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-1.02308,VA254M,GHRHR
9,11502843,ghrhr_human,57,A,T,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,1.4,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.587666,AA57T,GHRHR
26,11502843,ghrhr_human,57,A,T,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,1.07,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.587666,AA57T,GHRHR
15,11502843,ghrhr_human,225,V,I,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-1.429,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-0.81952,VA225I,GHRHR
18,11502843,ghrhr_human,225,V,I,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,-1.429,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-0.81952,VA225I,GHRHR
19,11502843,ghrhr_human,262,S,N,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,-2.0,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-0.223131,SA262N,GHRHR
56,11502843,ghrhr_human,262,S,N,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-1.667,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,-0.223131,SA262N,GHRHR
20,11502843,ghrhr_human,183,D,N,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,-2.0,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.659921,DA183N,GHRHR
21,11502843,ghrhr_human,183,D,N,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-1.667,,,[125I]GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,0.659921,DA183N,GHRHR
25,11502843,ghrhr_human,423,C,Y,GHRH 1– 44 amide ,PubChem CID,16132353,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-1.25,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,2.49894,CA423Y,GHRHR
50,11502843,ghrhr_human,423,C,Y,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,%,=,,0.0,-1.429,,,GHRH 1– 44 amide ,100.0,0.0,,0.0,,Q02643,2.49894,CA423Y,GHRHR
48,9178745,ghrhr_human,165,H,R,GHRH 1– 44 amide ,PubChem CID,16132353,Full agonist,Single-point,Functional - cAMP accumulation,0.0,,=,,0.0,-8.5,,,GHRH 1– 44 amide ,0.0,90.0,,0.0,,Q02643,-0.420489,HA165R,GHRHR
0,11027527,vipr1_human,47,H,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,1.0,1.667,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",81.48148148,0.0,,0.0,,P32241,-0.215605,HA47A,VIPR1
5,12475394,vipr1_human,200,F,Y,VIP-[Thr11Citrullinel] ,,,Full agonist,pEC50,Functional - cAMP accumulation,8.45,M,=,,7.13,20.893,Abolished effect,,VIP,0.0,0.0,,74.03846154,VIP,P32241,0.147886,FA200Y,VIPR1
26,12475394,vipr1_human,200,F,Y,VIP-[Thr11Val] ,FASTA sequence (peptide),HSDAVFTDNYVRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.63,M,=,,8.63,1.0,,,[125I]-VIP,100.0,0.0,,0.0,,P32241,0.147886,FA200Y,VIPR1
96,12475394,vipr1_human,200,F,Y,VIP-[Thr11Arg] ,FASTA sequence (peptide),HSDAVFTDNYRRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.45,M,=,,7.8,44.668,,,[125I]-VIP,100.0,0.0,,0.0,,P32241,0.147886,FA200Y,VIPR1
101,12475394,vipr1_human,200,F,Y,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.57,M,=,,8.5,1.175,,,[125I]-VIP,100.0,0.0,,0.0,,P32241,0.147886,FA200Y,VIPR1
111,12475394,vipr1_human,200,F,Y,VIP-[Thr11Citrullinel] ,,,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.55,M,=,,7.45,12.589,,,[125I]-VIP,100.0,0.0,,0.0,,P32241,0.147886,FA200Y,VIPR1
115,12475394,vipr1_human,200,F,Y,VIP-[Thr11Arg] ,FASTA sequence (peptide),HSDAVFTDNYRRLRKQMAVKKYLNSILN,Full agonist,pEC50,Functional - cAMP accumulation,9.15,M,=,,6.67,301.995,Abolished effect,,VIP,0.0,0.0,,42.85714286,VIP,P32241,0.147886,FA200Y,VIPR1
116,12475394,vipr1_human,200,F,Y,VIP-[Thr11Val] ,FASTA sequence (peptide),HSDAVFTDNYVRLRKQMAVKKYLNSILN,Full agonist,pEC50,Functional - cAMP accumulation,9.18,M,=,,8.26,8.318,Abolished effect,,VIP,0.0,0.0,,83.33333333,VIP,P32241,0.147886,FA200Y,VIPR1
181,12475394,vipr1_human,200,F,Y,VIP,PubChem CID,16129679,Full agonist,pEC50,Functional - cAMP accumulation,8.71,M,=,,8.4,2.042,Abolished effect,,VIP,0.0,0.0,,100.0,VIP,P32241,0.147886,FA200Y,VIPR1
7,11013258,vipr1_human,188,R,Q,VIP(1-7)[Asp3Asn]/GRF(8-27)-amide,FASTA sequence (peptide),HSNAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,200.0,nM,=,,5.0,-40.0,,,VIP,0.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
21,11013258,vipr1_human,188,R,Q,VIP(1-7)/GRF(8-27)-amide,FASTA sequence (peptide),HSDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,5.0,nM,=,,20.0,4.0,,,VIP,0.0,0.0,,62.5,VIP,P32241,0.25164,RA188Q,VIPR1
37,11013258,vipr1_human,188,R,Q,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,3.0,nM,=,,300.0,100.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
46,11013258,vipr1_human,188,R,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,100.0,nM,=,,4.0,-25.0,,,VIP,0.0,0.0,,300.0,VIP,P32241,0.25164,RA188Q,VIPR1
54,11013258,vipr1_human,188,R,Q,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,5.0,1.25,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
59,11013258,vipr1_human,188,R,Q,VIP-[Thr16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,0.2,nM,=,,10.0,50.0,,,VIP,0.0,0.0,,150.0,VIP,P32241,0.25164,RA188Q,VIPR1
75,11013258,vipr1_human,188,R,Q,VIP(1-7)/GRF(8-27)-amide,FASTA sequence (peptide),HSDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.0,nM,=,,20.0,10.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
102,11013258,vipr1_human,188,R,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,30.0,nM,=,,200.0,6.667,,,VIP,0.0,0.0,,25.0,VIP,P32241,0.25164,RA188Q,VIPR1
113,11013258,vipr1_human,188,R,Q,VIP-[Thr16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.6,nM,=,,15.0,25.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
129,11013258,vipr1_human,188,R,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,300.0,nM,=,,5.0,-58.824,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
133,11013258,vipr1_human,188,R,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,150.0,nM,=,,4.0,-37.037,,,VIP,0.0,0.0,,680.0,VIP,P32241,0.25164,RA188Q,VIPR1
137,11013258,vipr1_human,188,R,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,40.0,nM,=,,1000.0,25.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
143,11013258,vipr1_human,188,R,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,100.0,nM,=,,5.0,-20.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
145,11013258,vipr1_human,188,R,Q,PG 97-269-[Asp3Asn],FASTA sequence (peptide),HFNAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.0,nM,=,,3.0,1.5,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
155,11013258,vipr1_human,188,R,Q,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,5.0,nM,=,,30.0,6.0,,,VIP,0.0,0.0,,100.0,VIP,P32241,0.25164,RA188Q,VIPR1
179,11013258,vipr1_human,188,R,Q,VIP(1-7)[Asp3Asn]/GRF(8-27)-amide,FASTA sequence (peptide),HSNAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,4.0,-5.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.25164,RA188Q,VIPR1
8,12145104,vipr1_human,146,Y,A,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,400.0,nM,=,,350.0,-1.143,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
17,12145104,vipr1_human,146,Y,A,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,200.0,nM,=,,550.0,2.75,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
35,12145104,vipr1_human,146,Y,A,VIP-[His1Phe] ,FASTA sequence (peptide),FSDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,20.0,nM,=,,500.0,25.0,,,VIP,0.0,0.0,,66.23376623,VIP,P32241,2.65852,YA146A,VIPR1
36,12145104,vipr1_human,146,Y,A,VIP-[Phe6Cys] ,FASTA sequence (peptide),HSDAVCTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,650.0,nM,=,,250.0,-2.597,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
39,12145104,vipr1_human,146,Y,A,VIP-[Gln16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,0.3,nM,=,,4.0,13.333,,,VIP,0.0,0.0,,100.0,VIP,P32241,2.65852,YA146A,VIPR1
42,12145104,vipr1_human,146,Y,A,VIP,PubChem CID,16129679,Full agonist,IC50,Binding - Radioligand competition/displacement,0.8,nM,=,,49.0,61.25,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
44,12145104,vipr1_human,146,Y,A,VIP-[Phe6Tyr] ,FASTA sequence (peptide),HSDAVYTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,6.0,nM,=,,2000.0,333.333,,,VIP,0.0,0.0,,18.60465116,VIP,P32241,2.65852,YA146A,VIPR1
49,12145104,vipr1_human,146,Y,A,VIP-[Gln16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,0.9,nM,=,,25.0,27.778,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
50,12145104,vipr1_human,146,Y,A,VIP-[His1Ala] ,FASTA sequence (peptide),ASDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,200.0,nM,=,,1200.0,6.0,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
51,12145104,vipr1_human,146,Y,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,IC50,Binding - Radioligand competition/displacement,0.8,nM,=,,3.0,3.75,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
62,12145104,vipr1_human,146,Y,A,VIP-[His1Phe] ,FASTA sequence (peptide),FSDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,360.0,7.2,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
67,12145104,vipr1_human,146,Y,A,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,90.0,nM,=,,140.0,1.556,,,VIP,0.0,0.0,,58.44155844,VIP,P32241,2.65852,YA146A,VIPR1
131,12145104,vipr1_human,146,Y,A,VIP-[Phe6His] ,FASTA sequence (peptide),HSDAVHTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,1500.0,nM,=,,900.0,-1.667,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
157,12145104,vipr1_human,146,Y,A,VIP-[Phe6Tyr] ,FASTA sequence (peptide),HSDAVYTDNYTRLRKQMAVKKYLNSILN,Full agonist,IC50,Binding - Radioligand competition/displacement,180.0,nM,=,,450.0,2.5,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,2.65852,YA146A,VIPR1
158,12145104,vipr1_human,146,Y,A,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,45.0,nM,=,,60.0,1.333,,,VIP,0.0,0.0,,25.71428571,VIP,P32241,2.65852,YA146A,VIPR1
167,12145104,vipr1_human,146,Y,A,VIP-[His1Ala] ,FASTA sequence (peptide),ASDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,60.0,nM,=,,2000.0,33.333,,,VIP,0.0,0.0,,40.625,VIP,P32241,2.65852,YA146A,VIPR1
196,12145104,vipr1_human,146,Y,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,5.0,nM,=,,40.0,8.0,,,VIP,0.0,0.0,,78.0,VIP,P32241,2.65852,YA146A,VIPR1
9,11013258,vipr1_human,195,K,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,100.0,nM,=,,30.0,-3.333,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
15,11013258,vipr1_human,195,K,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,40.0,nM,=,,150.0,3.75,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
33,11013258,vipr1_human,195,K,Q,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,5.0,nM,=,,200.0,40.0,,,VIP,0.0,0.0,,100.0,VIP,P32241,0.541952,KA195Q,VIPR1
38,11013258,vipr1_human,195,K,Q,VIP-[Thr16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,0.2,nM,=,,20.0,100.0,,,VIP,0.0,0.0,,150.0,VIP,P32241,0.541952,KA195Q,VIPR1
66,11013258,vipr1_human,195,K,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,100.0,nM,=,,30.0,-3.333,,,VIP,0.0,0.0,,80.0,VIP,P32241,0.541952,KA195Q,VIPR1
84,11013258,vipr1_human,195,K,Q,VIP(1-7)[Asn3]/GRF(8-27)-amide,FASTA sequence (peptide),HSNAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,20.0,nM,=,,1.0,-20.0,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
112,11013258,vipr1_human,195,K,Q,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,3.0,nM,=,,200.0,66.667,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
122,11013258,vipr1_human,195,K,Q,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,4.0,nM,=,,1.0,-4.0,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
123,11013258,vipr1_human,195,K,Q,VIP-[Thr16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.6,nM,=,,20.0,33.333,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
126,11013258,vipr1_human,195,K,Q,VIP(1-7)/GRF(8-27)-amide,FASTA sequence (peptide),HSDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.0,nM,=,,2.0,1.0,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
142,11013258,vipr1_human,195,K,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,300.0,nM,=,,15.0,-20.0,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
148,11013258,vipr1_human,195,K,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,30.0,nM,=,,200.0,6.667,,,VIP,0.0,0.0,,62.5,VIP,P32241,0.541952,KA195Q,VIPR1
162,11013258,vipr1_human,195,K,Q,PG 97-269-[Asp3Asn],FASTA sequence (peptide),HFNAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,2.0,nM,=,,0.3,-6.667,,,"[125I]-VIP(wild-type), [125I]-VIP1 agonist (mutant) radioligand",100.0,0.0,,0.0,,P32241,0.541952,KA195Q,VIPR1
177,11013258,vipr1_human,195,K,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,150.0,nM,=,,100.0,-1.499,,,VIP,0.0,0.0,,80.0,VIP,P32241,0.541952,KA195Q,VIPR1
10,22291440,vipr1_human,378,S,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.65,1.043,,,,100.0,0.0,,0.0,,P32241,-0.420923,SA378A,VIPR1
52,22291440,vipr1_human,378,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,2.53,nM,=,,11.57,4.573,,,,100.0,0.0,,0.0,,P32241,-0.420923,SA378A,VIPR1
11,22291440,vipr1_human,104,S,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2.6,1.028,,,,100.0,0.0,,0.0,,P32241,-0.416109,SA104A,VIPR1
86,22291440,vipr1_human,104,S,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.32,-1.054,,,,100.0,0.0,,0.0,,P32241,-0.416109,SA104A,VIPR1
12,14645688,vipr1_human,447,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.15,nM,=,,0.55,-5.714,,,,160.6666667,0.0,,0.0,,P32241,0.866846,SA447A,VIPR1
171,14645688,vipr1_human,447,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.3,nM,=,,0.5,1.667,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",160.6666667,0.0,,0.0,,P32241,0.866846,SA447A,VIPR1
186,14645688,vipr1_human,447,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.57,2.111,,,,160.6666667,0.0,,0.0,,P32241,0.866846,SA447A,VIPR1
14,22291440,vipr1_human,147,T,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,8.5,2.429,,,VIP,100.0,0.0,,0.0,,P32241,-0.611831,TA147A,VIPR1
105,22291440,vipr1_human,147,T,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2070.0,818.182,,,VIP,100.0,0.0,,0.0,,P32241,-0.611831,TA147A,VIPR1
16,11027527,vipr1_human,41,Q,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.3,-2.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",62.96296296,0.0,,0.0,,P32241,0.316438,QA41A,VIPR1
19,22291440,vipr1_human,134,Q,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,270.0,106.719,,,,100.0,0.0,,0.0,,P32241,0.431039,QA134A,VIPR1
188,22291440,vipr1_human,134,Q,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,332.0,94.857,,,,100.0,0.0,,0.0,,P32241,0.431039,QA134A,VIPR1
20,11027527,vipr1_human,57,E,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.5,-1.2,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",118.5185185,0.0,,0.0,,P32241,-0.394821,EA57A,VIPR1
22,22291440,vipr1_human,117,P,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,21.0,8.3,,,,100.0,0.0,,0.0,,P32241,1.25685,PA117A,VIPR1
97,22291440,vipr1_human,117,P,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,14.21,4.06,,,,100.0,0.0,,0.0,,P32241,1.25685,PA117A,VIPR1
23,22291440,vipr1_human,193,F,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.98,1.137,,,,100.0,0.0,,0.0,,P32241,1.98781,FA193A,VIPR1
144,22291440,vipr1_human,193,F,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,2.53,nM,=,,3.52,1.391,,,,100.0,0.0,,0.0,,P32241,1.98781,FA193A,VIPR1
24,22291440,vipr1_human,374,L,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,2.53,nM,=,,414.0,163.636,,,,100.0,0.0,,0.0,,P32241,1.86287,LA374A,VIPR1
166,22291440,vipr1_human,374,L,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.5,nM,=,,5.05,1.443,,,,100.0,0.0,,0.0,,P32241,1.86287,LA374A,VIPR1
29,22291440,vipr1_human,80,Q,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,9.09,3.593,,,,100.0,0.0,,0.0,,P32241,0.0914934,QA80A,VIPR1
190,22291440,vipr1_human,80,Q,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,6.96,1.989,,,,100.0,0.0,,0.0,,P32241,0.0914934,QA80A,VIPR1
30,22291440,vipr1_human,135,Q,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,5.5,1.571,,,,100.0,0.0,,0.0,,P32241,0.196811,QA135A,VIPR1
61,22291440,vipr1_human,135,Q,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2.52,-1.004,,,,100.0,0.0,,0.0,,P32241,0.196811,QA135A,VIPR1
34,22291440,vipr1_human,125,D,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,3.67,1.451,,,,100.0,0.0,,0.0,,P32241,1.75045,DA125A,VIPR1
169,22291440,vipr1_human,125,D,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.17,-1.104,,,,100.0,0.0,,0.0,,P32241,1.75045,DA125A,VIPR1
40,11027527,vipr1_human,59,E,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.6,1.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",111.1111111,0.0,,0.0,,P32241,0.107731,EA59A,VIPR1
43,12145104,vipr1_human,150,Y,A,VIP-[Phe6His] ,FASTA sequence (peptide),HSDAVHTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,80.0,nM,=,,4500.0,56.25,,,VIP,0.0,0.0,,0.0,VIP,P32241,1.94504,YA150A,VIPR1
63,12145104,vipr1_human,150,Y,A,VIP-[Phe6Tyr] ,FASTA sequence (peptide),HSDAVYTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,6.0,nM,=,,290.0,48.333,,,VIP,0.0,0.0,,66.27906977,VIP,P32241,1.94504,YA150A,VIPR1
83,12145104,vipr1_human,150,Y,A,VIP-[Gln16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,0.3,nM,=,,8.0,26.667,,,VIP,0.0,0.0,,100.0,VIP,P32241,1.94504,YA150A,VIPR1
107,12145104,vipr1_human,150,Y,A,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,45.0,nM,=,,170.0,3.778,,,VIP,0.0,0.0,,148.5714286,VIP,P32241,1.94504,YA150A,VIPR1
110,12145104,vipr1_human,150,Y,A,VIP-[His1Ala] ,FASTA sequence (peptide),ASDAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,200.0,nM,=,,230.0,1.15,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
118,12145104,vipr1_human,150,Y,A,VIP-[Phe6Cys] ,FASTA sequence (peptide),HSDAVCTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,650.0,nM,=,,200.0,-3.247,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
119,12145104,vipr1_human,150,Y,A,VIP-[Phe6Cys] ,FASTA sequence (peptide),HSDAVCTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,4500.0,450.0,,,VIP,0.0,0.0,,0.0,VIP,P32241,1.94504,YA150A,VIPR1
120,12145104,vipr1_human,150,Y,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,5.0,nM,=,,80.0,16.0,,,VIP,0.0,0.0,,87.0,VIP,P32241,1.94504,YA150A,VIPR1
124,12145104,vipr1_human,150,Y,A,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,400.0,nM,=,,190.0,-2.105,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
138,12145104,vipr1_human,150,Y,A,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,200.0,nM,=,,150.0,-1.333,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
151,12145104,vipr1_human,150,Y,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.8,nM,=,,4.0,5.0,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
153,12145104,vipr1_human,150,Y,A,VIP-[Gln16Arg] ,FASTA sequence (peptide),HSDAVFTDNYTRLRKRMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.9,nM,=,,0.2,-4.505,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
161,12145104,vipr1_human,150,Y,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,0.8,nM,=,,2.6,3.25,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
174,12145104,vipr1_human,150,Y,A,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,90.0,nM,=,,115.0,1.278,,,VIP,0.0,0.0,,62.33766234,VIP,P32241,1.94504,YA150A,VIPR1
178,12145104,vipr1_human,150,Y,A,VIP-[Phe6His] ,FASTA sequence (peptide),HSDAVHTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1500.0,nM,=,,600.0,-2.5,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
180,12145104,vipr1_human,150,Y,A,VIP-[His1Ala] ,FASTA sequence (peptide),ASDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,60.0,nM,=,,920.0,15.333,,,VIP,0.0,0.0,,57.8125,VIP,P32241,1.94504,YA150A,VIPR1
183,12145104,vipr1_human,150,Y,A,VIP-[His1Phe] ,FASTA sequence (peptide),FSDAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,20.0,nM,=,,200.0,10.0,,,VIP,0.0,0.0,,90.90909091,VIP,P32241,1.94504,YA150A,VIPR1
187,12145104,vipr1_human,150,Y,A,VIP-[Phe6Tyr] ,FASTA sequence (peptide),HSDAVYTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,180.0,nM,=,,120.0,-1.499,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
191,12145104,vipr1_human,150,Y,A,VIP-[His1Phe] ,FASTA sequence (peptide),FSDAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,75.0,1.5,,,[125I]-PG 97-269 (radioligand),69.23076923,0.0,,0.0,,P32241,1.94504,YA150A,VIPR1
45,14645688,vipr1_human,250,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.3,nM,=,,0.7,2.333,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",258.0,0.0,,0.0,,P32241,0.119208,SA250A,VIPR1
176,14645688,vipr1_human,250,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.15,nM,=,,1.08,-2.915,,,,258.0,0.0,,0.0,,P32241,0.119208,SA250A,VIPR1
192,14645688,vipr1_human,250,S,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.11,-2.457,,,,258.0,0.0,,0.0,,P32241,0.119208,SA250A,VIPR1
47,22291440,vipr1_human,120,I,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.55,1.014,,,,100.0,0.0,,0.0,,P32241,0.582715,IA120A,VIPR1
90,22291440,vipr1_human,120,I,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2.33,-1.086,,,,100.0,0.0,,0.0,,P32241,0.582715,IA120A,VIPR1
53,22291440,vipr1_human,119,P,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2.67,1.055,,,,100.0,0.0,,0.0,,P32241,2.22239,PA119A,VIPR1
89,22291440,vipr1_human,119,P,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,4.01,1.146,,,,100.0,0.0,,0.0,,P32241,2.22239,PA119A,VIPR1
68,22291440,vipr1_human,112,H,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,229.0,90.514,,,,100.0,0.0,,0.0,,P32241,-0.17709,HA112A,VIPR1
125,22291440,vipr1_human,112,H,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,296.0,84.571,,,,100.0,0.0,,0.0,,P32241,-0.17709,HA112A,VIPR1
72,22291440,vipr1_human,126,D,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.11,-1.125,,,,100.0,0.0,,0.0,,P32241,0.617573,DA126A,VIPR1
134,22291440,vipr1_human,126,D,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,3.62,1.431,,,,100.0,0.0,,0.0,,P32241,0.617573,DA126A,VIPR1
76,22291440,vipr1_human,143,K,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,5.18,1.48,,,,100.0,0.0,,0.0,,P32241,0.575408,KA143A,VIPR1
108,22291440,vipr1_human,143,K,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,1035.0,409.091,,,,100.0,0.0,,0.0,,P32241,0.575408,KA143A,VIPR1
77,22291440,vipr1_human,373,E,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.5,nM,=,,6.33,1.809,,,,100.0,0.0,,0.0,,P32241,0.53847,EA373A,VIPR1
139,22291440,vipr1_human,373,E,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,2.53,nM,=,,6.24,2.466,,,,100.0,0.0,,0.0,,P32241,0.53847,EA373A,VIPR1
79,11027527,vipr1_human,48,K,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,1.0,1.667,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",114.8148148,0.0,,0.0,,P32241,0.208798,KA48A,VIPR1
82,14645688,vipr1_human,447,S,D,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,0.27,nM,=,,0.37,1.37,,,,167.3333333,0.0,,0.0,,P32241,0.333268,SA447D,VIPR1
93,14645688,vipr1_human,447,S,D,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,EC50,Functional - cAMP accumulation,3.15,nM,=,,0.54,-5.848,,,,167.3333333,0.0,,0.0,,P32241,0.333268,SA447D,VIPR1
159,14645688,vipr1_human,447,S,D,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.3,nM,=,,0.8,2.667,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",167.3333333,0.0,,0.0,,P32241,0.333268,SA447D,VIPR1
87,22291440,vipr1_human,131,L,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,253.0,72.286,,,,100.0,0.0,,0.0,,P32241,0.299811,LA131A,VIPR1
149,22291440,vipr1_human,131,L,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,264.0,104.348,,,,100.0,0.0,,0.0,,P32241,0.299811,LA131A,VIPR1
91,22291440,vipr1_human,108,E,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,2.35,-1.076,,,,100.0,0.0,,0.0,,P32241,0.286065,EA108A,VIPR1
128,22291440,vipr1_human,108,E,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.22,-1.087,,,,100.0,0.0,,0.0,,P32241,0.286065,EA108A,VIPR1
95,22291440,vipr1_human,144,T,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,10.25,2.929,,,,100.0,0.0,,0.0,,P32241,-0.57073,TA144A,VIPR1
184,22291440,vipr1_human,144,T,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,874.0,345.455,,,,100.0,0.0,,0.0,,P32241,-0.57073,TA144A,VIPR1
104,7818527,vipr1_human,110,W,G,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.62,1.033,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",80.40435459,0.0,,0.0,,P32241,5.41516,WA110G,VIPR1
114,22291440,vipr1_human,106,T,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,20.0,7.905,,,,100.0,0.0,,0.0,,P32241,-0.454015,TA106A,VIPR1
182,22291440,vipr1_human,106,T,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,16.69,4.769,,,,100.0,0.0,,0.0,,P32241,-0.454015,TA106A,VIPR1
121,22291440,vipr1_human,132,D,A,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,2.53,nM,=,,3.65,1.443,,,,100.0,0.0,,0.0,,P32241,-0.565939,DA132A,VIPR1
154,22291440,vipr1_human,132,D,A,PG 97-269,FASTA sequence (peptide),HFDAVFTNSYRKVLKRLSARKLLQDIL,Full agonist,EC50,Functional - cAMP accumulation,3.5,nM,=,,3.54,1.011,,,,100.0,0.0,,0.0,,P32241,-0.565939,DA132A,VIPR1
135,7818527,vipr1_human,87,P,G,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.59,-1.017,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",11.35303266,0.0,,0.0,,P32241,4.10992,PA87G,VIPR1
147,11027527,vipr1_human,53,E,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.4,-1.499,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",100.0,0.0,,0.0,,P32241,-0.526472,EA53A,VIPR1
160,11027527,vipr1_human,46,Q,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,1.2,2.0,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",103.7037037,0.0,,0.0,,P32241,0.00858868,QA46A,VIPR1
168,11027527,vipr1_human,49,Q,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,1.0,1.667,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",118.5185185,0.0,,0.0,,P32241,0.00663931,QA49A,VIPR1
185,11027527,vipr1_human,55,Q,A,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.6,nM,=,,0.7,1.167,,,"[125I]-VIP(wild-type), [125I]-VIP-[Gln3] (mutant) radioligand",148.1481481,0.0,,0.0,,P32241,0.303333,QA55A,VIPR1
1,10.1124/mol.112.078808,grm5_human,809,S,F,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,5000.0,63.291,,,Glutamate,0.0,0.0,,37.0,Glutamate,P41594,2.80737,SA809F,GRM5
21,10.1124/mol.112.078808,grm5_human,809,S,F,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,5000.0,2.381,,,Glutamate,0.0,0.0,,0.0,,P41594,2.80737,SA809F,GRM5
41,10.1124/mol.112.078808,grm5_human,809,S,F,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,6300.0,2.864,,,Glutamate,0.0,0.0,,0.0,,P41594,2.80737,SA809F,GRM5
90,10.1124/mol.112.078808,grm5_human,809,S,F,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,4000.0,493.827,,,Glutamate,52.22222222,0.0,,0.0,,P41594,2.80737,SA809F,GRM5
2,10.1124/mol.112.078808,grm5_human,792,Y,F,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,2500.0,1.136,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.671598,YA792F,GRM5
29,10.1124/mol.112.078808,grm5_human,792,Y,F,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,110.0,1.392,,,Glutamate,0.0,0.0,,109.0,Glutamate,P41594,-0.671598,YA792F,GRM5
38,10.1124/mol.112.078808,grm5_human,792,Y,F,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,13.0,1.605,,,Glutamate,66.66666667,0.0,,0.0,,P41594,-0.671598,YA792F,GRM5
102,10.1124/mol.112.078808,grm5_human,792,Y,F,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,1600.0,-1.312,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.671598,YA792F,GRM5
3,10.1124/mol.112.078808,grm5_human,788,F,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,98.0,1.241,,,Glutamate,0.0,0.0,,102.0,Glutamate,P41594,3.63496,FA788A,GRM5
5,10.1124/mol.112.078808,grm5_human,788,F,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,>,,45000.0,21.429,,,Glutamate,0.0,0.0,,0.0,,P41594,3.63496,FA788A,GRM5
12,10.1124/mol.112.078808,grm5_human,788,F,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,220.0,27.16,,,Glutamate,103.3333333,0.0,,0.0,,P41594,3.63496,FA788A,GRM5
87,10.1124/mol.112.078808,grm5_human,788,F,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,1900.0,-1.157,,,Glutamate,0.0,0.0,,0.0,,P41594,3.63496,FA788A,GRM5
4,10.1124/mol.112.078808,grm5_human,813,A,F,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,10.0,1.235,,,Glutamate,66.66666667,0.0,,0.0,,P41594,-0.438404,AA813F,GRM5
32,10.1124/mol.112.078808,grm5_human,813,A,F,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,120.0,1.519,,,Glutamate,0.0,0.0,,69.0,Glutamate,P41594,-0.438404,AA813F,GRM5
47,10.1124/mol.112.078808,grm5_human,813,A,F,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,3500.0,1.667,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.438404,AA813F,GRM5
48,10.1124/mol.112.078808,grm5_human,813,A,F,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,3400.0,1.545,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.438404,AA813F,GRM5
6,10.1124/mol.112.078808,grm5_human,809,S,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,1500.0,18.987,,,Glutamate,0.0,0.0,,85.0,Glutamate,P41594,-0.400042,SA809A,GRM5
9,10.1124/mol.112.078808,grm5_human,809,S,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,1000.0,-2.101,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.400042,SA809A,GRM5
24,10.1124/mol.112.078808,grm5_human,809,S,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,420.0,51.852,,,Glutamate,66.66666667,0.0,,0.0,,P41594,-0.400042,SA809A,GRM5
88,10.1124/mol.112.078808,grm5_human,809,S,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,2500.0,1.136,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.400042,SA809A,GRM5
8,10.1124/mol.112.078808,grm5_human,810,A,V,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,1.85267,AA810V,GRM5
33,10.1124/mol.112.078808,grm5_human,810,A,V,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,7600.0,3.619,,,Glutamate,0.0,0.0,,0.0,,P41594,1.85267,AA810V,GRM5
53,10.1124/mol.112.078808,grm5_human,810,A,V,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,510.0,62.963,,,Glutamate,88.88888889,0.0,,0.0,,P41594,1.85267,AA810V,GRM5
68,10.1124/mol.112.078808,grm5_human,810,A,V,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,790.0,10.0,,,Glutamate,0.0,0.0,,92.0,Glutamate,P41594,1.85267,AA810V,GRM5
10,10.1074/jbc.M006230200,grm5_human,649,I,L,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.0,-1.167,,,,0.0,0.0,,0.0,,P41594,0.0492457,IA649L,GRM5
14,10.1124/mol.112.078808,grm5_human,747,N,S,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,25000.0,11.364,,,Glutamate,0.0,0.0,,0.0,,P41594,0.924855,NA747S,GRM5
28,10.1124/mol.112.078808,grm5_human,747,N,S,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,34.0,4.198,,,Glutamate,84.44444444,0.0,,0.0,,P41594,0.924855,NA747S,GRM5
55,10.1124/mol.112.078808,grm5_human,747,N,S,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,5000.0,2.381,,,Glutamate,0.0,0.0,,0.0,,P41594,0.924855,NA747S,GRM5
60,10.1124/mol.112.078808,grm5_human,747,N,S,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,430.0,5.443,,,Glutamate,0.0,0.0,,108.0,Glutamate,P41594,0.924855,NA747S,GRM5
16,10.1124/mol.112.078808,grm5_human,651,I,F,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,500.0,61.728,,,Glutamate,103.3333333,0.0,,0.0,,P41594,-1.57717,IA651F,GRM5
30,10.1124/mol.112.078808,grm5_human,651,I,F,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,>,,45000.0,21.429,,,Glutamate,0.0,0.0,,0.0,,P41594,-1.57717,IA651F,GRM5
69,10.1124/mol.112.078808,grm5_human,651,I,F,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,-1.57717,IA651F,GRM5
77,10.1124/mol.112.078808,grm5_human,651,I,F,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,3200.0,40.506,,,Glutamate,0.0,0.0,,105.0,Glutamate,P41594,-1.57717,IA651F,GRM5
19,10.1124/mol.112.078808,grm5_human,655,P,S,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,160.0,2.025,,,Glutamate,0.0,0.0,,77.0,Glutamate,P41594,4.04788,PA655S,GRM5
35,10.1124/mol.112.078808,grm5_human,655,P,S,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,60.0,7.407,,,Glutamate,80.0,0.0,,0.0,,P41594,4.04788,PA655S,GRM5
49,10.1074/jbc.M006230200,grm5_human,655,P,S,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,27.1,7.743,,,,0.0,0.0,,0.0,,P41594,4.04788,PA655S,GRM5
63,10.1124/mol.112.078808,grm5_human,655,P,S,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,3200.0,1.524,,,Glutamate,0.0,0.0,,0.0,,P41594,4.04788,PA655S,GRM5
74,10.1124/mol.112.078808,grm5_human,655,P,S,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,4.04788,PA655S,GRM5
20,10.1124/mol.112.078808,grm5_human,659,Y,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,1100.0,13.924,,,Glutamate,0.0,0.0,,81.0,Glutamate,P41594,3.42749,YA659A,GRM5
46,10.1124/mol.112.078808,grm5_human,659,Y,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,3.42749,YA659A,GRM5
51,10.1124/mol.112.078808,grm5_human,659,Y,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,950.0,117.284,,,Glutamate,110.0,0.0,,0.0,,P41594,3.42749,YA659A,GRM5
78,10.1124/mol.112.078808,grm5_human,659,Y,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,>,,45000.0,21.429,,,Glutamate,0.0,0.0,,0.0,,P41594,3.42749,YA659A,GRM5
26,10.1124/mol.112.078808,grm5_human,648,R,E,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,590.0,-3.731,,,Glutamate,0.0,0.0,,0.0,,P41594,1.40453,RA648E,GRM5
71,10.1124/mol.112.078808,grm5_human,648,R,E,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,2000.0,-1.05,,,Glutamate,0.0,0.0,,0.0,,P41594,1.40453,RA648E,GRM5
75,10.1124/mol.112.078808,grm5_human,648,R,E,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,0.91,-8.929,,,Glutamate,17.77777778,0.0,,0.0,,P41594,1.40453,RA648E,GRM5
101,10.1124/mol.112.078808,grm5_human,648,R,E,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,12.0,-6.579,,,Glutamate,0.0,0.0,,23.0,Glutamate,P41594,1.40453,RA648E,GRM5
27,10.1124/mol.112.078808,grm5_human,632,T,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,1800.0,-1.222,,,Glutamate,0.0,0.0,,0.0,,P41594,1.00514,TA632A,GRM5
37,10.1124/mol.112.078808,grm5_human,632,T,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,3500.0,1.667,,,Glutamate,0.0,0.0,,0.0,,P41594,1.00514,TA632A,GRM5
70,10.1124/mol.112.078808,grm5_human,632,T,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,83.0,1.051,,,Glutamate,0.0,0.0,,58.0,Glutamate,P41594,1.00514,TA632A,GRM5
93,10.1124/mol.112.078808,grm5_human,632,T,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,4.5,-1.799,,,Glutamate,63.33333333,0.0,,0.0,,P41594,1.00514,TA632A,GRM5
34,10.1124/mol.112.078808,grm5_human,659,Y,F,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,38.0,-2.079,,,Glutamate,0.0,0.0,,91.0,Glutamate,P41594,0.277719,YA659F,GRM5
45,10.1124/mol.112.078808,grm5_human,659,Y,F,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,630.0,-3.333,,,Glutamate,0.0,0.0,,0.0,,P41594,0.277719,YA659F,GRM5
86,10.1124/mol.112.078808,grm5_human,659,Y,F,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,5.5,-1.473,,,Glutamate,86.66666667,0.0,,0.0,,P41594,0.277719,YA659F,GRM5
92,10.1124/mol.112.078808,grm5_human,659,Y,F,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,1200.0,-1.835,,,Glutamate,0.0,0.0,,0.0,,P41594,0.277719,YA659F,GRM5
36,10.1124/mol.112.078808,grm5_human,788,F,W,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,1.24666,FA788W,GRM5
39,10.1124/mol.112.078808,grm5_human,788,F,W,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,79.0,9.753,,,Glutamate,82.22222222,0.0,,0.0,,P41594,1.24666,FA788W,GRM5
40,10.1124/mol.112.078808,grm5_human,788,F,W,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,~,,4500.0,2.143,,,Glutamate,0.0,0.0,,0.0,,P41594,1.24666,FA788W,GRM5
98,10.1124/mol.112.078808,grm5_human,788,F,W,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,260.0,3.291,,,Glutamate,0.0,0.0,,84.0,Glutamate,P41594,1.24666,FA788W,GRM5
52,10.1074/jbc.M006230200,grm5_human,658,S,C,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,16.5,4.714,,,,0.0,0.0,,0.0,,P41594,-0.907786,SA658C,GRM5
56,10.1074/jbc.M006230200,grm5_human,802,M,T,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.8,1.086,,,,0.0,0.0,,0.0,,P41594,3.118,MA802T,GRM5
58,10.1074/jbc.M006230200,grm5_human,805,S,A,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,6.7,1.914,,,,0.0,0.0,,0.0,,P41594,-1.08794,SA805A,GRM5
61,10.1124/mol.112.078808,grm5_human,785,W,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,4300.0,1.955,,,Glutamate,0.0,0.0,,0.0,,P41594,3.59621,WA785A,GRM5
79,10.1124/mol.112.078808,grm5_human,785,W,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,2300.0,283.951,,,Glutamate,60.0,0.0,,0.0,,P41594,3.59621,WA785A,GRM5
91,10.1124/mol.112.078808,grm5_human,785,W,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,6000.0,2.857,,,Glutamate,0.0,0.0,,0.0,,P41594,3.59621,WA785A,GRM5
95,10.1124/mol.112.078808,grm5_human,785,W,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,890.0,11.266,,,Glutamate,0.0,0.0,,59.0,Glutamate,P41594,3.59621,WA785A,GRM5
62,10.1074/jbc.M006230200,grm5_human,822,V,M,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,3.1,-1.129,,,,0.0,0.0,,0.0,,P41594,0.0878757,VA822M,GRM5
66,10.1074/jbc.M006230200,grm5_human,819,V,T,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,4.1,1.171,,,,0.0,0.0,,0.0,,P41594,0.420025,VA819T,GRM5
67,10.1124/mol.112.078808,grm5_human,632,T,P,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,2500.0,1.19,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.167528,TA632P,GRM5
72,10.1124/mol.112.078808,grm5_human,632,T,P,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,2.0,-4.049,,,Glutamate,80.0,0.0,,0.0,,P41594,-0.167528,TA632P,GRM5
73,10.1124/mol.112.078808,grm5_human,632,T,P,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,13.0,-6.061,,,Glutamate,0.0,0.0,,67.0,Glutamate,P41594,-0.167528,TA632P,GRM5
89,10.1124/mol.112.078808,grm5_human,632,T,P,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,=,,790.0,-2.786,,,Glutamate,0.0,0.0,,0.0,,P41594,-0.167528,TA632P,GRM5
82,10.1124/mol.112.078808,grm5_human,792,Y,A,2-BisPEB,PubChem CID,57328469,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,79.0,nM,=,,160.0,2.025,,,Glutamate,0.0,0.0,,58.0,Glutamate,P41594,2.86704,YA792A,GRM5
97,10.1124/mol.112.078808,grm5_human,792,Y,A,MPEP,PubChem CID,3025961,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,8.1,nM,=,,66.0,8.148,,,Glutamate,66.66666667,0.0,,0.0,,P41594,2.86704,YA792A,GRM5
99,10.1124/mol.112.078808,grm5_human,792,Y,A,4-BisPEB,PubChem CID,69032688,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2100.0,nM,=,,6300.0,3.0,,,Glutamate,0.0,0.0,,0.0,,P41594,2.86704,YA792A,GRM5
100,10.1124/mol.112.078808,grm5_human,792,Y,A,3-BisPEB,SMILES,C1(=CC(=CC=C1)C#CC2=CN=CC=C2)C#CC3=CC=CN=C3,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,2200.0,nM,>,,45000.0,20.455,,,Glutamate,0.0,0.0,,0.0,,P41594,2.86704,YA792A,GRM5
84,10.1074/jbc.M006230200,grm5_human,650,G,L,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,2.6,-1.346,,,,0.0,0.0,,0.0,,P41594,-1.59665,GA650L,GRM5
85,10.1074/jbc.M006230200,grm5_human,651,I,V,[3H]M-MPEP,PubChem CID,5311462,Negative allosteric modulator - noncompetitive antagonist,K(d),Binding - Radioligand saturation,3.5,nM,=,,5.1,1.457,,,,0.0,0.0,,0.0,,P41594,1.19367,IA651V,GRM5
0,10.1038/cr.2016.36,casr_human,616,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.63,1.072,,,Ca2+,0.0,0.0,,109.5238095,Ca2+,P41180,3.66107,LA616A,CASR
241,10.1038/cr.2016.36,casr_human,616,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.09,1.514,,,Ca2+,0.0,0.0,,0.0,,P41180,3.66107,LA616A,CASR
379,10.1038/cr.2016.36,casr_human,616,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.21,1.349,,,Ca2+,28.0,0.0,,0.0,,P41180,3.66107,LA616A,CASR
4,10.1038/cr.2016.36,casr_human,668,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,5.77,7.762,,,Ca2+,0.0,0.0,,97.61904762,Ca2+,P41180,3.10531,FA668A,CASR
25,10.1038/cr.2016.36,casr_human,668,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,5.15,16.218,,,Ca2+,0.0,0.0,,0.0,,P41180,3.10531,FA668A,CASR
43,10.1038/cr.2016.36,casr_human,668,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,5.21,13.49,,,Ca2+,20.0,0.0,,0.0,,P41180,3.10531,FA668A,CASR
244,10.1038/cr.2016.36,casr_human,668,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,6.57,1.288,,,Ca2+,0.0,0.0,,0.0,,P41180,3.10531,FA668A,CASR
315,10.1038/cr.2016.36,casr_human,668,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.08,1.549,,,Ca2+,0.0,0.0,,0.0,,P41180,3.10531,FA668A,CASR
485,10.1038/cr.2016.36,casr_human,668,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,5.3,16.596,,,Ca2+,0.0,0.0,,0.0,,P41180,3.10531,FA668A,CASR
5,10.1038/cr.2016.36,casr_human,817,V,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.95,-1.949,,,Ca2+,0.0,0.0,,71.42857143,Ca2+,P41180,0.992512,VA817A,CASR
20,10.1038/cr.2016.36,casr_human,817,V,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.36,-1.23,,,Ca2+,0.0,0.0,,0.0,,P41180,0.992512,VA817A,CASR
311,10.1038/cr.2016.36,casr_human,817,V,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.41,-1.175,,,Ca2+,38.0,0.0,,0.0,,P41180,0.992512,VA817A,CASR
12,10.1074/jbc.M400724200,casr_human,841,I,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,4.17,11.914,,,Ca2+,0.0,0.0,,0.0,,P41180,2.88005,IA841A,CASR
374,10.1038/cr.2016.36,casr_human,841,I,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.04,1.698,,,Ca2+,0.0,0.0,,0.0,,P41180,2.88005,IA841A,CASR
576,10.1074/jbc.M308010200,casr_human,841,I,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,2.71,6.949,,,Ca2+,0.0,0.0,,98.0,Ca2+,P41180,2.88005,IA841A,CASR
16,10.1038/cr.2016.36,casr_human,776,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.66,-2.457,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
40,10.1038/cr.2016.36,casr_human,776,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,7.53,-7.092,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
96,10.1074/jbc.M308010200,casr_human,776,L,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,0.07,-5.587,,,Ca2+,0.0,0.0,,121.0,Ca2+,P41180,3.04945,LA776A,CASR
117,10.1038/cr.2016.36,casr_human,776,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.28,1.148,,,Ca2+,76.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
129,10.1038/cr.2016.36,casr_human,776,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.22,1.38,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
170,10.1074/jbc.M400724200,casr_human,776,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,0.37,1.057,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
245,10.1038/cr.2016.36,casr_human,776,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.21,2.818,,,Ca2+,0.0,0.0,,102.3809524,Ca2+,P41180,3.04945,LA776A,CASR
377,10.1038/cr.2016.36,casr_human,776,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,6.95,-2.688,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04945,LA776A,CASR
22,10.1038/cr.2016.36,casr_human,615,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,6.52,1.0,,,Ca2+,0.0,0.0,,0.0,,P41180,0.596481,AA615V,CASR
65,10.1038/cr.2016.36,casr_human,615,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.86,-3.165,,,Ca2+,0.0,0.0,,0.0,,P41180,0.596481,AA615V,CASR
284,10.1038/cr.2016.36,casr_human,615,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,7.12,-7.092,,,Ca2+,0.0,0.0,,0.0,,P41180,0.596481,AA615V,CASR
433,10.1038/cr.2016.36,casr_human,615,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.74,-1.202,,,Ca2+,0.0,0.0,,123.8095238,Ca2+,P41180,0.596481,AA615V,CASR
491,10.1038/cr.2016.36,casr_human,615,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.05,1.95,,,Ca2+,79.0,0.0,,0.0,,P41180,0.596481,AA615V,CASR
502,10.1038/cr.2016.36,casr_human,615,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,7.54,-7.246,,,Ca2+,0.0,0.0,,0.0,,P41180,0.596481,AA615V,CASR
29,10.1038/cr.2016.36,casr_human,825,Y,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,7.04,-5.0,,,Ca2+,172.0,0.0,,0.0,,P41180,1.26629,YA825A,CASR
78,10.1038/cr.2016.36,casr_human,825,Y,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.14,1.349,,,Ca2+,0.0,0.0,,0.0,,P41180,1.26629,YA825A,CASR
254,10.1038/cr.2016.36,casr_human,825,Y,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.49,1.479,,,Ca2+,0.0,0.0,,132.1428571,Ca2+,P41180,1.26629,YA825A,CASR
35,10.1038/cr.2016.36,casr_human,821,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.8,-2.882,,,Ca2+,61.0,0.0,,0.0,,P41180,3.34617,FA821A,CASR
74,10.1038/cr.2016.36,casr_human,821,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.03,4.266,,,Ca2+,0.0,0.0,,127.3809524,Ca2+,P41180,3.34617,FA821A,CASR
290,10.1074/jbc.M400724200,casr_human,821,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,0.57,1.629,,,Ca2+,0.0,0.0,,0.0,,P41180,3.34617,FA821A,CASR
395,10.1038/cr.2016.36,casr_human,821,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.79,-3.311,,,Ca2+,0.0,0.0,,0.0,,P41180,3.34617,FA821A,CASR
447,10.1074/jbc.M308010200,casr_human,821,F,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,0.06,-6.494,,,Ca2+,0.0,0.0,,112.0,Ca2+,P41180,3.34617,FA821A,CASR
39,10.1210/en.2012-1887,casr_human,832,F,S,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,6.64,-2.755,,,Ca2+,55.0,0.0,,0.0,,P41180,-0.0984877,FA832S,CASR
53,10.1210/en.2012-1887,casr_human,680,R,H,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,5.65,1.778,,,Ca2+,7.0,0.0,,0.0,,P41180,8.09629,RA680H,CASR
58,10.1038/cr.2016.36,casr_human,844,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.35,-4.902,,,Ca2+,0.0,0.0,,88.0952381,Ca2+,P41180,2.99252,AA844V,CASR
80,10.1038/cr.2016.36,casr_human,844,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.65,-2.041,,,Ca2+,91.0,0.0,,0.0,,P41180,2.99252,AA844V,CASR
176,10.1038/cr.2016.36,casr_human,844,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,7.17,-4.464,,,Ca2+,0.0,0.0,,0.0,,P41180,2.99252,AA844V,CASR
266,10.1038/cr.2016.36,casr_human,844,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,7.27,-10.0,,,Ca2+,0.0,0.0,,0.0,,P41180,2.99252,AA844V,CASR
487,10.1038/cr.2016.36,casr_human,844,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.57,-1.621,,,Ca2+,0.0,0.0,,0.0,,P41180,2.99252,AA844V,CASR
515,10.1038/cr.2016.36,casr_human,844,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,7.59,-8.13,,,Ca2+,0.0,0.0,,0.0,,P41180,2.99252,AA844V,CASR
71,10.1038/cr.2016.36,casr_human,772,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.79,-2.817,,,Ca2+,67.0,0.0,,0.0,,P41180,2.21182,AA772V,CASR
124,10.1038/cr.2016.36,casr_human,772,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.92,-1.818,,,Ca2+,0.0,0.0,,86.9047619,Ca2+,P41180,2.21182,AA772V,CASR
545,10.1038/cr.2016.36,casr_human,772,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.49,-1.658,,,Ca2+,0.0,0.0,,0.0,,P41180,2.21182,AA772V,CASR
73,10.1074/jbc.M308010200,casr_human,766,H,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,0.64,1.641,,,Ca2+,0.0,0.0,,102.0,Ca2+,P41180,-0.212496,HA766A,CASR
552,10.1074/jbc.M400724200,casr_human,766,H,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,0.54,1.543,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.212496,HA766A,CASR
75,10.1038/cr.2016.36,casr_human,840,A,V,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.74,-2.95,,,Ca2+,0.0,0.0,,0.0,,P41180,0.52463,AA840V,CASR
182,10.1038/cr.2016.36,casr_human,840,A,V,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,5.88,2.884,,,Ca2+,93.0,0.0,,0.0,,P41180,0.52463,AA840V,CASR
278,10.1038/cr.2016.36,casr_human,840,A,V,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.48,1.514,,,Ca2+,0.0,0.0,,92.85714286,Ca2+,P41180,0.52463,AA840V,CASR
86,10.1074/jbc.M400724200,casr_human,818,W,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,0.65,1.857,,,Ca2+,0.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
114,10.1074/jbc.M308010200,casr_human,818,W,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,3.3,8.462,,,Ca2+,0.0,0.0,,72.0,Ca2+,P41180,3.83014,WA818A,CASR
140,10.1038/cr.2016.36,casr_human,818,W,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,6.36,2.089,,,Ca2+,0.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
150,10.1038/cr.2016.36,casr_human,818,W,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.47,1.549,,,Ca2+,0.0,0.0,,96.42857143,Ca2+,P41180,3.83014,WA818A,CASR
253,10.1038/cr.2016.36,casr_human,818,W,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.18,1.514,,,Ca2+,0.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
272,10.1038/cr.2016.36,casr_human,818,W,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,5.21,11.482,,,Ca2+,0.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
342,10.1038/cr.2016.36,casr_human,818,W,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,5.81,3.388,,,Ca2+,118.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
559,10.1038/cr.2016.36,casr_human,818,W,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,5.92,3.981,,,Ca2+,0.0,0.0,,0.0,,P41180,3.83014,WA818A,CASR
92,10.1074/jbc.M308010200,casr_human,837,E,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,>,,100.0,256.41,,,Ca2+,0.0,0.0,,72.0,Ca2+,P41180,-0.209751,EA837A,CASR
101,10.1074/jbc.M400724200,casr_human,837,E,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,>,,100.0,285.714,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.209751,EA837A,CASR
97,10.1038/cr.2016.36,casr_human,832,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.44,-1.479,,,Ca2+,0.0,0.0,,0.0,,P41180,0.330073,FA832A,CASR
366,10.1038/cr.2016.36,casr_human,832,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.05,-2.457,,,Ca2+,0.0,0.0,,120.2380952,Ca2+,P41180,0.330073,FA832A,CASR
404,10.1038/cr.2016.36,casr_human,832,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.36,-1.047,,,Ca2+,30.0,0.0,,0.0,,P41180,0.330073,FA832A,CASR
102,10.1074/jbc.M308010200,casr_human,764,T,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,0.28,-1.393,,,Ca2+,0.0,0.0,,120.0,Ca2+,P41180,0.359754,TA764A,CASR
481,10.1074/jbc.M400724200,casr_human,764,T,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,0.44,1.257,,,Ca2+,0.0,0.0,,0.0,,P41180,0.359754,TA764A,CASR
104,10.1038/cr.2016.36,casr_human,831,K,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.73,-2.882,,,Ca2+,0.0,0.0,,0.0,,P41180,0.44683,KA831A,CASR
167,10.1038/cr.2016.36,casr_human,831,K,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.59,-1.779,,,Ca2+,108.0,0.0,,0.0,,P41180,0.44683,KA831A,CASR
383,10.1038/cr.2016.36,casr_human,831,K,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.04,-2.398,,,Ca2+,0.0,0.0,,100.0,Ca2+,P41180,0.44683,KA831A,CASR
110,10.1210/en.2012-1887,casr_human,727,L,Q,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,6.45,-1.779,,,Ca2+,0.0,0.0,,0.0,,P41180,0.737734,LA727Q,CASR
111,10.1038/cr.2016.36,casr_human,612,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.32,-4.566,,,Ca2+,0.0,0.0,,100.0,Ca2+,P41180,1.96511,FA612A,CASR
265,10.1038/cr.2016.36,casr_human,612,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.7,-2.688,,,Ca2+,0.0,0.0,,0.0,,P41180,1.96511,FA612A,CASR
392,10.1038/cr.2016.36,casr_human,612,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.69,-2.237,,,Ca2+,59.0,0.0,,0.0,,P41180,1.96511,FA612A,CASR
135,10.1038/cr.2016.36,casr_human,680,R,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.16,1.288,,,Ca2+,0.0,0.0,,0.0,,P41180,0.0253516,RA680A,CASR
196,10.1038/cr.2016.36,casr_human,680,R,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,5.93,5.37,,,Ca2+,0.0,0.0,,126.1904762,Ca2+,P41180,0.0253516,RA680A,CASR
375,10.1074/jbc.M400724200,casr_human,680,R,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,0.12,-3.247,,,Ca2+,0.0,0.0,,0.0,,P41180,0.0253516,RA680A,CASR
471,10.1074/jbc.M400724200,casr_human,680,R,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,=,,4.1,11.714,,,Ca2+,0.0,0.0,,0.0,,P41180,0.0253516,RA680A,CASR
570,10.1038/cr.2016.36,casr_human,680,R,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.11,1.698,,,Ca2+,130.0,0.0,,0.0,,P41180,0.0253516,RA680A,CASR
138,10.1038/cr.2016.36,casr_human,780,T,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.31,2.239,,,Ca2+,0.0,0.0,,108.3333333,Ca2+,P41180,-0.0946589,TA780A,CASR
431,10.1038/cr.2016.36,casr_human,780,T,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.03,2.042,,,Ca2+,72.0,0.0,,0.0,,P41180,-0.0946589,TA780A,CASR
541,10.1038/cr.2016.36,casr_human,780,T,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.23,1.096,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.0946589,TA780A,CASR
145,10.1038/cr.2016.36,casr_human,848,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.22,1.318,,,Ca2+,109.0,0.0,,0.0,,P41180,2.91728,LA848A,CASR
281,10.1038/cr.2016.36,casr_human,848,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,6.66,-1.381,,,Ca2+,0.0,0.0,,0.0,,P41180,2.91728,LA848A,CASR
327,10.1038/cr.2016.36,casr_human,848,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,7.51,-6.757,,,Ca2+,0.0,0.0,,0.0,,P41180,2.91728,LA848A,CASR
526,10.1038/cr.2016.36,casr_human,848,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.38,-1.047,,,Ca2+,0.0,0.0,,0.0,,P41180,2.91728,LA848A,CASR
551,10.1038/cr.2016.36,casr_human,848,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.62,-2.237,,,Ca2+,0.0,0.0,,0.0,,P41180,2.91728,LA848A,CASR
579,10.1038/cr.2016.36,casr_human,848,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.06,-2.513,,,Ca2+,0.0,0.0,,79.76190476,Ca2+,P41180,2.91728,LA848A,CASR
146,10.1210/en.2012-1887,casr_human,680,R,C,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,5.63,1.862,,,Ca2+,9.0,0.0,,0.0,,P41180,-0.0320203,RA680C,CASR
153,10.1038/cr.2016.36,casr_human,748,P,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.46,-1.318,,,Ca2+,133.0,0.0,,0.0,,P41180,2.74069,PA748A,CASR
211,10.1038/cr.2016.36,casr_human,748,P,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.86,-1.585,,,Ca2+,0.0,0.0,,102.3809524,Ca2+,P41180,2.74069,PA748A,CASR
158,10.1038/cr.2016.36,casr_human,767,E,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.86,-3.311,,,Ca2+,113.0,0.0,,0.0,,P41180,1.77607,EA767A,CASR
388,10.1038/cr.2016.36,casr_human,767,E,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,7.21,-8.696,,,Ca2+,0.0,0.0,,0.0,,P41180,1.77607,EA767A,CASR
556,10.1038/cr.2016.36,casr_human,767,E,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.62,1.096,,,Ca2+,0.0,0.0,,92.85714286,Ca2+,P41180,1.77607,EA767A,CASR
163,10.1038/cr.2016.36,casr_human,679,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.09,1.778,,,Ca2+,55.0,0.0,,0.0,,P41180,1.74492,LA679A,CASR
419,10.1038/cr.2016.36,casr_human,679,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.87,-1.621,,,Ca2+,0.0,0.0,,132.1428571,Ca2+,P41180,1.74492,LA679A,CASR
187,10.1038/cr.2016.36,casr_human,669,I,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.05,1.95,,,Ca2+,8.0,0.0,,0.0,,P41180,3.19544,IA669A,CASR
268,10.1038/cr.2016.36,casr_human,669,I,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.18,1.23,,,Ca2+,0.0,0.0,,0.0,,P41180,3.19544,IA669A,CASR
412,10.1038/cr.2016.36,casr_human,669,I,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.61,1.122,,,Ca2+,0.0,0.0,,103.5714286,Ca2+,P41180,3.19544,IA669A,CASR
188,10.1038/cr.2016.36,casr_human,672,P,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.11,-2.817,,,Ca2+,0.0,0.0,,77.38095238,Ca2+,P41180,2.00764,PA672A,CASR
456,10.1038/cr.2016.36,casr_human,672,P,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.23,1.288,,,Ca2+,40.0,0.0,,0.0,,P41180,2.00764,PA672A,CASR
209,10.1038/cr.2016.36,casr_human,775,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.46,-1.318,,,Ca2+,129.0,0.0,,0.0,,P41180,0.680835,FA775A,CASR
384,10.1038/cr.2016.36,casr_human,775,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.79,-1.35,,,Ca2+,0.0,0.0,,98.80952381,Ca2+,P41180,0.680835,FA775A,CASR
400,10.1038/cr.2016.36,casr_human,775,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.63,-2.288,,,Ca2+,0.0,0.0,,0.0,,P41180,0.680835,FA775A,CASR
223,10.1038/cr.2016.36,casr_human,682,P,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.41,-1.175,,,Ca2+,75.0,0.0,,0.0,,P41180,2.94602,PA682A,CASR
318,10.1038/cr.2016.36,casr_human,682,P,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.22,-3.636,,,Ca2+,0.0,0.0,,110.7142857,Ca2+,P41180,2.94602,PA682A,CASR
343,10.1038/cr.2016.36,casr_human,682,P,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.17,1.259,,,Ca2+,0.0,0.0,,0.0,,P41180,2.94602,PA682A,CASR
224,10.1038/cr.2016.36,casr_human,684,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,5.4,8.71,,,Ca2+,120.0,0.0,,0.0,,P41180,4.02587,FA684A,CASR
382,10.1074/jbc.M400724200,casr_human,684,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,>,,100.0,285.714,,,Ca2+,0.0,0.0,,0.0,,P41180,4.02587,FA684A,CASR
423,10.1074/jbc.M308010200,casr_human,684,F,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,>,,100.0,256.41,,,Ca2+,0.0,0.0,,50.0,Ca2+,P41180,4.02587,FA684A,CASR
567,10.1038/cr.2016.36,casr_human,684,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,5.19,12.023,,,Ca2+,0.0,0.0,,0.0,,P41180,4.02587,FA684A,CASR
230,10.1038/cr.2016.36,casr_human,670,G,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.16,1.288,,,Ca2+,0.0,0.0,,0.0,,P41180,3.04364,GA670A,CASR
285,10.1038/cr.2016.36,casr_human,670,G,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.47,-1.35,,,Ca2+,6.0,0.0,,0.0,,P41180,3.04364,GA670A,CASR
482,10.1038/cr.2016.36,casr_human,670,G,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.38,-5.236,,,Ca2+,0.0,0.0,,89.28571429,Ca2+,P41180,3.04364,GA670A,CASR
243,10.1210/en.2012-1887,casr_human,767,E,K,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,6.29,-1.23,,,Ca2+,0.0,0.0,,0.0,,P41180,1.00423,EA767K,CASR
269,10.1038/cr.2016.36,casr_human,688,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - ERK activation,6.68,,=,,6.74,-1.148,,,Ca2+,0.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
325,10.1038/cr.2016.36,casr_human,688,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,5.65,4.898,,,Ca2+,104.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
397,10.1038/cr.2016.36,casr_human,688,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - ERK activation,6.36,,=,,6.28,1.202,,,Ca2+,0.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
440,10.1038/cr.2016.36,casr_human,688,F,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,5.61,4.571,,,Ca2+,0.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
486,10.1074/jbc.M400724200,casr_human,688,F,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.35,µM,>,,100.0,285.714,,,Ca2+,0.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
510,10.1038/cr.2016.36,casr_human,688,F,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - ERK activation,6.52,,=,,7.02,-3.165,,,Ca2+,0.0,0.0,,0.0,,P41180,2.86135,FA688A,CASR
531,10.1074/jbc.M308010200,casr_human,688,F,A,Calhex231,PubChem CID,11849514,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - IP accumulation,0.39,µM,=,,3.2,8.205,,,Ca2+,0.0,0.0,,50.0,Ca2+,P41180,2.86135,FA688A,CASR
283,10.1038/cr.2016.36,casr_human,744,Y,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.48,-1.381,,,Ca2+,42.0,0.0,,0.0,,P41180,0.56002,YA744A,CASR
314,10.1038/cr.2016.36,casr_human,744,Y,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.13,1.38,,,Ca2+,0.0,0.0,,0.0,,P41180,0.56002,YA744A,CASR
316,10.1038/cr.2016.36,casr_human,744,Y,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.57,1.23,,,Ca2+,0.0,0.0,,130.952381,Ca2+,P41180,0.56002,YA744A,CASR
293,10.1038/cr.2016.36,casr_human,773,L,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.56,1.259,,,Ca2+,0.0,0.0,,72.61904762,Ca2+,P41180,1.99615,LA773A,CASR
413,10.1038/cr.2016.36,casr_human,773,L,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.28,-1.024,,,Ca2+,0.0,0.0,,0.0,,P41180,1.99615,LA773A,CASR
573,10.1038/cr.2016.36,casr_human,773,L,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.46,-1.318,,,Ca2+,82.0,0.0,,0.0,,P41180,1.99615,LA773A,CASR
302,10.1210/en.2012-1887,casr_human,612,F,S,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,6.42,-1.658,,,Ca2+,0.0,0.0,,0.0,,P41180,2.41223,FA612S,CASR
329,10.1038/cr.2016.36,casr_human,833,V,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.24,1.072,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.210855,VA833A,CASR
426,10.1038/cr.2016.36,casr_human,833,V,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.21,-3.546,,,Ca2+,0.0,0.0,,100.0,Ca2+,P41180,-0.210855,VA833A,CASR
429,10.1038/cr.2016.36,casr_human,833,V,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.94,-3.984,,,Ca2+,100.0,0.0,,0.0,,P41180,-0.210855,VA833A,CASR
338,10.1210/en.2012-1887,casr_human,773,L,R,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,5.49,5.129,,,Ca2+,0.0,0.0,,0.0,,P41180,1.43465,LA773R,CASR
354,10.1038/cr.2016.36,casr_human,838,V,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,6.17,3.09,,,Ca2+,0.0,0.0,,107.1428571,Ca2+,P41180,2.03699,VA838A,CASR
402,10.1038/cr.2016.36,casr_human,838,V,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,5.85,2.63,,,Ca2+,0.0,0.0,,0.0,,P41180,2.03699,VA838A,CASR
536,10.1038/cr.2016.36,casr_human,838,V,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.1,1.738,,,Ca2+,99.0,0.0,,0.0,,P41180,2.03699,VA838A,CASR
367,10.1210/en.2012-1887,casr_human,817,V,I,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,6.04,-1.381,,,Ca2+,77.0,0.0,,0.0,,P41180,-0.879104,VA817I,CASR
410,10.1210/en.2012-1887,casr_human,185,R,Q,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,6.24,-2.188,,,Ca2+,0.0,0.0,,0.0,,P41180,4.89199,RA185Q,CASR
430,10.1038/cr.2016.36,casr_human,834,S,A,CInacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.34,,=,,6.01,2.138,,,Ca2+,78.0,0.0,,0.0,,P41180,-0.742045,SA834A,CASR
549,10.1038/cr.2016.36,casr_human,834,S,A,AC-265347,PubChem CID,52943938,Positive allosteric modulator,pK(b),Functional - Ca2+ accumulation,6.27,,=,,6.3,-1.072,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.742045,SA834A,CASR
561,10.1038/cr.2016.36,casr_human,834,S,A,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Ca2+ accumulation,6.66,,=,,7.14,-3.021,,,Ca2+,0.0,0.0,,114.2857143,Ca2+,P41180,-0.742045,SA834A,CASR
450,10.1210/en.2012-1887,casr_human,820,S,F,NPS-2143,PubChem CID,6918446,Negative allosteric modulator - noncompetitive antagonist,pK(b),Functional - Other,6.2,,=,,6.61,-2.571,,,Ca2+,0.0,0.0,,0.0,,P41180,-0.188303,SA820F,CASR
455,10.1210/en.2012-1887,casr_human,804,A,D,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,6.38,-3.021,,,Ca2+,0.0,0.0,,0.0,,P41180,3.34417,AA804D,CASR
509,10.1210/en.2012-1887,casr_human,670,G,E,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,5.97,-1.175,,,Ca2+,13.0,0.0,,0.0,,P41180,2.45852,GA670E,CASR
525,10.1210/en.2012-1887,casr_human,657,S,Y,Cinacalcet,PubChem CID,156419,Positive allosteric modulator,pK(b),Functional - Other,5.9,,=,,5.25,4.467,,,Ca2+,16.0,0.0,,0.0,,P41180,4.6146,SA657Y,CASR
1,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.0,nM,=,,0.0,-1.19,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
25,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,Compound 1,PubChem CID,11695894,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,9.3,nM,=,,0.0,-2.273,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
28,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,>,,10000.0,200.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
52,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,JNJ16259685,PubChem CID,11313361,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,3.6,nM,=,,0.0,13.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
54,10.1124/jpet.106.116574,grm1_human,805,Y,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,10.0,nM,=,,14.0,1.4,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
67,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,YM-298198,PubChem CID,9819432,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,120.0,nM,=,,0.0,12.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
73,10.1016/j.neuropharm.2009.06.017,grm1_human,805,Y,A,LY456066,PubChem CID,9840951,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,28.0,nM,=,,0.0,9.1,,,Glutamate,0.0,0.0,,0.0,,Q13255,2.13047,YA805A,GRM1
5,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,LY456066,PubChem CID,9840951,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,28.0,nM,=,,0.0,2.6,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
17,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,YM-298198,PubChem CID,9819432,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,120.0,nM,=,,0.0,-1.786,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
20,10.1124/jpet.106.116574,grm1_human,798,W,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,10.0,nM,=,,8.0,-1.25,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
37,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,Compound 1,PubChem CID,11695894,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,9.3,nM,=,,0.0,-3.704,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
38,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.0,nM,=,,0.0,-1.587,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
48,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,12.0,-4.167,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
74,10.1016/j.neuropharm.2009.06.017,grm1_human,798,W,A,JNJ16259685,PubChem CID,11313361,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,3.6,nM,=,,0.0,-1.266,,,Glutamate,0.0,0.0,,0.0,,Q13255,4.20145,WA798A,GRM1
6,10.1016/j.neuropharm.2009.06.017,grm1_human,755,A,T,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,22.0,-2.273,,,Glutamate,0.0,0.0,,0.0,,Q13255,1.99757,AA755T,GRM1
8,10.1016/j.neuropharm.2009.06.017,grm1_human,715,S,C,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,33.0,-1.515,,,Glutamate,0.0,0.0,,0.0,,Q13255,0.419947,SA715C,GRM1
10,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,>,,10000.0,200.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
19,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,YM-298198,PubChem CID,9819432,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,120.0,nM,>,,0.0,110.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
30,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,JNJ16259685,PubChem CID,11313361,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,3.6,nM,>,,0.0,2700.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
33,10.1126/science.1249489,grm1_human,815,T,M,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,1520.0,5.714,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
61,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.0,nM,=,,0.0,38.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
62,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,LY456066,PubChem CID,9840951,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,28.0,nM,>,,0.0,350.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
72,10.1016/j.neuropharm.2009.06.017,grm1_human,815,T,M,Compound 1,PubChem CID,11695894,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,9.3,nM,=,,0.0,4.2,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
80,10.1124/jpet.106.116574,grm1_human,815,T,M,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,10.0,nM,=,,720.0,72.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,-3.0845,TA815M,GRM1
11,10.1126/science.1249489,grm1_human,756,P,S,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,692.0,2.602,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.68918,PA756S,GRM1
12,10.1126/science.1249489,grm1_human,664,V,I,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,263.0,-1.011,,,Glutamate,0.0,0.0,,0.0,,Q13255,-0.688967,VA664I,GRM1
16,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,Compound 1,PubChem CID,11695894,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,9.3,nM,=,,0.0,-1.538,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
27,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,510.0,10.2,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
32,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.0,nM,=,,0.0,-2.381,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
36,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,YM-298198,PubChem CID,9819432,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,120.0,nM,=,,0.0,-1.471,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
40,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,JNJ16259685,PubChem CID,11313361,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,3.6,nM,=,,0.0,-2.041,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
56,10.1016/j.neuropharm.2009.06.017,grm1_human,725,I,F,LY456066,PubChem CID,9840951,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,28.0,nM,=,,0.0,-1.724,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.86959,IA725F,GRM1
22,10.1126/science.1249489,grm1_human,815,T,A,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,753.0,2.831,,,Glutamate,0.0,0.0,,0.0,,Q13255,0.0381456,TA815A,GRM1
23,10.1016/j.neuropharm.2009.06.017,grm1_human,769,Y,F,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,27.0,-1.852,,,Glutamate,0.0,0.0,,0.0,,Q13255,-0.233865,YA769F,GRM1
24,10.1126/science.1249489,grm1_human,748,T,A,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,505.0,1.898,,,Glutamate,0.0,0.0,,0.0,,Q13255,0.219572,TA748A,GRM1
31,10.1016/j.neuropharm.2009.06.017,grm1_human,801,F,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,11.0,nM,=,,0.0,67.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
34,10.1016/j.neuropharm.2009.06.017,grm1_human,801,F,A,JNJ16259685,PubChem CID,11313361,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,3.6,nM,>,,0.0,2700.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
35,10.1124/jpet.106.116574,grm1_human,801,F,A,FTIDC,PubChem CID,11245287,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,10.0,nM,=,,900.0,90.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
55,10.1016/j.neuropharm.2009.06.017,grm1_human,801,F,A,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,>,,6900.0,138.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
69,10.1016/j.neuropharm.2009.06.017,grm1_human,801,F,A,LY456066,PubChem CID,9840951,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,28.0,nM,=,,0.0,-5.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
79,10.1016/j.neuropharm.2009.06.017,grm1_human,801,F,A,Compound 1,PubChem CID,11695894,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,9.3,nM,=,,0.0,380.0,,,Glutamate,0.0,0.0,,0.0,,Q13255,3.3933,FA801A,GRM1
43,10.1126/science.1249489,grm1_human,660,Q,A,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,265.0,-1.004,,,Glutamate,0.0,0.0,,0.0,,Q13255,0.0923564,QA660A,GRM1
47,10.1126/science.1249489,grm1_human,794,T,A,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,162.0,-1.642,,,Glutamate,0.0,0.0,,0.0,,Q13255,-1.11005,TA794A,GRM1
51,10.1016/j.neuropharm.2009.06.017,grm1_human,723,T,A,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,27.0,-1.852,,,Glutamate,0.0,0.0,,0.0,,Q13255,-0.406717,TA723A,GRM1
64,10.1126/science.1249489,grm1_human,822,S,A,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,214.0,-1.242,,,Glutamate,0.0,0.0,,0.0,,Q13255,-0.682139,SA822A,GRM1
71,10.1126/science.1249489,grm1_human,668,S,P,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,548.0,2.06,,,Glutamate,0.0,0.0,,0.0,,Q13255,-0.348372,SA668P,GRM1
75,10.1016/j.neuropharm.2009.06.017,grm1_human,719,T,G,CFMMC,PubChem CID,73755208,Negative allosteric modulator - noncompetitive antagonist,IC50,Functional - Ca2+ accumulation,50.0,nM,=,,27.0,-1.852,,,Glutamate,0.0,0.0,,0.0,,Q13255,0.1942,TA719G,GRM1
77,10.1126/science.1249489,grm1_human,818,A,S,FITM,PubChem CID,16660135,Negative allosteric modulator - noncompetitive antagonist,K(b),Functional - Ca2+ accumulation,266.0,nM,=,,174.0,-1.529,,,Glutamate,0.0,0.0,,0.0,,Q13255,1.42331,AA818S,GRM1
0,15900517,ada1a_human,166,R,K,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.42,,=,,8.41,1.023,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
1,15900517,ada1a_human,166,R,K,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.67,,=,,7.61,1.148,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
3,15900517,ada1a_human,166,R,K,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.64,2.344,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
4,15900517,ada1a_human,166,R,K,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.44,,=,,8.38,1.148,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
40,15900517,ada1a_human,166,R,K,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.77,-1.175,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
73,15900517,ada1a_human,166,R,K,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.39,,=,,9.19,1.585,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
93,15900517,ada1a_human,166,R,K,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,42.1,pM,=,,35.9,-1.172,,,,133.9,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
96,15900517,ada1a_human,166,R,K,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.69,,=,,4.44,1.778,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
116,15900517,ada1a_human,166,R,K,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.68,,=,,4.37,2.042,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
119,15900517,ada1a_human,166,R,K,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.31,2.63,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
140,15900517,ada1a_human,166,R,K,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.34,2.455,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
152,15900517,ada1a_human,166,R,K,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.51,,=,,9.32,1.549,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
167,15900517,ada1a_human,166,R,K,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.73,-1.122,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
176,15900517,ada1a_human,166,R,K,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.65,,=,,7.63,1.047,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
183,15900517,ada1a_human,166,R,K,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.62,2.512,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.0118363,RA166K,ADRA1A
2,15900517,ada1a_human,200,I,S,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.69,,=,,4.82,-1.35,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
14,15900517,ada1a_human,200,I,S,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.65,,=,,7.65,1.0,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
26,15900517,ada1a_human,200,I,S,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.31,2.344,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
32,15900517,ada1a_human,200,I,S,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.82,-1.23,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
47,15900517,ada1a_human,200,I,S,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,5.15,-1.35,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
61,15900517,ada1a_human,200,I,S,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.67,,=,,7.84,-1.479,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
68,15900517,ada1a_human,200,I,S,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.39,,=,,9.69,-1.996,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
74,15900517,ada1a_human,200,I,S,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.42,,=,,8.43,-1.024,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
79,15900517,ada1a_human,200,I,S,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.51,,=,,9.54,-1.072,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
92,15900517,ada1a_human,200,I,S,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.44,,=,,8.4,1.096,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
114,15900517,ada1a_human,200,I,S,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,42.1,pM,=,,34.5,-1.221,,,,86.4,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
125,15900517,ada1a_human,200,I,S,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,5.18,-1.479,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
151,15900517,ada1a_human,200,I,S,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.68,,=,,4.75,-1.175,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
174,15900517,ada1a_human,200,I,S,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.9,-1.479,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
175,15900517,ada1a_human,200,I,S,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.2,3.162,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,4.40372,IA200S,ADRA1A
5,15900517,ada1a_human,154,S,A,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.69,,=,,4.6,1.23,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
8,15900517,ada1a_human,154,S,A,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,42.1,pM,=,,38.1,-1.105,,,,86.4,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
52,15900517,ada1a_human,154,S,A,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.65,,=,,7.78,-1.35,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
75,15900517,ada1a_human,154,S,A,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.73,1.0,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
76,15900517,ada1a_human,154,S,A,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.87,1.38,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
104,15900517,ada1a_human,154,S,A,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.97,1.122,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
120,15900517,ada1a_human,154,S,A,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.67,,=,,7.57,1.259,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
122,15900517,ada1a_human,154,S,A,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.78,-1.122,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
123,15900517,ada1a_human,154,S,A,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.51,,=,,9.36,1.413,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
127,15900517,ada1a_human,154,S,A,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.44,,=,,8.45,-1.024,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
143,15900517,ada1a_human,154,S,A,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.39,,=,,9.34,1.122,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
148,15900517,ada1a_human,154,S,A,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.77,-1.175,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
149,15900517,ada1a_human,154,S,A,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.64,1.096,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
158,15900517,ada1a_human,154,S,A,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.42,,=,,8.38,1.096,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
187,15900517,ada1a_human,154,S,A,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.68,,=,,4.72,-1.096,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.897105,SA154A,ADRA1A
6,15900517,ada1a_human,311,V,I,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.7,,=,,7.6,1.259,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
10,15900517,ada1a_human,311,V,I,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.67,,=,,7.82,-1.412,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
11,15900517,ada1a_human,311,V,I,Phentolamine,ChEMBL Compound ID,CHEMBL597,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.68,,=,,7.49,1.549,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
18,15900517,ada1a_human,311,V,I,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.42,,=,,8.94,-3.311,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
29,15900517,ada1a_human,311,V,I,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.68,,=,,4.24,2.754,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
30,15900517,ada1a_human,311,V,I,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,42.1,pM,=,,42.7,1.014,,,,98.9,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
54,15900517,ada1a_human,311,V,I,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.01,,=,,4.57,2.754,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
95,15900517,ada1a_human,311,V,I,Epinephrine,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.02,,=,,4.36,4.571,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
101,15900517,ada1a_human,311,V,I,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.34,2.455,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
109,15900517,ada1a_human,311,V,I,Norepinephrine,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.73,,=,,4.32,2.57,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
110,15900517,ada1a_human,311,V,I,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.65,,=,,7.78,-1.35,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
124,15900517,ada1a_human,311,V,I,5-Methylurapidil,ChEMBL Compound ID,CHEMBL420060,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.44,,=,,8.87,-2.688,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
135,15900517,ada1a_human,311,V,I,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.69,,=,,4.27,2.63,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
163,15900517,ada1a_human,311,V,I,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.51,,=,,9.5,1.023,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
172,15900517,ada1a_human,311,V,I,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.39,,=,,9.2,1.549,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.91482,VA311I,ADRA1A
7,9548959,ada1a_human,85,I,T,compound 5,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.59,,=,,8.59,1.0,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
20,9548959,ada1a_human,85,I,T,compound 3,SMILES,CCCCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.13,,=,,8.08,1.122,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
25,9548959,ada1a_human,85,I,T,compound 2,SMILES,CCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(=O)(=O)NCCNCOC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.83,,=,,8.77,1.148,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
50,8916917,ada1a_human,85,I,T,compound1,SMILES,C1C=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.32,,=,,9.52,-1.585,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
113,9548959,ada1a_human,85,I,T,compound 6,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.2,,=,,9.1,1.259,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
130,9548959,ada1a_human,85,I,T,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,66.0,pM,=,,21.0,-3.145,,,,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
162,9548959,ada1a_human,85,I,T,compound 1,SMILES,Oc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.43,,=,,9.56,-1.35,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
165,9548959,ada1a_human,85,I,T,compound 4,SMILES,COCNCCNS(=O)(=O)c1cc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)ccc1OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.95,,=,,8.69,1.82,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.33868,IA85T,ADRA1A
9,11015306,ada1a_human,271,A,T,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.2,,=,,5.9,-5.0,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
15,11015306,ada1a_human,271,A,T,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.3,,=,,7.5,-1.585,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
24,11015306,ada1a_human,271,A,T,[3H]-KMD-3213,ChEMBL Compound ID,CHEMBL24778,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,10.4,,=,,10.5,-1.259,,,,83.3,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
39,11015306,ada1a_human,271,A,T,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,7.0,,=,,7.7,-5.0,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
56,11015306,ada1a_human,271,A,T,Noradrenaline,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.8,,=,,6.2,-2.513,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
64,11015306,ada1a_human,271,A,T,[3H]Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(d),Binding - Radioligand saturation,9.9,,=,,9.8,1.259,,,,109.1,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
91,11015306,ada1a_human,271,A,T,KMD-3213,ChEMBL Compound ID,CHEMBL24778,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.4,,=,,10.2,1.585,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
106,11015306,ada1a_human,271,A,T,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.7,,=,,9.8,-1.259,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
132,11015306,ada1a_human,271,A,T,Methoxamine,ChEMBL Compound ID,CHEMBL524,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.3,,=,,5.7,-2.513,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
139,11015306,ada1a_human,271,A,T,KMD-3213,ChEMBL Compound ID,CHEMBL24778,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,10.2,,=,,10.3,-1.259,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
145,11015306,ada1a_human,271,A,T,Phenylephrine,ChEMBL Compound ID,CHEMBL1215,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.0,,=,,5.6,-3.984,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
150,11015306,ada1a_human,271,A,T,Methoxamine,ChEMBL Compound ID,CHEMBL524,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,4.8,,=,,5.6,-6.329,,,[3H]-KMD-3213,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
155,11015306,ada1a_human,271,A,T,Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.8,,=,,9.8,1.0,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
185,11015306,ada1a_human,271,A,T,Noradrenaline,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.7,,=,,6.2,-3.165,,,[3H]Prazosin,0.0,0.0,,0.0,,P35348,-0.654086,AA271T,ADRA1A
13,9548959,ada1a_human,185,V,A,compound 4,SMILES,COCNCCNS(=O)(=O)c1cc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)ccc1OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.95,,=,,8.22,5.37,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
31,9548959,ada1a_human,185,V,A,compound 8,SMILES,CCOCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.56,,=,,8.17,2.455,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
34,9548959,ada1a_human,185,V,A,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,66.0,pM,=,,13.0,-5.076,,,,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
41,9548959,ada1a_human,185,V,A,compound 10,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(C)c(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.86,,=,,9.46,2.512,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
46,9548959,ada1a_human,185,V,A,compound 5,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.59,,=,,7.91,4.786,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
58,9548959,ada1a_human,185,V,A,compound 7,SMILES,COCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.31,,=,,8.62,-2.041,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
69,9548959,ada1a_human,185,V,A,compound 3,SMILES,CCCCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.13,,=,,7.28,7.079,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
85,9548959,ada1a_human,185,V,A,compound 11,SMILES,CCCCOCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.15,,=,,7.99,1.445,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
102,9548959,ada1a_human,185,V,A,compound 2,SMILES,CCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(=O)(=O)NCCNCOC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.83,,=,,7.86,9.333,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
126,9548959,ada1a_human,185,V,A,compound 6,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.2,,=,,8.4,6.31,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
134,9548959,ada1a_human,185,V,A,compound 1,SMILES,Oc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.43,,=,,8.45,9.55,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
141,9548959,ada1a_human,185,V,A,compound 9,SMILES,COc1ccc(CCN2CCC(CC2)c2ncc(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.47,,=,,9.44,1.072,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,1.92185,VA185A,ADRA1A
16,9548959,ada1a_human,86,F,M,compound 7,SMILES,COCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.31,,=,,8.32,-1.024,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
21,9548959,ada1a_human,86,F,M,compound 9,SMILES,COc1ccc(CCN2CCC(CC2)c2ncc(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.47,,=,,9.13,2.188,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
22,9548959,ada1a_human,86,F,M,compound 1,SMILES,Oc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.43,,=,,9.28,1.413,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
27,9548959,ada1a_human,86,F,M,compound 6,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.2,,=,,8.99,1.622,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
43,9548959,ada1a_human,86,F,M,compound 12,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(=O)(=O)NCC(N)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.55,,=,,8.0,3.548,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
51,8916917,ada1a_human,86,F,M,(+)-compound1,SMILES,C1C=C([C@@H](C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.5,,=,,5.54,9.12,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
60,8916917,ada1a_human,86,F,M,compound2,SMILES,CC1=C(C(C(C(=O)NCCCN2CCC(CC2)C(C#N)c2ccccc2)=C(C)N1)c1ccc(cc1)N(=O)=O)C(N)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.54,,=,,6.71,67.608,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
62,8916917,ada1a_human,86,F,M,compound1,SMILES,C1C=C(C(C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.32,,=,,6.62,501.187,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
82,9548959,ada1a_human,86,F,M,compound 5,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.59,,=,,7.79,6.31,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
87,9548959,ada1a_human,86,F,M,compound 10,SMILES,COc1ccc(CCN2CCC(CC2)c2nc(C)c(o2)-c2ccccc2)cc1S(N)(=O)=O,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.86,,=,,9.59,1.862,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
88,8916917,ada1a_human,86,F,M,compound3,SMILES,COC(=O)C(C1CCN(CCCNC(=O)C2=C(C)NC(C)=C(C2c2ccc(cc2)N(=O)=O)C(N)=O)CC1)c1ccccc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.92,,=,,6.35,371.535,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
90,9548959,ada1a_human,86,F,M,compound 3,SMILES,CCCCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.13,,=,,7.37,5.754,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
111,8916917,ada1a_human,86,F,M,(-)-compound1,SMILES,C1C=C([C@H](C(=C(N1)C)C(=O)OC)C2=CC=C(C=C2)[N+](=O)[O-])C(=O)NCCCN3CCC(CC3)(C4=CC=CC=C4)C5=CC=CC=C5,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,9.22,,=,,6.45,588.844,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
129,9548959,ada1a_human,86,F,M,[125I]HEAT,PubChem CID,73754995,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,66.0,pM,=,,30.0,-2.198,,,,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
146,9548959,ada1a_human,86,F,M,compound 8,SMILES,CCOCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.56,,=,,8.42,1.38,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
161,9548959,ada1a_human,86,F,M,compound 2,SMILES,CCOc1ccc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)cc1S(=O)(=O)NCCNCOC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.83,,=,,7.4,26.915,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
171,9548959,ada1a_human,86,F,M,compound 4,SMILES,COCNCCNS(=O)(=O)c1cc(CCN2CCC(CC2)c2nc(OCC(F)(F)F)c(o2)-c2ccccc2)ccc1OC,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.95,,=,,8.22,5.37,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
179,9548959,ada1a_human,86,F,M,compound 11,SMILES,CCCCOCc1nc(oc1-c1ccccc1)C1CCN(CCc2ccc(OC)c(c2)S(N)(=O)=O)CC1,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.15,,=,,8.0,1.413,,,[125I]HEAT,0.0,0.0,,0.0,,P35348,-0.794776,FA86M,ADRA1A
35,18379048,ada1a_human,106,D,A,[3H]Prazosin,ChEMBL Compound ID,CHEMBL2,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.13,nM,>,,30.0,230.769,,,,0.0,0.0,,0.0,,P35348,0.276367,DA106A,ADRA1A
0,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,A,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,158.0,3.147,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.226884,VA208A,HTR2C
37,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,A,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.91,5.688,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.226884,VA208A,HTR2C
98,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,A,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,2.12,1.812,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.226884,VA208A,HTR2C
111,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,A,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,1.07,1.783,,,[3H]-Mesulergine,98.0,0.0,,0.0,,P28335,0.226884,VA208A,HTR2C
1,8700116,5ht2c_human,222,A,S,Tryptamine,ChEMBL Compound ID,CHEMBL6640,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,284.0,nM,=,,174.0,-1.631,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
6,8700116,5ht2c_human,222,A,S,Lisuride,ChEMBL Compound ID,CHEMBL157138,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.1,nM,=,,1.4,-4.348,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
25,8700116,5ht2c_human,222,A,S,Ketanserin,ChEMBL Compound ID,CHEMBL54,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,28.0,nM,=,,94.0,3.357,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
66,8700116,5ht2c_human,222,A,S,Psilocin,ChEMBL Compound ID,CHEMBL65547,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,140.0,nM,=,,73.0,-1.919,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
76,8700116,5ht2c_human,222,A,S,Ergonovine,ChEMBL Compound ID,CHEMBL119443,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,19.0,nM,=,,3.1,-6.135,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
77,8700116,5ht2c_human,222,A,S,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.74,nM,=,,21.0,28.378,,,,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
93,8700116,5ht2c_human,222,A,S,4-HT,ChEMBL Compound ID,CHEMBL18845,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,695.0,nM,=,,330.0,-2.105,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
94,8700116,5ht2c_human,222,A,S,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,41.0,nM,=,,120.0,2.927,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
124,8700116,5ht2c_human,222,A,S,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,126.0,nM,=,,76.0,-1.658,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
135,8700116,5ht2c_human,222,A,S,Bufotenine,ChEMBL Compound ID,CHEMBL416526,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,234.0,nM,=,,176.0,-1.33,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
144,8700116,5ht2c_human,222,A,S,LSD,ChEMBL Compound ID,CHEMBL463207,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,6.4,nM,=,,1.3,-4.926,,,[3H]mesulergine,0.0,0.0,,0.0,,P28335,0.188763,AA222S,HTR2C
2,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,T,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.4,nM,=,,0.91,2.275,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.167444,VA208T,HTR2C
67,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,T,[3H]-Mesulergine,PubChem CID,4081,Inverse agonist,K(d),Binding - Radioligand saturation,0.64,nM,=,,0.7,1.094,,,,0.0,0.0,,0.0,,P28335,0.167444,VA208T,HTR2C
72,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,T,Clozapine,PubChem CID,2818,Inverse agonist,K(i),Binding - Radioligand competition/displacement,9.8,nM,=,,12.0,1.224,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.167444,VA208T,HTR2C
109,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,T,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,450.0,1.011,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.167444,VA208T,HTR2C
7,11113535,5ht2c_human,368,Y,C,Mianserin,ChEMBL Compound ID,CHEMBL6437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.29,nM,=,,1.33,1.031,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
28,11113535,5ht2c_human,368,Y,C,SB206553,ChEMBL Compound ID,CHEMBL297784,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.0,nM,=,,14.0,1.4,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
29,11113535,5ht2c_human,368,Y,C,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,51.0,nM,=,,15.0,-3.401,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
81,11113535,5ht2c_human,368,Y,C,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,25.0,-4.405,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
90,11113535,5ht2c_human,368,Y,C,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.78,nM,=,,1.36,1.744,,,,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
99,11113535,5ht2c_human,368,Y,C,Quipazine,ChEMBL Compound ID,CHEMBL18772,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,489.0,nM,=,,222.0,-2.203,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.3255,YA368C,HTR2C
9,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,F,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,55.1,1.098,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-2.01897,NA351F,HTR2C
62,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,F,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.84,1.4,,,[3H]-Mesulergine,49.0,0.0,,0.0,,P28335,-2.01897,NA351F,HTR2C
91,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,F,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,1.36,1.162,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-2.01897,NA351F,HTR2C
166,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,F,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.76,4.75,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-2.01897,NA351F,HTR2C
10,22020288,5ht2c_human,138,S,A,Tryptamine,ChEMBL Compound ID,CHEMBL6640,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,57.1,nM,=,,1513.0,26.497,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
26,10.1080/00268976.2014.952695,5ht2c_human,138,S,A,3'-Br-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(Br)c1)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,103.0,3.962,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
48,22020288,5ht2c_human,138,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.0,nM,=,,118.2,13.133,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
57,10.1080/00268976.2014.952695,5ht2c_human,138,S,A,3'-CF3-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(c1)C(F)(F)F)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,52.0,nM,=,,208.0,4.0,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
84,22020288,5ht2c_human,138,S,A,Lisuride,ChEMBL Compound ID,CHEMBL157138,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.4,nM,=,,11.3,-1.009,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
125,22020288,5ht2c_human,138,S,A,trans-PAT,ChEMBL Compound ID,CHEMBL127307,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,78.4,nM,=,,210.0,2.679,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
136,22020288,5ht2c_human,138,S,A,[3H]mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.8,nM,=,,2.0,1.111,,,,0.0,0.0,,0.0,,P28335,-0.888227,SA138A,HTR2C
11,10.1016/j.cell.2018.01.001,5ht2c_human,324,W,L,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,2920.0,18250.0,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.524499,WA324L,HTR2C
139,10.1016/j.cell.2018.01.001,5ht2c_human,324,W,L,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,4.39,7.317,,,[3H]-Mesulergine,45.0,0.0,,0.0,,P28335,0.524499,WA324L,HTR2C
141,10.1016/j.cell.2018.01.001,5ht2c_human,324,W,L,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,22.7,-2.212,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.524499,WA324L,HTR2C
147,10.1016/j.cell.2018.01.001,5ht2c_human,324,W,L,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,2.58,2.205,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.524499,WA324L,HTR2C
12,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,S,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,1.68,1.436,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.0839893,VA208S,HTR2C
21,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,S,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.62,3.875,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.0839893,VA208S,HTR2C
32,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,S,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,99.1,1.974,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.0839893,VA208S,HTR2C
161,10.1016/j.cell.2018.01.001,5ht2c_human,208,V,S,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.72,1.2,,,[3H]-Mesulergine,127.0,0.0,,0.0,,P28335,0.0839893,VA208S,HTR2C
13,10.1016/j.cell.2018.01.001,5ht2c_human,350,L,G,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.4,nM,=,,1.5,3.75,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,3.15814,LA350G,HTR2C
46,10.1016/j.cell.2018.01.001,5ht2c_human,350,L,G,[3H]-Mesulergine,PubChem CID,4081,Inverse agonist,K(d),Binding - Radioligand saturation,0.64,nM,=,,1.26,1.969,,,,0.0,0.0,,0.0,,P28335,3.15814,LA350G,HTR2C
69,10.1016/j.cell.2018.01.001,5ht2c_human,350,L,G,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,1186.0,2.665,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,3.15814,LA350G,HTR2C
171,10.1016/j.cell.2018.01.001,5ht2c_human,350,L,G,Clozapine,PubChem CID,2818,Inverse agonist,K(i),Binding - Radioligand competition/displacement,9.8,nM,=,,6.2,-1.58,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,3.15814,LA350G,HTR2C
15,11113535,5ht2c_human,368,Y,A,Quipazine,ChEMBL Compound ID,CHEMBL18772,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,489.0,nM,=,,228.0,-2.146,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
35,11113535,5ht2c_human,368,Y,A,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.78,nM,=,,1.0,1.282,,,,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
44,11113535,5ht2c_human,368,Y,A,Mianserin,ChEMBL Compound ID,CHEMBL6437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.29,nM,=,,1.46,1.132,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
78,11113535,5ht2c_human,368,Y,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,29.0,-3.788,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
133,11113535,5ht2c_human,368,Y,A,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,51.0,nM,=,,15.0,-3.401,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
145,11113535,5ht2c_human,368,Y,A,SB206553,ChEMBL Compound ID,CHEMBL297784,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.0,nM,=,,15.0,1.5,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.24962,YA368A,HTR2C
20,10.1016/j.cell.2018.01.001,5ht2c_human,118,Y,A,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,116.0,2.311,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.823143,YA118A,HTR2C
56,10.1016/j.cell.2018.01.001,5ht2c_human,118,Y,A,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.29,1.812,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.823143,YA118A,HTR2C
104,10.1016/j.cell.2018.01.001,5ht2c_human,118,Y,A,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.82,1.367,,,[3H]-Mesulergine,45.0,0.0,,0.0,,P28335,0.823143,YA118A,HTR2C
153,10.1016/j.cell.2018.01.001,5ht2c_human,118,Y,A,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,1.02,-1.147,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.823143,YA118A,HTR2C
22,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,S,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,6310.0,14.18,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.931707,GA218S,HTR2C
107,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,S,Clozapine,PubChem CID,2818,Inverse agonist,K(i),Binding - Radioligand competition/displacement,9.8,nM,=,,24.0,2.449,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.931707,GA218S,HTR2C
138,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,S,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.4,nM,=,,24.0,60.0,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.931707,GA218S,HTR2C
175,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,S,[3H]-Mesulergine,PubChem CID,4081,Inverse agonist,K(d),Binding - Radioligand saturation,0.64,nM,=,,3.21,5.016,,,,0.0,0.0,,0.0,,P28335,0.931707,GA218S,HTR2C
23,10.1016/j.cell.2018.01.001,5ht2c_human,354,V,N,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,23.0,-19.231,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.750966,VA354N,HTR2C
42,10.1016/j.cell.2018.01.001,5ht2c_human,354,V,N,[3H]-Mesulergine,PubChem CID,4081,Inverse agonist,K(d),Binding - Radioligand saturation,0.64,nM,=,,2.37,3.703,,,,0.0,0.0,,0.0,,P28335,0.750966,VA354N,HTR2C
110,10.1016/j.cell.2018.01.001,5ht2c_human,354,V,N,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.4,nM,=,,170.0,425.0,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.750966,VA354N,HTR2C
143,10.1016/j.cell.2018.01.001,5ht2c_human,354,V,N,Clozapine,PubChem CID,2818,Inverse agonist,K(i),Binding - Radioligand competition/displacement,9.8,nM,=,,27.0,2.755,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.750966,VA354N,HTR2C
24,10.1080/00268976.2014.952695,5ht2c_human,361,S,A,3'-Br-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(Br)c1)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,14.0,-1.859,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,0.199262,SA361A,HTR2C
33,16880620,5ht2c_human,361,S,A,[3H]Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,573.0,pM,=,,3557.0,6.208,,,,0.0,0.0,,0.0,,P28335,0.199262,SA361A,HTR2C
105,16880620,5ht2c_human,361,S,A,Sarpogrelate,ChEMBL Compound ID,CHEMBL52939,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.42,,=,,4.87,35.481,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,0.199262,SA361A,HTR2C
173,10.1080/00268976.2014.952695,5ht2c_human,361,S,A,3'-CF3-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(c1)C(F)(F)F)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,52.0,nM,=,,38.0,-1.368,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,0.199262,SA361A,HTR2C
30,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,F,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,12.7,21.167,,,[3H]-Mesulergine,79.0,0.0,,0.0,,P28335,-1.03314,VA135F,HTR2C
64,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,F,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,5.52,34.5,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.03314,VA135F,HTR2C
96,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,F,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,8350.0,166.335,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.03314,VA135F,HTR2C
112,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,F,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,134.0,114.53,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.03314,VA135F,HTR2C
38,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,A,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,4.04,25.25,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.493788,GA218A,HTR2C
45,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,A,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,616.0,1.384,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.493788,GA218A,HTR2C
51,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,A,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.56,-1.072,,,[3H]-Mesulergine,98.0,0.0,,0.0,,P28335,-0.493788,GA218A,HTR2C
75,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,A,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,2.28,1.949,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.493788,GA218A,HTR2C
137,10.1016/j.cell.2018.01.001,5ht2c_human,218,G,A,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,586.0,11.673,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.493788,GA218A,HTR2C
49,10.1016/j.cell.2018.01.001,5ht2c_human,219,S,T,[3H]-Mesulergine,PubChem CID,4081,Inverse agonist,K(d),Binding - Radioligand saturation,0.64,nM,=,,0.35,-1.828,,,,0.0,0.0,,0.0,,P28335,2.12517,SA219T,HTR2C
68,10.1016/j.cell.2018.01.001,5ht2c_human,219,S,T,Clozapine,PubChem CID,2818,Inverse agonist,K(i),Binding - Radioligand competition/displacement,9.8,nM,=,,13.0,1.327,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,2.12517,SA219T,HTR2C
146,10.1016/j.cell.2018.01.001,5ht2c_human,219,S,T,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,156.0,-2.849,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,2.12517,SA219T,HTR2C
159,10.1016/j.cell.2018.01.001,5ht2c_human,219,S,T,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.4,nM,=,,1.3,3.25,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,2.12517,SA219T,HTR2C
50,11113535,5ht2c_human,368,Y,F,SB206553,ChEMBL Compound ID,CHEMBL297784,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,10.0,nM,=,,14.0,1.4,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
59,11113535,5ht2c_human,368,Y,F,Mianserin,ChEMBL Compound ID,CHEMBL6437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1.29,nM,=,,2.1,1.628,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
70,11113535,5ht2c_human,368,Y,F,DOI,ChEMBL Compound ID,CHEMBL6616,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,51.0,nM,=,,13.0,-3.922,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
116,11113535,5ht2c_human,368,Y,F,Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.78,nM,=,,2.64,3.385,,,,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
128,11113535,5ht2c_human,368,Y,F,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,110.0,nM,=,,25.0,-4.405,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
167,11113535,5ht2c_human,368,Y,F,Quipazine,ChEMBL Compound ID,CHEMBL18772,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,489.0,nM,=,,188.0,-2.604,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.671876,YA368F,HTR2C
54,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,L,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,1.98,3.3,,,[3H]-Mesulergine,108.0,0.0,,0.0,,P28335,-1.06605,VA135L,HTR2C
82,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,L,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,7.87,6.726,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.06605,VA135L,HTR2C
86,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,L,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,690.0,13.745,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.06605,VA135L,HTR2C
87,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,L,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,1.45,9.062,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.06605,VA135L,HTR2C
150,10.1016/j.cell.2018.01.001,5ht2c_human,135,V,L,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,3981.0,8.946,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-1.06605,VA135L,HTR2C
55,10.1016/j.cell.2018.01.001,5ht2c_human,358,Y,F,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,0.65,-1.799,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.58976,YA358F,HTR2C
80,10.1016/j.cell.2018.01.001,5ht2c_human,358,Y,F,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.41,-1.464,,,[3H]-Mesulergine,37.0,0.0,,0.0,,P28335,0.58976,YA358F,HTR2C
114,10.1016/j.cell.2018.01.001,5ht2c_human,358,Y,F,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,201.0,4.004,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.58976,YA358F,HTR2C
115,10.1016/j.cell.2018.01.001,5ht2c_human,358,Y,F,Lorcaserin,PubChem CID,11658860,Full agonist,K(i),Binding - Radioligand competition/displacement,445.0,nM,=,,1166.0,2.62,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.58976,YA358F,HTR2C
131,10.1016/j.cell.2018.01.001,5ht2c_human,358,Y,F,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.12,-1.333,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.58976,YA358F,HTR2C
58,10.1016/j.cell.2018.01.001,5ht2c_human,142,I,F,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,2.99,2.556,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.778906,IA142F,HTR2C
60,10.1016/j.cell.2018.01.001,5ht2c_human,142,I,F,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,2.88,4.8,,,[3H]-Mesulergine,75.0,0.0,,0.0,,P28335,0.778906,IA142F,HTR2C
74,10.1016/j.cell.2018.01.001,5ht2c_human,142,I,F,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,3.2,20.0,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.778906,IA142F,HTR2C
127,10.1016/j.cell.2018.01.001,5ht2c_human,142,I,F,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,490.0,9.761,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,0.778906,IA142F,HTR2C
61,10.1080/00268976.2014.952695,5ht2c_human,139,T,A,3'-CF3-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(c1)C(F)(F)F)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,52.0,nM,=,,260.0,5.0,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,0.168421,TA139A,HTR2C
100,10.1080/00268976.2014.952695,5ht2c_human,139,T,A,[3H]Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,2.0,fmol/mg,=,,3.8,1.9,,,,0.0,0.0,,0.0,,P28335,0.168421,TA139A,HTR2C
174,10.1080/00268976.2014.952695,5ht2c_human,139,T,A,3'-Br-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(Br)c1)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,210.0,8.077,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,0.168421,TA139A,HTR2C
71,10.1080/00268976.2014.952695,5ht2c_human,223,F,A,[3H]Mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,2.0,fmol/mg,=,,4.6,2.3,,,,0.0,0.0,,0.0,,P28335,3.98152,FA223A,HTR2C
119,10.1080/00268976.2014.952695,5ht2c_human,223,F,A,3'-CF3-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(c1)C(F)(F)F)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,52.0,nM,=,,371.0,7.135,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.98152,FA223A,HTR2C
163,10.1080/00268976.2014.952695,5ht2c_human,223,F,A,3'-Br-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(Br)c1)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,275.0,10.577,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,3.98152,FA223A,HTR2C
83,10.1080/00268976.2014.952695,5ht2c_human,360,C,A,3'-Br-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(Br)c1)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,26.0,nM,=,,22.0,-1.182,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.10512,CA360A,HTR2C
160,10.1080/00268976.2014.952695,5ht2c_human,360,C,A,3'-CF3-PAT,SMILES,[H][C@]1(Cc2ccccc2[C@]([H])(C1)c1cccc(c1)C(F)(F)F)N(C)C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,52.0,nM,=,,38.0,-1.368,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,-0.10512,CA360A,HTR2C
89,22020288,5ht2c_human,358,Y,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,9.0,nM,=,,152.0,16.889,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,4.35458,YA358A,HTR2C
132,22020288,5ht2c_human,358,Y,A,trans-PAT,ChEMBL Compound ID,CHEMBL127307,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,78.4,nM,=,,354.0,4.515,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,4.35458,YA358A,HTR2C
151,22020288,5ht2c_human,358,Y,A,Lisuride,ChEMBL Compound ID,CHEMBL157138,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,11.4,nM,=,,7.9,-1.443,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,4.35458,YA358A,HTR2C
156,22020288,5ht2c_human,358,Y,A,[3H]mesulergine,ChEMBL Compound ID,CHEMBL12314,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,1.8,nM,=,,3.0,1.667,,,,0.0,0.0,,0.0,,P28335,4.35458,YA358A,HTR2C
165,22020288,5ht2c_human,358,Y,A,Tryptamine,ChEMBL Compound ID,CHEMBL6640,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,57.1,nM,=,,298.5,5.228,,,[3H]Mesulergine,0.0,0.0,,0.0,,P28335,4.35458,YA358A,HTR2C
95,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,L,5-HT,PubChem CID,5202,Full agonist,K(i),Binding - Radioligand competition/displacement,50.2,nM,=,,135.0,2.689,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.931034,NA351L,HTR2C
117,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,L,Ergotamine,PubChem CID,8223,Full agonist,K(i),Binding - Radioligand competition/displacement,1.17,nM,=,,1.25,1.068,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.931034,NA351L,HTR2C
142,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,L,Mesulergine,PubChem CID,68848,Inverse agonist,K(d),Binding - Radioligand competition/displacement,0.6,nM,=,,0.95,1.583,,,[3H]-Mesulergine,84.0,0.0,,0.0,,P28335,-0.931034,NA351L,HTR2C
152,10.1016/j.cell.2018.01.001,5ht2c_human,351,N,L,Ritanserin,PubChem CID,5074,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.16,nM,=,,0.77,4.812,,,[3H]-Mesulergine,0.0,0.0,,0.0,,P28335,-0.931034,NA351L,HTR2C
0,11498510,vipr2_human,172,R,Q,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,7.0,nM,=,,190.0,27.143,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
2,11498510,vipr2_human,172,R,Q,C6-VIP,,,Full agonist,EC50,Functional - cAMP accumulation,0.9,nM,=,,17.0,18.889,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
3,11498510,vipr2_human,172,R,Q,C6-VIP,,,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,1.0,nM,=,,13.0,13.0,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
4,11498510,vipr2_human,172,R,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,900.0,18.0,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
5,11498510,vipr2_human,172,R,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,70.0,nM,=,,700.0,10.0,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
7,11498510,vipr2_human,172,R,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,300.0,nM,=,,3.0,-100.0,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
15,11498510,vipr2_human,172,R,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Partial agonist,EC50,Functional - cAMP accumulation,200.0,nM,=,,2.0,-100.0,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
23,11498510,vipr2_human,172,R,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Partial agonist,EC50,Functional - cAMP accumulation,2000.0,nM,=,,2.0,-1000.0,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
24,11498510,vipr2_human,172,R,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,200.0,nM,=,,3.0,-66.667,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
34,11498510,vipr2_human,172,R,Q,Ro 25-1553 ,PubChem CID,16131327,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,>,,10000.0,1000.0,,,VIP,0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
36,11498510,vipr2_human,172,R,Q,Ro 25-1553 ,PubChem CID,16131327,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,5.0,nM,=,,150.0,30.0,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
37,11498510,vipr2_human,172,R,Q,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,3.0,nM,=,,150.0,50.0,,,[125I]-VIP (radioligand),0.0,0.0,,0.0,,P41587,1.73306,RA172Q,VIPR2
6,11498510,vipr2_human,179,K,Q,VIP,PubChem CID,16129679,Full agonist,EC50,Functional - cAMP accumulation,7.0,nM,=,,4000.0,571.429,Abolished effect,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
13,11498510,vipr2_human,179,K,Q,Ro 25-1553 ,PubChem CID,16131327,Full agonist,EC50,Functional - cAMP accumulation,10.0,nM,=,,5000.0,500.0,Abolished effect,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
22,11498510,vipr2_human,179,K,Q,VIP-[Asp3Asn] ,FASTA sequence (peptide),HSNAVFTDNYTRLRKQMAVKKYLNSILN,Partial agonist,EC50,Functional - cAMP accumulation,2000.0,nM,=,,2000.0,1.0,Abolished effect,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
28,11498510,vipr2_human,179,K,Q,C6-VIP,,,Full agonist,EC50,Functional - cAMP accumulation,0.9,nM,=,,900.0,1000.0,,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
31,11498510,vipr2_human,179,K,Q,VIP-[Asp3Gln] ,FASTA sequence (peptide),HSQAVFTDNYTRLRKQMAVKKYLNSILN,Partial agonist,EC50,Functional - cAMP accumulation,200.0,nM,=,,5000.0,25.0,Abolished effect,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
35,11498510,vipr2_human,179,K,Q,VIP-[Asp3Glu] ,FASTA sequence (peptide),HSEAVFTDNYTRLRKQMAVKKYLNSILN,Full agonist,EC50,Functional - cAMP accumulation,70.0,nM,=,,2500.0,35.714,Abolished effect,,VIP,0.0,0.0,,0.0,,P41587,0.604215,KA179Q,VIPR2
9,12475394,vipr2_human,184,Y,F,VIP-[Thr11Arg] ,FASTA sequence (peptide),HSDAVFTDNYRRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.84,M,=,,6.75,-8.13,,,[125I]-VIP,100.0,0.0,,0.0,,P41587,-0.441648,YA184F,VIPR2
14,12475394,vipr2_human,184,Y,F,VIP-[Thr11Citrullinel] ,,,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,5.75,M,=,,6.92,-14.706,,,[125I]-VIP,100.0,0.0,,0.0,,P41587,-0.441648,YA184F,VIPR2
17,12475394,vipr2_human,184,Y,F,VIP,PubChem CID,16129679,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,8.08,M,=,,7.37,5.129,,,[125I]-VIP,100.0,0.0,,0.0,,P41587,-0.441648,YA184F,VIPR2
18,12475394,vipr2_human,184,Y,F,VIP,PubChem CID,16129679,Full agonist,pEC50,Functional - cAMP accumulation,8.34,M,=,,8.4,-1.148,Abolished effect,,VIP,0.0,0.0,,100.0,VIP,P41587,-0.441648,YA184F,VIPR2
19,12475394,vipr2_human,184,Y,F,VIP-[Thr11Val] ,FASTA sequence (peptide),HSDAVFTDNYVRLRKQMAVKKYLNSILN,Binding - unknown pharmacological activity,pK(i),Binding - Radioligand competition/displacement,6.45,M,=,,7.55,-12.658,,,[125I]-VIP,100.0,0.0,,0.0,,P41587,-0.441648,YA184F,VIPR2
21,12475394,vipr2_human,184,Y,F,VIP-[Thr11Arg] ,FASTA sequence (peptide),HSDAVFTDNYRRLRKQMAVKKYLNSILN,Full agonist,pEC50,Functional - cAMP accumulation,5.9,M,=,,6.67,-5.882,Abolished effect,,VIP,0.0,0.0,,225.0,VIP,P41587,-0.441648,YA184F,VIPR2
27,12475394,vipr2_human,184,Y,F,VIP-[Thr11Val] ,FASTA sequence (peptide),HSDAVFTDNYVRLRKQMAVKKYLNSILN,Full agonist,pEC50,Functional - cAMP accumulation,7.12,M,=,,8.26,-13.889,Abolished effect,,VIP,0.0,0.0,,92.39130435,VIP,P41587,-0.441648,YA184F,VIPR2
32,12475394,vipr2_human,184,Y,F,VIP-[Thr11Citrullinel] ,,,Full agonist,pEC50,Functional - cAMP accumulation,5.95,M,=,,7.13,-15.152,Abolished effect,,VIP,0.0,0.0,,192.5,VIP,P41587,-0.441648,YA184F,VIPR2
0,17599916,cxcr4_human,259,I,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,0.91,-1.869,,,CXCL12,0.0,0.0,,68.81918819,,P61073,2.65166,IA259A,CXCR4
149,25039237,cxcr4_human,259,I,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.4,-1.3,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
164,26397724,cxcr4_human,259,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,2.1,1.4,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
457,14585837,cxcr4_human,259,I,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.03,1.5,,,radioligand:12G5(Bolton-Hunter),29.19708029,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
464,25039237,cxcr4_human,259,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,2.1,1.4,,,,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
471,17599916,cxcr4_human,259,I,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.01,1.0,,,CXCL12,0.0,0.0,,68.81918819,,P61073,2.65166,IA259A,CXCR4
559,17599916,cxcr4_human,259,I,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.07,1.75,,,CXCL12,0.0,0.0,,68.81918819,,P61073,2.65166,IA259A,CXCR4
624,25039237,cxcr4_human,259,I,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.41,-7.299,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
642,17599916,cxcr4_human,259,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.5,1.685,,,radioligand:[125I] -12G5,51.82481752,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
665,17599916,cxcr4_human,259,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.29,1.318,,,CXCL12,0.0,0.0,,95.55145551,,P61073,2.65166,IA259A,CXCR4
680,25039237,cxcr4_human,259,I,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.53,-5.464,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
751,17599916,cxcr4_human,259,I,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,2.5,-8.0,,,CXCL12,0.0,0.0,,95.55145551,,P61073,2.65166,IA259A,CXCR4
900,14585837,cxcr4_human,259,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.5,1.685,,,radioligand:12G5(Bolton-Hunter),29.19708029,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
967,17599916,cxcr4_human,259,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,6.6,8.148,,,radioligand: [125I]-CXCL12,0.0,0.0,,68.81918819,,P61073,2.65166,IA259A,CXCR4
1000,17599916,cxcr4_human,259,I,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.03,3.0,,,CXCL12,0.0,0.0,,95.55145551,,P61073,2.65166,IA259A,CXCR4
1024,26397724,cxcr4_human,259,I,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,2.6,5.2,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
1052,25039237,cxcr4_human,259,I,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.08,-5.0,,,CXCL12,3.0,0.0,,0.0,,P61073,2.65166,IA259A,CXCR4
1,12534283,cxcr4_human,182,D,N,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,1.6,-1.876,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
323,11154697/12534283,cxcr4_human,182,D,N,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,12.0,-1.083,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
358,11154697,cxcr4_human,182,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.43,-1.139,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
483,12534283,cxcr4_human,182,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,130.0,1.757,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
489,12534283,cxcr4_human,182,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,62.0,5.167,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
551,12534283,cxcr4_human,182,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,3.21,3.21,,,radioligand: [125I]-12G5,202.5641026,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
572,11154697,cxcr4_human,182,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,130.0,1.757,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
606,12534283,cxcr4_human,182,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.072,2.571,,,radioligand: [125I]-12G5,202.5641026,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
664,11154697,cxcr4_human,182,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,3100.0,5.636,,,radioligand: [125I]-12G5,202.5641026,0.0,,0.0,,P61073,-0.523361,DA182N,CXCR4
5,11923301,cxcr4_human,119,N,S,ALX40-4C,PubChem CID,25077385,Partial agonist,IC50,Binding - Radioligand competition/displacement,717.0,nM,=,,4060.0,5.662,,,radioligand: [125I]-CXCL12,100.0,0.0,,0.0,,P61073,0.245493,NA119S,CXCR4
814,11923301,cxcr4_human,119,N,S,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,106.0,nM,=,,3440.0,32.453,,,radioligand: [125I]-CXCL12,100.0,0.0,,0.0,,P61073,0.245493,NA119S,CXCR4
828,17197449,cxcr4_human,119,N,S,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Functional - cAMP accumulation,25.0,%,~,,17.0,1.471,,,,120.0,0.0,,0.0,,P61073,0.245493,NA119S,CXCR4
830,11923301,cxcr4_human,119,N,S,T140,PubChem CID,16130395,Inverse agonist,IC50,Binding - Radioligand competition/displacement,16.0,nM,=,,27.6,1.725,,,radioligand: [125I]-CXCL12,100.0,0.0,,0.0,,P61073,0.245493,NA119S,CXCR4
7,10620340,cxcr4_human,275,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,15.7,4.618,,,,106.2256809,0.0,,0.0,,P61073,1.4278,EA275A,CXCR4
8,25039237,cxcr4_human,255,Y,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.8,1.538,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
17,25039237,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.1,-1.364,,,,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
54,17599916,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,1.3,1.605,,,radioligand: [125I]-CXCL12,0.0,0.0,,22.34522345,,P61073,3.12549,YA255A,CXCR4
74,17599916,cxcr4_human,255,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.45,4.091,,,radioligand:125I-12G5,171.5328467,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
75,18768385,cxcr4_human,255,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,225.0,4.592,,,radioligand: [125I]-CXCL12,96.7,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
151,17599916,cxcr4_human,255,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,9.7,10.899,,,radioligand:[125I] -12G5,171.5328467,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
198,18768385,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,11.8,-3.03,,,,96.7,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
231,26397724,cxcr4_human,255,Y,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,1.7,3.4,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
238,14585837,cxcr4_human,255,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,9.7,10.899,,,radioligand:12G5(Bolton-Hunter),171.5328467,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
289,16188969/16306611,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,7.9,3.591,,,radioligand: [125I]-CXCL12,64.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
310,18768385,cxcr4_human,255,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,2390.0,2.838,,,radioligand: [125I]-CXCL12,96.7,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
400,14585837,cxcr4_human,255,Y,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,,K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.53,26.5,,,radioligand:12G5(Bolton-Hunter),171.5328467,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
405,17599916,cxcr4_human,255,Y,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.09,9.0,,,CXCL12,0.0,0.0,,22.34522345,,P61073,3.12549,YA255A,CXCR4
501,17599916,cxcr4_human,255,Y,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,37.0,1.85,,,CXCL12,0.0,0.0,,67.6096761,,P61073,3.12549,YA255A,CXCR4
511,25039237,cxcr4_human,255,Y,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.27,-1.481,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
514,17599916,cxcr4_human,255,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.02,2.0,,,CXCL12,0.0,0.0,,67.6096761,,P61073,3.12549,YA255A,CXCR4
556,25039237,cxcr4_human,255,Y,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,3.2,1.067,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
652,25039237,cxcr4_human,255,Y,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,8.5,2.931,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
658,17599916,cxcr4_human,255,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.66,3.0,,,CXCL12,0.0,0.0,,67.6096761,,P61073,3.12549,YA255A,CXCR4
776,17599916,cxcr4_human,255,Y,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,8.8,5.176,,,CXCL12,0.0,0.0,,22.34522345,,P61073,3.12549,YA255A,CXCR4
910,17599916,cxcr4_human,255,Y,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.11,2.75,,,CXCL12,0.0,0.0,,22.34522345,,P61073,3.12549,YA255A,CXCR4
914,26397724,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.1,-1.364,,,CXCL12,47.0,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
930,18768385,cxcr4_human,255,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,42.0,1.235,,,,96.7,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
1028,18768385,cxcr4_human,255,Y,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,13.0,1.182,,,radioligand: [125I]-CXCL24,96.7,0.0,,0.0,,P61073,3.12549,YA255A,CXCR4
9,11551942,cxcr4_human,190,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,75.0,,,12G5,140.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
49,25039237,cxcr4_human,190,Y,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,4.0,1.379,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
184,25039237,cxcr4_human,190,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.2,-1.25,,,,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
395,26397724,cxcr4_human,190,Y,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.27,-1.852,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
537,26397724,cxcr4_human,190,Y,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,12.0,1.0,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
657,25039237,cxcr4_human,190,Y,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.47,1.175,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
679,25039237,cxcr4_human,190,Y,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.66,1.269,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
682,26397724,cxcr4_human,190,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.2,-1.25,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
683,25039237,cxcr4_human,190,Y,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,2.6,-1.153,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
745,26397724,cxcr4_human,190,Y,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,12.0,1.412,,,CXCL12,105.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
848,11551942,cxcr4_human,190,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,230.0,,,12G5,140.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
854,11551942,cxcr4_human,190,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,120.0,,,[125I]-SDF-1α,140.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
957,11551942,cxcr4_human,190,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,125.0,,,[125I]-SDF-1α,140.0,0.0,,0.0,,P61073,3.4597,YA190A,CXCR4
10,25039237,cxcr4_human,171,D,N,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,25.0,8.333,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
37,11154697,cxcr4_human,171,D,N,AMD3106,SMILES,N1(CCCNCCNCCCNCC1)Cc2nc(CN3CCCNCCNCCCNCC3)ccc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.083,uM,=,,17.0,204.819,,,radioligand: Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
93,17599916,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,4.2,5.185,,,radioligand: [125I]-CXCL12,0.0,0.0,,52.76752768,,P61073,0.620283,DA171N,CXCR4
102,17599916,cxcr4_human,171,D,N,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.43,10.75,,,CXCL12,0.0,0.0,,52.76752768,,P61073,0.620283,DA171N,CXCR4
106,18768385,cxcr4_human,171,D,N,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,13760.0,1250.909,,,radioligand: [125I]-CXCL12,39.7,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
129,17599916,cxcr4_human,171,D,N,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,14.0,8.235,,,CXCL12,0.0,0.0,,52.76752768,,P61073,0.620283,DA171N,CXCR4
131,18768385,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,9584.0,11.382,,,radioligand: [125I]-CXCL12,39.7,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
133,14585837,cxcr4_human,171,D,N,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.28,14.0,,,radioligand:12G5(Bolton-Hunter),51.09489051,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
202,25039237,cxcr4_human,171,D,N,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,47.0,9.592,,,radioligand:[125I]-12G9,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
239,18768385,cxcr4_human,171,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,1350.0,27.551,,,radioligand: [125I]-CXCL12,39.7,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
241,14585837,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,13.0,14.607,,,radioligand:12G5(Bolton-Hunter),51.09489051,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
279,11154697/12534283,cxcr4_human,171,D,N,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,370.0,28.462,,,radioligand: [125I]-Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
288,26397724,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,3.2,2.133,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
308,17599916,cxcr4_human,171,D,N,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,107.0,5.35,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.620283,DA171N,CXCR4
346,17599916,cxcr4_human,171,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,3.2,29.091,,,radioligand:125I-12G5,51.09489051,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
407,11154697,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,100000.0,181.818,,,radioligand: [125I]-12G5,71.79487179,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
443,17599916,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,13.0,14.607,,,radioligand:[125I] -12G5,51.09489051,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
444,17599916,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,1.8,8.182,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.620283,DA171N,CXCR4
509,25039237,cxcr4_human,171,D,N,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,100.0,263.158,,,radioligand:[125I]-12G5,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
530,25039237,cxcr4_human,171,D,N,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,100.0,34.483,,,radioligand:[125I]-12G9,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
532,17599916,cxcr4_human,171,D,N,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.13,13.0,,,CXCL12,0.0,0.0,,52.76752768,,P61073,0.620283,DA171N,CXCR4
569,11154697,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,2800.0,37.838,,,radioligand: [125I]Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
574,11154697,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.58,1.184,,,radioligand: [125I]Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
601,11154697,cxcr4_human,171,D,N,AMD2936,SMILES,[H][C@@]1(CCCN2CCNCCCNCCNCCC2)NCCCNCCNCCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.65,uM,=,,58.0,89.231,,,radioligand: [125I]Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
628,12534283,cxcr4_human,171,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,1700.0,141.667,,,radioligand: [125I]-Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
632,18768385,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,137.9,4.056,,,,39.7,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
644,12534283,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,12.0,12.0,,,radioligand: [125I]-12G5,71.79487179,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
671,11154697,cxcr4_human,171,D,N,AMD2763,SMILES,N1(CCCN2CCNCCCNCCNCCC2)CCCNCCNCCCNCC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.18,uM,=,,45.0,250.0,,,radioligand: [125I]Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
681,25039237,cxcr4_human,171,D,N,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,28.0,53.846,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
708,26397724,cxcr4_human,171,D,N,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,68.0,8.0,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
799,17599916,cxcr4_human,171,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.18,18.0,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.620283,DA171N,CXCR4
801,11154697,cxcr4_human,171,D,N,AMD3108,SMILES,N1(CCCNCCNCCCNCC1)Cc2cc(CN3CCCNCCNCCCNCC3)ncc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.85,uM,=,,68.0,80.0,,,radioligand: Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
849,11154697,cxcr4_human,171,D,N,AMD2849,SMILES,N1(CCCCCCN2CCNCCCNCCNCCC2)CCCNCCNCCCNCC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.3,uM,=,,23.0,10.0,,,radioligand: [125I]Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
878,25039237,cxcr4_human,171,D,N,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,55.0,72.368,,,radioligand:[125I]-12G9,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
936,25039237,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,3.2,2.133,,,,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
944,25039237,cxcr4_human,171,D,N,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,4.6,11.5,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
953,12534283,cxcr4_human,171,D,N,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,200.0,66.667,,,radioligand: [125I]-Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
979,26397724,cxcr4_human,171,D,N,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,231.0,19.25,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
988,26397724,cxcr4_human,171,D,N,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,2.7,5.4,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
996,12534283,cxcr4_human,171,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.52,18.571,,,radioligand: [125I]-12G5,71.79487179,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
1010,26397724,cxcr4_human,171,D,N,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,67.0,8.375,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
1011,18768385,cxcr4_human,171,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,73.6,2.056,,,,39.7,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
1025,12534283,cxcr4_human,171,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,6900.0,93.243,,,radioligand: [125I]-Met-CXCL12,29.41176471,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
1049,25039237,cxcr4_human,171,D,N,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,6.2,2.138,,,CXCL12,67.0,0.0,,0.0,,P61073,0.620283,DA171N,CXCR4
11,25039237,cxcr4_human,281,H,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,5.2,1.733,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
38,12534283,cxcr4_human,281,H,A,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,5.0,1.667,,,radioligand: [125I]-Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
101,25039237,cxcr4_human,281,H,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.6,1.154,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
111,18768385,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,136.3,4.009,,,,133.2,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
224,17599916,cxcr4_human,281,H,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,22.0,1.1,,,CXCL12,0.0,0.0,,63.69413694,,P61073,0.172652,HA281A,CXCR4
264,18768385,cxcr4_human,281,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,6514.0,132.939,,,radioligand: [125I]-CXCL12,133.2,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
275,12534283,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,24.0,-3.086,,,radioligand: [125I]-Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
325,25039237,cxcr4_human,281,H,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,31.0,6.327,,,radioligand:[125I]-12G12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
329,17599916,cxcr4_human,281,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,519.0,4718.182,,,radioligand:125I-12G5,84.67153285,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
343,17599916,cxcr4_human,281,H,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,1.8,1.059,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.172652,HA281A,CXCR4
354,11154697,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,26.0,-21.277,,,radioligand: [125I]-12G5,14.87179487,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
402,17599916,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,3.5,4.321,,,radioligand: [125I]-CXCL12,0.0,0.0,,134.9323493,,P61073,0.172652,HA281A,CXCR4
426,18768385,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,137.0,-6.135,,,radioligand: [125I]-CXCL12,133.2,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
466,17599916,cxcr4_human,281,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,1.6,160.0,,,CXCL12,0.0,0.0,,63.69413694,,P61073,0.172652,HA281A,CXCR4
470,26397724,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
525,25039237,cxcr4_human,281,H,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,107.0,281.579,,,radioligand:[125I]-12G5,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
536,14585837,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.16,-5.556,,,radioligand:12G5(Bolton-Hunter),84.67153285,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
539,18768385,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,6.9,-5.181,,,,133.2,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
560,11154697/12534283,cxcr4_human,281,H,A,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,33.0,2.538,,,radioligand: [125I]-Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
563,12534283,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,1.1,1.1,,,radioligand: [125I]-12G5,14.87179487,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
570,17599916,cxcr4_human,281,H,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.2,20.0,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.172652,HA281A,CXCR4
576,11154697,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,24.0,-3.086,,,radioligand: [125I]Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
589,12534283,cxcr4_human,281,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.052,1.857,,,radioligand: [125I]-12G5,14.87179487,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
602,25039237,cxcr4_human,281,H,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.36,-8.065,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
638,11154697,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.28,-1.751,,,radioligand: [125I]Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
690,26397724,cxcr4_human,281,H,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,63.0,7.875,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
718,26397724,cxcr4_human,281,H,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,31.0,62.0,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
781,12534283,cxcr4_human,281,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,8.7,-1.379,,,radioligand: [125I]-Met-CXCL12,21.17647059,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
783,25039237,cxcr4_human,281,H,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.8,2.0,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
892,26397724,cxcr4_human,281,H,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,53.0,6.235,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
894,25039237,cxcr4_human,281,H,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,13.0,17.105,,,radioligand:[125I]-12G12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
949,14585837,cxcr4_human,281,H,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,,K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.03,1.5,,,radioligand:12G5(Bolton-Hunter),84.67153285,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
952,17599916,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.19,-1.157,,,CXCL12,0.0,0.0,,63.69413694,,P61073,0.172652,HA281A,CXCR4
990,25039237,cxcr4_human,281,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
997,17599916,cxcr4_human,281,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.16,-5.556,,,radioligand:[125I] -12G5,84.67153285,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
998,18768385,cxcr4_human,281,H,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,24.0,2.182,,,radioligand: [125I]-CXCL17,133.2,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
1013,26397724,cxcr4_human,281,H,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,155.0,12.917,,,CXCL12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
1034,25039237,cxcr4_human,281,H,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,91.0,31.379,,,radioligand:[125I]-12G12,169.0,0.0,,0.0,,P61073,0.172652,HA281A,CXCR4
1040,17599916,cxcr4_human,281,H,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,2.2,55.0,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.172652,HA281A,CXCR4
12,11551942,cxcr4_human,21,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,40.0,,,12G5,150.0,0.0,,0.0,,P61073,-1.7752,YA21A,CXCR4
120,11551942,cxcr4_human,21,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,25.0,,,12G5,150.0,0.0,,0.0,,P61073,-1.7752,YA21A,CXCR4
631,11551942,cxcr4_human,21,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,10.0,,,[125I]-SDF-1α,150.0,0.0,,0.0,,P61073,-1.7752,YA21A,CXCR4
791,11551942,cxcr4_human,21,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,10.0,,,[125I]-SDF-1α,150.0,0.0,,0.0,,P61073,-1.7752,YA21A,CXCR4
13,12534283,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,130.0,1.757,,,radioligand: [125I]-Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
29,17599916,cxcr4_human,113,H,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,18.0,10.588,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.374522,HA113A,CXCR4
113,14585837,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.8,2.022,,,radioligand:12G5(Bolton-Hunter),35.76642336,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
175,26397724,cxcr4_human,113,H,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,100.0,12.5,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
204,25039237,cxcr4_human,113,H,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,48.0,63.158,,,radioligand:[125I]-12G7,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
222,11154697,cxcr4_human,113,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.28,-1.751,,,radioligand: [125I]Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
268,17599916,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,2.0,2.247,,,radioligand:[125I] -12G5,40.87591241,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
286,17599916,cxcr4_human,113,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,2.5,22.727,,,radioligand:125I-12G5,40.87591241,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
313,14585837,cxcr4_human,113,H,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.1,5.0,,,radioligand:12G5(Bolton-Hunter),35.76642336,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
335,17599916,cxcr4_human,113,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,0.7,-1.157,,,radioligand: [125I]-CXCL12,0.0,0.0,,109.4915949,,P61073,0.374522,HA113A,CXCR4
345,26397724,cxcr4_human,113,H,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,100.0,8.333,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
362,25039237,cxcr4_human,113,H,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,100.0,34.483,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
409,12534283,cxcr4_human,113,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.1,3.571,,,radioligand: [125I]-12G5,64.1025641,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
437,17599916,cxcr4_human,113,H,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,1.2,30.0,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.374522,HA113A,CXCR4
453,17599916,cxcr4_human,113,H,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,275.0,13.75,,,CXCL12,0.0,0.0,,98.64698647,,P61073,0.374522,HA113A,CXCR4
497,25039237,cxcr4_human,113,H,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,100.0,192.308,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
529,17599916,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.74,3.364,,,CXCL12,0.0,0.0,,98.64698647,,P61073,0.374522,HA113A,CXCR4
538,26397724,cxcr4_human,113,H,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,13.0,26.0,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
668,26397724,cxcr4_human,113,H,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,100.0,11.765,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
684,11154697,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,1500.0,2.727,,,radioligand: [125I]-12G5,64.1025641,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
775,11154697/12534283,cxcr4_human,113,H,A,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,8.5,-1.529,,,radioligand: [125I]-Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
793,25039237,cxcr4_human,113,H,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,100.0,33.333,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
806,25039237,cxcr4_human,113,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.84,-1.786,,,,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
815,12534283,cxcr4_human,113,H,A,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,5.3,1.767,,,radioligand: [125I]-Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
823,12534283,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,1.4,1.4,,,radioligand: [125I]-12G5,64.1025641,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
833,17599916,cxcr4_human,113,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.13,13.0,,,CXCL12,0.0,0.0,,98.64698647,,P61073,0.374522,HA113A,CXCR4
884,11154697,cxcr4_human,113,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,130.0,1.757,,,radioligand: [125I]Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
893,17599916,cxcr4_human,113,H,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.17,17.0,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.374522,HA113A,CXCR4
1005,25039237,cxcr4_human,113,H,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,100.0,20.408,,,radioligand:[125I]-12G7,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
1020,26397724,cxcr4_human,113,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.84,-1.786,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
1043,12534283,cxcr4_human,113,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,23.0,1.917,,,radioligand: [125I]-Met-CXCL12,27.05882353,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
1053,25039237,cxcr4_human,113,H,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,48.0,120.0,,,CXCL12,80.0,0.0,,0.0,,P61073,0.374522,HA113A,CXCR4
14,16188969/16306611,cxcr4_human,302,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,11.5,5.227,,,radioligand: [125I]-CXCL12,141.7,0.0,,0.0,,P61073,1.92773,YA302A,CXCR4
15,25039237,cxcr4_human,189,F,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.15,-3.472,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
95,26397724,cxcr4_human,189,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
234,26397724,cxcr4_human,189,F,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.13,-3.846,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
356,22039044,cxcr4_human,189,F,A,Ubiquitin,UniProt Entry Code,P0CG48,Agonist,Single-point,,100.0,%,=,,0.0,35.0,,,,38.70967742,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
474,25039237,cxcr4_human,189,F,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.79,-3.802,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
496,26397724,cxcr4_human,189,F,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,1.0,-12.048,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
524,16188969/16306611,cxcr4_human,189,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,8.0,3.636,,,radioligand: [125I]-CXCL12,98.5,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
545,25039237,cxcr4_human,189,F,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.31,-9.346,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
760,22039044,cxcr4_human,189,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,,100.0,,~,,0.0,130.0,,,,38.70967742,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
853,25039237,cxcr4_human,189,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
909,25039237,cxcr4_human,189,F,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.1,-4.0,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
923,26397724,cxcr4_human,189,F,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,0.74,-11.494,,,CXCL12,97.0,0.0,,0.0,,P61073,2.50023,FA189A,CXCR4
16,26397724,cxcr4_human,117,T,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.7,1.133,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
73,14585837,cxcr4_human,117,T,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.46,-1.934,,,radioligand:12G5(Bolton-Hunter),44.52554745,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
242,26397724,cxcr4_human,117,T,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,0.87,-9.804,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
431,25039237,cxcr4_human,117,T,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,4.2,1.4,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
475,26397724,cxcr4_human,117,T,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.17,-2.941,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
705,26397724,cxcr4_human,117,T,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,1.4,-8.547,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
723,25039237,cxcr4_human,117,T,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.14,-2.857,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
734,25039237,cxcr4_human,117,T,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,1.0,-2.899,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
908,25039237,cxcr4_human,117,T,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.74,1.423,,,CXCL12,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
1042,14585837,cxcr4_human,117,T,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.01,-2.0,,,radioligand:12G5(Bolton-Hunter),44.52554745,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
1050,25039237,cxcr4_human,117,T,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.7,1.133,,,,74.0,0.0,,0.0,,P61073,1.09145,TA117A,CXCR4
20,25039237,cxcr4_human,187,D,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.14,-2.857,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
45,25039237,cxcr4_human,187,D,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,2.6,-1.115,,,radioligand:[125I]-12G10,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
63,25039237,cxcr4_human,187,D,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.49,-5.917,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
148,26397724,cxcr4_human,187,D,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,26.0,3.25,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
168,26397724,cxcr4_human,187,D,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,5.4,-2.222,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
240,25039237,cxcr4_human,187,D,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,4.3,-1.139,,,radioligand:[125I]-12G10,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
380,17599916,cxcr4_human,187,D,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,14.0,15.73,,,radioligand:[125I] -12G5,95.62043796,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
420,16188969/16306611,cxcr4_human,187,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,4.7,2.136,,,radioligand: [125I]-CXCL12,111.9,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
610,26397724,cxcr4_human,187,D,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,4.1,-2.075,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
633,25039237,cxcr4_human,187,D,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.76,-3.953,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
653,26397724,cxcr4_human,187,D,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.35,-1.429,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
722,26397724,cxcr4_human,187,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,13.0,8.667,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
838,25039237,cxcr4_human,187,D,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.35,-1.486,,,CXCL12,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
875,25468967,cxcr4_human,187,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,pEC50,Functional - Ca2+ accumulation,8.8,,=,,7.46,21.878,,,,100.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
966,25039237,cxcr4_human,187,D,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,12.0,31.579,,,radioligand:[125I]-12G5,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
985,25039237,cxcr4_human,187,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,13.0,8.667,,,,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
987,25039237,cxcr4_human,187,D,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,7.7,10.132,,,radioligand:[125I]-12G10,49.0,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
1032,17599916,cxcr4_human,187,D,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.53,4.818,,,radioligand:125I-12G5,95.62043796,0.0,,0.0,,P61073,-0.130368,DA187A,CXCR4
21,18768385,cxcr4_human,288,E,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,29445.0,34.97,,,radioligand: [125I]-CXCL12,53.1,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
41,26397724,cxcr4_human,288,E,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,100.0,12.5,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
55,25039237,cxcr4_human,288,E,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,100.0,263.158,,,radioligand:[125I]-12G5,77.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
90,17599916,cxcr4_human,288,E,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,63.0,70.787,,,radioligand:[125I] -12G5,102.189781,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
195,25039237,cxcr4_human,288,E,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,2.1,-2.331,,,radioligand:[125I]-12G13,77.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
271,17599916,cxcr4_human,288,E,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,6.4,29.091,,,CXCL12,0.0,0.0,,22.34522345,,P61073,0.847845,EA288A,CXCR4
285,17599916,cxcr4_human,288,E,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,1.9,190.0,,,CXCL12,0.0,0.0,,22.34522345,,P61073,0.847845,EA288A,CXCR4
327,17599916,cxcr4_human,288,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,53.0,65.432,,,radioligand: [125I]-CXCL12,0.0,0.0,,105.7400574,,P61073,0.847845,EA288A,CXCR4
375,17599916,cxcr4_human,288,E,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,11.0,6.471,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.847845,EA288A,CXCR4
391,17599916,cxcr4_human,288,E,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,2.7,270.0,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.847845,EA288A,CXCR4
460,17599916,cxcr4_human,288,E,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,303.0,15.15,,,CXCL12,0.0,0.0,,22.34522345,,P61073,0.847845,EA288A,CXCR4
472,18768385,cxcr4_human,288,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,44.1,1.232,,,,53.1,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
491,16188969/16306611,cxcr4_human,288,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,4.4,2.0,,,radioligand: [125I]-CXCL12,101.2,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
492,17599916,cxcr4_human,288,E,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,11.0,100.0,,,radioligand:125I-12G5,102.189781,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
527,25039237,cxcr4_human,288,E,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,4.1,5.395,,,radioligand:[125I]-12G13,77.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
555,18768385,cxcr4_human,288,E,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,5073.0,461.182,,,radioligand: [125I]-CXCL15,53.1,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
677,18768385,cxcr4_human,288,E,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,3404.0,69.469,,,radioligand: [125I]-CXCL12,53.1,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
746,25039237,cxcr4_human,288,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,100.0,66.667,,,,77.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
778,17599916,cxcr4_human,288,E,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.54,13.5,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.847845,EA288A,CXCR4
786,14585837,cxcr4_human,288,E,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,63.0,70.787,,,radioligand:12G5(Bolton-Hunter),102.189781,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
818,25039237,cxcr4_human,288,E,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,4.2,1.448,,,radioligand:[125I]-12G13,77.0,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
1044,14585837,cxcr4_human,288,E,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,2.3,115.0,,,radioligand:12G5(Bolton-Hunter),102.189781,0.0,,0.0,,P61073,0.847845,EA288A,CXCR4
22,16188969/16306611,cxcr4_human,121,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,2.3,1.045,,,radioligand: [125I]-CXCL12,87.5,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
135,18768385,cxcr4_human,121,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,17.0,-2.882,,,radioligand: [125I]-CXCL12,58.4,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
158,18768385,cxcr4_human,121,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,86.2,2.408,,,,58.4,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
171,18768385,cxcr4_human,121,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,401.0,-2.101,,,radioligand: [125I]-CXCL12,58.4,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
620,18768385,cxcr4_human,121,Y,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,19.0,1.727,,,radioligand: [125I]-CXCL23,58.4,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
660,18768385,cxcr4_human,121,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,100.0,2.941,,,,58.4,0.0,,0.0,,P61073,3.28953,YA121A,CXCR4
24,17599916,cxcr4_human,175,A,F,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,215.0,1954.545,,,radioligand:125I-12G5,30.65693431,0.0,,0.0,,P61073,17.7944,AA175F,CXCR4
85,17599916,cxcr4_human,175,A,F,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,128.0,75.294,,,CXCL12,0.0,0.0,,98.64698647,,P61073,17.7944,AA175F,CXCR4
331,14585837,cxcr4_human,175,A,F,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,8.6,430.0,,,radioligand:12G5(Bolton-Hunter),30.65693431,0.0,,0.0,,P61073,17.7944,AA175F,CXCR4
361,17599916,cxcr4_human,175,A,F,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,1.8,2.222,,,radioligand: [125I]-CXCL12,0.0,0.0,,98.64698647,,P61073,17.7944,AA175F,CXCR4
421,17599916,cxcr4_human,175,A,F,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,36.0,40.449,,,radioligand:[125I] -12G5,30.65693431,0.0,,0.0,,P61073,17.7944,AA175F,CXCR4
440,14585837,cxcr4_human,175,A,F,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,36.0,40.449,,,radioligand:12G5(Bolton-Hunter),30.65693431,0.0,,0.0,,P61073,17.7944,AA175F,CXCR4
523,17599916,cxcr4_human,175,A,F,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,1.3,130.0,,,CXCL12,0.0,0.0,,68.96268963,,P61073,17.7944,AA175F,CXCR4
626,17599916,cxcr4_human,175,A,F,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,8.5,38.636,,,CXCL12,0.0,0.0,,68.96268963,,P61073,17.7944,AA175F,CXCR4
634,17599916,cxcr4_human,175,A,F,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,10.0,250.0,,,CXCL12,0.0,0.0,,98.64698647,,P61073,17.7944,AA175F,CXCR4
700,17599916,cxcr4_human,175,A,F,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.58,58.0,,,CXCL12,0.0,0.0,,98.64698647,,P61073,17.7944,AA175F,CXCR4
991,17599916,cxcr4_human,175,A,F,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,2239.0,111.95,,,CXCL12,0.0,0.0,,68.96268963,,P61073,17.7944,AA175F,CXCR4
25,17599916,cxcr4_human,196,V,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,1.3,-1.307,,,CXCL12,0.0,0.0,,73.49323493,,P61073,0.409646,VA196A,CXCR4
42,17599916,cxcr4_human,196,V,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.04,4.0,,,CXCL12,0.0,0.0,,73.49323493,,P61073,0.409646,VA196A,CXCR4
94,26397724,cxcr4_human,196,V,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,13.0,1.083,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
100,18768385,cxcr4_human,196,V,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,28.0,2.545,,,radioligand: [125I]-CXCL20,89.2,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
115,17599916,cxcr4_human,196,V,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.6,5.169,,,radioligand:[125I] -12G5,19.7080292,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
214,17599916,cxcr4_human,196,V,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,28.0,1.4,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.409646,VA196A,CXCR4
250,26397724,cxcr4_human,196,V,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,1.4,2.8,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
258,25039237,cxcr4_human,196,V,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,4.6,1.586,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
364,18768385,cxcr4_human,196,V,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,1205.0,1.431,,,radioligand: [125I]-CXCL12,89.2,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
369,14585837,cxcr4_human,196,V,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,,K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,1.7,85.0,,,radioligand:12G5(Bolton-Hunter),19.7080292,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
389,25039237,cxcr4_human,196,V,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,3.6,1.2,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
429,25039237,cxcr4_human,196,V,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.47,1.175,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
458,14585837,cxcr4_human,196,V,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.6,5.169,,,radioligand:12G5(Bolton-Hunter),19.7080292,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
499,18768385,cxcr4_human,196,V,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,22.7,-1.577,,,,89.2,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
581,17599916,cxcr4_human,196,V,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.02,2.0,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.409646,VA196A,CXCR4
640,17599916,cxcr4_human,196,V,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.14,-1.572,,,CXCL12,0.0,0.0,,109.4915949,,P61073,0.409646,VA196A,CXCR4
697,26397724,cxcr4_human,196,V,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
827,18768385,cxcr4_human,196,V,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,138.2,4.065,,,,89.2,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
860,17599916,cxcr4_human,196,V,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,1.8,16.364,,,radioligand:125I-12G5,19.7080292,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
865,25039237,cxcr4_human,196,V,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,1.6,3.077,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
897,17599916,cxcr4_human,196,V,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,2.1,2.593,,,radioligand: [125I]-CXCL12,0.0,0.0,,73.49323493,,P61073,0.409646,VA196A,CXCR4
1012,25039237,cxcr4_human,196,V,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
1035,18768385,cxcr4_human,196,V,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,124.0,2.531,,,radioligand: [125I]-CXCL12,89.2,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
1046,17599916,cxcr4_human,196,V,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.07,1.75,,,CXCL12,0.0,0.0,,73.49323493,,P61073,0.409646,VA196A,CXCR4
1055,26397724,cxcr4_human,196,V,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,4.2,-2.024,,,CXCL12,101.0,0.0,,0.0,,P61073,0.409646,VA196A,CXCR4
26,26397724,cxcr4_human,284,I,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,3.4,6.8,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
36,25039237,cxcr4_human,284,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,2.3,1.533,,,,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
70,17599916,cxcr4_human,284,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,1.2,5.455,,,CXCL12,0.0,0.0,,80.29930299,,P61073,1.99458,IA284A,CXCR4
109,14585837,cxcr4_human,284,I,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.23,11.5,,,radioligand:12G5(Bolton-Hunter),84.67153285,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
112,25039237,cxcr4_human,284,I,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,3.8,1.31,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
139,17599916,cxcr4_human,284,I,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.06,1.5,,,CXCL12,0.0,0.0,,95.55145551,,P61073,1.99458,IA284A,CXCR4
146,17599916,cxcr4_human,284,I,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.03,3.0,,,CXCL12,0.0,0.0,,80.29930299,,P61073,1.99458,IA284A,CXCR4
211,17599916,cxcr4_human,284,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,3.6,4.444,,,radioligand: [125I]-CXCL12,0.0,0.0,,95.55145551,,P61073,1.99458,IA284A,CXCR4
252,17599916,cxcr4_human,284,I,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,2.3,-8.696,,,CXCL12,0.0,0.0,,80.29930299,,P61073,1.99458,IA284A,CXCR4
416,25039237,cxcr4_human,284,I,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,2.6,5.0,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
517,17599916,cxcr4_human,284,I,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,0.42,-4.049,,,CXCL12,0.0,0.0,,95.55145551,,P61073,1.99458,IA284A,CXCR4
580,25039237,cxcr4_human,284,I,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,15.0,5.0,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
662,25039237,cxcr4_human,284,I,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.27,-1.481,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
698,17599916,cxcr4_human,284,I,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,46.0,418.182,,,radioligand:125I-12G5,84.67153285,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
727,26397724,cxcr4_human,284,I,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,306.0,25.5,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
741,14585837,cxcr4_human,284,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.1,1.236,,,radioligand:12G5(Bolton-Hunter),84.67153285,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
790,26397724,cxcr4_human,284,I,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,2.3,1.533,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
962,17599916,cxcr4_human,284,I,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.02,2.0,,,CXCL12,0.0,0.0,,95.55145551,,P61073,1.99458,IA284A,CXCR4
984,17599916,cxcr4_human,284,I,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.1,1.236,,,radioligand:[125I] -12G5,84.67153285,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
1045,26397724,cxcr4_human,284,I,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,34.0,4.0,,,CXCL12,56.0,0.0,,0.0,,P61073,1.99458,IA284A,CXCR4
27,11551942,cxcr4_human,5,S,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,105.0,,,[125I]-SDF-1α,170.0,0.0,,0.0,,P61073,-0.198066,SA5A,CXCR4
573,11551942,cxcr4_human,5,S,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,30.0,,,12G5,170.0,0.0,,0.0,,P61073,-0.198066,SA5A,CXCR4
852,11551942,cxcr4_human,5,S,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,100.0,,,12G5,170.0,0.0,,0.0,,P61073,-0.198066,SA5A,CXCR4
1054,11551942,cxcr4_human,5,S,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,95.0,,,[125I]-SDF-1α,170.0,0.0,,0.0,,P61073,-0.198066,SA5A,CXCR4
28,26397724,cxcr4_human,94,W,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,0.64,-18.868,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
182,25039237,cxcr4_human,94,W,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,0.27,-18.182,,,radioligand:[125I]-12G5,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
208,26397724,cxcr4_human,94,W,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,0.55,-15.385,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
254,18768385,cxcr4_human,94,W,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,1185.0,107.727,,,radioligand: [125I]-CXCL21,43.4,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
316,25039237,cxcr4_human,94,W,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,0.03,-12.658,,,radioligand:[125I]-12G5,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
370,25039237,cxcr4_human,94,W,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.01,-40.0,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
456,26397724,cxcr4_human,94,W,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.06,-8.333,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
459,26397724,cxcr4_human,94,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,18.0,12.0,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
463,25039237,cxcr4_human,94,W,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.05,-10.417,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
498,18768385,cxcr4_human,94,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,54.9,1.534,,,,43.4,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
554,18768385,cxcr4_human,94,W,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,4437.0,90.551,,,radioligand: [125I]-CXCL12,43.4,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
712,18768385,cxcr4_human,94,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,45.0,1.324,,,,43.4,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
728,25039237,cxcr4_human,94,W,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,0.14,-20.833,,,radioligand:[125I]-12G5,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
748,25039237,cxcr4_human,94,W,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,0.03,-25.641,,,radioligand:[125I]-12G5,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
809,25039237,cxcr4_human,94,W,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.17,-17.544,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
810,26397724,cxcr4_human,94,W,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,1.7,-4.717,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
891,25039237,cxcr4_human,94,W,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.02,-142.857,,,CXCL12,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
896,18768385,cxcr4_human,94,W,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,11800.0,14.014,,,radioligand: [125I]-CXCL12,43.4,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
943,25039237,cxcr4_human,94,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,18.0,12.0,,,,38.0,0.0,,0.0,,P61073,2.71599,WA94A,CXCR4
34,11154697,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,1.2,2.449,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
47,17599916,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,7.5,9.259,,,radioligand: [125I]-CXCL12,0.0,0.0,,75.97375974,,P61073,0.343397,DA262N,CXCR4
76,12534283,cxcr4_human,262,D,N,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,2.3,-1.304,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
128,18768385,cxcr4_human,262,D,N,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,137.0,12.455,,,radioligand: [125I]-CXCL13,32.5,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
143,18768385,cxcr4_human,262,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,8524.0,173.959,,,radioligand: [125I]-CXCL12,32.5,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
156,26397724,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,5.8,3.867,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
161,25039237,cxcr4_human,262,D,N,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,4.3,1.483,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
163,18768385,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,80.3,2.243,,,,32.5,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
170,14585837,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,46.0,51.685,,,radioligand:12G5(Bolton-Hunter),118.2481752,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
178,25039237,cxcr4_human,262,D,N,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,100.0,263.158,,,radioligand:[125I]-12G5,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
179,26397724,cxcr4_human,262,D,N,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,13.0,26.0,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
187,17599916,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,46.0,51.685,,,radioligand:[125I] -12G5,118.2481752,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
216,25039237,cxcr4_human,262,D,N,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,6.1,15.25,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
227,12534283,cxcr4_human,262,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,1000.0,83.333,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
263,17599916,cxcr4_human,262,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,7.8,780.0,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.343397,DA262N,CXCR4
281,17599916,cxcr4_human,262,D,N,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.82,82.0,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.343397,DA262N,CXCR4
296,17599916,cxcr4_human,262,D,N,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,21.0,525.0,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.343397,DA262N,CXCR4
309,11154697,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,100000.0,181.818,,,radioligand: [125I]-12G5,197.4358974,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
342,17599916,cxcr4_human,262,D,N,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,2.9,-6.897,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.343397,DA262N,CXCR4
353,25039237,cxcr4_human,262,D,N,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,10.0,19.231,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
383,25039237,cxcr4_human,262,D,N,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,5.5,1.833,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
438,11154697,cxcr4_human,262,D,N,AMD3108,SMILES,N1(CCCNCCNCCCNCC1)Cc2cc(CN3CCCNCCNCCCNCC3)ncc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.85,uM,=,,2.2,2.588,,,radioligand: Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
439,11154697,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,1100.0,14.865,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
495,11154697,cxcr4_human,262,D,N,AMD2936,SMILES,[H][C@@]1(CCCN2CCNCCCNCCNCCC2)NCCCNCCNCCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.65,uM,=,,3.4,5.231,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
500,17599916,cxcr4_human,262,D,N,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,2.3,1.353,,,CXCL12,0.0,0.0,,75.97375974,,P61073,0.343397,DA262N,CXCR4
521,11154697,cxcr4_human,262,D,N,AMD2763,SMILES,N1(CCCN2CCNCCCNCCNCCC2)CCCNCCNCCCNCC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.18,uM,=,,1.6,8.889,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
528,25039237,cxcr4_human,262,D,N,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,100.0,34.483,,,radioligand:[125I]-12G11,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
710,11154697,cxcr4_human,262,D,N,AMD3106,SMILES,N1(CCCNCCNCCCNCC1)Cc2nc(CN3CCCNCCNCCCNCC3)ccc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.083,uM,=,,1.8,21.687,,,radioligand: Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
743,26397724,cxcr4_human,262,D,N,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,11.0,-1.091,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
777,25039237,cxcr4_human,262,D,N,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,61.0,12.449,,,radioligand:[125I]-12G11,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
800,11154697,cxcr4_human,262,D,N,AMD2849,SMILES,N1(CCCCCCN2CCNCCCNCCNCCC2)CCCNCCNCCCNCC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,2.3,uM,=,,2.0,-1.149,,,radioligand: [125I]Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
821,14585837,cxcr4_human,262,D,N,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,13.0,650.0,,,radioligand:12G5(Bolton-Hunter),118.2481752,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
836,17599916,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,4.7,21.364,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.343397,DA262N,CXCR4
846,12534283,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,1300.0,17.568,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
872,12534283,cxcr4_human,262,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,13.0,464.286,,,radioligand: [125I]-12G5,197.4358974,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
895,18768385,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,96.5,2.838,,,,32.5,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
904,26397724,cxcr4_human,262,D,N,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,100.0,12.5,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
934,12534283,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,17.4,17.4,,,radioligand: [125I]-12G5,197.4358974,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
935,26397724,cxcr4_human,262,D,N,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,27.0,3.176,,,CXCL12,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
946,17599916,cxcr4_human,262,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,600.0,5454.545,,,radioligand:125I-12G5,118.2481752,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
950,11154697/12534283,cxcr4_human,262,D,N,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,9.6,-1.355,,,radioligand: [125I]-Met-CXCL12,58.82352941,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
999,18768385,cxcr4_human,262,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,15030.0,17.85,,,radioligand: [125I]-CXCL12,32.5,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
1019,25039237,cxcr4_human,262,D,N,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,73.0,96.053,,,radioligand:[125I]-12G11,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
1021,25039237,cxcr4_human,262,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,5.8,3.867,,,,54.0,0.0,,0.0,,P61073,0.343397,DA262N,CXCR4
35,14585837,cxcr4_human,174,F,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.16,3.551,,,radioligand:12G5(Bolton-Hunter),32.11678832,0.0,,0.0,,P61073,3.26521,FA174A,CXCR4
287,17599916,cxcr4_human,174,F,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.98,8.909,,,radioligand:125I-12G5,32.11678832,0.0,,0.0,,P61073,3.26521,FA174A,CXCR4
322,14585837,cxcr4_human,174,F,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.68,34.0,,,radioligand:12G5(Bolton-Hunter),32.11678832,0.0,,0.0,,P61073,3.26521,FA174A,CXCR4
557,17599916,cxcr4_human,174,F,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.2,3.596,,,radioligand:[125I] -12G5,32.11678832,0.0,,0.0,,P61073,3.26521,FA174A,CXCR4
40,12534283,cxcr4_human,203,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,36.0,3.0,,,radioligand: [125I]-Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
57,26397724,cxcr4_human,203,H,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.71,1.42,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
92,18768385,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,484.0,-1.739,,,radioligand: [125I]-CXCL12,97.9,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
105,11154697,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,2100.0,3.818,,,radioligand: [125I]-12G5,225.6410256,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
110,17599916,cxcr4_human,203,H,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,7.2,4.235,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-0.032663,HA203A,CXCR4
124,17599916,cxcr4_human,203,H,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,32.0,1.6,,,CXCL12,0.0,0.0,,68.81918819,,P61073,-0.032663,HA203A,CXCR4
183,17599916,cxcr4_human,203,H,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.02,2.0,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-0.032663,HA203A,CXCR4
219,17599916,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,1.8,2.022,,,radioligand:[125I] -12G5,72.26277372,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
269,25039237,cxcr4_human,203,H,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,20.0,6.897,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
393,18768385,cxcr4_human,203,H,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,9.0,-1.222,,,radioligand: [125I]-CXCL16,97.9,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
436,17599916,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.29,1.318,,,CXCL12,0.0,0.0,,68.81918819,,P61073,-0.032663,HA203A,CXCR4
513,18768385,cxcr4_human,203,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,31.0,-1.58,,,radioligand: [125I]-CXCL12,97.9,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
547,17599916,cxcr4_human,203,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.44,4.0,,,radioligand:125I-12G5,72.26277372,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
548,12534283,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,68.0,-1.088,,,radioligand: [125I]-Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
562,17599916,cxcr4_human,203,H,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.04,4.0,,,CXCL12,0.0,0.0,,68.81918819,,P61073,-0.032663,HA203A,CXCR4
586,25039237,cxcr4_human,203,H,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.58,1.45,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
591,12534283,cxcr4_human,203,H,A,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,1.3,-2.309,,,radioligand: [125I]-Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
609,25039237,cxcr4_human,203,H,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.98,1.885,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
630,17599916,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,0.97,1.198,,,radioligand: [125I]-CXCL12,0.0,0.0,,84.15334153,,P61073,-0.032663,HA203A,CXCR4
676,25039237,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
732,11154697,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,68.0,-1.088,,,radioligand: [125I]Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
737,26397724,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
750,17599916,cxcr4_human,203,H,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.14,3.5,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-0.032663,HA203A,CXCR4
754,12534283,cxcr4_human,203,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,2.04,2.04,,,radioligand: [125I]-12G5,225.6410256,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
768,12534283,cxcr4_human,203,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.052,1.857,,,radioligand: [125I]-12G5,225.6410256,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
835,18768385,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,26.1,-1.302,,,,97.9,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
917,11154697,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.53,1.082,,,radioligand: [125I]Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
954,18768385,cxcr4_human,203,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,42.3,1.182,,,,97.9,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
982,25039237,cxcr4_human,203,H,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,8.0,2.667,,,CXCL12,111.0,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
1002,11154697/12534283,cxcr4_human,203,H,A,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,16.0,1.231,,,radioligand: [125I]-Met-CXCL12,22.94117647,0.0,,0.0,,P61073,-0.032663,HA203A,CXCR4
44,26397724,cxcr4_human,252,W,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,27.0,3.176,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
119,25039237,cxcr4_human,252,W,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,16.0,5.517,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
123,25039237,cxcr4_human,252,W,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,3.1,5.962,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
410,25039237,cxcr4_human,252,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.78,-1.923,,,,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
451,26397724,cxcr4_human,252,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.78,-1.923,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
552,26397724,cxcr4_human,252,W,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,3.8,7.6,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
629,26397724,cxcr4_human,252,W,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,173.0,14.417,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
678,16188969/16306611,cxcr4_human,252,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,4.6,2.091,,,radioligand: [125I]-CXCL12,84.6,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
831,25039237,cxcr4_human,252,W,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.71,1.775,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
920,25039237,cxcr4_human,252,W,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,13.0,4.333,,,CXCL12,51.0,0.0,,0.0,,P61073,3.44435,WA252A,CXCR4
58,25039237,cxcr4_human,97,D,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,0.87,-5.618,,,radioligand:[125I]-12G6,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
155,25039237,cxcr4_human,97,D,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.35,-8.264,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
336,25039237,cxcr4_human,97,D,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.04,-10.0,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
381,25039237,cxcr4_human,97,D,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,0.17,-4.464,,,radioligand:[125I]-12G6,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
484,26397724,cxcr4_human,97,D,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.21,-2.381,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
541,26397724,cxcr4_human,97,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,20.0,13.333,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
635,25039237,cxcr4_human,97,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,20.0,13.333,,,,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
763,25039237,cxcr4_human,97,D,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,2.9,uM,=,,1.2,-2.415,,,radioligand:[125I]-12G6,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
824,26397724,cxcr4_human,97,D,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,1.4,-8.547,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
842,25039237,cxcr4_human,97,D,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.44,-6.803,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
859,25039237,cxcr4_human,97,D,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.06,-8.696,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
905,26397724,cxcr4_human,97,D,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,0.54,-15.625,,,CXCL12,99.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
932,26397724,cxcr4_human,97,D,A,KRK1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,8.0,uM,=,,8.5,1.062,,,radioligand:[125I] -12G5,0.0,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
1015,16188969/16306611,cxcr4_human,97,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,2.1,-1.047,,,radioligand: [125I]-CXCL12,223.5,0.0,,0.0,,P61073,-1.53728,DA97A,CXCR4
59,18768385,cxcr4_human,97,D,N,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,3185.0,289.545,,,radioligand: [125I]-CXCL14,72.6,0.0,,0.0,,P61073,-0.720154,DA97N,CXCR4
441,18768385,cxcr4_human,97,D,N,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,176.0,3.592,,,radioligand: [125I]-CXCL12,72.6,0.0,,0.0,,P61073,-0.720154,DA97N,CXCR4
733,18768385,cxcr4_human,97,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,47.6,1.33,,,,72.6,0.0,,0.0,,P61073,-0.720154,DA97N,CXCR4
817,18768385,cxcr4_human,97,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,2950.0,3.504,,,radioligand: [125I]-CXCL12,72.6,0.0,,0.0,,P61073,-0.720154,DA97N,CXCR4
60,26397724,cxcr4_human,200,Q,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,17.0,2.0,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
132,17599916,cxcr4_human,200,Q,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.56,-1.59,,,radioligand:[125I] -12G5,94.89051095,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
169,25039237,cxcr4_human,200,Q,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
278,17599916,cxcr4_human,200,Q,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.62,15.5,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.784732,QA200A,CXCR4
283,17599916,cxcr4_human,200,Q,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.15,15.0,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.784732,QA200A,CXCR4
291,14585837,cxcr4_human,200,Q,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.56,-1.59,,,radioligand:12G5(Bolton-Hunter),101.459854,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
448,25039237,cxcr4_human,200,Q,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,0.61,-4.926,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
454,25039237,cxcr4_human,200,Q,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,6.9,2.379,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
561,26397724,cxcr4_human,200,Q,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,250.0,20.833,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
673,25039237,cxcr4_human,200,Q,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.57,1.096,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
725,26397724,cxcr4_human,200,Q,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
740,17599916,cxcr4_human,200,Q,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.27,27.0,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.784732,QA200A,CXCR4
868,17599916,cxcr4_human,200,Q,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.93,4.227,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.784732,QA200A,CXCR4
871,17599916,cxcr4_human,200,Q,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,12.0,7.059,,,CXCL12,0.0,0.0,,96.10496105,,P61073,0.784732,QA200A,CXCR4
907,17599916,cxcr4_human,200,Q,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,80.0,4.0,,,CXCL12,0.0,0.0,,134.9323493,,P61073,0.784732,QA200A,CXCR4
922,25039237,cxcr4_human,200,Q,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.36,-1.111,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
942,17599916,cxcr4_human,200,Q,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,0.67,-1.209,,,radioligand: [125I]-CXCL12,0.0,0.0,,96.10496105,,P61073,0.784732,QA200A,CXCR4
995,26397724,cxcr4_human,200,Q,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,3.7,7.4,,,CXCL12,4.7,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
1006,14585837,cxcr4_human,200,Q,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.02,1.0,,,radioligand:12G5(Bolton-Hunter),101.459854,0.0,,0.0,,P61073,0.784732,QA200A,CXCR4
61,11551942,cxcr4_human,184,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,125.0,,,12G5,100.0,0.0,,0.0,,P61073,1.25786,YA184A,CXCR4
138,11551942,cxcr4_human,184,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,130.0,,,[125I]-SDF-1α,100.0,0.0,,0.0,,P61073,1.25786,YA184A,CXCR4
344,11551942,cxcr4_human,184,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,120.0,,,12G5,100.0,0.0,,0.0,,P61073,1.25786,YA184A,CXCR4
604,11551942,cxcr4_human,184,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,115.0,,,[125I]-SDF-1α,100.0,0.0,,0.0,,P61073,1.25786,YA184A,CXCR4
71,17197449,cxcr4_human,135,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Functional - cAMP accumulation,25.0,%,~,,17.0,1.471,,,,80.0,0.0,,0.0,,P61073,2.61916,YA135A,CXCR4
77,11154697,cxcr4_human,294,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,140.0,1.892,,,radioligand: [125I]Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
89,12534283,cxcr4_human,294,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,0.51,-1.961,,,radioligand: [125I]-12G5,341.025641,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
266,11154697/12534283,cxcr4_human,294,H,A,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,26.0,2.0,,,radioligand: [125I]-Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
301,11154697,cxcr4_human,294,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,930.0,1.691,,,radioligand: [125I]-12G5,341.025641,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
333,16188969/16306611,cxcr4_human,294,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,2.8,1.273,,,radioligand: [125I]-CXCL12,112.7,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
408,12534283,cxcr4_human,294,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,34.0,2.833,,,radioligand: [125I]-Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
418,12534283,cxcr4_human,294,H,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,140.0,1.892,,,radioligand: [125I]-Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
447,12534283,cxcr4_human,294,H,A,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.022,-1.272,,,radioligand: [125I]-12G5,341.025641,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
625,11154697,cxcr4_human,294,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.88,1.796,,,radioligand: [125I]Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
960,12534283,cxcr4_human,294,H,A,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,3.4,1.133,,,radioligand: [125I]-Met-CXCL12,214.7058824,0.0,,0.0,,P61073,0.0246296,HA294A,CXCR4
81,22039044,cxcr4_human,271,K,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,,100.0,%,~,,0.0,130.0,,,,35.48387097,0.0,,0.0,,P61073,0.993505,KA271A,CXCR4
661,22039044,cxcr4_human,271,K,A,Ubiquitin,UniProt Entry Code,P0CG48,Agonist,Single-point,,100.0,%,=,,0.0,35.0,,,,35.48387097,0.0,,0.0,,P61073,0.993505,KA271A,CXCR4
83,17599916,cxcr4_human,200,Q,W,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.36,36.0,,,CXCL12,0.0,0.0,,63.69413694,,P61073,-1.0429,QA200W,CXCR4
194,26397724,cxcr4_human,200,Q,W,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,14.0,1.647,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
197,17599916,cxcr4_human,200,Q,W,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.81,20.25,,,CXCL12,0.0,0.0,,63.69413694,,P61073,-1.0429,QA200W,CXCR4
297,17599916,cxcr4_human,200,Q,W,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,7.2,4.235,,,CXCL12,0.0,0.0,,63.69413694,,P61073,-1.0429,QA200W,CXCR4
365,26397724,cxcr4_human,200,Q,W,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
462,17599916,cxcr4_human,200,Q,W,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.22,22.0,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-1.0429,QA200W,CXCR4
558,17599916,cxcr4_human,200,Q,W,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,60.0,3.0,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-1.0429,QA200W,CXCR4
596,25039237,cxcr4_human,200,Q,W,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.8,1.2,,,,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
600,25039237,cxcr4_human,200,Q,W,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,2.8,-1.035,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
650,26397724,cxcr4_human,200,Q,W,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,85.0,7.083,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
714,17599916,cxcr4_human,200,Q,W,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,2.0,2.469,,,radioligand: [125I]-CXCL12,0.0,0.0,,63.69413694,,P61073,-1.0429,QA200W,CXCR4
798,25039237,cxcr4_human,200,Q,W,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.86,1.654,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
822,25039237,cxcr4_human,200,Q,W,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,2.7,-1.111,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
873,17599916,cxcr4_human,200,Q,W,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,1.2,10.909,,,radioligand:125I-12G5,94.89051095,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
994,25039237,cxcr4_human,200,Q,W,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.33,-1.212,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
1003,17599916,cxcr4_human,200,Q,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,2.7,3.034,,,radioligand:[125I] -12G5,118.9781022,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
1022,26397724,cxcr4_human,200,Q,W,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,10.0,20.0,,,CXCL12,75.0,0.0,,0.0,,P61073,-1.0429,QA200W,CXCR4
1036,17599916,cxcr4_human,200,Q,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.4,1.818,,,CXCL12,0.0,0.0,,84.15334153,,P61073,-1.0429,QA200W,CXCR4
88,18768385,cxcr4_human,45,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,1069.0,21.816,,,radioligand: [125I]-CXCL12,70.8,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
125,25039237,cxcr4_human,45,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,3.4,2.267,,,,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
347,25039237,cxcr4_human,45,Y,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,1.6,3.077,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
352,18768385,cxcr4_human,45,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,8465.0,10.053,,,radioligand: [125I]-CXCL12,70.8,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
360,26397724,cxcr4_human,45,Y,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,56.0,6.588,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
404,18768385,cxcr4_human,45,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,22.8,-1.57,,,,70.8,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
490,18768385,cxcr4_human,45,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,33.9,-1.003,,,,70.8,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
639,16188969/16306611,cxcr4_human,45,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,1.0,-2.198,,,radioligand: [125I]-CXCL12,139.6,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
645,25039237,cxcr4_human,45,Y,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,1.6,4.0,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
695,25039237,cxcr4_human,45,Y,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,17.0,5.667,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
711,26397724,cxcr4_human,45,Y,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,181.0,15.083,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
789,18768385,cxcr4_human,45,Y,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,438.0,39.818,,,radioligand: [125I]-CXCL25,70.8,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
802,26397724,cxcr4_human,45,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,3.4,2.267,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
931,26397724,cxcr4_human,45,Y,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,4.0,8.0,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
986,25039237,cxcr4_human,45,Y,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,46.0,15.862,,,CXCL12,90.0,0.0,,0.0,,P61073,3.55199,YA45A,CXCR4
98,14585837,cxcr4_human,168,T,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,,K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.01,-2.0,,,radioligand:12G5(Bolton-Hunter),62.04379562,0.0,,0.0,,P61073,1.88372,TA168A,CXCR4
401,14585837,cxcr4_human,168,T,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,0.74,-1.203,,,radioligand:12G5(Bolton-Hunter),62.04379562,0.0,,0.0,,P61073,1.88372,TA168A,CXCR4
107,11551942,cxcr4_human,7,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,75.0,,,12G5,125.0,0.0,,0.0,,P61073,0.138283,YA7A,CXCR4
397,11551942,cxcr4_human,7,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,[125I]-SDF-1α,125.0,0.0,,0.0,,P61073,0.138283,YA7A,CXCR4
735,11551942,cxcr4_human,7,Y,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,75.0,,,[125I]-SDF-1α,125.0,0.0,,0.0,,P61073,0.138283,YA7A,CXCR4
116,14585837,cxcr4_human,256,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.0,4.494,,,radioligand:12G5(Bolton-Hunter),125.5474453,0.0,,0.0,,P61073,3.29191,YA256A,CXCR4
193,16188969/16306611,cxcr4_human,256,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,3.7,1.682,,,radioligand: [125I]-CXCL12,174.2,0.0,,0.0,,P61073,3.29191,YA256A,CXCR4
217,17599916,cxcr4_human,256,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.0,4.494,,,radioligand:[125I] -12G5,125.5474453,0.0,,0.0,,P61073,3.29191,YA256A,CXCR4
363,17599916,cxcr4_human,256,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.32,2.909,,,radioligand:125I-12G5,125.5474453,0.0,,0.0,,P61073,3.29191,YA256A,CXCR4
795,14585837,cxcr4_human,256,Y,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.19,9.5,,,radioligand:12G5(Bolton-Hunter),125.5474453,0.0,,0.0,,P61073,3.29191,YA256A,CXCR4
118,17599916,cxcr4_human,172,F,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.04,1.0,,,CXCL12,0.0,0.0,,68.96268963,,P61073,0.836651,FA172A,CXCR4
134,17599916,cxcr4_human,172,F,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.05,5.0,,,CXCL12,0.0,0.0,,68.96268963,,P61073,0.836651,FA172A,CXCR4
235,17599916,cxcr4_human,172,F,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.17,-1.294,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.836651,FA172A,CXCR4
392,17599916,cxcr4_human,172,F,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,1.2,-1.416,,,CXCL12,0.0,0.0,,68.96268963,,P61073,0.836651,FA172A,CXCR4
577,17599916,cxcr4_human,172,F,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.01,1.0,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.836651,FA172A,CXCR4
706,17599916,cxcr4_human,172,F,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.7,5.281,,,radioligand:[125I] -12G5,27.73722628,0.0,,0.0,,P61073,0.836651,FA172A,CXCR4
762,17599916,cxcr4_human,172,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,1.7,2.099,,,radioligand: [125I]-CXCL12,0.0,0.0,,68.96268963,,P61073,0.836651,FA172A,CXCR4
874,17599916,cxcr4_human,172,F,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,15.0,-1.333,,,CXCL12,0.0,0.0,,105.7400574,,P61073,0.836651,FA172A,CXCR4
941,17599916,cxcr4_human,172,F,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.56,5.091,,,radioligand:125I-12G5,27.73722628,0.0,,0.0,,P61073,0.836651,FA172A,CXCR4
122,16188969/16306611,cxcr4_human,191,P,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,2.5,1.136,,,radioligand: [125I]-CXCL12,114.2,0.0,,0.0,,P61073,1.54306,PA191A,CXCR4
126,23219524,cxcr4_human,171,D,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,39.6,2.329,,,,22.31404959,0.0,,0.0,,P61073,0.606252,DA171C,CXCR4
144,17599916,cxcr4_human,259,I,W,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.18,4.5,,,CXCL12,0.0,0.0,,67.6096761,,P61073,1.89212,IA259W,CXCR4
159,25039237,cxcr4_human,259,I,W,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.15,-2.667,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
215,14585837,cxcr4_human,259,I,W,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.84,42.0,,,radioligand:12G5(Bolton-Hunter),51.82481752,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
233,25039237,cxcr4_human,259,I,W,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.66,1.269,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
299,17599916,cxcr4_human,259,I,W,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,18.0,163.636,,,radioligand:125I-12G5,29.19708029,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
314,25039237,cxcr4_human,259,I,W,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,0.68,-4.274,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
422,17599916,cxcr4_human,259,I,W,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,3.1,1.824,,,CXCL12,0.0,0.0,,67.6096761,,P61073,1.89212,IA259W,CXCR4
519,17599916,cxcr4_human,259,I,W,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,24.0,1.2,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89212,IA259W,CXCR4
522,17599916,cxcr4_human,259,I,W,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,2.3,2.84,,,radioligand: [125I]-CXCL12,0.0,0.0,,67.6096761,,P61073,1.89212,IA259W,CXCR4
535,25039237,cxcr4_human,259,I,W,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,2.2,-1.364,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
567,25039237,cxcr4_human,259,I,W,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.3,-1.153,,,,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
622,26397724,cxcr4_human,259,I,W,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,1.5,3.0,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
623,17599916,cxcr4_human,259,I,W,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.08,8.0,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89212,IA259W,CXCR4
730,14585837,cxcr4_human,259,I,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.6,5.169,,,radioligand:12G5(Bolton-Hunter),51.82481752,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
785,17599916,cxcr4_human,259,I,W,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.05,5.0,,,CXCL12,0.0,0.0,,67.6096761,,P61073,1.89212,IA259W,CXCR4
877,17599916,cxcr4_human,259,I,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,4.6,5.169,,,radioligand:[125I] -12G5,29.19708029,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
880,26397724,cxcr4_human,259,I,W,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.3,-1.153,,,CXCL12,34.0,0.0,,0.0,,P61073,1.89212,IA259W,CXCR4
933,17599916,cxcr4_human,259,I,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.63,2.864,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89212,IA259W,CXCR4
150,17599916,cxcr4_human,120,L,F,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.014,-2.857,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89283,LA120F,CXCR4
350,17599916,cxcr4_human,120,L,F,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,2.8,3.457,,,radioligand: [125I]-CXCL12,0.0,0.0,,59.61459615,,P61073,1.89283,LA120F,CXCR4
414,17599916,cxcr4_human,120,L,F,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.33,1.5,,,CXCL12,0.0,0.0,,52.76752768,,P61073,1.89283,LA120F,CXCR4
480,17599916,cxcr4_human,120,L,F,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,13.0,-1.538,,,CXCL12,0.0,0.0,,52.76752768,,P61073,1.89283,LA120F,CXCR4
796,17599916,cxcr4_human,120,L,F,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,0.44,-3.861,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89283,LA120F,CXCR4
813,17599916,cxcr4_human,120,L,F,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.01,1.0,,,CXCL12,0.0,0.0,,52.76752768,,P61073,1.89283,LA120F,CXCR4
858,17599916,cxcr4_human,120,L,F,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.01,1.0,,,CXCL12,0.0,0.0,,59.61459615,,P61073,1.89283,LA120F,CXCR4
153,23219524,cxcr4_human,157,Y,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,43.0,2.529,,,,96.69421488,0.0,,0.0,,P61073,1.60561,YA157C,CXCR4
160,25039237,cxcr4_human,188,R,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,10.0,3.448,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
237,25039237,cxcr4_human,188,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.53,-2.833,,,,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
290,26397724,cxcr4_human,188,R,A,KRH1636-6,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CN)C=C1)=O)=O)C2=CC=CC3=C2C=CC=C3,Antagonist (neutral/silent),EC50,Functional - IP accumulation,12.0,uM,=,,25.0,2.083,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
326,26397724,cxcr4_human,188,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.53,-2.833,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
359,26397724,cxcr4_human,188,R,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.86,1.72,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
729,25039237,cxcr4_human,188,R,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.72,1.8,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
847,26397724,cxcr4_human,188,R,A,KRH1636-5,SMILES,C[C@H](NC([C@H](CCCNC(N)=N)NC(C1=CC=C(CNCC2=CC=CC=C2)C=C1)=O)=O)C3=CC=CC4=C3C=CC=C4,Antagonist (neutral/silent),EC50,Functional - IP accumulation,8.5,uM,=,,8.4,-1.012,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
862,25039237,cxcr4_human,188,R,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,44.0,14.667,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
1007,25039237,cxcr4_human,188,R,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,2.2,4.231,,,CXCL12,174.0,0.0,,0.0,,P61073,1.29397,RA188A,CXCR4
174,25039237,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.1,-14.925,,,,17.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
257,25039237,cxcr4_human,183,R,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.49,1.225,,,CXCL12,17.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
311,11551942,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,80.0,,,12G5,115.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
319,18768385,cxcr4_human,183,R,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,52.0,1.061,,,radioligand: [125I]-CXCL12,79.2,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
330,18768385,cxcr4_human,183,R,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,501.0,-1.681,,,radioligand: [125I]-CXCL12,79.2,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
424,26397724,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,0.1,-14.925,,,CXCL12,17.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
531,18768385,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,16.4,-2.183,,,,79.2,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
692,18768385,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - Ca2+ accumulation,34.0,nM,=,,42.9,1.262,,,,79.2,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
696,18768385,cxcr4_human,183,R,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,15.0,1.364,,,radioligand: [125I]-CXCL19,79.2,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
766,11551942,cxcr4_human,183,R,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,110.0,,,[125I]-SDF-1α,115.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
840,26397724,cxcr4_human,183,R,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,1.0,2.0,,,CXCL12,17.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
915,11551942,cxcr4_human,183,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,130.0,,,[125I]-SDF-1α,115.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
947,11551942,cxcr4_human,183,R,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,100.0,,,12G5,115.0,0.0,,0.0,,P61073,1.28224,RA183A,CXCR4
185,17599916,cxcr4_human,263,S,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.53,4.818,,,radioligand:125I-12G5,73.72262774,0.0,,0.0,,P61073,-0.255082,SA263A,CXCR4
294,14585837,cxcr4_human,263,S,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,5.4,6.067,,,radioligand:12G5(Bolton-Hunter),73.72262774,0.0,,0.0,,P61073,-0.255082,SA263A,CXCR4
485,17599916,cxcr4_human,263,S,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,5.4,6.067,,,radioligand:[125I] -12G5,73.72262774,0.0,,0.0,,P61073,-0.255082,SA263A,CXCR4
855,14585837,cxcr4_human,263,S,A,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.08,4.0,,,radioligand:12G5(Bolton-Hunter),73.72262774,0.0,,0.0,,P61073,-0.255082,SA263A,CXCR4
186,25039237,cxcr4_human,199,F,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.52,uM,=,,0.31,-1.678,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
245,26397724,cxcr4_human,199,F,A,KRH1636,SMILES,CC(C1=CC=CC2=CC=CC=C21)NC(=O)C(CCCN=C(N)N)NC(=O)C3=CC=C(C=C3)CNCC4=CC=C,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.5,uM,=,,0.69,1.38,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
461,25039237,cxcr4_human,199,F,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),EC50,Functional - IP accumulation,0.4,uM,=,,0.21,-1.905,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
808,25039237,cxcr4_human,199,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
864,25039237,cxcr4_human,199,F,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,3.0,uM,=,,2.3,-1.304,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
881,25039237,cxcr4_human,199,F,A,[Aib]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(C)(C)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),EC50,Functional - IP accumulation,2.9,uM,=,,2.9,1.0,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
961,26397724,cxcr4_human,199,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,EC50,Functional - IP accumulation,1.5,nM,=,,1.4,-1.072,,,CXCL12,79.0,0.0,,0.0,,P61073,2.14474,FA199A,CXCR4
191,17197449,cxcr4_human,133,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Functional - cAMP accumulation,25.0,%,~,,15.0,1.667,,,,50.0,0.0,,0.0,,P61073,0.310282,DA133N,CXCR4
196,11551942,cxcr4_human,268,E,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,50.0,,,[125I]-SDF-1α,200.0,0.0,,0.0,,P61073,0.219329,EA268A,CXCR4
430,10620340,cxcr4_human,268,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,3.3,-1.03,,,,125.4863813,0.0,,0.0,,P61073,0.219329,EA268A,CXCR4
911,11551942,cxcr4_human,268,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,50.0,,,[125I]-SDF-1α,200.0,0.0,,0.0,,P61073,0.219329,EA268A,CXCR4
206,11923301,cxcr4_human,119,N,D,T140,PubChem CID,16130395,Inverse agonist,IC50,Binding - Radioligand competition/displacement,16.0,nM,=,,16.6,1.038,,,radioligand: [125I]-CXCL12,100.0,0.0,,0.0,,P61073,2.05681,NA119D,CXCR4
540,17197449,cxcr4_human,119,N,D,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Functional - cAMP accumulation,25.0,%,~,,21.0,1.19,,,,130.0,0.0,,0.0,,P61073,2.05681,NA119D,CXCR4
829,11923301,cxcr4_human,119,N,D,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,106.0,nM,=,,81.7,-1.297,,,radioligand: [125I]-CXCL12,100.0,0.0,,0.0,,P61073,2.05681,NA119D,CXCR4
207,17599916,cxcr4_human,287,T,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.1,3.483,,,radioligand:[125I] -12G5,187.5912409,0.0,,0.0,,P61073,-0.462521,TA287A,CXCR4
334,17599916,cxcr4_human,287,T,A,AMD8721,SMILES,N(CCN1CCCN2CC3)([Cu]124)CCC[N@]34Cc5ccc(CNCC6=CC=CC=N6)cc5,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.04,uM,=,,0.01,-4.0,,,CXCL12,0.0,0.0,,80.29930299,,P61073,-0.462521,TA287A,CXCR4
455,17599916,cxcr4_human,287,T,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.81,nM,=,,2.1,2.593,,,radioligand: [125I]-CXCL12,0.0,0.0,,80.29930299,,P61073,-0.462521,TA287A,CXCR4
469,17599916,cxcr4_human,287,T,A,AMD3389,SMILES,Cc1ccc(CN2CCCNCCNCCCNCC2)cc1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,20.0,uM,=,,3.3,-6.061,,,CXCL12,0.0,0.0,,73.49323493,,P61073,-0.462521,TA287A,CXCR4
659,17599916,cxcr4_human,287,T,A,AMD8899,SMILES,N1([Ni]234)CCC[N@@]4(Cc5ccc(CNCC6=CC=CC=N6)cc5)CCN3CCCN2CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.02,2.0,,,CXCL12,0.0,0.0,,80.29930299,,P61073,-0.462521,TA287A,CXCR4
666,17599916,cxcr4_human,287,T,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,2.0,18.182,,,radioligand:125I-12G5,187.5912409,0.0,,0.0,,P61073,-0.462521,TA287A,CXCR4
757,17599916,cxcr4_human,287,T,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.22,uM,=,,0.29,1.318,,,CXCL12,0.0,0.0,,73.49323493,,P61073,-0.462521,TA287A,CXCR4
948,17599916,cxcr4_human,287,T,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.01,uM,=,,0.01,1.0,,,CXCL12,0.0,0.0,,73.49323493,,P61073,-0.462521,TA287A,CXCR4
1039,17599916,cxcr4_human,287,T,A,AMD3529,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=C3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.7,uM,=,,0.34,-5.0,,,CXCL12,0.0,0.0,,80.29930299,,P61073,-0.462521,TA287A,CXCR4
220,12534283,cxcr4_human,193,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,81.0,1.095,,,radioligand: [125I]-Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
262,11154697,cxcr4_human,193,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,550.0,nM,=,,3200.0,5.818,,,radioligand: [125I]-12G5,233.3333333,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
715,12534283,cxcr4_human,193,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,12.0,nM,=,,49.0,4.083,,,radioligand: [125I]-Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
804,11154697,cxcr4_human,193,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,74.0,nM,=,,81.0,1.095,,,radioligand: [125I]Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
805,11154697/12534283,cxcr4_human,193,D,N,cyclam,SMILES,C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,13.0,uM,=,,9.2,-1.412,,,radioligand: [125I]-Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
898,12534283,cxcr4_human,193,D,N,Cyclam (Zn),SMILES,[Zn+2].C1CNCCNCCCNCCNC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,3.0,uM,=,,1.6,-1.876,,,radioligand: [125I]-Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
928,12534283,cxcr4_human,193,D,N,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.0,uM,=,,0.91,-1.099,,,radioligand: [125I]-12G5,233.3333333,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
977,12534283,cxcr4_human,193,D,N,AMD3100(Zn)2,SMILES,N12CCC[N](Cc3ccc(C[N@@]45[Zn]67N(CCN6CCCN7CC5)CCC4)cc3)([Zn]289)CCN9CCCN8CC1,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.028,nM,=,,0.069,2.464,,,radioligand: [125I]-12G5,233.3333333,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
980,11154697,cxcr4_human,193,D,N,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,0.49,nM,=,,0.44,-1.114,,,radioligand: [125I]Met-CXCL12,70.58823529,0.0,,0.0,,P61073,0.107666,DA193N,CXCR4
226,10620340,cxcr4_human,109,C,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,31.9,9.382,,,,136.381323,0.0,,0.0,,P61073,4.61209,CA109A,CXCR4
229,23219524,cxcr4_human,169,I,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,8.7,-1.953,,,,25.61983471,0.0,,0.0,,P61073,0.946682,IA169C,CXCR4
243,16188969/16306611,cxcr4_human,182,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,3.4,1.545,,,radioligand: [125I]-CXCL12,98.2,0.0,,0.0,,P61073,0.0890029,DA182A,CXCR4
844,17599916,cxcr4_human,182,D,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.2,3.596,,,radioligand:[125I] -12G5,173.7226277,0.0,,0.0,,P61073,0.0890029,DA182A,CXCR4
856,17599916,cxcr4_human,182,D,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.3,2.727,,,radioligand:125I-12G5,173.7226277,0.0,,0.0,,P61073,0.0890029,DA182A,CXCR4
259,23219524,cxcr4_human,178,S,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,21.1,1.241,,,,55.37190083,0.0,,0.0,,P61073,0.143468,SA178C,CXCR4
276,23219524,cxcr4_human,163,P,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,45.1,2.653,,,,55.37190083,0.0,,0.0,,P61073,3.031,PA163C,CXCR4
277,17599916,cxcr4_human,207,G,F,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.0,3.371,,,radioligand:[125I] -12G5,85.40145985,0.0,,0.0,,P61073,9.70773,GA207F,CXCR4
1051,17599916,cxcr4_human,207,G,F,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.16,1.455,,,radioligand:125I-12G5,85.40145985,0.0,,0.0,,P61073,9.70773,GA207F,CXCR4
292,18768385,cxcr4_human,116,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand competition/displacement,35.8,nM,=,,33.7,-1.063,,,,170.7,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
355,25039237,cxcr4_human,116,Y,A,[D-Arg]FC131,SMILES,N\C(N)=N\CCCC1NC(=O)[C@H](CCC\N=C(\N)N)NC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(Cc2ccc3ccccc3c2)NC1=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.38,uM,=,,100.0,263.158,,,radioligand:[125I]-12G5,69.0,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
442,25039237,cxcr4_human,116,Y,A,FC131,PubChem CID,5275843,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,0.76,uM,=,,100.0,131.579,,,radioligand:[125I]-12G8,69.0,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
595,18768385,cxcr4_human,116,Y,A,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,49.0,nM,=,,777.0,15.857,,,radioligand: [125I]-CXCL12,170.7,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
883,18768385,cxcr4_human,116,Y,A,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,842.0,nM,=,,8099.0,9.619,,,radioligand: [125I]-CXCL12,170.7,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
940,25039237,cxcr4_human,116,Y,A,[Cit]FC131,SMILES,O=C(NC(CC1=CC=C(O)C=C1)C(NC(CCCNC(N)=O)C(NC(CCC/N=C(N)\N)C(NC2CC3=CC4=CC=CC=C4C=C3)=O)=O)=O)CNC2=O,Antagonist (neutral/silent),IC50,Binding - Radioligand competition/displacement,4.9,uM,=,,100.0,20.408,,,radioligand:[125I]-12G8,69.0,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
955,18768385,cxcr4_human,116,Y,A,AMD11070,SMILES,NCCCCN(CC1=NC2=CC=CC=C2N1)[C@@H]3C4=NC=CC=C4CCC3,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,11.0,nM,=,,39.0,3.545,,,radioligand: [125I]-CXCL22,170.7,0.0,,0.0,,P61073,1.96653,YA116A,CXCR4
293,16188969/16306611,cxcr4_human,262,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,4.4,2.0,,,radioligand: [125I]-CXCL12,137.9,0.0,,0.0,,P61073,-0.143737,DA262A,CXCR4
992,10620340,cxcr4_human,262,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,14.9,4.382,,,,174.3190661,0.0,,0.0,,P61073,-0.143737,DA262A,CXCR4
303,11551942,cxcr4_human,26,E,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,65.0,,,[125I]-SDF-1α,165.0,0.0,,0.0,,P61073,0.591856,EA26A,CXCR4
614,11551942,cxcr4_human,26,E,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,100.0,,,12G5,165.0,0.0,,0.0,,P61073,0.591856,EA26A,CXCR4
747,11551942,cxcr4_human,26,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,110.0,,,12G5,165.0,0.0,,0.0,,P61073,0.591856,EA26A,CXCR4
918,11551942,cxcr4_human,26,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,60.0,,,[125I]-SDF-1α,165.0,0.0,,0.0,,P61073,0.591856,EA26A,CXCR4
307,23219524,cxcr4_human,164,A,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,31.8,1.871,,,,80.16528926,0.0,,0.0,,P61073,1.59224,AA164C,CXCR4
315,11551942,cxcr4_human,20,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,40.0,,,[125I]-SDF-1α,160.0,0.0,,0.0,,P61073,-0.0425148,DA20A,CXCR4
564,11551942,cxcr4_human,20,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,20.0,,,12G5,160.0,0.0,,0.0,,P61073,-0.0425148,DA20A,CXCR4
672,11551942,cxcr4_human,20,D,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,50.0,,,[125I]-SDF-1α,160.0,0.0,,0.0,,P61073,-0.0425148,DA20A,CXCR4
929,11551942,cxcr4_human,20,D,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,60.0,,,12G5,160.0,0.0,,0.0,,P61073,-0.0425148,DA20A,CXCR4
348,23219524,cxcr4_human,177,V,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,19.6,1.153,,,,54.54545455,0.0,,0.0,,P61073,1.92966,VA177C,CXCR4
376,17197449,cxcr4_human,134,R,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Functional - cAMP accumulation,25.0,%,~,,10.0,2.5,,,,60.0,0.0,,0.0,,P61073,0.759364,RA134A,CXCR4
417,23219524,cxcr4_human,158,V,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,14.0,-1.214,,,,68.59504132,0.0,,0.0,,P61073,-0.219695,VA158C,CXCR4
432,25468967,cxcr4_human,171,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,pEC50,Functional - Ca2+ accumulation,8.8,,=,,7.99,6.457,,,,100.0,0.0,,0.0,,P61073,0.48817,DA171A,CXCR4
465,23219524,cxcr4_human,170,P,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,23.6,1.388,,,,24.79338843,0.0,,0.0,,P61073,2.07977,PA170C,CXCR4
477,16188969/16306611,cxcr4_human,161,W,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,12.5,5.682,,,radioligand: [125I]-CXCL12,259.0,0.0,,0.0,,P61073,3.02021,WA161A,CXCR4
503,16188969/16306611,cxcr4_human,163,P,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,8.6,3.909,,,radioligand: [125I]-CXCL12,112.4,0.0,,0.0,,P61073,2.70296,PA163A,CXCR4
508,23219524,cxcr4_human,165,L,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,29.7,1.747,,,,80.99173554,0.0,,0.0,,P61073,1.75489,LA165C,CXCR4
510,10620340,cxcr4_human,274,C,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,18.2,5.353,,,,173.540856,0.0,,0.0,,P61073,4.68405,CA274A,CXCR4
515,23219524,cxcr4_human,159,G,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,19.5,1.147,,,,76.03305785,0.0,,0.0,,P61073,0.0147981,GA159C,CXCR4
575,16188969/16306611,cxcr4_human,79,H,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,1.6,-1.376,,,radioligand: [125I]-CXCL12,121.9,0.0,,0.0,,P61073,0.764768,HA79A,CXCR4
594,23219524,cxcr4_human,174,F,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,8.6,-1.976,,,,23.14049587,0.0,,0.0,,P61073,2.66891,FA174C,CXCR4
603,10620340,cxcr4_human,10,D,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,7.3,2.147,,,,150.3891051,0.0,,0.0,,P61073,0.115358,DA10A,CXCR4
608,23219524,cxcr4_human,173,I,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,23.7,1.394,,,,65.2892562,0.0,,0.0,,P61073,1.15767,IA173C,CXCR4
613,10620340,cxcr4_human,28,C,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,17.9,5.265,,,,96.88715953,0.0,,0.0,,P61073,5.34753,CA28A,CXCR4
618,16188969/16306611,cxcr4_human,219,Y,A,CXCL12,UniProt Entry Code,P48061,Full agonist,IC50,Binding - Radioligand saturation,2.2,nM,=,,4.7,2.136,,,radioligand: [125I]-CXCL12,87.3,0.0,,0.0,,P61073,3.22736,YA219A,CXCR4
647,23219524,cxcr4_human,168,T,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,11.2,-1.517,,,,94.21487603,0.0,,0.0,,P61073,1.06014,TA168C,CXCR4
667,14585837,cxcr4_human,207,G,W,AMD3479,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(C[N@@]3([Zn]456)CCCN4CCN6CCCN5CC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.02,uM,=,,0.25,12.5,,,radioligand:12G5(Bolton-Hunter),85.40145985,0.0,,0.0,,P61073,11.8096,GA207W,CXCR4
869,17599916,cxcr4_human,207,G,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,2.7,3.034,,,radioligand:[125I] -12G5,118.9781022,0.0,,0.0,,P61073,11.8096,GA207W,CXCR4
888,14585837,cxcr4_human,207,G,W,AMD3100,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.89,uM,=,,3.02,3.393,,,radioligand:12G5(Bolton-Hunter),85.40145985,0.0,,0.0,,P61073,11.8096,GA207W,CXCR4
989,17599916,cxcr4_human,207,G,W,AMD3465,SMILES,N1(CCCNCCNCCCNCC1)Cc2ccc(CNCC3=CC=CC=N3)cc2,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,0.11,uM,=,,0.13,1.182,,,radioligand:125I-12G5,118.9781022,0.0,,0.0,,P61073,11.8096,GA207W,CXCR4
670,11551942,cxcr4_human,272,Q,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,80.0,,,12G5,145.0,0.0,,0.0,,P61073,1.351,QA272A,CXCR4
983,11551942,cxcr4_human,272,Q,A,vMIP-II,UniProt Entry Code,Q98157,Antagonist (neutral/silent),Single-point,Binding - Radioligand competition/displacement,100.0,%,=,,0.0,130.0,,,[125I]-SDF-1α,145.0,0.0,,0.0,,P61073,1.351,QA272A,CXCR4
1014,11551942,cxcr4_human,272,Q,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,130.0,,,[125I]-SDF-1α,145.0,0.0,,0.0,,P61073,1.351,QA272A,CXCR4
1026,11551942,cxcr4_human,272,Q,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,Binding - Radioligand competition/displacement,100.0,%,~,,0.0,50.0,,,12G5,145.0,0.0,,0.0,,P61073,1.351,QA272A,CXCR4
717,23219524,cxcr4_human,162,I,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,13.6,-1.25,,,,59.50413223,0.0,,0.0,,P61073,1.24706,IA162C,CXCR4
726,10620340,cxcr4_human,186,C,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,27.7,8.147,,,,110.8949416,0.0,,0.0,,P61073,4.8073,CA186A,CXCR4
761,23219524,cxcr4_human,160,V,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,35.5,2.088,,,,93.38842975,0.0,,0.0,,P61073,1.31084,VA160C,CXCR4
765,22039044,cxcr4_human,29,F,A,CXCL12,UniProt Entry Code,P48061,Full agonist,Single-point,,100.0,%,~,,0.0,115.0,,,,48.38709677,0.0,,0.0,,P61073,0.297457,FA29A,CXCR4
972,22039044,cxcr4_human,29,F,A,Ubiquitin,UniProt Entry Code,P0CG48,Agonist,Single-point,,100.0,%,=,,0.0,30.0,,,,48.38709677,0.0,,0.0,,P61073,0.297457,FA29A,CXCR4
767,23219524,cxcr4_human,172,F,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,22.1,1.3,,,,93.38842975,0.0,,0.0,,P61073,1.36141,FA172C,CXCR4
927,10620340,cxcr4_human,277,E,A,CXCL12,UniProt Entry Code,P48061,Full agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,18.4,5.412,,,,133.07393,0.0,,0.0,,P61073,-0.40891,EA277A,CXCR4
1027,23219524,cxcr4_human,156,V,C,FC131,PubChem CID,5275843,Antagonist (neutral/silent),K(d),Binding - Radioligand saturation,17.0,nM,=,,21.2,1.247,,,,51.23966942,0.0,,0.0,,P61073,1.559,VA156C,CXCR4
2,1356984,hrh2_human,190,T,C,Cemetidine,ChEMBL Compound ID,CHEMBL30,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,400.0,8.0,,,"[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine (radioligand)",0.0,0.0,,0.0,,P25021,0.108383,TA190C,HRH2
6,1356984,hrh2_human,190,T,C,[3H]-methyltiotidine,ChEMBL Compound ID,CHEMBL269646,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,3.3,nM,=,,71.0,21.515,,,"[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine (radioligand)",0.0,0.0,,0.0,,P25021,0.108383,TA190C,HRH2
4,1356984,hrh2_human,190,T,A,Cemetidine,ChEMBL Compound ID,CHEMBL30,Binding - unknown pharmacological activity,IC50,Binding - Radioligand competition/displacement,50.0,nM,=,,300.0,6.0,,,"[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine (radioligand)",0.0,0.0,,0.0,,P25021,0.339219,TA190A,HRH2
5,1356984,hrh2_human,190,T,A,[3H]-methyltiotidine,ChEMBL Compound ID,CHEMBL269646,Binding - unknown pharmacological activity,K(d),Binding - Radioligand competition/displacement,3.3,nM,=,,79.0,23.939,,,"[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine
[3H]-methyltiotidine (radioligand)",0.0,0.0,,0.0,,P25021,0.339219,TA190A,HRH2
57,9415408,crfr1_human,257,K,Q,CRF,PubChem CID,16132265,Full agonist,EC50,Functional - cAMP accumulation,0.16,nM,=,,0.15,-1.066,,,CRF,0.0,0.0,,0.0,,P34998,0.0203376,KA257Q,CRHR1
71,12029097,crfr1_human,257,K,R,"sauvagine-[Tyr0,Gln1, Leu17]",FASTA sequence (peptide),YSEQPPISLDLTFHLLRLVLEMARAEQLAQQAHSNRKLMEII,Full agonist,EC50,Functional - cAMP accumulation,0.22,nM,=,,2.51,11.409,,,CRF,0.0,0.0,,31.6,,P34998,0.234344,KA257R,CRHR1
88,12029097,crfr1_human,257,K,R,sauvagine,PubChem CID,16132335,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.8,nM,=,,5.1,-1.138,,,"[125I]sauvagine-[Tyr0,Gln1, Leu17] (radioligand)",90.1,0.0,,0.0,,P34998,0.234344,KA257R,CRHR1
94,23863939,crfr1_human,323,L,A,[ 3H]CP-376395,PubChem CID,9862166,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,,=,,0.0,-3.774,,,[ 3H]CP-376395 (radioligand),100.0,0.0,,0.0,,P34998,2.08176,LA323A,CRHR1
115,23863939,crfr1_human,280,L,A,[ 3H]CP-376395,PubChem CID,9862166,Binding - unknown pharmacological activity,Single-point,Binding - Radioligand competition/displacement,0.0,%,=,,0.0,-47.619,,,[ 3H]CP-376395 (radioligand),100.0,0.0,,0.0,,P34998,0.944262,LA280A,CRHR1
0,11022192,tshr_human,512,L,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P16473,1.9083,LA512R,TSHR
911,11022192,tshr_human,512,L,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P16473,1.9083,LA512R,TSHR
1114,11022192,tshr_human,512,L,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,1.9083,LA512R,TSHR
1,21628383,tshr_human,296,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,0.909019,LA296V,TSHR
3,16410307,tshr_human,281,S,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,-1.73904,SA281F,TSHR
1070,18381815,tshr_human,281,S,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,114.0,-1.14,,,,0.0,0.0,,0.0,,P16473,-1.73904,SA281F,TSHR
1658,16410307,tshr_human,281,S,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,114.0,-1.14,,,,0.0,0.0,,0.0,,P16473,-1.73904,SA281F,TSHR
4,22112806,tshr_human,639,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,3.0,33.333,,,,0.0,0.0,,0.0,,P16473,1.18507,PA639L,TSHR
1002,22112806,tshr_human,639,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,2.0,50.0,,,,0.0,0.0,,0.0,,P16473,1.18507,PA639L,TSHR
5,16955277,tshr_human,604,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P16473,2.43827,IA604A,TSHR
540,16955277,tshr_human,604,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P16473,2.43827,IA604A,TSHR
2640,16955277,tshr_human,604,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,2.43827,IA604A,TSHR
9,9329388,tshr_human,390,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,4.02615,CA390W,TSHR
122,8954020,tshr_human,390,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,4.02615,CA390W,TSHR
1006,8954020,tshr_human,390,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,4.02615,CA390W,TSHR
2325,9329388,tshr_human,390,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,148.0,-1.479,,,,0.0,0.0,,0.0,,P16473,4.02615,CA390W,TSHR
12,16150909,tshr_human,656,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P16473,0.518455,VA656A,TSHR
1539,16150909,tshr_human,656,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,0.518455,VA656A,TSHR
1557,16150909,tshr_human,656,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,6.0,16.667,,,,0.0,0.0,,0.0,,P16473,0.518455,VA656A,TSHR
15,18850313,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
655,9360556,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
1336,15817920,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
1474,11012571,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
1668,15817920,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
1728,18381815,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
2105,15817920,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
2736,11012571,tshr_human,656,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,-2.23461,VA656F,TSHR
26,21525003,tshr_human,263,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,2.50953,LA263V,TSHR
569,21525003,tshr_human,263,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P16473,2.50953,LA263V,TSHR
32,12950268,tshr_human,486,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P16473,0.0378381,IA486M,TSHR
373,18850313,tshr_human,486,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P16473,0.0378381,IA486M,TSHR
1853,12950268,tshr_human,486,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,175.0,-1.751,,,,0.0,0.0,,0.0,,P16473,0.0378381,IA486M,TSHR
1983,12950268,tshr_human,486,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P16473,0.0378381,IA486M,TSHR
33,21628383,tshr_human,309,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,1.22396,LA309V,TSHR
34,21628383,tshr_human,314,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.218897,SA314A,TSHR
581,21525003,tshr_human,314,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,-0.218897,SA314A,TSHR
35,17079233,tshr_human,640,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,44.0,2.273,,,,0.0,0.0,,0.0,,P16473,0.401341,IA640M,TSHR
600,17079233,tshr_human,640,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,0.401341,IA640M,TSHR
40,21628383,tshr_human,379,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,0.235801,QA379A,TSHR
1448,21525003,tshr_human,379,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,54.0,1.852,,,,0.0,0.0,,0.0,,P16473,0.235801,QA379A,TSHR
44,15498884,tshr_human,534,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,-0.610471,RA534A,TSHR
885,15498884,tshr_human,534,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,-0.610471,RA534A,TSHR
2208,15498884,tshr_human,534,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,-0.610471,RA534A,TSHR
45,9224711,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
525,9589634,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
606,9589634,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
660,15817920,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
896,16410307,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
1630,15817920,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
2382,9224711,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
2450,15817920,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
2460,16410307,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
2747,9589634,tshr_human,281,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,35.0,2.857,,,,0.0,0.0,,0.0,,P16473,1.20617,SA281N,TSHR
53,18441013,tshr_human,293,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,1.0594,RA293A,TSHR
1425,23002040,tshr_human,293,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P16473,1.0594,RA293A,TSHR
1987,16899458,tshr_human,293,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P16473,1.0594,RA293A,TSHR
2159,23002040,tshr_human,293,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,1.0594,RA293A,TSHR
58,17725428,tshr_human,43,D,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.486394,DA43A,TSHR
2708,17725428,tshr_human,43,D,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.486394,DA43A,TSHR
59,15498884,tshr_human,523,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P16473,1.72725,IA523A,TSHR
770,15498884,tshr_human,523,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,1.72725,IA523A,TSHR
2176,15498884,tshr_human,523,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,1.72725,IA523A,TSHR
60,21525003,tshr_human,282,H,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,55.0,1.818,,,,0.0,0.0,,0.0,,P16473,-1.48765,HA282F,TSHR
62,16410307,tshr_human,484,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P16473,1.11858,HA484A,TSHR
2594,16410307,tshr_human,484,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,1.11858,HA484A,TSHR
63,20736161,tshr_human,80,R,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,1.54434,RA80A,TSHR
338,17725428,tshr_human,80,R,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.54434,RA80A,TSHR
374,17725428,tshr_human,80,R,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.54434,RA80A,TSHR
66,15817920,tshr_human,568,I,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,2.94342,IA568T,TSHR
1409,15817920,tshr_human,568,I,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,2.94342,IA568T,TSHR
2731,15817920,tshr_human,568,I,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,2.94342,IA568T,TSHR
69,23002040,tshr_human,290,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,44.0,2.273,,,,0.0,0.0,,0.0,,P16473,0.184494,KA290A,TSHR
1350,16899458,tshr_human,290,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,142.0,-1.42,,,,0.0,0.0,,0.0,,P16473,0.184494,KA290A,TSHR
1844,23002040,tshr_human,290,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P16473,0.184494,KA290A,TSHR
2643,16899458,tshr_human,290,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,0.184494,KA290A,TSHR
77,21628383,tshr_human,300,M,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,1.05756,MA300V,TSHR
1295,21628383,tshr_human,300,M,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,1.05756,MA300V,TSHR
79,21525003,tshr_human,274,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,1.65187,RA274A,TSHR
1695,21525003,tshr_human,274,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,1.65187,RA274A,TSHR
82,16410307,tshr_human,481,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.852047,YA481F,TSHR
2297,16410307,tshr_human,481,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.852047,YA481F,TSHR
87,17079233,tshr_human,563,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,4.0,25.0,,,,0.0,0.0,,0.0,,P16473,4.60961,YA563A,TSHR
2768,17079233,tshr_human,563,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,15.0,6.667,,,,0.0,0.0,,0.0,,P16473,4.60961,YA563A,TSHR
88,16756474,tshr_human,631,F,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.563906,FA631S,TSHR
1348,16756474,tshr_human,631,F,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,35.0,2.857,,,,0.0,0.0,,0.0,,P16473,0.563906,FA631S,TSHR
101,21525003,tshr_human,377,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,0.0100647,TA377A,TSHR
492,21628383,tshr_human,377,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,0.0100647,TA377A,TSHR
105,9100579,tshr_human,109,R,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.344584,RA109Q,TSHR
524,9100579,tshr_human,109,R,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,0.344584,RA109Q,TSHR
108,16899458,tshr_human,405,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,1.5685,FA405A,TSHR
2149,16899458,tshr_human,405,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,1.5685,FA405A,TSHR
109,11463854,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
812,11463854,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
941,11463854,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
1009,15817920,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
1131,15817920,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
1905,15817920,tshr_human,633,D,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-3.32592,DA633F,TSHR
116,15817920,tshr_human,486,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,3.82107,IA486F,TSHR
1606,15817920,tshr_human,486,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,55.0,1.818,,,,0.0,0.0,,0.0,,P16473,3.82107,IA486F,TSHR
1681,15817920,tshr_human,486,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,3.82107,IA486F,TSHR
2376,12062436,tshr_human,486,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P16473,3.82107,IA486F,TSHR
117,18441013,tshr_human,382,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,-0.157713,DA382N,TSHR
376,19386596,tshr_human,382,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,-0.157713,DA382N,TSHR
662,19386596,tshr_human,382,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,-0.157713,DA382N,TSHR
1238,18441013,tshr_human,382,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-0.157713,DA382N,TSHR
118,18989620,tshr_human,512,L,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P16473,1.55917,LA512Q,TSHR
178,18850313,tshr_human,512,L,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,1.55917,LA512Q,TSHR
272,11434721,tshr_human,512,L,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,1.55917,LA512Q,TSHR
631,18989620,tshr_human,512,L,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,1.55917,LA512Q,TSHR
121,21525003,tshr_human,266,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,123.0,-1.23,,,,0.0,0.0,,0.0,,P16473,-0.281679,SA266A,TSHR
2256,21525003,tshr_human,266,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,-0.281679,SA266A,TSHR
125,16410307,tshr_human,481,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P16473,1.66089,YA481A,TSHR
1639,16410307,tshr_human,481,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,1.66089,YA481A,TSHR
127,15498884,tshr_human,528,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P16473,0.483155,RA528A,TSHR
1365,15498884,tshr_human,528,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P16473,0.483155,RA528A,TSHR
1863,15498884,tshr_human,528,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P16473,0.483155,RA528A,TSHR
128,10691307,tshr_human,601,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,120.0,-1.2,,,,0.0,0.0,,0.0,,P16473,0.822877,YA601N,TSHR
510,12062436,tshr_human,601,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,0.822877,YA601N,TSHR
1172,10691307,tshr_human,601,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,0.822877,YA601N,TSHR
2097,10691307,tshr_human,601,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,0.822877,YA601N,TSHR
132,16899458,tshr_human,402,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,-0.092298,SA402A,TSHR
974,16899458,tshr_human,402,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.092298,SA402A,TSHR
133,18441013,tshr_human,371,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,0.518514,KA371A,TSHR
287,21525003,tshr_human,371,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P16473,0.518514,KA371A,TSHR
146,20736161,tshr_human,157,E,Q,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.451039,EA157Q,TSHR
149,21628383,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
425,23002040,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
1254,21525003,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
1285,18441013,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
2430,23002040,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
2675,21628383,tshr_human,395,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.0146909,DA395A,TSHR
158,9185526,tshr_human,553,A,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,3.06363,AA553T,TSHR
1956,9185526,tshr_human,553,A,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,3.06363,AA553T,TSHR
159,16410307,tshr_human,281,S,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,-2.51927,SA281L,TSHR
1691,12062436,tshr_human,281,S,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,-2.51927,SA281L,TSHR
1845,16410307,tshr_human,281,S,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P16473,-2.51927,SA281L,TSHR
161,16899458,tshr_human,406,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,0.546195,NA406D,TSHR
300,16899458,tshr_human,406,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.546195,NA406D,TSHR
168,7989485,tshr_human,623,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-2.13072,AA623V,TSHR
1514,7989485,tshr_human,623,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-2.13072,AA623V,TSHR
2029,7989485,tshr_human,623,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-2.13072,AA623V,TSHR
2236,18850313,tshr_human,623,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P16473,-2.13072,AA623V,TSHR
176,21628383,tshr_human,384,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,-0.0572124,HA384A,TSHR
179,11463854,tshr_human,633,D,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,150.0,-1.499,,,,0.0,0.0,,0.0,,P16473,-0.277176,DA633R,TSHR
1358,11463854,tshr_human,633,D,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,-0.277176,DA633R,TSHR
1896,11463854,tshr_human,633,D,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,11.0,9.091,,,,0.0,0.0,,0.0,,P16473,-0.277176,DA633R,TSHR
180,17079233,tshr_human,566,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P16473,0.29208,VA566F,TSHR
689,17079233,tshr_human,566,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,0.29208,VA566F,TSHR
181,16899458,tshr_human,399,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P16473,0.920679,TA399A,TSHR
2388,16899458,tshr_human,399,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.920679,TA399A,TSHR
192,18025759,tshr_human,619,D,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,1.58791,DA619G,TSHR
571,12062436,tshr_human,619,D,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,114.0,-1.14,,,,0.0,0.0,,0.0,,P16473,1.58791,DA619G,TSHR
2003,18025759,tshr_human,619,D,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,1.58791,DA619G,TSHR
200,16955277,tshr_human,617,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.332896,DA617A,TSHR
209,16955277,tshr_human,617,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,146.0,-1.46,,,,0.0,0.0,,0.0,,P16473,0.332896,DA617A,TSHR
1737,16955277,tshr_human,617,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.332896,DA617A,TSHR
203,17725428,tshr_human,129,K,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.11168,KA129A,TSHR
745,17725428,tshr_human,129,K,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.11168,KA129A,TSHR
205,16899458,tshr_human,406,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.58174,NA406S,TSHR
2764,16899458,tshr_human,406,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,121.0,-1.211,,,,0.0,0.0,,0.0,,P16473,0.58174,NA406S,TSHR
207,7805857,tshr_human,631,F,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,1.08316,FA631C,TSHR
315,7805857,tshr_human,631,F,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.08316,FA631C,TSHR
449,7805857,tshr_human,631,F,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,1.08316,FA631C,TSHR
210,21628383,tshr_human,370,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.0614114,LA370V,TSHR
211,24608569,tshr_human,453,M,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,2.26054,MA453R,TSHR
961,24608569,tshr_human,453,M,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P16473,2.26054,MA453R,TSHR
212,18441013,tshr_human,297,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,-0.649062,EA297K,TSHR
774,19386596,tshr_human,297,E,K,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,59.0,1.695,,,,0.0,0.0,,0.0,,P16473,-0.649062,EA297K,TSHR
1393,18441013,tshr_human,297,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,-0.649062,EA297K,TSHR
1858,19386596,tshr_human,297,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,46.0,2.174,,,,0.0,0.0,,0.0,,P16473,-0.649062,EA297K,TSHR
213,16756469,tshr_human,519,R,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,2.46123,RA519G,TSHR
220,21586576,tshr_human,591,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,0.724723,IA591V,TSHR
222,20305779,tshr_human,444,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,0.101789,YA444A,TSHR
796,20305779,tshr_human,444,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.101789,YA444A,TSHR
225,20736161,tshr_human,160,D,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,0.749127,DA160A,TSHR
229,21628383,tshr_human,386,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,0.0412543,DA386A,TSHR
2438,21628383,tshr_human,386,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,0.0412543,DA386A,TSHR
232,15345720,tshr_human,404,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,-0.946403,EA404K,TSHR
1074,15345720,tshr_human,404,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-0.946403,EA404K,TSHR
1503,15345720,tshr_human,404,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P16473,-0.946403,EA404K,TSHR
236,9224711,tshr_human,281,S,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.717017,SA281T,TSHR
696,16410307,tshr_human,281,S,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,-0.717017,SA281T,TSHR
1353,16410307,tshr_human,281,S,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.717017,SA281T,TSHR
2766,9224711,tshr_human,281,S,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.717017,SA281T,TSHR
237,16756469,tshr_human,519,R,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,1.58052,RA519C,TSHR
2293,16756469,tshr_human,519,R,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P16473,1.58052,RA519C,TSHR
251,17456567,tshr_human,653,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.339274,LA653V,TSHR
552,17456567,tshr_human,653,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,0.339274,LA653V,TSHR
2286,17456567,tshr_human,653,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,0.339274,LA653V,TSHR
254,16955277,tshr_human,619,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,0.350142,DA619A,TSHR
355,16955277,tshr_human,619,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,115.0,-1.149,,,,0.0,0.0,,0.0,,P16473,0.350142,DA619A,TSHR
622,16955277,tshr_human,619,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,149.0,-1.49,,,,0.0,0.0,,0.0,,P16473,0.350142,DA619A,TSHR
255,20179143,tshr_human,501,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,129.0,-1.29,,,,0.0,0.0,,0.0,,P16473,0.507033,TA501A,TSHR
266,18381815,tshr_human,488,W,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,4.0,25.0,,,,0.0,0.0,,0.0,,P16473,5.22928,WA488A,TSHR
273,20652618,tshr_human,582,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,4.7318,YA582A,TSHR
1049,20652618,tshr_human,582,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,4.7318,YA582A,TSHR
274,18381815,tshr_human,488,W,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,2.72831,WA488L,TSHR
278,18727713,tshr_human,403,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,0.127955,DA403N,TSHR
2255,16899458,tshr_human,403,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,127.0,-1.271,,,,0.0,0.0,,0.0,,P16473,0.127955,DA403N,TSHR
2563,16899458,tshr_human,403,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,0.127955,DA403N,TSHR
279,20305779,tshr_human,439,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,2.92181,LA439A,TSHR
2401,20305779,tshr_human,439,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,2.92181,LA439A,TSHR
280,16150909,tshr_human,652,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,1.01188,PA652A,TSHR
736,16150909,tshr_human,652,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,1.01188,PA652A,TSHR
837,16150909,tshr_human,652,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P16473,1.01188,PA652A,TSHR
281,16955277,tshr_human,621,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,-0.186266,KA621A,TSHR
1219,16955277,tshr_human,621,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,-0.186266,KA621A,TSHR
1560,16955277,tshr_human,621,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.186266,KA621A,TSHR
283,16150909,tshr_human,660,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.65188,KA660A,TSHR
2191,16150909,tshr_human,660,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,6.0,16.667,,,,0.0,0.0,,0.0,,P16473,0.65188,KA660A,TSHR
2674,16150909,tshr_human,660,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P16473,0.65188,KA660A,TSHR
288,21628383,tshr_human,381,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,0.414329,FA381A,TSHR
2409,21628383,tshr_human,381,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,0.414329,FA381A,TSHR
289,21525003,tshr_human,276,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,0.191604,DA276A,TSHR
2695,21525003,tshr_human,276,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.191604,DA276A,TSHR
293,20305779,tshr_human,443,H,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,-0.293129,HA443F,TSHR
2556,20305779,tshr_human,443,H,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-0.293129,HA443F,TSHR
294,16410307,tshr_human,478,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P16473,-0.013382,HA478A,TSHR
1992,16410307,tshr_human,478,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,-0.013382,HA478A,TSHR
301,16899458,tshr_human,409,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P16473,0.364224,EA409A,TSHR
347,16899458,tshr_human,409,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P16473,0.364224,EA409A,TSHR
404,23002040,tshr_human,409,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,0.364224,EA409A,TSHR
2181,23002040,tshr_human,409,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,0.364224,EA409A,TSHR
302,21525003,tshr_human,277,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,35.0,2.857,,,,0.0,0.0,,0.0,,P16473,3.73407,LA277A,TSHR
2129,21525003,tshr_human,277,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,3.73407,LA277A,TSHR
305,16955277,tshr_human,615,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.685843,PA615A,TSHR
432,16955277,tshr_human,615,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.685843,PA615A,TSHR
1282,16955277,tshr_human,615,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.685843,PA615A,TSHR
309,24608569,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
476,24608569,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
1216,18989620,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
1250,8964822,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
2152,18989620,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
2413,8964822,tshr_human,453,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,3.76131,MA453T,TSHR
311,20305779,tshr_human,441,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P16473,-0.250445,TA441A,TSHR
1801,20305779,tshr_human,441,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,-0.250445,TA441A,TSHR
312,17079233,tshr_human,567,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-1.16005,SA567A,TSHR
2742,17079233,tshr_human,567,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P16473,-1.16005,SA567A,TSHR
324,15817920,tshr_human,281,S,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,0.204733,SA281D,TSHR
714,15817920,tshr_human,281,S,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,0.204733,SA281D,TSHR
2112,15817920,tshr_human,281,S,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,59.0,1.695,,,,0.0,0.0,,0.0,,P16473,0.204733,SA281D,TSHR
2407,16410307,tshr_human,281,S,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P16473,0.204733,SA281D,TSHR
2423,16410307,tshr_human,281,S,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,0.204733,SA281D,TSHR
326,15498884,tshr_human,529,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,111.0,-1.11,,,,0.0,0.0,,0.0,,P16473,-0.179497,LA529A,TSHR
1890,15498884,tshr_human,529,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,-0.179497,LA529A,TSHR
2754,15498884,tshr_human,529,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P16473,-0.179497,LA529A,TSHR
344,7805857,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
593,7989485,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
1340,7805857,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
1461,7989485,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
2049,7805857,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
2771,7989485,tshr_human,632,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-1.47907,TA632I,TSHR
351,20305779,tshr_human,442,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P16473,-0.252294,SA442A,TSHR
546,20305779,tshr_human,442,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,-0.252294,SA442A,TSHR
353,18441013,tshr_human,382,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P16473,0.153544,DA382A,TSHR
713,18441013,tshr_human,382,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P16473,0.153544,DA382A,TSHR
787,19386596,tshr_human,382,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,0.153544,DA382A,TSHR
1860,19386596,tshr_human,382,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,0.153544,DA382A,TSHR
356,21525003,tshr_human,272,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,4.03224,LA272A,TSHR
2729,21525003,tshr_human,272,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,4.03224,LA272A,TSHR
362,16899458,tshr_human,400,P,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,3.0,33.333,,,,0.0,0.0,,0.0,,P16473,3.45023,PA400D,TSHR
370,23002040,tshr_human,410,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P16473,-0.597432,DA410A,TSHR
529,16899458,tshr_human,410,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,-0.597432,DA410A,TSHR
815,23002040,tshr_human,410,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,-0.597432,DA410A,TSHR
1208,16899458,tshr_human,410,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,-0.597432,DA410A,TSHR
388,20305779,tshr_human,445,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.311175,KA445A,TSHR
900,20305779,tshr_human,445,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,-0.311175,KA445A,TSHR
395,11095460,tshr_human,310,R,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,0.885341,RA310C,TSHR
397,16899458,tshr_human,287,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,173.0,-1.73,,,,0.0,0.0,,0.0,,P16473,0.0543671,KA287A,TSHR
937,16899458,tshr_human,287,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,0.0543671,KA287A,TSHR
1759,23002040,tshr_human,287,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,0.0543671,KA287A,TSHR
2314,23002040,tshr_human,287,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,0.0543671,KA287A,TSHR
401,19386596,tshr_human,297,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,-0.151239,EA297A,TSHR
765,18441013,tshr_human,297,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-0.151239,EA297A,TSHR
1136,19386596,tshr_human,297,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,-0.151239,EA297A,TSHR
1427,18441013,tshr_human,297,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,-0.151239,EA297A,TSHR
402,15498884,tshr_human,525,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,2.35498,FA525A,TSHR
580,15498884,tshr_human,525,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,2.35498,FA525A,TSHR
983,15498884,tshr_human,525,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,2.35498,FA525A,TSHR
403,16955277,tshr_human,622,I,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,1.48029,IA622D,TSHR
1511,16955277,tshr_human,622,I,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,1.48029,IA622D,TSHR
2055,16955277,tshr_human,622,I,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,1.48029,IA622D,TSHR
406,12062436,tshr_human,518,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,33.0,3.03,,,,0.0,0.0,,0.0,,P16473,-0.475102,EA518A,TSHR
418,10691307,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
645,18850313,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,26.0,3.846,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
1368,9806755,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
1826,9806755,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
1917,10691307,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
1971,10691307,tshr_human,601,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P16473,-1.8628,YA601F,TSHR
419,9854118,tshr_human,183,K,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.905754,KA183R,TSHR
420,18441013,tshr_human,369,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.651936,EA369A,TSHR
865,21525003,tshr_human,369,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P16473,0.651936,EA369A,TSHR
424,16899458,tshr_human,406,N,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,0.280782,NA406L,TSHR
2590,16899458,tshr_human,406,N,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,0.280782,NA406L,TSHR
443,20305779,tshr_human,449,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P16473,1.98862,PA449A,TSHR
994,20305779,tshr_human,449,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,1.98862,PA449A,TSHR
445,21628383,tshr_human,373,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,0.440864,PA373A,TSHR
450,21525003,tshr_human,268,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.0061687,SA268A,TSHR
2791,21525003,tshr_human,268,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-0.0061687,SA268A,TSHR
457,11549687,tshr_human,431,G,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.806323,GA431S,TSHR
534,11549687,tshr_human,431,G,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,131.0,-1.311,,,,0.0,0.0,,0.0,,P16473,0.806323,GA431S,TSHR
754,11549687,tshr_human,431,G,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,189.0,-1.89,,,,0.0,0.0,,0.0,,P16473,0.806323,GA431S,TSHR
1206,18989620,tshr_human,431,G,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,0.806323,GA431S,TSHR
2448,18989620,tshr_human,431,G,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,0.806323,GA431S,TSHR
464,18025759,tshr_human,617,D,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.277785,DA617Y,TSHR
721,18025759,tshr_human,617,D,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,0.277785,DA617Y,TSHR
467,11463854,tshr_human,633,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,46.0,2.174,,,,0.0,0.0,,0.0,,P16473,-0.256332,DA633N,TSHR
1331,11463854,tshr_human,633,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,-0.256332,DA633N,TSHR
1723,15722344,tshr_human,633,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,167.0,-1.669,,,,0.0,0.0,,0.0,,P16473,-0.256332,DA633N,TSHR
2418,11463854,tshr_human,633,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P16473,-0.256332,DA633N,TSHR
469,16990652,tshr_human,428,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,1.16865,AA428V,TSHR
474,20305779,tshr_human,448,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,2.06567,VA448A,TSHR
1394,20305779,tshr_human,448,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,2.06567,VA448A,TSHR
475,21628383,tshr_human,391,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,1.05987,GA391A,TSHR
481,16899458,tshr_human,400,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,3.12465,PA400L,TSHR
1030,16899458,tshr_human,400,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,3.0,33.333,,,,0.0,0.0,,0.0,,P16473,3.12465,PA400L,TSHR
501,16150909,tshr_human,654,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,2.13409,IA654A,TSHR
620,16150909,tshr_human,654,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,2.13409,IA654A,TSHR
2710,16150909,tshr_human,654,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,2.13409,IA654A,TSHR
503,9806755,tshr_human,601,Y,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P16473,2.96412,YA601D,TSHR
651,9806755,tshr_human,601,Y,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,2.96412,YA601D,TSHR
506,17079233,tshr_human,664,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,2.37934,VA664A,TSHR
969,17079233,tshr_human,664,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P16473,2.37934,VA664A,TSHR
514,15498884,tshr_human,527,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,0.511064,MA527A,TSHR
1765,15498884,tshr_human,527,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P16473,0.511064,MA527A,TSHR
2111,15498884,tshr_human,527,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,9.0,11.111,,,,0.0,0.0,,0.0,,P16473,0.511064,MA527A,TSHR
521,25978107,tshr_human,449,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,17.0,5.882,,,,0.0,0.0,,0.0,,P16473,1.15489,PA449L,TSHR
685,25978107,tshr_human,449,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,1.15489,PA449L,TSHR
522,8636266,tshr_human,670,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-1.20334,NA670S,TSHR
614,11463854,tshr_human,670,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,118.0,-1.181,,,,0.0,0.0,,0.0,,P16473,-1.20334,NA670S,TSHR
1553,8636266,tshr_human,670,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-1.20334,NA670S,TSHR
1754,11463854,tshr_human,670,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,11.0,9.091,,,,0.0,0.0,,0.0,,P16473,-1.20334,NA670S,TSHR
1779,11463854,tshr_human,670,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-1.20334,NA670S,TSHR
527,15876166,tshr_human,630,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.770745,IA630M,TSHR
1662,15876166,tshr_human,630,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,46.0,2.174,,,,0.0,0.0,,0.0,,P16473,-0.770745,IA630M,TSHR
1682,15876166,tshr_human,630,I,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P16473,-0.770745,IA630M,TSHR
532,20305779,tshr_human,438,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P16473,2.2681,IA438A,TSHR
1296,20305779,tshr_human,438,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,2.2681,IA438A,TSHR
535,21586576,tshr_human,642,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,0.411877,FA642I,TSHR
1944,21586576,tshr_human,642,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,0.411877,FA642I,TSHR
539,12950268,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,32.0,3.125,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
568,15817920,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
875,12950268,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,23.0,4.348,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
1882,12950268,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
2038,15817920,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
2711,15817920,tshr_human,477,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P16473,-1.15109,TA477I,TSHR
541,17079233,tshr_human,575,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,-0.377346,EA575A,TSHR
587,17079233,tshr_human,575,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,-0.377346,EA575A,TSHR
545,15876166,tshr_human,631,F,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.782638,FA631V,TSHR
1289,15876166,tshr_human,631,F,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.782638,FA631V,TSHR
2212,15876166,tshr_human,631,F,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.782638,FA631V,TSHR
547,21525003,tshr_human,255,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,1.64115,RA255A,TSHR
2113,21525003,tshr_human,255,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,1.64115,RA255A,TSHR
553,21525003,tshr_human,282,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,0.930878,HA282A,TSHR
559,16410307,tshr_human,476,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,0.362319,YA476A,TSHR
1304,16410307,tshr_human,476,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,0.362319,YA476A,TSHR
563,15498884,tshr_human,533,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,1.73053,IA533A,TSHR
1895,15498884,tshr_human,533,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,1.73053,IA533A,TSHR
2386,15498884,tshr_human,533,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,1.73053,IA533A,TSHR
565,21628383,tshr_human,381,F,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.226367,FA381Y,TSHR
2068,21628383,tshr_human,381,F,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,0.226367,FA381Y,TSHR
567,16488885,tshr_human,643,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,-0.705563,YA643F,TSHR
1594,20179143,tshr_human,643,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.705563,YA643F,TSHR
2066,20179143,tshr_human,643,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P16473,-0.705563,YA643F,TSHR
573,21525003,tshr_human,262,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,0.542903,KA262A,TSHR
2701,21525003,tshr_human,262,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,0.542903,KA262A,TSHR
577,9806755,tshr_human,601,Y,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,144.0,-1.441,,,,0.0,0.0,,0.0,,P16473,-1.14192,YA601W,TSHR
2604,9806755,tshr_human,601,Y,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-1.14192,YA601W,TSHR
578,20305779,tshr_human,440,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,1.3467,LA440A,TSHR
2475,20305779,tshr_human,440,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,1.3467,LA440A,TSHR
585,21628383,tshr_human,311,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,-0.168475,QA311A,TSHR
850,21525003,tshr_human,311,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,145.0,-1.449,,,,0.0,0.0,,0.0,,P16473,-0.168475,QA311A,TSHR
590,17079233,tshr_human,470,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P16473,1.28017,IA470V,TSHR
2493,17079233,tshr_human,470,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,1.28017,IA470V,TSHR
595,21525003,tshr_human,289,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,-0.198536,QA289A,TSHR
693,16899458,tshr_human,289,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,-0.198536,QA289A,TSHR
602,11463854,tshr_human,633,D,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-0.934867,DA633C,TSHR
1719,11463854,tshr_human,633,D,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.934867,DA633C,TSHR
1870,11463854,tshr_human,633,D,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P16473,-0.934867,DA633C,TSHR
603,17079233,tshr_human,564,A,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,1.33757,AA564F,TSHR
680,17079233,tshr_human,564,A,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P16473,1.33757,AA564F,TSHR
605,17079233,tshr_human,574,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.392648,TA574A,TSHR
842,17079233,tshr_human,574,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,0.392648,TA574A,TSHR
607,20652618,tshr_human,502,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,1.86189,VA502A,TSHR
1804,20652618,tshr_human,502,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P16473,1.86189,VA502A,TSHR
611,21525003,tshr_human,267,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P16473,0.714143,LA267V,TSHR
1545,21525003,tshr_human,267,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,0.714143,LA267V,TSHR
619,21525003,tshr_human,375,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,1.84672,EA375A,TSHR
2587,18441013,tshr_human,375,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,1.84672,EA375A,TSHR
621,18381815,tshr_human,490,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,0.431385,TA490A,TSHR
628,18381815,tshr_human,568,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,0.767001,IA568V,TSHR
1572,17079233,tshr_human,568,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,0.767001,IA568V,TSHR
2125,17079233,tshr_human,568,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,0.767001,IA568V,TSHR
639,21628383,tshr_human,381,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,0.246487,FA381I,TSHR
1457,21628383,tshr_human,381,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.246487,FA381I,TSHR
649,15498884,tshr_human,531,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,0.60603,RA531A,TSHR
2014,15498884,tshr_human,531,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P16473,0.60603,RA531A,TSHR
2780,15498884,tshr_human,531,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.60603,RA531A,TSHR
654,21628383,tshr_human,286,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,3.59141,FA286A,TSHR
2110,21628383,tshr_human,286,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P16473,3.59141,FA286A,TSHR
658,17079233,tshr_human,561,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,0.656214,SA561A,TSHR
2580,17079233,tshr_human,561,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,0.656214,SA561A,TSHR
663,20179143,tshr_human,645,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.06593,LA645V,TSHR
1769,20179143,tshr_human,645,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,1.06593,LA645V,TSHR
668,15722344,tshr_human,456,L,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,4.96888,LA456W,TSHR
671,15722344,tshr_human,674,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,169.0,-1.689,,,,0.0,0.0,,0.0,,P16473,4.48441,NA674D,TSHR
1439,11463854,tshr_human,674,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,4.48441,NA674D,TSHR
1583,11463854,tshr_human,674,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P16473,4.48441,NA674D,TSHR
2808,11463854,tshr_human,674,N,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,4.48441,NA674D,TSHR
672,22112806,tshr_human,639,P,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,3.12001,PA639G,TSHR
1607,22112806,tshr_human,639,P,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,3.12001,PA639G,TSHR
674,16899458,tshr_human,404,E,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,161.0,-1.61,,,,0.0,0.0,,0.0,,P16473,0.299373,EA404S,TSHR
1527,16899458,tshr_human,404,E,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.299373,EA404S,TSHR
676,22112806,tshr_human,636,C,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P16473,1.32792,CA636R,TSHR
1640,22112806,tshr_human,636,C,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,200.0,-2.0,,,,0.0,0.0,,0.0,,P16473,1.32792,CA636R,TSHR
683,21525003,tshr_human,312,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,136.0,-1.361,,,,0.0,0.0,,0.0,,P16473,0.31726,RA312A,TSHR
2118,18441013,tshr_human,312,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,0.31726,RA312A,TSHR
692,19386596,tshr_human,297,E,Q,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,-0.234432,EA297Q,TSHR
1171,18441013,tshr_human,297,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.234432,EA297Q,TSHR
2151,18441013,tshr_human,297,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-0.234432,EA297Q,TSHR
2365,19386596,tshr_human,297,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,46.0,2.174,,,,0.0,0.0,,0.0,,P16473,-0.234432,EA297Q,TSHR
709,9360555,tshr_human,505,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,-0.544538,SA505N,TSHR
2040,9360555,tshr_human,505,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,-0.544538,SA505N,TSHR
2077,11012571,tshr_human,505,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P16473,-0.544538,SA505N,TSHR
2700,11012571,tshr_human,505,S,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.544538,SA505N,TSHR
712,11847099,tshr_human,387,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.024027,YA387F,TSHR
718,21586576,tshr_human,644,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.979259,AA644V,TSHR
2751,21586576,tshr_human,644,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,-0.979259,AA644V,TSHR
722,22112806,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
950,9467563,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,54.0,1.852,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
1931,12950268,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
2202,22112806,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
2242,12950268,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,114.0,-1.14,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
2714,12950268,tshr_human,639,P,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,207.0,-2.07,,,,0.0,0.0,,0.0,,P16473,3.30817,PA639S,TSHR
730,16756469,tshr_human,473,V,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.618029,VA473I,TSHR
2303,16756469,tshr_human,473,V,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,-0.618029,VA473I,TSHR
2530,16756469,tshr_human,473,V,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.618029,VA473I,TSHR
733,16955277,tshr_human,606,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,0.202526,IA606A,TSHR
2525,16955277,tshr_human,606,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,0.202526,IA606A,TSHR
2723,16955277,tshr_human,606,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,135.0,-1.35,,,,0.0,0.0,,0.0,,P16473,0.202526,IA606A,TSHR
734,20652618,tshr_human,467,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,2.90267,LA467V,TSHR
2320,20652618,tshr_human,467,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,2.90267,LA467V,TSHR
739,17079233,tshr_human,568,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,128.0,-1.28,,,,0.0,0.0,,0.0,,P16473,-1.12419,IA568F,TSHR
2518,17079233,tshr_human,568,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,-1.12419,IA568F,TSHR
742,10560955,tshr_human,597,V,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.8399,VA597L,TSHR
1257,10560955,tshr_human,597,V,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-0.8399,VA597L,TSHR
1276,12062436,tshr_human,597,V,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-0.8399,VA597L,TSHR
757,16410307,tshr_human,279,Y,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,0.152889,YA279W,TSHR
1848,16410307,tshr_human,279,Y,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,0.152889,YA279W,TSHR
760,21525003,tshr_human,265,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,0.61022,LA265V,TSHR
1273,21525003,tshr_human,265,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,0.61022,LA265V,TSHR
768,21628383,tshr_human,389,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.0245947,IA389V,TSHR
790,11463854,tshr_human,633,D,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,115.0,-1.149,,,,0.0,0.0,,0.0,,P16473,-1.75737,DA633H,TSHR
1529,11463854,tshr_human,633,D,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-1.75737,DA633H,TSHR
1536,11463854,tshr_human,633,D,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,-1.75737,DA633H,TSHR
793,17079233,tshr_human,568,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,55.0,1.818,,,,0.0,0.0,,0.0,,P16473,2.44775,IA568A,TSHR
1021,17079233,tshr_human,568,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,4.0,25.0,,,,0.0,0.0,,0.0,,P16473,2.44775,IA568A,TSHR
797,16079263,tshr_human,509,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.0223557,VA509A,TSHR
799,17725428,tshr_human,107,E,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.655478,EA107A,TSHR
893,17725428,tshr_human,107,E,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.655478,EA107A,TSHR
802,20305779,tshr_human,687,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,33.0,3.03,,,,0.0,0.0,,0.0,,P16473,0.546851,RA687A,TSHR
1407,20305779,tshr_human,687,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.546851,RA687A,TSHR
803,21525003,tshr_human,263,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,3.94199,LA263A,TSHR
1543,21525003,tshr_human,263,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,3.94199,LA263A,TSHR
807,17079233,tshr_human,640,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,-0.0914052,IA640L,TSHR
2279,17079233,tshr_human,640,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-0.0914052,IA640L,TSHR
809,17725428,tshr_human,82,Y,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.65013,YA82A,TSHR
2389,17725428,tshr_human,82,Y,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.65013,YA82A,TSHR
816,15722344,tshr_human,625,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P16473,1.25018,RA625A,TSHR
820,16150909,tshr_human,660,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,2.01383,KA660E,TSHR
2557,16150909,tshr_human,660,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P16473,2.01383,KA660E,TSHR
2798,16150909,tshr_human,660,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,2.01383,KA660E,TSHR
827,20179143,tshr_human,641,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,-0.0717475,SA641A,TSHR
829,20305779,tshr_human,450,R,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,-0.266062,RA450M,TSHR
1191,20305779,tshr_human,450,R,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P16473,-0.266062,RA450M,TSHR
833,9806755,tshr_human,605,Y,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,0.406871,YA605H,TSHR
2691,9806755,tshr_human,605,Y,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,149.0,-1.49,,,,0.0,0.0,,0.0,,P16473,0.406871,YA605H,TSHR
851,16899458,tshr_human,407,P,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,2.19384,PA407K,TSHR
936,16899458,tshr_human,407,P,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P16473,2.19384,PA407K,TSHR
862,16955277,tshr_human,605,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P16473,-0.187867,YA605A,TSHR
1047,9806755,tshr_human,605,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,252.0,-2.519,,,,0.0,0.0,,0.0,,P16473,-0.187867,YA605A,TSHR
1595,16955277,tshr_human,605,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.187867,YA605A,TSHR
1989,16955277,tshr_human,605,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,-0.187867,YA605A,TSHR
2466,9806755,tshr_human,605,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,-0.187867,YA605A,TSHR
868,21525003,tshr_human,271,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,0.238693,HA271A,TSHR
2605,21525003,tshr_human,271,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.238693,HA271A,TSHR
872,16150909,tshr_human,657,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,-0.514012,SA657A,TSHR
1402,16150909,tshr_human,657,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,-0.514012,SA657A,TSHR
1424,16150909,tshr_human,657,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-0.514012,SA657A,TSHR
877,16150909,tshr_human,655,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.628709,TA655A,TSHR
948,16150909,tshr_human,655,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P16473,-0.628709,TA655A,TSHR
1679,16150909,tshr_human,655,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-0.628709,TA655A,TSHR
882,17079233,tshr_human,572,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,3.10043,MA572A,TSHR
2031,17079233,tshr_human,572,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,3.10043,MA572A,TSHR
2074,18850313,tshr_human,572,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P16473,3.10043,MA572A,TSHR
886,16955277,tshr_human,618,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-0.170564,KA618A,TSHR
1004,16955277,tshr_human,618,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,-0.170564,KA618A,TSHR
1833,16955277,tshr_human,618,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,-0.170564,KA618A,TSHR
887,11549687,tshr_human,431,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P16473,-0.625955,GA431A,TSHR
1151,11549687,tshr_human,431,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,-0.625955,GA431A,TSHR
1842,11549687,tshr_human,431,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,164.0,-1.639,,,,0.0,0.0,,0.0,,P16473,-0.625955,GA431A,TSHR
889,12062436,tshr_human,518,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,-0.581332,EA518Q,TSHR
890,16899458,tshr_human,400,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P16473,2.93365,PA400A,TSHR
1810,16899458,tshr_human,400,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,2.93365,PA400A,TSHR
895,21586576,tshr_human,593,A,P,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,3.24476,AA593P,TSHR
919,20736161,tshr_human,84,S,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,145.0,-1.449,,,,0.0,0.0,,0.0,,P16473,-0.796338,SA84A,TSHR
925,21628383,tshr_human,299,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P16473,0.461227,LA299A,TSHR
1344,21628383,tshr_human,299,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,0.461227,LA299A,TSHR
928,9398745,tshr_human,630,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P16473,-0.854069,IA630L,TSHR
1820,9398745,tshr_human,630,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,-0.854069,IA630L,TSHR
2302,9467563,tshr_human,630,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,-0.854069,IA630L,TSHR
2428,11012571,tshr_human,630,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,-0.854069,IA630L,TSHR
2606,11012571,tshr_human,630,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.854069,IA630L,TSHR
932,21586576,tshr_human,594,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,41.0,2.439,,,,0.0,0.0,,0.0,,P16473,0.895537,FA594I,TSHR
1181,21586576,tshr_human,594,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,0.895537,FA594I,TSHR
934,18727713,tshr_human,34,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,1.29313,EA34K,TSHR
954,21525003,tshr_human,305,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,-0.49022,SA305A,TSHR
1904,21628383,tshr_human,305,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,-0.49022,SA305A,TSHR
962,16955277,tshr_human,616,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,-0.246151,GA616A,TSHR
1264,16955277,tshr_human,616,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,-0.246151,GA616A,TSHR
2718,16955277,tshr_human,616,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,155.0,-1.55,,,,0.0,0.0,,0.0,,P16473,-0.246151,GA616A,TSHR
968,16410307,tshr_human,279,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,2.57528,YA279N,TSHR
2240,16410307,tshr_human,279,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P16473,2.57528,YA279N,TSHR
975,9294132,tshr_human,281,S,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-1.85085,SA281I,TSHR
1315,16410307,tshr_human,281,S,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-1.85085,SA281I,TSHR
1575,9294132,tshr_human,281,S,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-1.85085,SA281I,TSHR
1921,16410307,tshr_human,281,S,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,-1.85085,SA281I,TSHR
979,17725428,tshr_human,58,K,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.09619,KA58A,TSHR
1954,17725428,tshr_human,58,K,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.09619,KA58A,TSHR
985,11549687,tshr_human,431,G,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,155.0,-1.55,,,,0.0,0.0,,0.0,,P16473,-0.368323,GA431C,TSHR
1103,11549687,tshr_human,431,G,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,-0.368323,GA431C,TSHR
1717,11549687,tshr_human,431,G,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.368323,GA431C,TSHR
992,21525003,tshr_human,269,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P16473,5.04797,FA269A,TSHR
2375,21525003,tshr_human,269,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,5.04797,FA269A,TSHR
995,20305779,tshr_human,446,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P16473,2.25069,LA446A,TSHR
2359,20305779,tshr_human,446,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,2.25069,LA446A,TSHR
1012,16410307,tshr_human,281,S,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P16473,0.44681,SA281Y,TSHR
1625,16410307,tshr_human,281,S,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,0.44681,SA281Y,TSHR
1015,17079233,tshr_human,565,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,0.691951,KA565A,TSHR
1593,17079233,tshr_human,565,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,14.0,7.143,,,,0.0,0.0,,0.0,,P16473,0.691951,KA565A,TSHR
1018,21586576,tshr_human,583,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P16473,0.636376,IA583V,TSHR
1019,17079233,tshr_human,640,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,18.0,5.556,,,,0.0,0.0,,0.0,,P16473,-0.0226855,IA640F,TSHR
1194,17079233,tshr_human,640,I,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,55.0,1.818,,,,0.0,0.0,,0.0,,P16473,-0.0226855,IA640F,TSHR
1027,7805857,tshr_human,633,D,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,-2.63304,DA633Y,TSHR
1628,7805857,tshr_human,633,D,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-2.63304,DA633Y,TSHR
1878,7805857,tshr_human,633,D,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-2.63304,DA633Y,TSHR
1034,20652618,tshr_human,643,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,1.21048,YA643A,TSHR
2788,20652618,tshr_human,643,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,1.21048,YA643A,TSHR
1035,20736161,tshr_human,130,F,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,3.53167,FA130A,TSHR
1041,12589819,tshr_human,593,A,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,126.0,-1.259,,,,0.0,0.0,,0.0,,P16473,-0.983702,AA593N,TSHR
1042,21835055,tshr_human,486,I,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,1.95938,IA486N,TSHR
2496,16990652,tshr_human,486,I,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,1.95938,IA486N,TSHR
2502,21835055,tshr_human,486,I,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,1.95938,IA486N,TSHR
1048,21525003,tshr_human,275,A,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P16473,2.38587,AA275L,TSHR
2616,21525003,tshr_human,275,A,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,2.38587,AA275L,TSHR
1053,17079233,tshr_human,417,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,1.47104,LA417V,TSHR
2308,17079233,tshr_human,417,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,1.47104,LA417V,TSHR
1054,17725428,tshr_human,109,R,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.46063,RA109A,TSHR
1684,17725428,tshr_human,109,R,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.46063,RA109A,TSHR
1060,11517004,tshr_human,597,V,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,2.65833,VA597F,TSHR
1066,21628383,tshr_human,383,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,115.0,-1.149,,,,0.0,0.0,,0.0,,P16473,-0.612926,SA383A,TSHR
2421,21525003,tshr_human,383,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,-0.612926,SA383A,TSHR
1089,15531543,tshr_human,252,L,P,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P16473,8.80927,LA252P,TSHR
2405,15531543,tshr_human,252,L,P,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,8.80927,LA252P,TSHR
1095,16955277,tshr_human,613,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,3.25621,YA613A,TSHR
1143,16955277,tshr_human,613,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,3.25621,YA613A,TSHR
1990,16955277,tshr_human,613,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,3.25621,YA613A,TSHR
1097,21525003,tshr_human,259,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,-0.934506,TA259A,TSHR
1227,21525003,tshr_human,259,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-0.934506,TA259A,TSHR
1104,18727713,tshr_human,27,P,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,1.00577,PA27T,TSHR
1106,8954020,tshr_human,410,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.870323,DA410N,TSHR
1550,8954020,tshr_human,410,D,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,28.0,3.571,,,,0.0,0.0,,0.0,,P16473,0.870323,DA410N,TSHR
1107,15722344,tshr_human,633,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,125.0,-1.25,,,,0.0,0.0,,0.0,,P16473,-1.38731,DA633A,TSHR
2033,12062436,tshr_human,633,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,-1.38731,DA633A,TSHR
1110,16899458,tshr_human,291,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,0.172274,KA291A,TSHR
1670,23002040,tshr_human,291,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,0.172274,KA291A,TSHR
2017,16899458,tshr_human,291,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,142.0,-1.42,,,,0.0,0.0,,0.0,,P16473,0.172274,KA291A,TSHR
2194,23002040,tshr_human,291,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,0.172274,KA291A,TSHR
1124,15722344,tshr_human,632,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,145.0,-1.449,,,,0.0,0.0,,0.0,,P16473,-0.108573,TA632A,TSHR
1584,12062436,tshr_human,632,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,-0.108573,TA632A,TSHR
1126,21628383,tshr_human,387,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,0.203852,YA387A,TSHR
1128,9806755,tshr_human,601,Y,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,65.0,1.538,,,,0.0,0.0,,0.0,,P16473,2.81908,YA601S,TSHR
2189,9806755,tshr_human,601,Y,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P16473,2.81908,YA601S,TSHR
1133,21628383,tshr_human,380,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,0.220572,AA380V,TSHR
1140,17725428,tshr_human,60,I,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,2.0773,IA60A,TSHR
1306,17725428,tshr_human,60,I,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,2.0773,IA60A,TSHR
1144,9806755,tshr_human,601,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,2.41343,YA601A,TSHR
1937,9806755,tshr_human,601,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,2.41343,YA601A,TSHR
1147,21525003,tshr_human,376,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P16473,-0.0329144,EA376A,TSHR
2058,18441013,tshr_human,376,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,-0.0329144,EA376A,TSHR
1153,21628383,tshr_human,288,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.144341,NA288S,TSHR
2182,21628383,tshr_human,288,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,76.0,1.316,,,,0.0,0.0,,0.0,,P16473,0.144341,NA288S,TSHR
1154,21525003,tshr_human,270,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.559719,LA270V,TSHR
2063,21525003,tshr_human,270,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.559719,LA270V,TSHR
1156,21628383,tshr_human,286,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,29.0,3.448,,,,0.0,0.0,,0.0,,P16473,4.95142,FA286I,TSHR
2434,21628383,tshr_human,286,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,4.95142,FA286I,TSHR
1173,21628383,tshr_human,394,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,59.0,1.695,,,,0.0,0.0,,0.0,,P16473,0.378326,EA394A,TSHR
2070,21525003,tshr_human,394,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P16473,0.378326,EA394A,TSHR
2476,21628383,tshr_human,394,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,0.378326,EA394A,TSHR
2520,18441013,tshr_human,394,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,0.378326,EA394A,TSHR
1183,19386596,tshr_human,303,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,-0.189744,EA303K,TSHR
1745,19386596,tshr_human,303,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-0.189744,EA303K,TSHR
1188,23002040,tshr_human,392,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,129.0,-1.29,,,,0.0,0.0,,0.0,,P16473,0.198793,DA392A,TSHR
1325,23002040,tshr_human,392,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P16473,0.198793,DA392A,TSHR
2282,21628383,tshr_human,392,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,0.198793,DA392A,TSHR
2671,21628383,tshr_human,392,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,0.198793,DA392A,TSHR
1196,20305779,tshr_human,450,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,1.32486,RA450A,TSHR
1450,20305779,tshr_human,450,R,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P16473,1.32486,RA450A,TSHR
1201,15722344,tshr_human,460,D,N,"P01217, P01223",UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P16473,-0.258267,DA460N,TSHR
1203,15498884,tshr_human,532,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,0.490767,KA532A,TSHR
1523,15498884,tshr_human,532,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,67.0,1.493,,,,0.0,0.0,,0.0,,P16473,0.490767,KA532A,TSHR
2333,15498884,tshr_human,532,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,0.490767,KA532A,TSHR
1209,21628383,tshr_human,368,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,0.0617821,QA368A,TSHR
2083,21525003,tshr_human,368,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,0.0617821,QA368A,TSHR
1214,15345720,tshr_human,403,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,-0.478867,DA403A,TSHR
1410,15345720,tshr_human,403,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P16473,-0.478867,DA403A,TSHR
2730,15345720,tshr_human,403,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,35.0,2.857,,,,0.0,0.0,,0.0,,P16473,-0.478867,DA403A,TSHR
1248,22112806,tshr_human,636,C,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,-2.36663,CA636F,TSHR
2707,22112806,tshr_human,636,C,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P16473,-2.36663,CA636F,TSHR
1252,21628383,tshr_human,299,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,0.518915,LA299V,TSHR
2238,21628383,tshr_human,299,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,0.518915,LA299V,TSHR
1259,20736161,tshr_human,157,E,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,2.14158,EA157A,TSHR
1262,18441013,tshr_human,303,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.285172,EA303Q,TSHR
1477,18441013,tshr_human,303,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,-0.285172,EA303Q,TSHR
1811,19386596,tshr_human,303,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,-0.285172,EA303Q,TSHR
2345,19386596,tshr_human,303,E,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.285172,EA303Q,TSHR
1268,21628383,tshr_human,286,F,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,2.03305,FA286W,TSHR
1549,21628383,tshr_human,286,F,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,2.03305,FA286W,TSHR
1270,16899458,tshr_human,403,D,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,-0.197699,DA403L,TSHR
1468,16899458,tshr_human,403,D,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,-0.197699,DA403L,TSHR
1279,21628383,tshr_human,298,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-0.00582238,SA298A,TSHR
2002,21525003,tshr_human,298,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P16473,-0.00582238,SA298A,TSHR
1288,22112806,tshr_human,636,C,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,-0.0363146,CA636A,TSHR
2156,22112806,tshr_human,636,C,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-0.0363146,CA636A,TSHR
1302,8636266,tshr_human,650,N,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,115.0,-1.149,,,,0.0,0.0,,0.0,,P16473,0.116604,NA650Y,TSHR
1532,8636266,tshr_human,650,N,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.116604,NA650Y,TSHR
2805,8636266,tshr_human,650,N,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,130.0,-1.3,,,,0.0,0.0,,0.0,,P16473,0.116604,NA650Y,TSHR
1313,17079233,tshr_human,573,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,-0.0307797,DA573A,TSHR
2447,17079233,tshr_human,573,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,-0.0307797,DA573A,TSHR
1323,21628383,tshr_human,288,N,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,-0.386525,NA288L,TSHR
1908,21628383,tshr_human,288,N,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,-0.386525,NA288L,TSHR
1341,17079233,tshr_human,562,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.390418,SA562A,TSHR
1766,17079233,tshr_human,562,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,15.0,6.667,,,,0.0,0.0,,0.0,,P16473,0.390418,SA562A,TSHR
1354,22112806,tshr_human,639,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,2.4699,PA639A,TSHR
2393,22112806,tshr_human,639,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,2.4699,PA639A,TSHR
1364,16955277,tshr_human,607,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.236658,TA607A,TSHR
1465,16955277,tshr_human,607,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,145.0,-1.449,,,,0.0,0.0,,0.0,,P16473,-0.236658,TA607A,TSHR
1851,16955277,tshr_human,607,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-0.236658,TA607A,TSHR
1367,16150909,tshr_human,653,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.408221,LA653A,TSHR
1709,16150909,tshr_human,653,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,18.0,5.556,,,,0.0,0.0,,0.0,,P16473,0.408221,LA653A,TSHR
2562,16150909,tshr_human,653,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,0.408221,LA653A,TSHR
1369,16410307,tshr_human,481,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P16473,1.91837,YA481N,TSHR
2277,16410307,tshr_human,481,Y,N,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P16473,1.91837,YA481N,TSHR
1375,19386596,tshr_human,303,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-0.00351026,EA303A,TSHR
1485,18441013,tshr_human,303,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,-0.00351026,EA303A,TSHR
2226,18441013,tshr_human,303,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,-0.00351026,EA303A,TSHR
2440,19386596,tshr_human,303,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.00351026,EA303A,TSHR
1387,21628383,tshr_human,285,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.41355,AA285V,TSHR
1396,16410307,tshr_human,281,S,P,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,-3.28072,SA281P,TSHR
2241,16410307,tshr_human,281,S,P,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-3.28072,SA281P,TSHR
1401,21525003,tshr_human,260,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,2.92958,LA260A,TSHR
2668,21525003,tshr_human,260,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,17.0,5.882,,,,0.0,0.0,,0.0,,P16473,2.92958,LA260A,TSHR
1419,20501679,tshr_human,636,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,-1.03782,CA636W,TSHR
2567,20501679,tshr_human,636,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-1.03782,CA636W,TSHR
2657,20501679,tshr_human,636,C,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,-1.03782,CA636W,TSHR
1423,21628383,tshr_human,381,F,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,0.463905,FA381V,TSHR
2402,21628383,tshr_human,381,F,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,38.0,2.632,,,,0.0,0.0,,0.0,,P16473,0.463905,FA381V,TSHR
1443,21525003,tshr_human,272,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,2.61973,LA272V,TSHR
2218,21525003,tshr_human,272,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,2.61973,LA272V,TSHR
1444,21525003,tshr_human,260,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,3.26538,LA260V,TSHR
1993,21525003,tshr_human,260,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,3.26538,LA260V,TSHR
1463,21628383,tshr_human,315,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P16473,-0.0709021,VA315A,TSHR
1479,17079233,tshr_human,566,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,1.62603,VA566A,TSHR
1743,17079233,tshr_human,566,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,1.62603,VA566A,TSHR
1490,9589634,tshr_human,528,R,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,59.0,1.695,,,,0.0,0.0,,0.0,,P16473,0.50452,RA528H,TSHR
2268,9589634,tshr_human,528,R,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,112.0,-1.12,,,,0.0,0.0,,0.0,,P16473,0.50452,RA528H,TSHR
2644,9589634,tshr_human,528,R,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,0.50452,RA528H,TSHR
1491,20179143,tshr_human,466,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,20.0,5.0,,,,0.0,0.0,,0.0,,P16473,4.26074,YA466A,TSHR
2489,20179143,tshr_human,466,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,4.26074,YA466A,TSHR
1498,16410307,tshr_human,281,S,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,-0.762963,SA281C,TSHR
1547,16410307,tshr_human,281,S,C,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P16473,-0.762963,SA281C,TSHR
1515,21586576,tshr_human,593,A,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,1.43571,AA593G,TSHR
1531,16990652,tshr_human,627,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,54.0,1.852,,,,0.0,0.0,,0.0,,P16473,0.206705,AA627V,TSHR
1534,21628383,tshr_human,378,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.112593,LA378V,TSHR
1537,11463854,tshr_human,508,S,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,31.0,3.226,,,,0.0,0.0,,0.0,,P16473,0.719885,SA508G,TSHR
2355,11463854,tshr_human,508,S,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,0.719885,SA508G,TSHR
2770,11463854,tshr_human,508,S,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,0.719885,SA508G,TSHR
1541,18381815,tshr_human,489,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P16473,0.423186,QA489A,TSHR
1555,16150909,tshr_human,659,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,118.0,-1.181,,,,0.0,0.0,,0.0,,P16473,-0.332561,SA659A,TSHR
1660,16150909,tshr_human,659,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,-0.332561,SA659A,TSHR
1690,16150909,tshr_human,659,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-0.332561,SA659A,TSHR
1561,16410307,tshr_human,279,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,7.0,14.286,,,,0.0,0.0,,0.0,,P16473,1.94501,YA279A,TSHR
1953,16410307,tshr_human,279,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,31.0,3.226,,,,0.0,0.0,,0.0,,P16473,1.94501,YA279A,TSHR
1562,20736161,tshr_human,136,T,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,1.3936,TA136A,TSHR
1570,11463854,tshr_human,633,D,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-4.88267,DA633W,TSHR
2154,11463854,tshr_human,633,D,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-4.88267,DA633W,TSHR
2487,11463854,tshr_human,633,D,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,-4.88267,DA633W,TSHR
1573,21525003,tshr_human,313,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,61.0,1.639,,,,0.0,0.0,,0.0,,P16473,0.428712,KA313A,TSHR
2442,18441013,tshr_human,313,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,0.428712,KA313A,TSHR
1588,21628383,tshr_human,307,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.348801,QA307A,TSHR
1601,20652618,tshr_human,665,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P16473,0.847442,LA665V,TSHR
1897,20652618,tshr_human,665,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.847442,LA665V,TSHR
1605,18727713,tshr_human,527,M,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,0.761361,MA527T,TSHR
1608,11463854,tshr_human,674,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P16473,0.823022,NA674S,TSHR
2488,11463854,tshr_human,674,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P16473,0.823022,NA674S,TSHR
2684,11463854,tshr_human,674,N,S,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,18.0,5.556,,,,0.0,0.0,,0.0,,P16473,0.823022,NA674S,TSHR
1615,15498884,tshr_human,527,M,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,9.0,11.111,,,,0.0,0.0,,0.0,,P16473,-0.229487,MA527K,TSHR
1995,15498884,tshr_human,527,M,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,21.0,4.762,,,,0.0,0.0,,0.0,,P16473,-0.229487,MA527K,TSHR
2688,15498884,tshr_human,527,M,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,140.0,-1.401,,,,0.0,0.0,,0.0,,P16473,-0.229487,MA527K,TSHR
1642,16410307,tshr_human,281,S,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,111.0,-1.11,,,,0.0,0.0,,0.0,,P16473,-0.891693,SA281H,TSHR
2501,16410307,tshr_human,281,S,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,-0.891693,SA281H,TSHR
1646,18381815,tshr_human,480,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,-0.0406641,EA480A,TSHR
1655,21628383,tshr_human,396,M,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,1.51357,MA396V,TSHR
1657,18381815,tshr_human,487,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,0.0856664,DA487A,TSHR
1669,18381815,tshr_human,479,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,0.753266,SA479A,TSHR
1671,17456567,tshr_human,162,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,1.23747,PA162A,TSHR
2337,17456567,tshr_human,162,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,1.23747,PA162A,TSHR
2721,17456567,tshr_human,162,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,26.0,3.846,,,,0.0,0.0,,0.0,,P16473,1.23747,PA162A,TSHR
1686,21586576,tshr_human,638,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,22.0,4.545,,,,0.0,0.0,,0.0,,P16473,0.272766,AA638V,TSHR
2020,21586576,tshr_human,638,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,0.272766,AA638V,TSHR
1693,16955277,tshr_human,608,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,1.16386,VA608A,TSHR
1821,16955277,tshr_human,608,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,1.16386,VA608A,TSHR
2522,16955277,tshr_human,608,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P16473,1.16386,VA608A,TSHR
1699,16899458,tshr_human,407,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,2.51962,PA407A,TSHR
2692,16899458,tshr_human,407,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,2.51962,PA407A,TSHR
1707,20179143,tshr_human,637,M,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.406077,MA637W,TSHR
1998,20179143,tshr_human,637,M,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.406077,MA637W,TSHR
1710,19499991,tshr_human,635,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,125.0,-1.25,,,,0.0,0.0,,0.0,,P16473,1.01958,IA635V,TSHR
1957,19499991,tshr_human,635,I,V,recombinant thyrotropin,ChEMBL Compound ID,,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,1.01958,IA635V,TSHR
1713,16410307,tshr_human,482,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,0.737825,YA482A,TSHR
2543,16410307,tshr_human,482,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,74.0,1.351,,,,0.0,0.0,,0.0,,P16473,0.737825,YA482A,TSHR
1715,18381815,tshr_human,486,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,1.97446,IA486A,TSHR
1735,15498884,tshr_human,530,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,0.17432,DA530A,TSHR
1750,15498884,tshr_human,530,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,0.17432,DA530A,TSHR
2140,15498884,tshr_human,530,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,0.17432,DA530A,TSHR
1739,16955277,tshr_human,620,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.239455,TA620A,TSHR
2006,16955277,tshr_human,620,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,-0.239455,TA620A,TSHR
2100,16955277,tshr_human,620,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,-0.239455,TA620A,TSHR
1746,21628383,tshr_human,295,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,0.606754,IA295V,TSHR
1758,20736161,tshr_human,80,R,E,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,0.797459,RA80E,TSHR
1767,17079233,tshr_human,570,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,2.34799,LA570A,TSHR
2319,17079233,tshr_human,570,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,17.0,5.882,,,,0.0,0.0,,0.0,,P16473,2.34799,LA570A,TSHR
1775,20736161,tshr_human,234,S,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,1.01893,SA234A,TSHR
1784,17725428,tshr_human,61,E,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,0.495662,EA61A,TSHR
1834,17725428,tshr_human,61,E,A,porcine thyrotropin,UniProt Entry Code (peptide),"P01219, P01224",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,0.495662,EA61A,TSHR
1785,21525003,tshr_human,261,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P16473,0.678876,KA261A,TSHR
1805,21525003,tshr_human,261,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,41.0,2.439,,,,0.0,0.0,,0.0,,P16473,0.678876,KA261A,TSHR
1808,15722344,tshr_human,460,D,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,19.0,5.263,,,,0.0,0.0,,0.0,,P16473,-0.739124,DA460A,TSHR
1814,21525003,tshr_human,374,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,56.0,1.786,,,,0.0,0.0,,0.0,,P16473,0.589816,QA374A,TSHR
2042,21628383,tshr_human,374,Q,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,0.589816,QA374A,TSHR
1825,17079233,tshr_human,640,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,1.2202,IA640V,TSHR
1830,16410307,tshr_human,281,S,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,-0.189815,SA281W,TSHR
2346,16410307,tshr_human,281,S,W,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-0.189815,SA281W,TSHR
1840,21628383,tshr_human,388,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.338902,TA388A,TSHR
1846,16150909,tshr_human,409,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,24.0,4.167,,,,0.0,0.0,,0.0,,P16473,-0.733346,EA409K,TSHR
1883,16150909,tshr_human,409,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,8.0,12.5,,,,0.0,0.0,,0.0,,P16473,-0.733346,EA409K,TSHR
2211,16150909,tshr_human,409,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-0.733346,EA409K,TSHR
1871,15345720,tshr_human,404,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.0616389,EA404A,TSHR
2048,15345720,tshr_human,404,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,116.0,-1.16,,,,0.0,0.0,,0.0,,P16473,-0.0616389,EA404A,TSHR
2663,15345720,tshr_human,404,E,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,121.0,-1.211,,,,0.0,0.0,,0.0,,P16473,-0.0616389,EA404A,TSHR
1874,11847099,tshr_human,385,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P16473,0.0616073,YA385F,TSHR
1876,21628383,tshr_human,381,F,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P16473,0.111302,FA381D,TSHR
2419,21628383,tshr_human,381,F,D,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,62.0,1.613,,,,0.0,0.0,,0.0,,P16473,0.111302,FA381D,TSHR
1888,19499991,tshr_human,623,A,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-2.20721,AA623F,TSHR
2315,19499991,tshr_human,623,A,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-2.20721,AA623F,TSHR
1891,21628383,tshr_human,394,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,26.0,3.846,,,,0.0,0.0,,0.0,,P16473,-0.0250052,EA394K,TSHR
1984,21628383,tshr_human,394,E,K,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,57.0,1.754,,,,0.0,0.0,,0.0,,P16473,-0.0250052,EA394K,TSHR
1901,16150909,tshr_human,651,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,0.807532,KA651E,TSHR
2283,16150909,tshr_human,651,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,0.807532,KA651E,TSHR
2349,16150909,tshr_human,651,K,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,128.0,-1.28,,,,0.0,0.0,,0.0,,P16473,0.807532,KA651E,TSHR
1933,21525003,tshr_human,304,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,-0.240245,SA304A,TSHR
1988,21628383,tshr_human,304,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P16473,-0.240245,SA304A,TSHR
1941,20652618,tshr_human,424,V,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P16473,-0.781862,VA424I,TSHR
2569,20652618,tshr_human,424,V,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P16473,-0.781862,VA424I,TSHR
1950,16410307,tshr_human,281,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P16473,-1.17475,SA281A,TSHR
2143,16410307,tshr_human,281,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,-1.17475,SA281A,TSHR
1970,21525003,tshr_human,277,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,1.01396,LA277V,TSHR
2757,21525003,tshr_human,277,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,1.01396,LA277V,TSHR
1974,20179143,tshr_human,667,Y,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,2.51578,YA667A,TSHR
1976,16756473,tshr_human,620,T,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P16473,-1.30726,TA620I,TSHR
1981,16410307,tshr_human,281,S,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,-3.34923,SA281M,TSHR
2485,16410307,tshr_human,281,S,M,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,-3.34923,SA281M,TSHR
2010,21628383,tshr_human,308,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,-0.0941624,SA308A,TSHR
2022,16410307,tshr_human,281,S,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,-1.96045,SA281V,TSHR
2127,16410307,tshr_human,281,S,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,-1.96045,SA281V,TSHR
2027,16955277,tshr_human,622,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,0.415128,IA622A,TSHR
2075,16955277,tshr_human,622,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,31.0,3.226,,,,0.0,0.0,,0.0,,P16473,0.415128,IA622A,TSHR
2538,16955277,tshr_human,622,I,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P16473,0.415128,IA622A,TSHR
2039,16756469,tshr_human,450,R,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,1.43215,RA450H,TSHR
2687,16756469,tshr_human,450,R,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P16473,1.43215,RA450H,TSHR
2062,21586576,tshr_human,634,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P16473,-0.108674,FA634I,TSHR
2542,21586576,tshr_human,634,F,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,15.0,6.667,,,,0.0,0.0,,0.0,,P16473,-0.108674,FA634I,TSHR
2123,21628383,tshr_human,393,S,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P16473,-0.11927,SA393A,TSHR
2132,20305779,tshr_human,443,H,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,-0.307014,HA443R,TSHR
2400,20305779,tshr_human,443,H,R,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P16473,-0.307014,HA443R,TSHR
2186,9806755,tshr_human,623,A,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,-0.30311,AA623Y,TSHR
2737,9806755,tshr_human,623,A,Y,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,-0.30311,AA623Y,TSHR
2188,16899458,tshr_human,401,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P16473,0.0747712,KA401A,TSHR
2734,16899458,tshr_human,401,K,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P16473,0.0747712,KA401A,TSHR
2232,21586576,tshr_human,648,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,1.37121,IA648V,TSHR
2248,16410307,tshr_human,281,S,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P16473,0.109786,SA281G,TSHR
2439,16410307,tshr_human,281,S,G,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,59.0,1.695,,,,0.0,0.0,,0.0,,P16473,0.109786,SA281G,TSHR
2260,15498884,tshr_human,607,T,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P16473,0.35479,TA607E,TSHR
2366,15498884,tshr_human,607,T,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P16473,0.35479,TA607E,TSHR
2572,15498884,tshr_human,607,T,E,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.35479,TA607E,TSHR
2266,21586576,tshr_human,580,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P16473,0.921462,LA580V,TSHR
2323,15498884,tshr_human,524,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,91.0,1.099,,,,0.0,0.0,,0.0,,P16473,0.971758,TA524A,TSHR
2570,15498884,tshr_human,524,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,45.0,2.222,,,,0.0,0.0,,0.0,,P16473,0.971758,TA524A,TSHR
2664,15498884,tshr_human,524,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P16473,0.971758,TA524A,TSHR
2351,21586576,tshr_human,584,V,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,125.0,-1.25,,,,0.0,0.0,,0.0,,P16473,0.416294,VA584A,TSHR
2377,21628383,tshr_human,367,G,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P16473,0.391864,GA367A,TSHR
2424,20652618,tshr_human,582,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,0.82574,YA582F,TSHR
2443,20652618,tshr_human,582,Y,F,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,0.82574,YA582F,TSHR
2429,10691307,tshr_human,601,Y,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P16473,1.38565,YA601H,TSHR
2716,10691307,tshr_human,601,Y,H,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,114.0,-1.14,,,,0.0,0.0,,0.0,,P16473,1.38565,YA601H,TSHR
2454,21525003,tshr_human,273,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,0.286882,TA273A,TSHR
2752,21525003,tshr_human,273,T,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P16473,0.286882,TA273A,TSHR
2461,21586576,tshr_human,593,A,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,103.0,-1.03,,,,0.0,0.0,,0.0,,P16473,0.897536,AA593V,TSHR
2462,21628383,tshr_human,300,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P16473,0.812912,MA300A,TSHR
2665,21628383,tshr_human,300,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P16473,0.812912,MA300A,TSHR
2486,20305779,tshr_human,443,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P16473,-0.331471,HA443A,TSHR
2536,20305779,tshr_human,443,H,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P16473,-0.331471,HA443A,TSHR
2497,15722344,tshr_human,456,L,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,42.0,2.381,,,,0.0,0.0,,0.0,,P16473,2.37784,LA456A,TSHR
2517,21628383,tshr_human,280,P,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P16473,1.52865,PA280A,TSHR
2531,20179143,tshr_human,587,L,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P16473,1.48604,LA587V,TSHR
2547,11434721,tshr_human,425,S,I,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P16473,0.237793,SA425I,TSHR
2555,20305779,tshr_human,451,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,43.0,2.326,,,,0.0,0.0,,0.0,,P16473,3.51874,FA451A,TSHR
2810,20305779,tshr_human,451,F,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P16473,3.51874,FA451A,TSHR
2597,16899458,tshr_human,407,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P16473,2.30472,PA407L,TSHR
2753,16899458,tshr_human,407,P,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P16473,2.30472,PA407L,TSHR
2617,16488885,tshr_human,585,F,T,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,92.0,1.087,,,,0.0,0.0,,0.0,,P16473,1.73296,FA585T,TSHR
2651,17079233,tshr_human,568,I,L,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P16473,-1.47261,IA568L,TSHR
2703,18162522,tshr_human,531,R,Q,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,90.0,1.111,,,,0.0,0.0,,0.0,,P16473,0.485073,RA531Q,TSHR
2726,21628383,tshr_human,306,M,A,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P16473,0.521773,MA306A,TSHR
2759,21628383,tshr_human,292,I,V,bovine thyrotropin,UniProt Entry Code (peptide),"P01217, P01223",Full agonist,Specific-binding,binding,100.0,%,,,104.0,-1.04,,,,0.0,0.0,,0.0,,P16473,0.453879,IA292V,TSHR
2807,20736161,tshr_human,232,D,A,human thyrotropin,IUPHAR/BPS Guide to pharmacology,4393,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P16473,2.47834,DA232A,TSHR
2,27889471,fshr_human,449,T,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P23945,0.305189,TA449N,FSHR
542,27889471,fshr_human,449,T,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,148.0,-1.479,,,,0.0,0.0,,0.0,,P23945,0.305189,TA449N,FSHR
633,15166252,fshr_human,449,T,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P23945,0.305189,TA449N,FSHR
8,20736161,fshr_human,150,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,60.0,1.667,,,,0.0,0.0,,0.0,,P23945,1.22412,DA150A,FSHR
447,20736161,fshr_human,150,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,115.0,-1.149,,,,0.0,0.0,,0.0,,P23945,1.22412,DA150A,FSHR
9,20736161,fshr_human,74,K,E,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,210.0,-2.101,,,,0.0,0.0,,0.0,,P23945,3.44604,KA74E,FSHR
585,20736161,fshr_human,74,K,E,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P23945,3.44604,KA74E,FSHR
15,22954680,fshr_human,431,N,I,recombinant follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P23945,0.912734,NA431I,FSHR
433,22954680,fshr_human,431,N,I,recombinant follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,147.0,-1.471,,,,0.0,0.0,,0.0,,P23945,0.912734,NA431I,FSHR
16,9786899,fshr_human,603,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P23945,0.0934639,TA603A,FSHR
38,15166252,fshr_human,615,H,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,142.0,-1.42,,,,0.0,0.0,,0.0,,P23945,-1.40292,HA615Y,FSHR
52,12963710,fshr_human,28,R,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,96.0,1.042,,,,0.0,0.0,,0.0,,P23945,1.59068,RA28A,FSHR
55,20736161,fshr_human,150,D,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,249.0,-2.488,,,,0.0,0.0,,0.0,,P23945,-0.338818,DA150N,FSHR
100,20736161,fshr_human,150,D,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,231.0,-2.309,,,,0.0,0.0,,0.0,,P23945,-0.338818,DA150N,FSHR
73,25581598,fshr_human,575,A,V,follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,0.189897,AA575V,FSHR
300,25581598,fshr_human,575,A,V,follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,31.0,3.226,,,,0.0,0.0,,0.0,,P23945,0.189897,AA575V,FSHR
91,12039074,fshr_human,477,L,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P23945,-0.0898818,LA477R,FSHR
404,12039074,fshr_human,477,L,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,73.0,1.37,,,,0.0,0.0,,0.0,,P23945,-0.0898818,LA477R,FSHR
94,15166252,fshr_human,449,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,150.0,-1.499,,,,0.0,0.0,,0.0,,P23945,-1.11904,TA449A,FSHR
101,9769327,fshr_human,160,I,T,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P23945,4.11361,IA160T,FSHR
117,12963710,fshr_human,34,E,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,95.0,1.053,,,,0.0,0.0,,0.0,,P23945,0.696415,EA34A,FSHR
124,27889471,fshr_human,222,I,T,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P23945,1.87077,IA222T,FSHR
378,27889471,fshr_human,222,I,T,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,53.0,1.887,,,,0.0,0.0,,0.0,,P23945,1.87077,IA222T,FSHR
125,12039074,fshr_human,477,L,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,107.0,-1.07,,,,0.0,0.0,,0.0,,P23945,-0.176077,LA477A,FSHR
592,12039074,fshr_human,477,L,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P23945,-0.176077,LA477A,FSHR
126,27889471,fshr_human,243,K,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,0.458151,KA243R,FSHR
621,27889471,fshr_human,243,K,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,171.0,-1.709,,,,0.0,0.0,,0.0,,P23945,0.458151,KA243R,FSHR
127,7608154,fshr_human,423,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,1.07781,IA423A,FSHR
135,26911863,fshr_human,408,D,Y,follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,51.0,1.961,,,,0.0,0.0,,0.0,,P23945,2.96941,DA408Y,FSHR
137,15166252,fshr_human,567,D,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,110.0,-1.1,,,,0.0,0.0,,0.0,,P23945,0.966801,DA567N,FSHR
143,12963710,fshr_human,48,A,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,116.0,-1.16,,,,0.0,0.0,,0.0,,P23945,1.94437,AA48G,FSHR
149,12039074,fshr_human,477,L,P,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P23945,-1.26028,LA477P,FSHR
557,12039074,fshr_human,477,L,P,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P23945,-1.26028,LA477P,FSHR
178,25791375,fshr_human,505,I,V,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,79.0,1.266,,,,0.0,0.0,,0.0,,P23945,0.958392,IA505V,FSHR
216,25791375,fshr_human,505,I,V,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,135.0,-1.35,,,,0.0,0.0,,0.0,,P23945,0.958392,IA505V,FSHR
185,12963710,fshr_human,26,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,98.0,1.02,,,,0.0,0.0,,0.0,,P23945,-0.0578323,SA26A,FSHR
186,12374801,fshr_human,601,L,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,75.0,1.333,,,,0.0,0.0,,0.0,,P23945,0.230398,LA601F,FSHR
194,12930927,fshr_human,449,T,I,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P23945,-0.650544,TA449I,FSHR
588,15166252,fshr_human,449,T,I,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,152.0,-1.52,,,,0.0,0.0,,0.0,,P23945,-0.650544,TA449I,FSHR
675,12930927,fshr_human,449,T,I,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P23945,-0.650544,TA449I,FSHR
201,15166252,fshr_human,567,D,H,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,70.0,1.429,,,,0.0,0.0,,0.0,,P23945,0.999569,DA567H,FSHR
204,12963710,fshr_human,38,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,94.0,1.064,,,,0.0,0.0,,0.0,,P23945,-0.325818,TA38A,FSHR
209,7608154,fshr_human,424,H,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,0.197783,HA424A,FSHR
223,20736161,fshr_human,224,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,39.0,2.564,,,,0.0,0.0,,0.0,,P23945,2.13296,DA224A,FSHR
249,20736161,fshr_human,224,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,41.0,2.439,,,,0.0,0.0,,0.0,,P23945,2.13296,DA224A,FSHR
225,25581598,fshr_human,514,V,A,follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P23945,1.94654,VA514A,FSHR
384,25581598,fshr_human,514,V,A,follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,1.94654,VA514A,FSHR
235,10935550,fshr_human,460,L,K,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P23945,0.0364343,LA460K,FSHR
242,16901970,fshr_human,330,Y,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P23945,0.0102418,YA330F,FSHR
245,12963710,fshr_human,45,P,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,108.0,-1.08,,,,0.0,0.0,,0.0,,P23945,2.26306,PA45A,FSHR
250,12963710,fshr_human,39,E,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,116.0,-1.16,,,,0.0,0.0,,0.0,,P23945,0.0913605,EA39A,FSHR
254,10551778,fshr_human,601,L,V,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P23945,1.31279,LA601V,FSHR
257,9786899,fshr_human,600,P,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P23945,1.21092,PA600A,FSHR
491,12374801,fshr_human,600,P,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,17.0,5.882,,,,0.0,0.0,,0.0,,P23945,1.21092,PA600A,FSHR
265,20736161,fshr_human,74,K,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,87.0,1.149,,,,0.0,0.0,,0.0,,P23945,1.03736,KA74A,FSHR
345,20736161,fshr_human,74,K,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,84.0,1.19,,,,0.0,0.0,,0.0,,P23945,1.03736,KA74A,FSHR
270,9769327,fshr_human,573,R,C,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P23945,1.80752,RA573C,FSHR
290,9769327,fshr_human,573,R,C,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,82.0,1.22,,,,0.0,0.0,,0.0,,P23945,1.80752,RA573C,FSHR
276,10935550,fshr_human,460,L,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P23945,0.742208,LA460R,FSHR
278,9786899,fshr_human,607,A,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,37.0,2.703,,,,0.0,0.0,,0.0,,P23945,1.38767,AA607G,FSHR
285,12374801,fshr_human,600,P,C,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,12.0,8.333,,,,0.0,0.0,,0.0,,P23945,0.742258,PA600C,FSHR
297,15166252,fshr_human,567,D,V,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,25.0,4.0,,,,0.0,0.0,,0.0,,P23945,0.360595,DA567V,FSHR
298,12374801,fshr_human,601,L,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - IP accumulation,100.0,%,,,27.0,3.704,,,,0.0,0.0,,0.0,,P23945,0.318108,LA601Y,FSHR
415,12374801,fshr_human,601,L,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,141.0,-1.41,,,,0.0,0.0,,0.0,,P23945,0.318108,LA601Y,FSHR
304,16901970,fshr_human,333,F,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,93.0,1.075,,,,0.0,0.0,,0.0,,P23945,0.00600038,FA333Y,FSHR
307,15166252,fshr_human,449,T,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,139.0,-1.391,,,,0.0,0.0,,0.0,,P23945,-2.41155,TA449F,FSHR
314,15166252,fshr_human,449,T,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P23945,-3.76475,TA449Y,FSHR
316,20736161,fshr_human,153,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P23945,0.155466,DA153A,FSHR
439,20736161,fshr_human,153,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,106.0,-1.06,,,,0.0,0.0,,0.0,,P23945,0.155466,DA153A,FSHR
319,27889471,fshr_human,197,E,S,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,31.0,3.226,,,,0.0,0.0,,0.0,,P23945,0.47969,EA197S,FSHR
376,27889471,fshr_human,197,E,S,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,68.0,1.471,,,,0.0,0.0,,0.0,,P23945,0.47969,EA197S,FSHR
335,12963710,fshr_human,33,Q,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,97.0,1.031,,,,0.0,0.0,,0.0,,P23945,0.854857,QA33A,FSHR
336,16278261,fshr_human,545,I,V,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,0.998277,IA545V,FSHR
340,12039074,fshr_human,467,R,K,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P23945,-0.456892,RA467K,FSHR
593,12039074,fshr_human,467,R,K,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,86.0,1.163,,,,0.0,0.0,,0.0,,P23945,-0.456892,RA467K,FSHR
341,12039074,fshr_human,467,R,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P23945,0.345605,RA467A,FSHR
632,12039074,fshr_human,467,R,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,9.0,11.111,,,,0.0,0.0,,0.0,,P23945,0.345605,RA467A,FSHR
347,16278261,fshr_human,545,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,80.0,1.25,,,,0.0,0.0,,0.0,,P23945,2.36142,IA545A,FSHR
362,12039074,fshr_human,470,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,99.0,1.01,,,,0.0,0.0,,0.0,,P23945,0.260479,TA470A,FSHR
467,12039074,fshr_human,470,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,10.0,10.0,,,,0.0,0.0,,0.0,,P23945,0.260479,TA470A,FSHR
375,10880516,fshr_human,177,L,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P23945,4.47711,LA177A,FSHR
377,9786899,fshr_human,599,V,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,58.0,1.724,,,,0.0,0.0,,0.0,,P23945,0.0934552,VA599A,FSHR
379,27889471,fshr_human,221,V,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P23945,1.16284,VA221G,FSHR
536,27889471,fshr_human,221,V,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P23945,1.16284,VA221G,FSHR
399,20736161,fshr_human,124,Y,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,52.0,1.923,,,,0.0,0.0,,0.0,,P23945,4.32628,YA124A,FSHR
408,20736161,fshr_human,124,Y,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,72.0,1.389,,,,0.0,0.0,,0.0,,P23945,4.32628,YA124A,FSHR
406,12039074,fshr_human,477,L,K,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,16.0,6.25,,,,0.0,0.0,,0.0,,P23945,-0.0792651,LA477K,FSHR
549,12039074,fshr_human,477,L,K,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,48.0,2.083,,,,0.0,0.0,,0.0,,P23945,-0.0792651,LA477K,FSHR
419,15166252,fshr_human,449,T,D,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,120.0,-1.2,,,,0.0,0.0,,0.0,,P23945,1.15644,TA449D,FSHR
445,12963710,fshr_human,31,L,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,83.0,1.205,,,,0.0,0.0,,0.0,,P23945,1.86437,LA31A,FSHR
448,16278261,fshr_human,545,I,L,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P23945,0.0792874,IA545L,FSHR
456,15166252,fshr_human,449,T,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,140.0,-1.401,,,,0.0,0.0,,0.0,,P23945,0.182545,TA449G,FSHR
461,12963710,fshr_human,50,E,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,109.0,-1.091,,,,0.0,0.0,,0.0,,P23945,0.143208,EA50A,FSHR
462,15166252,fshr_human,567,D,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,69.0,1.449,,,,0.0,0.0,,0.0,,P23945,2.01456,DA567G,FSHR
489,9973249,fshr_human,567,D,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P23945,2.01456,DA567G,FSHR
572,9973249,fshr_human,567,D,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,40.0,2.5,,,,0.0,0.0,,0.0,,P23945,2.01456,DA567G,FSHR
465,12963710,fshr_human,37,V,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P23945,2.27799,VA37A,FSHR
470,15166252,fshr_human,567,D,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,30.0,3.333,,,,0.0,0.0,,0.0,,P23945,0.562043,DA567Y,FSHR
474,15166252,fshr_human,567,D,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,63.0,1.587,,,,0.0,0.0,,0.0,,P23945,0.916328,DA567A,FSHR
492,9786899,fshr_human,598,K,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,13.0,7.692,,,,0.0,0.0,,0.0,,P23945,0.999104,KA598A,FSHR
495,10880516,fshr_human,77,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,6.0,16.667,,,,0.0,0.0,,0.0,,P23945,4.30055,IA77A,FSHR
508,12963710,fshr_human,29,V,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P23945,1.53287,VA29A,FSHR
509,16278261,fshr_human,545,I,N,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,3.01736,IA545N,FSHR
510,20736161,fshr_human,226,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,5.0,20.0,,,,0.0,0.0,,0.0,,P23945,0.777882,SA226A,FSHR
514,12963710,fshr_human,46,R,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,105.0,-1.05,,,,0.0,0.0,,0.0,,P23945,0.924707,RA46A,FSHR
519,20736161,fshr_human,130,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,310.0,-3.096,,,,0.0,0.0,,0.0,,P23945,2.74425,TA130A,FSHR
651,20736161,fshr_human,130,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,258.0,-2.577,,,,0.0,0.0,,0.0,,P23945,2.74425,TA130A,FSHR
523,10935550,fshr_human,460,L,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P23945,1.93481,LA460A,FSHR
533,15166252,fshr_human,615,H,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,135.0,-1.35,,,,0.0,0.0,,0.0,,P23945,0.543382,HA615A,FSHR
546,20736161,fshr_human,78,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,66.0,1.515,,,,0.0,0.0,,0.0,,P23945,-0.312546,SA78A,FSHR
553,20736161,fshr_human,78,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,89.0,1.124,,,,0.0,0.0,,0.0,,P23945,-0.312546,SA78A,FSHR
548,15166252,fshr_human,615,H,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,117.0,-1.17,,,,0.0,0.0,,0.0,,P23945,-2.29524,HA615F,FSHR
552,15166252,fshr_human,567,D,R,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,50.0,2.0,,,,0.0,0.0,,0.0,,P23945,0.255375,DA567R,FSHR
554,12963710,fshr_human,42,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,77.0,1.299,,,,0.0,0.0,,0.0,,P23945,-0.13746,SA42A,FSHR
556,12145341,fshr_human,581,D,G,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,81.0,1.235,,,,0.0,0.0,,0.0,,P23945,0.597509,DA581G,FSHR
568,7608154,fshr_human,425,T,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,49.0,2.041,,,,0.0,0.0,,0.0,,P23945,-0.515032,TA425A,FSHR
577,9786899,fshr_human,605,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,85.0,1.176,,,,0.0,0.0,,0.0,,P23945,-0.109604,SA605A,FSHR
581,12963710,fshr_human,35,S,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,101.0,-1.01,,,,0.0,0.0,,0.0,,P23945,0.0324218,SA35A,FSHR
590,9786899,fshr_human,606,K,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,54.0,1.852,,,,0.0,0.0,,0.0,,P23945,0.200587,KA606A,FSHR
591,12374801,fshr_human,600,P,Y,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,34.0,2.941,,,,0.0,0.0,,0.0,,P23945,0.580279,PA600Y,FSHR
594,12963710,fshr_human,49,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,102.0,-1.02,,,,0.0,0.0,,0.0,,P23945,0.999003,IA49A,FSHR
602,9786899,fshr_human,604,V,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,22.0,4.545,,,,0.0,0.0,,0.0,,P23945,1.2805,VA604A,FSHR
603,12374801,fshr_human,600,P,D,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,71.0,1.408,,,,0.0,0.0,,0.0,,P23945,1.259,PA600D,FSHR
619,9100567,fshr_human,591,F,S,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Specific-binding,binding,100.0,%,,,35.0,2.857,,,,0.0,0.0,,0.0,,P23945,3.1485,FA591S,FSHR
622,12374801,fshr_human,600,P,S,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,64.0,1.562,,,,0.0,0.0,,0.0,,P23945,1.06719,PA600S,FSHR
630,15166252,fshr_human,567,D,T,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,47.0,2.128,,,,0.0,0.0,,0.0,,P23945,0.349444,DA567T,FSHR
634,16278261,fshr_human,545,I,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,5.39371,IA545F,FSHR
639,10880516,fshr_human,151,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,33.0,3.03,,,,0.0,0.0,,0.0,,P23945,4.09593,IA151A,FSHR
643,12963710,fshr_human,36,K,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,88.0,1.136,,,,0.0,0.0,,0.0,,P23945,0.823505,KA36A,FSHR
663,12963710,fshr_human,30,F,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,121.0,-1.211,,,,0.0,0.0,,0.0,,P23945,3.69854,FA30A,FSHR
672,12963710,fshr_human,40,I,A,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,36.0,2.778,,,,0.0,0.0,,0.0,,P23945,3.76839,IA40A,FSHR
676,16901970,fshr_human,335,Y,F,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,78.0,1.282,,,,0.0,0.0,,0.0,,P23945,-0.115919,YA335F,FSHR
691,16278261,fshr_human,545,I,T,human follitropin,IUPHAR/BPS Guide to pharmacology,1157,Full agonist,Single-point,Functional - cAMP accumulation,100.0,%,,,100.0,1.0,,,,0.0,0.0,,0.0,,P23945,2.66688,IA545T,FSHR
0,10821780,5ht4r_human,150,T,V,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,38.8,-1.138,Unchanged,,,0.0,0.0,,0.0,,Q13639,0.142147,TA150V,HTR4
39,10821780,5ht4r_human,150,T,V,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.5,2.174,,,,0.0,0.0,,0.0,,Q13639,0.142147,TA150V,HTR4
47,10821780,5ht4r_human,150,T,V,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,1.4,2.5,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.142147,TA150V,HTR4
55,10821780,5ht4r_human,150,T,V,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,6.1,-1.393,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.142147,TA150V,HTR4
98,10821780,5ht4r_human,150,T,V,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,=,,235.0,-3.289,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.142147,TA150V,HTR4
2,10821780,5ht4r_human,279,N,L,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,41.2,-1.208,Unchanged,,,0.0,0.0,,0.0,,Q13639,-2.08465,NA279L,HTR4
21,10821780,5ht4r_human,279,N,L,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,1.2,5.217,,,,0.0,0.0,,0.0,,Q13639,-2.08465,NA279L,HTR4
84,10821780,5ht4r_human,279,N,L,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,3.7,-2.299,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.08465,NA279L,HTR4
92,10821780,5ht4r_human,279,N,L,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,>,,100000.0,129.534,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.08465,NA279L,HTR4
7,10821780,5ht4r_human,196,C,A,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.07,-3.289,,,,0.0,0.0,,0.0,,Q13639,0.203339,CA196A,HTR4
18,10821780,5ht4r_human,196,C,A,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,1.6,2.857,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.203339,CA196A,HTR4
58,10821780,5ht4r_human,196,C,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,=,,378.0,-2.041,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.203339,CA196A,HTR4
66,10821780,5ht4r_human,196,C,A,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,1.8,-4.717,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.203339,CA196A,HTR4
78,10821780,5ht4r_human,196,C,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,36.4,-1.067,Unchanged,,,0.0,0.0,,0.0,,Q13639,0.203339,CA196A,HTR4
10,15351779,5ht4r_human,302,Y,F,ML11411,SMILES,COc1cc(N)c(Cl)cc1C(=O)OCCC1CCC(CCCCNS(=O)(=O)c2cccc3c(cccc23)N(C)C)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,53.5,nM,=,,79.7,1.49,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.728501,YA302F,HTR4
24,15351779,5ht4r_human,302,Y,F,GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.23,nM,=,,3.06,13.304,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.728501,YA302F,HTR4
70,15351779,5ht4r_human,302,Y,F,RS39604,ChEMBL Compound ID,CHEMBL66114,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.15,nM,=,,15.0,6.977,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.728501,YA302F,HTR4
86,15351779,5ht4r_human,302,Y,F,RS100235,ChEMBL Compound ID,CHEMBL69733,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.11,nM,=,,1.1,-1.919,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,0.728501,YA302F,HTR4
91,15351779,5ht4r_human,302,Y,F,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,3.06,13.304,,,,0.0,0.0,,0.0,,Q13639,0.728501,YA302F,HTR4
13,15351779,5ht4r_human,96,R,L,RS39604,ChEMBL Compound ID,CHEMBL66114,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.15,nM,=,,55.8,25.953,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
25,15351779,5ht4r_human,96,R,L,ML11411,SMILES,COc1cc(N)c(Cl)cc1C(=O)OCCC1CCC(CCCCNS(=O)(=O)c2cccc3c(cccc23)N(C)C)CC1,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,53.5,nM,=,,1.16,-45.455,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
31,15351779,5ht4r_human,96,R,L,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.55,2.391,,,,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
45,15351779,5ht4r_human,96,R,L,GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.23,nM,=,,0.55,2.391,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
59,15351779,5ht4r_human,96,R,L,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.57,nM,=,,0.85,1.491,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
62,15351779,5ht4r_human,96,R,L,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,653.0,nM,=,,402.0,-1.623,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
71,15351779,5ht4r_human,96,R,L,RS100235,ChEMBL Compound ID,CHEMBL69733,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,2.11,nM,=,,3.84,1.82,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-2.22725,RA96L,HTR4
14,10821780,5ht4r_human,66,D,N,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,57.5,6.765,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.157714,DA66N,HTR4
49,10821780,5ht4r_human,66,D,N,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,14.7,26.25,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.157714,DA66N,HTR4
57,10821780,5ht4r_human,66,D,N,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,35.3,-1.035,Unchanged,,,0.0,0.0,,0.0,,Q13639,-0.157714,DA66N,HTR4
64,10821780,5ht4r_human,66,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,=,,672.0,-1.149,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.157714,DA66N,HTR4
79,10821780,5ht4r_human,66,D,N,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.42,1.826,,,,0.0,0.0,,0.0,,Q13639,-0.157714,DA66N,HTR4
16,10821780,5ht4r_human,276,F,V,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,6.8,-1.25,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,1.57305,FA276V,HTR4
19,10821780,5ht4r_human,276,F,V,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,25.6,1.332,Unchanged,,,0.0,0.0,,0.0,,Q13639,1.57305,FA276V,HTR4
35,10821780,5ht4r_human,276,F,V,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.45,1.957,,,,0.0,0.0,,0.0,,Q13639,1.57305,FA276V,HTR4
52,10821780,5ht4r_human,276,F,V,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,=,,695.0,-1.111,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,1.57305,FA276V,HTR4
100,10821780,5ht4r_human,276,F,V,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,1.6,2.857,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,1.57305,FA276V,HTR4
27,10821780,5ht4r_human,275,F,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,45.1,-1.323,Unchanged,,,0.0,0.0,,0.0,,Q13639,2.88328,FA275A,HTR4
33,10821780,5ht4r_human,100,D,N,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.32,1.391,,,,0.0,0.0,,0.0,,Q13639,-0.488312,DA100N,HTR4
38,10821780,5ht4r_human,100,D,N,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,29.6,3.482,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.488312,DA100N,HTR4
65,10821780,5ht4r_human,100,D,N,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,>,,100000.0,129.534,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.488312,DA100N,HTR4
68,10821780,5ht4r_human,100,D,N,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,35.2,62.857,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.488312,DA100N,HTR4
81,10821780,5ht4r_human,100,D,N,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,1.1,31.0,Abolished,,,0.0,0.0,,0.0,,Q13639,-0.488312,DA100N,HTR4
46,10821780,5ht4r_human,153,S,A,ML10302,ChEMBL Compound ID,CHEMBL286136,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,8.5,nM,=,,3.1,-2.74,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.674831,SA153A,HTR4
72,10821780,5ht4r_human,153,S,A,ML10375,ChEMBL Compound ID,CHEMBL155917,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,0.56,nM,=,,0.84,1.5,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.674831,SA153A,HTR4
80,10821780,5ht4r_human,153,S,A,5-HT,ChEMBL Compound ID,CHEMBL39,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,772.0,nM,=,,1043.0,1.351,,,[3H]GR 113808,0.0,0.0,,0.0,,Q13639,-0.674831,SA153A,HTR4
89,10821780,5ht4r_human,153,S,A,[3H]GR 113808,ChEMBL Compound ID,CHEMBL33884,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,0.23,nM,=,,0.34,1.478,,,,0.0,0.0,,0.0,,Q13639,-0.674831,SA153A,HTR4
95,10821780,5ht4r_human,153,S,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,50.5,-1.481,Unchanged,,,0.0,0.0,,0.0,,Q13639,-0.674831,SA153A,HTR4
50,10821780,5ht4r_human,197,S,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,5.2,6.558,Abolished,,,0.0,0.0,,0.0,,Q13639,-0.836119,SA197A,HTR4
60,10821780,5ht4r_human,302,Y,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,0.7,48.714,Abolished,,,0.0,0.0,,0.0,,Q13639,5.07723,YA302A,HTR4
97,10821780,5ht4r_human,149,P,A,5-HT,PubChem CID,5202,Full agonist,Single-point,Functional - cAMP accumulation,34.1,%,=,,56.01,-1.642,Unchanged,,,0.0,0.0,,0.0,,Q13639,2.77276,PA149A,HTR4
1,10.1038/nature19319,ednrb_human,369,Y,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.0,3.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.92506,YA369A,EDNRB
3,10.1038/nature19319,ednrb_human,369,Y,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,4.6,15.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.92506,YA369A,EDNRB
5,10.1038/nature19319,ednrb_human,273,K,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.7,5.667,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.562004,KA273A,EDNRB
101,10.1038/nature19319,ednrb_human,273,K,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,54.7,182.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.562004,KA273A,EDNRB
7,10.1038/nature19319,ednrb_human,339,L,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,2.9,9.667,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.41538,LA339A,EDNRB
47,10.1038/nature19319,ednrb_human,339,L,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,7.7,25.667,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.41538,LA339A,EDNRB
8,10.1038/nature19319,ednrb_human,368,D,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.6,5.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,-1.05041,DA368A,EDNRB
85,10.1038/nature19319,ednrb_human,368,D,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.6,5.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,-1.05041,DA368A,EDNRB
10,10.1038/nature19319,ednrb_human,247,Y,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,3.3,11.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.28467,YA247A,EDNRB
59,10.1038/nature19319,ednrb_human,247,Y,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.3,4.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.28467,YA247A,EDNRB
12,10.1038/nature19319,ednrb_human,277,L,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,2.1,7.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.52086,LA277A,EDNRB
48,10.1038/nature19319,ednrb_human,277,L,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,4.2,14.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.52086,LA277A,EDNRB
14,10.1038/nature19319,ednrb_human,357,R,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,66.7,222.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,3.08285,RA357A,EDNRB
69,10.1038/nature19319,ednrb_human,357,R,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.8,6.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,3.08285,RA357A,EDNRB
18,10.1038/nature19319,ednrb_human,181,Q,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,0.6,2.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.841999,QA181A,EDNRB
60,10.1038/nature19319,ednrb_human,181,Q,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,2.7,9.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.841999,QA181A,EDNRB
22,10.1038/nature19319,ednrb_human,364,L,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.5,5.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,3.42476,LA364A,EDNRB
102,10.1038/nature19319,ednrb_human,364,L,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,0.7,2.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,3.42476,LA364A,EDNRB
25,10.1038/nature19319,ednrb_human,336,W,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.4,4.667,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.5474,WA336A,EDNRB
91,10.1038/nature19319,ednrb_human,336,W,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.8,6.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.5474,WA336A,EDNRB
26,10.1038/nature19319,ednrb_human,343,R,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,0.9,3.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,-0.0964488,RA343A,EDNRB
72,10.1038/nature19319,ednrb_human,343,R,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.2,4.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,-0.0964488,RA343A,EDNRB
28,10.1038/nature19319,ednrb_human,365,L,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,2.1,7.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.68422,LA365A,EDNRB
65,10.1038/nature19319,ednrb_human,365,L,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,8.4,28.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.68422,LA365A,EDNRB
33,10.1038/nature19319,ednrb_human,182,K,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,114.0,380.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.13697,KA182A,EDNRB
71,10.1038/nature19319,ednrb_human,182,K,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,2.1,7.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.13697,KA182A,EDNRB
37,10.1038/nature19319,ednrb_human,161,K,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,51.3,171.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.46727,KA161A,EDNRB
62,10.1038/nature19319,ednrb_human,161,K,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.0,3.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,1.46727,KA161A,EDNRB
52,10.1038/nature19319,ednrb_human,270,K,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.1,3.667,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.121102,KA270A,EDNRB
93,10.1038/nature19319,ednrb_human,270,K,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,1.0,3.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,0.121102,KA270A,EDNRB
74,10.1038/nature19319,ednrb_human,350,Y,A,Endothelin-1,PubChem CID,16133807,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,0.9,3.0,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.65104,YA350A,EDNRB
80,10.1038/nature19319,ednrb_human,350,Y,A,Endothelin-3,pubChem CID,16219334,Full agonist,IC50,Binding - Radioligand competition/displacement,0.3,nM,=,,11.8,39.333,,,125I-Endothelin-1,0.0,0.0,,0.0,,P24530,2.65104,YA350A,EDNRB
1,10.1124/mol.114.097360,aa2ar_human,67,S,A,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - cAMP accumulation,9.05,,=,,8.5,3.548,,,,0.0,0.0,=,0.0,,P29274,-0.0544798,SA67A,ADORA2A
356,10.1124/mol.115.102657,aa2ar_human,67,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.93,-1.259,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.0544798,SA67A,ADORA2A
457,10.1124/mol.114.097360,aa2ar_human,67,S,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,8.27,,=,,8.4,-1.35,,,,0.0,0.0,=,0.0,,P29274,-0.0544798,SA67A,ADORA2A
673,10.1124/mol.115.102657,aa2ar_human,67,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0077,-1.546,,,,0.0,0.0,=,0.0,,P29274,-0.0544798,SA67A,ADORA2A
2,10.1021/jm2003798,aa2ar_human,167,L,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.7,1.585,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
141,10.1021/jm2003798,aa2ar_human,167,L,A,Chromone1a,PubChem CID,740769,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,7.2,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
157,10.1021/jm2003798,aa2ar_human,167,L,A,Caffeine,PubChem CID,2519,Inverse agonist,pK(d),Biing - Surface plasmon resonance,4.6,,=,,4.7,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
181,10.1021/jm2003798,aa2ar_human,167,L,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,7.6,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
285,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,6.6,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
326,10.1021/jm2003798,aa2ar_human,167,L,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.8,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
352,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,8.8,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
368,10.1021/jm2003798,aa2ar_human,167,L,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,5.7,1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
407,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3e,PubChem CID,86676119,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,8.3,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
543,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,7.5,2.512,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
561,10.1021/jm2003798,aa2ar_human,167,L,A,Chromone1d,PubChem CID,5310837,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.1,,=,,5.6,3.162,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
652,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.6,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
744,10.1021/jm2003798,aa2ar_human,167,L,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),pK(d),Biing - Surface plasmon resonance,5.5,,=,,5.5,1.0,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
787,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,8.3,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
788,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,8.5,5.012,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
958,10.1021/jm2003798,aa2ar_human,167,L,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,6.0,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
1006,10.1021/jm2003798,aa2ar_human,167,L,A,NOTDISCLOSED,,NOT DISCLOSED,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.0,,=,,5.6,2.512,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
1075,10.1021/jm2003798,aa2ar_human,167,L,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,8.5,10.0,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
1088,10.1021/jm2003798,aa2ar_human,167,L,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,9.3,1.0,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
1116,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,7.9,25.119,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
1127,10.1021/jm2003798,aa2ar_human,167,L,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.8,-1.996,,,,0.0,0.0,=,0.0,,P29274,0.228003,LA167A,ADORA2A
4,8794889,aa2ar_human,89,Q,S,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand competition/displacement,31.0,nM,=,,93.3,3.01,,,,0.0,0.0,=,0.0,,P29274,2.42463,QA89S,ADORA2A
7,10.1021/jm2003798,aa2ar_human,66,I,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,8.5,10.0,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
56,10.1021/jm2003798,aa2ar_human,66,I,A,Chromone1a,,,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,6.6,5.012,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
177,10.1021/jm2003798,aa2ar_human,66,I,A,NOTDISCLOSED,,NOT DISCLOSED,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.0,,=,,5.3,5.012,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
222,10.1021/jm2003798,aa2ar_human,66,I,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.7,1.585,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
269,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,8.4,3.162,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
331,10.1021/jm2003798,aa2ar_human,66,I,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,8.7,3.981,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
371,10.1124/mol.115.102657,aa2ar_human,66,I,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.84,-1.024,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
388,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.1,2.512,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
397,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,5.6,12.589,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
414,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,7.9,1.995,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
504,10.1124/mol.115.102657,aa2ar_human,66,I,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0071,-1.675,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
649,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,8.0,-1.259,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
666,10.1021/jm2003798,aa2ar_human,66,I,A,Caffeine,PubChem CID,2519,Inverse agonist,pK(d),Biing - Surface plasmon resonance,4.6,,=,,3.0,39.811,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
685,10.1021/jm2003798,aa2ar_human,66,I,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.4,3.162,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
728,10.1021/jm2003798,aa2ar_human,66,I,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,5.3,3.162,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
755,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,8.0,15.849,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
802,10.1021/jm2003798,aa2ar_human,66,I,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.2,5.012,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
806,10.1021/jm2003798,aa2ar_human,66,I,A,Chromone1d,PubChem CID,5310837,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.1,,=,,5.8,1.995,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
884,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,7.8,5.012,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
964,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3e,PubChem CID,86676119,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,7.4,6.31,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
1031,10.1021/jm2003798,aa2ar_human,66,I,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),pK(d),Biing - Surface plasmon resonance,5.5,,=,,5.4,1.259,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
1102,10.1021/jm2003798,aa2ar_human,66,I,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,6.8,7.943,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
1134,10.1021/jm2003798,aa2ar_human,66,I,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,7.8,31.623,,,,0.0,0.0,=,0.0,,P29274,2.00689,IA66A,ADORA2A
9,10.1074/jbc.M109.096974,aa2ar_human,168,F,Y,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,7.63,nM,=,,7.0,-1.091,,,,0.0,0.0,=,0.0,,P29274,-0.4571,FA168Y,ADORA2A
290,10.1074/jbc.M109.096974,aa2ar_human,168,F,Y,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,357.0,nM,=,,8990.0,25.182,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.4571,FA168Y,ADORA2A
523,10.1074/jbc.M109.096974,aa2ar_human,168,F,Y,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,1.6,nM,=,,13.0,8.125,,,,42.0,0.0,=,0.0,,P29274,-0.4571,FA168Y,ADORA2A
570,10.1074/jbc.M109.096974,aa2ar_human,168,F,Y,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Other,2.4,nM,=,,5.5,2.292,,,,23.0,0.0,=,0.0,,P29274,-0.4571,FA168Y,ADORA2A
627,10.1074/jbc.M109.096974,aa2ar_human,168,F,Y,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,94.0,nM,=,,1190.0,12.66,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.4571,FA168Y,ADORA2A
14,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57394421,PubChem CID,57394421,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,96.0,%,=,,48.0,2.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
15,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12n,SMILES,CCCCOc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,66.0,%,=,,3.4,19.412,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
78,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57390907,PubChem CID,57390907,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,84.0,%,=,,35.0,2.4,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
80,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12g,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(O)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,72.0,%,=,,9.5,7.579,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
92,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12l,SMILES,CCOc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,27.0,%,=,,3.5,7.714,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
98,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12a,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NC2CC3C=CC=CC3C2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,68.0,%,=,,6.6,10.303,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
120,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57403156,PubChem CID,57403156,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,71.0,%,=,,46.0,1.543,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
135,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12i,SMILES,COc1cccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)c1,Allosteric inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),42.0,min,=,,0.8,-52.632,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
137,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12k,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc3OCOc3c2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,35.0,%,=,,1.0,35.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
149,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12d,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(Cl)c(Cl)c2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,82.0,%,=,,11.0,7.455,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
159,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,ZM241385,PubChem CID,5311506,Inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),61.0,min,=,,2.8,-21.739,,,,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
243,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12l,SMILES,CCOc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,3.4,µM,=,,0.05,-66.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
251,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57394423,PubChem CID,57394423,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,82.0,%,=,,18.0,4.556,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
275,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57399649,PubChem CID,57399649,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,77.0,%,=,,21.0,3.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
280,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12o,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(OCc3ccccc3)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,75.0,%,=,,4.0,18.75,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
287,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID11277660,PubChem CID,11277660,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,88.0,%,=,,111.0,-1.261,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
304,10.1124/mol.114.095737,aa2ar_human,246,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.5,µM,=,,0.43,-5.814,,,NECA,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
314,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57401407,PubChem CID,57401407,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,85.0,%,=,,32.0,2.656,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
341,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12h,SMILES,COc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),44.0,min,=,,2.0,-22.222,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
348,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12m,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(OCC=C)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,43.0,%,=,,2.2,19.545,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
351,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,5.1,µM,=,,0.27,-18.868,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
365,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12k,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc3OCOc3c2)nc1N,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,5.6,µM,=,,0.07,-76.923,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
374,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12k,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc3OCOc3c2)nc1N,Allosteric inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),61.0,min,=,,1.2,-50.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
386,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12f,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(cc2)[N+]([O-])=O)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,68.0,%,=,,5.8,11.724,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
428,10.1124/mol.114.095737,aa2ar_human,246,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,8.9,µM,=,,0.36,-25.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
433,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID44574895,PubChem CID,44574895,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,54.0,%,=,,1.1,49.091,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
438,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57396267,PubChem CID,57396267,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,96.0,%,=,,70.0,1.371,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
448,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12j,SMILES,COc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1OC,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,51.0,%,=,,1.8,28.333,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
452,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12i,SMILES,COc1cccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)c1,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,8.1,µM,=,,0.25,-32.258,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
521,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57390905,PubChem CID,57390905,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,85.0,%,=,,53.0,1.604,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
533,10.1124/mol.114.095737,aa2ar_human,246,W,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,4.6,nM,=,,23.2,5.043,,,,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
605,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57392707,PubChem CID,57392707,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,99.0,%,=,,101.0,-1.02,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
616,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12e,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(Br)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,67.0,%,=,,4.8,13.958,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
724,10.1124/mol.111.075937,aa2ar_human,246,W,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,6.1,39.811,,,,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
734,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57397997,PubChem CID,57397997,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,90.0,%,=,,65.0,1.385,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
742,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),28.0,min,=,,1.4,-20.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
746,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,30.0,%,=,,1.8,16.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
749,10.1124/mol.114.095737,aa2ar_human,246,W,A,NECA,PubChem CID,448222,Full agonist,K(d),Binding - Radioligand saturation,81.0,nM,=,,1942.0,23.975,,,,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
760,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12l,SMILES,CCOc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,RT,Binding - Radioligand kinetics (association/dissociation),40.0,min,=,,1.3,-30.303,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
775,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,compound_13,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCCc2ccccc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,60.0,%,=,,9.0,6.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
822,10.1124/mol.114.095737,aa2ar_human,246,W,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,63.0,µM,=,,2.6,-24.39,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
839,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57392705,PubChem CID,57392705,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,65.0,%,=,,17.0,3.824,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
855,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57399651,PubChem CID,57399651,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,87.0,%,=,,73.0,1.192,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
857,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12b,SMILES,Cc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,50.0,%,=,,2.1,23.81,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
923,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12c,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(Cl)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,92.0,%,=,,32.0,2.875,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
924,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12p,SMILES,NC(N)=NC(=O)c1nc(Cl)c(NCCc2ccc(OC(F)(F)F)cc2)nc1N,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,63.0,%,=,,5.2,12.115,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
960,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,71.0,%,=,,11.0,6.455,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
969,10.1124/mol.111.075937,aa2ar_human,246,W,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,8.3,-3.165,,,,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
1054,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12i,SMILES,COc1cccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)c1,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,41.0,%,=,,5.4,7.593,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
1059,10.1124/mol.114.095737,aa2ar_human,246,W,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,16.0,µM,=,,2.7,-5.917,,,NECA,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
1064,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,CID57403241,PubChem CID,57403241,Allosteric inverse agonist,%,Binding - Radioligand competition/displacement,87.0,%,=,,48.0,1.812,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
1082,10.1124/mol.114.095737,aa2ar_human,246,W,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,7.1,5.012,,,,0.0,0.0,=,46.0,CGS21680,P29274,2.64264,WA246A,ADORA2A
1085,10.1021/acs.jmedchem.6b00142,aa2ar_human,246,W,A,12h,SMILES,COc1ccc(CCNc2nc(N)c(nc2Cl)C(=O)N=C(N)N)cc1,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,4.4,µM,=,,0.12,-37.037,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.64264,WA246A,ADORA2A
23,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,CID 75022550,PubChem CID,75022550,Full agonist,K(i),Binding - Radioligand competition/displacement,11.0,µM,=,,1.18,-9.346,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
150,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,NONAME,SMILES,CCNC(=O)C1OC(C(O)C1O)n2cnc3c(NC(N)=N)ncnc23,Full agonist,K(i),Binding - Radioligand competition/displacement,4510.0,nM,=,,1140.0,-3.953,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
246,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,NONAME,SMILES,CCNC(=O)C1OC(C(O)C1O)n2cnc3c(NC(N)=N)ncnc23,Full agonist,EC50,Functional - cAMP accumulation,826.0,nM,=,,120.0,-6.897,,,,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
255,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,2.4,nM,=,,4.1,1.708,,,,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
441,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,Cid76018686,PubChem CID,76018686,Full agonist,EC50,Functional - cAMP accumulation,5.8,µM,=,,0.052,-111.111,,,,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
599,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,ST092443,PubChem CID,2868392,Full agonist,K(i),Binding - Radioligand competition/displacement,21.4,nM,=,,9.3,-2.299,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
623,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,Cid13307390,PubChem CID,13307390,Full agonist,K(i),Binding - Radioligand competition/displacement,46.1,µM,=,,0.493,-90.909,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
774,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,Oprea1_724488,PubChem CID,24052235,Full agonist,K(i),Binding - Radioligand competition/displacement,2590.0,nM,=,,3470.0,1.34,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
868,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,Cid76018682,PubChem CID,76018682,Full agonist,K(i),Binding - Radioligand competition/displacement,74.2,µM,=,,4.14,-17.857,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
889,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.84,nM,=,,0.45,-1.866,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
930,10.1016/j.chembiol.2004.12.010,aa2ar_human,181,N,D,CAS35788-28-4,PubChem CID,53464002,Full agonist,K(i),Binding - Radioligand competition/displacement,2.11,µM,=,,13.3,6.303,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.23019,NA181D,ADORA2A
24,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,4.78,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
99,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,7.3,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
238,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.58,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
260,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.79,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
309,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-1.19,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
422,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.67,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
812,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.51,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
849,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.67,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
876,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.9,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
1081,10.1016/j.str.2017.06.012,aa2ar_human,67,S,N,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.87,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55319,SA67N,ADORA2A
27,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.7,µM,=,,98.5,20.957,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
526,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.06,µM,=,,13.8,230.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
635,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.002,µM,=,,0.006,3.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
639,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,0.28,µM,=,,19.6,70.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
643,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.008,µM,=,,0.003,-2.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
731,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,ZM241385,PubChem CID,176407,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.29,min-1,=,,0.51,1.759,,,,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
843,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,ZM241385,PubChem CID,176407,Inverse agonist,k1,Binding - Radioligand kinetics (association/dissociation),0.15,nM-1 min-1,=,,0.25,1.667,,,,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
972,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,ZM241385,PubChem CID,176407,Inverse agonist,K(d),Binding - Radioligand saturation,1.8,nM,=,,4.3,2.389,,,,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
997,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,0.31,µM,=,,3.0,9.677,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
1008,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,37.6,13.926,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
1090,10.1016/S0006-2952(00)00357-9,aa2ar_human,278,H,Y,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.032,µM,=,,0.065,2.031,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.952709,HA278Y,ADORA2A
29,10.1021/jm0300431,aa2ar_human,88,T,E,Cid13307390,PubChem CID,13307390,Full agonist,K(i),Binding - Radioligand competition/displacement,46.1,µM,=,,57.0,1.236,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.0999683,TA88E,ADORA2A
219,10.1021/jm0300431,aa2ar_human,88,T,E,CID 85129620,PubChem CID,85129620,Full agonist,K(i),Binding - Radioligand competition/displacement,67.0,µM,=,,57.0,-1.175,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.0999683,TA88E,ADORA2A
468,10.1021/jm0300431,aa2ar_human,88,T,E,5'-Deoxy-5'-aminoadenosine,PubChem CID,266234,Full agonist,K(i),Binding - Radioligand competition/displacement,534.0,µM,=,,492.0,-1.086,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.0999683,TA88E,ADORA2A
722,10.1021/jm0300431,aa2ar_human,88,T,E,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.84,nM,=,,0.67,-1.253,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.0999683,TA88E,ADORA2A
753,10.1021/jm0300431,aa2ar_human,88,T,E,522607-99-4,PubChem CID,85116573,Full agonist,K(i),Binding - Radioligand competition/displacement,79.0,µM,=,,64.0,-1.235,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.0999683,TA88E,ADORA2A
31,7775460,aa2ar_human,281,S,T,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,17.3,-3.65,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
225,7775460,aa2ar_human,281,S,T,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,30.5,-10.417,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
336,7775460,aa2ar_human,281,S,T,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,17.1,-1.269,,,,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
629,7775460,aa2ar_human,281,S,T,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,6.6,-3.012,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
738,7775460,aa2ar_human,281,S,T,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,13.7,-11.111,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
799,7775460,aa2ar_human,281,S,T,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,15.6,1.545,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
852,7775460,aa2ar_human,281,S,T,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,80.5,-3.03,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0477951,SA281T,ADORA2A
33,7775460,aa2ar_human,277,S,A,XAC,PubChem CID,5697,Inverse agonist,K(d),Binding - Radioligand saturation,9.4,nM,=,,6.7,-1.403,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
69,10.1021/jm2003798,aa2ar_human,277,S,A,Chromone1d,PubChem CID,5310837,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.1,,=,,6.2,-1.259,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
71,7775460,aa2ar_human,277,S,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand saturation,0.208,µM,=,,81.3,390.865,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
128,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,10.0,-5.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
162,7775460,aa2ar_human,277,S,A,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand saturation,0.0407,µM,=,,43.6,1071.253,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
185,10.1021/jm2003798,aa2ar_human,277,S,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,8.6,7.943,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
279,7775460,aa2ar_human,277,S,A,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand saturation,1.45,µM,=,,96.0,66.207,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
289,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,9.9,-25.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
293,10.1021/jm2003798,aa2ar_human,277,S,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,6.1,-1.585,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
317,10.1021/jm2003798,aa2ar_human,277,S,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,6.2,-1.996,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
393,10.1021/jm2003798,aa2ar_human,277,S,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,5.8,1.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
411,7775460,aa2ar_human,277,S,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand saturation,0.792,µM,=,,33.8,42.677,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
469,10.1124/mol.111.075937,aa2ar_human,277,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,2.9,-1.172,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
483,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,7.7,-10.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
485,10.1124/mol.111.075937,aa2ar_human,277,S,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,8.2,-2.513,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
490,10.1021/jm2003798,aa2ar_human,277,S,A,Chromone1a,PubChem CID,740769,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,7.6,-1.996,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
518,10.1021/jm2003798,aa2ar_human,277,S,A,NOTDISCLOSED,,NOT DISCLOSED,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.0,,=,,5.4,3.981,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
546,10.1021/jm2003798,aa2ar_human,277,S,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,8.9,2.512,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
575,10.1124/mol.111.075937,aa2ar_human,277,S,A,CGS21680,PubChem CID,3086599,Full agonist,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,7.8,-5.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
592,10.1021/jm2003798,aa2ar_human,277,S,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),pK(d),Biing - Surface plasmon resonance,5.5,,=,,5.5,1.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
622,10.1021/jm2003798,aa2ar_human,277,S,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,8.0,-1.996,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
680,10.1021/jm2003798,aa2ar_human,277,S,A,Caffeine,PubChem CID,2519,Inverse agonist,pK(d),Biing - Surface plasmon resonance,4.6,,=,,5.3,-5.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
743,7775460,aa2ar_human,277,S,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,210.0,70.0,,,,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
798,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,9.1,-7.937,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
832,7775460,aa2ar_human,277,S,A,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand saturation,0.373,µM,=,,40.0,107.239,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
859,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,9.2,-1.996,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
874,7775460,aa2ar_human,277,S,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand saturation,20.7,nM,=,,17.5,-1.183,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
883,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,9.3,-6.329,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
898,10.1124/mol.111.075937,aa2ar_human,277,S,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,5.6,125.893,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
906,10.1021/jm2003798,aa2ar_human,277,S,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,6.6,-5.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
1017,7775460,aa2ar_human,277,S,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand saturation,0.0725,µM,=,,29.1,401.379,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
1021,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3e,PubChem CID,86676119,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,9.4,-15.873,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
1044,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,6.9,10.0,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
1056,7775460,aa2ar_human,277,S,A,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand saturation,663.0,nM,=,,219.0,-3.03,,,XAC,25.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
1067,10.1021/jm2003798,aa2ar_human,277,S,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,10.0,-6.329,,,,0.0,0.0,=,0.0,,P29274,-0.503333,SA277A,ADORA2A
37,10.1021/jm0300431,aa2ar_human,278,H,D,CID 85129620,PubChem CID,85129620,Full agonist,K(i),Binding - Radioligand competition/displacement,67.0,µM,=,,87.0,1.299,,,ZM241385,0.0,0.0,=,0.0,,P29274,6.4285,HA278D,ADORA2A
175,10.1021/jm0300431,aa2ar_human,278,H,D,Cid13307390,PubChem CID,13307390,Full agonist,K(i),Binding - Radioligand competition/displacement,46.1,µM,=,,121.0,2.625,,,ZM241385,0.0,0.0,=,0.0,,P29274,6.4285,HA278D,ADORA2A
187,10.1021/jm0300431,aa2ar_human,278,H,D,522607-99-4,PubChem CID,85116573,Full agonist,K(i),Binding - Radioligand competition/displacement,79.0,µM,=,,59.0,-1.339,,,ZM241385,0.0,0.0,=,0.0,,P29274,6.4285,HA278D,ADORA2A
463,10.1021/jm0300431,aa2ar_human,278,H,D,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.84,nM,=,,0.41,-2.049,,,ZM241385,0.0,0.0,=,0.0,,P29274,6.4285,HA278D,ADORA2A
1007,10.1021/jm0300431,aa2ar_human,278,H,D,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,21.4,nM,=,,19.1,-1.12,,,ZM241385,0.0,0.0,=,0.0,,P29274,6.4285,HA278D,ADORA2A
40,10.1124/mol.111.075937,aa2ar_human,85,L,R,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,4.9,630.957,,,,0.0,0.0,=,0.0,,P29274,1.74569,LA85R,ADORA2A
1146,10.1124/mol.111.075937,aa2ar_human,85,L,R,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,6.4,25.119,,,,0.0,0.0,=,0.0,,P29274,1.74569,LA85R,ADORA2A
41,7775460,aa2ar_human,277,S,T,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,39.8,2.0,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
111,7775460,aa2ar_human,277,S,T,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,305.0,1.25,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
220,7775460,aa2ar_human,277,S,T,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,201.0,1.322,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
256,7775460,aa2ar_human,277,S,T,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,12.2,1.208,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
503,7775460,aa2ar_human,277,S,T,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,65.9,1.043,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
908,7775460,aa2ar_human,277,S,T,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,23.6,1.088,,,,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
947,7775460,aa2ar_human,277,S,T,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,534.0,1.679,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.971542,SA277T,ADORA2A
43,8794889,aa2ar_human,88,T,R,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,5.0,4.167,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
427,8794889,aa2ar_human,88,T,R,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,0.118,µM,=,,9.14,77.458,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
571,8794889,aa2ar_human,88,T,R,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,65.5,nM,=,,4090.0,62.443,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
648,8794889,aa2ar_human,88,T,R,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.758,nM,=,,2.0,2.639,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
763,8794889,aa2ar_human,88,T,R,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,0.0267,µM,=,,4.62,173.034,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
764,8794889,aa2ar_human,88,T,R,XAC,PubChem CID,5697,Inverse agonist,K(d),Binding - Radioligand saturation,8.83,nM,=,,4.21,-2.096,,,,0.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
881,8794889,aa2ar_human,88,T,R,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.1,nM,=,,2660.0,139.267,,,XAC,134.0,0.0,=,0.0,,P29274,-0.320327,TA88R,ADORA2A
44,10.1021/jm2003798,aa2ar_human,85,L,A,NOTDISCLOSED,,NOT DISCLOSED,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.0,,=,,5.2,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
51,10.1124/mol.111.075937,aa2ar_human,85,L,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,5.7,100.0,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
70,10.1021/jm2003798,aa2ar_human,85,L,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,3.0,794.328,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
104,10.1021/jm2003798,aa2ar_human,85,L,A,Caffeine,PubChem CID,2519,Inverse agonist,pK(d),Biing - Surface plasmon resonance,4.6,,=,,3.0,39.811,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
118,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,7.8,5.012,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
121,10.1021/jm2003798,aa2ar_human,85,L,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),pK(d),Biing - Surface plasmon resonance,5.5,,=,,3.7,63.096,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
161,10.1021/jm2003798,aa2ar_human,85,L,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.1,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
228,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,8.2,12.589,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
319,10.1021/jm2003798,aa2ar_human,85,L,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,4.8,12.589,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
378,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,8.1,12.589,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
439,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3e,PubChem CID,86676119,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,7.4,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
470,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,7.4,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
544,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,5.6,12.589,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
551,10.1021/jm2003798,aa2ar_human,85,L,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,7.5,63.096,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
618,10.1021/jm2003798,aa2ar_human,85,L,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,3.0,630.957,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
670,10.1021/jm2003798,aa2ar_human,85,L,A,Chromone1d,PubChem CID,5310837,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.1,,=,,5.3,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
729,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,7.0,7.943,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
752,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,8.1,6.31,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
781,10.1021/jm2003798,aa2ar_human,85,L,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,7.2,199.526,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
818,10.1021/jm2003798,aa2ar_human,85,L,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,7.6,7.943,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
1015,10.1021/jm2003798,aa2ar_human,85,L,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,7.4,1.995,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
1104,10.1021/jm2003798,aa2ar_human,85,L,A,Chromone1a,PubChem CID,740769,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,6.0,19.953,,,,0.0,0.0,=,0.0,,P29274,2.17898,LA85A,ADORA2A
48,8794889,aa2ar_human,89,Q,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,19.1,-5.236,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
240,8794889,aa2ar_human,89,Q,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand competition/displacement,31.0,nM,=,,6.7,-4.63,,,,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
247,8794889,aa2ar_human,89,Q,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,31.0,nM,=,,6.7,-4.63,,,,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
295,8794889,aa2ar_human,89,Q,A,NECA,PubChem CID,448222,Full agonist,EC50,Functional - cAMP accumulation,44.5,nM,=,,2.91,-15.385,,,,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
410,8794889,aa2ar_human,89,Q,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,27.6,nM,=,,1.9,-14.493,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
415,8794889,aa2ar_human,89,Q,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,0.915,nM,=,,0.223,-4.098,,,,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
492,8794889,aa2ar_human,89,Q,A,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,435.0,nM,=,,3.21,-142.857,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
645,8794889,aa2ar_human,89,Q,A,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,1330.0,nM,=,,41.2,-32.258,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
721,8794889,aa2ar_human,89,Q,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,8.71,nM,=,,2.01,-4.329,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
771,8794889,aa2ar_human,89,Q,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.95,nM,=,,0.455,-4.292,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
784,8794889,aa2ar_human,89,Q,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,299.0,nM,=,,28.6,-10.417,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
863,8794889,aa2ar_human,89,Q,A,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,859.0,nM,=,,133.0,-6.452,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
918,8794889,aa2ar_human,89,Q,A,DPMA,PubChem CID,10391971,Full agonist,EC50,Functional - cAMP accumulation,10.8,nM,=,,2.73,-3.953,,,,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
984,8794889,aa2ar_human,89,Q,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.525,nM,=,,0.197,-2.667,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
1133,8794889,aa2ar_human,89,Q,A,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.85,nM,=,,0.246,-7.519,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.0884,QA89A,ADORA2A
52,10.1124/mol.115.102657,aa2ar_human,68,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.85,-1.047,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.66902,TA68A,ADORA2A
168,10.1124/mol.115.102657,aa2ar_human,68,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0113,-1.053,,,,0.0,0.0,=,0.0,,P29274,1.66902,TA68A,ADORA2A
55,7775460,aa2ar_human,278,H,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,920.0,306.667,,,,72.0,0.0,=,0.0,,P29274,1.87367,HA278A,ADORA2A
57,7775460,aa2ar_human,180,F,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,46.0,2.312,,,CGS21680,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
93,7775460,aa2ar_human,180,F,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,90.3,1.429,,,CGS21680,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
110,7775460,aa2ar_human,180,F,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,15.1,-1.437,,,,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
480,7775460,aa2ar_human,180,F,A,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,104.0,-2.347,,,CGS21680,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
789,7775460,aa2ar_human,180,F,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,4500.0,14.151,,,CGS21680,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
1083,7775460,aa2ar_human,180,F,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,13.7,1.356,,,CGS21680,0.0,0.0,=,0.0,,P29274,2.80849,FA180A,ADORA2A
62,10.1021/jm2003798,aa2ar_human,271,Y,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,8.6,7.943,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
105,10.1021/jm2003798,aa2ar_human,271,Y,A,NOTDISCLOSED,,NOT DISCLOSED,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.0,,=,,5.5,3.162,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
389,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.2,1.995,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
429,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3e,PubChem CID,86676119,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,8.0,1.585,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
440,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,8.6,1.995,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
446,10.1021/jm2003798,aa2ar_human,271,Y,A,Chromone1a,PubChem CID,740769,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,6.6,5.012,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
491,10.1021/jm2003798,aa2ar_human,271,Y,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),pK(d),Biing - Surface plasmon resonance,5.5,,=,,5.6,-1.259,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
545,10.1021/jm2003798,aa2ar_human,271,Y,A,Chromone1d,PubChem CID,5310837,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.1,,=,,5.5,3.981,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
548,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,7.8,1.259,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
586,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,7.9,1.995,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
604,10.1021/jm2003798,aa2ar_human,271,Y,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,8.7,3.981,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
640,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,7.9,25.119,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
641,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,5.9,6.31,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
687,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,8.1,12.589,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
735,10.1021/jm2003798,aa2ar_human,271,Y,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,5.5,1.995,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
762,10.1021/jm2003798,aa2ar_human,271,Y,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.9,1.0,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
780,10.1021/jm2003798,aa2ar_human,271,Y,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.4,1.259,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
1041,10.1021/jm2003798,aa2ar_human,271,Y,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,6.0,-1.259,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
1111,10.1021/jm2003798,aa2ar_human,271,Y,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.9,1.0,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
1112,10.1021/jm2003798,aa2ar_human,271,Y,A,Caffeine,PubChem CID,2519,Inverse agonist,pK(d),Biing - Surface plasmon resonance,4.6,,=,,4.6,1.0,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
1144,10.1021/jm2003798,aa2ar_human,271,Y,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,7.2,3.162,,,,0.0,0.0,=,0.0,,P29274,1.81543,YA271A,ADORA2A
68,10.1124/mol.115.102657,aa2ar_human,148,Q,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.78,1.122,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.612197,QA148A,ADORA2A
401,10.1124/mol.115.102657,aa2ar_human,148,Q,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0148,1.244,,,,0.0,0.0,=,0.0,,P29274,-0.612197,QA148A,ADORA2A
76,10.1021/jm2003798,aa2ar_human,177,M,A,Chromone1c,SMILES,CCc1cc2C(=O)C(=COc2cc1OC(N)=O)c3scc(C)n3,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.9,1.0,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
132,10.1074/jbc.M109.096974,aa2ar_human,177,M,A,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,357.0,nM,=,,2440.0,6.835,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
180,10.1021/jm2003798,aa2ar_human,177,M,A,ZM241385,SMILES,Nc1nc(NCCc2ccc(O)cc2)nc3nc(nn13)c4occc4,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,9.2,1.259,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
329,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3b,PubChem CID,70689850,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.9,,=,,8.9,1.0,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
394,10.1021/jm2003798,aa2ar_human,177,M,A,SCH420814,PubChem CID,10117987,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.5,,=,,8.6,7.943,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
464,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3d,PubChem CID,56844240,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.2,,=,,8.3,-1.259,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
497,10.1021/jm2003798,aa2ar_human,177,M,A,XAC,PubChem CID,5697,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.7,,=,,7.5,1.585,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
613,10.1021/jm2003798,aa2ar_human,177,M,A,Chromone1a,PubChem CID,740769,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.3,,=,,7.4,-1.259,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
712,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine15,SMILES,CN1CCN(CC1)C(=O)c2cccc(c2)c3nc(N)nc(n3)c4ccccc4O,Inverse agonist,pK(d),Biing - Surface plasmon resonance,7.9,,=,,7.6,1.995,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
725,10.1021/jm2003798,aa2ar_human,177,M,A,Chromone1e,PubChem CID,5425546,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.8,,=,,5.6,1.585,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
800,10.1074/jbc.M109.096974,aa2ar_human,177,M,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,1.6,nM,=,,12.0,7.5,,,,26.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
853,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3c,PubChem CID,53353516,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,8.5,1.0,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
909,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3f,PubChem CID,87370822,Inverse agonist,pK(d),Biing - Surface plasmon resonance,8.5,,=,,9.0,-3.165,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
926,10.1074/jbc.M109.096974,aa2ar_human,177,M,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Other,2.4,nM,=,,10.4,4.333,,,,46.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
931,10.1021/jm2003798,aa2ar_human,177,M,A,KW6002,PubChem CID,5311037,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.6,1.995,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
985,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3h,PubChem CID,56964225,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.2,,=,,8.4,6.31,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
1046,10.1074/jbc.M109.096974,aa2ar_human,177,M,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,7.63,nM,=,,6.86,-1.112,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
1051,10.1021/jm2003798,aa2ar_human,177,M,A,Chromone1b,PubChem CID,5413075,Inverse agonist,pK(d),Biing - Surface plasmon resonance,5.9,,=,,5.6,1.995,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
1078,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3g,PubChem CID,86676123,Inverse agonist,pK(d),Biing - Surface plasmon resonance,9.3,,=,,8.5,6.31,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
1098,10.1074/jbc.M109.096974,aa2ar_human,177,M,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,94.0,nM,=,,66.0,-1.425,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
1122,10.1021/jm2003798,aa2ar_human,177,M,A,Triazine3a,PubChem CID,53354627,Inverse agonist,pK(d),Biing - Surface plasmon resonance,6.7,,=,,6.1,3.981,,,,0.0,0.0,=,0.0,,P29274,2.86763,MA177A,ADORA2A
81,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,CPA,PubChem CID,4402,Full agonist,K(i),Binding - Radioligand competition/displacement,2.7,µM,=,,21.9,8.111,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
151,10.1016/0014-2999(96)00495-5,aa2ar_human,13,E,Q,CGS15943,PubChem CID,2690,Inverse agonist,IC50,Binding - Radioligand competition/displacement,2.2,nM,=,,2.7,1.227,,,XAC,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
172,10.1016/0014-2999(96)00495-5,aa2ar_human,13,E,Q,XAC,PubChem CID,5697,Inverse agonist,IC50,Binding - Radioligand saturation,18.0,nM,=,,42.0,2.333,,,,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
297,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.032,µM,=,,0.031,-1.032,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
391,10.1016/0014-2999(96)00495-5,aa2ar_human,13,E,Q,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,52.0,µM,=,,46.0,-1.13,,,XAC,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
424,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,ZM241385,PubChem CID,176407,Inverse agonist,K(d),Binding - Radioligand saturation,1.8,nM,=,,3.0,1.667,,,,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
445,10.1016/0014-2999(96)00495-5,aa2ar_human,13,E,Q,CGS21680,PubChem CID,3086599,Full agonist,IC50,Binding - Radioligand competition/displacement,0.85,µM,=,,13.0,15.294,,,XAC,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
481,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,0.28,µM,=,,2.5,8.929,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
495,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,ZM241385,PubChem CID,176407,Inverse agonist,k1,Binding - Radioligand kinetics (association/dissociation),0.15,nM-1 min-1,=,,0.32,2.133,,,,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
689,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,0.31,µM,=,,0.94,3.032,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
834,10.1016/0014-2999(96)00495-5,aa2ar_human,13,E,Q,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,2.1,nM,=,,17.0,8.095,,,,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
879,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.008,µM,=,,0.003,-2.667,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
882,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,Theophylline,PubChem CID,2153,Inverse agonist,K(i),Binding - Radioligand competition/displacement,4.7,µM,=,,9.9,2.106,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
934,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.06,µM,=,,0.33,5.5,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
986,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.002,µM,=,,0.002,1.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
1039,10.1016/S0006-2952(00)00357-9,aa2ar_human,13,E,Q,ZM241385,PubChem CID,176407,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.29,min-1,=,,0.6,2.069,,,,0.0,0.0,=,0.0,,P29274,0.925869,EA13Q,ADORA2A
84,8609897,aa2ar_human,161,E,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.71,nM,=,,0.287,-5.952,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
230,8609897,aa2ar_human,161,E,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,6.98,nM,=,,7.19,1.03,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
568,8609897,aa2ar_human,161,E,A,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,456.0,nM,=,,433.0,-1.053,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
626,8609897,aa2ar_human,161,E,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,11.4,nM,=,,23.9,2.096,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
829,8609897,aa2ar_human,161,E,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,144.0,nM,=,,221.0,1.535,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
846,8609897,aa2ar_human,161,E,A,(r)-N6-Phenylisopropyladenosine,PubChem CID,93205,Full agonist,K(i),Binding - Radioligand competition/displacement,158.0,nM,=,,264.0,1.671,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
895,8609897,aa2ar_human,161,E,A,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,36.3,nM,=,,61.2,1.686,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
996,8609897,aa2ar_human,161,E,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,22.3,nM,=,,41.7,1.87,,,,0.0,0.0,=,0.0,,P29274,0.126809,EA161A,ADORA2A
90,10.1124/mol.115.102657,aa2ar_human,153,K,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.91,-1.202,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.479467,KA153A,ADORA2A
529,10.1007/s11302-016-9549-9,aa2ar_human,153,K,A,ZM241385,PubChem CID,176408,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.91,,=,,7.83,1.202,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.479467,KA153A,ADORA2A
598,10.1021/ml5002486,aa2ar_human,153,K,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,1.81,nM,=,,1.47,-1.232,,,,0.0,0.0,=,0.0,,P29274,0.479467,KA153A,ADORA2A
686,10.1124/mol.115.102657,aa2ar_human,153,K,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0094,-1.266,,,,0.0,0.0,=,0.0,,P29274,0.479467,KA153A,ADORA2A
94,10.1124/mol.114.097360,aa2ar_human,267,L,A,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - cAMP accumulation,9.05,,=,,8.81,1.738,,,,0.0,0.0,=,0.0,,P29274,0.719236,LA267A,ADORA2A
576,10.1124/mol.115.102657,aa2ar_human,267,L,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0051,-2.331,,,,0.0,0.0,=,0.0,,P29274,0.719236,LA267A,ADORA2A
861,10.1124/mol.115.102657,aa2ar_human,267,L,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.78,1.122,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.719236,LA267A,ADORA2A
1074,10.1124/mol.114.097360,aa2ar_human,267,L,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,8.27,,=,,9.66,-24.39,,,,0.0,0.0,=,0.0,,P29274,0.719236,LA267A,ADORA2A
95,8794889,aa2ar_human,90,S,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,27.6,nM,=,,5.9,-4.673,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
192,8794889,aa2ar_human,90,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.525,nM,=,,0.36,-1.458,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
443,8794889,aa2ar_human,90,S,A,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.85,nM,=,,1.5,-1.233,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
486,8794889,aa2ar_human,90,S,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,8.71,nM,=,,16.6,1.906,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
506,8794889,aa2ar_human,90,S,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,31.0,nM,=,,16.1,-1.927,,,,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
517,8794889,aa2ar_human,90,S,A,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,859.0,nM,=,,508.0,-1.692,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
700,8794889,aa2ar_human,90,S,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,299.0,nM,=,,76.1,-3.922,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
761,8794889,aa2ar_human,90,S,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,19.4,-5.155,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
769,8794889,aa2ar_human,90,S,A,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,1330.0,nM,=,,675.0,-1.969,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
946,8794889,aa2ar_human,90,S,A,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,435.0,nM,=,,78.5,-5.556,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
981,8794889,aa2ar_human,90,S,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.95,nM,=,,0.925,-2.11,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.974103,SA90A,ADORA2A
102,10.1021/jm970084v,aa2ar_human,250,H,N,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,106.0,µM,=,,54.3,-1.953,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
217,10.1021/jm970084v,aa2ar_human,250,H,N,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,38.1,nM,=,,35.9,-1.062,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
355,10.1021/jm970084v,aa2ar_human,250,H,N,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,21.6,nM,=,,5.24,-4.115,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
361,10.1021/jm970084v,aa2ar_human,250,H,N,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,226.0,nM,=,,291.0,1.288,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
381,10.1021/jm970084v,aa2ar_human,250,H,N,Nifedipine,PubChem CID,4485,Inverse agonist,K(i),Binding - Radioligand competition/displacement,24.4,µM,=,,22.2,-1.099,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
609,10.1021/jm970084v,aa2ar_human,250,H,N,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,nM,=,,0.457,3.218,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
892,10.1021/jm970084v,aa2ar_human,250,H,N,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,36.4,nM,=,,7.6,-4.785,,,,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
951,10.1021/jm970084v,aa2ar_human,250,H,N,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,7.89,nM,=,,15.6,1.977,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
977,10.1021/jm970084v,aa2ar_human,250,H,N,Galangin,PubChem CID,5281616,Inverse agonist,K(i),Binding - Radioligand competition/displacement,16.7,µM,=,,33.0,1.976,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
1001,10.1021/jm970084v,aa2ar_human,250,H,N,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,370.0,nM,=,,32.0,-11.628,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
1061,10.1021/jm970084v,aa2ar_human,250,H,N,Amiloride,PubChem CID,16231,Allosteric inverse agonist,K(i),Binding - Radioligand competition/displacement,12.0,µM,=,,3.28,-3.663,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.33042,HA250N,ADORA2A
109,8794889,aa2ar_human,89,Q,R,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand competition/displacement,31.0,nM,=,,50.8,1.639,,,,0.0,0.0,=,0.0,,P29274,2.2476,QA89R,ADORA2A
116,10.1124/mol.111.075937,aa2ar_human,168,F,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,5.0,630.957,,,,0.0,0.0,=,0.0,,P29274,2.56409,FA168A,ADORA2A
920,10.1124/mol.111.075937,aa2ar_human,168,F,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,4.9,630.957,,,,0.0,0.0,=,0.0,,P29274,2.56409,FA168A,ADORA2A
1053,10.1074/jbc.M109.096974,aa2ar_human,168,F,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,7.63,nM,=,,5.84,-1.307,,,,0.0,0.0,=,0.0,,P29274,2.56409,FA168A,ADORA2A
131,10.1124/mol.115.102657,aa2ar_human,156,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0128,1.076,,,,0.0,0.0,=,0.0,,P29274,-0.279454,SA156A,ADORA2A
1050,10.1124/mol.115.102657,aa2ar_human,156,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.98,-1.412,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.279454,SA156A,ADORA2A
134,10.1124/mol.115.102657,aa2ar_human,256,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.1994,16.756,,,,0.0,0.0,=,0.0,,P29274,0.299297,TA256A,ADORA2A
865,10.1124/mol.115.102657,aa2ar_human,256,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.43,2.512,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.299297,TA256A,ADORA2A
145,8794889,aa2ar_human,91,S,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,27.6,nM,=,,35.5,1.286,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
226,8794889,aa2ar_human,91,S,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.95,nM,=,,1.95,1.0,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
276,10.1124/mol.114.095737,aa2ar_human,91,S,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,8.9,µM,=,,8.2,-1.086,,,ZM241385,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
315,8794889,aa2ar_human,91,S,A,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,859.0,nM,=,,1880.0,2.189,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
408,8794889,aa2ar_human,91,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.525,nM,=,,1.09,2.076,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
444,8794889,aa2ar_human,91,S,A,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.85,nM,=,,2.3,1.243,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
552,8794889,aa2ar_human,91,S,A,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,1330.0,nM,=,,2530.0,1.902,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
573,8794889,aa2ar_human,91,S,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,8.71,nM,=,,18.1,2.078,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
657,8794889,aa2ar_human,91,S,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,224.0,2.24,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
681,8794889,aa2ar_human,91,S,A,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,435.0,nM,=,,614.0,1.411,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
723,10.1124/mol.114.095737,aa2ar_human,91,S,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,16.0,µM,=,,13.0,-1.232,,,NECA,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
801,8794889,aa2ar_human,91,S,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,31.0,nM,=,,59.7,1.926,,,,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
803,8794889,aa2ar_human,91,S,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,299.0,nM,=,,314.0,1.05,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
880,10.1124/mol.114.095737,aa2ar_human,91,S,A,NECA,PubChem CID,448222,Full agonist,K(d),Binding - Radioligand saturation,81.0,nM,=,,258.0,3.185,,,,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
979,10.1124/mol.114.095737,aa2ar_human,91,S,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,4.6,nM,=,,7.0,1.522,,,,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
998,10.1124/mol.114.095737,aa2ar_human,91,S,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.5,µM,=,,2.3,-1.087,,,NECA,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
1052,10.1124/mol.114.095737,aa2ar_human,91,S,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,63.0,µM,=,,82.0,1.302,,,ZM241385,0.0,0.0,=,0.0,,P29274,-1.08194,SA91A,ADORA2A
176,10.1021/acs.jmedchem.6b00653,aa2ar_human,264,H,A,ZM241385,PubChem CID,5311506,Inverse agonist,%,Binding - Radioligand saturation,105.0,%,=,,106.0,-1.009,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
183,10.1124/mol.111.075937,aa2ar_human,264,H,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,8.2,-2.513,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
207,10.1124/mol.115.102657,aa2ar_human,264,H,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.69,1.38,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
409,10.1124/mol.114.097360,aa2ar_human,264,H,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,8.27,,=,,7.52,5.623,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
449,10.1021/acs.jmedchem.6b00653,aa2ar_human,264,H,A,CID44394716,PubChem CID,44394716,Inverse agonist,%,Binding - Radioligand saturation,76.0,%,=,,97.0,-1.276,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
845,10.1021/acs.jmedchem.6b00653,aa2ar_human,264,H,A,CID86302363,PubChem CID,86302363,Inverse agonist,%,Binding - Radioligand saturation,105.0,%,=,,105.0,1.0,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
878,10.1124/mol.115.102657,aa2ar_human,264,H,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.2235,18.782,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
973,10.1124/mol.111.075937,aa2ar_human,264,H,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,7.1,3.981,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
1049,10.1124/mol.114.097360,aa2ar_human,264,H,A,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - cAMP accumulation,9.05,,=,,8.18,7.413,,,,0.0,0.0,=,0.0,,P29274,-0.0605712,HA264A,ADORA2A
178,10.1074/jbc.M109.096974,aa2ar_human,168,F,W,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,7.63,nM,=,,7.49,-1.018,,,,0.0,0.0,=,0.0,,P29274,1.24638,FA168W,ADORA2A
203,10.1074/jbc.M109.096974,aa2ar_human,168,F,W,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,94.0,nM,=,,39.0,-2.41,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.24638,FA168W,ADORA2A
412,10.1074/jbc.M109.096974,aa2ar_human,168,F,W,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,1.6,nM,=,,6.4,4.0,,,,40.0,0.0,=,0.0,,P29274,1.24638,FA168W,ADORA2A
534,10.1074/jbc.M109.096974,aa2ar_human,168,F,W,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Other,2.4,nM,=,,3.6,1.5,,,,97.0,0.0,=,0.0,,P29274,1.24638,FA168W,ADORA2A
693,10.1074/jbc.M109.096974,aa2ar_human,168,F,W,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,357.0,nM,=,,534.0,1.496,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.24638,FA168W,ADORA2A
179,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.11,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
236,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.61,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
284,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.48,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
454,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.85,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
540,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.44,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
542,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.11,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
637,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.88,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
695,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.35,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
823,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-2.222,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
886,10.1016/j.str.2017.06.012,aa2ar_human,59,A,V,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,2.89,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.10813,AA59V,ADORA2A
182,8794889,aa2ar_human,277,S,C,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.525,nM,=,,1.35,2.571,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
210,8794889,aa2ar_human,277,S,C,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,299.0,nM,=,,1590.0,5.318,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
334,8794889,aa2ar_human,277,S,C,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,435.0,nM,=,,1755.0,4.034,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
400,8794889,aa2ar_human,277,S,C,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,859.0,nM,=,,279.0,-3.077,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
507,8794889,aa2ar_human,277,S,C,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,27.6,nM,=,,129.0,4.674,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
508,8794889,aa2ar_human,277,S,C,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.85,nM,=,,4.7,2.541,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
554,8794889,aa2ar_human,277,S,C,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,1330.0,nM,=,,3580.0,2.692,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
615,8794889,aa2ar_human,277,S,C,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,100.0,nM,=,,384.0,3.84,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
773,8794889,aa2ar_human,277,S,C,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.95,nM,=,,1.53,-1.274,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
1040,8794889,aa2ar_human,277,S,C,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,8.71,nM,=,,10.3,1.183,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
1143,8794889,aa2ar_human,277,S,C,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,31.0,nM,=,,37.2,1.2,,,,0.0,0.0,=,0.0,,P29274,-0.532007,SA277C,ADORA2A
205,10.1074/jbc.M109.096974,aa2ar_human,249,L,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,7.63,nM,=,,6.51,-1.172,,,,0.0,0.0,=,0.0,,P29274,1.85305,LA249A,ADORA2A
229,10.1021/jm970084v,aa2ar_human,84,V,L,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,38.1,nM,=,,18.9,-2.016,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
350,10.1021/jm970084v,aa2ar_human,84,V,L,Nifedipine,PubChem CID,4485,Inverse agonist,K(i),Binding - Radioligand competition/displacement,24.4,µM,=,,22.2,-1.099,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
405,10.1021/jm970084v,aa2ar_human,84,V,L,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,7.89,nM,=,,45.6,5.779,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
447,10.1021/jm970084v,aa2ar_human,84,V,L,Amiloride,PubChem CID,16231,Allosteric inverse agonist,K(i),Binding - Radioligand competition/displacement,12.0,µM,=,,11.6,-1.034,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
608,10.1021/jm970084v,aa2ar_human,84,V,L,Galangin,PubChem CID,5281616,Inverse agonist,K(i),Binding - Radioligand competition/displacement,16.7,µM,=,,18.1,1.084,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
663,10.1021/jm970084v,aa2ar_human,84,V,L,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,21.6,nM,=,,21.5,-1.005,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
751,10.1021/jm970084v,aa2ar_human,84,V,L,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,370.0,nM,=,,143.0,-2.591,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
820,10.1021/jm970084v,aa2ar_human,84,V,L,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,nM,=,,0.842,5.93,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
858,10.1021/jm970084v,aa2ar_human,84,V,L,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,226.0,nM,=,,788.0,3.487,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
1037,10.1021/jm970084v,aa2ar_human,84,V,L,BTH4,ChEMBL Compound ID,CHEMBL87496,Inverse agonist,K(i),Binding - Radioligand competition/displacement,106.0,µM,=,,72.6,-1.46,,,CGS21680,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
1048,10.1021/jm970084v,aa2ar_human,84,V,L,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,36.4,nM,=,,27.3,-1.333,,,,0.0,0.0,=,0.0,,P29274,-1.10516,VA84L,ADORA2A
239,7775460,aa2ar_human,277,S,N,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,12.8,1.267,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
311,7775460,aa2ar_human,277,S,N,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,311.0,1.275,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
321,7775460,aa2ar_human,277,S,N,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,43.0,2.161,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
550,7775460,aa2ar_human,277,S,N,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,25.0,1.152,,,,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
669,7775460,aa2ar_human,277,S,N,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,60.0,-1.054,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
965,7775460,aa2ar_human,277,S,N,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,631.0,1.984,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
991,7775460,aa2ar_human,277,S,N,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,221.0,1.454,,,CGS21680,0.0,0.0,=,0.0,,P29274,4.76428,SA277N,ADORA2A
254,8609897,aa2ar_human,169,E,Q,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,144.0,nM,=,,946.0,6.569,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
338,8609897,aa2ar_human,169,E,Q,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,6.98,nM,=,,11.5,1.648,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
344,8609897,aa2ar_human,169,E,Q,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,11.4,nM,=,,253.0,22.193,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
395,8609897,aa2ar_human,169,E,Q,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,36.3,nM,=,,1.62,-22.222,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
625,8609897,aa2ar_human,169,E,Q,(r)-N6-Phenylisopropyladenosine,PubChem CID,93205,Full agonist,K(i),Binding - Radioligand competition/displacement,158.0,nM,=,,33.9,-4.651,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
655,8609897,aa2ar_human,169,E,Q,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,22.3,nM,=,,57.0,2.556,,,,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
658,8609897,aa2ar_human,169,E,Q,IB-MECA,PubChem CID,123683,Full agonist,K(i),Binding - Radioligand competition/displacement,456.0,nM,=,,53.4,-8.547,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
808,10.1124/mol.115.102657,aa2ar_human,169,E,Q,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.7329,61.588,,,,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
945,8609897,aa2ar_human,169,E,Q,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.71,nM,=,,2.26,1.322,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
1126,10.1124/mol.115.102657,aa2ar_human,169,E,Q,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,7.46,2.344,,,ZM241385,0.0,0.0,=,0.0,,P29274,-0.44715,EA169Q,ADORA2A
259,7775460,aa2ar_human,182,F,W,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,66.8,1.057,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
294,7775460,aa2ar_human,182,F,W,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,10.3,1.02,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
363,7775460,aa2ar_human,182,F,W,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,776.0,5.105,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
676,7775460,aa2ar_human,182,F,W,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,1600.0,5.031,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
703,7775460,aa2ar_human,182,F,W,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,756.0,3.098,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
730,7775460,aa2ar_human,182,F,W,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,66.0,3.041,,,,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
936,7775460,aa2ar_human,182,F,W,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,144.0,7.236,,,CGS21680,0.0,0.0,=,0.0,,P29274,1.15085,FA182W,ADORA2A
266,7775460,aa2ar_human,181,N,S,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,16.4,-1.214,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
426,7775460,aa2ar_human,181,N,S,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,24.8,1.143,,,,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
590,7775460,aa2ar_human,181,N,S,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,23.7,2.347,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
932,7775460,aa2ar_human,181,N,S,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,1340.0,8.816,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
1089,7775460,aa2ar_human,181,N,S,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,130.0,2.057,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
1121,7775460,aa2ar_human,181,N,S,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,981.0,4.02,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.0131492,NA181S,ADORA2A
271,8794889,aa2ar_human,88,T,A,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,0.0267,µM,=,,22.1,827.715,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
312,8794889,aa2ar_human,88,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.1,nM,=,,1590.0,83.246,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
385,10.1073/pnas.0804396105,aa2ar_human,88,T,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.52,mM,=,,0.86,-1.767,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
387,10.1124/mol.111.075937,aa2ar_human,88,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,3.4,nM,=,,3.1,-1.096,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
487,10.1124/mol.111.075937,aa2ar_human,88,T,A,CGS21680,PubChem CID,3086599,Full agonist,pK(i),Binding - Radioligand competition/displacement,7.1,,=,,6.9,1.585,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
527,8794889,aa2ar_human,88,T,A,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,65.5,nM,=,,5710.0,87.176,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
555,10.1124/mol.111.075937,aa2ar_human,88,T,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,7.9,-1.259,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
588,8794889,aa2ar_human,88,T,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,0.118,µM,=,,16.4,138.983,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
701,8794889,aa2ar_human,88,T,A,XAC,PubChem CID,5697,Inverse agonist,K(d),Binding - Radioligand saturation,8.83,nM,=,,10.8,1.223,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
711,8794889,aa2ar_human,88,T,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,7.98,6.65,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
795,10.1073/pnas.0804396105,aa2ar_human,88,T,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.002,mM,=,,0.002,1.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
814,8794889,aa2ar_human,88,T,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.758,nM,=,,3.47,4.578,,,XAC,77.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
826,10.1073/pnas.0804396105,aa2ar_human,88,T,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.16,mM,=,,30.0,187.5,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
862,10.1111/bph.12165,aa2ar_human,88,T,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,1.01,µM,=,,187.0,185.149,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
890,8794889,aa2ar_human,88,T,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,0.915,nM,=,,14.4,15.738,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
948,10.1111/bph.12165,aa2ar_human,88,T,A,Adenosine,PubChem CID,60961,Full agonist,EC50,Functional - Other,0.37,µM,=,,32.0,86.486,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
954,10.1111/bph.12165,aa2ar_human,88,T,A,Adenosine,PubChem CID,60961,Full agonist,K(i),Binding - Radioligand competition/displacement,0.36,µM,=,,2.71,7.528,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
1055,10.1124/mol.111.075937,aa2ar_human,88,T,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,4.5,1584.893,,,,0.0,0.0,=,0.0,,P29274,0.008595,TA88A,ADORA2A
273,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,DPCPX,PubChem CID,1329,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-5.556,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
291,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,SCH58261,PubChem CID,176408,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,3.8,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
631,10.1016/j.cell.2017.01.042,aa2ar_human,270,M,T,ZM241385,PubChem CID,176408,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,8.7,,=,,7.8,7.943,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
667,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,KW3902,PubChem CID,64627,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-5.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
690,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.47,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
718,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,SCH442416,PubChem CID,10668061,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,6.68,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
838,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,Istradefylline,PubChem CID,5311037,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.51,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
896,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,SLV320,PubChem CID,9953065,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.1,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
900,10.1016/j.cell.2017.01.042,aa2ar_human,270,M,T,DPCPX,PubChem CID,1329,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,6.2,,=,,7.0,-6.329,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
1003,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,PSB36,PubChem CID,11689583,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,-5.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
1028,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,4.03,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
1070,10.1016/j.str.2017.06.012,aa2ar_human,270,M,T,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.0,,=,,0.0,1.38,,,ZM241385,0.0,0.0,=,0.0,,P29274,1.55339,MA270T,ADORA2A
302,10.1073/pnas.0804396105,aa2ar_human,239,V,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.002,mM,=,,0.002,1.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.43318,VA239A,ADORA2A
522,10.1073/pnas.0804396105,aa2ar_human,239,V,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.16,mM,=,,30.0,187.5,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.43318,VA239A,ADORA2A
628,10.1111/bph.12165,aa2ar_human,239,V,A,NECA,PubChem CID,448222,Full agonist,EC50,,0.033,µM,=,,3.5,106.061,,,,0.0,0.0,=,0.0,,P29274,2.43318,VA239A,ADORA2A
757,10.1073/pnas.0804396105,aa2ar_human,239,V,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.52,mM,=,,0.86,-1.767,,,ZM241385,0.0,0.0,=,0.0,,P29274,2.43318,VA239A,ADORA2A
318,10.1016/j.bbamem.2014.11.010,aa2ar_human,146,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,51.7,-1.828,,,,0.0,0.0,=,0.0,,P29274,4.76553,CA146A,ADORA2A
322,10.1124/mol.115.102657,aa2ar_human,157,Q,A,ZM241385,PubChem CID,5311506,Inverse agonist,pK(i),Binding - Radioligand competition/displacement,7.83,,=,,8.03,-1.585,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.400636,QA157A,ADORA2A
903,10.1124/mol.115.102657,aa2ar_human,157,Q,A,ZM241385,PubChem CID,5311506,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.0119,min-1,=,,0.0112,-1.063,,,,0.0,0.0,=,0.0,,P29274,0.400636,QA157A,ADORA2A
323,10.1021/ml5002486,aa2ar_human,150,K,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,1.81,nM,=,,1.99,1.099,,,,0.0,0.0,=,0.0,,P29274,0.246203,KA150A,ADORA2A
328,8794889,aa2ar_human,88,T,S,XAC,PubChem CID,5697,Inverse agonist,K(d),Binding - Radioligand saturation,8.83,nM,=,,5.76,-1.534,,,,0.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
373,8794889,aa2ar_human,88,T,S,ZM241385,PubChem CID,5311506,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.758,nM,=,,1.16,1.53,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
423,8794889,aa2ar_human,88,T,S,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,0.0267,µM,=,,0.422,15.805,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
434,8794889,aa2ar_human,88,T,S,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,65.5,nM,=,,655.0,10.0,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
674,8794889,aa2ar_human,88,T,S,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,0.915,nM,=,,48.0,52.459,,,,0.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
938,8794889,aa2ar_human,88,T,S,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,0.118,µM,=,,0.776,6.576,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
1009,8794889,aa2ar_human,88,T,S,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.2,nM,=,,6.28,5.233,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
1030,8794889,aa2ar_human,88,T,S,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.1,nM,=,,778.0,40.733,,,XAC,90.0,0.0,=,0.0,,P29274,0.643463,TA88S,ADORA2A
346,10.1016/j.bbamem.2014.11.010,aa2ar_human,166,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,64.4,-1.468,,,,0.0,0.0,=,0.0,,P29274,3.79355,CA166A,ADORA2A
347,10.1124/mol.111.075937,aa2ar_human,13,E,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,6.9,6.31,,,,0.0,0.0,=,0.0,,P29274,1.88788,EA13A,ADORA2A
854,10.1124/mol.111.075937,aa2ar_human,13,E,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,8.4,-3.984,,,,0.0,0.0,=,0.0,,P29274,1.88788,EA13A,ADORA2A
383,10.1124/mol.114.095737,aa2ar_human,52,D,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,16.0,µM,=,,175.0,10.938,,,NECA,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
569,10.1124/mol.114.095737,aa2ar_human,52,D,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,8.9,µM,=,,164.0,18.427,,,ZM241385,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
587,10.1124/mol.114.095737,aa2ar_human,52,D,A,ZM241385,PubChem CID,5311506,Inverse agonist,K(d),Binding - Radioligand saturation,4.6,nM,=,,3.5,-1.314,,,,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
678,10.1124/mol.114.095737,aa2ar_human,52,D,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,63.0,µM,=,,1065.0,16.905,,,ZM241385,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
794,10.1124/mol.114.095737,aa2ar_human,52,D,A,NECA,PubChem CID,448222,Full agonist,K(d),Binding - Radioligand saturation,81.0,nM,=,,77.0,-1.052,,,,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
1142,10.1124/mol.114.095737,aa2ar_human,52,D,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.5,µM,=,,35.0,14.0,,,NECA,0.0,0.0,=,0.0,,P29274,-1.20615,DA52A,ADORA2A
384,7775460,aa2ar_human,250,H,F,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,1650.0,6.762,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
458,7775460,aa2ar_human,250,H,F,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,2130.0,14.013,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
484,7775460,aa2ar_human,250,H,F,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,14.4,-1.506,,,,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
607,7775460,aa2ar_human,250,H,F,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,60.3,-1.048,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
619,7775460,aa2ar_human,250,H,F,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,7950.0,25.0,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
750,7775460,aa2ar_human,250,H,F,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,25.7,2.545,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
1005,7775460,aa2ar_human,250,H,F,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,41.9,2.106,,,CGS21680,0.0,0.0,=,0.0,,P29274,-3.18962,HA250F,ADORA2A
416,10.1016/j.bbamem.2014.11.010,aa2ar_human,159,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,49.8,-1.898,,,,0.0,0.0,=,0.0,,P29274,3.9942,CA159A,ADORA2A
451,10.1124/mol.111.075937,aa2ar_human,169,E,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,7.7,,=,,7.6,1.259,,,,0.0,0.0,=,0.0,,P29274,0.300339,EA169A,ADORA2A
499,10.1124/mol.111.075937,aa2ar_human,169,E,A,ZM241385,PubChem CID,5311506,Inverse agonist,pIC50,Functional - Ca2+ accumulation,8.51,,=,,7.04,29.512,,,,0.0,0.0,=,0.0,,P29274,0.300339,EA169A,ADORA2A
675,10.1124/mol.111.075937,aa2ar_human,169,E,A,LUF-5834,PubChem CID,10066330,Full agonist,pEC50,Functional - cAMP accumulation,7.8,,=,,8.3,-3.165,,,,0.0,0.0,=,0.0,,P29274,0.300339,EA169A,ADORA2A
717,10.1124/mol.114.097360,aa2ar_human,169,E,A,NECA,PubChem CID,448222,Full agonist,pEC50,Functional - cAMP accumulation,9.05,,=,,7.87,15.136,,,,0.0,0.0,=,0.0,,P29274,0.300339,EA169A,ADORA2A
912,10.1124/mol.114.097360,aa2ar_human,169,E,A,CGS21680,PubChem CID,3086599,Full agonist,pEC50,Functional - cAMP accumulation,8.27,,=,,8.07,1.585,,,,0.0,0.0,=,0.0,,P29274,0.300339,EA169A,ADORA2A
516,7775460,aa2ar_human,250,H,Y,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,8250.0,54.276,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
614,7775460,aa2ar_human,250,H,Y,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,52.7,-1.199,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
783,7775460,aa2ar_human,250,H,Y,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,3000.0,12.295,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
797,7775460,aa2ar_human,250,H,Y,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,14.9,-1.456,,,,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
860,7775460,aa2ar_human,250,H,Y,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,43.8,2.201,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
952,7775460,aa2ar_human,250,H,Y,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,8.4,-1.202,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
1140,7775460,aa2ar_human,250,H,Y,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,9580.0,30.126,,,CGS21680,0.0,0.0,=,0.0,,P29274,-2.93932,HA250Y,ADORA2A
578,7775460,aa2ar_human,254,C,A,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,99.6,-2.451,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0848003,CA254A,ADORA2A
720,7775460,aa2ar_human,254,C,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,54.1,-1.168,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0848003,CA254A,ADORA2A
975,7775460,aa2ar_human,254,C,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,18.2,-1.093,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0848003,CA254A,ADORA2A
1016,7775460,aa2ar_human,254,C,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,19.4,1.921,,,CGS21680,0.0,0.0,=,0.0,,P29274,-0.0848003,CA254A,ADORA2A
1058,7775460,aa2ar_human,254,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,23.7,1.092,,,,0.0,0.0,=,0.0,,P29274,-0.0848003,CA254A,ADORA2A
591,10.1016/j.bbamem.2014.11.010,aa2ar_human,77,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,70.0,-1.35,,,,0.0,0.0,=,0.0,,P29274,3.84542,CA77A,ADORA2A
624,8794889,aa2ar_human,89,Q,L,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand competition/displacement,31.0,nM,=,,35.6,1.148,,,,0.0,0.0,=,0.0,,P29274,-1.99357,QA89L,ADORA2A
697,7775460,aa2ar_human,182,F,Y,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,19.9,nM,=,,170.0,8.543,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
713,7775460,aa2ar_human,182,F,Y,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,10.1,nM,=,,19.2,1.901,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
726,7775460,aa2ar_human,182,F,Y,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,318.0,nM,=,,2800.0,8.805,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
737,7775460,aa2ar_human,182,F,Y,DPMA,PubChem CID,10391971,Full agonist,K(i),Binding - Radioligand competition/displacement,244.0,nM,=,,1720.0,7.049,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
805,7775460,aa2ar_human,182,F,Y,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,63.2,nM,=,,140.0,2.215,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
921,7775460,aa2ar_human,182,F,Y,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,21.7,nM,=,,57.0,2.627,,,,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
1099,7775460,aa2ar_human,182,F,Y,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,152.0,nM,=,,1890.0,12.434,,,CGS21680,0.0,0.0,=,0.0,,P29274,0.673682,FA182Y,ADORA2A
810,10.1016/j.bbamem.2014.11.010,aa2ar_human,74,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,60.7,-1.558,,,,0.0,0.0,=,0.0,,P29274,4.23937,CA74A,ADORA2A
856,10.1073/pnas.0804396105,aa2ar_human,122,K,A,Theophylline,PubChem CID,2153,Antagonist (neutral/silent),K(i),Binding - Radioligand competition/displacement,1.52,mM,=,,0.86,-1.767,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.447552,KA122A,ADORA2A
1069,10.1073/pnas.0804396105,aa2ar_human,122,K,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.002,mM,=,,0.002,1.0,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.447552,KA122A,ADORA2A
1137,10.1073/pnas.0804396105,aa2ar_human,122,K,A,R-PIA,PubChem CID,114854,Full agonist,K(i),Binding - Radioligand competition/displacement,0.16,mM,=,,30.0,187.5,,,ZM241385,0.0,0.0,=,0.0,,P29274,0.447552,KA122A,ADORA2A
956,10.1016/j.bbamem.2014.11.010,aa2ar_human,71,C,A,CGS21680,PubChem CID,3086599,Full agonist,K(d),Binding - Radioligand saturation,94.5,nM,=,,61.5,-1.536,,,,0.0,0.0,=,0.0,,P29274,4.35935,CA71A,ADORA2A
1014,7775460,aa2ar_human,274,I,A,CGS21680,PubChem CID,3086599,Full agonist,EC50,Functional - cAMP accumulation,3.0,nM,=,,100.0,33.333,,,,72.0,0.0,=,0.0,,P29274,1.7938,IA274A,ADORA2A
0,12821136,ada2b_human,109,D,A,Clonidine,ChEMBL Compound ID,CHEMBL134,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,75.0,nM,=,,28.0,-2.681,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
1,12821136,ada2b_human,109,D,A,Levomedetomidine,SMILES,C[C@@H](c1c[nH]cn1)c2cccc(C)c2C,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,140.0,nM,=,,57.0,-2.457,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
2,12821136,ada2b_human,109,D,A,Dexmedetomidine,ChEMBL Compound ID,CHEMBL778,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,5.4,nM,=,,1.4,-3.861,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
3,12821136,ada2b_human,109,D,A,Oxymetazoline,ChEMBL Compound ID,CHEMBL762,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1082.0,nM,=,,840.0,-1.289,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
4,12821136,ada2b_human,109,D,A,UK-14304,ChEMBL Compound ID,CHEMBL844,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,443.0,nM,=,,345.0,-1.284,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
5,12821136,ada2b_human,109,D,A,R-noradrenaline,ChEMBL Compound ID,CHEMBL1437,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,479.0,nM,=,,196.0,-2.445,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
7,12821136,ada2b_human,109,D,A,R-adrenaline,ChEMBL Compound ID,CHEMBL679,Binding - unknown pharmacological activity,K(i),Binding - Radioligand competition/displacement,1495.0,nM,=,,603.0,-2.481,,,[3H]RX821002 (radioligand),116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
9,12821136,ada2b_human,109,D,A,[3H]RX821002,ChEMBL Compound ID,CHEMBL10332,Binding - unknown pharmacological activity,K(d),Binding - Radioligand saturation,5.1,nM,=,,4.5,-1.134,,,,116.0,0.0,,0.0,,P18089,1.54031,DA109A,ADRA2B
1,10.1021/jm050968b,aa3r_human,94,T,A,CID75022615,PubChem CID,75022615,Full agonist,K(i),Binding - Radioligand competition/displacement,0.14,µM,=,,0.12,-1.167,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
18,10.1124/mol.63.5.1021,aa3r_human,94,T,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,2.7,2.25,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
22,10.1021/jm050968b,aa3r_human,94,T,A,CHEMBL377071,ChEMBL Compound ID,CHEMBL377071,Full agonist,K(i),Binding - Radioligand competition/displacement,2.26,µM,=,,1.37,-1.65,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
44,10.1124/mol.63.5.1021,aa3r_human,94,T,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.038,1.357,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
53,10.1124/mol.63.5.1021,aa3r_human,94,T,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,11.2,4.87,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
64,10.1124/mol.63.5.1021,aa3r_human,94,T,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,4.3,3.583,,,,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
84,10.1021/jm050968b,aa3r_human,94,T,A,CID75022525,PubChem CID,75022525,Full agonist,K(i),Binding - Radioligand competition/displacement,13.8,µM,=,,9.8,-1.408,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
87,10.1124/mol.63.5.1021,aa3r_human,94,T,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.041,1.414,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
100,10.1124/mol.63.5.1021,aa3r_human,94,T,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,2.2,1.222,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
126,10.1124/mol.63.5.1021,aa3r_human,94,T,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.062,-1.032,,,,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
161,10.1124/mol.63.5.1021,aa3r_human,94,T,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.034,1.36,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
201,10.1124/mol.63.5.1021,aa3r_human,94,T,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,6.4,2.286,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
261,10.1124/mol.63.5.1021,aa3r_human,94,T,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,33.0,11.786,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
307,10.1124/mol.63.5.1021,aa3r_human,94,T,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,10.1,6.312,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
368,10.1021/jm050968b,aa3r_human,94,T,A,CID85116573,PubChem CID,85116573,Full agonist,K(i),Binding - Radioligand competition/displacement,9.5,µM,=,,10.7,1.126,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.149619,TA94A,ADORA3
4,10.1124/mol.63.5.1021,aa3r_human,247,S,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.035,1.25,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
10,10.1074/jbc.M110960200,aa3r_human,247,S,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,333.0,1.83,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
37,10.1124/mol.63.5.1021,aa3r_human,247,S,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.7,1.417,,,,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
118,10.1124/mol.63.5.1021,aa3r_human,247,S,A,PSB-11,PubChem CID,9882625,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.23,min-1,=,,0.24,1.043,,,,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
119,10.1074/jbc.M110960200,aa3r_human,247,S,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,µM,=,,0.165,1.162,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
144,10.1124/mol.63.5.1021,aa3r_human,247,S,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.2,-1.045,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
154,10.1124/mol.63.5.1021,aa3r_human,247,S,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.46,min-1,=,,0.47,1.022,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
173,10.1124/mol.63.5.1021,aa3r_human,247,S,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,0.9,-2.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
240,10.1074/jbc.M110960200,aa3r_human,247,S,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,3.1,1.938,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
256,10.1074/jbc.M110960200,aa3r_human,247,S,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.7,nM,=,,1.7,1.0,,,,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
267,10.1124/mol.63.5.1021,aa3r_human,247,S,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.067,1.047,,,,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
272,10.1074/jbc.M110960200,aa3r_human,247,S,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.2,-1.045,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
283,10.1124/mol.63.5.1021,aa3r_human,247,S,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,3.9,1.393,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
285,10.1124/mol.63.5.1021,aa3r_human,247,S,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,2.9,1.036,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
292,10.1124/mol.63.5.1021,aa3r_human,247,S,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.035,1.4,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
301,10.1074/jbc.M110960200,aa3r_human,247,S,A,MRS1898,PubChem CID,44354130,Full agonist,K(i),Binding - Radioligand competition/displacement,1.4,nM,=,,1.5,1.071,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
326,10.1124/mol.63.5.1021,aa3r_human,247,S,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,3.1,1.938,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
345,10.1124/mol.63.5.1021,aa3r_human,247,S,A,Na+,PubChem CID,923,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.1,min-1,=,,0.12,1.2,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
358,10.1074/jbc.M110960200,aa3r_human,247,S,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,523.0,nM,=,,927.0,1.772,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
360,10.1074/jbc.M110960200,aa3r_human,247,S,A,DBXRM,PubChem CID,11743031,Full agonist,K(i),Binding - Radioligand competition/displacement,2.83,µM,=,,3.04,1.074,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
363,10.1124/mol.63.5.1021,aa3r_human,247,S,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.037,1.276,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
365,10.1074/jbc.M110960200,aa3r_human,247,S,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,249.0,nM,=,,247.0,-1.008,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
373,10.1074/jbc.M110960200,aa3r_human,247,S,A,VUF8504,PubChem CID,10832101,Inverse agonist,K(i),Binding - Radioligand competition/displacement,68.0,nM,=,,81.0,1.191,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
417,10.1124/mol.63.5.1021,aa3r_human,247,S,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,1.0,-1.2,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.517014,SA247A,ADORA3
6,10.1124/mol.63.5.1021,aa3r_human,152,K,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,1.9,1.056,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
40,10.1124/mol.63.5.1021,aa3r_human,152,K,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,23.0,8.214,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
43,10.1074/jbc.M110960200,aa3r_human,152,K,A,DBXRM,PubChem CID,11743031,Full agonist,K(i),Binding - Radioligand competition/displacement,2.83,µM,=,,6.03,2.131,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
45,10.1074/jbc.M110960200,aa3r_human,152,K,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,µM,=,,0.726,5.113,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
72,10.1124/mol.63.5.1021,aa3r_human,152,K,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,3.2,2.667,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
73,10.1124/mol.63.5.1021,aa3r_human,152,K,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,7.0,3.043,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
110,10.1074/jbc.M110960200,aa3r_human,152,K,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.7,nM,=,,3.7,2.176,,,,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
122,10.1124/mol.63.5.1021,aa3r_human,152,K,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,26.0,9.286,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
123,10.1124/mol.63.5.1021,aa3r_human,152,K,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.029,1.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
127,10.1124/mol.63.5.1021,aa3r_human,152,K,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.028,1.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
133,10.1124/mol.63.5.1021,aa3r_human,152,K,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.027,1.08,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
232,10.1074/jbc.M110960200,aa3r_human,152,K,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,5.4,3.375,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
244,10.1124/mol.63.5.1021,aa3r_human,152,K,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.052,-1.232,,,,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
251,10.1074/jbc.M110960200,aa3r_human,152,K,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,571.0,3.137,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
254,10.1074/jbc.M110960200,aa3r_human,152,K,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,249.0,nM,=,,278.0,1.116,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
257,10.1074/jbc.M110960200,aa3r_human,152,K,A,MRS1898,PubChem CID,44354130,Full agonist,K(i),Binding - Radioligand competition/displacement,1.4,nM,=,,2.3,1.643,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
321,10.1124/mol.63.5.1021,aa3r_human,152,K,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,3.7,3.083,,,,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
325,10.1074/jbc.M110960200,aa3r_human,152,K,A,VUF8504,PubChem CID,10832101,Inverse agonist,K(i),Binding - Radioligand competition/displacement,68.0,nM,=,,575.0,8.456,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
431,10.1124/mol.63.5.1021,aa3r_human,152,K,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,5.4,3.375,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
444,10.1074/jbc.M110960200,aa3r_human,152,K,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,523.0,nM,=,,323.0,-1.618,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
448,10.1074/jbc.M110960200,aa3r_human,152,K,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,1.7,-1.353,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.46978,KA152A,ADORA3
7,10.1124/mol.63.5.1021,aa3r_human,107,D,N,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.55,-2.183,,,,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
52,10.1124/mol.63.5.1021,aa3r_human,107,D,N,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,1.8,-1.277,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
65,10.1124/mol.63.5.1021,aa3r_human,107,D,N,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,9.7,3.464,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
70,10.1124/mol.63.5.1021,aa3r_human,107,D,N,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.03,1.034,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
80,10.1006/bbrc.2001.5027,aa3r_human,107,D,N,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,1.3,-2.924,,,,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
139,10.1124/mol.63.5.1021,aa3r_human,107,D,N,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.013,-1.923,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
140,10.1006/bbrc.2001.5027,aa3r_human,107,D,N,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.55,-2.183,,,,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
174,10.1124/mol.63.5.1021,aa3r_human,107,D,N,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,9.2,5.75,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
226,10.1124/mol.63.5.1021,aa3r_human,107,D,N,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,2.0,1.111,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
241,10.1124/mol.63.5.1021,aa3r_human,107,D,N,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,27.0,9.643,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
302,10.1124/mol.63.5.1021,aa3r_human,107,D,N,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,2.8,2.333,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
355,10.1124/mol.63.5.1021,aa3r_human,107,D,N,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.028,-2.283,,,,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
435,10.1006/bbrc.2001.5027,aa3r_human,107,D,N,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,1.69,1.777,,,,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
447,10.1124/mol.63.5.1021,aa3r_human,107,D,N,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.014,-2.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.00223,DA107N,ADORA3
13,10.1124/mol.63.5.1021,aa3r_human,244,L,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,1.9,1.056,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
32,10.1074/jbc.M110960200,aa3r_human,244,L,A,DBXRM,PubChem CID,11743031,Full agonist,K(i),Binding - Radioligand competition/displacement,2.83,µM,=,,7.55,2.668,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
33,10.1074/jbc.M110960200,aa3r_human,244,L,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,209.0,1.148,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
83,10.1124/mol.63.5.1021,aa3r_human,244,L,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.12,1.875,,,,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
90,10.1124/mol.63.5.1021,aa3r_human,244,L,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.062,2.48,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
92,10.1124/mol.63.5.1021,aa3r_human,244,L,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,4.6,1.643,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
97,10.1074/jbc.M110960200,aa3r_human,244,L,A,MRS1898,PubChem CID,44354130,Full agonist,K(i),Binding - Radioligand competition/displacement,1.4,nM,=,,0.73,-1.919,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
105,10.1124/mol.63.5.1021,aa3r_human,244,L,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.5,1.087,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
142,10.1124/mol.63.5.1021,aa3r_human,244,L,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.068,2.429,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
180,10.1124/mol.63.5.1021,aa3r_human,244,L,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,2.3,-1.218,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
188,10.1124/mol.63.5.1021,aa3r_human,244,L,A,PSB-11,PubChem CID,9882625,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.23,min-1,=,,0.22,-1.045,,,,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
192,10.1074/jbc.M110960200,aa3r_human,244,L,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,µM,=,,0.061,-2.326,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
195,10.1074/jbc.M110960200,aa3r_human,244,L,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,0.63,-2.538,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
224,10.1074/jbc.M110960200,aa3r_human,244,L,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.5,1.087,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
231,10.1124/mol.63.5.1021,aa3r_human,244,L,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.46,min-1,=,,0.45,-1.022,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
253,10.1124/mol.63.5.1021,aa3r_human,244,L,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.068,2.345,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
293,10.1124/mol.63.5.1021,aa3r_human,244,L,A,Na+,PubChem CID,923,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.1,min-1,=,,0.11,1.1,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
297,10.1074/jbc.M110960200,aa3r_human,244,L,A,VUF8504,PubChem CID,10832101,Inverse agonist,K(i),Binding - Radioligand competition/displacement,68.0,nM,=,,42.0,-1.618,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
303,10.1124/mol.63.5.1021,aa3r_human,244,L,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,0.63,-2.538,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
308,10.1074/jbc.M110960200,aa3r_human,244,L,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.7,nM,=,,0.85,-2.0,,,,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
346,10.1074/jbc.M110960200,aa3r_human,244,L,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,260.0,,=,,9430.0,36.269,,,,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
377,10.1074/jbc.M110960200,aa3r_human,244,L,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,249.0,nM,=,,68.0,-3.663,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
383,10.1124/mol.63.5.1021,aa3r_human,244,L,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.85,-1.412,,,,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
459,10.1124/mol.63.5.1021,aa3r_human,244,L,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,2.1,1.75,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.61891,LA244A,ADORA3
14,10.1080/15257770500265778,aa3r_human,167,Q,E,APEC,PubChem CID,3081741,Full agonist,K(i),Binding - Radioligand competition/displacement,305.0,nM,=,,850.0,2.787,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
28,10.1080/15257770500265778,aa3r_human,167,Q,E,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,665.0,nM,=,,5800.0,8.722,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
48,10.1080/15257770500265778,aa3r_human,167,Q,E,NONAME,SMILES,COC(=O)c1nc(NCc2cc(Cl)ccc2OC)c3ncn(C4OC(CO)C(O)C4O)c3n1,Full agonist,K(i),Binding - Radioligand competition/displacement,21.1,nM,=,,56.2,2.664,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
55,10.1080/15257770500265778,aa3r_human,167,Q,E,Cid22948626,PubChem CID,22948626,Full agonist,K(i),Binding - Radioligand competition/displacement,775.0,nM,=,,8030.0,10.361,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
59,10.1080/15257770500265778,aa3r_human,167,Q,E,CGS23058,PubChem CID,14775497,Full agonist,K(i),Binding - Radioligand competition/displacement,682.0,nM,=,,1640.0,2.405,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
98,10.1080/15257770500265778,aa3r_human,167,Q,E,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,408.0,nM,=,,1630.0,3.995,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
111,10.1080/15257770500265778,aa3r_human,167,Q,E,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,7.2,nM,=,,71.8,9.972,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
132,10.1080/15257770500265778,aa3r_human,167,Q,E,6-methylaminopurinearabinoside,PubChem CID,1869,Full agonist,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,81.5,9.939,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
141,10.1080/15257770500265778,aa3r_human,167,Q,E,NONAME,SMILES,OCC1OC(C(O)C1O)n2cnc3c(NC4CC4c5ccccc5)nc(nc23)C(O)=O,Full agonist,K(i),Binding - Radioligand competition/displacement,1260.0,nM,=,,5310.0,4.214,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
148,10.1080/15257770500265778,aa3r_human,167,Q,E,NONAME,SMILES,CNc1nc(nc2n(cnc12)C3OC(CO)C(O)C3O)N(C)C=N,Full agonist,K(i),Binding - Radioligand competition/displacement,5.5,µM,=,,10.8,1.964,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
198,10.1021/jm050968b,aa3r_human,167,Q,E,CID75022483,PubChem CID,75022483,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,7.2,12.857,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
225,10.1080/15257770500265778,aa3r_human,167,Q,E,Cid44289609,PubChem CID,44289609,Full agonist,K(i),Binding - Radioligand competition/displacement,17.0,nM,=,,56.6,3.329,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
353,10.1080/15257770500265778,aa3r_human,167,Q,E,NONAME,SMILES,COc1ccc(Cl)cc1CNc2nc(nc3n(cnc23)C4OC(CO)C(O)C4O)C(O)=O,Full agonist,K(i),Binding - Radioligand competition/displacement,274.0,nM,=,,1500.0,5.474,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
359,10.1080/15257770500265778,aa3r_human,167,Q,E,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,46.2,nM,=,,918.0,19.87,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
372,10.1021/jm050968b,aa3r_human,167,Q,E,CID75022615,PubChem CID,75022615,Full agonist,K(i),Binding - Radioligand competition/displacement,0.14,µM,=,,0.57,4.071,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
375,10.1080/15257770500265778,aa3r_human,167,Q,E,Cid44280242,PubChem CID,44280242,Full agonist,K(i),Binding - Radioligand competition/displacement,57.1,nM,=,,406.0,7.11,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
388,10.1080/15257770500265778,aa3r_human,167,Q,E,SPA,PubChem CID,73087488,Full agonist,K(i),Binding - Radioligand competition/displacement,342.0,nM,=,,2910.0,8.509,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
392,10.1080/15257770500265778,aa3r_human,167,Q,E,34349-36-5,PubChem CID,13506473,Full agonist,K(i),Binding - Radioligand competition/displacement,2.9,nM,=,,26.3,9.069,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.523916,QA167E,ADORA3
15,10.1124/mol.63.5.1021,aa3r_human,243,W,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.029,1.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
21,10.1124/mol.63.5.1021,aa3r_human,243,W,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,1.1,-1.091,,,,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
30,10.1124/mol.63.5.1021,aa3r_human,243,W,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,17.0,6.071,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
42,10.1124/mol.63.5.1021,aa3r_human,243,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,0.44,-4.098,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
94,10.1074/jbc.M110960200,aa3r_human,243,W,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,1160.0,6.374,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
121,10.1021/jm020211+,aa3r_human,243,W,A,MRS542,PubChem CID,21989785,Full agonist,K(i),Binding - Radioligand competition/displacement,1.9,nM,=,,2.4,1.263,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
125,10.1124/mol.63.5.1021,aa3r_human,243,W,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.027,-1.037,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
138,10.1124/mol.63.5.1021,aa3r_human,243,W,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.9,1.261,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
153,10.1124/mol.63.5.1021,aa3r_human,243,W,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.031,1.24,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
155,10.1124/mol.63.5.1021,aa3r_human,243,W,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,45.0,28.125,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
163,10.1021/jm020211+,aa3r_human,243,W,A,CID18506750,PubChem CID,18506750,Full agonist,K(i),Binding - Radioligand competition/displacement,1.7,nM,=,,1.3,-1.307,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
164,10.1074/jbc.M110960200,aa3r_human,243,W,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,2.9,1.261,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
167,10.1021/jm020211+,aa3r_human,243,W,A,CID 13506456,PubChem CID,13506456,Full agonist,K(i),Binding - Radioligand competition/displacement,114.0,nM,=,,100.0,-1.14,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
182,10.1074/jbc.M110960200,aa3r_human,243,W,A,VUF8504,PubChem CID,10832101,Inverse agonist,K(i),Binding - Radioligand competition/displacement,68.0,nM,=,,2570.0,37.794,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
217,10.1074/jbc.M110960200,aa3r_human,243,W,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,45.0,28.125,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
250,10.1021/jm020211+,aa3r_human,243,W,A,CID44359214,PubChem CID,44359214,Full agonist,K(i),Binding - Radioligand competition/displacement,83.0,nM,=,,46.0,-1.805,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
263,10.1021/jm020211+,aa3r_human,243,W,A,AC1L1E8Z,PubChem CID,2692,Full agonist,K(i),Binding - Radioligand competition/displacement,142.0,nM,=,,137.0,-1.036,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
266,10.1021/jm020211+,aa3r_human,243,W,A,CID44359257,PubChem CID,44359257,Full agonist,K(i),Binding - Radioligand competition/displacement,584.0,nM,=,,490.0,-1.192,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
274,10.1021/jm020211+,aa3r_human,243,W,A,MRS1191,PubChem CID,393594,Inverse agonist,K(i),Binding - Radioligand competition/displacement,78.0,nM,=,,818.0,10.487,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
275,10.1074/jbc.M110960200,aa3r_human,243,W,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,µM,=,,0.552,3.887,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
336,10.1124/mol.63.5.1021,aa3r_human,243,W,A,Amiloride,PubChem CID,16231,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,74.0,µM,=,,36.0,-2.058,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
337,10.1124/mol.63.5.1021,aa3r_human,243,W,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,44.0,15.714,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
349,10.1074/jbc.M110960200,aa3r_human,243,W,A,MRS1898,PubChem CID,44354130,Full agonist,K(i),Binding - Radioligand competition/displacement,1.4,nM,=,,2.1,1.5,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
352,10.1074/jbc.M110960200,aa3r_human,243,W,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,249.0,nM,=,,166.0,-1.499,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
366,10.1074/jbc.M110960200,aa3r_human,243,W,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.7,nM,=,,1.1,-1.546,,,,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
374,10.1074/jbc.M110960200,aa3r_human,243,W,A,DBXRM,PubChem CID,11743031,Full agonist,K(i),Binding - Radioligand competition/displacement,2.83,µM,=,,4.39,1.551,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
405,10.1021/jm020211+,aa3r_human,243,W,A,IB-MECA,PubChem CID,3668,Full agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,0.9,-1.779,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
416,10.1021/jm020211+,aa3r_human,243,W,A,MRS1939,PubChem CID,44359364,Full agonist,K(i),Binding - Radioligand competition/displacement,2.1,nM,=,,1.2,-1.751,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
420,10.1021/jm020211+,aa3r_human,243,W,A,NU006999,PubChem CID,21989774,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,6.0,1.579,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
426,10.1074/jbc.M110960200,aa3r_human,243,W,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,523.0,nM,=,,334.0,-1.565,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
433,10.1021/jm020211+,aa3r_human,243,W,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,0.8,nM,=,,0.9,1.125,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
439,10.1021/jm020211+,aa3r_human,243,W,A,CID21989784,PubChem CID,21989784,Full agonist,K(i),Binding - Radioligand competition/displacement,3.9,nM,=,,2.7,-1.445,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
455,10.1021/jm020211+,aa3r_human,243,W,A,Compound39,SMILES,CCCC1C(=C(CC)N=C(c2ccccc2)C1(CCC)C([O-])=O)C(=O)SCC,Inverse agonist,K(i),Binding - Radioligand competition/displacement,238.0,nM,=,,2150.0,9.034,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
456,10.1124/mol.63.5.1021,aa3r_human,243,W,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,3.6,3.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
460,10.1124/mol.63.5.1021,aa3r_human,243,W,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.051,-1.255,,,,0.0,0.0,=,0.0,,P0DMS8,2.14513,WA243A,ADORA3
17,10.1080/15257770500265778,aa3r_human,167,Q,R,34349-36-5,PubChem CID,13506473,Full agonist,K(i),Binding - Radioligand competition/displacement,2.9,nM,=,,11.8,4.069,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
54,10.1080/15257770500265778,aa3r_human,167,Q,R,APEC,PubChem CID,3081741,Full agonist,K(i),Binding - Radioligand competition/displacement,305.0,nM,=,,7260.0,23.803,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
56,10.1080/15257770500265778,aa3r_human,167,Q,R,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,665.0,nM,=,,2380.0,3.579,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
128,10.1080/15257770500265778,aa3r_human,167,Q,R,Cid44289609,PubChem CID,44289609,Full agonist,K(i),Binding - Radioligand competition/displacement,17.0,nM,=,,37.8,2.224,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
150,10.1080/15257770500265778,aa3r_human,167,Q,R,6-methylaminopurinearabinoside,PubChem CID,1869,Full agonist,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,52.0,6.341,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
216,10.1080/15257770500265778,aa3r_human,167,Q,R,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,408.0,nM,=,,2600.0,6.373,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
298,10.1080/15257770500265778,aa3r_human,167,Q,R,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,46.2,nM,=,,1230.0,26.623,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
314,10.1080/15257770500265778,aa3r_human,167,Q,R,CGS23058,PubChem CID,14775497,Full agonist,K(i),Binding - Radioligand competition/displacement,682.0,nM,=,,1300.0,1.906,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
318,10.1080/15257770500265778,aa3r_human,167,Q,R,NONAME,SMILES,COc1ccc(Cl)cc1CNc2nc(nc3n(cnc23)C4OC(CO)C(O)C4O)C(O)=O,Full agonist,K(i),Binding - Radioligand competition/displacement,274.0,nM,=,,397.0,1.449,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
342,10.1080/15257770500265778,aa3r_human,167,Q,R,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,7.2,nM,=,,87.1,12.097,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
344,10.1080/15257770500265778,aa3r_human,167,Q,R,NONAME,SMILES,COC(=O)c1nc(NCc2cc(Cl)ccc2OC)c3ncn(C4OC(CO)C(O)C4O)c3n1,Full agonist,K(i),Binding - Radioligand competition/displacement,21.1,nM,=,,81.8,3.877,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
362,10.1080/15257770500265778,aa3r_human,167,Q,R,SPA,PubChem CID,73087488,Full agonist,K(i),Binding - Radioligand competition/displacement,342.0,nM,=,,1100.0,3.216,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
419,10.1080/15257770500265778,aa3r_human,167,Q,R,Cid44280242,PubChem CID,44280242,Full agonist,K(i),Binding - Radioligand competition/displacement,57.1,nM,=,,477.0,8.354,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
425,10.1080/15257770500265778,aa3r_human,167,Q,R,Cid22948626,PubChem CID,22948626,Full agonist,K(i),Binding - Radioligand competition/displacement,775.0,nM,=,,7040.0,9.084,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,-0.192708,QA167R,ADORA3
19,10.1006/bbrc.2001.5027,aa3r_human,108,R,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,0.0375,-25.641,,,,0.0,0.0,=,0.0,,P0DMS8,1.45736,RA108A,ADORA3
278,10.1006/bbrc.2001.5027,aa3r_human,108,R,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.7,-1.715,,,,0.0,0.0,=,0.0,,P0DMS8,1.45736,RA108A,ADORA3
371,10.1006/bbrc.2001.5027,aa3r_human,108,R,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,0.9,-4.219,,,,0.0,0.0,=,0.0,,P0DMS8,1.45736,RA108A,ADORA3
23,10.1006/bbrc.2001.5027,aa3r_human,88,C,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,53.6,14.105,,,,0.0,0.0,=,0.0,,P0DMS8,8.76704,CA88F,ADORA3
288,10.1006/bbrc.2001.5027,aa3r_human,88,C,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,39.3,41.325,,,,0.0,0.0,=,0.0,,P0DMS8,8.76704,CA88F,ADORA3
304,10.1006/bbrc.2001.5027,aa3r_human,88,C,F,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,8.3,6.917,,,,0.0,0.0,=,0.0,,P0DMS8,8.76704,CA88F,ADORA3
27,10.1080/15257770500265778,aa3r_human,167,Q,A,Cid22948626,PubChem CID,22948626,Full agonist,K(i),Binding - Radioligand competition/displacement,775.0,nM,=,,7590.0,9.794,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
67,10.1080/15257770500265778,aa3r_human,167,Q,A,34349-36-5,PubChem CID,13506473,Full agonist,K(i),Binding - Radioligand competition/displacement,2.9,nM,=,,12.6,4.345,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
91,10.1080/15257770500265778,aa3r_human,167,Q,A,Cid44280242,PubChem CID,44280242,Full agonist,K(i),Binding - Radioligand competition/displacement,57.1,nM,=,,551.0,9.65,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
134,10.1080/15257770500265778,aa3r_human,167,Q,A,CGS23058,PubChem CID,14775497,Full agonist,K(i),Binding - Radioligand competition/displacement,682.0,nM,=,,1050.0,1.54,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
146,10.1080/15257770500265778,aa3r_human,167,Q,A,NONAME,SMILES,COc1ccc(Cl)cc1CNc2nc(nc3n(cnc23)C4OC(CO)C(O)C4O)C(O)=O,Full agonist,K(i),Binding - Radioligand competition/displacement,274.0,nM,=,,794.0,2.898,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
159,10.1080/15257770500265778,aa3r_human,167,Q,A,6-methylaminopurinearabinoside,PubChem CID,1869,Full agonist,K(i),Binding - Radioligand competition/displacement,8.2,nM,=,,52.5,6.402,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
179,10.1080/15257770500265778,aa3r_human,167,Q,A,ADAC,PubChem CID,23789715,Full agonist,K(i),Binding - Radioligand competition/displacement,408.0,nM,=,,4000.0,9.804,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
207,10.1080/15257770500265778,aa3r_human,167,Q,A,Cid44289609,PubChem CID,44289609,Full agonist,K(i),Binding - Radioligand competition/displacement,17.0,nM,=,,36.6,2.153,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
227,10.1080/15257770500265778,aa3r_human,167,Q,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,46.2,nM,=,,893.0,19.329,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
230,10.1080/15257770500265778,aa3r_human,167,Q,A,NONAME,SMILES,OCC1OC(C(O)C1O)n2cnc3c(NC4CC4c5ccccc5)nc(nc23)C(O)=O,Full agonist,K(i),Binding - Radioligand competition/displacement,1260.0,nM,=,,9350.0,7.421,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
264,10.1080/15257770500265778,aa3r_human,167,Q,A,APEC,PubChem CID,3081741,Full agonist,K(i),Binding - Radioligand competition/displacement,305.0,nM,=,,2550.0,8.361,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
330,10.1080/15257770500265778,aa3r_human,167,Q,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,7.2,nM,=,,94.8,13.167,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
376,10.1080/15257770500265778,aa3r_human,167,Q,A,CGS21680,PubChem CID,3086599,Full agonist,K(i),Binding - Radioligand competition/displacement,665.0,nM,=,,8130.0,12.226,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
391,10.1080/15257770500265778,aa3r_human,167,Q,A,NONAME,SMILES,CNc1nc(nc2n(cnc12)C3OC(CO)C(O)C3O)N(C)C=N,Full agonist,K(i),Binding - Radioligand competition/displacement,5.5,µM,=,,16.2,2.945,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
398,10.1080/15257770500265778,aa3r_human,167,Q,A,NONAME,SMILES,COC(=O)c1nc(NCc2cc(Cl)ccc2OC)c3ncn(C4OC(CO)C(O)C4O)c3n1,Full agonist,K(i),Binding - Radioligand competition/displacement,21.1,nM,=,,65.8,3.118,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
446,10.1080/15257770500265778,aa3r_human,167,Q,A,SPA,PubChem CID,73087488,Full agonist,K(i),Binding - Radioligand competition/displacement,342.0,nM,=,,4090.0,11.959,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.782839,QA167A,ADORA3
31,10.1124/mol.63.5.1021,aa3r_human,58,D,N,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.122,1.906,,,,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
75,10.1124/mol.63.5.1021,aa3r_human,58,D,N,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,2.9,1.036,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
78,10.1124/mol.63.5.1021,aa3r_human,58,D,N,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.122,4.88,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
120,10.1124/mol.63.5.1021,aa3r_human,58,D,N,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.46,min-1,=,,0.52,1.13,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
147,10.1124/mol.63.5.1021,aa3r_human,58,D,N,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,4.6,2.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
170,10.1124/mol.63.5.1021,aa3r_human,58,D,N,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,1.3,1.083,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
185,10.1124/mol.63.5.1021,aa3r_human,58,D,N,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,1.9,1.056,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
202,10.1124/mol.63.5.1021,aa3r_human,58,D,N,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.064,2.286,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
212,10.1124/mol.63.5.1021,aa3r_human,58,D,N,Na+,PubChem CID,923,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.1,min-1,=,,0.31,3.1,,,PSB-11,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
215,10.1124/mol.63.5.1021,aa3r_human,58,D,N,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,2.1,1.75,,,,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
218,10.1124/mol.63.5.1021,aa3r_human,58,D,N,PSB-11,PubChem CID,9882625,Inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.23,min-1,=,,0.27,1.174,,,,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
229,10.1124/mol.63.5.1021,aa3r_human,58,D,N,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,1.2,-1.333,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
357,10.1124/mol.63.5.1021,aa3r_human,58,D,N,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.133,4.586,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
397,10.1124/mol.63.5.1021,aa3r_human,58,D,N,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,2.5,-1.12,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.580538,DA58N,ADORA3
35,10.1021/jm020211+,aa3r_human,95,H,A,CID21989784,PubChem CID,21989784,Full agonist,K(i),Binding - Radioligand competition/displacement,3.9,nM,=,,99.0,25.385,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
38,10.1021/jm020211+,aa3r_human,95,H,A,AC1L1E8Z,PubChem CID,2692,Full agonist,K(i),Binding - Radioligand competition/displacement,142.0,nM,=,,615.0,4.331,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
46,10.1124/mol.63.5.1021,aa3r_human,95,H,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.067,2.31,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
50,10.1074/jbc.M110960200,aa3r_human,95,H,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.7,nM,=,,5.7,3.353,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
69,10.1074/jbc.M110960200,aa3r_human,95,H,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,976.0,610.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
107,10.1021/jm020211+,aa3r_human,95,H,A,CID18506750,PubChem CID,18506750,Full agonist,K(i),Binding - Radioligand competition/displacement,1.7,nM,=,,460.0,270.588,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
112,10.1124/mol.63.5.1021,aa3r_human,95,H,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,36.0,30.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
124,10.1021/jm020211+,aa3r_human,95,H,A,MRS542,PubChem CID,21989785,Full agonist,K(i),Binding - Radioligand competition/displacement,1.9,nM,=,,132.0,69.474,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
143,10.1124/mol.63.5.1021,aa3r_human,95,H,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,28.0,10.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
149,10.1074/jbc.M110960200,aa3r_human,95,H,A,IB-MECA,PubChem CID,123683,Full agonist,,Binding - Other,0.0,,=,,0.0,9.8,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
152,10.1124/mol.63.5.1021,aa3r_human,95,H,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.07,2.5,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
190,10.1074/jbc.M110960200,aa3r_human,95,H,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,,Binding - Other,0.0,,=,,0.0,26.0,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
191,10.1124/mol.63.5.1021,aa3r_human,95,H,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.112,1.75,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
213,10.1124/mol.63.5.1021,aa3r_human,95,H,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.055,2.2,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
220,10.1074/jbc.M110960200,aa3r_human,95,H,A,DBXRM,PubChem CID,11743031,Full agonist,K(i),Binding - Radioligand competition/displacement,2.83,µM,=,,36.3,12.827,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
221,10.1074/jbc.M110960200,aa3r_human,95,H,A,VUF8504,PubChem CID,10832101,Inverse agonist,K(i),Binding - Radioligand competition/displacement,68.0,nM,=,,4000.0,58.824,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
252,10.1074/jbc.M110960200,aa3r_human,95,H,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,260.0,nM,=,,224.0,-1.16,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
259,10.1074/jbc.M110960200,aa3r_human,95,H,A,MRS1898,PubChem CID,44354130,Full agonist,K(i),Binding - Radioligand competition/displacement,1.4,nM,=,,143.0,102.143,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
281,10.1021/jm020211+,aa3r_human,95,H,A,NU006999,PubChem CID,21989774,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,85.0,22.368,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
306,10.1074/jbc.M110960200,aa3r_human,95,H,A,CADO,PubChem CID,8974,Full agonist,K(i),Binding - Radioligand competition/displacement,0.523,µM,=,,58.2,111.281,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
316,10.1124/mol.63.5.1021,aa3r_human,95,H,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,5.7,4.75,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
323,10.1124/mol.63.5.1021,aa3r_human,95,H,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,976.0,610.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
339,10.1074/jbc.M110960200,aa3r_human,95,H,A,XAC,PubChem CID,5697,Inverse agonist,K(i),Binding - Radioligand competition/displacement,0.142,µM,=,,9.44,66.479,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
356,10.1074/jbc.M110960200,aa3r_human,95,H,A,CADO,PubChem CID,8974,Full agonist,,Binding - Other,0.0,,=,,0.0,111.0,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
378,10.1124/mol.63.5.1021,aa3r_human,95,H,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,1120.0,400.0,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
379,10.1074/jbc.M110960200,aa3r_human,95,H,A,MRS1898,PubChem CID,44354130,Full agonist,,Binding - Other,0.0,,=,,0.0,100.0,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
382,10.1074/jbc.M110960200,aa3r_human,95,H,A,CGS15943,PubChem CID,2690,Inverse agonist,K(i),Binding - Radioligand competition/displacement,182.0,nM,=,,5130.0,28.187,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
386,10.1074/jbc.M110960200,aa3r_human,95,H,A,NECA,PubChem CID,448222,Full agonist,K(i),Binding - Radioligand competition/displacement,249.0,nM,=,,3430.0,13.775,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
394,10.1124/mol.63.5.1021,aa3r_human,95,H,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,48.0,26.667,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
396,10.1074/jbc.M110960200,aa3r_human,95,H,A,MRS1939,PubChem CID,44359364,Full agonist,,Binding - Other,0.0,,=,,0.0,92.0,,,,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
410,10.1021/jm020211+,aa3r_human,95,H,A,CID 13506456,PubChem CID,13506456,Full agonist,K(i),Binding - Radioligand competition/displacement,114.0,nM,=,,796.0,6.982,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
422,10.1074/jbc.M110960200,aa3r_human,95,H,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,60.0,26.087,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
449,10.1124/mol.63.5.1021,aa3r_human,95,H,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,60.0,26.087,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,0.940448,HA95A,ADORA3
41,10.1006/bbrc.2001.5027,aa3r_human,108,R,E,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.86,-1.395,,,,0.0,0.0,=,0.0,,P0DMS8,1.02354,RA108E,ADORA3
176,10.1006/bbrc.2001.5027,aa3r_human,108,R,E,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,0.279,-3.413,,,,0.0,0.0,=,0.0,,P0DMS8,1.02354,RA108E,ADORA3
351,10.1006/bbrc.2001.5027,aa3r_human,108,R,E,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,5.4,1.421,,,,0.0,0.0,=,0.0,,P0DMS8,1.02354,RA108E,ADORA3
68,10.1006/bbrc.2001.5027,aa3r_human,282,Y,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,33.6,8.842,,,,0.0,0.0,=,0.0,,P0DMS8,-0.747348,YA282F,ADORA3
312,10.1006/bbrc.2001.5027,aa3r_human,282,Y,F,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,9.3,7.75,,,,0.0,0.0,=,0.0,,P0DMS8,-0.747348,YA282F,ADORA3
423,10.1006/bbrc.2001.5027,aa3r_human,282,Y,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,27.6,29.022,,,,0.0,0.0,=,0.0,,P0DMS8,-0.747348,YA282F,ADORA3
95,10.1021/jm050968b,aa3r_human,272,H,D,CHEMBL377071,ChEMBL Compound ID,377071,Full agonist,K(i),Binding - Radioligand competition/displacement,2.26,µM,=,,0.14,-16.129,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,6.2731,HA272D,ADORA3
238,10.1021/jm050968b,aa3r_human,272,H,D,CID75022615,PubChem CID,75022615,Full agonist,K(i),Binding - Radioligand competition/displacement,0.14,µM,=,,0.12,-1.167,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,6.2731,HA272D,ADORA3
295,10.1021/jm050968b,aa3r_human,272,H,D,CID75022483,PubChem CID,75022483,Full agonist,K(i),Binding - Radioligand competition/displacement,0.56,µM,=,,0.39,-1.437,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,6.2731,HA272D,ADORA3
409,10.1021/jm050968b,aa3r_human,272,H,D,CID75022525,PubChem CID,75022525,Full agonist,K(i),Binding - Radioligand competition/displacement,13.8,µM,=,,2.0,-6.897,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,6.2731,HA272D,ADORA3
458,10.1021/jm050968b,aa3r_human,272,H,D,CID85116573,PubChem CID,85116573,Full agonist,K(i),Binding - Radioligand competition/displacement,9.5,µM,=,,0.85,-11.236,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,6.2731,HA272D,ADORA3
109,10.1124/mol.63.5.1021,aa3r_human,182,F,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,2.8,µM,=,,2.9,1.036,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
129,10.1124/mol.63.5.1021,aa3r_human,182,F,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.2,µM,=,,29.6,24.667,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
186,10.1124/mol.63.5.1021,aa3r_human,182,F,A,PSB-11,PubChem CID,9882625,Inverse agonist,K(i),Binding - Radioligand competition/displacement,2.8,nM,=,,9.2,3.286,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
315,10.1124/mol.63.5.1021,aa3r_human,182,F,A,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,3.5,2.917,,,,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
317,10.1124/mol.63.5.1021,aa3r_human,182,F,A,HMA,PubChem CID,1794,Allosteric inverse agonist,IC50,Binding - Radioligand competition/displacement,1.8,µM,=,,2.4,1.333,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
328,10.1124/mol.63.5.1021,aa3r_human,182,F,A,HMA,PubChem CID,1794,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.028,min-1,=,,0.085,3.036,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
334,10.1124/mol.63.5.1021,aa3r_human,182,F,A,I-AB-MECA,PubChem CID,44208896,Full agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.064,min-1,=,,0.079,1.234,,,,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
364,10.1124/mol.63.5.1021,aa3r_human,182,F,A,MRS1220,PubChem CID,393595,Inverse agonist,K(i),Binding - Radioligand competition/displacement,1.6,nM,=,,2.7,1.688,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
412,10.1124/mol.63.5.1021,aa3r_human,182,F,A,VUF-5455,PubChem CID,10339071,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.025,min-1,=,,0.074,2.96,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
418,10.1124/mol.63.5.1021,aa3r_human,182,F,A,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,2.3,nM,=,,5.2,2.261,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
450,10.1124/mol.63.5.1021,aa3r_human,182,F,A,DU124183,PubChem CID,10426659,Allosteric inverse agonist,k-1,Binding - Radioligand kinetics (association/dissociation),0.029,min-1,=,,0.079,2.724,,,I-AB-MECA,0.0,0.0,=,0.0,,P0DMS8,1.78999,FA182A,ADORA3
130,10.1006/bbrc.2001.5027,aa3r_human,109,Y,F,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,2.0,1.667,,,,0.0,0.0,=,0.0,,P0DMS8,1.51356,YA109F,ADORA3
277,10.1006/bbrc.2001.5027,aa3r_human,109,Y,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,17.0,4.474,,,,0.0,0.0,=,0.0,,P0DMS8,1.51356,YA109F,ADORA3
387,10.1006/bbrc.2001.5027,aa3r_human,109,Y,F,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,11.6,12.198,,,,0.0,0.0,=,0.0,,P0DMS8,1.51356,YA109F,ADORA3
166,10.1006/bbrc.2001.5027,aa3r_human,108,R,K,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,4.1,1.079,,,,0.0,0.0,=,0.0,,P0DMS8,-1.83133,RA108K,ADORA3
327,10.1006/bbrc.2001.5027,aa3r_human,108,R,K,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,0.341,-2.786,,,,0.0,0.0,=,0.0,,P0DMS8,-1.83133,RA108K,ADORA3
343,10.1006/bbrc.2001.5027,aa3r_human,108,R,K,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.95,-1.263,,,,0.0,0.0,=,0.0,,P0DMS8,-1.83133,RA108K,ADORA3
199,10.1006/bbrc.2001.5027,aa3r_human,107,D,R,Cl-IB-MECA,PubChem CID,393593,Full agonist,K(i),Binding - Radioligand competition/displacement,3.8,nM,=,,1.8,-2.11,,,,0.0,0.0,=,0.0,,P0DMS8,4.65475,DA107R,ADORA3
436,10.1006/bbrc.2001.5027,aa3r_human,107,D,R,Cl-IB-MECA,PubChem CID,393593,Full agonist,EC50,Functional - IP accumulation,0.951,µM,=,,1.42,1.493,,,,0.0,0.0,=,0.0,,P0DMS8,4.65475,DA107R,ADORA3
438,10.1006/bbrc.2001.5027,aa3r_human,107,D,R,I-AB-MECA,PubChem CID,44208896,Full agonist,K(d),Binding - Radioligand saturation,1.2,nM,=,,0.86,-1.395,,,,0.0,0.0,=,0.0,,P0DMS8,4.65475,DA107R,ADORA3
